

OS Unidentified.
 XX WO200259259-A2.
 PN
 XX
 PD 01-AUG-2002.
 XX
 PF 23-JAN-2002; 2002WO-IL00071.
 XX
 PR 23-JAN-2001; 2001US-263158P.
 XX
 PA (UYRA-) UNIV RAMOT APPLIED RES & IND DEV LTD.
 XX
 PI Wreschner DH;
 XX
 XX WPI: 2002-599769/64.
 DR P-PSDB; ABG98328.
 DR
 XX
 PT Differential display method for identifying secreted or transmembrane
 PT protein, comprises contacting a DNA with a first primer that hybridizes
 PT to a sequence coding for a leucine-rich motif and with a second
 PT oligonucleotide primer -
 XX
 XX Disclosure; Fig 2; 37pp; English.
 PS
 XX
 CC The invention relates to a differential display comprising contacting
 CC cDNA with a first primer that hybridizes to an oligonucleic sequence
 CC coding for a leucine-rich motif, and with a second oligonucleotide primer
 CC to form a cDNA-hybrid molecule. The method comprises obtaining mRNA from
 CC at least 2 samples, synthesising cDNA from the RNA of each sample,
 CC contacting the cDNA with a first primer that hybridizes to an
 CC oligonucleic sequence coding for a leucine-rich motif, and with a second
 CC oligonucleotide primer to form cDNA-hybrid molecules, amplifying the
 CC cDNA-hybrid molecules, detecting amplified products and comparing the
 CC amplified products from each sample to identify distinctive amplified
 CC products coding for at least one secreted or transmembrane protein. The
 CC method is useful for discovering novel secreted and/or transmembrane
 CC proteins which are important for cell processes and play an important
 CC role in determining its phenotype, and which act as mediators for the
 CC transfer of signals from external environment into the cell itself, thus
 CC modulating gene expression. Sequences ABX03792-ABX03869 represent DNA
 CC encoding secreted protein signal peptide sequences.
 XX
 SQ Sequence 18 BP; 1 A; 8 C; 5 G; 4 T; 0 other;
 Query Match 1.0%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 566 CACTGCTCCAGCGCC 582
 Db ||||| ||||| |||||
 2 CACTGCTCCAGCGCC 18
 RESULT 276
 ABS52111/c
 ID ABS52111 standard; DNA; 18 BP.
 XX
 AC ABS52111;
 XX
 DT 05-NOV-2002 (first entry)
 XX
 XX Human adipocyte Clq Tumour Necrosis Factor-like PCR primer 1.
 XX
 KW Human; NOVX; NOVX-associated disorder; cardiomyopathy; atherosclerosis;
 KW cell signal processing; metabolic pathway modulation; metabolic disorder;
 KW obesity; diabetes; infectious disease; neurodegenerative disorder; acne;
 KW Alzheimer's disease; Parkinson's disease; immune disorder; cancer;
 KW haematopoietic disorder; cirrhosis; pancreatitis; learning defect;
 KW memory defect; infertility; congenital heart defect; hair growth;
 KW pigmentation disorder; endocrine disorder; respiratory disease; health;
 KW gastro-intestinal disease; reproductive; neurological disease;
 KW bone marrow transplantation; endocrine disease; allergy; inflammation;
 KW nephrological disorder; urinary system disorder; age-related disorder;

KW neuropsychiatric disorder; EGF-related protein; SCUBE1; TEN-M4;
 KW adipocyte complement-related Clq tumour necrosis factor; out at first;
 KW beta adrenergic receptor kinase; EphA6/enk-2; glucose transporter;
 KW type Ia membrane sushi-containing domain; butyrophilin;
 KW type Ia membrane-sushi domain containing; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200257453-A2.
 PN
 XX 25-JUL-2002.
 XX
 PF 19-DEC-2001; 2001WO-US50331.
 XX
 XX 19-DEC-2000; 2000US-265704P.
 PR 20-DEC-2000; 2000US-257314P.
 PR 02-MAY-2001; 2001US-288153P.
 PR 29-MAY-2001; 2001US-294075P.
 PR 24-JUL-2001; 2001US-307506P.
 PR 10-AUG-2001; 2001US-311590P.
 PR 10-AUG-2001; 2001US-311613P.
 PR 29-AUG-2001; 2001US-315617P.
 PR 14-SEP-2001; 2001US-322358P.
 XX
 XX (CURA-) CURAGEN CORP.
 PA
 XX Gangolli EA, Patturajan M, Vernet CAM, Malyankar UM, Kekuda R;
 PI Stone DJ, Anderson D, Shinkets RA, Burgess CE, Zerhusen BD, Liu X;
 PI Spytek KA, Casman SJ, Boldog FL, Smithson G, Li L, Ji W;
 XX WPI; 2002-590744/63.
 DR
 XX Novel isolated NOVX polypeptide useful for treating cardiomyopathy,
 PT atherosclerosis, metabolic disorders, diabetes, obesity, infectious
 PT disease, anorexia, neurodegenerative disorders, Alzheimer's disease or
 PT cancer -
 XX
 XX Example 1; Page 198; 318pp; English.
 PS
 XX The present invention relates to new NOVX polypeptides. The invention is
 CC useful for treating or preventing a NOVX-associated disorder such as
 CC cardiomyopathy or atherosclerosis, where the disorder is related to cell
 CC signal processing and metabolic pathway modulation in a subject.
 CC preferably human. The invention is also useful for treating metabolic
 CC disorders (e.g. obesity), diabetes, infectious disease, neurodegenerative
 CC disorders (e.g. Alzheimer's disease, Parkinson's disease), immune
 CC disorders, haematopoietic disorders and various cancers. The molecules of
 CC the invention are also useful for treating or preventing cirrhosis,
 CC pancreatitis, learning and memory defects, infertility, congenital heart
 CC defects, acne, hair growth, pigmentation disorders, endocrine disorders,
 CC respiratory diseases, gastro-intestinal diseases, reproductive diseases,
 CC neurological diseases, bone marrow transplantation, endocrine diseases,
 CC allergy and inflammation, nephrological disorders, urinary system
 CC disorders, neuropsychiatric disorders and age-related disorders.
 CC The present nucleic acid sequence represents a PCR primer that was used
 CC in the methods of the invention.
 XX
 SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 other;
 Query Match 1.0%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.9e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 725 AGCAGGGGGCTGGCTG 741
 Db ||||| ||||| |||||
 18 AGCATGGCGCTGGCTG 2
 RESULT 277
 AAQ27299/c
 ID AAQ27299 standard; DNA; 19 BP.
 XX
 AC AAQ27299;

XX DT 25-MAR-2003 (updated)
XX DT 02-FEB-1993 (first entry)
XX DE PSPL1 primer DHAL4.
XX KW Cosmid; MalphaG#9; exon; Na, K-ATPase; in vivo splicing splasmid;
XX KW HIV-1 tat; splice site; beta-globin; ss.
XX OS Synthetic.
XX XX WO92113071-A1.
XX PN 06-AUG-1992.
XX DF 27-JAN-1992; 92WO-US00692.
XX PR 28-JAN-1991; 91US-0646664.
XX PA (MASI) MASSACHUSETTS INST TECHNOLOGY.
XX PI Buckler AJ, Chang DD, Housman DE, Sharp PA;
XX DR WPI; 1992-284656/34.
XX XX
XX PT Isolating coding sequence from mammalian genomic DNA - by
XX PT providing fragmented DNA, inserting DNA into intron of in vivo
XX PT splicing plasmid, introducing obtd. in vivo splicing plasmid
XX PT construct into host cell, etc.
XX XX
XX PS Claim 24; Page 33; 38pp; English.
XX XX
XX CC Fragments of a mouse cosmid clone, MalphaG#9, known to contain
XX CC exon sequences of the Na, K-ATPase alpha subunit gene (Tam, S.-
XX CC Y., et al., Mol. Cell. Biol. 10:6619-6623 (1990) were used to
XX CC demonstrate that when a fragment contg. an entire exon with
XX CC flanking intron sequences (in the proper orientation) is inserted
XX CC into an intron of an in vivo splicing plasmid, the exon is retained
XX CC in the mature poly A+ cytoplasmic RNA. In vivo splicing plasmid
XX CC PSPL1 was used. The insertion site is within an intron from the
XX CC HIV-1 tat gene whose flanking exons and splice sites were substituted
XX CC for the second intron of the rabbit beta-globin gene.
XX CC Oligonucleotide pairs for PCR are represented in AAQ27298-304.
XX CC Beta-globin specific primers are SD2 and SA2 (AAQ27300-01).
XX CC The antisense primers DHAB14 and SA2 (AAQ27299 and AAQ27301) were used
XX CC as primer in the first strand cDNA synthesis reactions.
XX CC SD1 and SA1 (AAQ27302-03) are internal to the initial RNA/PCR prod.
XX CC and were used for reamplification of RNA/PCR prods.
XX CC (Updated on 25-MAR-2003 to correct PN field.)
XX XX
XX SQ Sequence 19 BP; 3 A; 5 C; 8 G; 3 T; 0 other;
XX XX
Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 788 CCAGTGCCTGGCTGC 804
DB 17 CCATGCGCTGGCTCAC 1
RESULT 278
AAQ47696/c
ID AAQ47696 standard; DNA; 19 BP.
XX AC AAQ47696;
XX XX
XX DT 25-MAR-2003 (updated)
XX DT 04-FEB-1994 (first entry)
XX XX
XX DE Sequence of primer CAMP-c #2 for cyclophilin associated
XX DE membrane protein (CAMP-c) cDNA.

KW Cyclophilin associated membrane protein; CAMP-c; primer; ss.
XX OS Synthetic.
XX PN WO9316183-A1.
XX PD 19-AUG-1993.
XX PF 08-FEB-1993; 93WO-US01123.
XX PR 07-FEB-1992; 92US-0832862.
XX PA (STRD) UNIV LELAND STANFORD JUNIOR.
XX PI Friedman JS, Weissman IL;
XX DR WPI; 1993-272887/34.
XX XX
XX PT Cyclophilin C-associated membrane proteins and DNA - used for
XX PT screening for immunomodulatory agents and for diagnosis and
XX PT therapy
XX PS Example; Page 64; 105pp; English.
XX CC Primers CAMP-c #2 and CAMP-c #4 were used to screen a plasmid
XX CC cDNA library derived from AC 6 cells for cDNA clones encoding
XX CC CAMP-c. These primers amplify a fragment of approx. 250 bp.
XX CC (Updated on 25-MAR-2003 to correct PN field.)
XX SQ Sequence 19 BP; 3 A; 6 C; 6 G; 4 T; 0 other;
XX XX
Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 235 CAGGCATCTGCATCTGG 251
DB 19 CAGGCATCTGCATCTGG 3
RESULT 279
AAQ36444/c
ID AAQ36444 standard; DNA; 19 BP.
XX AC AAQ36444;
XX XX
XX DT 06-JUL-1999 (first entry)
XX XX
XX DE Target sequence for 2'-substituted oligonucleotide.
XX KW RNaseH; RNA cleavage; DNA cleavage; hybridisation; protein kinase C gene;
XX KW gene expression modulation; ras; raf; therapy; AIDS; atherosclerosis;
XX KW infection; cell growth; ss.
XX OS Synthetic.
XX PN WO9730067-A1.
XX PD 21-AUG-1997.
XX PF 07-FEB-1997; 97WO-US02043.
XX PR 14-FEB-1996; 96US-0011620.
XX PA (ISIS-) ISIS PHARM INC.
XX PA (NOVS) NOVARTIS AG.
XX PI Altmann K, Cook PD, Martin P, Monia B;
XX DR WPI; 1997-424968/39.
XX XX
XX PT Oligonucleotide with RNaseH activity, which specifically hybridises
XX PT to DNA or RNA - comprises 1st and 2nd sub-sequence(s) having

PT 2'-O-CH2-CH2-O-CH3 and 2'-deoxy sugar moieties, useful for therapy
 XX or diagnosis
 PS Example 2; Page 21; 86pp; English.
 XX
 CC This sequence represents a target sequence used to test the
 CC oligonucleotides of the invention.
 CC The invention relates to oligonucleotides (A), which specifically
 CC hybridises to RNA or DNA, comprises a linear sequence of nucleotide units
 CC linked by phosphodiester or phosphorothioate linkages, comprising a first
 CC subsequence having 2'-O-CH2-CH2-O-CH3 sugar moieties and a second
 CC subsequence having 2'-deoxy sugar moieties. (A), which has RNaseH
 CC activity for cleaving a complementary strand, can be used to modulate the
 CC expression of ras, raf and protein kinase C genes, useful in the therapy
 CC of AIDS, atherosclerosis, bacterial or other infections, or to control
 CC aberrant cell growth in humans, animals or plants. (A) can also be used
 CC diagnostically, particularly when labelled, to detect overexpression of
 CC mRNA or expression of abnormal RNA, including imaging of tissue sections,
 CC and as a research reagent. (A) has increased binding affinity for
 CC complementary strands (attributable to the 2'-O-CH2-CH2-O-CH3 sugar
 CC moiety, which overcomes the loss of affinity caused by altered intersugar
 CC links), and increased resistance to nuclease (from the modified links and
 CC the 2'-O-CH2-CH2-O-CH3 sugar moiety).
 XX
 SQ Sequence 19 BP; 13 A; 4 C; 2 G; 0 U; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTCTTTTCTTTG 1157
 |||||
 Db 19 GCGTTTTTTTTTTT 3

RESULT 280
 AAT95586/c
 ID AAT95586 standard; DNA; 19 BP.
 XX
 AC AAT95586;
 XX
 DT 25-MAR-2003 (updated)
 DT 11-MAR-1998 (first entry)
 XX
 DE Primer for SSCP analysis of SRP19.
 XX
 KW Human; adenomatous Polyposis coli; APC; diagnosis; prognosis;
 KW neoplastic tissue; tumour tissue; tumour repressor; mutation;
 KW sporadic colorectal cancer; detection; PCR primer; SRP19;
 KW SSCP; single stranded conformation polymorphism; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN US5648212-A.
 XX
 PD 15-JUL-1997.
 XX
 PF 12-AUG-1994; 94US-0289548.
 XX
 PR 16-JAN-1991; 91GB-0000962.
 PR 16-JAN-1991; 91GB-0000963.
 PR 16-JAN-1991; 91GB-0000974.
 PR 16-JAN-1991; 91GB-0000975.
 PR 08-AUG-1991; 91US-0741940.
 XX
 PA (NICA-) JAPANESE FOUND CANCER RES.
 PA (UYJO) UNIV JOHNS HOPKINS.
 PA (OTAH) UNIV UTAH.
 PA (ZENE) ZENECA LTD.
 XX
 PI Albertsen H, Anand R, Carlson M, Groden J, Hedge PJ;
 PI Joslyn G, Kinzler K, Markham A, Nakamura Y, Thliveris A;

PI Vogelstein B, White RL;
 XX WPI; 1997-372053/34.
 XX
 DR Cancer diagnosis - by detecting mutation(s) in adenomatous polyposis
 XX coli gene
 PT
 PS Example 8; Columns 31-32; 140pp; English.
 XX
 CC The present sequence is a primer for the SSCP analysis of SRP19,
 CC which was used in the development of a novel method of diagnosing
 CC or prognosing a human adenomatous Polyposis coli (APC) gene
 CC associated neoplastic tissue. The method comprises comparing APC
 CC gene coding sequences or mRNA in a tumour tissue, to APC gene
 CC coding sequences or mRNA in a non-neoplastic tissue, where a
 CC difference indicates an APC gene associated neoplasia of the tumour
 CC tissue. APC is a tumour repressor expressed in most normal tissues.
 CC APC mutations are found in familial adenomatous polyposis and
 CC sporadic colorectal cancer patients. The method enables mutations
 CC to be detected to provide an indication of predisposition to
 CC cancer.
 CC (Updated on 25-MAR-2003 to correct PR field.)
 XX

SQ Sequence 19 BP; 0 A; 4 C; 8 G; 7 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 100 ACAACCCGAGGCGCA 116
 |||||
 Db 17 ACAACCCGAGGCGCA 1

RESULT 281
 AAT51286/c
 ID AAT51286 standard; DNA; 19 BP.
 XX
 AC AAT51286;
 XX
 DT 11-NOV-1997 (first entry)
 DT Human AD4 gene PCR primer INT1R.
 XX
 DE Autosomal dominant early-onset Alzheimer's Disease; AD4; STM2;
 KW neurodegeneration; senile dementia; human chromosome 1;
 KW Volga German kindred; VG; yeast artificial chromosome library;
 KW expressed sequence tag database; polymerase chain reaction;
 KW PCR primer; Homo sapiens; ss.
 XX
 OS Synthetic.
 OS
 PN WO9703192-A2.
 XX
 PD 30-JAN-1997.
 XX
 PF 05-JUL-1996; 96WO-US11386.
 XX
 PR 14-AUG-1995; 95US-0002328.
 PR 07-JUL-1995; 95US-0000956.
 PR 28-JUL-1995; 95US-0001675.
 PR 11-AUG-1995; 95US-0002174.
 XX
 PA (DARW-) DARWIN MOLECULAR CORP.
 PA (GEHO) GEN HOSPITAL CORP.
 PA (VAME-) VA MEDICAL CENT.
 XX
 PI Bird TD, Galas DJ, Levy-Lahad E, Mulligan J, Schellenberg GD;
 PI Tanzi RE, Wasco W;
 XX
 DR WPI; 1997-119048/11.
 XX
 PT New Alzheimer's disease related gene, AD4 - used to develop prods.

PT for detecting pre-disposition to or for diagnosis, prevention or
 PT treatment of Alzheimer's disease
 XX
 PS Disclosure; Fig 11; 83pp; English.

XX A genetically isolated group of families with autosomal dominant
 CC early-onset Alzheimer's Disease (AD) has been studied and initial
 CC mapping analyses have predicted the AD4 locus (also known as STM2)
 CC resides on chromosome 1. The present sequence corresponds to a PCR
 CC primer which was used during the cloning procedure to isolate and
 CC sequence the AD4 gene. The group of families has been designated
 CC the Voiga German (VG) kindreds. The entire gene has been amplified
 CC from VG individuals and unaffected individuals (from VG and
 CC unrelated lineages). Sequence analysis has shown that affected
 CC individuals have a nucleotide change at codon 141 resulting in an
 CC amino acid alteration from Asn to Ile. Portions of a mutant AD4,
 CC especially one in which Asn at position 141 has been replaced by
 CC Ile, can be used in a peptide vaccine. Detection of mutant AD4, for
 CC example using antibodies specific for the protein or using nucleic
 CC acid probes specific for the mutant gene, provides a means of
 CC diagnosing Alzheimer's disease.

XX Sequence 19 BP; 6 A; 2 C; 10 G; 1 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02; 0; Mismatches 2; Indels 0; Gaps 0;
 Matches 15; Conservative 0;

QY 581 CCTCGGTCGTCGCCCC 597
 DB 17 CTCCTCGTCGTCGCCAC 1

RESULT 282

AAV51978
 ID AAV51978 standard; DNA; 19 BP.

XX AAV51978;

DT 02-FEB-1999 (first entry)

DE Zea mays genome reverse PCR primer #274.

XX Polymorphic marker; allele-specific; probe; amplification; PCR primer;
 KW hybridisation; plant; hybrid certification; genetic contribution;
 KW progeny; back-cross; hybrid; ancestry; corn; ss.

XX Synthetic.

OS Zea mays.

XX WO9824796-A1.

FN 11-JUN-1998.

PD 01-DEC-1997; 97WO-US21782.

XX 07-MAR-1997; 97US-0813507.

PR 02-DEC-1996; 96US-0032069.

XX (AFPY-) AFFYMETRIX INC.

PI Landry BS, Lemieux B, Murigneux A, Sapolsky RJ;

XX WPI; 1998-333252/29.

XX Brassica species allele-specific oligonucleotide probes and primers
 PT - useful for plant breeding

XX Example 1; Page Page 54; 65pp; English.

XX AAV51705-V52008 are reverse PCR primers used to amplify fragments of the
 CC Zea mays genome in order to detect polymorphic markers. Such markers can
 CC be used in the construction of allele-specific primers and probes for

CC amplification or hybridisation, e.g. to determine common or disparate
 CC ancestry between 2 or more plants, to monitor the genetic contribution
 CC of an ancestral plant, to trace the progeny of proprietary plants, in
 CC certification of a hybrid plant or to identify the progeny of a
 CC back-crossed plant with an ancestral plant.

XX Sequence 19 BP; 5 A; 6 C; 7 G; 1 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02; 0; Mismatches 2; Indels 0; Gaps 0;
 Matches 15; Conservative 0;

QY 552 GGCAGGCGATGCACAC 568
 DB 1 GGCAGGCGAGCGACGAC 17

RESULT 283

AAV51979

ID AAV51979 standard; DNA; 19 BP.

XX AAV51979;

DT 02-FEB-1999 (first entry)

DE Zea mays genome reverse PCR primer #275.

XX Polymorphic marker; allele-specific; probe; amplification; PCR primer;
 KW hybridisation; plant; hybrid certification; genetic contribution;
 KW progeny; back-cross; hybrid; ancestry; corn; ss.

XX Synthetic.

OS Zea mays.

XX WO9824796-A1.

FN 11-JUN-1998.

PD 01-DEC-1997; 97WO-US21782.

XX 07-MAR-1997; 97US-0813507.

PR 02-DEC-1996; 96US-0032069.

XX (AFPY-) AFFYMETRIX INC.

PI Landry BS, Lemieux B, Murigneux A, Sapolsky RJ;

XX WPI; 1998-333252/29.

XX Brassica species allele-specific oligonucleotide probes and primers
 PT - useful for plant breeding

XX Example 1; Page Page 54; 65pp; English.

XX AAV51705-V52008 are reverse PCR primers used to amplify fragments of the
 CC Zea mays genome in order to detect polymorphic markers. Such markers can
 CC be used in the construction of allele-specific primers and probes for
 CC amplification or hybridisation, e.g. to determine common or disparate
 CC ancestry between 2 or more plants, to monitor the genetic contribution
 CC of an ancestral plant, to trace the progeny of proprietary plants, in
 CC certification of a hybrid plant or to identify the progeny of a
 CC back-crossed plant with an ancestral plant.

XX Sequence 19 BP; 5 A; 6 C; 7 G; 1 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02; 0; Mismatches 2; Indels 0; Gaps 0;
 Matches 15; Conservative 0;

QY 552 GGCAGGCGATGCACAC 568
 DB 1 GGCAGGCGAGCGACGAC 17

RESULT 284

AAV56488/c
ID AAV56488 standard; DNA; 19 BP.

XX AC
XX AAV56488;
XX AC
XX 25-MAR-2003 (updated)
DT 23-NOV-1998 (first entry)
XX
XX Human DP2.5 APC primer #11.
XX
XX Familial adenomatous polyposis coli; APC; tumour suppressor; therapy;
KW chromosome 5q21; tumorigenesis; retinoblastoma; colorectal tumour;
KW FAP; Gardner's Syndrome; GS; predisposition; primer; ss.
XX

OS Synthetic.
OS Homo sapiens.

XX PN US5783666-A.
XX
XX 21-JUL-1998.

XX PF 25-MAY-1995; 95US-0452655.
XX
XX 16-JAN-1991; 91GB-0000962.
PR 16-JAN-1991; 91GB-0000963.
PR 16-JAN-1991; 91GB-0000974.
PR 16-JAN-1991; 91GB-0000975.
PR 08-AUG-1991; 91US-0741940.
PR 12-AUG-1994; 94US-0289548.

XX (CANC-) CANCER INST.
PA (UYJO) UNIV JOHNS HOPKINS.
PA (UTAH) UNIV UTAH.
PA (ZENE) ZENECA PHARM.

XX PI Albertsen H, Anand R, Carlson M, Groden J, Hedge PJ;
PI Joslyn G, Kinzler K, Markham AF, Nakamura Y, Thliveris A;
PI Vogelstein B, White RL;
XX WPI; 1998-427100/36.
XX
XX Adenomatous polyposis coli protein - useful in the treatment of
PT cancers associated with mutation(s) on human chromosome 5q21
XX
XX Example 8; Column 31-32; 102pp; English.

XX AAV56477-V56581 are primers used in the isolation of a human familial
CC adenomatous polyposis coli (APC) protein from clone DP2.5. The gene
CC for the protein is present on human chromosome 5q21 and is also referred
CC to as adenomatous polyposis coli gene. It is a tumour suppressor gene,
CC and mutations in this gene have been associated with tumorigenesis in
CC retinoblastoma and colorectal tumours, and especially familial
CC adenomatous polyposis (FAP) and Gardner's Syndrome (GS). The protein can
CC be used in therapy to replace lack of native functional protein and the
CC nucleic acids can be used for gene therapy. The nucleic acids that
CC encode them can also be used as probes and primers in detection of the
CC cancers and predisposition to it.
CC (Updated on 25-MAR-2003 to correct PR field.)
XX

SQ Sequence 19 BP; 0 A; 4 C; 8 G; 7 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 100 ACAACCCCGGAGCGCA 116
DB 17 ACAACCCCGGAGCGCA 1

RESULT 285

AAT96201/c

ID AAT96201 standard; DNA; 19 BP.

XX AC
XX AAT96201;
XX DT 25-MAR-2003 (updated)
DT 08-APR-1998 (first entry)
XX
XX Primer for SSCP analysis of SRP19.

XX Human; adenomatous Polyposis coli; APC; diagnosis; prognosis;
KW neoplastic tissue; tumour tissue; tumour repressor; mutation;
KW sporadic colorectal cancer; detection; PCR primer; SRP19;
KW SSCP; single stranded conformation polymorphism; ss.
XX

OS Synthetic.
OS Homo sapiens.

XX PN US5691454-A.
XX
XX 25-NOV-1997.

XX PF 25-MAY-1995; 95US-0452654.
XX
XX 16-JAN-1991; 91GB-0000962.
PR 16-JAN-1991; 91GB-0000963.
PR 16-JAN-1991; 91GB-0000974.
PR 16-JAN-1991; 91GB-0000975.
PR 08-AUG-1991; 91US-0741940.
PR 12-AUG-1994; 94US-0289548.

XX (CANC-) CANCER INST.
PA (ICIL) IMPERIAL CHEM IND PLC.
PA (UYJO) UNIV JOHNS HOPKINS.
PA (UTAH) UNIV UTAH.

XX PI Albertsen H, Anand R, Carlson M, Groden J, Hedge PJ;
PI Joslyn G, Kinzler K, Markham AF, Nakamura Y, Thliveris A;
PI Vogelstein B, White RL;
XX WPI; 1998-017712/02.
XX
XX Antibodies to normal and mutant adenomatous polyposis coli proteins
PT - useful for detecting genetic predisposition to cancer
XX
XX Example 8; Columns 25-26; 107pp; English.

XX The present sequence is a primer for the SSCP analysis of SRP19,
CC which was used in the development of a novel method of diagnosing
CC or prognosing a human adenomatous Polyposis coli (APC) gene
CC associated neoplastic tissue. The method comprises comparing APC
CC gene coding sequences or mRNA in a tumour tissue, to APC gene
CC coding sequences or mRNA in a non-neoplastic tissue, where a
CC difference indicates an APC gene associated neoplasia of the tumour
CC tissue. APC is a tumour repressor expressed in most normal tissues.
CC APC mutations are found in familial adenomatous polyposis and
CC sporadic colorectal cancer patients. The method enables mutations
CC to be detected to provide an indication of predisposition to
CC cancer.
CC (Updated on 25-MAR-2003 to correct PR field.)
XX

SQ Sequence 19 BP; 0 A; 4 C; 8 G; 7 T; 0 other;

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 2e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 100 ACAACCCCGGAGCGCA 116
DB 17 ACAACCCCGGAGCGCA 1

RESULT 286

AAZ10311/c
 ID AAZ10311 standard; DNA; 19 BP.
 XX
 AC AAZ10311;
 XX
 DT 20-MAR-2003 (updated)
 DT 08-NOV-1999 (first entry)
 XX
 DE Antisense oligonucleotide which is gapped 2' modified.
 XX
 KW Antisense oligonucleotide; nuclease resistance; RNase H strand cleavage;
 KW phosphorothioate; oligonucleotide therapeutic; AIDS; atherosclerosis; ss.
 XX
 OS Synthetic.
 XX
 PN US5955589-A.
 XX
 PD 21-SEP-1999.
 XX
 PF 06-JUN-1995; 95US-0465880.
 XX
 PR 24-DEC-1991; 91US-0814961.
 PR 23-DEC-1992; 92WO-US11339.
 PR 21-JUN-1994; 94US-0244993.
 XX
 PA (ISIS-) ISIS PHARM INC.
 XX
 PI Cook PD, Monia BP;
 XX
 DR WPI; 1999-539598/45.
 XX
 PT Oligonucleotides eliciting RNase H activity useful for diagnosis
 PT and treatment of diseases e.g AIDS or atherosclerosis
 XX
 PS Example 2; Column 13; 34pp; English.
 XX
 CC The present sequence represents a phosphorothioate antisense
 CC oligonucleotide which is gapped 2' modified oligonucleotide,
 CC whereby one part has at least two consecutive 2'-F (2'-H) nucleotides
 CC and the second part has at least five consecutive nucleotides with 2'-H
 CC sugar moieties. The modified oligonucleotide has increased nuclease
 CC resistance, and increased binding affinity for substrates. The
 CC oligonucleotide elicits RNase H strand cleavage of specific RNAs.
 CC Oligonucleotides of the invention are useful for the diagnosis, detection
 CC and treatment of conditions susceptible to oligonucleotide therapeutics
 CC (e.g. AIDS and atherosclerosis).
 CC (Updated on 20-MAR-2003 to correct PR field.)
 XX
 SQ Sequence 19 BP; 13 A; 4 C; 2 G; 0 U; 0 other;
 XX
 Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
 Matches 15; Conservative 0; Indels 0; Gaps 0;
 QY 1141 GCCTTTTCTTTTCTTTT 1157
 Db 19 GCGTTTCTTTTCTTTT 3
 XX
 RESULT 287
 AAX33236/c
 ID AAX33236 standard; DNA; 19 BP.
 XX
 AC AAX33236;
 XX
 DT 25-JUN-1999 (first entry)
 XX
 DE Wheat viviparous 1 (taVP1) primer #3.
 XX
 KW Wheat; oat; viviparous 1; VP1; afVP1; taVP1; maize; detection; PHS;
 KW pre-harvest sprouting; dormant; germination; crop plant; primer; ss.
 XX
 OS Synthetic.

OS Triticum aestivum.
 XX
 PN WO9915667-A1.
 XX
 PD 01-APR-1999.
 XX
 PF 18-SEP-1998; 98WO-GB02835.
 XX
 PR 19-SEP-1997; 97GB-0020060.
 XX
 PA (PLAN-) PLANT BIOSCIENCE LTD.
 XX
 PI Flinham JE, Gale MD, Holdsworth MJ;
 XX
 DR WPI; 1999-244424/20.
 XX
 PT New isolated oat and wheat VP1 genes, used, e.g. to impose
 PT sufficient dormancy to avoid pre-harvest sprouting
 XX
 PS Claim 56; Page 89; 120pp; English.
 XX
 CC The present sequence represents a primer for the wheat viviparous 1 (VP1)
 CC gene, which keeps mature seeds dormant and inhibits germination. The
 CC present invention describes genes which are homologues of the maize
 CC Viviparous 1 gene, obtained from oat Avena fatua and wheat which encode
 CC polypeptides designated afVP1 and taVP1 respectively. The VP1 activity
 CC keeps mature seeds dormant and inhibits germination and can be used to
 CC maintain or impose sufficient intensity and duration of dormancy to
 CC avoid pre-harvest sprouting (PHS) before harvest. The products can be
 CC used in the production of transformed crop plants having desirable
 CC primary or secondary dormancy, or after-ripening properties, and in
 CC particular may be resistant to PHS.
 XX
 SQ Sequence 19 BP; 3 A; 4 C; 11 G; 1 T; 0 other;
 XX
 Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02; Mismatches 0; Gaps 0;
 Matches 15; Conservative 0; Indels 0; Gaps 0;
 QY 800 CTGCTCTCTCTGAGCCG 816
 Db 18 CTGCGACCTCTGCTCGG 2
 XX
 RESULT 288
 AAX05488/c
 ID AAX05488 standard; DNA; 19 BP.
 XX
 AC AAX05488;
 XX
 DT 20-APR-1999 (first entry)
 XX
 DE 2' modified oligo used in the course of the invention.
 XX
 KW Nuclease resistant; modified; deoxyfuranosyl moiety; therapy; infection;
 KW AIDS; atherosclerosis; tumour; ss.
 XX
 OS Synthetic.
 XX
 PN US5859221-A.
 XX
 PD 12-JAN-1999.
 XX
 PF 06-JUN-1995; 95US-0468037.
 XX
 PR 06-JUN-1995; 95US-0468037.
 PR 11-JAN-1990; 90US-0463358.
 PR 13-AUG-1990; 90US-0566977.
 PR 12-AUG-1991; 91WO-US05720.
 PR 05-MAR-1992; 92US-0835932.
 PR 01-JUL-1992; 92US-0854634.
 XX
 PA (ISIS-) ISIS PHARM INC.

XX Cook PD, Kawasaki AM;
 XX WPI; 1999-120005/10.
 XX Nuclease resistant oligonucleotide analogues - having nucleosides
 PT including modified deoxyfuranosyl moiety bearing 2'-substituent to
 PT increase binding affinity
 XX Example 19; Column 40; 49pp; English.
 XX The invention relates to a nuclease resistant compound that hybridises
 CC with RNA or DNA. The compound comprises covalently-bound nucleosides
 CC that individually include a ribose or deoxyribose sugar portion and a
 CC base portion, where the nucleosides are joined together by
 CC internucleoside linkages such that the base portion of the nucleosides
 CC form a mixed base sequence that is complementary to a RNA base sequence
 CC or to a DNA base sequence; and where at least 1 of the nucleosides
 CC includes a modified deoxyfuranosyl moiety bearing a 2'-substituent
 CC selected from cyano, fluoromethyl, thioalkoxyl, alkylsulphonyl,
 CC alkylsulphonyl, allyloxy and alkeneoxy groups. The nuclease resistant
 CC oligonucleotides (ONs) can bind to and modulate the activity of DNA or
 CC RNA and can be used for treating organisms having a disease characterised
 CC by the undesired production of a protein. They can be used in therapeutic
 CC or prophylactic treatment in organisms such as bacteria, yeast, protozoa,
 CC algae, plant and higher animal forms including warm-blooded animals. The
 CC ONs can also be used for treating infections, AIDS, atherosclerosis or
 CC tumours. The products can be used for detection and diagnosis. The ONs
 CC provide enhanced binding to targets. Increased binding of 2'-sugar
 CC modified sequence-specific ONs provides superior potency and specificity
 CC compared to phosphorus-modified ONs. The present sequence represents a
 CC 2' modified oligonucleotide that was used in the course of the invention.
 XX SQ Sequence 19 BP; 13 A; 4 C; 2 G; 0 U; 0 other;
 Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1141 GCCTTTTCTCTTTTG 1157
 Db 19 GCGTTTTTTTTTTT 3
 RESULT 289
 AAA93490/c
 ID AAA93490 standard; DNA; 19 BP.
 AC AAA93490;
 XX 16-JAN-2001 (first entry)
 DT Human SRP19 gene exon 1 PCR primer 1.
 DE SRP19 gene; signal recognition particle protein; human; chromosome 5q21;
 XX familial adenomatous polyposis; FAP locus; Gardner's syndrome; GS;
 KW sporadic tumour; adenoma; carcinoma; cancer; lung; breast; colon; rectum;
 KW bladder; liver; sarcoma; stomach; prostate; leukaemia; lymphoma;
 KW tumour suppressor; anti-APC antibody; detection; diagnosis; prognosis;
 KW genetic predisposition; drug screening; Adenomatous Polyposis Coli;
 KW APC gene; exon; PCR primer; ss.
 XX Homo sapiens.
 OS US6114124-A.
 PN 05-SEP-2000.
 XX 25-MAY-1995; 95US-0450582.
 XX 16-JAN-1991; 91GB-0000962.
 PR 16-JAN-1991; 91GB-0000963.
 PR 16-JAN-1991; 91GB-0000974.

PR 16-JAN-1991; 91GB-0000975.
 PR 08-AUG-1991; 91US-0741940.
 PR 12-AUG-1994; 94US-0289548.
 XX (ICIL) IMPERIAL CHEM IND PLC.
 PA (UYJO) UNIV JOHNS HOPKINS.
 PA (UTAH) UNIV UTAH.
 PA (CANC-) CANCER INST.
 XX Carlsson M, Groden J, Joslyn G, Kinzler K, Markham AF, Anand R;
 PI Albertsen H, White RL, Thliveris A, Nakamura Y, Vogelstein B;
 PI Hedge PJ;
 XX WPI; 2000-565003/52.
 DR Detecting Adenomatous Polyposis Coli (APC) protein in a sample for
 PT diagnosing cancers, involves contacting the sample with antibodies that
 PT specifically bind to APC protein and detecting the complex formed -
 XX Example 8; Column 31; 125pp; English.
 XX The invention relates to a novel method for detecting Adenomatous
 CC Polyposis Coli (APC) protein in a sample. The method involves
 CC contacting the sample with antibodies which specifically binds to the
 CC 2843 amino acid form of the human APC protein, or to a mutant APC
 CC protein, and detecting an APC-antibody complex. Mutations in the APC
 CC gene play a role in tumorigenesis, indicating that it is a tumour
 CC suppressor gene. It is located on chromosome 5q21, which corresponds to
 CC the FAP (familial adenomatous polyposis) locus. FAP is an autosomal
 CC dominant inherited disease in which affected individuals develop
 CC hundreds to thousands of adenomatous polyps in the colon and rectum,
 CC some of which progress to malignancy. The FAP locus is often found to
 CC be deleted in sporadic (i.e., non-familial) adenomas and carcinomas, and
 CC chromosome 5q deletions have also been observed in tumours of the lung,
 CC breast, colon, rectum, bladder, liver, sarcomas, stomach, and prostate,
 CC and in leukaemias and lymphomas. Although the FAP locus contains
 CC several other genes such as FRR, TBL1, TB2, and MCC, it is thought that
 CC mutations in the APC gene play a key role in the development of FAP and
 CC sporadic tumours. The method is useful for detecting APC protein and its
 CC mutant forms in foetal tissue, placental tissue, amniotic fluid, blood,
 CC serum or a tumour sample. The method is useful for diagnosing or
 CC prognosing neoplastic tissue, for detecting a genetic predisposition to
 CC cancer, for detecting germline and somatic alteration of wild-type APC
 CC genes, and for testing therapeutic agents for the ability to suppress
 CC tumours. Sequences AAA93490-A93499 represent PCR primers used in an
 CC exemplification of the invention to amplify exonic regions of the human
 CC SRP19 (signal recognition particle protein) gene.
 XX SQ Sequence 19 BP; 0 A; 4 C; 8 G; 7 T; 0 other;
 Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 100 ACAACCCCGAGCGCA 116
 Db 17 ACAACCCAGAGCCGCA 1
 RESULT 290
 AAA84760
 ID AAA84760 standard; DNA; 19 BP.
 XX AAA84760;
 AC AAA84760;
 XX 04-DEC-2000 (first entry)
 DT Cyclin F ribozyme binding site #28.
 DE Ribozyme; hairpin; hammerhead; gene therapy; vasotropic;
 XX restenosis; ss.
 KW Mammalia.

```

XX PN WO200032765-A2.
XX PD
XX PF
XX PR 08-JUN-2000.
XX PR 06-DEC-1999; 99WO-US28772.
XX PR 04-DEC-1998; 98US-0110954.
XX PA (IMMU-) IMMUSOL INC.
XX PI Tritz R, Welch PJ, Barber JR, Robbins JM;
XX DR WPI; 2000-412314/35.
XX PT New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
XX FT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
XX FT PCNA and Cyclin B1
XX PS Disclosure; Page 82; 109pp; English.
XX CC The present invention relates to a hairpin or hammerhead ribozyme,
XX CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
XX CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
XX CC Representative examples of ribozyme recognition sites are given in
XX CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
XX CC inhibiting restenosis by introduction of the ribozyme into cells.
XX CC The ribozyme is resistant to endonuclease activity and hence is
XX CC efficient in restenosis treatment.
XX SQ Sequence 19 BP; 3 A; 6 C; 6 G; 4 T; 0 other;
    Query Match      1.0%; Score 13.8; DB 1; Length 19;
    Best Local Similarity 88.2%; Pred. No. 2e+02;
    Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
    QY 877 GCCAAGTTCAGGAGCT 893
    Db 3 GCCAGCTTCAGGAGCT 19
RESULT 291
AAA06830/c
ID AAA06830 standard; DNA; 19 BP.
XX AC AAA06830;
XX DT 19-JUN-2000 (first entry)
XX DE Phosphorothioate oligonucleotide, SEQ ID NO:4.
XX KW Phosphorothioate, modified nucleoside; 2'-substituted;
XX KW 2'-deoxy-erythro-pentofuranosyl sugar moiety; nuclease resistant;
XX KW hybridisation; binding affinity; ss.
XX OS Synthetic.
XX FH Key
XX FT modified_base 1..19
XX FT /tag= a
XX FT /note= "Phosphorothioate linkages"
XX FT modified_base 1..3
XX FT /tag= b
XX FT /note= "Contains a 2'-O-substituent selected from
XX FT 2'-O-aminooxyethyl, 2'-O-ethylaminooxyethyl and
XX FT 2'-O-dimethylaminooxyethyl"
XX FT modified_base 18..19
XX FT /tag= c
XX FT /note= "Contains a 2'-O-substituent selected from
XX FT 2'-O-aminooxyethyl, 2'-O-ethylaminooxyethyl and
XX FT 2'-O-dimethylaminooxyethyl"
XX PN WO200008042-A1.

```

```

XX PD 17-FEB-2000.
XX PF
XX PR 09-AUG-1999; 99WO-US17988.
XX PR 07-AUG-1998; 98US-0130973.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Manoharan M, Cook PD, Prakash TP, Kawasaki AM;
XX DR WPI; 2000-224020/19.
XX PT Aminoxy-modified nucleosides and oligonucleotides useful in
XX FT diagnostic, therapeutic and research reagents and for modulating the
XX FT expression of protein in organisms -
XX PS Example 40; Page 75; 195pp; English.
XX CC The invention relates to aminoxy-modified nucleosides and
XX CC oligonucleotides and to oligonucleotides that elicit RNase H for
XX CC cleavage in a complementary nucleic acid strand. It also relates to
XX CC oligonucleotides wherein at least some of the nucleotides are
XX CC functionalised to be nuclease resistant, at least some of the
XX CC nucleotides include a substituent that potentiates hybridisation of the
XX CC oligonucleotide to a complementary strand, and at least some of the
XX CC nucleotides include a 2'-deoxy-erythro-pentofuranosyl sugar moiety. The
XX CC inclusion of one or more aminoxy moieties in such oligonucleotides
XX CC provides for improved binding of such oligonucleotides to a
XX CC complementary strand. The oligonucleotides of the invention are used as
XX CC diagnostic, therapeutic or research reagents, and can be used to modulate
XX CC gene expression in organisms. The oligonucleotides containing the
XX CC modified nucleosides have increased nuclease resistance and increased
XX CC binding affinity to a complementary strand. The present sequence
XX CC represents a phosphorothioate oligonucleotide used in an exemplification
XX CC of the present invention which has 2'-substituted regions flanking a
XX CC central region. This sequence is the complement of AAA06829.
XX SQ Sequence 19 BP; 13 A; 4 C; 2 G; 0 U; 0 other;
    Query Match      1.0%; Score 13.8; DB 1; Length 19;
    Best Local Similarity 88.2%; Pred. No. 2e+02;
    Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
    QY 1141 GCCTTTTTCCTTTTG 1157
    Db 19 GCGTTTTTTTTTTTG 3
RESULT 292
AAA23478
ID AAA23478 standard; DNA; 19 BP.
XX AC AAA23478;
XX DT 19-JUN-2000 (first entry)
XX DE Clone vc46_1 hybridisation probe, SEQ ID NO:96.
XX KW Human; secreted protein; cancer; tumour; cardiovascular disorder;
XX KW blood disorder; haemophilia; autoimmune disease; diabetes; inflammation;
XX KW infection; fungal; bacterial; viral; HIV; allergy; arthritis;
XX KW neurodegenerative disease; asthma; contraceptive; hybridisation probe;
XX KW ss.
XX OS Homo sapiens.
XX PN WO200011015-A1.
XX PD 02-MAR-2000.
XX PF 24-AUG-1999; 99WO-US19351.
XX

```

OS	Homo sapiens.
XX	WC200014198-A2.
XX	16-MAR-2000.
XX	13-AUG-1999; 99WO-US18463.
XX	02-SEP-1998; 98US-0146218.
XX	(RESE) RESEARCH CORP TECHNOLOGIES INC.
XX	Vance DE, Walkey CJ, Cui Z;
XX	WPI; 2000-256956/22.
XX	Isolated nucleic acid molecule encoding phosphatidylethanolamine
XX	N-methyltransferase protein used to treat phosphatidylethanolamine
XX	N-methyltransferase-associated disorders such as liver cancer -
XX	Example 8; Page 57; 11lpp; English.
XX	The present sequence is that of a primer used in the PCR
XX	amplification of the open reading frame of a cDNA clone (see
XX	AAZ94150) encoding human phosphatidylethanolamine N-methyltransferase
XX	(PEMT-2, see AAY73199). The PCR product was subcloned into
XX	mammalian expression vector pCI, and PEMT-2 was expressed in
XX	rat hepatoma McArdle-RH777 cells. The invention relates to
XX	novel human PEMT2 polynucleotides and protein (see AAY79199), and
XX	to methods of using them in the treatment and diagnosis of liver
XX	disorders, such as liver cancer.
XX	Sequence 19 BP; 2 A; 7 C; 7 G; 3 T; 0 Other;
XX	Query Match 1.0%; Score 13.8; DB 1; Length 19;
XX	Best Local Similarity 88.2%; Pred. NO. 2e+02;
XX	Matches 15; Conservative 0; Mismatches 2; Indels 0; Gap
XX	715 GTGGCCCGCAGCAGCGG 731
XX	18 GTAGCCCGCAGCAGCGGG 2
XX	RESULT 294
XX	AAZ48149/c
XX	ID AAZ48149 standard; DNA; 19 BP.
XX	AC AAZ48149;
XX	14-MAR-2000 (first entry)
XX	Oligonucleotide SEQ ID NO:33.
XX	Polyribonucleotide solid phase synthesis; diagnosis; hybridisation;
XX	protein production modulation; 2'-deoxyfuranosyl moiety; anti-HIV;
XX	antiartherosclerotic; nuclease resistant; atherosclerosis; AIDS;
XX	abnormal cell proliferation; tumour formation; ss.
XX	Synthetic.
XX	US6005087-A.
XX	21-DEC-1999.
XX	05-MAR-1998; 98US-0035357.
XX	06-JUN-1995; 95US-0458037.
XX	11-JAN-1990; 90US-0463358.
XX	13-AUG-1990; 90US-0566977.
XX	12-AUG-1991; 91WO-US05720.
XX	05-MAR-1992; 92US-0835932.
XX	01-JUL-1992; 92US-0854634.

PA (ISIS-) ISIS PHARM INC.
 XX Kawasaki AM, Cook PD;
 XX WPI; 2000-072074/06.
 DR Nuclease resistant oligonucleotides useful as research agents,
 PT diagnostic agents, and in the treatment of atherosclerosis and AIDS -
 PT Example 19; Column 40; 49pp; English.
 PS The present invention describes nuclease resistant oligonucleotides (I)
 CC comprising 2'-fluoro modified ribofuranosyl nucleotides. (I) comprise
 CC covalently bound nucleotides, where the nucleotides are joined together
 CC by: (a) internucleotide linkages such that the base portion of the
 CC nucleotides forms a mixed base sequence; and (b) at least one of the
 CC nucleotides includes a modified ribofuranosyl group bearing a 2'-fluoro
 CC substituent; provided that at least two of the nucleotides are 2'-fluoro
 CC modified ribofuranosyl nucleotides when the internucleotide linkages are
 CC phosphodiester nucleotides. (I) bind to their target mRNA and inhibit its
 CC expression. (I) are resistant to nuclease degradation and hybridize with
 CC appropriate strength and fidelity to its target RNA/DNA. (I) are also
 CC useful as research agents, diagnostic agents and as oligonucleotide
 CC therapeutics. (I) may be used to treat atherosclerosis following
 CC angioplasty to prevent reocclusion of the treated arteries. (I) may also
 CC be used in conjunction with AZT to treat AIDS patients. (I) have been
 CC used to modulate the expression of RAR gene, a cellular gene whose
 CC activate form has been implicated in abnormal cell proliferation and
 CC tumour formation. (I) are also used to modulate the expression of protein
 CC kinase C. (I) exhibit hybridisation properties of higher quality than
 CC phosphorous modified oligonucleotide duplexes containing
 CC methylphosphonates, phosphoranidates and phosphate triesters. The present
 CC sequence represent an oligonucleotide used in the exemplification of the
 CC present invention.
 XX
 SQ Sequence 19 BP; 13 A; 4 C; 2 G; 0 U; 0 other;
 Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 1141 GCCTTTTCTTTTCTTTG 1157
 Db |||||
 19 GCGTTTCTTTTCTTTG 3
 RESULT 295
 AAS11124/c
 ID AAS11124 standard; DNA; 19 BP.
 AC AAS11124;
 XX
 DT 24-OCT-2001 (first entry)
 XX Bacterial 16s RNA antisense oligomer #90.
 DE Antisense; bacterial 16s ribosomal RNA; rRNA; bacterial infection;
 KW human; food grain supplement; livestock; poultry; therapeutic; ss.
 XX Enterococcus faecium.
 OS WO200142457-A2.
 XX
 FN 14-JUN-2001.
 PD 29-NOV-2000; 2000WO-US42391.
 PF 29-NOV-1999; 99US-0168150.
 PR (AVIB-) AVI BIOPHARMA INC.
 PA Iversen PL;
 PI
 XX

DR WPI; 2001-457295/49.
 XX Antibacterial compound, useful for treating bacterial infections and as
 PT livestock and poultry food supplement, comprises antisense
 PT oligonucleotides complementary to bacterial 16S and 23S rRNA -
 XX Disclosure; Page 35; 62pp; English.
 PS AAS11035-AAS11157 represent the coding sequences of bacterial 16S
 CC ribosomal RNA (rRNA) antisense oligomers. These sequences are
 CC antibacterial compounds comprising substantially uncharged antisense
 CC oligomers containing 8-40 nucleotide subunits, including a targeting
 CC nucleic acid sequence at least 10 nucleotides in length which is
 CC complementary to a bacterial 16S or 23S rRNA nucleic acid sequence.
 CC The antisense oligomers are used for treating a bacterial infection
 CC in a human or a mammalian animal produced by Escherichia coli, Salmonella
 CC typhimurium, Pseudomonas aeruginosa, Vibrio cholera, Neisseria
 CC gonorrhoea, Helicobacter pylori, Bartonella henselae, Haemophilus
 CC influenza, Shigella dysenteriae, Staphylococcus aureus, Mycobacterium
 CC tuberculosis, Streptococcus pneumoniae, Treponema pallidum and Chlamydia
 CC trachomatis. The antibacterial compound may be used as a food grain
 CC supplement in livestock and poultry food composition.
 XX Sequence 19 BP; 4 A; 5 C; 8 G; 2 T; 0 other;
 SQ Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 Qy 685 TTTGGGAGCCAGCGGCC 701
 Db |||||
 17 TTTGGGAGCCAGCGGCC 1
 RESULT 296
 AAS11035
 ID AAS11035 standard; DNA; 19 BP.
 AC AAS11035;
 XX
 DT 10-SEP-2001 (first entry)
 XX Cyclin F ribozyme binding site SEQ ID NO:2346.
 DE Human; ribozyme therapy; hairpin ribozyme; hammerhead ribozyme;
 KW recognition site; target; ribozyme binding site; eye disease; vulvarry;
 KW proliferative disease; skin disease; psoriasis; diabetic retinopathy;
 KW cytokine; inflammation; cell-cycle dependent kinase; cyclin; MMP;
 KW matrix metalloproteinase; growth factor; reductase; scarring; cytostatic;
 KW antiproliferative; dermatological; antiseborrheic; antidiabetic; virucide;
 KW antiscaling; ophthalmological; keratolytic; gene therapy; viral wart;
 KW atopic dermatitis; actinic keratosis; squamous cell carcinoma;
 KW basal cell carcinoma; seborrheic wart; vitreoretinopathy; scar;
 KW sickle cell retinopathy; ss.
 XX Homo sapiens.
 OS Synthetic.
 XX WO200130362-A2.
 FN 03-MAY-2001.
 PD 26-OCT-2000; 2000WO-US29500.
 PF 26-OCT-1999; 99US-0161532.
 PR (INMU-) INMUSOL INC.
 PA Robbins JM, Tritz R;
 PI WPI; 2001-300427/31.
 DR Treating proliferative skin or eye diseases and scarring, using
 XX

PT ribozymes that cleave RNA encoding cytokines involved in inflammation,
 PT matrix metalloproteinases, growth factors and cell-cycle dependent
 XX kinases -
 XX
 PS Example 1; Page 242; 408pp; English.
 XX
 CC The present invention describes a method for treating a proliferative
 CC skin or eye disease and scarring. The method involves administering a
 CC ribozyme (I) which cleaves RNA encoding a cytokine involved in
 CC inflammation, matrix metalloproteinase (MMP), cyclin, cell-cycle
 CC dependent kinase, growth factor or a reductase, or administering a
 CC nucleic acid molecule (II) comprising a promoter operably linked to a
 CC nucleic acid segment encoding (I). (I) can have antiproliferative,
 CC dermatological, cytostatic, antiseborrheic, antidiabetic, antiscikling,
 CC ophthalmological, vulnary, keratolytic and virucide activities, and
 CC cleaves RNA encoding cytokine involved in inflammation. (I) can be used
 CC in gene therapy. (I) and (II) are useful for treating proliferative
 CC skin diseases such as psoriasis, atopic dermatitis, actinic keratosis,
 CC squamous or basal cell carcinoma and viral or seborrheic wart. They can
 CC also be used for treating proliferative eye diseases such as diabetic
 CC retinopathy, vitreoretinopathy, sickle cell retinopathy, retinopathy of
 CC prematurity and retinal detachment, and for treating and preventing
 CC scarring such as keloid, adhesion and hypertrophic or hypertrophic burn
 CC scar. AAH57577 to AAH62099 represent sequences used in the
 CC exemplification of the present invention.

XX Sequence 19 BP; 3 A; 6 C; 6 G; 4 T; 0 other;
 SQ Query Match 1.0%; Score 13.8; DB 1; Length 19;
 Best Local Similarity 88.2%; Pred. No. 2e+02; Indels 0; Gaps 0;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 877 GCCAAGTTCAGGAGCT 893
 ||||| ||||| ||||| |||||
 Db 3 GCCAGCTTCAGGAGCT 19

RESULT 297

ABS67159/c
 ID ABS67159 standard; DNA; 19 BP.

XX ABS67159;

XX 29-NOV-2002 (first entry)

DE DP1, SRP19, DP25 gene SSCP primer #11.

KW Adenomatous polyposis coli; APC; human; neoplastic tissue;
 KW mutation detection; tumour; cancer;
 KW single stranded conformational polymorphism; primer; ss.

XX Homo sapiens.

XX US6413727-B1.

XX 02-JUL-2002.

XX 25-MAY-1995; 95US-0449731.

XX 16-JAN-1991; 91GB-0000962.

XX 16-JAN-1991; 91GB-0000963.

XX 16-JAN-1991; 91GB-0000974.

XX 08-AUG-1991; 91GB-0000975.

XX 12-AUG-1994; 91US-0741940.

XX 12-AUG-1994; 94US-0289548.

PA (UJJO) UNIV JOHNS HOPKINS.

PA (UTAH) UNIV UTAH.

PA (NICA-) JAPANESE FOUND CANCER RES.

PA (ZENE) ZENECA LTD.

XX Albertsen H, Anand R, Carlson M, Groden J, Hedge PJ, Joslyn G;

PI Kinzler K, Markham AF, Nakamura Y, Thliveris A, Vogelstein B;

PI White RL;

XX WPI; 2002-641559/69.

XX Method to aid in the diagnosis/prognosis of neoplastic tissues in
 PT humans, by detecting somatic alteration of wild-type APC protein in
 PT tumor tissue isolated from human, the alteration indicating neoplasia
 XX of the tissue -

PS Example 15; Column 31-32; 140pp; English.

XX This invention relates to a novel method to aid in the diagnosis or
 CC prognosis of a neoplastic tissue of a human. The method involves
 CC detecting somatic alteration of wild-type adenomatous polyposis coli
 CC protein in a tumour tissue isolated from a human (the alteration
 CC indicating neoplasia of the tissue). The method of the invention
 CC is useful in diagnosis or prognosis of a neoplastic tissue of a human.
 CC The method is useful in detection of genetic predisposition to cancer.
 CC The present sequence represents a DNA sequence used in the method
 CC of the invention

XX Sequence 19 BP; 0 A; 4 C; 8 G; 7 T; 0 other;

XX Query Match 1.0%; Score 13.8; DB 1; Length 19;

XX Best Local Similarity 88.2%; Pred. No. 2e+02; Indels 0; Gaps 0;

XX Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 100 ACAACCCCGGAGCGCA 116

||||| ||||| ||||| |||||
 Db 17 ACAACCCCGGAGCGCA 1

RESULT 298

ABA81571

ID ABA81571 standard; DNA; 15 BP.

XX ABA81571;

XX 24-JAN-2002 (first entry)

DE Human phospholipid transfer protein gene ASO probe SEQ ID NO: 20.

KW Human; phospholipid transfer protein; PLTP; SNP; atherosclerosis;
 KW single nucleotide polymorphism; high-density lipoprotein metabolism;
 KW allele-specific oligonucleotide; probe; ss.

XX Homo sapiens.

XX WO200172761-A2.

XX 04-OCT-2001.

XX 15-MAR-2001; 2001WO-US08283.

XX 24-MAR-2000; 2000US-192127P.

XX (GENA-) GENAISSANCE PHARM INC.

XX Chew A, Choi JY, Koshiy B;

XX WPI; 2001-662922/76.

XX Genotyping phospholipid transfer protein gene of individual for
 PT haplotyping individual's gene, comprises determining identity of
 PT nucleotide pair at polymorphic sites for two copies of PLTP gene
 PT present in the individual -

XX Claim 15; Page 13; 98pp; English.

XX The present invention relates to a method for haplotyping the human
 CC phospholipid transfer protein (PLTP) gene, involving determining the
 CC identity of the nucleotide present at one or more of the 25 polymorphic
 CC sites within the gene. This can be used to aid drug development for the

CC treatment of diseases associated with different haplotypes of the PLTP
 CC gene, possibly including atherosclerosis. The present sequence is an
 CC allele-specific probe used for detecting polymorphisms in the PLTP gene.

XX SQ Sequence 15 BP; 6 A; 2 C; 5 G; 1 T; 1 other;

Query Match 1.0%; Score 13.6; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.6e+02;
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 918 AAAGGAGATGGCAG 931
 |||||:|||||
 Db 2 AAAGGARATGGCAG 15

RESULT 299

ABL91860
 ID ABL91860 standard; DNA; 15 BP.

XX AC ABL91860;

XX DT 11-JUL-2002 (first entry)

XX DE Human LIPG gene allele specific oligonucleotide primer 39.

XX KW Human; ss; allele specific oligonucleotide; primer;
 KW single nucleotide polymorphism; SNP; lipase endothelial isogene; LIPG;
 KW drug screening; atherosclerosis; cardiovascular disorder;
 KW LIPG haplotyping; LIPG genotyping.

XX OS Homo sapiens.

XX PN WO200216397-A2.

XX PD 28-FEB-2002.

XX PF 17-AUG-2001; 2001WO-US26639.

XX PR 25-AUG-2000; 2000US-227825P.

XX PA (GENA-) GENAISSANCE PHARM INC.

XX PI Duda A, Kazemi A, Kliem SE, Messer C;

XX DR WPI; 2002-292055/33.

XX PT Novel genetic variants of Lipase, Endothelial isogenes, useful for
 PT improving efficiency and reliability in drug development for treating
 PT diseases associated with LIPG activity, e.g. atherosclerosis

XX PS Claim 16; Page 14; 134pp; English.

XX CC The invention comprises the DNA and amino acid sequence of the human
 CC lipase, endothelial (LIPG) isogene. Specifically, the invention relates
 CC to the discovery of 20 novel polymorphic sites within the LIPG gene. The
 CC LIPG coding sequence and protein are useful for screening drugs that can
 CC be used to treat atherosclerosis and other cardiovascular disorders. The
 CC LIPG coding sequence can also be used to haplotype and genotype the LIPG
 CC gene of an individual. The DNA sequences ABL91822 - ABL91861 represent
 CC LIPG gene allele specific oligonucleotide primers.

XX SQ Sequence 15 BP; 1 A; 4 C; 7 G; 2 T; 1 other;

Query Match 1.0%; Score 13.6; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.6e+02;
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 534 GCAGCTGGGTGCC 547
 |||||:|||||
 Db 1 GCAGCTGGGTGCC 14

RESULT 300

AAS94583

ID AAS94583 standard; DNA; 15 BP.

XX AC AAS94583;

XX DT 14-FEB-2002 (first entry)

XX DE Human PLTP gene allele-specific oligonucleotide probe #17.

XX KW Human; phospholipid transfer protein; PLTP; haplotyping; haplotype pair;
 KW single nucleotide polymorphism; genotyping; gene therapy; drug screening;
 KW binding affinity; atherosclerosis; ss; sequencing primer; PCR primer;
 KW probe.

XX OS Homo sapiens.

XX PN WO200172966-A2.

XX PD 04-OCT-2001.

XX PF 26-MAR-2001; 2001WO-US09776.

XX PR 24-MAR-2000; 2000US-192127P.

XX PA (GENA-) GENAISSANCE PHARM INC.

XX PI Chew A, Choi JY, Koshy B;

XX DR WPI; 2002-010724/01.

XX PT New isolated polynucleotide which is polymorphic variant of
 PT phospholipid transfer protein (PLTP) gene, having any one of
 PT polymorphic sites PSI-PS25, for studying function of PLTP, and
 PT expressing PLTP protein

XX PS Claim 15; Page 70; 99pp; English.

XX CC The invention relates to single nucleotide polymorphisms in the gene
 CC encoding the human phospholipid transfer protein (PLTP). A method for
 CC haplotyping the PLTP gene in an individual comprises identifying the
 CC nucleotide at one or more polymorphic sites and determining whether one
 CC of the copies of the gene is defined by one of the PLTP haplotypes given
 CC in the specification or whether both copies are defined by a haplotype
 CC pair. This method is useful in genotyping, whereby all possible haplotype
 CC pairs can be assigned to specific genotypes. An association between a
 CC trait and a haplotype or haplotype pair of the PLTP gene can be
 CC identified by comparing the frequency of the haplotype or haplotype pair
 CC in a population exhibiting the trait with the frequency of the haplotype
 CC or haplotype pair in a reference population, where a higher haplotype
 CC frequency in the trait population indicates the trait is associated with
 CC the haplotype or haplotype pair. PLTP and its corresponding DNA are used
 CC for studying the expression and function of PLTP, for use in screening
 CC for candidate drugs to treat diseases related to PLTP activity. The
 CC sequences are also useful for studying the effect of variation on the
 CC biological activity of PLTP as well as on the binding affinity of
 CC candidate drugs targeting PLTP for treating atherosclerosis. Sequences
 CC AAS94586-AAS94691 represent allele-specific oligonucleotide probes,
 CC sequencing primers and PCR primers used for detecting PLTP gene
 CC polymorphisms.

XX SQ Sequence 15 BP; 6 A; 2 C; 5 G; 1 T; 1 other;

Query Match 1.0%; Score 13.6; DB 1; Length 15;
 Best Local Similarity 92.9%; Pred. No. 1.6e+02;
 Matches 13; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 918 AAAGGAGATGGCAG 931
 |||||:|||||
 Db 2 AAAGGARATGGCAG 15

RESULT 301
AAC67429

ID AC AC67429 standard; DNA; 21 BP.
 AC AC67429;
 XX
 DT 14-FEB-2001 (first entry)
 XX
 DE Alzheimer's disease-linked mitochondrial SNP PCR primer #129.
 XX
 KW Human; mitochondrial genome; single nucleotide polymorphism; SNP;
 KW Alzheimer's disease; mtDNA; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200063441-A2.
 XX
 PD 26-OCT-2000.
 XX
 PF 19-APR-2000; 200WO-US10906.
 XX
 PR 20-APR-1999; 99US-0130447.
 PR 22-OCT-1999; 99US-0160901.
 XX
 PA (MITO-) MITOKOR.
 XX
 PI Herrnstadt C, Davis RE;
 XX
 DR WPI; 2000-672748/65.
 XX
 PT Diagnosing a subject at the risk for or having Alzheimer's disease
 PT comprises determining at least one single nucleotide polymorphism in
 PT mitochondrial DNA associated with the disease in the sample from the
 PT subject -
 XX
 PS Example 4; Page 40; 89pp; English.
 XX
 CC The present invention describes a novel method for determining the risk
 CC of or diagnosing Alzheimer's disease using single nucleotide
 CC polymorphisms (SNPs) present in an individual's mitochondrial DNA
 CC (mtDNA). In addition, the SNPs identified can be used to identify agents
 CC suitable for use in treating Alzheimer's disease. Sequences
 CC AAC67301-C67610 are PCR primers used to demonstrate the method of the
 CC invention.
 XX
 SQ Sequence 21 BP; 5 A; 2 C; 8 G; 6 T; 0 other;
 Query Match 1.0%; Score 13.6; DB 1; Length 21;
 Best Local Similarity 80.0%; Pred. No. 2.5e+02;
 Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Qy 268 TGGCTGATCAAGAGGAGC 287
 Db 2 TGGCTGATCAAGAGGATGC 21
 RESULT 302
 AAZ57277
 ID AAZ57277 standard; DNA; 21 BP.
 XX
 AC AAZ57277;
 XX
 DT 30-MAR-2000 (first entry)
 XX
 DE Human mitochondrial DNA NADH dehydrogenase PCR primer SEQ ID NO:76.
 XX
 KW Human; mitochondrial DNA; extramitochondrial DNA; mtDNA; exmtDNA;
 KW diagnosis; quantification; detection; dystonia; Alzheimer's disease;
 KW Huntington's disease; Parkinson's disease; schizophrenia; stroke;
 KW non-insulin dependent diabetes mellitus; mitochondrial encephalopathy;
 KW lactic acidosis; myoclonic epilepsy ragged red fibre syndrome;
 KW Leber's hereditary optic neuropathy; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX

PN WO9966075-A2.
 XX
 PD 23-DEC-1999.
 XX
 PF 14-JUN-1999; 99WO-US13426.
 XX
 PR 15-JUN-1998; 98US-0097889.
 PR 15-JUN-1998; 98US-0098079.
 PR 30-APR-1999; 99US-0302681.
 XX
 PA (MITO-) MITOKOR.
 XX
 PI Herrnstadt C, Ghosh SS, Clevenger W, Fahy ED, Davis RE;
 XX
 DR WPI; 2000-097754/08.
 XX
 PT Quantification of extramitochondrial DNA for diagnosis of, e.g.
 PT Alzheimer's, Huntington's and Parkinson's disease -
 XX
 PS Disclosure; Page 32; 157pp; English.
 XX
 CC The present invention describes a method for the quantification of
 CC extramitochondrial DNA (exmtDNA) by determining the ratio of a first
 CC and second biological sample containing exmtDNA and mitochondrial DNA
 CC (mtDNA) to determine the risk or presence of a disease associated with
 CC altered mitochondrial function. The method can be used to determine
 CC the risk of or presence of a disease associated with altered
 CC mitochondrial function, especially Alzheimer's disease, Huntington's
 CC disease, Parkinson's disease, dystonia, schizophrenia, non-insulin
 CC dependent diabetes mellitus, mitochondrial encephalopathy, lactic
 CC acidosis, stroke, myoclonic epilepsy ragged red fibre syndrome and
 CC Leber's hereditary optic neuropathy. The method can also be used to
 CC identify agents suitable for treating such diseases, in particular
 CC Alzheimer's disease. AAZ57202 to AAZ57313 represent nucleotide sequences
 CC used in the exemplification of the present invention. More specifically
 CC AAZ57206 to AAZ57313 are PCR primers used in the detection of exmtDNA
 CC and mtDNA.
 XX
 SQ Sequence 21 BP; 5 A; 2 C; 8 G; 6 T; 0 other;
 Query Match 1.0%; Score 13.6; DB 1; Length 21;
 Best Local Similarity 80.0%; Pred. No. 2.5e+02;
 Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 Qy 268 TGGCTGATCAAGAGGAGC 287
 Db 2 TGGCTGATCAAGAGGATGC 21
 RESULT 303
 AAX18364
 ID AAX18364 standard; DNA; 15 BP.
 XX
 AC AAX18364;
 XX
 DT 11-MAY-1999 (first entry)
 XX
 DE RT-PCR primer of the invention SEQ ID 5.
 XX
 KW RT-PCR primer; DNA sequence determination; gene sequence analysis; ss.
 XX
 OS Synthetic.
 XX
 PN JP11032765-A.
 XX
 PD 09-FEB-1999.
 XX
 PF 18-JUL-1997; 97JP-0208312.
 XX
 PR 18-JUL-1997; 97JP-0208312.
 XX
 PA (TAKI) TAKARA SHUZO CO LTD.
 XX

DR WPI; 1999-183822/16.
 XX Peptides having at least two new nucleotides - useful as primers in
 PT RT-PCR
 XX
 PS Disclosure; Page 10; 19pp; Japanese.
 XX
 CC This sequence represents a primer of the invention. The invention relates
 CC to sequences of at least two nucleotides of formula:
 CC (X)m5'-(alpha)n-beta-N3'; or (X)m5'-(gamma)k-delta-N3'; where
 CC X = a labelled compound and/or a nucleotide with voluntary sequence;
 CC m = 0 or 1; alpha = thymine; n = natural number indicating the repetition
 CC of alpha; beta, delta = V or N; V = adenine, guanine or cytosine;
 CC N = adenine, guanine, cytosine or thymine; gamma = thymine;
 CC k = natural number of 3 or over indicating the repetition of gamma, in
 CC which thymine expressed by gamma is composed of 1/3 or less of adenine,
 CC guanine and/or cytosine. The new nucleotides are useful as primers for
 CC RT-PCR and determination of base sequences. The new sequences allow for
 CC reproductive and highly efficient analysis of gene sequences.
 XX
 SQ Sequence 15 BP; 0 A; 0 C; 2 G; 13 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1144 TTTTTCCTTTTGG 1158
 DB 1 TTTTTCCTTTTGG 15
 RESULT 304
 AAF95031
 ID AAF95031 standard; DNA; 15 BP.
 AC AAF95031;
 XX
 DT 23-MAY-2001 (first entry)
 XX
 DE Mutant capture oligonucleotide #24.
 XX
 KW Tubercle bacillus; drug sensitivity; drug resistance; rifampicin;
 KW streptomycin; kanamycin; isoniazid; ethambutol; rpoB gene; rrs gene;
 KW rpsL gene; inhA gene; katG gene; embB gene; probe; PCR primer; ss.
 XX
 OS Mycobacterium tuberculosis.
 XX
 PN EP1076099-A2.
 XX
 PD 14-FEB-2001.
 XX
 PF 02-AUG-2000; 2000EP-0306563.
 XX
 PR 03-AUG-1999; 95JP-0220357.
 XX
 PA (NISON) NISSHINBO IND INC.
 PA (SYST-) SYSTEM RES INC.
 XX
 PI Suzuki Y, Nishida M, Takenishi S;
 XX
 DR WPI; 2001-246696/26.
 XX
 PT New oligonucleotides, nucleic acid probes and primers are useful for
 PT differentiating drug-resistance and determining infection with tubercle
 PT bacilli -
 XX
 PS Claim 10; Page 25; 114pp; English.
 XX
 CC The present invention relates to oligonucleotides based on nucleotide
 CC sequences obtained from both wild-type tubercle bacilli (wtTB) that are
 CC susceptible to a drug and mutant-type tubercle bacilli (mtTB) that are
 CC resistant to a drug. The drugs used in the present invention are
 CC rifampicin (RFP), streptomycin (SM), kanamycin (KM), isoniazid (INH) and

CC ethambutol (EB). The rpoB gene is responsible for resistance to RFP; the
 CC rrs gene is responsible for resistance to SM and KM; the rpsL gene is
 CC responsible for resistance to SM; the inhA gene is responsible for
 CC resistance to INH; the katG gene is responsible for resistance to INH;
 CC and the embB gene is responsible for resistance to EB. The present
 CC invention also relates to nucleic acid probes having part of a nucleotide
 CC sequence of tubercle bacilli (TB) responsible for drug resistance and
 CC primers used to generate the probes. The present sequence is an
 CC oligonucleotide of the present invention. The oligonucleotides of the
 CC present invention can be used to enable the differentiation of drug
 CC resistance and the determination of infection with tubercle bacilli
 CC simultaneously.
 XX
 SQ Sequence 15 BP; 3 A; 5 C; 5 G; 2 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 885 CCAGGAGCTGCGTA 899
 DB 1 CCAGGAGCTGCGTA 15
 RESULT 305
 AAF45161
 ID AAF45161 standard; RNA; 15 BP.
 AC AAF45161;
 XX
 DT 30-MAR-2001 (first entry)
 XX
 DE Antisense oligonucleotide #10.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WC200078341-A1.
 XX
 PD 28-DEC-2000.
 XX
 PF 21-JUN-2000; 2000WO-AU00693.
 XX
 PR 21-JUN-1999; 99US-0140345.
 XX
 PA (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 PI Wraight CJ, Werther GA, Edmondson SR;
 XX
 DR WPI; 2001-041421/05.
 XX
 PT Ameliorating the effects of a disorder, e.g. psoriasis, by
 PT administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -
 XX
 PS Claim 15; Page 115; 201pp; English.
 XX
 CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is one such
 CC antisense oligonucleotide. The method is useful for ameliorating the

CC effects of psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea,
 CC keloids, keratosis, neoplasias, scleroderma, warts, benign growths,
 CC cancers of the skin, a hyperneovascular condition such as a neovascular
 CC condition of the retina, brain or skin, growth factor-mediated
 CC malignancies, other sclerotic disease, kidney disease, hyperproliferation
 CC of the inside of blood vessels or any other hyperplasia.
 XX
 SQ Sequence 15 BP; 4 A; 5 C; 6 G; 0 U; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 552 GGCAGGCGATGCACAC 566
 |||||
 Db 1 GGCAGGCGAGGCAC 15

RESULT 306
 AAF46436/C
 ID AAF46436 standard; DNA; 15 BP.

XX AC AAF46436;

XX DT 30-MAR-2001 (first entry)

XX DE IGFBP2 oligonucleotide #1275.

XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

XX OS Homo sapiens.

XX PN WO200078341-A1.

XX PD 28-DEC-2000.

XX PF 21-JUN-2000; 2000WO-AU00693.

XX PR 21-JUN-1999; 99US-0140345.

XX PA (MURD-) MURDOCH CHILDRENS RES INST.

XX PI Wraight CJ, Werther GA, Edmondson SR;

XX DR WPI; 2001-041421/05.

XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by
 PT administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -

XX PS Example 6; Page 42; 201pp; English.

XX CC The present invention relates to a method for ameliorating the effects
 CC of skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and
 CC AAF45153-F45161). The method is useful for ameliorating the effects of
 CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids,
 CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
 CC skin, a hyperneovascular condition such as a neovascular condition of the
 CC retina, brain or skin, growth factor-mediated malignancies, other

CC sclerotic disease, kidney disease, hyperproliferation of the inside of
 CC blood vessels or any other hyperplasia.

XX SQ Sequence 15 BP; 3 A; 5 C; 4 G; 3 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 239 CATCTGCATCTGGGA 253
 |||||
 Db 15 CATCTGCAGCTGGGA 1

RESULT 307
 AAF46437/C
 ID AAF46437 standard; DNA; 15 BP.

XX AC AAF46437;

XX DT 30-MAR-2001 (first entry)

XX DE IGFBP2 oligonucleotide #1276.

XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

XX OS Homo sapiens.

XX PN WO200078341-A1.

XX PD 28-DEC-2000.

XX PF 21-JUN-2000; 2000WO-AU00693.

XX PR 21-JUN-1999; 99US-0140345.

XX PA (MURD-) MURDOCH CHILDRENS RES INST.

XX PI Wraight CJ, Werther GA, Edmondson SR;

XX DR WPI; 2001-041421/05.

XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by
 PT administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -

XX PS Example 6; Page 42; 201pp; English.

XX CC The present invention relates to a method for ameliorating the effects
 CC of skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and
 CC AAF45153-F45161). The method is useful for ameliorating the effects of
 CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids,
 CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
 CC skin, a hyperneovascular condition such as a neovascular condition of the
 CC retina, brain or skin, growth factor-mediated malignancies, other
 CC sclerotic disease, kidney disease, hyperproliferation of the inside of
 CC blood vessels or any other hyperplasia.

XX SQ Sequence 15 BP; 3 A; 6 C; 4 G; 2 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 238 GCATCTGCATCTGGG 252
DB 15 GCATCTGCATCTGGG 1

RESULT 308
AAF46438/c
ID AAF46438 standard; DNA; 15 BP.

XX AAF46438;
XX
DT 30-MAR-2001 (first entry)
DE IGFBP2 oligonucleotide #1277.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.

XX Homo sapiens.
XX WO200078341-A1.
XX 28-DEC-2000.

XX 21-JUN-2000; 2000WO-AU00693.
XX 21-JUN-1999; 99US-0140345.
XX (MURD-) MURDOCH CHILDRENS RES INST.

PI Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX Ameliorating the effects of a disorder, e.g. psoriasis, by
XX administering UV (ultra-violet) treatment (optional) and an antisense
XX nucleic acid that inhibits or reduces growth factor mediated cell
XX proliferation and/or inflammation -
XX Example 6; Page 42; 201pp; English.

XX The present invention relates to a method for ameliorating the effects
XX of skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and
XX AAF45153-F45161). The method is useful for ameliorating the effects of
XX psoriasis, ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids,
XX keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
XX skin, a hyperneovascular condition such as a neovascular condition of the
XX retina, brain or skin, growth factor-mediated malignancies, other
XX sclerotic disease, kidney disease, hyperproliferation of the inside of
XX blood vessels or any other hyperplasia.

SQ Sequence 15 BP; 3 A; 6 C; 4 G; 2 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 237 GCATCTGCATCTGG 251
DB 15 GCATCTGCATCTGG 1

RESULT 309
AAF46503
ID AAF46503 standard; DNA; 15 BP.

XX AAF46503;
XX
DT 30-MAR-2001 (first entry)
DE IGFBP2 oligonucleotide #1342.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
XX cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
XX skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
XX growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
XX hyperneovascular condition; hyperplasia; kidney disease;
XX neovascular condition of the retina; ss.

XX Homo sapiens.
XX WO200078341-A1.
XX 28-DEC-2000.

XX 21-JUN-2000; 2000WO-AU00693.
XX 21-JUN-1999; 99US-0140345.
XX (MURD-) MURDOCH CHILDRENS RES INST.

PI Wright CJ, Werther GA, Edmondson SR;
XX WPI; 2001-041421/05.
XX Ameliorating the effects of a disorder, e.g. psoriasis, by
XX administering UV (ultra-violet) treatment (optional) and an antisense
XX nucleic acid that inhibits or reduces growth factor mediated cell
XX proliferation and/or inflammation -
XX Example 6; Page 42; 201pp; English.

XX The present invention relates to a method for ameliorating the effects
XX of skin disorders. The method comprises contacting the skin with an
XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
XX inhibiting or reducing growth factor mediated cell proliferation,
XX inflammation and/or other disorders. The present sequence is an
XX oligonucleotide which can be used to design the antisense
XX oligonucleotides of the present invention (see AAF45151 and
XX AAF45153-F45161). The method is useful for ameliorating the effects of
XX psoriasis, ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids,
XX keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
XX skin, a hyperneovascular condition such as a neovascular condition of the
XX retina, brain or skin, growth factor-mediated malignancies, other
XX sclerotic disease, kidney disease, hyperproliferation of the inside of
XX blood vessels or any other hyperplasia.

SQ Sequence 15 BP; 3 A; 2 C; 8 G; 2 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 888 GGAGCTGCGGTACAG 902
DB 1 GGAGCTGCGGTACAG 15

```

RESULT 310
AAF49863/c
ID AAF49863 standard; DNA; 15 BP.
XX
XX
AC AAF49863;
XX
XX
DT 30-MAR-2001 (first entry)
XX
XX
DE IGF-I oligonucleotide #823.
XX
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
FN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CU, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 8; Page 66; 20pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 0 A; 5 C; 5 G; 5 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 553 GCAGGCATGCACACA 567
Db 15 GCAGGCAGGCACACA 1
|||||
|||||

RESULT 311
AAF49864/c
ID AAF49864 standard; DNA; 15 BP.
XX
XX
AC AAF49864;
XX
XX
DT 30-MAR-2001 (first entry)
XX
XX
DE IGF-I oligonucleotide #824.
XX
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
FN WO200078341-A1.
XX
PD 28-DEC-2000.
XX
PF 21-JUN-2000; 2000WO-AU00693.
XX
PR 21-JUN-1999; 99US-0140345.
XX
PA (MURD-) MURDOCH CHILDRENS RES INST.
XX
PI Wright CU, Werther GA, Edmondson SR;
XX
DR WPI; 2001-041421/05.
XX
PT Ameliorating the effects of a disorder, e.g. psoriasis, by
PT administering UV (ultra-violet) treatment (optional) and an antisense
PT nucleic acid that inhibits or reduces growth factor mediated cell
PT proliferation and/or inflammation -
XX
PS Example 8; Page 66; 20pp; English.
XX
CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF45151 and
CC AAF45153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 0 A; 5 C; 5 G; 5 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 15;
Best Local Similarity 93.3%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 552 GCAGGCATGCACACA 566
Db 15 GCAGGCAGGCACACA 1
|||||
|||||

RESULT 312
AAF51703/c
ID AAF51703 standard; DNA; 15 BP.
XX
XX
AC AAF51703;
XX
XX

```

DT 30-MAR-2001 (first entry)
 DE IGF-1 oligonucleotide #2663.
 XX
 KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytosolic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP-3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200078341-A1.
 XX
 XX 28-DEC-2000.
 XX
 XX 21-JUN-2000; 2000WO-AU00693.
 XX
 XX 21-JUN-1999; 99US-0140345.
 XX
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 XX
 XX Wright CJ, Werther GA, Edmondson SR;
 XX
 XX WPI; 2001-041421/05.
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by
 PT administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -
 XX
 XX Example 8; Page 78; 201pp; English.
 XX
 XX The present invention relates to a method for ameliorating the effects
 CC of skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP-3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAP45151 and
 CC AAP45153-45161). The method is useful for ameliorating the effects of
 CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids,
 CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
 CC retina, brain or skin, growth factor-mediated malignancies, other
 CC sclerotic disease, kidney disease, hyperproliferation of the inside of
 CC blood vessels or any other hyperplasia.
 XX
 SQ Sequence 15 BP; 4 A; 2 C; 6 G; 3 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 158 CGCGCTGATCTCTCAA 172
 Db 15 CTCGCTGATCTCTCAA 1
 RESULT 313
 ABS97176/c
 ID ABS97176 standard; DNA; 15 BP.
 XX
 AC ABS97176;
 XX
 DT 23-DEC-2002 (first entry)
 XX
 DE Human CYP4501A2 Exon 4 and 5 sequencing primer #4.
 XX

Human; ss; primer; cytochrome P450 A1; CYP4501A1; UGT2B4; MDR1;
 cytochrome P450 A2; CYP4501A2; cytochrome P450 02E; CYP45002E1; LTF;
 adrenergic receptor beta1; ADRB1; aryl hydrocarbon; AHR; MRP3; NR112;
 aryl hydrocarbon receptor nuclear translocator; ARNT; cathepsin S; CTSS;
 cyclooxygenase 2; COX2; diazepam binding inhibitor; DBI; haematological;
 epoxide hydrolase 2; EPHX2; 5-lipoxygenase activating protein; FLAP;
 glutathione-S-transferase 12; GST12; histamine-N-methyl transferase;
 HNMT; kallikrein 2; KLK2; nicotinamide-N-methyl transferase; NNMT;
 NADPH quinone oxidoreductase 2; NQO2; sulfoltransferase thermolabile;
 STM; UDP-glucuronosyl transferase 2B4; UDP-glucuronosyl transferase 2B7;
 UGT2B7; UDP-glucuronosyl transferase; UGT2B15; urokinase receptor; uPA;
 multidrug resistance 1; lactotransferrin; orphan nuclear receptor;
 multidrug resistance associated protein 3; cancer; prostate;
 acetylcholine muscarinic receptor; CHMR1; CHMR2; CHMR3; CHMR4; CHMR5;
 altered drug metabolism; cardiovascular function; colorectal tumour;
 central nervous system; pulmonary; immunological; sequencing.
 Homo sapiens.
 WO200257410-A2.
 25-JUL-2002.
 28-NOV-2001; 2001WO-US44838.
 28-NOV-2000; 2000US-0724389.
 (DNAS-) DNA SCI LAB INC.
 Guida M, Hall J;
 WPI; 2002-698522/75.
 Isolated nucleic acid molecules having polymorphisms in known human
 genes e.g. cytochrome p450 and cathepsin S useful as genetic linkage
 markers for locating, identifying and characterizing the genes
 responsible for disorder-related traits -
 Example 2; Page 101; 714pp; English.
 This invention relates to the sequence of an isolated nucleic acid
 molecule comprising at least one base variation from that of a known
 human cytochrome P450 A1 (CYP4501A1), cytochrome P450 A2 (CYP4501A2),
 cytochrome P450 02E1 (CYP45002E1), adrenergic receptor beta1 (ADBR1),
 aryl hydrocarbon (AHR), aryl hydrocarbon receptor nuclear translocator
 (ARNT), cathepsin S (CTSS), cyclooxygenase 2 (COX2), diazepam binding
 inhibitor (DBI), epoxide hydrolase 2 (EPHX2), 5-lipoxygenase
 activating protein (FLAP), glutathione-S-transferase 12 (GST12),
 histamine-N-methyl transferase (HNMT), kallikrein 2 (KLK2), nicotinamide
 -N-methyl transferase (NNMT), NADPH quinone oxidoreductase 2 (NQO2),
 sulfoltransferase thermolabile (STM), UDP-glucuronosyl transferase 2B4
 (UGT2B4), UDP-glucuronosyl transferase 2B7 (UGT2B7), UDP-glucuronosyl
 transferase (UGT2B15), urokinase receptor (uPA), multidrug resistance
 protein 3 (MRP3), orphan nuclear receptor (NR112), or acetylcholine
 muscarinic receptor 1, 2, 3, 4, or 5 (CHMR1, CHMR2, CHMR3, CHMR4 or
 CHMR5) sequence. The polymorphisms in the human genes cited in the
 invention are useful as genetic linkage markers for locating and
 characterising the genes that are responsible for specific traits within
 the genome and eventually identifying the genes responsible for a
 variety of disorder-related traits as a result of their e.g.,
 overexpression, constitutive expression, mutation or underexpression,
 which may be used in diagnosing and/or treating the disorders. The
 nucleic acid molecules comprising the polymorphic sequences contained
 in CYP4501A1, CYP4501A2, CYP4502E1, ARNT, EPHX2, GST12, NNMT, NQO2,
 NR112, STM, UGT2B4, UGT2B7, UGT2B15, AHR, MDR1 and/or MDR3 are useful
 for screening individuals for altered drug metabolism. The polymorphic
 sequences contained in CYP4501A1, CYP4501A2, AHR, MDR1 and/or MDR3 may
 also be used to screen individuals for susceptibility to cancer.
 Polymorphic sequences in ADRB1 or CHMR2 are used to screen for altered
 cardiovascular function, in COX2 for altered susceptibility to
 colorectal tumours, in DBI or CHMR1 for altered central nervous system
 function, in FLAP and HNMT for altered pulmonary, immunological or

CC haematological function, in KLK2 for altered serine protease activity in
 CC the prostate, in LTF for altered immunological or haematological
 CC function, in CHMR3, CHMR4 or CHMR5 for altered central and peripheral
 CC nervous system function. The present sequence represents a sequencing
 CC primer used to sequence the polymorphic genes of the invention.
 XX
 SQ Sequence 15 BP; 3 A; 2 C; 9 G; 1 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 582 CCTCCGCTGCCCC 596
 DB 15 CCTCAGTCTGCCCC 1

RESULT 314
 AAL48126
 ID AAL48126 standard; DNA; 15 BP.
 XX
 AC AAL48126;
 XX
 DT 27-SEP-2002 (first entry)
 XX
 DE Human neuropeptide Y allele specific primer SEQ ID NO: 50.
 XX
 KW Human; neuropeptide Y; NPY; isogene; SNP; atherosclerosis; obesity;
 KW psychological disorder; single nucleotide polymorphism; alcoholism;
 KW antiarteriosclerotic; anorectic; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200251857-A1.
 XX
 PD 04-JUL-2002.
 XX
 PF 21-DEC-2000; 2000WO-US34758.
 XX
 PR 21-DEC-2000; 2000WO-US34758.
 XX
 PA (GENA-) GENAISSANCE PHARM INC.
 XX
 PI Chew A, Denton RR, Lanz EM, Nandabalan K, Stephens JC;
 XX
 DR WPI; 2002-566671/60.
 XX
 PT New genetic variants of the human Neuropeptide Y (NPY) gene useful for
 PT treating disorders affected by abnormal expression or function of NPY
 PT isogene e.g., atherosclerosis or obesity -
 XX
 PS Claim 11; Page 17; 80pp; English.
 XX
 CC The present invention provides the human neuropeptide Y (NPY) gene and
 CC single nucleotide polymorphisms (SNPs) identified therein. The sequence
 CC can be used in the treatment of disorders associated with NPY, including
 CC atherosclerosis, obesity, psychological disorders and alcoholism. The
 CC present sequence is an allele specific primer used to isolate the human
 CC NPY coding sequence.
 XX
 SQ Sequence 15 BP; 3 A; 7 C; 2 G; 2 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 15;
 Best Local Similarity 93.3%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 639 GCTCTGCATCCCCA 653
 DB 1 GCTCTGAATCCCCA 15

RESULT 315
 AAT06918

ID AAT06918 standard; DNA; 17 BP.
 XX
 AC AAT06918;
 XX
 DT 04-JUL-1996 (first entry)
 XX
 DE Chromosomal locus E15 primer #2.
 XX
 KW prostate/colon tumour suppressor gene; allelic loss; colorectal cancers;
 KW microsatellite analysis; sequence tagged site; primer; probe; PCR;
 KW amplification; chromosome; ss.
 OS
 XX
 PN WO9532214-A1.
 XX
 PD 30-NOV-1995.
 XX
 PF 22-MAY-1995; 95WO-US06593.
 XX
 PR 20-MAY-1994; 94US-0246604.
 XX
 PA (CANG-) CANJI INC.
 XX
 PI Bookstein R, Isaacs WB;
 XX
 DR WPI; 1996-020526/02.
 XX
 PT New DNA encoding a prostate tumour suppressor protein - from
 PT chromosome 8, for the diagnosis and treatment of prostatic and
 PT colorectal cancer
 XX
 PS Disclosure; Page 86; 122pp; English.
 XX
 CC Primers AAT06887-932 were used to analyse the breakpoints at chromosomal
 CC locus 8p22-21, contained in patients having prostate cancer, by
 CC microsatellite analysis and sequence tagged sites (STS). The region
 CC contains a prostate/colon tumour suppressor gene (PTSG). The primers
 CC and amplified fragments were used to screen a YAC library of prostate
 CC cancer DNA to isolate the PTSG (AAT06880), which can be used in the
 CC diagnosis and treatment of prostate and colorectal cancers.
 CC The primers AAT06917-8 amplify an 86 bp fragment from chromosomal locus
 CC E15.
 XX
 SQ Sequence 17 BP; 1 A; 4 C; 6 G; 6 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 237 GGCATCTGCATCTGG 251
 DB 3 GGCATCTGCATCTGG 17

RESULT 316
 AAT64712
 ID AAT64712 standard; DNA; 17 BP.
 XX
 AC AAT64712;
 XX
 DT 25-MAR-2003 (updated)
 DT 12-FEB-1998 (first entry)
 XX
 DE Primer E15 for mapping prostate/colon tumour suppressor gene.
 XX
 KW Prostate/colon tumour suppressor; allelic loss; prostate cancer;
 KW colorectal cancer; microsatellite analysis; sequence tagged site;
 KW STS; amplification; chromosomal location 8q22-21; probe;
 KW primer; gene mapping; diagnosis; treatment; ss.
 OS
 XX
 OS Synthetic.
 OS Homo sapiens.

XX JP09098790-A.
 XX 15-APR-1997.
 XX 22-FEB-1996; 96JP-0062144.
 XX 22-MAY-1995; 95US-0445515.
 XX (CANJ-) CANJI INC.
 XX (UYJO) UNIV JOHNS HOPKINS.
 XX Isaacs WB, Bookstein R;
 XX WPI; 1997-275447/25.
 XX New prostate/colon tumour suppressor gene - mapped to a locus on
 XX human chromosome 8
 XX Disclosure; Page 26; 45pp; Japanese.
 XX The present primer was used in the mapping of a gene encoding 2
 XX forms of a prostate/colon tumour suppressor (P/CTS). The P/CTS gene
 XX was isolated by analysis of allelic loss in patients with prostate
 XX cancer, and was putatively located to the chromosomal location
 XX 8q22-21 via microsatellite analysis and the use of sequence tagged
 XX sites (STS). Primers and probes derived from the gene can be used
 XX to screen lambda cDNA libraries for genes encoding P/CTS form 1 and
 XX 2. The P/CTS or its cDNA can be used in the diagnosis and treatment
 XX of prostate and colorectal cancers.
 XX (Updated on 25-MAR-2003 to correct PA field.)
 XX (Updated on 25-MAR-2003 to correct PI field.)
 XX
 SQ Sequence 17 BP; 1 A; 4 C; 6 G; 6 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 237 GGCATCTGCTCTGG 251
 Db 3 GGCATCTGCTCTGG 17
 RESULT 317
 ID AAA21346
 XX AAA21346 standard; RNA; 17 BP.
 XX
 AC AAA21346;
 XX
 DT 19-JUN-2000 (first entry)
 XX
 DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:4572.
 XX
 KW Human; aryl hydrocarbon nuclear transport; ARNT; TIE-2; angiogenesis;
 KW integrin alpha 6 subunit; integrin subunit beta 3; hairpin ribozyme;
 KW hammerhead ribozyme; angiogenic factor; cytosolic; antidiabetic;
 KW ophthalmologic; antiinflammatory; antiarthritic; antipsoriatic; ARMD;
 KW dermatologic; RNA cleavage; cancer; diabetic retinopathy; arthritis;
 KW age related macular degeneration; inflammation; neovascular glaucoma;
 KW myopic degeneration; psoriasis; verruca vulgaris; angiofibroma;
 KW tuberosus sclerosis; pot-wine stain; Sturge Weber syndrome;
 KW Kippel-Trenaunay-Weber syndrome; Osler-Weber-Rendu syndrome; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9950403-A2.
 XX
 PD 07-OCT-1999.
 XX
 XX 24-MAR-1999; 99WO-US06507.
 XX
 XX 27-MAR-1998; 98US-0079678.
 XX

XX (RIBO-) RIBOZYME PHARM INC.
 XX Pavco PA, Roberts E, Jarvis T, Coeshott C, McSwiggen JA;
 XX WPI; 1999-591315/50.
 XX Novel ribozymes for modulating the synthesis, expression and/or
 XX stability of an mRNA encoding an angiogenic factors -
 XX Claim 55; Page 202; 305pp; English.
 XX
 XX The present invention describes enzymatic nucleic acid molecules with
 XX RNA cleaving activity, which specifically cleave RNA encoded by an aryl
 XX hydrocarbon nuclear transporter (ARNT) gene, an integrin subunit beta 3
 XX gene, an integrin alpha 6 subunit gene, or a Tie-2 gene. AAA16775 to
 XX AAA17167 and AAA17561 to AAA17622 represent ribozyme sequences for ARNT,
 XX and AAA17168 to AAA17560 and AAA17623 to AAA17684 represent their
 XX corresponding target sequences; AAA17685 to AAA18385 and AAA19087 to
 XX AAA19154 represent ribozyme sequences for Tie-2, and AAA18386 to AAA19086
 XX and AAA19155 to AAA19222 represent their corresponding target sequences;
 XX AAA19223 to AAA20361 and AAA21501 to AAA21595 represent ribozyme
 XX sequences for integrin alpha 6 subunit, and AAA20362 to AAA21500 and
 XX AAA21596 to AAA21688 represent their corresponding target sequences;
 XX AAA21689 to AAA22475 and AAA23263 to AAA23342 represent ribozyme sequences
 XX for integrin subunit beta 3, and AAA22476 to AAA23262, AAA23343 to
 XX AAA23422 represent their corresponding target sequences. The ribozymes of
 XX the invention are used for modulating the synthesis, expression and/or
 XX stability of an mRNA encoding angiogenic factor, especially ARNT,
 XX integrin subunit beta-3, integrin subunit alpha-6, or Tie-2. They are
 XX especially used to treat cancer, diabetic retinopathy, age related
 XX macular degeneration (ARMD), inflammation, and arthritis, as well as
 XX neovascular glaucoma, myopic degeneration, psoriasis, verruca vulgaris,
 XX angiofibroma of tuberosus sclerosis, pot-wine stains, Sturge Weber
 XX syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-Rendu syndrome,
 XX and other syndromes and diseases related to the levels of ARNT, Tie-2,
 XX integrin subunit alpha-6, or integrin subunit beta-3.
 XX
 SQ Sequence 17 BP; 0 A; 2 C; 4 G; 11 U; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 20.0%; Pred. No. 2.1e+02;
 Matches 3; Conservative 11; Mismatches 1; Indels 0; Gaps 0;
 Qy 1141 GCCTTTTCTCTTTT 1155
 Db 3 GCGUUUUUUUUUUU 17
 RESULT 318
 ID AAC66363/c
 XX AAC66363 standard; DNA; 17 BP.
 XX
 AC AAC66363;
 XX
 DT 22-FEB-2001 (first entry)
 XX
 DE PCR primer used to amplify B. pertussis-S1 DNA.
 XX
 KW Protection; pathogen infection; vaccination; immunisation; poliovirus;
 KW Bordetella pertussis; respiratory syncytial virus; Mycoplasma pneumoniae;
 KW meningococcus; pneumococcus; rotavirus; influenza; parainfluenza;
 KW Corynebacterium diphtheriae; Clostridium tetani; hepatitis B virus;
 KW Chlamydia pneumoniae; Chlamydia trachomatis; Moraxella catarrhalis;
 KW PCR primer; ss.
 XX
 OS Bordetella pertussis.
 XX
 PN WO200064457-A1.
 XX
 PD 02-NOV-2000.
 XX
 XX 21-APR-2000; 2000WO-US10954.
 XX

XX 23-APR-1999; 99US-0298135.
 XX (UYDA-) UNIV DALHOUSIE.
 XX Lee SF, Halperin SA;
 XX WPI; 2000-687261/67.
 XX Composition having genetically modified live oral commensal bacteria
 PT which express immunogenic fragments of mucosal pathogens, used as oral
 PT vaccines to treat host against Bordetella pertussis, poliovirus
 PT infection -
 XX Example 1; Page 25; 52pp; English.
 XX A composition for stimulating protection against infection by a pathogen,
 CC comprises a live commensal oral organism genetically modified to express
 CC multiple immunogenic fragments of the pathogen. The composition has
 CC antibacterial and antiviral activity and acts as a vaccine. The
 CC composition which is administered orally or intranasally, is used for
 CC prophylactically treating a host against infection by a pathogen such as
 CC Bordetella pertussis, respiratory syncytial virus, poliovirus, Mycoplasma
 CC pneumoniae, meningococcus, pneumococcus, rotavirus, influenza,
 CC parainfluenza, Corynebacterium diphtheriae, Clostridium tetani, hepatitis
 CC B virus, Neisseria gonorrhoeae non-typeable Haemophilus influenzae
 CC Chlamydia pneumoniae, Chlamydia trachomatis, Moraxella catarrhalis, or
 CC their combinations. The composition can also be used for chronic
 CC immunisation of a host against infection by a pathogen. The present
 CC sequence represents a PCR primer used to amplify a Bordetella pertussis
 CC DNA sequence, which is used in an example illustrating the use of the
 CC composition of the invention.
 XX Sequence 17 BP; 2 A; 9 C; 3 G; 3 T; 0 other;
 SQ Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 760 CGGTGGCGGTGGAT 774
 DB 16 CGGTGGCGGGAGGAT 2
 RESULT 319
 AAF02209
 ID AAF02209 standard; DNA; 17 BP.
 XX AAF02209;
 AC AAF02209;
 XX 16-FEB-2001 (first entry)
 XX Hammerhead ribozyme substrate #504.
 DE Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 XX interferon alpha; ss.
 XX Homo sapiens.
 OS WO200061729-A2.
 XX 19-OCT-2000.
 XX 11-APR-2000; 2000WO-US09721.
 XX 12-APR-1999; 99US-0129390.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Blatt L, Zwick M, Pavco P, McSwiggen J;
 XX WPI; 2000-647423/62.
 XX

PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor
 PT protein, interferon alpha and erythropoietin -
 XX Claim 37; Page 67; 164pp; English.
 XX The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA
 CC transcription factor gene, IRF-2 and/or the CAAT Displacement
 CC Protein (CDP). Inhibition of the repressors removes prevents
 CC inhibition (and consequently increases expression of) genes involved in
 CC the production of erythropoietin, granulocyte colony stimulating factor
 CC protein and interferon alpha.
 XX Sequence 17 BP; 1 A; 10 C; 3 G; 3 T; 0 other;
 SQ Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 583 CTCGGTCTGCCCCC 597
 DB 1 CTCGGTCTACCCCC 15
 RESULT 320
 AAA36112
 ID AAA36112 standard; DNA; 17 BP.
 XX AAA36112;
 AC AAA36112;
 XX 26-JUL-2000 (first entry)
 DT Human genomic SNP allele specific oligonucleotide SEQ ID NO:169.
 DE Human; single nucleotide polymorphism; SNP; genotyping; DNA analysis;
 XX allele specific oligonucleotide; ASO; reduced complexity genome; RCG;
 KW genomic classification; identification; DNA fingerprinting;
 KW tumour characterisation; hybridisation; ss.
 XX Homo sapiens.
 OS WO200018960-A2.
 XX 06-APR-2000.
 PD 24-SEP-1999; 99WO-US22283.
 XX 25-SEP-1998; 98US-0101757.
 XX (NASI) MASSACHUSETTS INST TECHNOLOGY.
 XX Landers JE, Jordan B, Houseman DE, Charest A;
 PI WPI; 2000-293181/25.
 XX Detection of single nucleotide polymorphisms in genomes by preparation
 PT and analysis of reduced complexity genomes, useful for genotyping,
 PT fingerprinting and determining allele frequency of SNPs -
 XX Disclosure; Page 58; 111pp; English.
 XX A method has been developed for detecting the presence or absence of a
 CC single nucleotide polymorphism (SNP) allele in a genomic sample. The
 CC method comprises preparing a reduced complexity genome (RCG) from the
 CC genomic sample and analysing the RCG for the presence or absence of a
 CC SNP allele. The method can be used to characterise a tumour, to generate
 CC a genomic pattern for an individual genome or to generate a genomic
 CC classification code for a genome. The method can be used to assess
 CC whether a subject is at risk for developing a disease or to identify a
 CC set of SNP alleles associated with a disease. The method can also be
 CC used to perform linkage analysis. AAA35944 to AAA35947 represent

CC sequences used in the exemplification of the present invention. AAA35948
CC to AAA36632 represent nucleotide sequences containing SNPs.

XX SQ Sequence 17 BP; 2 A; 0 C; 2 G; 13 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1145 TTTTCTTTTGGG 1159
|||||
Db 1 TTTTCTTTTGGG 1159

RESULT 321
AAA25574/C
ID AAA25574 standard; DNA; 17 BP.
XX AC AAA25574;
XX AC AAA25574;
XX DT 19-JUL-2000 (first entry)
XX DE Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:2072.
XX KW Oestrogen receptor; c-ras; k-ras; bcl-2; ribozyme; cleavage;
XX KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
XX KW gene expression modification; cancer; phosphorothioate; endonuclease;
XX KW anticancer; breast cancer; endometrium cancer; ss.
XX OS Homo sapiens.
XX KW WO954459-A2.
XX PN 28-OCT-1999.
XX PF 19-APR-1999; 99WO-US08547.
XX PR 20-APR-1998; 98US-0082404.
XX PR 23-JUN-1998; 98US-0103636.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX Thompson JD, Beigelman L, McSwiggen JA, Karpaisky A, Bellion L;
PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerli P;
PI Matulic-Adamic J;
XX WPI; 2000-013248/01.
XX New nucleic acids that interact, and optionally cleave, target
PT sequences, used to treat cancer -
XX Claim 77; Page 83; 148pp; English.

CC The present invention describes nucleic acids (A) that interact stably
CC with a target sequence and contain at least one phosphorodithioate
CC link, having endonuclease activity. (A), and more generally any
CC catalytic nucleic acid (A') that modulates expression of the oestrogen
CC receptor gene, are used to treat cancer (particularly of breast or
CC endometrium), in vivo or by transforming cells ex vivo and implanting
CC treated cells, or for other conditions associated with levels of
CC oestrogen receptor. Because of the high selectivity for targeted RNA, (A)
CC can also be used to correlate inhibition of gene expression with
CC alterations in phenotype, particularly for identification of therapeutic
CC targets, and as research reagents (for RNA, in the same way that
CC restriction endonucleases are used with DNA). The combination of
CC modifications in (A) improves resistance to nucleases, binding affinity
CC and/or activity. AAA3503 to AAA24747 represent oestrogen receptor
CC hammerhead ribozyme sequences, and AAA24748 to AAA25992 represent their
CC corresponding target sequences. AAA25993 to AAA26105 represent oestrogen
CC receptor hairpin ribozyme sequences, and AAA26107 to AAA26218 represent
CC their corresponding target sequences. AAA26219 to AAA26271 represent
CC other ribozyme sequences and antisense oligonucleotides used in the
CC exemplification of the present invention.

XX SQ Sequence 17 BP; 6 A; 4 C; 1 G; 6 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 71 CATGGATGAATAAT 85
|||||
Db 17 CATGGATGAATAAT 3
RESULT 322
ABA77189
ID ABA77189 standard; DNA; 17 BP.
XX AC ABA77189;
XX AC ABA77189;
XX DT 24-JAN-2002 (first entry)
XX DE Adenosine deaminase deficiency correcting oligo SEQ ID NO: 35.
XX KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX KW Alzheimer's disease; cytostatic; anticlacking; antianaemic; haemostatic;
XX KW antilipemic; ss.
XX OS Homo sapiens.
XX KW WO200173002-A2.
XX PN 04-OCT-2001.
XX PD 27-MAR-2001; 2001WO-US09761.
XX PF 27-MAR-2000; 2000US-192176P.
XX PR 27-MAR-2000; 2000US-192179P.
XX PR 01-JUN-2000; 2000US-208538P.
XX PR 30-OCT-2000; 2000US-244989P.
XX PA (UYDE) UNIV DELAWARE.
XX PI Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX Oligonucleotide for targeted alterations of genetic sequences and for
PT treating cystic fibrosis, comprises at least one mismatch and chemical
PT modification -
XX Claim 7; Page 43; 294pp; English.
CC The present invention provides single-stranded oligonucleotides which can
CC be used for the targeted alteration of genomic sequences, where the
CC oligonucleotide has at least one mismatch compared with the genomic
CC sequence to be altered. In particular, these sequences are directed at
CC the following genes: adenosine deaminase, p53, beta-globin,
CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
CC (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
CC various syndromes. The present sequence is one of the gene correcting

CC oligonucleotides of the invention.

XX Sequence 17 BP; 3 A; 3 C; 8 G; 3 T; 0 other;

SQ Query Match 1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. NO. 2.1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 888 GGAGCTGCGGTACAG 902

|||||

Db 1 GGAGTGGGTACAG 15

RESULT 323

ABA77190/C

ID ABA77190 standard; DNA; 17 BP.

XX ABA77190;

DT 24-JAN-2002 (first entry)

XX Adenosine deaminase deficiency correcting oligo SEQ ID NO: 36.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antileptic; ss.

XX Homo sapiens.

XX WO200173002-A2.

XX 04-OCT-2001.

XX 27-MAR-2001; 2001WO-US09761.

XX 27-MAR-2000; 2000US-192176P.

XX 27-MAR-2000; 2000US-192179P.

XX 01-JUN-2000; 2000US-208538P.

XX 30-OCT-2000; 2000US-244989P.

XX (UYDE) UNIV DELAWARE.

XX Kmiec EB, Gamper HB, Rice MC;

XX WPI; 2001-639230/73.

XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification -

XX Claim 7; Page 43; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and

CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention.

SQ Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. NO. 2.1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 888 GGAGCTGCGGTACAG 902

|||||

Db 17 GGAGTGGGTACAG 3

RESULT 324

ABA77193

ID ABA77193 standard; DNA; 17 BP.

XX ABA77193;

DT 24-JAN-2002 (first entry)

XX Adenosine deaminase deficiency correcting oligo SEQ ID NO: 39.

XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antileptic; ss.

XX Homo sapiens.

XX WO200173002-A2.

XX 04-OCT-2001.

XX 27-MAR-2001; 2001WO-US09761.

XX 27-MAR-2000; 2000US-192176P.

XX 27-MAR-2000; 2000US-192179P.

XX 01-JUN-2000; 2000US-208538P.

XX 30-OCT-2000; 2000US-244989P.

XX (UYDE) UNIV DELAWARE.

XX Kmiec EB, Gamper HB, Rice MC;

XX WPI; 2001-639230/73.

XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification -

XX Claim 7; Page 43; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassemia, sickle cell anaemia,

CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention.
 XX
 SQ Sequence 17 BP; 3 A; 3 C; 8 G; 3 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 888 GGAGCTCGGTACAG 902
 DB 1 GGAGCTCGGTACAG 15
 RESULT 325
 ABA77194/c
 ID ABA77194 standard; DNA; 17 BP.
 XX
 AC ABA77194;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE Adenosine deaminase deficiency correcting oligo SEQ ID NO: 40.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOB;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US09761.
 XX
 PR 27-MAR-2000; 2000US-192176P.
 PR 27-MAR-2000; 2000US-192179P.
 PR 01-JUN-2000; 2000US-208538P.
 PR 30-OCT-2000; 2000US-244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 PI Kmiec EB, Gamper HB, Rice MC;
 XX
 DR WPI; 2001-639230/73.
 XX
 PT Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification -
 XX
 PS Claim 7; Page 43; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOB), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,

CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention.
 XX
 SQ Sequence 17 BP; 3 A; 8 C; 3 G; 3 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 888 GGAGCTCGGTACAG 902
 DB 17 GGAGCTCGGTACAG 3
 RESULT 326
 ABA77197
 ID ABA77197 standard; DNA; 17 BP.
 XX
 AC ABA77197;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE Adenosine deaminase deficiency correcting oligo SEQ ID NO: 43.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOB;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antiskilling; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 OS Homo sapiens.
 XX
 FN WO200173002-A2.
 XX
 PD 04-OCT-2001.
 XX
 PF 27-MAR-2001; 2001WO-US09761.
 XX
 PR 27-MAR-2000; 2000US-192176P.
 PR 27-MAR-2000; 2000US-192179P.
 PR 01-JUN-2000; 2000US-208538P.
 PR 30-OCT-2000; 2000US-244989P.
 XX
 PA (UYDE) UNIV DELAWARE.
 XX
 PI Kmiec EB, Gamper HB, Rice MC;
 XX
 DR WPI; 2001-639230/73.
 XX
 PT Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification -
 XX
 PS Claim 7; Page 43; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOB), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases

CC such as cancer, adenosine deaminase deficiency, cystic fibrosis.
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention.
 XX
 SQ Sequence 17 BP; 3 A; 2 C; 8 G; 4 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 888 GGAGCTGGCGTACAG 902
 DB 2 GGAGGTGGGTACAG 16
 RESULT 327
 ABA77198/c
 ID ABA77198 standard; DNA; 17 BP.
 XX
 AC ABA77198;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE Adenosine deaminase deficiency correcting oligo SEQ ID NO: 44.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antickling; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200173002-A2.
 PN
 PD 04-OCT-2001.
 XX
 XX 27-MAR-2001; 2001WO-US09761.
 PF
 XX 27-MAR-2000; 2000US-192176P.
 PR
 XX 27-MAR-2000; 2000US-192179P.
 PR
 XX 01-JUN-2000; 2000US-208538P.
 PR
 XX 30-OCT-2000; 2000US-244989P.
 PR
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamper HB, Rice MC;
 XX
 XX WPI; 2001-639230/73.
 DR
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification -
 XX
 XX Claim 7; Page 43; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and

CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention.
 XX
 SQ Sequence 17 BP; 4 A; 8 C; 2 G; 3 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 888 GGAGCTGGCGTACAG 902
 DB 16 GGAGGTGGGTACAG 2
 RESULT 328
 ABA80972/c
 ID ABA80972 standard; DNA; 17 BP.
 XX
 AC ABA80972;
 XX
 DT 24-JAN-2002 (first entry)
 XX
 DE LDLR mutation correcting oligonucleotide SEQ ID NO: 3818.
 XX
 KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antickling; antianaemic; haemostatic;
 KW antileptic; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200173002-A2.
 PN
 PD 04-OCT-2001.
 XX
 XX 27-MAR-2001; 2001WO-US09761.
 PF
 XX 27-MAR-2000; 2000US-192176P.
 PR
 XX 27-MAR-2000; 2000US-192179P.
 PR
 XX 01-JUN-2000; 2000US-208538P.
 PR
 XX 30-OCT-2000; 2000US-244989P.
 PR
 XX (UYDE) UNIV DELAWARE.
 PA
 XX Kmiec EB, Gamper HB, Rice MC;
 XX
 XX WPI; 2001-639230/73.
 DR
 XX Oligonucleotide for targeted alterations of genetic sequences and for
 PT treating cystic fibrosis, comprises at least one mismatch and chemical
 PT modification -
 XX
 XX Claim 7; Page 251; 294pp; English.
 XX
 CC The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
 CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase

CC (UTG1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention.

XX SQ Sequence 17 BP; 6 A; 4 C; 4 G; 3 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 745 CATGTTGCTGACTTT 759
 Db 15 CATGTTGCAGACTTT 1

RESULT 329
 ABA80973
 ID ABA80973 standard; DNA; 17 BP.
 XX AC ABA80973;
 XX DT 24-JAN-2002 (first entry)
 XX DE LDLR mutation correcting oligonucleotide SEQ ID NO: 3819.
 XX KW Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
 KW retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
 KW cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
 KW adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
 KW haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
 KW mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
 KW familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
 KW UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
 KW Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
 KW antileptic; ss.

XX OS Homo sapiens.
 XX PN WO200173002-A2.
 XX PD 04-OCT-2001.
 XX PF 27-MAR-2001; 2001WO-US09761.
 XX PR 27-MAR-2000; 2000US-192176P.
 XX PR 27-MAR-2000; 2000US-192179P.
 XX PR 01-JUN-2000; 2000US-208538P.
 XX PR 30-OCT-2000; 2000US-244989P.
 XX PA (UYDE) UNIV DELAWARE.
 XX PI Kmiec EB, Gampier HB, Rice MC;
 XX WPI; 2001-639230/73.
 XX PT Oligonucleotide for targeted alterations of genetic sequences and for
 XX treating cystic fibrosis, comprises at least one mismatch and chemical
 XX modification -
 XX Claim 7; Page 251; 294pp; English.

XX The present invention provides single-stranded oligonucleotides which can
 CC be used for the targeted alteration of genomic sequences, where the
 CC oligonucleotide has at least one mismatch compared with the genomic
 CC sequence to be altered. In particular, these sequences are directed at
 CC the following genes: adenosine deaminase, p53, beta-globin,
 CC retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
 CC (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
 CC 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,

CC apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
 CC (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
 CC presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
 CC such as cancer, adenosine deaminase deficiency, cystic fibrosis,
 CC haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
 CC Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
 CC various syndromes. The present sequence is one of the gene correcting
 CC oligonucleotides of the invention.

XX SQ Sequence 17 BP; 3 A; 4 C; 4 G; 6 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 745 CATGTTGCTGACTTT 759
 Db 3 CATGTTGCAGACTTT 17

RESULT 330
 AAF4454
 ID AAF4454 standard; DNA; 17 BP.
 XX AC AAF4454;
 XX DT 02-APR-2001 (first entry)
 XX DE Human PRO1245 reverse PCR primer SEQ ID NO:493.
 XX KW Human; secreted and transmembrane protein; PRO; cytostatic;
 KW cell death; cancer; chromosomal mapping; gene mapping; tissue typing;
 KW diagnostic assay; PCR primer; hybridisation; probe; ss.

XX OS Homo sapiens.
 XX PN WO200073454-A1.
 XX PD 07-DEC-2000.
 XX PF 30-MAR-2000; 2000WO-US08439.
 XX PR 02-JUN-1999; 99WO-US12252.
 XX PR 23-JUN-1999; 99US-0141037.
 XX PR 07-JUL-1999; 99US-0143048.
 XX PR 20-JUL-1999; 99US-0144758.
 XX PR 26-JUL-1999; 99US-0145698.
 XX PR 28-JUL-1999; 99US-0146222.
 XX PR 17-AUG-1999; 99US-0149396.
 XX PR 15-SEP-1999; 99WO-US21090.
 XX PR 15-SEP-1999; 99WO-US21547.
 XX PR 08-OCT-1999; 99US-0158663.
 XX PR 30-NOV-1999; 99WO-US28313.
 XX PR 01-DEC-1999; 99WO-US28301.
 XX PR 16-DEC-1999; 99WO-US30095.
 XX PR 20-DEC-1999; 99WO-US30911.
 XX PR 05-JAN-2000; 2000WO-US00219.
 XX PR 06-JAN-2000; 2000WO-US00376.
 XX PR 11-FEB-2000; 2000WO-US03565.
 XX PR 18-FEB-2000; 2000WO-US04341.
 XX PR 22-FEB-2000; 2000WO-US04414.
 XX PR 24-FEB-2000; 2000WO-US04914.
 XX PR 24-FEB-2000; 2000WO-US05004.
 XX PR 02-MAR-2000; 2000WO-US05841.
 XX PR 15-MAR-2000; 2000WO-US06884.
 XX PR 20-MAR-2000; 2000WO-US07377.
 XX PA (GETH) GENENTECH INC.
 XX PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Fong S, Gerber H, Gerritsen MF, Goddard A, Godowski PJ;
 PI Grimaldi CJ, Gurney AL, Kijavini IU, Napier MA, Pan J, Faoni NF;
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood W;

PI Zhang Z;
 XX WPI; 2001-032160/04.
 DR
 XX
 CC PRO polynucleotides used to produce polypeptides used to target
 PT bioactive molecules such as toxins, radiolabels or antibodies, to
 PT specific cells, to cause targeted cell death -
 XX
 PS Example 170; Page 544; 935pp; English.
 XX
 CC The present invention describes human secreted and transmembrane PRO
 CC proteins. The PRO proteins have cytostatic activity. The PRO proteins
 CC can be used for targeted delivery of bioactive molecules, such as
 CC toxins, radiolabels or antibodies, that cause cell death. PRO nucleotide
 CC sequences, and their fragments, can be used as hybridisation probes, in
 CC chromosomal and gene mapping, and in the generation of anti-sense RNA
 CC and DNA. They may also be used to produce transgenic animals which are
 CC used to develop and screen therapeutically useful reagents. The PRO
 CC nucleotide and protein sequence can be used for tissue typing and in
 CC treating cancer. Anti-PRO antibodies can be used in diagnostic assays.
 CC AAF44270 to AAF44470 represent PCR primers and hybridisation probes used
 CC in the isolation of human PRO sequences. AAF44087 to AAF44269 and
 CC AAB65154 to AAB65300 represent human PRO polynucleotide and protein
 CC sequences given in the exemplification of the present invention.
 XX
 SQ Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 494 GTGTGACGCGCTCTTG 508
 DB 1 GTGGGCGACGCTCTTG 15
 RESULT 331
 ABV73116
 ID ABV73116 standard; DNA; 17 BP.
 XX
 AC ABV73116;
 XX
 DT 08-JAN-2003 (first entry)
 XX
 DE LGALS1 cDNA quantifying primer LGALS13.
 XX
 KW Nucleic acid sequencing; gene expression; nucleic acid amplification;
 KW LGALS1; PCR; primer; ss.
 XX
 OS Synthetic.
 XX
 PN W0200272772-A2.
 XX
 PD 19-SEP-2002.
 XX
 PF 11-MAR-2002; 2002WO-US07306.
 XX
 PR 09-MAR-2001; 2001US-274550P.
 XX
 PA (NUGE-) NUGEN TECHNOLOGIES INC.
 XX
 PI Kurn N;
 XX
 DR WPI; 2002-740809/80.
 XX
 CC Generating multiple copies of polynucleotide complementary to RNA, by
 PT amplifying RNA with composite primer, second primer, and strand
 PT displacement to generate DNA products comprising sequences
 PT complementary to RNA -
 XX
 PS Example 5; Page 105; 148pp; English.
 XX
 CC The invention relates to generating multiple copies of polynucleotide

CC complementary to RNA sequence. The method involves extending first primer
 CC hybridized to target RNA (1) with enzyme to form complex having first
 CC primer extension product (EP1) and (1), cleaving (1) from the complex,
 CC extending second primer hybridized to EP1 with enzyme to form complex
 CC having EP1 and EP2, and cleaving RNA from the composite primer in the
 CC complex. The method is useful for sequencing RNA sequence of interest;
 CC for detecting a mutation in a target RNA using single stranded
 CC conformation polymorphism; for determining presence or absence of a
 CC sequence of interest; for producing a nucleic acid immobilized to a
 CC substrate; for characterizing an RNA sequence of interest; for
 CC determining gene expression profile in a sample; and for preparing a
 CC library. The method is also useful for differential amplification of one
 CC or more sequence of interest, and for making a cDNA library by preparing
 CC a subtractive hybridization probe. Sequences ABV73113-120 represent
 CC primer pairs used for quantification of the four specific expressed genes
 CC in either cDNA or amplification products generated using the method of
 CC the invention.
 XX
 SQ Sequence 17 BP; 2 A; 3 C; 6 G; 6 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 261 CCTGGCGTGGCTGAT 275
 DB 1 CATGGCGTGGCTGAT 15
 RESULT 332
 ABV79137
 ID ABV79137 standard; DNA; 17 BP.
 XX
 AC ABV79137;
 XX
 DT 03-JAN-2003 (first entry)
 XX
 DE Human HTPL scanning oligonucleotide SEQ ID 383.
 XX
 KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 KW human testis expressed Patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX
 OS Homo sapiens.
 XX
 PN EP1229046-A2.
 XX
 PD 07-AUG-2002.
 XX
 PF 28-JAN-2002; 2002EP-0001167.
 XX
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 23-MAY-2001; 2001US-0864761.
 PR 09-OCT-2001; 2001US-0327898.
 XX
 PA (ABOM-) ABOMICA INC.
 XX
 PI Zhan J;
 XX
 DR WPI; 2002-676592/73.
 XX
 CC Novel isolated human testis expressed Patched like protein (HTPL),
 PT useful for identifying agonist and antagonist and specific binding
 PT partners, and for treating subjects having defects in HTPL -
 XX
 PS Example 2; Page 114; 718pp; English.
 XX

CC The present invention relates to human testis expressed Patched like
 CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
 CC has two isoforms, with a few single base pair differences between the
 CC two. One of the single base pair changes introduces a premature stop
 CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
 CC shares an overall structure organisation with the Patched protein. The
 CC shared structural features strongly imply that HTPL plays a role similar
 CC to that of Patched, and is a potential tumour suppressor. HTPL is
 CC important in regulating male germ cell development, and the HTPL gene was
 CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in
 CC therapy and manufacture of a medicament for treatment or prevention of
 CC such disorder associated with decreased expression or activity of human
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
 CC clinically useful diagnostic markers and potential therapeutic agents for
 CC male infertility and cancer. The present oligonucleotide was used in an
 CC example from the invention.
 XX
 SQ Sequence 17 BP; 3 A; 6 C; 7 G; 1 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 522 CCTGCCGAGGAGCA 536
 |||||
 Db 3 CCTGCCGAGGAGCA 17

RESULT 333
 ABV79138
 ID ABV79138 standard; DNA; 17 BP.

XX AC ABV79138;
 XX DT 03-JAN-2003 (first entry)
 XX DE Human HTPL scanning oligonucleotide SEQ ID 384.
 XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 KW human testis expressed Patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX OS Homo sapiens.

XX FN EP1229046-A2.
 XX PD 07-AUG-2002.
 XX PF 28-JAN-2002; 2002EP-0001167.
 XX PR 30-JAN-2001; 2001WO-US00663.
 XX PR 30-JAN-2001; 2001WO-US00664.
 XX PR 30-JAN-2001; 2001WO-US00665.
 XX PR 30-JAN-2001; 2001WO-US00666.
 XX PR 30-JAN-2001; 2001WO-US00667.
 XX PR 30-JAN-2001; 2001WO-US00668.
 XX PR 23-MAY-2001; 2001US-0864761.
 XX PR 09-OCT-2001; 2001US-0327898.

XX PA (AEOM-) AEOMICA INC.
 XX PI Zhan J;
 XX WPI; 2002-676582/73.

XX Novel isolated human testis expressed Patched like protein (HTPL),
 PT useful for identifying agonist and antagonist and specific binding
 PT partners, and for treating subjects having defects in HTPL -
 XX

PS Example 2; Page 114; 718pp; English.

XX The present invention relates to human testis expressed Patched like
 CC protein (HTPL, see ABV78759 to ABV78762 and ABB98519 to ABB98520). HTPL
 CC has two isoforms, with a few single base pair differences between the
 CC two. One of the single base pair changes introduces a premature stop
 CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
 CC shares an overall structure organisation with the Patched protein. The
 CC shared structural features strongly imply that HTPL plays a role similar
 CC to that of Patched, and is a potential tumour suppressor. HTPL is
 CC important in regulating male germ cell development, and the HTPL gene was
 CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in
 CC therapy and manufacture of a medicament for treatment or prevention of
 CC such disorder associated with decreased expression or activity of human
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
 CC clinically useful diagnostic markers and potential therapeutic agents for
 CC male infertility and cancer. The present oligonucleotide was used in an
 CC example from the invention.
 XX

SQ Sequence 17 BP; 4 A; 5 C; 7 G; 1 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 522 CCTGCCGAGGAGCA 536
 |||||
 Db 2 CCTGCCGAGGAGCA 16

RESULT 334
 ABV79139
 ID ABV79139 standard; DNA; 17 BP.

XX AC ABV79139;
 XX DT 03-JAN-2003 (first entry)
 XX DE Human HTPL scanning oligonucleotide SEQ ID 385.
 XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 KW human testis expressed Patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.

XX OS Homo sapiens.
 XX FN EP1229046-A2.
 XX PD 07-AUG-2002.
 XX PF 28-JAN-2002; 2002EP-0001167.
 XX PR 30-JAN-2001; 2001WO-US00663.
 XX PR 30-JAN-2001; 2001WO-US00664.
 XX PR 30-JAN-2001; 2001WO-US00665.
 XX PR 30-JAN-2001; 2001WO-US00666.
 XX PR 30-JAN-2001; 2001WO-US00667.
 XX PR 30-JAN-2001; 2001WO-US00668.
 XX PR 23-MAY-2001; 2001US-0864761.
 XX PR 09-OCT-2001; 2001US-0327898.

XX PA (AEOM-) AEOMICA INC.
 XX PI Zhan J;
 XX WPI; 2002-676582/73.

XX Novel isolated human testis expressed Patched like protein (HTPL),
 PT useful for identifying agonist and antagonist and specific binding


```

XX
PI Shannon M;
XX
DR WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
PT POSHL-1, useful for treating disorders associated with decreased
PT expression or activity of human POSHL1 -
XX
XX Example 2; SEQ ID NO 495; 60pp + Sequence Listing; English.
PS
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB8399), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC cancer, they are useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention.
CC Note: The present sequence did not form part of the printed
CC specification, but is based on sequence information supplied to Derwent
CC by the European Patent Office.
XX
SQ Sequence 17 BP; 4 A; 4 C; 8 G; 1 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 631 CTCGAGGAGCTCTGC 645
Db 16 CTCGCGGAGCTCTGC 2
RESULT 337
ABV89783/C
ID ABV89783 standard; DNA; 17 BP.
XX
AC ABV89783;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 496.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
FN EP1239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-0001165.
XX
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.

```

```

PR 23-MAY-2001; 2001US-0864761.
PR 10-OCT-2001; 2001US-0328205.
XX
PA (AEOM-) AROMICA INC.
XX
PI Shannon M;
XX
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
PT POSHL-1, useful for treating disorders associated with decreased
PT expression or activity of human POSHL1 -
XX
XX Example 2; SEQ ID NO 496; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, ABB8399), a sequence having 65% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC cancer, they are useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention.
CC Note: The present sequence did not form part of the printed
CC specification, but is based on sequence information supplied to Derwent
CC by the European Patent Office.
XX
SQ Sequence 17 BP; 4 A; 4 C; 8 G; 1 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
Qy 631 CTCGAGGAGCTCTGC 645
Db 15 CTCGCGGAGCTCTGC 1
RESULT 338
ABV90552/C
ID ABV90552 standard; DNA; 17 BP.
XX
AC ABV90552;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1265.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
FN EP1239051-A2.
XX
PD 11-SEP-2002.
XX
PF 28-JAN-2002; 2002EP-0001165.
XX
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.

```

PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 23-MAY-2001; 2001US-0864761.
 PR 10-OCT-2001; 2001US-0328205.
 XX (AEOM-) AEOMICA INC.
 PA Shannon M;
 XX
 XX
 XX WPI; 2002-684061/74.
 DR
 XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
 PT POSHL-1, useful for treating disorders associated with decreased
 PT expression or activity of human POSHL1 -
 XX
 XX Example 2; SEQ ID NO 1265; 60pp + Sequence Listing; English.
 XX
 CC The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (SI, ABB83999), a sequence having 65% sequence identity to (SI),
 CC (SI) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with Rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they are useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention.
 CC Note: The present sequence did not form part of the printed
 CC specification, but is based on sequence information supplied to Derwent
 CC by the European Patent Office.
 XX
 SQ Sequence 17 BP; 4 A; 7 C; 3 G; 3 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 263 TGGGCTGGCTGATCA 277
 Db 16 TGGGCTGGCTGATCA 2
 RESULT 339
 ABK40398
 ID ABK40398 standard; DNA; 17 BP.
 XX
 AC ABK40398;
 XX
 XX 15-JUL-2002 (first entry)
 XX Reverse PCR primer #2 for gene amplification analysis of human PRO1245.
 DE Human; PRO; benign tumour; malignant tumour; lymphoid malignancy;
 KW leukaemia; neuronal disorder; stromal disorder; blastocoele disorder;
 KW inflammatory disorder; immune disorder; angiogenic disorder;
 KW cytostatic; neuroprotective; PCR; primer; ss.
 XX Homo sapiens.
 OS
 XX WO200153486-A1.
 EN
 XX 26-JUL-2001.
 XX
 XX 11-FEB-2000; 2000WO-US03565.
 PF

XX 08-MAR-1999; 99WO-US05028.
 PR 11-MAR-1999; 99US-123972P.
 PR 11-MAY-1999; 99US-133459P.
 PR 02-JUN-1999; 99WO-US12252.
 PR 22-JUN-1999; 99US-140650P.
 PR 22-JUN-1999; 99US-140653P.
 PR 20-JUL-1999; 99US-144758P.
 PR 26-JUL-1999; 99US-145698P.
 PR 28-JUL-1999; 99US-146222P.
 PR 17-AUG-1999; 99US-149395P.
 PR 31-AUG-1999; 99US-151689P.
 PR 01-SEP-1999; 99WO-US20111.
 PR 15-SEP-1999; 99WO-US21090.
 PR 30-NOV-1999; 99WO-US28313.
 PR 01-DEC-1999; 99WO-US28301.
 PR 01-DEC-1999; 99WO-US28634.
 PR 05-JAN-2000; 2000WO-US00219.
 XX (GETH) GENENTECH INC.
 PA Ashkenazi AJ, Goddard A, Godowski PJ, Gurney AL, Hillan KJ;
 PI Marsters SA, Pan J, Pitti RM, Roy MA, Smith V, Stone DM;
 PI Watanabe CK, Wood WI;
 XX WPI; 2002-205567/26.
 DR Thirty five nucleic acids encoding PRO polypeptides, useful for
 PT treating benign or malignant tumours, leukaemias and lymphoid
 PT malignancies, inflammatory, angiogenic and immunologic disorders -
 XX Example 26; Page 143; 302pp; English.
 XX The present invention relates to the isolation of novel human PRO
 CC polypeptides (AAU86128-AAU86162) and the polynucleotide sequences
 CC encoding them. The PRO polypeptides, agonists, antagonists or anti-PRO
 CC antibodies are useful for treating benign or malignant tumours
 CC (e.g. renal, kidney, bladder, breast, etc), leukaemias and lymphoid
 CC malignancies, other disorders such as neuronal, glial, astrocytal,
 CC hypochalamic, glandular, macrophagal, stromal and blastocoele disorders,
 CC inflammatory, immune and angiogenic disorders. The polynucleotide
 CC sequences are also useful in gene therapy. The present sequence
 CC represents a PCR primer used in the methods of the present invention.
 XX
 SQ Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 494 GTGTGCGAGCGCTCTTG 508
 Db 1 GTGGGCGAGCGCTCTTG 15
 RESULT 340
 ABK56691
 ID ABK56691 standard; RNA; 17 BP.
 XX
 AC ABK56691;
 XX
 XX 02-JUL-2002 (first entry)
 XX Human CLCA1 gene enzymatic nucleic acid #1062.
 DE Human; chloride channel calcium activated 1; CLCA1; ss; antiaesthatic;
 KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
 KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
 KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
 KW acetylcysteine.
 XX Homo sapiens.
 OS
 XX

PN WO200211674-A2.
 XX 14-FEB-2002.
 PD 09-AUG-2001; 2001WO-US24970.
 PF 09-AUG-2000; 2000US-224383P.
 XX 09-AUG-2000; 2000US-224383P.
 PR (RIBO-) RIBOZYME PHARM INC.
 PA (SYNT) SYNTAX USA LLC.
 PA (THOM/) THOMPSON J.
 XX Thompson J, McSwiggen J, McKenzie T, Ayers D, Szymkowski DE,
 PI Grupe A;
 XX WPI; 2002-217145/27.
 DR Enzymatic polynucleotide that down regulates expression of chloride
 XX channel calcium activated gene, useful for treating Chronic obstructive
 PT pulmonary disease (COPD), chronic bronchitis and asthma
 XX
 PS Claim 4; Page 78; 152pp; English.
 XX The invention relates to enzymatic nucleic acid molecules that down
 XX regulate expression of chloride channel calcium activated 1 (CLCA1) genes
 CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of CLCA1 in a cell or
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
 CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of CLCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of CLCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention.
 XX
 SQ Sequence 17 BP; 7 A; 6 C; 2 G; 2 U; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 80.0%; Pred. No. 2.1e+02;
 Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 646 ATCCCCCAAGACCTG 660
 Db :||| ||||| :|
 2 AUCCACCAAGACCG 16
 RESULT 341
 ABK18409
 ID ABK18409 standard; RNA; 17 BP.
 XX
 AC ABK18409;
 XX
 DT 09-APR-2002 (first entry)
 XX
 DE Human ERG hammerhead ribozyme target sequence, Seq ID No 1056.
 XX
 KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNAzyme; inozyme;
 KW amberzyme.
 XX
 CS Homo sapiens.

XX WO200188124-A2.
 XX 22-NOV-2001.
 PD 16-MAY-2001; 2001WO-US15866.
 PF 16-MAY-2000; 2000US-0572021.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 XX Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin P, Randi AM;
 PI WPI; 2002-082995/11.
 XX Novel polynucleotide which down regulates expression of Ets-related
 PT gene, useful for treating cancer, diabetic retinopathy, macular
 PT degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber
 XX syndrome
 XX
 PS Claim 4; Page 78; 149pp; English.
 XX The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiofibroma of tuberosus sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention.
 XX
 SQ Sequence 17 BP; 6 A; 5 C; 2 G; 4 U; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 80.0%; Pred. No. 2.1e+02;
 Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 21 TTAACCAACCCAG 35
 Db :||| ||||| :|
 3 UUAUACCAACCCAG 17
 RESULT 342
 ABK18410
 ID ABK18410 standard; RNA; 17 BP.
 XX
 AC ABK18410;
 XX
 DT 09-APR-2002 (first entry)
 XX
 DE Human ERG hammerhead ribozyme target sequence, Seq ID No 1057.
 XX
 KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;

KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNazyme; inozyme;
 KW amberzyme.
 XX Homo sapiens.
 OS WO200188124-A2.
 FN 22-NOV-2001.
 XX 16-MAY-2001; 2001WO-US15866.
 XX 16-MAY-2000; 2000US-0572021.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 PA Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin F, Randi AM;
 PI WPI; 2002-082995/11.
 XX Novel polynucleotide which down regulates expression of Ets-related
 PT gene, useful for treating cancer, diabetic retinopathy, macular
 PT degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber
 PT syndrome -
 XX Claim 4; Page 78; 149pp; English.
 XX The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention.
 XX Sequence 17 BP; 6 A; 5 C; 2 G; 4 U; 0 other;
 SQ Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 80.0%; Pred.No. 2.1e+02;
 Matches 12; Conservative 2; Mismatches 1; Indels 0; Gaps 0;
 QY 21 TTAACCAACCCAG 35
 : : |||||
 Db 2 UTAUACCAACCCAG 16
 RESULT 343
 ABK19335/C
 ID ABK19335 standard; RNA; 17 BP.
 XX
 AC ABK19335;

XX 09-APR-2002 (first entry)
 DE Human ERG Amberzyme target sequence Seq ID No 1982.
 XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 KW vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;
 KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNazyme; inozyme;
 KW amberzyme.
 XX Homo sapiens.
 OS WO200188124-A2.
 FN 22-NOV-2001.
 XX 16-MAY-2001; 2001WO-US15866.
 XX 16-MAY-2000; 2000US-0572021.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (GLAX) GLAXO GROUP LTD.
 PA Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin F, Randi AM;
 PI WPI; 2002-082995/11.
 XX Novel polynucleotide which down regulates expression of Ets-related
 PT gene, useful for treating cancer, diabetic retinopathy, macular
 PT degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber
 PT syndrome -
 XX Claim 4; Page 126; 149pp; English.
 XX The invention relates to a nucleic acid molecule (I) which down regulates
 CC expression of an Ets-related gene (ERG). (I) is useful for treating
 CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 CC tumour angiogenesis, diabetic retinopathy, macular degeneration,
 CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 CC vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 CC syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 CC treating a patient having a condition associated with the level of ERG,
 CC by contacting cells of the patient with (I) under conditions suitable for
 CC the treatment. The method comprises the use of one or more therapies
 CC under conditions suitable for the treatment. Leukaemia or tumour
 CC angiogenesis is treated by administering (I) to the patient in
 CC conjunction with one or more of other therapies such as radiation or
 CC chemotherapy treatment. (I) is useful for reducing ERG activity in a
 CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 CC ERG gene, by contacting (I) with RNA, in the presence of a divalent
 CC cation such as Mg2+. (I) is useful for diagnosis of conditions and
 CC diseases related to the expression of ERG, and as diagnostic tool to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of ERG RNA in a cell. (I) is useful for specifically
 CC targeting genes that share homology with ERG gene or ERG fusion genes.
 CC ABK17354-ABK22719 represent nucleic acids, including antisense and
 CC enzymatic nucleic acid molecules which regulate expression of ERG, and
 CC related PCR primers of the invention.
 XX Sequence 17 BP; 7 A; 1 C; 6 G; 3 U; 0 other;
 SQ Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred.No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 48 TTACGATCTCTCA 62
 ||||| |||||

Db 16 TTAGCATCTCTCTCA 2

RESULT 344
ABT39230
ID ABT39230.standard; DNA; 17 BP.
XX AC ABT39230;
XX DT 12-JUN-2003 (first entry)
XX DE Tumour suppression related human fukutin oligo SEQ ID No 4867.
XX DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
XX KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
XX KW schizophrenia; protein chip; gene therapy; tumour suppression;
XX KW human fukutin; ds.
XX OS Homo sapiens.
XX PN W02003025175-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB04208.
XX PR 17-SEP-2001; 2001FR-0011978.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-313353/30.
XX DR New isolated nucleic acid, useful for treating viral diseases
XX PT associated with tumors and cell degeneration, also related
XX PT polypeptides, antibodies and transfected cells -
XX PS Disclosure; Page 603; 720pp; French.
XX CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX CC given in the specification, a sequence containing at least 15
XX CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
XX CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
XX CC sequence that hybridizes to them under highly stringent conditions, or
XX CC the complement of any of them, or the corresponding RNA. The novel
XX CC isolated nucleic acids of the invention are useful as probes and primers
XX CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
XX CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
XX CC and for production of recombinant polypeptides. Any of the nucleic acids,
XX CC polypeptides, vectors containing the nucleic acids, cells containing the
XX CC vector or antibodies directed against the nucleic acids, cells containing the
XX CC preparation of pharmaceuticals for prevention and/or treatment of viral
XX CC diseases that are characterised by development of tumours or cell
XX CC degeneration, specifically cancer but also Alzheimer's disease and
XX CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
XX CC patient samples is useful for diagnosis and/or prognosis of these
XX CC diseases. The polypeptides can also be used to generate antibodies, and
XX CC both the polypeptide and antibodies are useful as components of protein
XX CC chips. The nucleic acid sequences of the invention can be used in gene
XX CC therapy. This polynucleotide sequence represents a tumour suppression
XX CC related human fukutin oligonucleotide of the invention.
XX SQ Sequence 17 BP; 8 A; 3 C; 4 G; 2 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 273 GATCAAGAGGAGC 287
DB 1 GATCAAGAGGAGTACG 15

Db 16 CCGAGCGCGGTGGAT 2

RESULT 345
ABT39985/c
ID ABT39985 standard; DNA; 17 BP.
XX AC ABT39985;
XX DT 13-JUN-2003 (first entry)
XX DE Tumour suppression related human fukutin oligo SEQ ID No 5622.
XX DE Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
XX KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
XX KW schizophrenia; protein chip; gene therapy; tumour suppression;
XX KW human fukutin; ds.
XX OS Homo sapiens.
XX PN W02003025175-A2.
XX PD 27-MAR-2003.
XX PF 17-SEP-2002; 2002WO-IB04208.
XX PR 17-SEP-2001; 2001FR-0011978.
XX PA (MOLE-) MOLECULAR ENGINES LAB.
XX PI Telerman A, Amson R, Tuijnder M;
XX WPI; 2003-313353/30.
XX DR New isolated nucleic acid, useful for treating viral diseases
XX PT associated with tumors and cell degeneration, also related
XX PT polypeptides, antibodies and transfected cells -
XX PS Disclosure; Page 691; 720pp; French.
XX CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
XX CC given in the specification, a sequence containing at least 15
XX CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
XX CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
XX CC sequence that hybridizes to them under highly stringent conditions, or
XX CC the complement of any of them, or the corresponding RNA. The novel
XX CC isolated nucleic acids of the invention are useful as probes and primers
XX CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
XX CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
XX CC and for production of recombinant polypeptides. Any of the nucleic acids,
XX CC polypeptides, vectors containing the nucleic acids, cells containing the
XX CC vector or antibodies directed against the polypeptides are useful for
XX CC preparation of pharmaceuticals for prevention and/or treatment of viral
XX CC diseases that are characterised by development of tumours or cell
XX CC degeneration, specifically cancer but also Alzheimer's disease and
XX CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
XX CC patient samples is useful for diagnosis and/or prognosis of these
XX CC diseases. The polypeptides can also be used to generate antibodies, and
XX CC both the polypeptide and antibodies are useful as components of protein
XX CC chips. The nucleic acid sequences of the invention can be used in gene
XX CC therapy. This polynucleotide sequence represents a tumour suppression
XX CC related human fukutin oligonucleotide of the invention.
XX SQ Sequence 17 BP; 2 A; 10 C; 3 G; 2 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 760 CCGTGGCGCGGTGGAT 774
DB 16 CCGAGCGCGGTGGAT 2

RESULT 346

ABX80463
 ID ABX80463 standard; DNA; 17 BP.
 XX AC ABX80463;
 XX DT 28-APR-2003 (first entry)
 XX DE Novel human secreted or transmembrane protein PRO183 DNA.
 XX KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
 KW cardiac insufficiency disorder; cancer; tumour; immune response;
 KW adrenal cortical capillary endothelial growth; c-fos induction;
 KW vascular endothelial growth factor inhibition; VEGF inhibition;
 KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
 KW retinal neurons cell survival; rod photoreceptor cell survival;
 KW retinal disorder; retinitis pigmentosa; kidney disorder;
 KW mammalian kidney mesangial cell proliferation; Berger disease;
 KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
 KW chondrocyte redifferentiation; sports injury; arthritis; gene; ds.
 XX OS Homo sapiens.
 XX PN US2002132252-A1.
 XX PD 19-SEP-2002.
 XX PF 14-NOV-2001; 2001US-0990442.
 XX PR 05-NOV-1997; 97WO-US200069.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 99WO-US00106.
 PR 08-MAR-1999; 99WO-US05028.
 PR 02-JUN-1999; 99WO-US12252.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 30-NOV-1999; 99WO-US28313.
 PR 01-DEC-1999; 99WO-US28301.
 PR 01-DEC-1999; 99WO-US28634.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.
 PR 06-JAN-2000; 2000WO-US00219.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 02-MAR-2000; 2000WO-US05004.
 PR 10-MAR-2000; 2000WO-US06319.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 15-MAY-2000; 2000WO-US13358.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 16-JUN-1997; 97US-049787P.
 PR 17-OCT-1997; 97US-062250P.
 PR 12-NOV-1997; 97US-065186P.
 PR 13-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-066770P.
 PR 25-FEB-1998; 98US-075945P.
 PR 20-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088026P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088326P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088555P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 11-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.
 PR 17-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089907P.
 PR 18-JUN-1998; 98US-089908P.
 PR 28-AUG-2001; 2001US-0941992.
 XX (GETH) GENENTECH INC.
 XX Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
 PI Zhang Z;
 XX WPI; 2003-247083/24.
 DR P-PSDB; ABUS9182.
 XX Novel isolated PRO polypeptides e.g., PRO826, PRO1068, PRO1184, PRO1346
 PT and PRO1375, which stimulate proliferation of stimulated T-lymphocytes
 PT are therapeutically useful for enhancing immune response and in cancer
 PT treatments -
 XX Claim 2; Fig 307; 649pp; English.
 XX The invention describes an isolated human PRO polypeptide. The PRO
 CC polypeptides are useful in detecting PRO polypeptides in a sample, in
 CC linking a bioactive molecule to a cell expressing a PRO polypeptide, and
 CC in modulating at least one biological activity of a cell expressing a PRO
 CC polypeptide. PRO1312 stimulates hypertrophy of neonatal heart and is thus
 CC useful for treating cardiac insufficiency disorders. PRO1154 and PRO1186

CC stimulate adrenal cortical capillary endothelial growth, and PRO336,
 CC PRO943, PRO828, PRO1068 or PRO335, PRO826, PRO819, PRO1126,
 CC PRO1360 and PRO1387 induce c-fos in endothelial cells, and are thus
 CC useful for treating conditions or disorders where angiogenesis would be
 CC beneficial, e.g. wound healing and antagonist of this polypeptide are
 CC useful for treating cancerous tumours. PRO812 inhibits vascular
 CC endothelial growth factor (VEGF) stimulated proliferation of endothelial
 CC cells and is thus useful for inhibiting endothelial cell growth in
 CC mammals which would be beneficial in inhibiting tumour growth. PRO826,
 CC PRO1068, PRO1184, PRO1346 and PRO1375 stimulate proliferation of
 CC stimulated T-lymphocytes and are therapeutically useful for enhancing
 CC immune response. PRO828, PRO826, PRO1068 or PRO1132 enhance survival of
 CC retinal neurons cells (PRO1132 is also enhances survival/proliferation of
 CC rod photoreceptor cells) and therefore are useful for treating retinal
 CC disorders of injuries, e.g. retinitis pigmentosa, AMD. PRO819, PRO813
 CC and PRO1066 induce proliferation of mammalian kidney mesangial cells,
 CC and therefore are useful for treating kidney disorders associated with
 CC decreased mesangial cell function such as Berger disease or Crohn's
 CC nephropathies associated with dermatitis, herpetiformis or Crohn's
 CC disease. PRO1310, PRO844, PRO1312, PRO1192 and PRO1387 induce the
 CC proliferation and/or redifferentiation of chondrocytes in culture and
 CC are thus useful for treating sports injuries, and arthritis. This
 CC sequence represents a novel human PRO protein polynucleotide.

XX Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 2.1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 494 GTGTGCGAGCGCTTG 508

Db 1 GTGGCGAGCGCTTG 15

RESULT 347

ABX80967

ID ABX80967 standard; DNA; 17 BP.

XX AC ABX80967;

XX DT 22-APR-2003 (first entry)

XX DE Human secreted/transmembrane protein, TagMan probe #22.

XX KW Human; probe; ss; PRO; secreted; transmembrane; pharmaceutical;

XX KW diagnostic; biosensor; bioreactor; tumour; therapeutic; TagMan;

XX KW gene therapy; tumour-associated antigenic target; TAT; ADEPT;

XX KW antibody-dependent enzyme mediated prodrug therapy; cytostatic.

XX OS Homo sapiens.

XX XX US2003027162-A1.

FN PD 06-FEB-2003.

XX PF 15-NOV-2001; 2001US-0997428.

XX PR 05-NOV-1997; 97WO-US20069.

PR 16-SEP-1998; 98WO-US19330.

PR 17-SEP-1998; 98WO-US19437.

PR 07-OCT-1998; 98WO-US21141.

PR 01-DEC-1998; 98WO-US25108.

PR 05-JAN-1999; 99WO-US00106.

PR 08-MAR-1999; 99WO-US05028.

PR 02-JUN-1999; 99WO-US12252.

PR 15-SEP-1999; 99WO-US21090.

PR 15-SEP-1999; 99WO-US21547.

PR 30-NOV-1999; 99WO-US28313.

PR 01-DEC-1999; 99WO-US28301.

PR 01-DEC-1999; 99WO-US28634.

PR 16-DEC-1999; 99WO-US30095.

PR 20-DEC-1999; 99WO-US30911.

PR 05-JAN-2000; 2000WO-US00219.

PR 06-JAN-2000; 2000WO-US00376.

PR 11-FEB-2000; 2000WO-US03565.

PR 18-FEB-2000; 2000WO-US04341.

PR 22-FEB-2000; 2000WO-US04414.

PR 24-FEB-2000; 2000WO-US04914.

PR 24-FEB-2000; 2000WO-US05004.

PR 02-MAR-2000; 2000WO-US05841.

PR 10-MAR-2000; 2000WO-US06319.

PR 15-MAR-2000; 2000WO-US06884.

PR 20-MAR-2000; 2000WO-US07377.

PR 30-MAR-2000; 2000WO-US08439.

PR 15-MAY-2000; 2000WO-US13358.

PR 17-MAY-2000; 2000WO-US13705.

PR 22-MAY-2000; 2000WO-US14042.

PR 30-MAY-2000; 2000WO-US14941.

PR 02-JUN-2000; 2000WO-US15264.

PR 28-JUL-2000; 2000WO-US20710.

PR 11-AUG-2000; 2000WO-US22031.

PR 23-AUG-2000; 2000WO-US23522.

PR 24-AUG-2000; 2000WO-US23328.

PR 08-NOV-2000; 2000WO-US30952.

PR 01-DEC-2000; 2000WO-US32678.

PR 28-FEB-2001; 2001WO-US06520.

PR 01-JUN-2001; 2001WO-US17800.

PR 20-JUN-2001; 2001WO-US19692.

PR 29-JUN-2001; 2001WO-US21066.

PR 09-JUL-2001; 2001WO-US21735.

PR 16-JUN-1997; 97US-049787P.

PR 17-OCT-1997; 97US-062250P.

PR 12-NOV-1997; 97US-065186P.

PR 13-NOV-1997; 97US-065311P.

PR 24-NOV-1997; 97US-066770P.

PR 25-FEB-1998; 98US-075945P.

PR 20-MAR-1998; 98US-078910P.

PR 28-APR-1998; 98US-083322P.

PR 07-MAY-1998; 98US-084600P.

PR 28-MAY-1998; 98US-087106P.

PR 02-JUN-1998; 98US-087607P.

PR 02-JUN-1998; 98US-087609P.

PR 02-JUN-1998; 98US-087759P.

PR 03-JUN-1998; 98US-087827P.

PR 04-JUN-1998; 98US-088021P.

PR 04-JUN-1998; 98US-088025P.

PR 04-JUN-1998; 98US-088028P.

PR 04-JUN-1998; 98US-088029P.

PR 04-JUN-1998; 98US-088030P.

PR 04-JUN-1998; 98US-088033P.

PR 04-JUN-1998; 98US-088126P.

PR 05-JUN-1998; 98US-088167P.

PR 05-JUN-1998; 98US-088202P.

PR 05-JUN-1998; 98US-088217P.

PR 05-JUN-1998; 98US-088217P.

PR 10-JUN-1998; 98US-088734P.

PR 10-JUN-1998; 98US-088738P.

PR 10-JUN-1998; 98US-088742P.

PR 10-JUN-1998; 98US-088810P.

PR 10-JUN-1998; 98US-088824P.

PR 10-JUN-1998; 98US-088826P.

PR 11-JUN-1998; 98US-088858P.

PR 11-JUN-1998; 98US-088861P.

PR 11-JUN-1998; 98US-088876P.

PR 12-JUN-1998; 98US-089105P.

PR 16-JUN-1998; 98US-089440P.

PR 16-JUN-1998; 98US-089512P.

PR 16-JUN-1998; 98US-089514P.

PR 17-JUN-1998; 98US-089532P.

PR 17-JUN-1998; 98US-089538P.

PR 17-JUN-1998; 98US-089598P.

PR 17-JUN-1998; 98US-089599P.

PR 17-JUN-1998; 98US-089600P.

```
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089907P.
PR 18-JUN-1998; 98US-089908P.
PR 19-JUN-1998; 98US-089947P.
PR 19-JUN-1998; 98US-089948P.
PR 19-JUN-1998; 98US-089952P.
PR 19-JUN-1998; 98US-089952P.
PR 22-JUN-1998; 98US-090245P.
PR 22-JUN-1998; 98US-090245P.
PR 22-JUN-1998; 98US-090252P.
PR 22-JUN-1998; 98US-090254P.
PR 23-JUN-1998; 98US-090349P.
PR 23-JUN-1998; 98US-090355P.
PR 24-JUN-1998; 98US-090423P.
PR 24-JUN-1998; 98US-090431P.
PR 24-JUN-1998; 98US-090433P.
PR 24-JUN-1998; 98US-090443P.
PR 24-JUN-1998; 98US-090444P.
PR 24-JUN-1998; 98US-090445P.
PR 24-JUN-1998; 98US-090472P.
PR 24-JUN-1998; 98US-090535P.
PR 24-JUN-1998; 98US-090540P.
PR 24-JUN-1998; 98US-090542P.
PR 24-JUN-1998; 98US-090557P.
PR 25-JUN-1998; 98US-090676P.
PR 25-JUN-1998; 98US-090678P.
PR 25-JUN-1998; 98US-090690P.
PR 25-JUN-1998; 98US-090694P.
PR 25-JUN-1998; 98US-090695P.
PR 25-JUN-1998; 98US-090696P.
PR 26-JUN-1998; 98US-090862P.
PR 26-JUN-1998; 98US-090863P.
PR 01-JUL-1998; 98US-091360P.
PR 01-JUL-1998; 98US-091544P.
PR 02-JUL-1998; 98US-091478P.
PR 02-JUL-1998; 98US-091519P.
PR 02-JUL-1998; 98US-091626P.
PR 02-JUL-1998; 98US-091628P.
PR 02-JUL-1998; 98US-091633P.
PR 02-JUL-1998; 98US-091646P.
PR 02-JUL-1998; 98US-091673P.
PR 07-JUL-1998; 98US-091678P.
PR 07-JUL-1998; 98US-091982P.
PR 09-JUL-1998; 98US-092182P.
PR 10-JUL-1998; 98US-092472P.
PR 20-JUL-1998; 98US-092339P.
PR 30-JUL-1998; 98US-094651P.
PR 04-AUG-1998; 98US-095282P.
PR 04-AUG-1998; 98US-095285P.
PR 04-AUG-1998; 98US-095301P.
PR 04-AUG-1998; 98US-095302P.
PR 04-AUG-1998; 98US-095318P.
PR 04-AUG-1998; 98US-095321P.
PR 04-AUG-1998; 98US-095325P.
PR 10-AUG-1998; 98US-095916P.
PR 10-AUG-1998; 98US-095929P.
PR 10-AUG-1998; 98US-096012P.
PR 11-AUG-1998; 98US-096143P.
PR 11-AUG-1998; 98US-096146P.
PR 12-AUG-1998; 98US-096322P.
PR 17-AUG-1998; 98US-096757P.
PR 17-AUG-1998; 98US-096766P.
PR 17-AUG-1998; 98US-096768P.
PR 17-AUG-1998; 98US-096773P.
PR 17-AUG-1998; 98US-096791P.
PR 17-AUG-1998; 98US-096867P.
PR 17-AUG-1998; 98US-096891P.
PR 17-AUG-1998; 98US-096894P.
PR 17-AUG-1998; 98US-096895P.
PR 17-AUG-1998; 98US-096897P.
PR 18-AUG-1998; 98US-096949P.
PR 18-AUG-1998; 98US-096950P.
PR 18-AUG-1998; 98US-096959P.
PR 18-AUG-1998; 98US-096960P.
PR 18-AUG-1998; 98US-097022P.

PR 19-AUG-1998; 98US-097141P.
PR 20-AUG-1998; 98US-097218P.
PR 24-AUG-1998; 98US-097661P.
PR 26-AUG-1998; 98US-097952P.
PR 26-AUG-1998; 98US-097954P.
PR 26-AUG-1998; 98US-097955P.
PR 26-AUG-1998; 98US-097971P.
PR 26-AUG-1998; 98US-097974P.
PR 26-AUG-1998; 98US-097978P.
PR 26-AUG-1998; 98US-097979P.
PR 26-AUG-1998; 98US-097986P.
PR 31-AUG-1998; 98US-098014P.
PR 31-AUG-1998; 98US-098525P.
PR 16-SEP-1998; 98US-100634P.
PR 17-SEP-1998; 98US-100858P.
PR 22-DEC-1998; 98US-113296P.
PR 12-MAR-1999; 99US-123957P.
PR 23-JUN-1999; 99US-141037P.

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 494 GTGTGACGCGTCTTG 508
Db 1 GTGGGACGCGTCTTG 15

RESULT 348
ABX81350
ID ABX81350 standard; DNA; 17 BP.
XX
AC ABX81350;
XX
XX 22-APR-2003 (first entry)
XX
DE Novel human secreted or transmembrane protein PRO183 DNA.
XX
KW Human; PRO; hypertrophy of neonatal heart; angiogenesis; wound healing;
KW cardiac insufficiency disorder; cancer; tumour; immune response;
KW adrenal cortical capillary endothelial growth; c-fos induction;
KW vascular endothelial growth factor inhibition; VEGF inhibition;
KW endothelial cell growth inhibitor; T-lymphocytes stimulation;
KW retinal neurons cell survival; rod photoreceptor cell survival;
KW retinal disorder; retinitis pigmentosa; kidney disorder;
KW mammalian kidney mesangial cell proliferation; Berger disease;
KW dermatitis; herpeticiformis; Crohn's disease; chondrocyte proliferation;
KW chondrocyte redifferentiation; sports injury; arthritis; gene; ds.
OS Homo sapiens.
XX
XX US2003027985-A1.
XX
XX 06-FEB-2003.
XX
XX 14-NOV-2001; 2001US-0990562.
XX
XX 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US25108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 15-SEP-1999; 99WO-US21547.
PR 30-NOV-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 01-DEC-1999; 99WO-US28634.
PR 16-DEC-1999; 99WO-US30095.
PR 20-DEC-1999; 99WO-US30911.
PR 05-JAN-2000; 2000WO-US00219.
```

PR	06-JAN-2000;	2000WO-US00376.	PR	18-JUN-1998;	98US-089801P.
PR	11-FEB-2000;	2000WO-US03565.	PR	18-JUN-1998;	98US-089907P.
PR	18-FEB-2000;	2000WO-US04341.	PR	18-JUN-1998;	98US-089908P.
PR	22-FEB-2000;	2000WO-US04414.	PR	19-JUN-1998;	98US-089947P.
PR	24-FEB-2000;	2000WO-US04914.	PR	19-JUN-1998;	98US-089948P.
PR	24-FEB-2000;	2000WO-US05004.	PR	19-JUN-1998;	98US-089952P.
PR	02-MAR-2000;	2000WO-US05841.	PR	22-JUN-1998;	98US-090246P.
PR	10-MAR-2000;	2000WO-US06319.	PR	22-JUN-1998;	98US-090252P.
PR	15-MAR-2000;	2000WO-US06884.	PR	22-JUN-1998;	98US-090254P.
PR	20-MAR-2000;	2000WO-US07377.	PR	23-JUN-1998;	98US-090349P.
PR	30-MAR-2000;	2000WO-US08439.	PR	23-JUN-1998;	98US-090355P.
PR	15-MAY-2000;	2000WO-US13358.	PR	24-JUN-1998;	98US-090429P.
PR	17-MAY-2000;	2000WO-US13705.	PR	24-JUN-1998;	98US-090431P.
PR	22-MAY-2000;	2000WO-US14042.	PR	24-JUN-1998;	98US-090435P.
PR	30-MAY-2000;	2000WO-US14941.	PR	24-JUN-1998;	98US-090444P.
PR	02-JUN-2000;	2000WO-US15264.	PR	24-JUN-1998;	98US-090445P.
PR	28-JUL-2000;	2000WO-US20710.	PR	24-JUN-1998;	98US-090472P.
PR	11-AUG-2000;	2000WO-US20231.	PR	24-JUN-1998;	98US-090540P.
PR	23-AUG-2000;	2000WO-US23522.	PR	24-JUN-1998;	98US-090542P.
PR	24-AUG-2000;	2000WO-US23328.	PR	24-JUN-1998;	98US-090557P.
PR	08-NOV-2000;	2000WO-US30952.	PR	25-JUN-1998;	98US-090676P.
PR	01-DEC-2000;	2000WO-US32678.	PR	25-JUN-1998;	98US-090678P.
PR	28-FEB-2001;	2001WO-US06520.	PR	25-JUN-1998;	98US-090690P.
PR	01-JUN-2001;	2001WO-US17800.	PR	25-JUN-1998;	98US-090694P.
PR	20-JUN-2001;	2001WO-US19692.	PR	25-JUN-1998;	98US-090695P.
PR	29-JUN-2001;	2001WO-US21066.	PR	25-JUN-1998;	98US-090696P.
PR	09-JUL-2001;	2001WO-US21735.	PR	26-JUN-1998;	98US-090862P.
PR	16-JUN-1997;	97US-049787P.	PR	26-JUN-1998;	98US-090863P.
PR	17-OCT-1997;	97US-062250P.	PR	01-JUL-1998;	98US-091360P.
PR	12-NOV-1997;	97US-065186P.	PR	01-JUL-1998;	98US-091544P.
PR	13-NOV-1997;	97US-065311P.	PR	02-JUL-1998;	98US-091478P.
PR	24-NOV-1997;	97US-066770P.	PR	02-JUL-1998;	98US-091513P.
PR	25-FEB-1998;	98US-075945P.	PR	02-JUL-1998;	98US-091628P.
PR	20-MAR-1998;	98US-078310P.	PR	02-JUL-1998;	98US-091628P.
PR	28-APR-1998;	98US-083322P.	PR	02-JUL-1998;	98US-091633P.
PR	07-MAY-1998;	98US-084600P.	PR	02-JUL-1998;	98US-091646P.
PR	28-MAY-1998;	98US-087106P.	PR	02-JUL-1998;	98US-091673P.
PR	02-JUN-1998;	98US-087607P.	PR	07-JUL-1998;	98US-091978P.
PR	02-JUN-1998;	98US-087609P.	PR	07-JUL-1998;	98US-091982P.
PR	02-JUN-1998;	98US-087759P.	PR	09-JUL-1998;	98US-092182P.
PR	03-JUN-1998;	98US-087827P.	PR	10-JUL-1998;	98US-092472P.
PR	04-JUN-1998;	98US-088021P.	PR	20-JUL-1998;	98US-093339P.
PR	04-JUN-1998;	98US-088025P.	PR	30-JUL-1998;	98US-094651P.
PR	04-JUN-1998;	98US-088026P.	PR	04-AUG-1998;	98US-095282P.
PR	04-JUN-1998;	98US-088028P.	PR	04-AUG-1998;	98US-095285P.
PR	04-JUN-1998;	98US-088029P.	PR	04-AUG-1998;	98US-095301P.
PR	04-JUN-1998;	98US-088030P.	PR	04-AUG-1998;	98US-095302P.
PR	04-JUN-1998;	98US-088033P.	PR	04-AUG-1998;	98US-095318P.
PR	05-JUN-1998;	98US-088167P.	PR	04-AUG-1998;	98US-095321P.
PR	05-JUN-1998;	98US-088202P.	PR	04-AUG-1998;	98US-095325P.
PR	05-JUN-1998;	98US-088212P.	PR	10-AUG-1998;	98US-095916P.
PR	05-JUN-1998;	98US-088217P.	PR	10-AUG-1998;	98US-095929P.
PR	09-JUN-1998;	98US-088655P.	PR	10-AUG-1998;	98US-096012P.
PR	10-JUN-1998;	98US-088734P.	PR	11-AUG-1998;	98US-096143P.
PR	10-JUN-1998;	98US-088738P.	PR	11-AUG-1998;	98US-096146P.
PR	10-JUN-1998;	98US-088742P.	PR	12-AUG-1998;	98US-096329P.
PR	10-JUN-1998;	98US-088810P.	PR	17-AUG-1998;	98US-096757P.
PR	10-JUN-1998;	98US-088824P.	PR	17-AUG-1998;	98US-096766P.
PR	10-JUN-1998;	98US-088826P.	PR	17-AUG-1998;	98US-096768P.
PR	11-JUN-1998;	98US-088858P.	PR	17-AUG-1998;	98US-096773P.
PR	11-JUN-1998;	98US-088861P.	PR	17-AUG-1998;	98US-096791P.
PR	12-JUN-1998;	98US-088876P.	PR	17-AUG-1998;	98US-096867P.
PR	12-JUN-1998;	98US-089105P.	PR	17-AUG-1998;	98US-096891P.
PR	16-JUN-1998;	98US-089440P.	PR	17-AUG-1998;	98US-096895P.
PR	16-JUN-1998;	98US-089512P.	PR	17-AUG-1998;	98US-096897P.
PR	16-JUN-1998;	98US-089514P.	PR	18-AUG-1998;	98US-096949P.
PR	17-JUN-1998;	98US-089532P.	PR	18-AUG-1998;	98US-096950P.
PR	17-JUN-1998;	98US-089538P.	PR	18-AUG-1998;	98US-096959P.
PR	17-JUN-1998;	98US-089598P.	PR	18-AUG-1998;	98US-096960P.
PR	17-JUN-1998;	98US-089599P.	PR	18-AUG-1998;	98US-097022P.
PR	17-JUN-1998;	98US-089600P.	PR	19-AUG-1998;	98US-097141P.
PR	17-JUN-1998;	98US-089653P.			

PT New transmembrane polypeptides and nucleic acids encoding the
PT polypeptides, useful in gene therapy, in chromosome identification, as
XX chromosome markers, or in generating probes -
XX Example 170; Page 297; 650pp; English.
XX
CC The invention discloses isolated PRO secreted/transmembrane polypeptides
CC comprising a sequence without signal peptide and the nucleic acid
CC encoding them. The polypeptides can be used to raise antibodies that
CC specifically bind to the PRO polypeptide, for linking a bioactive
CC molecule to a cell expressing a PRO protein and for modulating at least
CC one biological activity of a cell. The PRO polypeptides or
CC polynucleotides are also useful in gene therapy, in chromosome
CC identification, as chromosome markers, or in generating probes. The PRO
CC polypeptides are useful as molecular markers for protein
CC electrophoresis, and the isolated nucleic acids may be used for
CC recombinantly expressing those markers. The PRO polypeptides and nucleic
CC acids may also be used in tissue typing. Anti-PRO antibodies are useful
CC in diagnostic assays for PRO, and in affinity purification of PRO from
CC recombinant cell culture or natural sources. The sequences presented in
CC ABX90083-ABX90468 are the genes encoding, the primers amplifying and the
CC probes detecting the PRO polynucleotides of the invention.
CC Note: The sequence data for this patent is also available in electronic
CC format from USPTO at seqdata.uspto.gov/sequence.html.
XX
SQ Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 494 GTGGGACGCGCTTG 508
Db 1 GTGGGACGCGCTTG 15

RESULT 350
ABX78051
ID ABX78051 standard; DNA; 17 BP.
XX
AC ABX78051;
XX
DT 14-APR-2003 (first entry)
XX
DE Human PRO PCR primer #127.
XX
KW Human; PRO; PCR; ss; cytostatic; tumour; cancer; breast; lung; stomach;
KW liver; horse; cow; dog; cat; sheep; pig; goat; rabbit; ADEPT; primer;
KW antibody-dependent enzyme mediated prodrug therapy.
XX
OS Homo sapiens.
XX
FN US2003027163-A1.
XX
PD 06-FEB-2003.
XX
PF 15-NOV-2001; 2001US-0997666.
XX
PR 05-NOV-1997; 97WO-US20069.
PR 16-SEP-1998; 98WO-US19330.
PR 17-SEP-1998; 98WO-US19437.
PR 07-OCT-1998; 98WO-US21141.
PR 01-DEC-1998; 98WO-US21108.
PR 05-JAN-1999; 99WO-US00106.
PR 08-MAR-1999; 99WO-US05028.
PR 02-JUN-1999; 99WO-US12252.
PR 15-SEP-1999; 99WO-US21090.
PR 30-NOV-1999; 99WO-US21547.
PR 01-DEC-1999; 99WO-US28313.
PR 01-DEC-1999; 99WO-US28301.
PR 16-DEC-1999; 99WO-US28634.
PR 20-DEC-1999; 99WO-US30095.
PR 99WO-US30911.

PR 05-JAN-2000; 2000WO-US00219.
PR 06-JAN-2000; 2000WO-US00376.
PR 11-FEB-2000; 2000WO-US03565.
PR 18-FEB-2000; 2000WO-US04341.
PR 22-FEB-2000; 2000WO-US04414.
PR 24-FEB-2000; 2000WO-US04914.
PR 24-FEB-2000; 2000WO-US05004.
PR 02-MAR-2000; 2000WO-US05841.
PR 10-MAR-2000; 2000WO-US06319.
PR 15-MAR-2000; 2000WO-US06884.
PR 20-MAR-2000; 2000WO-US07377.
PR 30-MAR-2000; 2000WO-US08439.
PR 15-MAY-2000; 2000WO-US13358.
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23322.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087106P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088026P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 10-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.

PR 17-JUN-1998; 98US-089553P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089907P.
 PR 18-JUN-1998; 98US-089908P.
 PR 19-JUN-1998; 98US-089947P.
 PR 19-JUN-1998; 98US-089948P.
 PR 19-JUN-1998; 98US-089952P.
 PR 22-JUN-1998; 98US-090246P.
 PR 22-JUN-1998; 98US-090252P.
 PR 22-JUN-1998; 98US-090254P.
 PR 23-JUN-1998; 98US-090349P.
 PR 23-JUN-1998; 98US-090355P.
 PR 24-JUN-1998; 98US-090439P.
 PR 24-JUN-1998; 98US-090431P.
 PR 24-JUN-1998; 98US-090435P.
 PR 24-JUN-1998; 98US-090444P.
 PR 24-JUN-1998; 98US-090445P.
 PR 24-JUN-1998; 98US-090472P.
 PR 24-JUN-1998; 98US-090535P.
 PR 24-JUN-1998; 98US-090540P.
 PR 24-JUN-1998; 98US-090542P.
 PR 24-JUN-1998; 98US-090557P.
 PR 25-JUN-1998; 98US-090676P.
 PR 25-JUN-1998; 98US-090678P.
 PR 25-JUN-1998; 98US-090690P.
 PR 25-JUN-1998; 98US-090694P.
 PR 25-JUN-1998; 98US-090695P.
 PR 25-JUN-1998; 98US-090696P.
 PR 26-JUN-1998; 98US-090862P.
 PR 26-JUN-1998; 98US-090863P.
 PR 01-JUL-1998; 98US-091360P.
 PR 01-JUL-1998; 98US-091544P.
 PR 02-JUL-1998; 98US-091478P.
 PR 02-JUL-1998; 98US-091519P.
 PR 02-JUL-1998; 98US-091628P.
 PR 02-JUL-1998; 98US-091633P.
 PR 02-JUL-1998; 98US-091646P.
 PR 02-JUL-1998; 98US-091673P.
 PR 07-JUL-1998; 98US-091978P.
 PR 07-JUL-1998; 98US-091982P.
 PR 09-JUL-1998; 98US-092182P.
 PR 10-JUL-1998; 98US-092472P.
 PR 20-JUL-1998; 98US-093339P.
 PR 30-JUL-1998; 98US-094651P.
 PR 04-AUG-1998; 98US-095282P.
 PR 04-AUG-1998; 98US-095285P.
 PR 04-AUG-1998; 98US-095301P.
 PR 04-AUG-1998; 98US-095302P.
 PR 04-AUG-1998; 98US-095318P.
 PR 04-AUG-1998; 98US-095321P.
 PR 04-AUG-1998; 98US-095325P.
 PR 10-AUG-1998; 98US-095916P.
 PR 10-AUG-1998; 98US-095929P.
 PR 10-AUG-1998; 98US-096012P.
 PR 11-AUG-1998; 98US-096143P.
 PR 11-AUG-1998; 98US-096146P.
 PR 12-AUG-1998; 98US-096329P.
 PR 17-AUG-1998; 98US-096757P.
 PR 17-AUG-1998; 98US-096766P.
 PR 17-AUG-1998; 98US-096768P.
 PR 17-AUG-1998; 98US-096773P.
 PR 17-AUG-1998; 98US-096791P.
 PR 17-AUG-1998; 98US-096867P.
 PR 17-AUG-1998; 98US-096891P.
 PR 17-AUG-1998; 98US-096894P.
 PR 17-AUG-1998; 98US-096895P.
 PR 17-AUG-1998; 98US-096897P.
 PR 18-AUG-1998; 98US-096949P.
 PR 18-AUG-1998; 98US-096950P.
 PR 18-AUG-1998; 98US-096959P.
 PR 18-AUG-1998; 98US-096960P.
 PR 18-AUG-1998; 98US-097022P.

PR 19-AUG-1998; 98US-097141P.
 PR 20-AUG-1998; 98US-097218P.
 PR 24-AUG-1998; 98US-097661P.
 PR 26-AUG-1998; 98US-097952P.
 PR 26-AUG-1998; 98US-097954P.
 PR 26-AUG-1998; 98US-097955P.
 PR 26-AUG-1998; 98US-097971P.
 PR 26-AUG-1998; 98US-097974P.
 PR 26-AUG-1998; 98US-097978P.
 PR 26-AUG-1998; 98US-097979P.
 PR 26-AUG-1998; 98US-097986P.
 PR 26-AUG-1998; 98US-098014P.
 PR 31-AUG-1998; 98US-098525P.
 PR 16-SEP-1998; 98US-100634P.
 PR 17-SEP-1998; 98US-100858P.
 PR 22-DEC-1998; 98US-113296P.
 PR 12-MAR-1999; 98US-123957P.
 PR 23-JUN-1999; 98US-141037P.
 PR 07-JUL-1999; 98US-143048P.
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 494 GTGTGACGGCTCTTG 508
 DB 1 GTGGGACGGCTCTTG 15
 RESULT 351
 ABX79647
 ID ABX79647 standard; DNA; 17 BP.
 AC ABX79647;
 XX
 XX 17-APR-2003 (first entry)
 DE Human secreted/transmembrane protein, TagMan probe #22.
 XX
 KW Human; probe; ss; PRO; secreted; transmembrane; signal peptide;
 KW pharmaceutical; diagnostic; biosensor; bio-reactor; tumour; therapeutic;
 KW colon cancer; lung cancer; breast cancer; cancer; gene therapy; TagMan.
 XX
 OS Homo sapiens.
 XX
 PN US2002142961-A1.
 PD
 PF 03-OCT-2002.
 XX
 XX 19-NOV-2001; 2001US-0989721.
 XX
 PR 05-NOV-1997; 97WO-US20069.
 PR 17-SEP-1998; 97WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 99WO-US00106.
 PR 08-MAR-1999; 99WO-US05028.
 PR 02-JUN-1999; 99WO-US12252.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 30-NOV-1999; 99WO-US28313.
 PR 01-DEC-1999; 99WO-US28301.
 PR 01-DEC-1999; 99WO-US28634.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.
 PR 05-JAN-2000; 2000WO-US00219.
 PR 05-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 02-MAR-2000; 2000WO-US05004.
 PR 02-MAR-2000; 2000WO-US05841.

PR 10-MAR-2000; 2000WO-US06319.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 20-MAR-2000; 2000WO-US07377.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 15-MAY-2000; 2000WO-US13358.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 16-JUN-1997; 97US-049787P.
 PR 17-OCT-1997; 97US-062250P.
 PR 12-NOV-1997; 97US-065186P.
 PR 13-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-066770P.
 PR 25-FEB-1998; 98US-075945P.
 PR 20-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088026P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088032P.
 PR 05-JUN-1998; 98US-088157P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.
 PR 17-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089907P.
 PR 18-JUN-1998; 98US-089908P.
 PR 28-AUG-2001; 2001US-0941992.
 (GETH) GENENTECH INC.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrera N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoi NF;
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
 PI Zhang Z;
 XX WPI; 2003-155950/15.
 DR
 XX
 XX New secreted and transmembrane PRO polypeptides (e.g. PRO183, PRO184,
 PT PRO361 or PRO846) useful as targets for therapeutic intervention in
 PT cancers (e.g. lung or breast cancers), or for diagnosing these cancers
 PT
 PT
 XX
 XX Example 170; Page 294; 647pp; English.
 PS
 XX The invention discloses isolated PRO secreted/transmembrane polypeptides
 CC comprising a sequence without signal peptide and the nucleic acid
 CC encoding them. The polypeptides can be used to raise antibodies that
 CC specifically bind to the PRO polypeptide, for linking a bioactive
 CC molecule to a cell expressing a PRO protein and for modulating at least
 CC one biological activity of a cell. The PRO polypeptides or
 CC polynucleotides are also useful as pharmaceuticals, diagnostics,
 CC biosensors or bioreactors, for detecting or treating e.g. tumours in
 CC mammals, e.g. humans, dogs, cats, cattle, horses, sheep, pigs, goats or
 CC rabbits as targets for therapeutic intervention in certain cancers (e.g.
 CC colon, lung or breast cancers) and diagnostic determination of the
 CC presence of these cancers. The PRO polypeptides are also useful as
 CC molecular weight markers or for chromosome identification. The PRO genes
 CC are useful as hybridisation probes or for screening libraries of human
 CC cDNA, genomic DNA or mRNA. The PRO genes may also be used in gene
 CC therapy, particularly for replacing a defective gene. The sequences
 CC presented in ABX79290-ABX79675 are the genes encoding, the primers
 CC amplifying and the probes detecting the PRO polynucleotides of the
 CC invention.
 CC Note: The sequence data for this patent is also available in electronic
 CC format from USPTO at seqdata.uspto.gov/sequence.html.
 XX
 XX Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 other;
 SQ
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred.No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 494 GTGTGACAGCGTCTTG 508
 |||||
 Db 1 GTGGGACAGCGTCTTG 15
 RESULT 352
 ABZ60185/c
 ID ABZ60185 standard; RNA; 17 BP.
 XX
 AC ABZ60185;
 XX
 DT 21-MAR-2003 (first entry)
 XX Human K-Ras DNAzyme substrate #297.
 DE
 XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
 KW anti-rheumatic; cancer; AIDS; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200297114-A2.
 PN
 PD 05-DEC-2002.
 XX
 XX 29-MAY-2002; 2002WO-US16840.
 PF
 XX 29-MAY-2001; 2001US-294140P.
 PR 06-JUN-2001; 2001US-296249P.
 PR 10-SEP-2001; 2001US-318471P.


```
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX DR WPI; 2003-140484/13.
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
XX PT treating cancer, modulates the expression of a nucleic acid encoding
XX PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX PT
XX PS Claim 58; Page 90; 185pp; English.
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
XX CC acid molecule or an enzymatic nucleic acid molecule, that modulates
XX CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX CC acid molecule of the invention has cytostatic, anti-HIV, and
XX CC anti-rheumatic activity. The nucleic acid molecules are useful for
XX CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
XX CC acids are also useful for treating breast, ovarian, colorectal, lung,
XX CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
XX CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
XX CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
XX CC sequences for the human ribozymes of the invention.
XX SQ Sequence 17 BP; 4 A; 5 C; 2 G; 6 U; 0 other;
    Query Match 1.0%; Score 13.4; DB 1; Length 17;
    Best Local Similarity 93.3%; Pred. No. 2.1e+02;
    Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    Qy 77 ATGACTAATAGCAGT 91
    Db 17 ATGACTAATAGCAGT 3
RESULT 353
ABZ61172
ID ABZ61172 standard; RNA; 17 BP.
XX AC ABZ61172;
XX DT 21-MAR-2003 (first entry)
XX DE Human K-Ras DNzyme substrate #1284.
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
XX KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX DR WPI; 2003-140484/13.
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
XX PT treating cancer, modulates the expression of a nucleic acid encoding
XX PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX PT
XX PS Claim 58; Page 109; 185pp; English.
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
XX CC acid molecule or an enzymatic nucleic acid molecule, that modulates
XX CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX CC acid molecule of the invention has cytostatic, anti-HIV, and
XX CC anti-rheumatic activity. The nucleic acid molecules are useful for
XX CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
XX CC acids are also useful for treating breast, ovarian, colorectal, lung,
XX CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
XX CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
XX CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
XX CC sequences for the human ribozymes of the invention.
XX SQ Sequence 17 BP; 7 A; 4 C; 5 G; 1 U; 0 other;
    Query Match 1.0%; Score 13.4; DB 1; Length 17;
    Best Local Similarity 93.3%; Pred. No. 2.1e+02;
    Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
    Qy 281 AGGAAGCAGCAGCAA 295
    Db 1 AGGAGCAGCAGCAA 15
RESULT 354
ABZ61566/C
ID ABZ61566 standard; RNA; 17 BP.
XX AC ABZ61566;
XX DT 21-MAR-2003 (first entry)
XX DE Human H-Ras DNzyme target #357.
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
XX KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX DR WPI; 2003-140484/13.
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
XX PT treating cancer, modulates the expression of a nucleic acid encoding
XX PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX PT
XX PS Claim 58; Page 117; 185pp; English.
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
XX CC acid molecule or an enzymatic nucleic acid molecule, that modulates
XX CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX CC acid molecule of the invention has cytostatic, anti-HIV, and
XX CC anti-rheumatic activity. The nucleic acid molecules are useful for
XX CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
XX CC acids are also useful for treating breast, ovarian, colorectal, lung,
XX CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
```

CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
 CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
 CC sequences for the human ribozymes of the invention.

XX SQ Sequence 17 BP; 2 A; 4 C; 8 G; 3 U; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 93.3%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

OY 1293 TGCTCAGCGTGGCC 1307
 DB 16 TGCTCAGCGGCCCC 2

RESULT 355
 ABZ61903
 ID ABZ61903 standard; RNA; 17 BP.

XX AC ABZ61903;
 XX DT 21-MAR-2003 (first entry)
 XX DE Human H-Ras DNase target #694.

XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
 KW anti-rheumatic; cancer; AIDS; ss.

XX OS Homo sapiens.
 XX PN WO200297114-A2.

XX PD 05-DEC-2002.
 XX XX 29-MAY-2002; 2002WO-US16940.

XX PR 29-MAY-2001; 2001US-294140P.
 PR 06-JUN-2001; 2001US-296249P.
 PR 10-SEP-2001; 2001US-318471P.

XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Mcswiggen J;

XX XX WPI; 2003-140484/13.
 XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -

XX PS Claim 58; Page 124; 185pp; English.

XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytostatic, anti-HIV, and
 CC anti-rheumatic activity. The nucleic acid molecules are useful for
 CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
 CC acids are also useful for treating breast, ovarian, colorectal, lung,
 CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
 CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
 CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
 CC sequences for the human ribozymes of the invention.

XX SQ Sequence 17 BP; 1 A; 8 C; 5 G; 3 U; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 17;
 Best Local Similarity 73.3%; Pred. No. 2.1e+02;
 Matches 11; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

OY 231 GCCTCAGGCATCTGC 245

Db |||:|||||:|:|
 2 GCCCAGGCCUCG 16
 RESULT 356
 ABX64286
 ID ABX64286 standard; DNA; 17 BP.
 XX AC ABX64286;
 XX DT 26-FEB-2003 (first entry)
 XX DE Human PRO DNA PCR primer #125.
 XX KW Human; PRO polypeptide; secreted protein; transmembrane protein;
 KW genetic disorder; antibacterial; immunosuppressive; PCR; primer; ss.
 XX OS Homo sapiens.
 XX PN US2002103125-A1.
 XX PD 01-AUG-2002.
 XX XX 20-NOV-2001; 2001US-0989731.
 XX XX 05-NOV-1997; 97WO-US20069.
 PR 16-SEP-1998; 98WO-US19330.
 PR 17-SEP-1998; 98WO-US19437.
 PR 07-OCT-1998; 98WO-US21141.
 PR 01-DEC-1998; 98WO-US25108.
 PR 05-JAN-1999; 99WO-US00106.
 PR 08-MAR-1999; 99WO-US05028.
 PR 02-JUN-1999; 99WO-US12252.
 PR 15-SEP-1999; 99WO-US21090.
 PR 15-SEP-1999; 99WO-US21547.
 PR 30-NOV-1999; 99WO-US28313.
 PR 01-DEC-1999; 99WO-US28301.
 PR 01-DEC-1999; 99WO-US28634.
 PR 16-DEC-1999; 99WO-US30095.
 PR 20-DEC-1999; 99WO-US30911.
 PR 06-JAN-2000; 2000WO-US00219.
 PR 06-JAN-2000; 2000WO-US00376.
 PR 11-FEB-2000; 2000WO-US03565.
 PR 18-FEB-2000; 2000WO-US04341.
 PR 22-FEB-2000; 2000WO-US04414.
 PR 24-FEB-2000; 2000WO-US04914.
 PR 24-FEB-2000; 2000WO-US05004.
 PR 02-MAR-2000; 2000WO-US05841.
 PR 10-MAR-2000; 2000WO-US06319.
 PR 15-MAR-2000; 2000WO-US06884.
 PR 20-MAR-2000; 2000WO-US07177.
 PR 30-MAR-2000; 2000WO-US08439.
 PR 15-MAY-2000; 2000WO-US13358.
 PR 17-MAY-2000; 2000WO-US13705.
 PR 22-MAY-2000; 2000WO-US14042.
 PR 30-MAY-2000; 2000WO-US14941.
 PR 02-JUN-2000; 2000WO-US15264.
 PR 28-JUL-2000; 2000WO-US20710.
 PR 11-AUG-2000; 2000WO-US22031.
 PR 23-AUG-2000; 2000WO-US23522.
 PR 24-AUG-2000; 2000WO-US23328.
 PR 08-NOV-2000; 2000WO-US30952.
 PR 01-DEC-2000; 2000WO-US32678.
 PR 28-FEB-2001; 2001WO-US06520.
 PR 01-JUN-2001; 2001WO-US17800.
 PR 20-JUN-2001; 2001WO-US19692.
 PR 29-JUN-2001; 2001WO-US21066.
 PR 09-JUL-2001; 2001WO-US21735.
 PR 16-JUN-1997; 97US-049787P.
 PR 17-OCT-1997; 97US-062250P.
 PR 12-NOV-1997; 97US-065186P.
 PR 13-NOV-1997; 97US-065311P.
 PR 24-NOV-1997; 97US-065770P.

PR 25-FEB-1998; 98US-075945P.
 PR 20-MAR-1998; 98US-078910P.
 PR 28-APR-1998; 98US-083322P.
 PR 07-MAY-1998; 98US-084600P.
 PR 28-MAY-1998; 98US-087106P.
 PR 02-JUN-1998; 98US-087607P.
 PR 02-JUN-1998; 98US-087609P.
 PR 02-JUN-1998; 98US-087759P.
 PR 03-JUN-1998; 98US-087827P.
 PR 04-JUN-1998; 98US-088021P.
 PR 04-JUN-1998; 98US-088025P.
 PR 04-JUN-1998; 98US-088026P.
 PR 04-JUN-1998; 98US-088028P.
 PR 04-JUN-1998; 98US-088029P.
 PR 04-JUN-1998; 98US-088030P.
 PR 04-JUN-1998; 98US-088033P.
 PR 04-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088167P.
 PR 05-JUN-1998; 98US-088202P.
 PR 05-JUN-1998; 98US-088212P.
 PR 05-JUN-1998; 98US-088217P.
 PR 09-JUN-1998; 98US-088655P.
 PR 10-JUN-1998; 98US-088734P.
 PR 10-JUN-1998; 98US-088738P.
 PR 10-JUN-1998; 98US-088742P.
 PR 10-JUN-1998; 98US-088810P.
 PR 10-JUN-1998; 98US-088824P.
 PR 10-JUN-1998; 98US-088826P.
 PR 11-JUN-1998; 98US-088858P.
 PR 11-JUN-1998; 98US-088861P.
 PR 11-JUN-1998; 98US-088876P.
 PR 12-JUN-1998; 98US-089105P.
 PR 16-JUN-1998; 98US-089440P.
 PR 16-JUN-1998; 98US-089512P.
 PR 16-JUN-1998; 98US-089514P.
 PR 17-JUN-1998; 98US-089532P.
 PR 17-JUN-1998; 98US-089538P.
 PR 17-JUN-1998; 98US-089598P.
 PR 17-JUN-1998; 98US-089599P.
 PR 17-JUN-1998; 98US-089600P.
 PR 17-JUN-1998; 98US-089653P.
 PR 18-JUN-1998; 98US-089801P.
 PR 18-JUN-1998; 98US-089907P.
 PR 18-JUN-1998; 98US-089908P.
 PR 28-AUG-2001; 2001US-0941992.

(GETH) GENENTECH LTD.

PI Ashkenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
 PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
 PI Grimaldi JC, Gurney AL, Kijavini U, Napier MA, Pan J, Paoni NF;
 PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WI;
 PI Zhang Z;

XX WFI; 2003-102117/09.

XX Novel secreted and transmembrane polypeptide for modulating biological
 PT activity of cell expressing the polypeptide, identifying agonists or
 PT antagonists of polypeptide, and as molecular weight markers -

XX Example 170; Page 295; 649pp; English.

XX The present invention relates to the isolation of novel human PRO
 CC polypeptides, and the polynucleotide sequences encoding them. The
 CC PRO polypeptides are secreted and transmembrane proteins. The PRO
 CC polypeptides are useful for detecting other PRO polypeptides, for
 CC linking bioactive molecules to cells expressing PRO polypeptides,
 CC for modulating biological activities of cells expressing PRO
 CC polypeptides, and for identifying agonists or antagonists.
 CC The polynucleotide sequences encoding PRO polypeptides are useful as
 CC hybridisation probes, in chromosome and gene mapping, in the generation
 CC of antisense RNA and DNA, in the preparation of PRO polypeptides, for
 CC generating transgenic animals or knockout animals, to construct

CC hybridisation probes for mapping the gene which encodes the PRO
 CC polypeptide, and for the genetic analysis of individuals with genetic
 CC disorders, in gene therapy, for chromosome identification, as
 CC chromosome markers, and for generating probes for PCR, Northern
 CC analysis, Southern analysis and Western analysis. The present
 CC sequence represents a PCR primer used in the examples of the present
 CC invention.
 CC Note: The sequence data for this patent was obtained in electronic
 CC format directly from the USPTO web site at
 CC seqdata.uspto.gov/psipdsIDentry.html.

XX Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 2.1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 494 GTGTGCGAGCGTCTTG 508

Db 1 GTGGGCGAGCGTCTTG 15

RESULT 357

ABX17250

ID ABX17250 standard; DNA; 17 BP.

AC ABX17250;

DT 04-FEB-2003 (first entry)

DE Human PRO probe #59.

XX Human; PRO; probe; ss; secreted polypeptide; transmembrane polypeptide;

XX toxin; radiolabel; cell death; gene mapping; chromosome mapping;

XX protein electrophoresis; genetic disorder; immunosuppressive; cytostatic;
 antibacterial.

OS Homo sapiens.

PN US2002123463-A1.

XX 05-SEP-2002.

XX 19-NOV-2001; 2001US-0989732.

XX 05-NOV-1997; 97WO-US200069.

XX 16-SEP-1998; 98WO-US19330.

XX 17-SEP-1998; 98WO-US19437.

XX 07-OCT-1998; 98WO-US21141.

XX 01-DEC-1998; 98WO-US25108.

XX 05-JAN-1999; 99WO-US00106.

XX 08-MAR-1999; 99WO-US05028.

XX 02-JUN-1999; 99WO-US12252.

XX 15-SEP-1999; 99WO-US21090.

XX 15-SEP-1999; 99WO-US21547.

XX 30-NOV-1999; 99WO-US28313.

XX 01-DEC-1999; 99WO-US28301.

XX 01-DEC-1999; 99WO-US28634.

XX 16-DEC-1999; 99WO-US30095.

XX 20-DEC-1999; 99WO-US30911.

XX 06-JAN-2000; 2000WO-US00219.

XX 06-JAN-2000; 2000WO-US00376.

XX 11-FEB-2000; 2000WO-US03565.

XX 18-FEB-2000; 2000WO-US04341.

XX 22-FEB-2000; 2000WO-US04414.

XX 24-FEB-2000; 2000WO-US04914.

XX 02-MAR-2000; 2000WO-US05004.

XX 02-MAR-2000; 2000WO-US05841.

XX 10-MAR-2000; 2000WO-US06319.

XX 15-MAR-2000; 2000WO-US06884.

XX 20-MAR-2000; 2000WO-US07377.

XX 30-MAR-2000; 2000WO-US08439.

XX 15-MAY-2000; 2000WO-US13358.

```
PR 17-MAY-2000; 2000WO-US13705.
PR 22-MAY-2000; 2000WO-US14042.
PR 30-MAY-2000; 2000WO-US14941.
PR 02-JUN-2000; 2000WO-US15264.
PR 28-JUL-2000; 2000WO-US20710.
PR 11-AUG-2000; 2000WO-US22031.
PR 23-AUG-2000; 2000WO-US23522.
PR 24-AUG-2000; 2000WO-US23328.
PR 08-NOV-2000; 2000WO-US30952.
PR 01-DEC-2000; 2000WO-US32678.
PR 28-FEB-2001; 2001WO-US06520.
PR 01-JUN-2001; 2001WO-US17800.
PR 20-JUN-2001; 2001WO-US19692.
PR 29-JUN-2001; 2001WO-US21066.
PR 09-JUL-2001; 2001WO-US21735.
PR 16-JUN-1997; 97US-049787P.
PR 17-OCT-1997; 97US-062250P.
PR 12-NOV-1997; 97US-065186P.
PR 13-NOV-1997; 97US-065311P.
PR 24-NOV-1997; 97US-066770P.
PR 25-FEB-1998; 98US-075945P.
PR 20-MAR-1998; 98US-078910P.
PR 28-APR-1998; 98US-083322P.
PR 07-MAY-1998; 98US-084600P.
PR 28-MAY-1998; 98US-087108P.
PR 02-JUN-1998; 98US-087607P.
PR 02-JUN-1998; 98US-087609P.
PR 02-JUN-1998; 98US-087759P.
PR 03-JUN-1998; 98US-087827P.
PR 04-JUN-1998; 98US-088021P.
PR 04-JUN-1998; 98US-088025P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088028P.
PR 04-JUN-1998; 98US-088029P.
PR 04-JUN-1998; 98US-088030P.
PR 04-JUN-1998; 98US-088033P.
PR 04-JUN-1998; 98US-088326P.
PR 05-JUN-1998; 98US-088167P.
PR 05-JUN-1998; 98US-088202P.
PR 05-JUN-1998; 98US-088212P.
PR 05-JUN-1998; 98US-088217P.
PR 09-JUN-1998; 98US-088655P.
PR 10-JUN-1998; 98US-088734P.
PR 10-JUN-1998; 98US-088738P.
PR 10-JUN-1998; 98US-088742P.
PR 10-JUN-1998; 98US-088810P.
PR 10-JUN-1998; 98US-088824P.
PR 11-JUN-1998; 98US-088826P.
PR 11-JUN-1998; 98US-088858P.
PR 11-JUN-1998; 98US-088861P.
PR 11-JUN-1998; 98US-088876P.
PR 12-JUN-1998; 98US-089105P.
PR 16-JUN-1998; 98US-089440P.
PR 16-JUN-1998; 98US-089512P.
PR 16-JUN-1998; 98US-089514P.
PR 17-JUN-1998; 98US-089532P.
PR 17-JUN-1998; 98US-089538P.
PR 17-JUN-1998; 98US-089598P.
PR 17-JUN-1998; 98US-089599P.
PR 17-JUN-1998; 98US-089600P.
PR 17-JUN-1998; 98US-089653P.
PR 18-JUN-1998; 98US-089801P.
PR 18-JUN-1998; 98US-089807P.
PR 18-JUN-1998; 98US-089908P.
PR 28-AUG-2001; 2001US-0941922.
XX
XX (GETH ) GENENTECH INC.
XX
PI Askenazi AJ, Baker KP, Botstein D, Desnoyers L, Eaton DL;
PI Ferrara N, Fong S, Gerber H, Gerritsen ME, Goddard A, Godowski PJ;
PI Grimaldi JC, Gurney AL, Kljavin IJ, Napier MA, Pan J, Paoni NF;
PI Roy MA, Stewart TA, Tumas D, Watanabe CK, Williams PM, Wood WT;
PI Zhang Z;
```

XX WPI; 2003-066810/06.

XX Novel secreted and transmembrane polypeptide for modulating biological

PT activity of cell expressing the polypeptide, identifying agonists or

PT antagonists of polypeptide, and as molecular weight markers

XX Example 170; Page 301; 655pp; English.

XX The invention relates to a secreted and transmembrane polypeptide, termed

CC PRO polypeptide, and the polynucleotide encoding it. The polypeptide is

CC useful for detecting PRO polypeptides and for linking a bioactive

CC molecule to a cell expressing the above polypeptides, where the bioactive

CC molecule is a toxin, radiolabel or an antibody. The bioactive material

CC causes the death of the cell. The polypeptide is useful for identifying

CC agonists or antagonists of the PRO polypeptide, for preparing variants of

CC PRO, as a molecular weight marker for protein electrophoresis purposes

CC and the PRO polynucleotide is useful for recombinantly expressing those

CC markers. The polynucleotide is also useful as a hybridisation probe, in

CC chromosome and gene mapping, in generation of antisense RNA and DNA, in

CC the preparation of PRO polypeptide, for generating transgenic animals or

CC knockout animals which in turn are useful in the development and

CC screening of therapeutically useful reagents, to construct hybridisation

CC probes for mapping the gene which encodes PRO and for the genetic

CC analysis of individuals with genetic disorders, in gene therapy, for

CC chromosome identification, as a chromosome marker and for generating

CC probes for PCR, Northern analysis, Southern analysis and Western

CC analysis. This sequence represents a human PRO probe of the invention.

XX

SQ Sequence 17 BP; 1 A; 4 C; 7 G; 5 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. NO. 2.1e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 494 GTGTGACAGCGCTCTTG 508

Db 1 GTGGGACAGCGCTCTTG 15

|||||

RESULT 358

AAQ26549/c

ID AAQ26549 standard; DNA; 18 BP.

XX AAQ26549;

XX

XX 08-JAN-1993 (first entry)

XX

XX Control probe #4 for caucosoid RING11 gene.

XX immunosuppressants; immunoenhancers, treatment; diagnosis; screening;

KW immune disorders; transporter peptides; proteasome complex;

KW MHC class I molecules; HLA; antigen processing;

KW antigen presentation; autoimmune disease; ankylosing spondylitis;

XX prenatal diagnosis; polymerase chain reaction; ss.

OS Synthetic.

XX

XX WO9211289-A.

XX

XX 09-JUL-1992.

XX

XX 19-DEC-1991; 91WO-GB02278.

XX

XX 19-DEC-1990; 90GB-0027520.

PR 16-SEP-1991; 91GB-0019711.

XX

XX (IMCR) IMPERIAL CANCER RES TECHNOLOGY.

XX

XX Glynne R, Kelly AP, Powis SH, Trowsdale J;

XX WPI; 1992-250030/30.

XX

PT DNA encoding RING4, RING10, RING11 AND RING12 proteins - for
PT treatment and diagnosis of immune disorders and screening of new
PT immunosuppressants and immuno-enhancers
XX
XX Example 2; Page 40; 101pp; English.
XX
XX This probe was used together with AAQ26546-51 to analyse caucosoid
CC controls by oligonucleotide typing, whilst investigating RING 11
CC polymorphisms - see AAQ26544,5.
XX
SQ Sequence 18 BP; 3 A; 6 C; 6 G; 3 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 625 GACACAGCTCCAGGAG 639
Db 16 GCCCAGCTCCAGGAG 2

RESULT 359
AAQ52841/c
ID AAQ52841 standard; RNA; 18 BP.
XX
AC AAQ52841;
XX
DT 25-MAR-2003 (updated)
DT 26-MAY-1994 (first entry)
XX
XX Cytomegalovirus target sequence 18.
XX
XX RNA; enzyme; enzymatic RNA molecule; ERM; cleave; RNA; mRNA; HnRNA;
KW picornavirus; HIV; immunodeficiency virus; hepatitis B virus; HBV;
KW papilloma virus; HPV; Epstein-Barr virus; EBV; TCLV;
KW T-cell leukaemia virus; hepatitis C virus; HCV; cytomegalovirus;
KW influenza virus; HSV; herpes simplex virus; vector; immune response;
KW antibody; ribozyme; viral RNA; treatment; ss.
XX
OS Synthetic.
XX
XX WO9323569-A1.
XX
XX 25-NOV-1993.
XX
XX 29-APR-1993; 93WO-US04020.
XX
XX 11-MAY-1992; 92US-0882689.
PR 14-MAY-1992; 92US-0882712.
PR 14-MAY-1992; 92US-0882713.
PR 14-MAY-1992; 92US-0882714.
PR 14-MAY-1992; 92US-0882823.
PR 14-MAY-1992; 92US-0882824.
PR 14-MAY-1992; 92US-0882886.
PR 14-MAY-1992; 92US-0882888.
PR 14-MAY-1992; 92US-0882889.
PR 14-MAY-1992; 92US-0882921.
PR 14-MAY-1992; 92US-0882922.
PR 14-MAY-1992; 92US-0883823.
PR 14-MAY-1992; 92US-0883849.
PR 14-MAY-1992; 92US-0884073.
PR 14-MAY-1992; 92US-0884074.
PR 14-MAY-1992; 92US-0884333.
PR 14-MAY-1992; 92US-0884422.
PR 14-MAY-1992; 92US-0884431.
PR 14-MAY-1992; 92US-0884436.
PR 31-JUL-1992; 92US-0923738.
PR 26-AUG-1992; 92US-0935854.
PR 26-AUG-1992; 92US-0936086.
PR 18-SEP-1992; 92US-0948359.
PR 15-OCT-1992; 92US-0963322.
PR 07-DEC-1992; 92US-0987129.

PR 07-DEC-1992; 92US-0987130.
PR 07-DEC-1992; 92US-0987133.
XX
XX (RIBO-) RIBOZYME PHARM INC.
XX
XX Draper KG, Dudycz LW, Mcswiggen JA, Macejak DG, Holecck JJ;
PI Mamone JA;
XX
XX WPI; 1993-386599/48.
XX
XX Enzymatic RNA molecules - used to inhibit viral replication,
PT infection and gene expression
XX
XX Claim 5; Fig 13; 287pp; English.
XX
XX The sequences (AAQ52824-Q52890) are pref. Cytomegalovirus target
CC sequences for enzymatic RNA molecules. The RNA molecules are
CC complementary to a substrate binding region in the specified gene
CC target. They also have enzymatic activity, in that they specifically
CC cleave RNA in the target. The ERMs interfere with viral replication and
CC therefore have anti-viral properties. They can be used to attenuate
CC viruses to be used in vaccines.
CC (Updated on 25-MAR-2003 to correct PN field.)
CC (Updated on 25-MAR-2003 to correct PR field.)
CC (Updated on 25-MAR-2003 to correct PI field.)
XX
XX Sequence 18 BP; 8 A; 4 C; 4 G; 2 U; 0 other;
SQ

Query Match 1.0%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 703 CTCCTTGATTCGTG 717
Db 15 CTCCTTGATTCGTG 1

RESULT 360
AAAX67098
ID AAX67098 standard; RNA; 18 BP.
XX
XX AAX67098;
XX
XX 20-JUL-1999 (first entry)
XX
XX Human B7-2 hairpin ribozyme target SEQ ID NO:3730.
XX
XX Arthritic condition; graft tolerance; immune response; target; cleavage;
KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
KW diagnosis; ss.
XX
XX Homo sapiens.
XX
XX WO9618736-A2.
XX
XX 20-JUN-1996.
XX
XX 22-NOV-1995; 95WO-US15516.
XX
XX 05-OCT-1995; 95US-0541365.
PR 13-DEC-1994; 94US-0354920.
PR 23-DEC-1994; 94US-0363253.
PR 23-DEC-1994; 94US-0363254.
PR 17-FEB-1995; 95US-0390850.
PR 20-APR-1995; 95US-0426124.
PR 02-MAY-1995; 95US-0432874.
PR 04-MAY-1995; 95US-0434509.
PR 07-JUL-1995; 95US-0000951.
PR 07-JUL-1995; 95US-0000974.
PR 07-AUG-1995; 95US-0512861.
XX

PA (RIBO-) RIBOZYME PHARM INC.
 XX Draper K, Gustofson J, McSwiggen J, Pavco P, Stinchcomb DT;
 PI Beigelman L, Karpeisky A, Modak A, Usman N, Burgin A;
 PI Matulich-Adamic J, Jarvis T, Thompson JD, Wincott F;
 XX WPI; 1996-300653/30.
 XX Enzymatic nucleic acid molecules having a hammer-head motif - used
 PT for the treatment of arthritis, induction of graft tolerance or
 PT treatment of auto-immune diseases
 XX Claim 10; Page 216; 307pp; English.
 XX The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose
 CC residues; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii)
 CC at least ten 2'-O-methyl modifications; and (iv) a 3'-end modification.
 CC The ENA's can inhibit collagenase and stromelysin production in the
 CC synovial membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention.
 XX Sequence 18 BP; 3 A; 3 C; 2 G; 10 U; 0 other;
 SQ Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 33.3%; Pred. No. 2.3e+02;
 Matches 5; Conservative 9; Mismatches 1; Indels 0; Gaps 0;
 QY 1111 GTTTTCTGTTTAATT 1125
 Db 1 GUUUUCUGCUAAU 15
 RESULT 361
 AAV54171
 ID AAV54171 standard; cDNA; 18 BP.
 AC AAV54171;
 AC AAV54171;
 DT 21-DEC-1998 (first entry)
 XX Nucleotide sequence PCR primer 8.
 DE PCR; primer; amplification; apoptosis; antibody; inhibition; ss;
 KW immunohistological staining.
 XX Synthetic.
 OS WO9839437-A1.
 PN 11-SEP-1998.
 PD 05-MAR-1998; 98WO-JF00905.
 PF 05-MAR-1997; 97JP-0050302.
 PR (KYOW) KYOWA HAKKO KOGYO KK.
 PA Sakaki Y;
 PI WPI; 1998-495844/42.
 DR
 XX

PT Novel apoptosis-related DNAs and proteins - for diagnosis,
 PT preventing or treating diseases associated with apoptosis
 XX Example 1; Page 49; 70pp; Japanese.
 XX This is the nucleotide sequence of a PCR primer used in the method
 CC of the invention, involving the use of novel apoptosis-related DNAs
 CC and proteins. The inventions can be used as diagnostic reagents for
 CC apoptosis e.g. (monoclonal) antibodies for the protein, as a reagent
 CC in immunohistological staining, as apoptosis inhibitors. It can also
 CC be used for treatment of apoptosis-related diseases.
 XX Sequence 18 BP; 0 A; 0 C; 3 G; 15 T; 0 other;
 SQ Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 1144 TTTTCTCTTTTGG 1158
 Db 4 TTTTCTTTTGG 18
 RESULT 362
 AAA48761/C
 ID AAA48761 standard; DNA; 18 BP.
 AC AAA48761;
 XX 08-SEP-2000 (first entry)
 DT Human G-alpha-16 antisense oligonucleotide ISIS# 20818.
 DE Human; G-alpha-16; G protein; cytostatic; hyperproliferative disorder;
 KW cancer; inflammation; infection; antisense inhibition; ss.
 OS Homo sapiens.
 XX WO200032817-A1.
 PN 08-JUN-2000.
 PD 25-AUG-1999; 99WO-US19613.
 PF 03-DEC-1998; 98US-0205143.
 PR (ISIS-) ISIS PHARM INC.
 PA Cowser LM;
 PI WPI; 2000-412354/35.
 DR A new antisense compound for inhibiting the expression of human
 PT G-alpha-16 and treating, preventing or delaying infections,
 PT inflammation or hyperproliferative disorders such as cancer -
 XX Example 15; Page 72; 100pp; English.
 XX The present sequence is an antisense oligonucleotide used to
 CC modulate expression of G-alpha-16. G-alpha-16 is a human G protein which
 CC interacts differentially with several receptor types including members
 CC of the opioid and chemokine receptor families. A series of antisense
 CC oligonucleotides have been designed to target different regions of the
 CC human G-alpha-16 RNA. They may be used to inhibit the expression of
 CC G-alpha-16 in human cells and tissues and thus to treat diseases
 CC associated with G-alpha-16, such as hyperproliferative disorders,
 CC especially cancer. Infections, inflammation or tumour formation can
 CC be prevented or delayed. The compounds can be used in research and
 CC diagnostics in sandwich and other assays.
 CC Note: The sequence has a phosphorothioate backbone and may be
 CC either an oligodeoxynucleotide or a chimeric oligonucleotide
 CC containing 2'-methoxyethyl (2'-MOE) wings and a deoxy gap. The ISIS
 CC number given above corresponds to the oligodeoxynucleotide sequence.

XX SQ Sequence 18 BP; 4 A; 8 C; 2 G; 4 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1336 GTGTTTCAGGCGAGG 1350
 Db 16 GTGTTTCAGGCGAAG 2

RESULT 363
 AAA10983
 ID AAA10983 standard; DNA; 18 BP.
 AC AAA10983;
 DT 20-JUL-2000 (first entry)
 DE DNA sequence #4 used in target nucleic acid detection method.
 XX Detect; target analyte; electrode array; environmental pollutant;
 KW pesticide; insecticide; toxin; chemical; virus; spore; ss.
 XX Synthetic.
 OS
 FH Key Location/Qualifiers
 FT modified_base 18 /*tag= a
 FT /mod_base= OTHER
 FT /note= "OTHER = T(CH2)16SH"
 XX WO200016089-A2.

XX PD 23-MAR-2000.
 XX PF 17-SEP-1999; 99WO-US21683.
 XX PR 17-SEP-1998; 98US-0100730.
 XX (CLIN-) CLINICAL MICRO SENSORS INC.
 XX O'Connor SD;
 DR WPI; 2000-271554/23.

XX PT Signal processing method useful for achieving higher signal to noise ratios and to increase detection limits of target analytes -
 XX Example 2; Page 122; 145pp; English.

XX CC This sequence represents an oligonucleotide used as a detection probe in an array for the detection of target analytes. The invention relates to the detection of target analytes in a sample using an electrode array. At least one electrode forms an assay complex consisting of a capture binding ligand covalently attached to the electrode, a target analyte, and an electron transfer moiety. An input signal is applied to the assay complex, and the resulting output signal is processed to detect the presence of the target analytes. Preferred analytes include proteins and nucleic acids. However, the analyte may also be an environmental pollutant (pesticides, insecticides or toxins), a chemical (solvent or organic material), biomolecules (hormones, cytokines, proteins, lipids, carbohydrates, cellular membrane antigens and receptors), whole cells (prokaryotic and eukaryotic cells), viruses, and spores. The method achieves higher signal to noise ratios to increase the detection limits of the target analytes.

XX SQ Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 GCAGTTGAGGTGGAT 21
 Db 4 GCAGTTGAGGTGGAT 18

RESULT 364
 AAA10986/c
 ID AAA10986 standard; DNA; 18 BP.
 AC AAA10986;
 DT 20-JUL-2000 (first entry)
 DE Partial signalling probe sequence used in analyte detection method.
 XX Detect; target analyte; electrode array; environmental pollutant; ss;
 KW pesticide; insecticide; toxin; chemical; virus; spore; signalling probe.
 XX Synthetic.
 OS
 FN WO200016089-A2.
 XX PD 23-MAR-2000.
 XX PF 17-SEP-1999; 99WO-US21683.
 XX PR 17-SEP-1998; 98US-0100730.
 XX (CLIN-) CLINICAL MICRO SENSORS INC.
 XX O'Connor SD;
 DR WPI; 2000-271554/23.

XX PT Signal processing method useful for achieving higher signal to noise ratios and to increase detection limits of target analytes -
 XX Example 2; Page 122; 145pp; English.

XX CC This sequence represents a signalling probe used in an example of the method of the invention. The invention relates to the detection of target analytes in a sample using an electrode array. At least one electrode forms an assay complex consisting of a capture binding ligand covalently attached to the electrode, a target analyte, and an electron transfer moiety. An input signal is applied to the assay complex, and the resulting output signal is processed to detect the presence of the target analytes. Preferred analytes include proteins and nucleic acids. However, the analyte may also be an environmental pollutant (pesticides, insecticides or toxins), a chemical (solvent or organic material), biomolecules (hormones, cytokines, proteins, lipids, carbohydrates, cellular membrane antigens and receptors), whole cells (prokaryotic and eukaryotic cells), viruses, and spores. The method achieves higher signal to noise ratios to increase the detection limits of the target analytes.

XX SQ Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 GCAGTTGAGGTGGAT 21
 Db 15 GCAGTTGAGGTGGAT 1

RESULT 365
 AAA290641
 ID AAA290641 standard; DNA; 18 BP.
 AC AAA290641;
 DT 13-JUN-2000 (first entry)

```

XX DE Human adipose tissue gene amplifying primer #2.
XX KW Adipose tissue; obesity; diabetes; hyperlipemia; hypertension; human;
XX KW arteriosclerosis; hyperuricemia; sleep apnea syndrome; PCR primer; ss.
XX OS Homo sapiens.
XX PN JF2000037190-A.
XX PD 08-FEB-2000.
XX PF 23-JUL-1998; 98JP-0225228.
XX PR 23-JUL-1998; 98JP-0225228.
XX PA (NISB ) JAPAN TOBACCO INC.
XX DR WPI; 2000-306578/27.
XX FT A physiologically active protein specifically derived from mammal
XX FT tissue -
XX PS Example 2; Page 18; 50pp; Japanese.
XX CC The invention relates to identification of genes and proteins of adipose
XX CC tissue relating to obesity, particularly complications of visceral
XX CC obesity including diabetes, hyperlipemia, hypertension,
XX CC arteriosclerosis, hyperuricemia and sleep apnea syndrome. The genes
XX CC (AAZ90631-633) and the proteins (AAV67598-Y67600) are used in the genetic
XX CC diagnosis, prevention and treatment of adipose tissue related diseases.
XX CC Sequences AAZ90640-51 represent PCR primers amplifying the human adipose
XX CC tissue genes.
XX SQ Sequence 18 BP; 0 A; 0 C; 3 G; 15 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1144 TTTTTCCTTTTTCG 1158
Db 4 TTTTTCCTTTTTCG 18

RESULT 366
AAZ97002
ID AAZ97002 standard; DNA; 18 BP.
XX AC AAZ97002;
XX DT 14-APR-2000 (first entry)
XX DE Nucleotide sequence of DNA4.
XX KW Target analyte; nucleic acid detection; capture ligand; pesticide;
XX KW electron transfer moiety; pollutant; therapeutic drug; cancer;
XX KW Alzheimer's disease; cystic fibrosis; blood screening; water testing;
XX KW forensic fingerprinting; ss.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 18
XX FT /*tag= a
XX FT /note= "T(CH2)16SH"
XX PN WO9967425-A2.
XX XX 29-DEC-1999.
XX PD 23-JUN-1999; 99WO-US14191.
XX PF 23-JUN-1999; 99WO-US14191.
XX XX

```

```

PR 23-JUN-1998; 98US-0090389.
PR 14-AUG-1998; 98US-0134058.
XX (CLIN-) CLINICAL MICRO SENSORS INC.
XX PI Kayyem JF, Blackburn G, O'Connor SD;
XX DR WPI; 2000-136990/12.
XX CC Complex-forming assay for analyte, particularly nucleic acid, used e.g.
XX CC in detecting genetic disease, with accelerated complex formation by
XX CC electrophoretic concentration of analyte -
XX PS Example 2; Page 113; 140pp; English.
XX CC The invention relates to a method of detecting a target analyte that
XX CC comprises concentrating the analyte in a detection chamber comprising a
XX CC detection electrode with a covalently attached capture ligand to form an
XX CC assay complex comprising the analyte, ligand and at least 1 electron
XX CC transfer moiety (ETM), and detecting the ETM with the the detection
XX CC electrode. The method is particularly used for assaying nucleic acids or
XX CC proteins, but more generally the target analyte is any compound for which
XX CC a binding partner is available, e.g. pesticide or other pollutants;
XX CC therapeutic or illicit drugs; whole cells; viruses etc. Particularly the
XX CC method is used in array formats, optionally with many thousands of
XX CC different capture ligands. Particular applications are detecting genes
XX CC associated with cancer, Alzheimer's disease, cystic fibrosis etc.;
XX CC detecting bacteria and viruses (e.g. for blood screening or testing water
XX CC or foods); for forensic fingerprinting; for sequencing and for detecting
XX CC successful gene amplification. The rate of complex formation is
XX CC increased, resulting in more sensitive detection, particularly down to
XX CC 100 molecules. The present sequence represents a DNA fragment used in the
XX CC course of the invention for detection of target sequences.
XX SQ Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 7 GCAGTTGAGGTGGAT 21
Db 4 GCAGTTGAGGTGGAT 18

RESULT 367
AAZ97005/C
ID AAZ97005 standard; DNA; 18 BP.
XX AC AAZ97005;
XX DT 14-APR-2000 (first entry)
XX DE Nucleotide sequence of a 30nm signalling probe D-1055.
XX KW Target analyte; nucleic acid detection; capture ligand; pesticide;
XX KW electron transfer moiety; pollutant; therapeutic drug; cancer;
XX KW Alzheimer's disease; cystic fibrosis; blood screening; water testing;
XX KW forensic fingerprinting; ss.
XX OS Synthetic.
XX PN WO9967425-A2.
XX XX 29-DEC-1999.
XX PD 23-JUN-1999; 99WO-US14191.
XX PF 23-JUN-1998; 98US-0090389.
XX PR 14-AUG-1998; 98US-0134058.
XX XX (CLIN-) CLINICAL MICRO SENSORS INC.
XX XX

```


PI Kayyem JF, Blackburn G, O'Connor SD;
 XX WPI; 2000-136990/12.
 XX
 XX Complex-forming assay for analyte, particularly nucleic acid, used e.g.
 PT in detecting genetic disease, with accelerated complex formation by
 PT electrophoretic concentration of analyte -
 XX
 XX Example 2; Page 113; 140pp; English.
 PS
 XX The invention relates to a method of detecting a target analyte that
 CC comprises concentrating the analyte in a detection chamber comprising a
 CC detection electrode with a covalently attached capture ligand to form an
 CC assay complex comprising the analyte, ligand and at least 1 electron
 CC transfer moiety (ETM), and detecting the ETM with the the detection
 CC electrode. The method is particularly used for assaying nucleic acids or
 CC proteins, but more generally the target analyte is any compound for which
 CC a binding partner is available, e.g. pesticide or other pollutants;
 CC therapeutic or illicit drugs; whole cells; viruses etc. Particularly the
 CC method is used in array formats, optionally with many thousands of
 CC different capture ligands. Particular applications are detecting genes
 CC associated with cancer, Alzheimer's disease, cystic fibrosis etc.;
 CC detecting bacteria and viruses (e.g. for blood screening or testing water
 CC or foods); for forensic fingerprinting; for sequencing and for detecting
 CC successful gene amplification. The rate of complex formation is
 CC increased, resulting in more sensitive detection, particularly down to
 CC 100 molecules. The present sequence represents a signalling probe used in
 CC the course of the invention for detection of target sequences.
 CC
 XX Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 other;
 SQ
 Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 7 GCAGTTGAGTGGAT 21
 DB 15 GCAGTTGACGTGGAT 1
 RESULT 368
 AA244140/C
 ID AA244140 standard; DNA; 18 BP.
 XX
 XX AA244140;
 AC
 XX
 DT 24-MAR-2000 (first entry)
 XX
 DE Human EGR-1 DNA antisense primer #24162.
 XX
 KW EGR-1; early growth response 1; antisense; inhibition; human; primer;
 KW anti-inflammatory; cytostatic; antiviral; detection; diagnosis;
 KW viral infection; inflammation; tumor; ss.
 XX
 OS Homo sapiens.
 XX
 XX US6008048-A.
 PN
 XX 28-DEC-1999.
 PD
 XX
 PF 04-DEC-1998; 98US-0205921.
 PP
 XX
 PR 04-DEC-1998; 98US-0205921.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Monia BP, Cowseert LM;
 PI
 XX WPI; 2000-096375/08.
 XX
 XX Antisense oligonucleotides that inhibit expression of human early
 PT growth response-1, useful for diagnosis, treatment and prevention of
 PT tumors, inflammation and infection -
 XX
 XX Claim 1; Column 37-38; 31pp; English.
 PS
 XX This invention describes novel antisense oligonucleotides (I) capable of
 CC inhibiting expression of human EGR-1 (early growth response-1). The
 CC products of the invention have anti-inflammatory, cytostatic and
 CC antiviral activity. (I) was tested for its effects on EGR-1 mRNA levels
 CC by real-time polymerase chain reaction (PCR), results indicated that 60%
 CC inhibition was achieved. When (I) was modified by 2'-O-methoxyethyl
 CC substitution of the first 4 and last 4 residues, and by replacing any C
 CC in these flanking regions with 5-methyl-C, the degree of inhibition was
 CC increased to 71%. (I) is used to inhibit expression of EGR-1 in cells
 CC and tissues in vitro, for research or diagnosis, e.g. detecting EGR-1
 CC encoding nucleic acid. (I) may also be used to treat or prevent
 CC EGR-1-associated diseases, particularly viral infections, inflammation
 CC and tumors. AA244124-244169 represent antisense primers used to inhibit
 CC the human EGR-1 protein.
 XX
 XX Sequence 18 BP; 4 A; 8 C; 3 G; 3 T; 0 other;
 SQ
 Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 348 CAGTGGCCGAGTGAG 362
 DB 15 CAGTGGCCCTAGTGAG 1
 RESULT 369
 AA235905/C
 ID AA235905 standard; DNA; 18 BP.
 XX
 XX AA235905;
 AC
 XX
 DT 03-FEB-2000 (first entry)
 XX
 DE Human sentrin phosphorothioate antisense oligonucleotide SEQ ID NO:47.
 XX
 KW Human; sentrin; antisense oligonucleotide; phosphorothioate;
 KW inhibition; modulation; expression; diagnosis; ss.
 XX
 OS Synthetic.
 XX
 XX Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FT modified_base 1..18
 FT /tag= a
 FT /note= "phosphorothioate linkages"
 XX
 XX US5985664-A.
 PN
 XX 16-NOV-1999.
 PD
 XX
 PF 17-DEC-1998; 98US-0213768.
 PP
 XX
 PR 17-DEC-1998; 98US-0213768.
 XX
 XX (ISIS-) ISIS PHARM INC.
 PA
 XX Baker BF, Cowseert LM;
 PI
 XX WPI; 2000-022284/02.
 XX
 XX Antisense compound which modulates human sentrin expression, useful for
 PT treating diseases associated with sentrin expression -
 XX
 XX Example 15; Column 38; 29pp; English.
 PS
 XX The present invention describes an antisense compound (I) 8-30
 CC nucleotides long targeted to a nucleic acid molecule encoding human
 CC sentrin. The antisense compound comprises a phosphorothioate antisense
 CC oligonucleotide which inhibits expression of human sentrin. (I) is

CC useful for inhibiting expression of sentrin in human cells or tissues
 CC in vitro, for treating humans or other animals suspected of having or
 CC being prone to a disease associated with sentrin expression. (1) can
 CC also be used for research or diagnostic purposes. The present
 CC sequence represents a human sentrin phosphorothioate antisense
 CC oligonucleotide from the present invention.
 XX
 SQ Sequence 18 BP; 4 A; 5 C; 3 G; 6 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 440 GAAAGTTCCTGAAGT 454
 DB 18 GAAAGTTACTGAAGT 4
 RESULT 370
 AAH75239
 ID AAH75239 standard; DNA; 18 BP.
 XX AC AAH75239;
 XX DT 02-OCT-2001 (first entry)
 XX DE Human inducible NOS antisense oligonucleotide SEQ ID NO 83.
 XX KW Antisense oligonucleotide; inducible nitric oxide synthase; NOS;
 KW modulate expression; immunomodulator; antidiabetic; cardiovascular;
 KW cardiant; neuroprotective; vasotropic; ischaemia; reperfusion injury;
 KW 2'-O-methoxyethyl; phosphorothioate; human; ss.
 XX OS Homo sapiens.
 XX FH Key Location/Qualifiers
 FT modified_base 1..18
 FT /*tag= a
 FT /mod_base= OTHER
 FT /note= "phosphorothioate backbone, 5' and 3' four
 FT nucleotide 2'-MOE (2'-methoxyethyl) wings, all
 FT cytidine residues are 5-methylcytidines and a
 FT deoxy gap"
 XX PN WO200152902-A1.
 XX DD 26-JUL-2001.
 XX PF 15-JAN-2001; 2001WO-US01381.
 XX PR 24-JAN-2000; 2000US-0490208.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Bennett CF, Dean NM, Cowseert LM;
 XX WPI; 2001-465340/50.
 XX PT New antisense oligonucleotides for modulating the expression of
 PT inducible nitric oxide synthase in cells or tissues, particularly
 PT useful for treating e.g. immunological, cardiovascular or neurological
 PT disorders, or ischaemia -
 XX PS Claim 3; Page 84; 144pp; English.
 CC The invention relates to antisense compounds, especially
 CC oligonucleotides, which are targeted to a nucleic acid encoding inducible
 CC nitric oxide synthase and which specifically hybridise to and modulate
 CC expression of inducible nitric oxide synthase. The antisense compounds
 CC have immunomodulator, antidiabetic, cardiovascular, cardiant,
 CC neuroprotective, disorder and vasotropic activity. The antisense
 CC oligonucleotides are useful for inhibiting the expression of inducible
 CC nitric oxide synthase in cells or tissues. In particular, the antisense

CC oligonucleotides are useful for treating diseases or disorders associated
 CC with inducible nitric oxide synthase, e.g. diabetes, immunological
 CC disorder, cardiovascular disorder, neurological disorder or
 CC ischaemia/reperfusion injury. The antisense oligonucleotides are also
 CC useful for research and diagnostics. The present sequence is that of an
 CC antisense 2'-O-methoxyethyl gapmer oligonucleotide with a
 CC phosphorothioate backbone, a central "gap" region of ten nucleotides
 CC flanked by four nucleotide 2'-MOE (2'-methoxyethyl) wings and
 CC 5-methylcytidine residues throughout the oligonucleotide. The antisense
 CC oligonucleotide is targeted to human inducible nitric oxide synthase (NOS)
 CC mRNA (AAH47973).
 XX
 SQ Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 other;
 Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 552 GGCAGGCATGCACAC 566
 DB 4 GGCAGGCACGCACAC 18
 RESULT 371
 AAH55881
 ID AAH55881 standard; DNA; 18 BP.
 XX AC AAH55881;
 XX DT 04-SEP-2001 (first entry)
 XX DE Human SCN1A PCR-SSCP PCR primer SEQ ID NO:125.
 XX KW Human; epilepsy; chromosome 2; SCN1A; SCN2A; SCN3A; identification;
 KW diagnosis; mutation; chromosome 2q23-q31; neurological disorder;
 KW anticonvulsant; neuroprotective; PCR primer; ss.
 XX OS Homo sapiens.
 XX OS Synthetic.
 XX PN WO200138564-A2.
 XX PD 31-MAY-2001.
 XX PF 24-NOV-2000; 2000WO-CA01404.
 XX PR 26-NOV-1999; 99US-0167623.
 XX PA (UYWC-) UNIV MCGILL.
 XX PI Rouleau GA, LaFreniere RG, Rochefort D, Cossette P, Ragsdale D;
 XX WPI; 2001-355945/37.
 XX PT Determining a predisposition to epilepsy and/or development of epilepsy
 PT comprises determining the genotype of SCN1A, SCN2A and/or SCN3A, or a
 PT DNA variant, equivalent, or mutation which shows a linkage
 PT disequilibrium -
 XX Example 3; Fig 2; 268pp; English.
 CC The present invention describes a method (M1) of determining an
 CC individual's predisposition to epilepsy and/or development of epilepsy,
 CC as well as predicting the individual's response to medication. The
 CC method comprises determining the genotype of at least one gene selected
 CC from SCN1A, SCN2A or SCN3A, or a DNA variant, equivalent, or mutation
 CC which shows a linkage disequilibrium. SCN1A, SCN2A and SCN3A are all
 CC sodium channel genes located on chromosome 2. The idiopathic generalised
 CC epilepsy (IGE) gene is more specifically localised on chromosome
 CC 2q23-q31. Compounds identified as modulators of the biological activity
 CC of SCN1A, SCN2A or SCN3A proteins or genes, are useful for treating
 CC epilepsy or other neurological disorders. They have anticonvulsant and
 CC neuroprotective activities. AAH55763 to AAH56164 and AAB99674 to

CC AAB99679 represent SCN1A, SCN2A, and SCN3A cDNAs, gene fragments, PCR
 CC primers, oligonucleotides and proteins given in the exemplification of
 CC the present invention.

XX Sequence 18 BP; 4 A; 6 C; 6 G; 2 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1068 CATCAGCAGGCTCT 1082
 |||||
 2 CAGCAGCAGGCTCT 16

RESULT 372

AAH25339

ID AAH25339 standard; DNA; 18 BP.

XX AC AAH25339;

XX 22-AUG-2001 (first entry)

DE Antisense oligonucleotide targeted to human Her-4 coding region.

XX Antisense oligonucleotide; Her-4; receptor kinase; tyrosine kinase;
 KW infection; inflammation; tumour; phosphorothioate; ss.

XX Homo sapiens.

FT Key Location/Qualifiers

FT modified_base 1..4

FT /tag= a

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

FT modified_base 1..18

FT /tag= b

FT /note= "all cytidine residues are 5-methylcytidines"

FT modified_base 1..18

FT /tag= c

FT /note= "all internucleoside linkages are

FT phosphorothioate linkages"

FT modified_base 5..14

FT /tag= d

FT /note= "2'-deoxynucleotides"

FT modified_base 15..18

FT /tag= e

FT /note= "2'-methoxyethyl (2'-MOE) nucleotides"

XX US6255111-B1.

XX 03-JUL-2001.

XX 31-JUL-2000; 2000US-0632580.

XX 31-JUL-2000; 2000US-0632580.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Cowser LM;

XX WPI; 2001-38977/41.

XX Compound for inhibiting the expression of Her-4 (a receptor/tyrosine
 FT kinase) e.g. in preventing tumour formation, comprises an antisense
 FT oligonucleotide that hybridizes to a nucleic acid encoding Her-4 -

PS Claim 1; Column 43-44; 44pp; English.

XX The specification describes antisense oligonucleotides which are
 CC targeted to a nucleic acid encoding Her-4 (a receptor/tyrosine kinase).
 CC The antisense oligonucleotides are used to inhibit the expression of
 CC Her-4 in cells or tissues in vitro. They can be used in diagnostics,
 CC therapeutics, prophylaxis and as a probe in research reagents. The

CC antisense oligonucleotides can be used to prevent or delay infection,
 CC inflammation or tumour formation. AAH25315-AAH25398 represent antisense
 CC oligonucleotides which are targeted to different regions of the human
 CC Her-4 gene.

XX Sequence 18 BP; 5 A; 6 C; 6 G; 1 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;
 Best Local Similarity 93.3%; Pred. No. 2.3e+02;
 Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 552 GGCAGGCATGCACAC 566
 |||||
 4 GGCAGGCACGCACAC 18

RESULT 373

AAH25861

ID AAH25861 standard; DNA; 18 BP.

XX AC AAH25861;

XX 22-AUG-2001 (first entry)

DE DNA array oligonucleotide #4.

XX DNA array; DNA binding acceleration; analyte detection; sequencing;
 KW genetic diagnosis; pathogen detection; DNA fingerprinting; probe;
 KW gene probe assay; ss.

XX Synthetic.

FT Key Location/Qualifiers

FT modified_base 18

FT /tag= a

FT /mod_base= "OTHER"

FT /note= "modified by (CH2)16SH"

XX WC200135100-A2.

XX 17-MAY-2001.

XX 13-NOV-2000; 2000WO-US31233.

XX 12-NOV-1999; 99US-0440371.

XX 23-DEC-1999; 99US-0171981.

XX (CLIN-) CLINICAL MICRO SENSORS INC.

XX Blackburn G, Vielmetter JG, Kayyem JF;
 XX WPI; 2001-38977/41.

XX Substrate composition, used of target analytes such as biomolecules,
 FT comprises a surface having an array of detection electrodes, each with
 FT a covalently attached capture ligand -

XX Example 2; Page 113; 146pp; English.

XX The present invention describes a composition containing a substrate
 CC comprising a first surface comprising an array of detection electrodes
 CC with covalently attached capture ligands and an electrophoresis
 CC electrode, a second surface comprising an electrophoresis electrode, and
 CC a channel connecting the two surfaces. This accelerates the binding of
 CC the target analyte to the detection electrode. It can be used to detect
 CC target analytes in sample solutions, for example in genetic diagnosis,
 CC pathogen detection, DNA fingerprinting, sequencing and gene probe assays.
 CC The present sequence is an oligonucleotide used in the exemplification of
 CC the invention.

XX Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 other;

XX Query Match 1.0%; Score 13.4; DB 1; Length 18;

Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 GCAGTTGAGGTGGAT 21
Db 4 GCAGTTGAGGTGGAT 18

RESULT 374
AAF62366/c
ID AAF62366 standard; DNA; 18 BP.
XX AC AAF62366;
XX DT 06-JUN-2001 (first entry)
XX DE Zinc finger coding sequence related oligo SEQ ID NO: 91.
XX KW Leptin; human; LSR; lipolysis stimulated receptor; obesity;
XX KW hypertension; anorexia; cachexia; stroke; atherosclerosis; ds.
XX OS Synthetic.
XX PN WO200121647-A2.
XX PD 29-MAR-2001.
XX PF 22-SEP-2000; 2000WO-IB01470.
XX PR 22-SEP-1999; 99US-0155506.
XX PA (GEST) GENSET.
XX PI Yen F, Erickson MR, Fruebis J, Bihain B;
XX DR WPI; 2001-218642/22.
XX PT New leptin polypeptide fragment and related polynucleotides, useful for
XX PT the prevention and treatment of obesity and obesity-related diseases
XX PT such as hypertension and diabetes -
XX PS Example 12; Page 244; 247pp; English.
XX CC The present invention provides the protein and coding sequences of leptin
XX CC fragments which modulate the activity of lipolysis stimulated factor
XX CC (LSR). These sequences are useful in the treatment of obesity related
XX CC diseases, including obesity, anorexia, cachexia, cardiac and coronary
XX CC insufficiency, stroke, hypertension, atherosclerosis, hyperlipidaemia,
XX CC hyperuricaemia and syndrome X.
XX SQ Sequence 18 BP; 2 A; 2 C; 12 G; 2 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 186 CCCCGCCGCCACCC 200
Db 18 CCCCGCCGCCACCC 4

RESULT 375
AAF58213
ID AAF58213 standard; DNA; 18 BP.
XX AC AAF58213;
XX XX
XX DT 06-DEC-2001 (updated)
XX DT 24-APR-2001 (first entry)
XX DE Sequence determination using electronic detection probe #4.
XX FT

Query Match 1.0%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 GCAGTTGAGGTGGAT 21
Db 4 GCAGTTGAGGTGGAT 18

RESULT 376
AAF58216/c
ID AAF58216 standard; DNA; 18 BP.
XX AC AAF58216;
XX XX
XX DT 06-DEC-2001 (updated)
XX DT 24-APR-2001 (first entry)
XX DE Sequence determination using electronic detection signalling probe #1.
XX KW Electron-transfer group; ETM; mismatch; genotyping;
XX KW gene expression; probe; ss.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 1 /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "(C23)4-N87-N87-adenosine, where each N87

Electron-transfer group; ETM; mismatch; genotyping;
gene expression; probe; ss.
Synthetic.
Key Location/Qualifiers
modified_base 18 /*tag= a
/mod_base= OTHER
/note= "modified by (CH2)16SH"
WO200107665-A2.
XX PN
XX PD 01-FEB-2001.
XX PF 26-JUL-2000; 2000WO-US20476.
XX PR 26-JUL-1999; 99US-0145695.
XX PR 17-MAR-2000; 2000US-0190259.
XX PA (CLIN-) CLINICAL MICRO SENSORS INC.
XX OS Umek RM;
XX PI WPI; 2001-159728/16.
XX DR Nucleic acids containing electron-transfer group, useful as labels in
XX PT hybridization assays, e.g. for genotyping, allowing repeat analyses on
XX PT a single surface -
XX PS Example 2; Page 111; 159pp; English.
XX CC The present invention relates to a composition comprising two nucleic
XX CC acids each containing an electron-transfer group (ETM) having
XX CC different redox potentials. The invention is used for electronic
XX CC detection of nucleic acids, especially of substitutions (mismatches)
XX CC and single-nucleotide polymorphisms, e.g. for genotyping and
XX CC monitoring gene expression. The present sequence is a probe used in the
XX CC exemplification of the invention.
XX CC (NOTE: Revised record submitted with a corrected sequence)
XX SQ Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 2.3e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 GCAGTTGAGGTGGAT 21
Db 4 GCAGTTGAGGTGGAT 18

RESULT 376
AAF58216/c
ID AAF58216 standard; DNA; 18 BP.
XX AC AAF58216;
XX XX
XX DT 06-DEC-2001 (updated)
XX DT 24-APR-2001 (first entry)
XX DE Sequence determination using electronic detection signalling probe #1.
XX KW Electron-transfer group; ETM; mismatch; genotyping;
XX KW gene expression; probe; ss.
XX OS Synthetic.
XX FH Key Location/Qualifiers
XX FT modified_base 1 /*tag= a
XX FT /mod_base= OTHER
XX FT /note= "(C23)4-N87-N87-adenosine, where each N87

FT group has (C23)4 appended, where N87 is a branch point
 PT comprising a ring structure and C23 is shown in Fig 1F of
 FT PCTUS99/01705"

XX WO200107665-A2.

XX 01-FEB-2001.

XX 26-JUL-2000; 2000WO-US20476.

XX 26-JUL-1999; 99US-0145695.

XX 17-MAR-2000; 2000US-0190259.

XX (CLIN-) CLINICAL MICRO SENSORS INC.

XX Umek RM;

XX WPI; 2001-159728/16.

XX Nucleic acids containing electron-transfer group, useful as labels in
 PT hybridization assays, e.g. for genotyping, allowing repeat analyses on
 PT a single surface -

XX Example 2; Page 111; 159pp; English.

XX The present invention relates to a composition comprising two nucleic
 CC acids each containing an electron-transfer group (ETM) having
 CC different redox potentials. The invention is used for electronic
 CC detection of nucleic acids, especially of substitutions (mismatches)
 CC and single-nucleotide polymorphisms, e.g. for genotyping and
 CC monitoring gene expression. The present sequence is a probe used in the
 CC exemplification of the invention.

XX (NOTE: Revised record submitted with a corrected sequence)

XX Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 other;

XX Query Match 1.0%; Score 13.4; DB 1; Length 18;

XX Best Local Similarity 93.3%; Pred. No. 2.3e+02;

XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 7 GCAGTTGAGTGGAT 21

DB 15 GCAGTTGAGTGGAT 1

RESULT 377

ABZ10842/c

ID ABZ10842 standard; DNA; 18 BP.

XX AC ABZ10842;

XX 16-JAN-2003 (first entry)

XX Haematopoietic cell proliferation disorder related oligonucleotide #982.

XX Human; haematopoietic cell proliferation disorder; cytostatic;
 KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
 KW cytosine methylation state; probe; primer; ss.

XX Homo sapiens.

XX Synthetic.

XX WO200277272-A2.

XX 03-OCT-2002.

XX 26-MAR-2002; 2002WO-EP03401.

XX 26-MAR-2001; 2001US-278333P.

XX (EPIG-) EPIGENOMICS AG.

XX Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;

PI Olek A, Piepenbrock C, Adorian P, Grabs G, Lesche R, Leu E;
 PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;
 PI Pelet C, Schwöpe I, Ziebarth H;
 XX WPI; 2003-018942/01.

XX Detecting and differentiating between hematopoietic cell proliferative
 XX disorders, comprises contacting a target nucleic acid with a reagent
 XX that distinguishes between methylated and non-methylated CpG
 XX dinucleotides -

XX Claim 15; Page 65; 117pp; English.

XX The present invention describes a method for detecting and
 CC differentiating between haematopoietic cell proliferative disorders
 CC associated with at least 1 gene and/or their regulatory regions in a
 CC subject. The method comprises contacting a target nucleic acid in a
 CC biological sample obtained from the subject with at least 1 reagent,
 CC which distinguishes between methylated and non-methylated CpG
 CC dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
 CC represent specifically claimed nucleotide sequences from the present
 CC invention. Oligonucleotides from the present invention can be used: for
 CC differentiating between healthy haematopoietic cells and proliferative
 CC disorder haematopoietic cells; for differentiating between acute
 CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
 CC determining the cytosine methylation state and/or single nucleotide
 CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
 CC related sequences and their complements; and as primers for the
 CC amplification of haematopoietic cell proliferation disorder related
 CC DNA sequences. The nucleotide sequences from the present invention can
 CC also be used for detecting a predisposition to, differentiation between
 CC subclasses, diagnosis, prognosis, treatment and/or monitoring of
 CC haematopoietic cell proliferative disorders. The present method enables
 CC a highly specific classification of haematopoietic cell proliferative
 CC disorders allowing for improved and informed treatment of patients.

XX Sequence 18 BP; 6 A; 0 C; 7 G; 5 T; 0 other;

XX Query Match 1.0%; Score 13.4; DB 1; Length 18;

XX Best Local Similarity 93.3%; Pred. No. 2.3e+02;

XX Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 54 TACTCTCAATTACC 68

DB 17 TACTCTCAATTAC 3

RESULT 378

AAQ75547

ID AAQ75547 standard; DNA; 19 BP.

XX AC AAQ75547;

XX 04-AUG-1995 (first entry)

XX Reverse transcription primer used in cDNA analysis technique.

XX Analysis; gene expression; reverse transcription; primer; cDNA;
 KW aggregate; restriction enzyme; ss.

XX Synthetic.

XX JP06303997-A.

XX 01-NOV-1994.

XX 16-APR-1993; 93JP-0112515.

XX 16-APR-1993; 93JP-0112515.

XX (NITE) NIPPON TELEGRAPH & TELEPHONE CORP.

XX WPI; 1995-018287/03.

XX Analysis of cDNA and gene expression - by amplification of mRNA
PT followed by digestion with restriction enzymes
XX
XX Disclosure; Page 5; 11pp; Japanese.
XX
XX A method for the analysis of cDNA comprises (a) preparing an
CC aggregate of double-stranded cDNAs by using an aggregate of mRNAs
CC and a plural type of labelled reverse transcription primers
CC (GENSEQ files AAQ5547-Q75798) and using the aggregate of mRNAs as the
CC template for each reverse transcription primer; (b) digesting each of
CC the prepared aggregates of the double-stranded cDNAs with restriction
CC enzyme and; (c) electrophoresing the digested aggregate of cDNAs in
CC separate lanes. The method can be used to analyse gene expression
CC rapidly and easily.
XX
SQ Sequence 19 BP; 0 A; 0 C; 2 G; 17 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 1144 TTTTTCCTTTTGG 1158
Db ||||| |||||
5 TTTTTCCTTTTGG 19
RESULT 379
AA06004
ID AAX06004 standard; DNA; 19 BP.
XX
AC AAX06004;
XX
DT 10-MAY-1999 (first entry)
XX
DE Oligo used in construction of plasmid pGP2.
XX
XX Human; Immunoglobulin transgene; Ig; VH gene; D gene; JH gene; mu gene;
KW switch sequence; gamma gene; IgM; IgG; ss.
XX
XX Synthetic.
OS
XX US5874299-A.
PN
XX 23-FEB-1999.
PD
XX 14-FEB-1997; 97US-0800353.
PF
XX 05-FEB-1992; 92US-0834539.
PR 29-AUG-1990; 90US-0574748.
PR 31-AUG-1990; 90US-0575962.
PR 28-AUG-1991; 91WO-US06185.
PR 14-FEB-1997; 97US-0800353.
XX
XX (GENP-) GENPHARM INT INC.
PA
XX Kay RM, Lonberg N;
PI
XX WPI; 1999-179989/15.
DR
XX Human immunoglobulin transgene - with mu and gamma isotype switching
PT segments
XX
XX Example 5; Column 33; 88pp; English.
PS
XX The invention relates to a heavy chain (human) immunoglobulin (Ig)
CC transgene. The transgene comprises: (i) human VH gene segments; (ii)
CC human D gene segments; (iii) human JH gene segments; and either (iv) a
CC mu constant region comprising a mu switch sequence upstream from a mu
CC coding segment; (v) a gamma constant region comprising a gamma switch
CC sequence upstream from a human gamma coding segment; where (vi) the mu
CC and gamma constant regions are closer than in wild type human Ig heavy
CC chain loci; or (vii) a heavy chain enhancer; (viii) a mu constant region

CC comprising a mu switch sequence upstream from a mu coding segment; (ix) a
CC gamma constant region comprising a gamma switch sequence upstream from a
CC human gamma coding segment; and (x) at least one discontinuity of at
CC least 2 kb between the mu and gamma gene segments as compared to a human
CC germ-line heavy chain locus; or (xi) a human mu CH gene and at least two
CC non-mu human CH genes and their associated isotype switching sequences;
CC where (xii) the human mu and human gamma switch sequences are closer than
CC in wild type human Ig heavy chain loci. The transgenes allow non-human
CC animals to produce heterologous (human) Ig's with varying specificities.
CC The presence of mu and gamma switch segments allows isotype switching of
CC the human heavy chain mini-locus from IgM (for maturation) to IgG.
XX
SQ Sequence 19 BP; 3 A; 7 C; 7 G; 2 T; 0 other;
Query Match 1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 391 GTGGCAGCAATGCGC 405
Db ||||| |||||
4 GTGGCAGCAATGCGC 18
RESULT 380
AA945588
ID AAS45588 standard; DNA; 19 BP.
XX
AC AAS45588;
XX
DT 18-DEC-2001 (first entry)
DT
XX Human PAPP-2 RT-PCR reverse primer.
DE
XX Human; ss; PAPP; Poly (ADP-ribose) polymerase; antisense oligonucleotide;
KW cytostatic; neurotrophic; neuroprotective; antiinflammatory; antidiabetic;
KW immunosuppressant; hyperproliferative disorder; cancer; cellular injury;
KW oxidative stress; neurological disorder; parkinsonism; apoptosis;
KW meningitis-associated intracranial complication; ischaemia; PCR primer;
KW inflammatory disorder; autoimmune disorder; arthritis; diabetes.
XX
XX Homo sapiens.
OS
XX WO200164955-A1.
PN
XX 07-SEP-2001.
PD
XX 01-MAR-2001; 2001WO-US06572.
PF
XX 02-MAR-2000; 2000US-0517467.
PR
XX (ISIS-) ISIS PHARM INC.
PA
XX Popoff I, Cowser LM;
PI
XX WPI; 2001-602570/68.
DR
XX Antisense compound useful for treating hyperproliferative,
PT neurological, inflammatory and autoimmune disorders and diabetes
PT inhibits human PAPP -
XX
XX Example 13; Page 80; 168pp; English.
PS
XX The invention relates to antisense oligonucleotides targeted to human
CC PAPP nucleic acid and inhibiting expression of human PAPP. PAPP
CC (Poly (ADP-ribose) polymerase plays an important role in chromatin
CC decondensation, DNA replication, DNA repair, gene expression, malignant
CC transformation, cellular differentiation and apoptosis. The antisense
CC oligonucleotide inhibitors are useful for inhibiting the expression of
CC PAPP in human cells or tissues. They are also useful for treating a
CC human with a disease associated with PAPP especially hyperproliferative
CC disorders (e.g. cancer), cellular injury resulting from oxidative stress,
CC neurological (e.g parkinsonism, meningitis-associated intracranial
CC complications and ischaemia) , inflammatory and autoimmune disorders (e.g

CC arthritis) and diabetes. The present sequence is an RT-PCR (reverse
CC transcriptase PCR) primer used to quantitate PARP mRNA levels.
CC
SQ Sequence 19 BP; 4 A; 9 C; 3 G; 3 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 229 CAGCCTCAGGCATCT 243
DB 5 CAGCCACAGGCATCT 19

RESULT 381
ABL88875/c
ID ABL88875 standard; DNA; 19 BP.
AC ABL88875;
XX
DT 22-MAY-2002 (first entry)
XX
DE HIV-1 related binding molecule oligonucleotide sequence SEQ ID NO:97.
XX
KW Binding molecule; HIV-1; human immunodeficiency virus type 1;
KW reverse transcriptase; binding group; ss.
XX
OS Human immunodeficiency virus type 1.
OS Synthetic.
XX
PN EP1174518-A1.
XX
PD 23-JAN-2002.
XX
PF 20-JUL-2000; 2000EP-0202611.
XX
PR 20-JUL-2000; 2000EP-0202611.
XX
PA (AMST-) AMSTERDAM SUPPORT DIAGNOSTICS BV.
XX
PI Loukachov VV, Van Gemen B, Goudsmit J;
XX WPI; 2002-156696/21.
DR

XX Collection of binding groups for determining or typing samples,
XX especially clinical samples, has groups capable to identify essentially
PT all members of the family of nucleic acids of relatively high
PT significance -
XX
PS Disclosure; Page 30; 166pp; English.
XX
CC The present invention describes a collection of binding groups for a
CC family of nucleic acids comprising members of relative high and relative
CC low significance, where the binding groups are selected to be capable to
CC identify, alone or in combination, essentially all members of the family
CC of nucleic acids of relatively high significance. The collection of
CC binding groups is useful for typing of nucleic acid in a clinical sample,
CC by contacting the nucleic acid with the collection and determining
CC whether one or more binding groups bound to the nucleic acid of the
CC sample. This method is useful for determining whether the sample
CC comprises at least a part of a member of relatively high significance of
CC a family of nucleic acids. The collection of binding groups is useful for
CC diagnosing the severity of a disease caused by a pathogen containing a
CC member of a family of nucleic acids. ABL88779 to ABL89321 represent
CC oligonucleotide sequences used in the exemplification of the present
CC invention.
XX
SQ Sequence 19 BP; 13 A; 3 C; 2 G; 1 T; 0 other;

Query Match 1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1144 TTTTCTTTTGG 1158
DB 15 TTTTCTTTTGG 1

RESULT 382
AAN92661
ID AAN92661 standard; DNA; 18 BP.
XX
AC AAN92661;
XX
DT 25-MAY-2003 (updated)
DT 16-MAY-1990 (first entry)
XX
DE Probe to polymorphic site of the second exon of DPbeta allele of HLA DP
DE gene.
XX
KW HLA; autoimmune diseases; probe; DP gene; DPbeta allele.
XX
OS Homo sapiens.
XX
PN WO8911547-A.
XX
PD 30-NOV-1989.
XX
PF 18-MAY-1989; 89WO-US02169.
XX
PR 20-MAY-1988; 88US-0196660.
PR 14-OCT-1988; 88US-0258212.
PR 04-MAY-1989; 89US-0347506.
XX
PA (CETU) CETUS CORP.
XX
PI Erlich H, Horn GT, Bugawan TL;
XX WPI; 1989-370738/50.
DR

XX HLA DP genotyping by amplifying target DNA then hybridisation -
PT with panel of sequence specific oligonucleotide(s), esp. for
PT assessing risk of autoimmune disease.
XX
PS Claim 8; Page 48; 54pp; English.
XX
CC Target region for probe is amplified by polymerase chain reaction, and
CC probe binds to complementary regions in very stringent conditions,
CC identifying variations in the hypervariable DP gene.
CC (Updated on 25-MAR-2003 to correct PI field.)
XX
SQ Sequence 18 BP; 5 A; 5 C; 6 G; 2 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 521 ACCTCCGAGGAGCAGC 538
DB 1 ACCTCTGGAGGAGAGC 18

RESULT 383
AAQ54537
ID AAQ54537 standard; DNA; 18 BP.
XX
AC AAQ54537;
XX
DT 25-MAR-2003 (updated)
DT 29-JUN-1994 (first entry)
XX
DE HLA-DP genotype determination probe #26.
XX
KW Polymerase chain reaction; PCR; amplify; primer; probe; HLA-DP;
KW genotype; sequence specific; polymorphic region; variable segment;
KW panel; autoimmune disease; insulin-dependant diabetes mellitus;

KW coeliac disease; CD; allele; DPB1; DPB3; DPB4.2; juvenile;
 KW rheumatoid arthritis; DPB2.1; forensic evidence; ss.
 OS Synthetic.
 XX
 XX
 XX BP575845-A2.
 XX
 XX 29-DEC-1993.
 XX
 XX
 PF 14-JUN-1993; 93EP-0109447.
 XX
 PR 23-JUN-1992; 92US-0903028.
 XX
 XX (HOFF) HOFFMANN LA ROCHE & CO AG F.
 PA
 XX Begovich AB, Bugawan TL, Erlich HA;
 FI
 XX WPI; 1994-001049/01.
 DR
 XX
 PT Method for HLA - DP typing - comprises amplification of target nucleic
 PT acid region and hybridisation with oligo-nucleotide probes
 XX
 PS Claim 2; Page 81; 85pp; English.
 XX
 CC The sequences given in AAQ54509-614 are primers and probes which were
 CC used in the method of the invention for determining the HLA-DP
 CC genotype of an individual. The method comprises amplifying a target
 CC region of the nucleic acid in the sample in question, under
 CC conditions suitable for carrying out PCR with a sequence specific
 CC primer. The target region contains a polymorphic region (variable
 CC segment) of an HLA DP gene. The amplified sequences are mixed with
 CC a panel of probes, where each probe is complementary to a variant
 CC sequence of a variable segment of an HLA DP gene, under stringent
 CC binding conditions. The method is useful for determining an
 CC individuals susceptibility to an autoimmune disease including
 CC insulin-dependent diabetes mellitus and coeliac disease (CD) by
 CC determining the HLA-DP genotype. CD is linked to the alleles DPB13,
 CC DPB1, DPB3 or DPB4.2. Susceptibility to particular juvenile rheumatoid
 CC arthritis is indicated by the DPB2.1 allele. The process can also be
 CC used to provide forensic evidence.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 CC (Updated on 25-MAR-2003 to correct PI field.)
 XX
 XX Sequence 18 BP; 5 A; 5 C; 6 G; 2 T; 0 other;
 SQ
 Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 521 ACCTGCGGAGGAGCAGC 538
 Db 1 ACCTCTGGAGGAGAGC 18
 RESULT 384
 AAQ89247/c
 ID AAQ89247 standard; DNA; 18 BP.
 XX
 XX
 AC AAQ89247;
 XX
 XX 09-MAY-1995 (first entry)
 DT
 XX Hepatitis C virus 8003-9388 fragment PCR primer.
 DE
 XX Non-A non-B hepatitis virus antigens; NANBH; hepatitis C virus; ss.
 KW
 XX Synthetic.
 OS
 XX JP06225770-A.
 XX
 XX 16-AUG-1994.
 PD
 XX 08-JUL-1993; 93JP-0193104.
 PF

XX 10-JUL-1992; 92JP-0207391.
 PR
 XX (KOKU-) KOKUSAI SHIYAKU KK.
 PA (SANW) SANWA KAGAKU KENKYUSHO CO.
 PA (TOFU) TONEN CORP.
 PA (TOKR-) ZH TOKYOTO RINSHO IGAKU SOGO KENKYUSHO.
 XX
 XX WPI; 1994-298800/37.
 DR
 XX
 XX A nucleic acid fragment coding Non-A Non-B Hepatitis virus
 PT antigens - for diagnosis of NANBH and detection of HCV
 PT
 XX
 PS Example 1; Page 7; 22pp; Japanese.
 XX
 CC AAQ89234-Q89253 are PCR primers for fragments of hepatitis C virus (HCV)
 CC or non-A non-B hepatitis virus (NANBH) cDNA. These cDNAs code for amino
 CC acid sequences, which are antigens to structural and non-structural
 CC regions of the HCV virus. These antigens can be used in the diagnosis
 CC of NANBH patients and the detection of HCV carriers.
 XX
 SQ Sequence 18 BP; 12 A; 2 C; 2 G; 2 T; 0 other;
 Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1139 ATGCCCTTTTCTTTT 1156
 Db 18 AGGCCATTTTCTTTT 1
 RESULT 385
 AAX75643
 ID AAX75643 standard; RNA; 18 BP.
 XX
 AC AAX75643;
 XX
 DT 28-JUL-1999 (first entry)
 DT
 XX Mouse flt-1 VEGF receptor hairpin ribozyme substrate #102.
 DE
 XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
 KW flk-1; KDR; hammethead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.
 XX
 OS Mus sp.
 XX
 XX WO9715662-A2.
 PN
 XX
 XX 01-MAY-1997.
 PD
 XX
 XX 25-OCT-1996; 96WO-US17480.
 PF
 XX
 PR 11-JAN-1996; 96US-0584040.
 PR 26-OCT-1995; 95US-0005974.
 PR
 XX (CHIR) CHIRON CORP.
 PA (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Escobedo J, McSwiggen J, Favco P, Stinchcomb D;
 PI
 XX WPI; 1997-259017/23.
 DR
 XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient
 XX
 XX Claim 4; Page 189; 218pp; English.
 PS
 XX The present invention describes nucleic acid molecules which modulate
 CC

CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flt-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.

SQ Sequence 18 BP; 3 A; 7 C; 4 G; 4 U; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 61.1%; Pred. No. 2.5e+02;
 Matches 11; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1053 CAGCCCTGGCTTCCCAT 1070
 Db 1 CAGGCCGACCCUCCGCAU 18

RESULT 386

AAAX71704
 ID AAX71704 standard; RNA; 18 BP.
 XX
 AC AAX71704;

XX
 DT 28-JUL-1999 (first entry)

XX Human KDR VEGF receptor hairpin ribozyme substrate #2.

XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
 KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.

XX Homo sapiens.

XX WO9715662-A2.

XX 01-MAY-1997.

XX 25-OCT-1996; 96WO-US17480.

XX 11-JAN-1996; 96US-0584040.

XX 26-OCT-1995; 95US-0005974.

XX (CHIR) CHIRON CORP.

XX (RIBO-) RIBOZYME PHARM INC.

XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

XX WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient

XX Claim 4; Page 118; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flt-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.

SQ Sequence 18 BP; 0 A; 7 C; 7 G; 4 U; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 61.1%; Pred. No. 2.5e+02;
 Matches 11; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1239 GCTGGACGTGGCCCATGTG 1256
 Db 1 GCUGGCCGUCGCCUGUG 18

RESULT 387

AAAX70233

ID AAX70233 standard; RNA; 18 BP.

XX
 AC AAX70233;

XX
 DT 28-JUL-1999 (first entry)

XX Human flt1 VEGF receptor hairpin ribozyme substrate #1.

XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
 KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.

XX Homo sapiens.

XX WO9715662-A2.

XX 01-MAY-1997.

XX 25-OCT-1996; 96WO-US17480.

XX 11-JAN-1996; 96US-0584040.

XX 26-OCT-1995; 95US-0005974.

XX (CHIR) CHIRON CORP.

XX (RIBO-) RIBOZYME PHARM INC.

XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

XX WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient

XX Claim 4; Page 91; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flt-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.

SQ Sequence 18 BP; 0 A; 11 C; 3 G; 4 U; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 72.2%; Pred. No. 2.5e+02;
 Matches 13; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 142 CCGCTCGGCTCCGCTCCG 159
 Db 1 CCUCUCGUCUCCUCCUG 18

RESULT 388

```

AAT84310
ID AAT84310 standard; DNA; 18 BP.
AC AAT84310;
XX
XX
DT 10-NOV-1997 (first entry)
XX
XX Human VEGF-C gene intron 4-exon 5 junction.
XX
XX VEGF-C; Flt4; receptor tyrosine kinase; VEGFR-3; human;
KW vascular endothelial growth factor receptor-3; ligand;
KW angiogenesis; wound healing; lymph vessel; lymphangioma; cancer;
KW metastasis; therapy; diagnosis; ss.
XX
XX Homo sapiens.
XX
XX Key Location/Qualifiers
FH intron 1..11
FT /*tag= a
FT /*note= "3' end of intron 4"
FT 12..18
FT /*tag= b
FT /*note= "5' end of exon 5, encodes amino acids
FT 231-233 of VEGF-C"
XX
XX WO9705250-A2.
XX
XX 13-FEB-1997.
XX
XX 01-AUG-1996; 96WO-FI00427.
XX
XX 28-JUN-1996; 96US-0671573.
XX
XX 01-AUG-1995; 95US-0510133.
XX
XX 12-JAN-1996; 96US-0585895.
XX
XX 14-FEB-1996; 96US-0601132.
XX
XX (UYHE-) UNIV HELSINKI LICENSING LTD OY.
XX
XX Alitalo K, Joukov V;
XX
XX WPI; 1997-145688/13.
XX
XX Flt4 receptor tyrosine kinase ligand and related nucleic acid - used
PT to modulate growth of endothelial cells and for diagnosis of
PT endothelial cell diseases
XX
XX Example 31; Page 130; 183pp; English.
XX
XX This DNA sequence comprises the junction region between intron 4
CC (over 10 kb) and exon 5 of the human VEGF-C gene (see also AAT84276).
CC Exon-intron junctions were determined (see AAT84303-14) for the
CC entire VEGF-C gene, which comprises 7 exons and 6 exons. The
CC VEGF-C gene on chromosome 4q23 codes for a novel ligand (AAW00932)
CC of Flt4 receptor tyrosine kinase that can be used in a claimed
CC method to modulate growth of endothelial cells.
XX
XX Sequence 18 BP; 4 A; 4 C; 4 G; 6 T; 0 other;
SQ
Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 380 TTCCTCCAGAGTGCGAC 397
DB 1 TTCTTCCAAAGGTGTGAC 18

RESULT 389
AAT80260/c
ID AAT80260 standard; DNA; 18 BP.
XX
XX AAT80260;
XX

DT 15-OCT-1997 (first entry)
XX
XX Oligo HCV91, targetted to HCV region -1 to -6.
XX
XX Complementary; 5' untranslated region; UTR; hepatitis C virus; HCV;
KW inhibition; replication; expression; detection; chronic hepatitis;
KW acute hepatitis; hepatocarcinoma; ss.
XX
XX Synthetic.
XX
XX Key Location/Qualifiers
FH modified_base 7..18
FT /*tag= a
FT /*note= "2' Ome modified"
FT 1..6
FT /*tag= b
FT /*note= "Phosphorothioate linkages"
XX
XX WO9639500-A2.
XX
XX 12-DEC-1996.
XX
XX 04-JUN-1996; 96WO-EP02427.
XX
XX 06-JUN-1995; 95US-0471968.
XX
XX (HOFF) HOFFMANN LA ROCHE & CO AG F.
XX (HYBR-) HYBRIDON INC.
XX
XX Frank BL, Goodchild J, Hamlin RA, Kilkuskie RE;
XX Roberts NA, Roberts PC, Walther DM, Wolfe JL;
XX WPI; 1997-043122/04.
XX
XX Oligo:nucleotide(s) complementary to HCV 5' untranslated region -
PT used in the treatment and detection of HCV infection, esp. hepatitis
PT and hepato-carcinoma
XX
XX Claim 19; Page 31; 100pp; English.
XX
XX The sequences given in AAT80211-382 represent synthetic oligonucleotides
CC which are complementary to a portion of the 5' untranslated region (UTR)
CC of hepatitis C virus (HCV). These sequences may be used in a
CC pharmaceutical composition for the control or prevention of HCV
CC infection. They may be used to inhibit replication or expression of
CC HCV or for detecting the presence of HCV in a sample. They may be used
CC to inhibit HCV replication in a cell and are therefore useful in the
CC treatment of HCV infections such as chronic and acute hepatitis and
CC hepatocarcinoma. This oligo was used in a luciferase assay to determine
CC whether it binds successfully to its target.
XX
XX Sequence 18 BP; 2 A; 3 C; 10 G; 1 T; 2 U; 0 other;
SQ
Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 631 CTCGAGGAGCTCTGCATC 648
DB 18 CTCGAGGAGCTCTGCATC 1

RESULT 390
AAQ67556
ID AAQ67556 standard; cDNA to mRNA; 18 BP.
XX
XX AAQ67556;
XX
XX 20-AUG-1997 (first entry)
XX
XX Anti-metallothionein phosphorothioate oligodeoxyribonucleotide.
DE PS-ODN; phosphorothioate oligodeoxyribonucleotide; chelate; ss;
XX

```

KW heavy metal poisoning; cadmium; mercury; lead; metallothionein.
 OS Synthetic.
 XX US5618796-A.
 PN 08-APR-1997.
 XX 12-SEP-1991; 91US-0759841.
 XX 12-SEP-1991; 91US-0759841.
 XX (UYNE-) UNIV NEBRASKA.
 PA Iversen PL;
 XX WPI; 1997-234701/21.
 XX Treatment for heavy metal poisoning - by chelating heavy metal ions
 PT with phosphorothioate oligonucleotide to cause excretion in urine
 XX Example 3; Column 10; 10pp; English.

PF 12-SEP-1991; 91US-0759841.
 PR 12-SEP-1991; 91US-0759841.
 XX (UYNE-) UNIV NEBRASKA.
 PA Iversen PL;
 XX WPI; 1997-234701/21.
 XX Treatment for heavy metal poisoning - by chelating heavy metal ions
 PT with phosphorothioate oligonucleotide to cause excretion in urine
 XX Example 3; Column 10; 10pp; English.

CC The invention relates to a new method of treating an animal suffering
 CC from heavy metal poisoning, comprising administering a phosphorothioate
 CC oligonucleotide to the animal in an amount sufficient to chelate heavy
 CC metals to cause their excretion in the urine of the animal.
 CC The method can be used to treat poisoning caused by cadmium, lead
 CC and/or mercury. The present sequence is one of two complementary
 CC phosphorothioate oligonucleotides (PS-ODNs) which were synthesised and
 CC tested for use in the method. Each PS-ODN is 18 bases in length
 CC and is associated with bases 7-24 downstream from the ATG translational
 CC start site of human metallothionein-II mRNA. The present sequence is
 CC the anti-WT antisense sequence, while the complementary sequence is
 CC shown in AAQ67557.

SQ Sequence 18 BP; 3 A; 3 C; 10 G; 2 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 525 GCCGAGGAGCAGCTGGG 542
 ||| ||||| |||||
 Db 1 GCCGAGGAGCAGCTGGG 18

RESULT 391
 AAQ67557/C
 ID AAQ67557 standard; cDNA to mRNA; 18 BP.
 XX
 AC AAQ67557;
 XX 20-AUG-1997 (first entry)
 XX Anti-metallithionein phosphorothioate oligodeoxyribonucleotide.
 DE PS-ODN; phosphorothioate oligodeoxyribonucleotide; chelate; ss;
 KW heavy metal poisoning; cadmium; mercury; lead; metallothionein.
 XX Synthetic.
 OS US5618796-A.
 PN 08-APR-1997.
 XX 12-SEP-1991; 91US-0759841.
 XX 12-SEP-1991; 91US-0759841.
 XX (UYNE-) UNIV NEBRASKA.
 PA Iversen PL;
 XX

XX WPI; 1997-234701/21.
 DR Treatment for heavy metal poisoning - by chelating heavy metal ions
 XX with phosphorothioate oligonucleotide to cause excretion in urine
 PT Example 3; Column 10; 10pp; English.
 XX The invention relates to a new method of treating an animal suffering
 CC from heavy metal poisoning, comprising administering a phosphorothioate
 CC oligonucleotide to the animal in an amount sufficient to chelate heavy
 CC metals to cause their excretion in the urine of the animal.
 CC The method can be used to treat poisoning caused by cadmium, lead
 CC and/or mercury. The present sequence is one of two complementary
 CC phosphorothioate oligonucleotides (PS-ODNs) which were synthesised and
 CC tested for use in the method. Each PS-ODN is 18 bases in length
 CC and is associated with bases 7-24 downstream from the ATG translational
 CC start site of human metallothionein-II mRNA. The anti-WT antisense
 CC sequence is shown in AAQ67556, and the present sequence is its
 CC complementary sequence.

SQ Sequence 18 BP; 2 A; 10 C; 3 G; 3 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 525 GCCGAGGAGCAGCTGGG 542
 ||| ||||| |||||
 Db 18 GCCGAGGAGCAGCTGGG 1

RESULT 392
 AAV16730
 ID AAV16730 standard; DNA; 18 BP.
 XX
 AC AAV16730;
 XX 18-JUN-1998 (first entry)
 XX Oligonucleotide of the specification.
 DE Thrombopoietic receptor; therapeutic drug; treatment; prevention;
 KW disease; abnormality; haematogenic process; megakaryocyte; ss.
 XX Synthetic.
 OS JP10072492-A.
 PN 17-MAR-1998.
 XX 02-SEP-1996; 96JP-0231807.
 XX 02-SEP-1996; 96JP-0231807.
 XX (HOKR) HOKURIKU PHARM CO LTD.
 XX WPI; 1998-234763/21.
 XX New recombinant therapeutic peptide - useful for, e.g. treating
 PT diseases caused by abnormality in megakaryocyte haematogenic process
 XX Disclosure; Page 6; 11pp; Japanese.

CC The present sequence represents an oligonucleotide of the specification.
 CC The specification describes a peptide which has affinity for
 CC thrombopoietic receptor. The peptide, which can be cyclic, can be used
 CC in the preparation of therapeutics useful for treating and preventing
 CC diseases caused by abnormality in haematogenic process of megakaryocytes.
 XX Sequence 18 BP; 1 A; 10 C; 5 G; 2 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;

PCR primer for G. oxydans D-sorbitol dehydrogenase coding sequence.
D-sorbitol dehydrogenase; L-sorbose; 2-keto-L-gulononic acid; precursor;
L-ascorbic acid production; PCR primer; ss.

Synthetic.
Gluconobacter oxydans.

WO9920763-A1.

29-APR-1999.

13-OCT-1998; 98WO-JP04612.

17-OCT-1997; 97JP-0285280.

(FUJI) FUJISAWA PHARM CO LTD.

Ishii Y, Noguchi Y, Saito Y, Soeda S, Yoshikawa K;

WPI; 1999-302741/25.

Gene group for D-sorbitol dehydrogenase, useful for simple
large-scale production of L-sorbose or 2-keto-L-gulononic acid as
precursor for L-ascorbic acid

Example 5; Page 26; 83pp; Japanese.

This sequence represents a PCR primer for DNA encoding the D-sorbitol
dehydrogenase of the invention. Cells transformed with a vector
containing DNA encoding the dehydrogenase can be used to produce
L-sorbose or 2-keto-L-gulononic acid as precursor for simple large-scale
L-ascorbic acid production.

Sequence 18 BP; 2 A; 8 C; 3 G; 5 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 474 GGGGAGGACTGCCGAGA 491
DB 18 GGGTGAGGAATGCCGAGA 1

RESULT 396

AA03321/c

ID AAX03321 standard; DNA; 18 BP.

AC AAX03321;

23-MAR-1999 (first entry)

PCR primer PCR53 used for amplification of isolated RNA.

Topoisomerase; 5' tagging; RNA transcript; isolating;

gene sequence; PCR primer; ss.

Synthetic.

WO9856943-A1.

17-DEC-1998.

12-JUN-1998; 98WO-US12372.

12-JUN-1997; 97US-0049405.

(INVI-) INVITROGEN CORP.

(SLOK) SLOAN KETTERING INST CANCER RES.

Comisky J, Fernandez J, Hoeffler J, Marcil R, Sekiguchi J;

Shuman S;

XX

DR

XX

PT

PT

PT

XX

XX

PS

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

WPI; 1999-080916/07.

Use of topoisomerase enzymes - for covalently joining a DNA strand
to an RNA strand, used particularly for isolating and cloning
full-length gene sequences

Disclosure; Page 63; 93pp; English.

PCR primers AAX03320-21 were used to amplify reverse-transcribed RNA
isolated using the method of the invention. The specification describes
a method for covalently joining a DNA strand to an RNA strand. The
method comprises forming a topoisomerase-DNA intermediate by incubating a
DNA cleavage substrate comprising a topoisomerase cleavage site with a
topoisomerase specific for that site, where the topoisomerase-DNA
intermediate has one or more 5' single-stranded tails, and adding to the
topoisomerase-DNA intermediate an acceptor RNA strand complementary to
the 5' single-strand tail to permit a ligation of the covalently bound
DNA strand to the RNA acceptor strand and dissociation of the
topoisomerase, thereby covalently joining the DNA strand to the RNA
strand. The products and methods can be used for the 5' tagging of RNA
transcripts. They are used particularly for isolating and cloning
full-length gene sequences.

Sequence 18 BP; 4 A; 7 C; 3 G; 4 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;

Best Local Similarity 83.3%; Pred. No. 2.5e+02;

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 677 GCGTGGTATTGGGAGCC 694

DB 18 GAGTCGTATATGGGAGCC 1

RESULT 397

AAZ71683/c

ID AAZ71683 standard; DNA; 18 BP.

AC AAZ71683;

10-SEP-2001 (first entry)

Human biallelic marker upstream amplification primer SEQ ID NO:6039.

Human genome; biallelic marker; high density disequilibrium map;
Genomic map; haplotype; phenotype; polymorphic base; genotyping;
haplotyping; hybridisation; identification; characterisation;
amplification; single nucleotide polymorphism; SNP; PCR primer;
diagnosis; ss.

Homo sapiens.

WO9954500-A2.

28-OCT-1999.

21-APR-1999; 99WO-IB00822.

21-APR-1998; 98US-0082614.

23-NOV-1998; 98US-0109732.

(GEST) GENSET.

Cohen D, Blumenfeld M, Chumakov I;

WPI; 2000-013267/01.

Novel biallelic markers used to construct a high density disequilibrium
map of the human genome

Claim 8; Page 1518; 2745pp; English.

CC AA265654 to AA269578 represent human biallelic markers from the present
CC invention, which contain a polymorphic base at position 24 of their
CC nucleotide sequences. AA269579 to AA277440 represent amplification
CC primers for the biallelic markers. The biallelic markers of the
CC invention have a variety of uses: they can be used for high density
CC mapping of the human genome, and in complex association studies and
CC haplotyping studies which are useful in determining the genetic basis
CC for disease states. Compositions and methods of the invention can also
CC be useful for the identification of the targets for the development of
CC pharmaceutical agents and diagnostic methods, as well as the
CC characterisation of the differential efficacious responses to and side
CC effects from pharmaceutical agents acting on a disease as well as other
CC treatment.
CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297
CC and 3367, are not actually given a sequence in the Sequence Listing
CC from the present invention.

CC Sequence 18 BP; 7 A; 0 C; 8 G; 3 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 56 CTCCTCAATTACCCACAT 73
DB 18 CTCCTCTCTTATCCACAT 1

RESULT 398
AAA92417
ID AAA92417 standard; DNA; 18 BP.
AC AAA92417;
XX
XX
DT 15-JAN-2001 (first entry)
XX
XX
DE Oligonucleotide PCR primer SEQ ID NO:16.
XX
XX
KW Phage display peptide; screening; biomolecule activity regulator;
KW drug development; liver disorder; sclerosis; cancer; hepatitis C virus;
KW HCV; infection; PCR primer; ss.
XX
XX
OS Synthetic.
XX
XX
PN WO200053740-A1.
XX
PD 14-SEP-2000.
XX
PF 10-MAR-2000; 2000WO-JP01478.
XX
PR 10-MAR-1999; 95JP-0063110.
XX
XX (AJIN) AJINOMOTO CO INC.
XX
XX Okamoto S, Miwa K, Eto Y;
XX
XX WPI; 2000-587433/55.
XX

PT Screening biomolecule activity regulators by their effect on a
PT biomolecule-peptide interactions for identification of potential drug
PT molecules -
XX
XX Example 1; Page 17; 45pp; Japanese.

XX The present invention describes a method for screening potential
XX regulators of the activity of a biomolecule. The method involves
XX screening the potential regulators by selecting from a library of
XX recombinants which express peptides at their surface, one which
XX expresses a peptide which interacts with the biomolecule and then
XX screening potential regulators to identify those which inhibit the
XX interaction of the biomolecule with the selected recombinant or the
XX peptide expressed by it. The method is used for the identification
XX of drug molecules for treatment and prevention of diseases, especially

CC of liver disorders such as sclerosis and cancer associated with
CC hepatitis C virus (HCV) infection. The present sequence represents a
CC PCR primer which is used in an example from the present invention.

CC Sequence 18 BP; 1 A; 10 C; 5 G; 2 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 686 TTGGGAGCCAGCGGCCCC 703
DB 1 TTGGGCCCCAGCGGCCCC 18

RESULT 399
AAA55497
ID AAA55497 standard; DNA; 18 BP.

XX AAA55497;
AC AAA55497;
XX
XX 30-AUG-2000 (first entry)
XX
XX TRAF1 antisense oligonucleotide ISIS# 26699.

DE Tumor necrosis factor receptor-associated factor; TRAF; human;
KW antisense oligonucleotide; phosphothioate; antiproliferative;
KW anti-inflammatory; E-selectin; jun kinase; ss.
XX
XX Synthetic.

OS
XX WO200020435-A1.
XX
XX 13-APR-2000.
XX
XX 05-OCT-1999; 99WO-US23171.
XX
XX 06-OCT-1998; 98US-0167109.

XX (ISIS-) ISIS PHARM INC.
XX
XX Baker BF, Cowsett LM, Monia BP, Xu XS;
XX
XX WPI; 2000-303732/26.

XX Antisense oligonucleotides targeted to nucleic acids encoding human
XX tumor necrosis factor receptor-associated factor (TRAF), useful for
XX treating diseases associated with TRAF expression such as inflammatory
XX diseases -
XX
XX Example 14; Page 46; 170pp; English.

XX The present invention relates to antisense oligonucleotides
XX (see AAA55496-A55757) which are targeted to nucleic acids encoding a
XX human tumor necrosis factor receptor-associated factor (TRAF). The
XX antisense sequences comprise at least one modified internucleotide
XX linkage, which is a phosphorothioate linkage. The oligonucleotides also
XX include at least one modified sugar moiety such as a 2'-O-methoxyethyl
XX sugar moiety. Sequences AAA55490-A55495 represent nucleotide sequences
XX encoding human TRAF1-6. Included in the invention is a method for
XX treating a human having a disease associated with the expression of TRAF
XX comprising administering an antisense oligonucleotide. The reduction of
XX jun kinase activation in cells comprises contacting the cells with an
XX antisense oligonucleotide targeted to TRAF-6. A method for the reduction
XX of E-selectin expression in cells or tissues comprises contacting the
XX cells or tissues with an antisense oligonucleotide targeted to TRAF-2 or
XX TRAF-6. The antisense oligonucleotides have antiproliferative and
XX anti-inflammatory activity and are useful for treating disorders
XX associated with cell proliferation and inflammation. The antisense
XX oligonucleotides may also be used as a diagnostic probe for studying
XX gene function.

XX Sequence 18 BP; 2 A; 5 C; 9 G; 2 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 471 GCAGGGGAGGACTGCG 488
 |||||
 1 GCCGGGGAGGACTGCTG 18

Db

RESULT 400
 AAA27086
 ID AAA27086 standard; DNA; 18 BP.
 XX
 AC
 XX
 XX
 DT 21-AUG-2000 (first entry)
 DE
 DE
 XX
 XX
 DE Human NF-kappa-B p65 subunit antisense oligodeoxynucleotide ISIS# 23738.
 KW Human; anti-inflammatory; cytostatic; antimicrobial; infection;
 KW antisense inhibition; inflammation; transcription factor;
 KW apoptosis; cancer; ss.
 XX
 XX Homo sapiens.
 OS
 XX
 XX Key Location/Qualifiers
 FT modified_base 1..18
 FT /*tag= a
 FT /note= "all or some internucleoside bonds are
 FT phosphorothioate and optionally some sugars may
 FT be 2' methoxyethyl"
 XX
 XX US6069008-A.
 XX
 XX
 XX 30-MAY-2000.
 XX
 XX 25-NOV-1998; 98US-0199859.
 XX 25-NOV-1998; 98US-0199859.
 XX (ISIS-) ISIS PHARM INC.
 XX
 XX Bennett CF, Cowser LM, Monia BP;
 XX
 XX WPI; 2000-410858/35.
 XX
 XX Antisense compounds which inhibit the expression of the human
 XX NF-kappa-B p65 subunit (p65) useful for treating diseases associated
 XX with p65 expression and as prophylaxis to prevent of delay infection,
 XX inflammation or tumor formation -
 XX
 XX Example 15; Column 40; 33pp; English.
 XX
 XX The present sequence is one of a number of oligonucleotides designed to
 XX target different regions of the human NF-kappa-B p65 subunit, which is a
 XX member of the Rel/NF-kappa-B family of transcription factors.
 XX Rel/NF-kappa-B proteins are involved in a diverse set of signaling
 XX pathways involving stress, apoptosis, cancer, growth, infection and
 XX inflammation. Antisense oligonucleotides are able to inhibit expression
 XX of the p65 subunit and may therefore be used in the treatment of
 XX disorders associated with NF-kappa-B p65 subunit expression. They may be
 XX used as a prophylaxis to prevent or delay infection, inflammation or
 XX tumor formation. Antisense compounds may also be used for research and
 XX diagnostics because they hybridize to nucleic acids encoding
 XX NF-kappa-B p65 subunit. The effect of antisense oligonucleotides on
 XX NF-kappa-B p65 subunit mRNA levels was measured using real-time
 XX quantitative PCR and Northern blot analysis. Antisense
 XX oligonucleotides were synthesised on an automated DNA synthesiser.

Sequence 18 BP; 2 A; 6 C; 5 G; 5 T; 0 other;
 Query Match 1.0%; Score 13.2; DB 1; Length 18;

Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1300 CCTGGCCCCCATGTAGCCA 1317
 |||||
 1 CCTGGTCTCTGTAGCCA 18

Db

RESULT 401
 AAA39029/C
 ID AAA39029 standard; DNA; 18 BP.
 XX
 AC AAA39029;
 XX
 XX
 DT 25-AUG-2000 (first entry)
 DE
 DE
 XX
 XX
 DE Unknown bacterial 16S rRNA gene primer 0531R SEQ ID NO:7.
 KW Bacterial; 16S rRNA; identification; polymorphism; microorganism;
 KW classification; primer; human medicine; veterinary medicine;
 KW agriculture; food science; industrial microbiology; infectious disease;
 KW food safety; ss.
 XX
 XX Unidentified.
 OS
 XX
 XX US6054278-A.
 XX
 XX 25-APR-2000.
 XX
 XX 05-MAY-1998; 98US-0073465.
 XX 05-MAY-1997; 97US-0045603.
 XX
 XX (PEKE) PERKIN-ELMER CORP.
 XX
 XX Smith DH, Dodge DE;
 XX
 XX WPI; 2000-338488/29.
 XX
 XX Identifying an unknown microorganism by generating a composite sequence
 XX of its ribosomal RNA gene region and comparing with composite ribosomal
 XX RNA region sequences of distinct microorganisms in a database -
 XX
 XX Example; Column 10; 11pp; English.
 XX
 XX The present invention describes a method for identifying a microorganism
 XX by comparing a composite sequence (I) of a ribosomal RNA gene region
 XX with RNA region sequences of unknown microorganisms in a database and
 XX identifying the region in the database that matches with (I). (I) is
 XX generated by simultaneously obtaining nucleotide base sequence data from
 XX every copy of the rRNA gene region in the genome of the unknown
 XX microorganism. Also described is a method for identifying the species of
 XX microorganism by generating (I) and entering it into a first data
 XX register of a programmable computer, comparing the first data register
 XX with reference data registers that encode a unique composite rRNA
 XX sequence corresponding to (I) and correlated with unique microorganism
 XX species name, and displaying the unique microorganism name correlated
 XX with the best matching first data register. The method is useful for
 XX identifying microorganisms which are useful in a variety of fields
 XX including human medicine, veterinary medicine, agriculture, food science
 XX and industrial microbiology. The microorganisms found in patients
 XX suffering from an infectious disease can also be identified.
 XX Microorganism identification is also useful for monitoring food safety
 XX by testing for pathogens. Plants harbouring phytopathogenic bacteria are
 XX also identified. The method is convenient and efficient as there is no
 XX need to isolate one or more individual 16S rRNA genes. AAA39023 to
 XX AAA39039 represent primers for the 16S rRNA gene, which are used in the
 XX exemplification of the present invention.

Sequence 18 BP; 2 A; 7 C; 6 G; 3 T; 0 other;
 Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 882 GTTCAGGAGCTGGGTA 899
 |||||
 Db 18 GTGCCAGCAGCGGGTA 1

RESULT 402

AAAI5532/C
 ID AAA15532 standard; DNA; 18 BP.

XX AC AAA15532;

XX DT 28-JUL-2000 (first entry)

DE Human G-alpha-i3 antisense oligonucleotide ISIS#25951.
 XX Human; G-alpha-i3; G protein; Gi protein; adenylyl cyclase;
 KW dopamine; thyrotropin-releasing hormone; somatostatin;
 KW signal transduction pathway; antisense oligonucleotide; ss.

XX OS Homo sapiens.

XX Key Location/Qualifiers

FT modified_base 1..18

FT /tag= a

FT /mod_base= OTHER

FT /note= "Optionally phosphorothioate

FT deoxynucleotides"

FT 1..4

FT /tag= b

FT /mod_base= OTHER

FT /note= "Optionally 2'-methoxyethyl nucleotides

FT providing bases 15..18 are also 2'-methoxyethyl

FT nucleotides. All cytidine residues within this region are

FT then 5-methylcytidine"

FT 15..18

FT /tag= c

FT /mod_base= OTHER

FT /note= "Optionally 2'-methoxyethyl nucleotides

FT providing bases 1..4 are also 2'-methoxyethyl

FT nucleotides. All cytidine residues within this region are

FT then 5-methylcytidine"

FT 15..18

FT /tag= c

FT /mod_base= OTHER

FT /note= "Optionally 2'-methoxyethyl nucleotides

FT providing bases 1..4 are also 2'-methoxyethyl

FT nucleotides. All cytidine residues within this region are

FT then 5-methylcytidine"

FT 15..18

FT /tag= c

FT /mod_base= OTHER

FT /note= "Optionally 2'-methoxyethyl nucleotides

FT providing bases 1..4 are also 2'-methoxyethyl

FT nucleotides. All cytidine residues within this region are

FT then 5-methylcytidine"

FT 15..18

FT /tag= c

FT /mod_base= OTHER

FT /note= "Optionally 2'-methoxyethyl nucleotides

FT providing bases 1..4 are also 2'-methoxyethyl

FT nucleotides. All cytidine residues within this region are

FT then 5-methylcytidine"

FT 15..18

FT /tag= c

FT /mod_base= OTHER

FT /note= "Optionally 2'-methoxyethyl nucleotides

FT providing bases 1..4 are also 2'-methoxyethyl

FT nucleotides. All cytidine residues within this region are

FT then 5-methylcytidine"

FT 15..18

FT /tag= c

FT /mod_base= OTHER

FT /note= "Optionally 2'-methoxyethyl nucleotides

FT providing bases 1..4 are also 2'-methoxyethyl

FT nucleotides. All cytidine residues within this region are

FT then 5-methylcytidine"

FT 15..18

FT /tag= c

FT /mod_base= OTHER

CC to prevent infection, inflammation and tumours.

XX SQ Sequence 18 BP; 5 A; 2 C; 8 G; 3 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;

Best Local Similarity 83.3%; Pred. No. 2.5e+02;

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 973 CTCACCTTGACCCACGCCA 990

|||||

Db 18 CTCACCTTGACCCACGCCA 1

|||||

RESULT 403

AAA09715/C

ID AAA09715 standard; DNA; 18 BP.

XX AC AAA09715;

XX DT 23-JUN-2000 (first entry)

XX G-alpha-i2 antisense inhibitor oligonucleotide #15 (ISIS #25823).

DE G-alpha-i2; antisense inhibitor; infection; inflammation; prevent;

KW tumour formation; treatment; inhibit; ss.

XX OS Homo sapiens.

XX US6040179-A.

XX 21-MAR-2000.

XX 25-JUN-1999; 99US-0339993.

XX 25-JUN-1999; 99US-0339993.

XX (ISIS-) ISIS PHARM INC.

XX Cowsert LM;

XX WPI; 2000-270140/23.

XX Novel antisense oligonucleotide containing compounds, useful for

XX inhibiting the expression of G-alpha-i2 in human cells and tissues and

XX treating infection, inflammation and cancer -

XX Claim 1; Column 40; 31pp; English.

XX This sequence represents an antisense oligonucleotide sequence targeted

XX to a nucleotide sequence encoding human G-alpha-i2. G-alpha-i2 is a

XX member of the Gi subfamily of G proteins, which is involved in hormonal

XX inhibition of adenylyl cyclase and in the regulation of plasma membrane

XX enzymes. The expression of G-alpha-i2 has been shown to be altered in

XX some tumours. Mice lacking the G-alpha-i2 gene display growth retardation

XX and develop adenocarcinoma of the colon and a form of lethal diffuse

XX colitis similar to ulcerative colitis in humans. The antisense molecules

XX are useful for inhibiting the expression of G-alpha-i2 in human cells or

XX tissues, and for treating and preventing various disorders such as

XX infection, inflammation and tumour formation. The antisense

XX oligonucleotides are also useful for research and diagnostic purposes.

XX SQ Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;

Best Local Similarity 83.3%; Pred. No. 2.5e+02;

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 860 GCTTTGAGGTCCACACAG 877

|||||

Db 18 GCTTTGAGGTCCACACAG 1

|||||

RESULT 404

The present sequence is an antisense oligonucleotide for the human

G-alpha-i3 gene. The protein produced from this gene is a member of the

G protein family, and more specifically of the Gi family. The Gi proteins

are involved in hormonal inhibition of adenylyl cyclase and the

regulation of plasma membrane enzymes. In addition, G-alpha-i3 has been

shown to have a role in the dopamine, thyrotropin-releasing hormone and

somatostatin signal transduction pathways. The oligonucleotide may

be used to modulate expression of the G-alpha-i3 gene and can be used


```

AAZ91440
ID AAZ91440 standard; DNA; 18 BP.
XX
AC AAZ91440;
XX
DT 22-MAY-2000 (first entry)
XX
DE Human Ship-2 phosphorothioate antisense oligonucleotide #30722.
XX
KW Human; Ship-2; antisense oligonucleotide; phosphorothioate; detection;
KW inhibition; SH2-containing phosphatidylinositol phosphatase-2; ss.
XX
OS Homo sapiens.
XX
FH Key Location/Qualifiers
FT modified_base 1..18
FT /*tag= a
FT /note= "phosphorothioate linkages"
XX
XX US6025198-A.
XX
XX 15-FEB-2000.
XX
XX 25-JUN-1999; 99US-0339964.
XX
XX 25-JUN-1999; 99US-0339964.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Bennett CF, Cowser LM;
XX
XX WPI; 2000-181819/16.
XX
XX Antisense oligonucleotides, useful for inhibiting human Ship-2
XX expression and for detecting nucleic acids encoding Ship-2 -
XX
XX Example 15; Column 39; 34pp; English.
XX
XX The present invention describes phosphorothioate antisense
XX oligonucleotides that specifically hybridise with, and inhibit the
XX expression of, nucleic acids encoding human Ship-2 (also called
XX SH2-containing phosphatidylinositol phosphatase-2). Also described
XX is a method of inhibiting the expression of Ship-2 in human cells
XX or tissues in vitro comprising contacting the cells with the
XX phosphorothioate antisense oligonucleotides. The phosphorothioate
XX antisense oligonucleotides can be used to treat animals (especially
XX humans) suspected of having or being prone to a disease or condition
XX associated with Ship-2 expression. The present sequence represents
XX a phosphorothioate antisense oligonucleotide for human Ship-2, from
XX the present invention.
XX
XX Sequence 18 BP; 2 A; 11 C; 1 G; 4 T; 0 other;
XX
Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 869 TCCCCACAGCCAGTCC 886
DB 1 TCCCCACTGCCACTTCC 18

RESULT 405
AAZ65527
ID AAZ65527 standard; DNA; 18 BP.
XX
AC AAZ65527;
XX
XX 30-MAR-2000 (first entry)
XX
DE Immunosuppressant inhibitor oligonucleotide TGF-beta1-98-15.
XX
KW Immunosuppressant inhibitor; transforming growth factor beta; TGF beta;

```

```

KW vascular endothelial growth factor; VEGF; interleukin-10; IL-10; cancer;
KW prostaglandin E2; PGE2; immune response; tumour; asthma; Crohn's disease;
KW monocyte chemotactic protein-1; MCP-1; ulcerative colitis; diabetes;
KW glomerulonephritis; acute respiratory distress syndrome; ss;
KW atherosclerosis.
XX
OS Unidentified.
XX
XX WO9963975-A2.
XX
XX 16-DEC-1999.
XX
XX 10-JUN-1999; 99WO-EP04013.
XX
XX 10-JUN-1998; 98EP-0110709.
XX
XX 25-JUL-1998; 98EP-0113974.
XX
XX (BIOG-) BIOGNOSTIK GES BIOMOLEKULARE DIAGNOSTIK.
XX
XX Schlingensiepen K, Schlingensiepen R, Brysch W;
XX
XX WPI; 2000-097470/08.
XX
XX Composition containing immune stimulant and inhibitor of agent that
XX adversely affects the immune response, for treating cancers and
XX infections -
XX
XX Claim 10; Figure 1; 30pp; English.
XX
XX This sequence is an immunosuppressant inhibitor oligonucleotide, which
XX is used in the invention. The invention relates to a composition which
XX contains at least one inhibitor (less than 100 kD) of a substance (e.g.
XX transforming growth factor TGF-beta, vascular endothelial growth factor
XX VEGF, interleukin-10 IL-10, prostaglandin E2 PGE2, or their receptors)
XX that adversely affects the immune response. The composition also includes
XX at least one stimulant that positively affects the immune response. This
XX oligonucleotide is an example of an inhibitor that is used in the
XX composition. The composition is used as an immunostimulant for the
XX treatment of neoplasms and infections, particularly hyperproliferation;
XX leukaemia; (non-Hodgkin's lymphoma; carcinoma (of oesophagus, bronchi,
XX colon-rectum, stomach, intestine, gall bladder or duct, pancreas, anus,
XX breast, ovary, cervix, endometrium, prostate or bladder), liver tumours,
XX malignant melanoma, brain tumours and sarcomas. The oligonucleotides,
XX most of which are directed against TGFbeta or VEGF, are inhibitors of
XX monocyte chemotactic protein-1 (MCP-1) and are useful as
XX anti-inflammatories for treating e.g. asthma, Crohn's disease, ulcerative
XX colitis, diabetes, glomerulonephritis, acute respiratory distress
XX syndrome and the formation of atherosclerotic plaque.
XX
XX Sequence 18 BP; 1 A; 9 C; 7 G; 1 T; 0 other;
XX
Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 191 CCGCCACCCGCGCGCG 208
DB 1 CCGCCACCCGCGTCCGG 18

RESULT 405
AAI66785/c
ID AAI66785 standard; DNA; 18 BP.
XX
XX AAI66785;
XX
XX 07-JAN-2002 (first entry)
XX
XX PPAR-gamma mRNA amplifying RT-PCR primer R.
XX
XX Adipocyte; hedgehog polypeptide; desert hedgehog; indian hedgehog; Dhh;
XX Ihh; sonic hedgehog; Shh; therapeutic; cytostatic; primer; RT-PCR; ss.
XX

```

```

OS Synthetic.
XX WO200164238-A2.
XX
XX
XX PD 07-SEP-2001.
XX
XX PT 28-FEB-2001; 2001WO-US06450.
XX PF
XX PR 29-FEB-2000; 2000US-186058P.
XX
XX PA (CURI-) CURIS INC.
XX
XX PI Zehentner B, Leser-Reiff U, Burtscher H;
XX
XX WPI; 2001-607352/69.
XX
XX PT Method for regulating formation and/or maintenance of adipocyte tissue
XX by contacting pre-adipocyte or adipocyte cells with a hedgehog
XX peptide or ptc therapeutic -
XX
XX PS Example; Page 76; 132pp; English.
XX
XX CC The invention provides a method for regulating formation and/or
XX maintenance of adipocyte tissue that comprises contacting pre adipocyte
XX or adipocyte cells with a hedgehog polypeptide or ptc therapeutic. The
XX method is used for regulating the growth state of an adipocyte stem/
XX progenitor cell, and treating or preventing disorders of, or surgical or
XX cosmetic repair of, adipocyte tissues, e.g. for treating or preventing
XX hyperplastic or neoplastic conditions affecting adipocyte tissue, such
XX as soft tissue tumors, especially adipose cell tumors, e.g. lipomas,
XX fibrolipomas, lipoblastomas, lipomatosis, hibernomas, hemangiomas and/or
XX liposarcomas. Hedgehog polypeptides can be used in combination with other
XX therapeutic agents. Sequences AA166784-793 represent primers used in
XX quantitative RT-PCR of PPARGgamma, ap2, gli, ptc and actin mRNAs, during
XX the course of the invention.
XX
XX SQ Sequence 18 BP; 4 A; 5 C; 6 G; 3 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 304 GTGGGGGTGCAACTCCA 321
Db 18 GTGGAGCTGCATCTCCA 1

RESULT 407
AAF89283
ID AAF89283 standard; DNA; 18 BP.
XX
XX AC AAF89283;
XX
XX DT 10-DEC-2001 (first entry)
XX
XX DE Sample member clustering method related human DNA PCR primer #20.
XX
XX KW Cluster; hierarchical clustering algorithm; population based study;
XX clinical trial; DNA fingerprint; genetic profile analysis; PCR primer;
XX SNP; single nucleotide polymorphism; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200129257-A2.
XX
XX PD 26-APR-2001.
XX
XX PF 20-OCT-2000; 2000WO-IB01632.
XX
XX PR 22-OCT-1999; 95US-0161231.
XX
XX PR 07-JUL-2000; 2000US-0216897.
XX
XX FA (GEST ) GENSET.

```

```

XX PI Schork N, Skierczynski B;
XX
XX DR WPI; 2001-316248/33.
XX
XX PT Genetic clustering by distributing members into optimal numbers of
XX clusters determined by a hierarchical clustering algorithm or by
XX paired-pair analysis of homozygous pairs in clusters got from
XX non-hierarchical clustering -
XX
XX PS Claim 61; Page 78; 100pp; English.
XX
XX CC The present invention describes methods of clustering members of a
XX sample, involving applying a hierarchical clustering algorithm to the
XX sample members, determining the optimal number of clusters based on this
XX and distributing the sample members into clusters using non-hierarchical
XX clustering. The methods are useful in population based studies such as
XX clinical trials, DNA fingerprinting and genetic profile analyses. The
XX present sequence was used to demonstrate the method of the invention.
XX
XX SQ Sequence 18 BP; 5 A; 8 C; 3 G; 2 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 869 TCCCCACAGCCAAAGTTCC 886
Db 1 TCCCCACAGCTAAGAGCC 18

RESULT 408
AAH75784
ID AAH75784 standard; DNA; 18 BP.
XX
XX AC AAH75784;
XX
XX DT 15-OCT-2001 (first entry)
XX
XX DE Human NOV 12 reverse PCR primer.
XX
XX KW NOV; olfactory; cytostatic; immunomodulator; vulnery; anti-HIV;
XX antiasthmatic; antiinflammatory; gastrointestinal; neuroprotective;
XX osteopathic; gene therapy; odorant receptor; olfactory receptor;
XX G-protein coupled receptor; GPCR; neuro-olfactory; trauma; PCR primer;
XX neoplastic disorder; cancer; adenocarcinoma; lymphoma; prostate cancer;
XX uterus cancer; immune response; AIDS; asthma; Crohn's disease;
XX multiple sclerosis; Albright hereditary osteodystrophy; ss.
XX
XX OS Homo sapiens.
XX
XX PN WO200155179-A2.
XX
XX PD 02-AUG-2001.
XX
XX PF 29-JAN-2001; 2001WO-US02849.
XX
XX PR 27-JAN-2000; 2000US-0178370.
XX
XX PR 27-JAN-2000; 2000US-0178371.
XX
XX PR 27-JAN-2000; 2000US-0178406.
XX
XX PR 27-JAN-2000; 2000US-0178408.
XX
XX PR 27-JAN-2000; 2000US-0178409.
XX
XX PR 27-JAN-2000; 2000US-0178413.
XX
XX PR 27-JAN-2000; 2000US-0178414.
XX
XX PR 07-FEB-2000; 2000US-0180634.
XX
XX PR 24-JUL-2000; 2000US-0220516.
XX
XX PR 28-JUL-2000; 2000US-0321408.
XX
XX PR 31-JUL-2000; 2000US-0221943.
XX
XX PR 21-DEC-2000; 2000US-0257599.
XX
XX PR 08-JAN-2001; 2001US-0260290.
XX
XX FA (CURA-) CURAGEN CORP.
XX
XX

```

PI Prayaga SK, Padigaru M, Spytek KA, Li L, Tchernev VT, Vernet CM;
 PI Peyman JA, Macdougall J;
 XX WPI; 2001-514556/56.
 XX
 XX New NOVX polypeptides and polynucleotides, useful for treating or
 PT preventing a syndrome associated with a human disease (e.g. disorders
 PT of the neuro-olfactory system), as well as in gene therapy -
 XX
 XX Example 2; Page 229; 242pp; English.
 XX
 CC The present invention relates to novel human NOVX proteins and coding
 CC sequences, where x is any number from 1 to 18 (see AAH5716-AAH7573, and
 CC AAG6400 and AAG66322-AAG66338). NOVX are members of the
 CC odorant/olfactory receptor (OR) family, which are G-protein coupled
 CC receptors (GPCRs). The NOVX proteins and coding sequences are useful as
 CC therapeutics, particularly in the manufacture of a medicament for
 CC treating a syndrome associated with a human disease/disorders of the
 CC neuro-olfactory system, e.g. those induced by trauma, surgery and/or
 CC neoplastic disorders. Furthermore, the coding sequences and proteins are
 CC useful in treating cancer e.g. adenocarcinoma, lymphoma, prostate cancer,
 CC uterus cancer, inappropriate immune response, AIDS, asthma, Crohn's
 CC disease, multiple sclerosis or Albright hereditary osteodystrophy. The
 CC coding sequences are also useful in gene therapy for treating the above
 CC conditions. The present PCR primer was used in an example from the
 CC present invention.
 XX
 XX Sequence 18 BP; 5 A; 5 C; 7 G; 1 T; 0 other;
 SQ
 Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 906 GGCCCTGGTCTCAAGGA 923
 Db 1 GGCCCGACCTGAAGGA 18
 RESULT 409
 AAH51027
 ID AAH51027 standard; DNA; 18 BP.
 XX
 AC AAH51027;
 XX
 XX 28-AUG-2001 (first entry)
 DT
 XX Human nGPCR3 PCR primer #2.
 XX
 KW G protein-coupled receptor; nGPCR; seven transmembrane receptor;
 KW signal transduction; schizophrenia; thyroid disorder; renal failure;
 KW rheumatoid arthritis; CNS disorder; infection; metabolic disease;
 KW cardiovascular disease; proliferative disorder; hormonal disorder;
 KW neurological disorder; neuronal disorder; Alzheimer's disease; cancer;
 KW attention deficit-hyperactivity disorder/attention deficit disorder;
 KW Parkinson's disease; migraine; senile dementia; inflammatory disease;
 KW rheumatoid arthritis; autoimmune disorder; respiratory ailment;
 KW neuroprotective; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200136473-A2.
 PN
 XX
 XX 25-MAY-2001.
 PD
 XX
 XX 16-NOV-2000; 2000WO-US31581.
 PF
 XX 16-NOV-1999; 99US-0165838.
 PR 17-NOV-1999; 99US-0166071.
 PR 19-NOV-1999; 99US-0166678.
 PR 28-DEC-1999; 99US-0173396.
 PR 22-FEB-2000; 2000US-0184129.
 PR 28-FEB-2000; 2000US-0185421.
 PR 28-FEB-2000; 2000US-0185554.

PR 02-MAR-2000; 2000US-0186530.
 PR 03-MAR-2000; 2000US-0186811.
 PR 09-MAR-2000; 2000US-0188114.
 PR 17-MAR-2000; 2000US-0190310.
 PR 21-MAR-2000; 2000US-0190800.
 PR 20-APR-2000; 2000US-0198568.
 PR 02-MAY-2000; 2000US-0201190.
 PR 08-MAY-2000; 2000US-0203111.
 PR 25-MAY-2000; 2000US-0207094.
 XX
 PA (PHAA) PHARMACIA & UPJOHN CO.
 XX
 XX Vogeli G, Wood LS, Parodi LA, Hiesch RR, Lind P, Slightom J;
 PI Schellin KA, Kaytes PS, Bannigan CM, Ruff V, Sejlitz T, Ruff RM;
 XX WPI; 2001-389826/41.
 DR
 XX New G protein-coupled receptor (nGPCR-x) and its encoding
 PT polynucleotide useful for diagnosing and treating e.g. schizophrenia -
 XX
 PS Example 4; Page 116; 261pp; English.
 XX
 CC The present invention relates to novel G protein-coupled receptors
 CC (nGPCRx; where x is 1, 3, 4, 5, 9, 11, 12, 14-18, 20, 21, 22, 24, 27,
 CC 28, 31-38, 40, 41, 53-60) and their coding sequences (see
 CC AAH50969-AAH51015 and AAH51105 and AAG80929-AAG80975 and AAG80977). The
 CC present sequence is a PCR primer, which was used in an example from the
 CC present invention. GPCRs are also known as seven transmembrane receptors
 CC and function in signal transduction. The nGPCRx coding sequences are
 CC useful for screening a human to diagnose a disorder affecting the brain
 CC or a genetic predisposition, specifically schizophrenia. nGPCRx are
 CC useful for identifying compounds useful for treating schizophrenia.
 CC Detection of nGPCRx in a sample is useful as a diagnostic tool for
 CC diseases or disorders e.g. thyroid disorders, renal failure, rheumatoid
 CC arthritis, CNS disorders, infections such as HIV-1, metabolic and
 CC cardiovascular diseases, proliferative disorders and hormonal disorders.
 CC Modulators of nGPCRx activity have the utility for treating neurological
 CC disorders, including schizophrenia, ADHD/ADD (attention deficit-
 CC hyperactivity disorder/attention deficit disorder), and neuronal
 CC disorders such as Alzheimer's disease, Parkinson's disease, migraine and
 CC senile dementia. Additional disorders include inflammatory conditions
 CC (e.g. Crohn's disease), rheumatoid arthritis, autoimmune disorders,
 CC cancers, respiratory ailments such as asthma, and inflammatory diseases
 CC e.g. inflammatory bowel disease.
 XX
 SQ Sequence 18 BP; 1 A; 5 C; 8 G; 4 T; 0 other;
 Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 524 TGCCTGTGGAGCGCTGG 541
 Db 1 TGCCTGTGGAGCGCTGG 18
 RESULT 410
 AAF26667
 ID AAF26667 standard; DNA; 18 BP.
 XX
 AC AAF26667;
 XX
 XX 02-APR-2001 (first entry)
 DT
 XX
 DE Human Smad7 phosphorothioate antisense oligonucleotide SEQ ID NO:10.
 XX
 KW Human; Smad7; antisense oligonucleotide; phosphorothioate; inhibition;
 KW antiinflammatory; cytostatic; infection; inflammation; tumour formation;
 KW ss.
 XX
 OS Homo sapiens.
 XX
 XX Key Location/Qualifiers
 FH


```

PA (PHAA ) PHARMACIA & UPJOHN CO.
XX
PI Lind P, Parodi LA, Vogeli G, Wood LS;
XX
DR WPI; 2002-674879/72.
XX
PT New nucleic acids and polypeptides of the nG protein-coupled receptor,
PT useful for treating or diagnosing a mental disorder or a disorder
PT affecting the brain, e.g. anxiety disorders, schizophrenia, stroke or
PT Parkinson's disease
XX
XX Example 4; Page 110; 244pp; English.
XX
XX The invention discloses an isolated human polypeptide, and encoding
XX nucleic acid, for a G protein-coupled receptor (GPCR), particularly the
XX nG protein coupled receptor-14 (nGPCR-14). GPCRs are vital in the
XX communication between cells and their environment and are characterised
XX by a serpentine structure that passes through the cell membrane seven
XX times, hence the reason such receptors are sometimes called seven
XX transmembrane receptors (7TM). The polynucleotides and polypeptides are
XX useful for identifying an nGPCR allelic variant that correlates with a
XX mental disorder, for isolating an antibody that binds to an epitope of
XX the polypeptide, for identifying a compound that binds to the polypeptide
XX or polynucleotide and/or modulates its biological activity, for
XX screening a human subject to diagnose a disorder, or a genetic
XX predisposition to a disorder, affecting the brain or a genetic
XX disposition of a mental disorder, for identifying compounds useful for the
XX treatment of a mental disorder and for identifying a compound useful as a
XX modulator of binding between nGPCR-14 and a binding partner of nGPCR-14.
XX The polypeptide is also useful for inducing an immune response in a
XX mammal. The nucleic acid or polypeptide is particularly useful, using
XX gene therapy, for treating e.g. anxiety disorders, depression, bipolar
XX disorder, schizophrenia, Huntington's disease, dyskinesias, manic
XX depression, stroke, Parkinson's disease or Alzheimer's disease. The
XX nucleic acid and polypeptide may also be used for treating diabetes,
XX inflammation or wounds. The sequences presented in ABS70249-ABS70352,
XX ABS70355-ABS703282, ABS70305-ABS70337 and ABS70339-ABS70242 are the PCR
XX primers which were used to amplify, and detect, the DNA encoding the
XX nGPCRs (also referred to as beGPCRs).
XX
SQ Sequence 18 BP; 1 A; 5 C; 8 G; 4 T; 0 other;
Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 524 TCCCGAGGAGCAGCTGG 541
DB 1 TGCCTGTGGAGCCGCTGG 18
RESULT 413
ABS65844/C
ID ABS65844 standard; DNA; 18 BP.
XX
AC ABS65844;
XX
DT 15-NOV-2002 (first entry)
XX
DE Inhibitory oligonucleotide specific for hepatitis C virus #50.
XX
DE Hepatitis C virus; HCV; hepatocyte infection; non-A hepatitis;
XX non-B hepatitis; acute hepatitis; chronic hepatitis;
XX hepatocellular carcinoma; virucide; cytostatic; antisense therapy;
XX gene therapy; ss; DNA-RNA hybrid.
XX
OS Synthetic.
XX
XX US2002081577-A1.
XX
PN 27-JUN-2002.
XX
PD 02-JUL-1997; 97US-0887505.
XX
PF

```

```

XX
PR 02-JUL-1996; 96US-021104P.
PR 06-JUN-1995; 95US-0471968.
XX
PA (KILK/) KILKUSKIE R L.
PA (FRAN/) FRANK B L.
PA (GOOD/) GOODCHILD J.
PA (WOLF/) WOLFE J L.
PA (ROBE/) ROBERTS P C.
PA (HAML/) HAMLIN H A.
PA (ROBE/) ROBERTS N A.
PA (WALT/) WALTHER D M.
XX
XX Kilkuskie RL, Frank BL, Goodchild J, Wolfe JL, Roberts PC;
XX Hamlin HA, Roberts NA, Walther DM;
XX WPI; 2002-537132/57.
XX
XX Synthetic oligonucleotides complementary to a portion of the 5'
XX untranslated region of hepatitis C virus (HCV), useful for diagnosing
XX PT and treating HCV infections and hepatocellular carcinoma -
XX Claim 22; Page 11; 74pp; English.
XX
XX The invention describes synthetic oligonucleotides complementary to a
XX portion of the 5' untranslated region of hepatitis C virus. The
XX oligonucleotides may be used in methods for controlling, preventing, and
XX treating hepatitis C virus infection, in antisense technology and gene
XX therapy, and of detecting the presence of hepatitis C virus in a sample.
XX Hepatitis C virus (HCV) is an enveloped, positive sense, single-stranded
XX RNA virus which infects hepatocytes. HCV is the major cause of non-A,
XX non-B, acute and chronic hepatitis, and has been associated with
XX hepatocellular carcinoma. The invention describes methods and kits for
XX inhibiting replication of HCV, inhibiting the expression of HCV nucleic
XX acid and protein, and for treating HCV infections. This sequence
XX represents a synthetic DNA-RNA hybrid oligonucleotide used for inhibiting
XX HCV replication and expression of HCV.
XX
SQ Sequence 18 BP; 2 A; 3 C; 10 G; 1 T; 2 U; 0 other;
Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 631 CTCGAGGAGCTCTGCATC 648
DB 18 CTCGAGGAGCCCTGCACC 1
RESULT 414
ABT06049/C
ID ABT06049 standard; DNA; 18 BP.
XX
AC ABT06049;
XX
DT 28-OCT-2002 (first entry)
XX
DE Human IgM heavy chain gene related PCR primer SEQ ID No 63.
XX
DE Single Primer Amplification; nested oligonucleotide extension reaction;
XX hairpin; SPA; library; PCR; primer; ss.
XX
OS Homo sapiens.
XX
XX WO200248401-A2.
XX
XX 20-JUN-2002.
XX
XX 10-DEC-2001; 2001WO-US47727.
XX
XX 11-DEC-2000; 2000US-254669P.
XX 19-SEP-2001; 2001US-323400P.
XX
XX

```

PA (ALEX-) ALEXION PHARM INC.
XX Bowdish KS, Barbas-frederickson S, Lin Y, Mcwhirter J, Maruyama T;
PI WPI; 2002-500537/53.
XX Amplifying nucleic acid by synthesizing template nucleic acid
PT containing a predetermined sequence and hairpin structure and using the
PT template for target amplification by Single Primer Amplification -
XX Example 3; Page 22; 54pp; English.
XX The invention relates to a method for amplifying a nucleic acid using
CC Single Primer Amplification (SPA). The method comprises synthesising a
CC template nucleic acid containing a predetermined sequence and hairpin
CC structure with the nested oligonucleotide extension reaction. The method
CC is useful for amplifying a nucleic acid, preferably for amplifying a
CC family of related nucleic acid sequences to build a complex library of
CC polypeptides encoded by the sequences. The engineered nucleic acid strand
CC is useful for amplifying a nucleic acid strand by providing a nucleic
CC acid with a predetermined sequence engineered onto its first end, a
CC sequence complementary to the predetermined sequence and a hairpin
CC structure between them and contacting the engineered nucleic acid strand
CC with a primer containing at least a portion of the predetermined
CC sequence. This process is done in the presence of a polymerase and
CC nucleotides under conditions suitable for polymerisation to produce a
CC complementary nucleic acid strand. The method of the invention is useful
CC for producing large amounts of a target nucleic acid sequence and for
CC amplifying simultaneously more than one different target nucleic acid
CC sequence located on the same or different nucleic acid molecules. This
CC polynucleotide sequence represents a PCR primer of the invention.
XX
SQ Sequence 18 BP; 1 A; 2 C; 7 G; 8 T; 0 other;
Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 28 AAACCCAGCTACGCCAAA 45
DB 18 AAACCCAGCTACGCCAAA 1
RESULT 415
ABK47739/c
ID ABK47739 standard; DNA; 18 BP.
XX AC ABK47739;
XX DT 18-JUN-2002 (first entry)
XX DE Beta-actin reverse PCR primer used in invention relating to TMOs.
XX KW Primer-dependent polymerase-mediated DNA synthesis; TMO;
KW template-mimic oligonucleotide; nucleic acid amplification;
KW multiplex RT-PCR; reverse transcriptase-PCR; Competimer method;
KW PCR; primer; beta-actin; ss.
XX OS Unidentified.
XX PN WO200218616-A1.
XX XX 07-MAR-2002.
XX PF 30-AUG-2001; 2001WO-US27287.
XX PR 01-SEP-2000; 2000US-230184P.
XX PA (HITB) HITACHI CHEM CO LTD.
XX PA (HITB) HITACHI CHEM RES CENT INC.
XX PI Ke S;
XX

DR WPI; 2002-315546/35.
XX Modulating amplification efficiency of a target sequence in
PT primer-dependent polymerase-mediated DNA synthesis, useful for
PT adjusting the efficiency nucleic acid amplification comprises adding a
PT template mimic-oligonucleotide -
XX Example; Page 12; 39pp; English.
XX The present invention relates to a method of modulating amplification
CC efficiency of a target sequence in primer-dependent polymerase-mediated
CC DNA synthesis. The method comprises adding a template-mimic
CC oligonucleotide (TMO) to a primer-dependent polymerase-mediated DNA
CC synthesis reaction mixture containing primers, to block a primer for
CC amplifying a target sequence in the mixture from hybridising to the
CC target sequence. The method is useful for adjusting the efficiency of
CC target template nucleic acid amplification by controlling the ratio of
CC template-like oligonucleotides to amplification primers. The new method
CC provides a convenient and efficient method for simultaneous detection
CC of high and low-abundant genes in multiplex RT-PCR, and is more potent
CC and easier to control than the Competimer method. The present sequence
CC represents a PCR primer used in a real-time PCR assay in the example
CC of the present invention.
XX SQ Sequence 18 BP; 2 A; 7 C; 3 G; 6 T; 0 other;
Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 935 TGGAGAAAGAGGTGTGAGC 952
DB 18 TGGAGAAAGAGCTACGAGC 1
RESULT 416
ABK24039/c
ID ABK24039 standard; DNA; 18 BP.
XX AC ABK24039;
XX DT 09-APR-2002 (first entry)
XX DE B7-related protein, BSL2, PCR primer #5.
XX KW Human; immunosuppressive; antirheumatic; antiarthritic; antiulcer;
KW antianaemic; antipsoriatic; B7-related polypeptide; BSL1; BSL2; BSL3;
KW autoimmune disease; rheumatoid arthritis; multiple sclerosis;
KW Hashimoto's thyroiditis; Graves' disease; Crohn's disease; psoriasis;
KW ulcerative colitis; pernicious anaemia; bone marrow transplantation;
KW graft versus host disease; organ transplantation; PCR primer; ss.
XX OS Homo sapiens.
XX PN WO200194413-A2.
XX XX 13-DEC-2001.
XX PF 06-JUN-2001; 2001WO-US18257.
XX PR 06-JUN-2000; 2000US-209811P.
XX PR 28-FEB-2001; 2001US-272107P.
XX PA (BRIM) BRISTOL-MYERS SQUIBB CO.
XX MIkesell GE, Chang H, Finger JN, Yang G, Lu P, Zhou X, Peach R;
XX WPI; 2002-090141/12.
XX Nucleic acids encoding B7-related polypeptides, i.e. BSL1, BSL2, or
PT BSL3 polypeptides, useful for treating autoimmune diseases (e.g.
PT rheumatoid arthritis, multiple sclerosis, and psoriasis), and graft
PT versus host disease -

XX Example 3; Page 101; 179pp; English.

XX

XX The invention relates to novel nucleic acids encoding B7-related

CC polypeptides. The B7-related polypeptides include the BSL1, BSL2, or BSL3

CC polypeptides, or their soluble fragments. The nucleic acid, polypeptide,

CC and antibodies are useful for treating autoimmune diseases (e.g.

CC rheumatoid arthritis, multiple sclerosis, Hashimoto's thyroiditis,

CC Graves' disease, Crohn's disease, ulcerative colitis, pernicious anaemia

CC and psoriasis). They may also be used to treat tissue, bone marrow, and

CC organ transplantation, and graft versus host disease. ABK24010-ABK24093

CC represent B7-related proteins, BSL1, BSL2 and BSL3 coding sequences and

CC PCR primers of the invention.

XX

SQ Sequence 18 BP; 4 A; 7 C; 3 G; 4 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;

Best Local Similarity 83.3%; Pred.No.2.5e+02;

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1014 CCTGAGATGGTCCCAAG 1031

DB 18 CCTGTGATGGTGCAGAG 1

RESULT 417

ABL43688

ID ABL43688 standard; DNA; 18 BP.

XX ABL43688;

AC

XX 11-APR-2002 (first entry)

DT

XX Human chromosome 1p36-35 PCR primer SEQ ID NO:732.

DE

XX Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis;

KW genome; PCR primer; ss.

KW

XX Homo sapiens.

OS

XX JP2001321190-A.

PN

XX 20-NOV-2001.

PD

XX 12-MAR-2001; 2001JP-0069285.

PF

XX 10-MAR-2000; 2000JP-0066716.

PR

XX (RIKA) RIKAGAKU KENKYUSHO.

PA (GENO-) GENOTEX YG.

PA

XX WPI; 2002-144136/19.

DR

XX Arraying genome clones -

PT

XX Claim 4; Page 19; 528pp; Japanese.

PS

XX The present invention describes a method of arraying genome clones. The

CC method comprises: (a) clones of the genomic libraries contained in

CC multiwell plates numbered for discrimination are mixed in each of the

CC multiwell plates; (b) a primer designed based on the chromosome marker

CC sequence is added to the mixture to carry out an amplification reaction;

CC (c) a signal corresponding to the marker is detected from the resultant

CC amplified product to specify the discrimination Nos. of the multiwell

CC plates containing the clones having said marker sequence; (d) the order to

CC of the markers is changed so that the same discrimination Nos. succeed to

CC the maximum in the specified discrimination Nos. to array the multiwell

CC plates; (e) the clones in the multiwell plates of the specified

CC discrimination Nos. are mixed respectively in each wells of longitudinal

CC and lateral directions; (f) the mixed clones are cultured and the

CC resultant cultures are amplified by using the above primer; (g) signals

CC are detected from the amplified products; (h) the clones in the multiwell

CC plates are specified from the detected result; and (i) the clones are

CC reconstituted as the positions on the chromosome and arrayed. The
CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
CC represent PCR primers for human chromosome 21q22.1, which are
CC specifically claimed for use in the present invention.

XX SQ Sequence 18 BP; 5 A; 7 C; 4 G; 2 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 559 ATGCACACACTGCTCCAG 576
| | | | | | | | | |
Db 1 AAGGCCACACTGTCCAG 18

RESULT 418
ABT21516/c

ID ABT21516 standard; DNA; 18 BP.
XX AC XX
XX AC XX
XX DT 16-APR-2003 (first entry)
XX DE Multiplex group PCR primer #263.
XX KW Racing potential; horse; grandpaternal DNA; over-represented; breeding;
XX KM grandmother; performance; progeny horse; PCR; primer; ss.
XX OS Unidentified.
XX XX WO200292851-A2.
XX FN 21-NOV-2002.
XX PD 15-MAY-2001; 2001GB-0011886.
XX PF 15-MAY-2002; 2002WO-GB02273.
XX PR 15-MAY-2001; 2001GB-0011886.
XX PA (ANIM-) ANIMAL HEALTH TRUST.
PA (BRHO-) BRITISH HORSERACING BOARD.
XX FI Binns MM, Swinburne JE;
DR WPI; 2003-129314/12.
XX PT Determining the racing potential of a horse comprises measuring whether
PT grandpaternal or grandmaternal DNA from the selected grandmother DNA is
PT over-represented in the genome of the horse -
XX Example 2; Page 25; 49pp; English.

XX The invention relates to a novel method for determining racing potential
CC of a horse. The method comprises measuring: whether grandpaternal DNA is
CC over-represented in the genome of the horse; or in the case where one of
CC the grandmothers was selected for breeding on the basis of racing
CC performance, whether grandmaternal DNA from the selected grandmother is
CC over-represented in the genome of the horse which indicates that the
CC horse has good racing potential. The method of the invention is useful
CC for determining the racing potential of a horse or for obtaining a
CC progeny horse with good racing potential. This polynucleotide sequence
CC represents a PCR primer used in the detection method of over-
CC representation of DNA from male grandparents of the invention.

XX SQ Sequence 18 BP; 2 A; 12 C; 2 G; 2 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 528 GGAGGAGCAGCTGGGTGC 545
| | | | | | | | | |

```
Db      18 GGTGAGCAGGTGGGGC 1
RESULT 419
ABT15904/c
ID      ABT15904 standard; DNA; 18 BP.
XX
XX      ABT15904;
AC
XX
XX      28-MAR-2003 (first entry)
DT
XX
XX      B7-related PCR primer - SEQ ID No 21.
DE
XX
XX      PCR; ss; gene therapy; B7-related fusion protein; BSL2; viral infection;
KW      immune response modulation; inflammatory response modulation; cancer;
KW      transplantation rejection; graft versus host disease; asthma; herpes;
KW      chronic obstructive pulmonary disease; HIV; encephalitis; psoriasis;
KW      autoimmune disease; rheumatoid arthritis; multiple sclerosis; primer.
XX
XX      Unidentified.
OS
XX
XX      WO200299119-A2.
PN
XX
XX      12-DEC-2002.
PD
XX
XX      06-JUN-2002; 2002WO-US18049.
PF
XX
XX      06-JUN-2001; 2001US-0875338.
PR
XX      15-FEB-2002; 2002US-0077023.
PR
XX      (BRIM ) BRISTOL-MYERS SQUIBB CO.
PA
XX
XX      Mikesell GE, Shen H;
PI
XX
XX      WPI; 2003-140629/13.
DR
XX
XX      New isolated B7-related nucleic acid fusion molecules and fusion
PT      polypeptides, useful for diagnostic applications, modulating the
PT      activation of immune or inflammatory response cells, preventing or
PT      treating cancer or psoriasis -
XX
XX      Example 1; Page 129; 180pp; English.
PS
XX
XX      The invention comprises the amino acid and coding sequence of B7-related
CC      (BSL2) fusion proteins. The B7-related fusion proteins of the invention
CC      are useful for modulating the activation of immune or inflammatory
CC      response cells (e.g. T cells). The B7-related fusion proteins are useful
CC      for treating or preventing: transplantation rejection; graft versus host
CC      disease; asthma; chronic obstructive pulmonary disease; cancers; viral
CC      infections (e.g. HIV, herpes or encephalitis); and autoimmune disease
CC      (e.g. rheumatoid arthritis, multiple sclerosis or psoriasis). The present
CC      DNA sequence represents a PCR primer that was used in an example of the
CC      invention.
XX
XX      Sequence 18 BP; 4 A; 7 C; 3 G; 4 T; 0 other;
SQ
Query Match      1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1014 CCTGAGATGGTGCCAAAG 1031
      |||||
Db      18 CCTGTGATGGTGACAG 1
      |||||

RESULT 420
ABV77248
ID      ABV77248 standard; DNA; 18 BP.
XX
XX      ABV77248;
AC
XX
XX      28-MAR-2003 (first entry)
DT
XX
```

```
DE
XX
KW      PCR primer for human early mitotic inhibitor 1 (Emil) cDNA.
KW      Early mitotic inhibitor 1; Emil; anaphase-promoting complex; APC;
KW      mitosis; cell cycling; hyperproliferative condition; oocyte activation;
KW      gene therapy; PCR; primer; ss.
XX
OS      Homo sapiens.
XX
XX      WO200294198-A2.
PN
XX
XX      28-NOV-2002.
PD
XX
XX      23-MAY-2002; 2002WO-US16346.
PF
XX
XX      24-MAY-2001; 2001US-293921P.
PR
XX
XX      (STRD ) UNIV LELAND STANFORD JUNIOR.
PA
XX
XX      Jackson PK, Reimann JDR;
PI
XX
XX      WPI; 2003-129363/12.
DR
XX
XX      Inhibiting the anaphase-promoting complex in a proliferating cell,
PT      useful for treating hyperproliferative conditions, comprises providing
PT      an early mitotic inhibitor 1 polypeptide to a cell undergoing mitosis
PT
XX
XX      Example 2; Page 42; 82pp; English.
PS
XX
XX      PCR primers ABV77248-49 were used to amplify cDNA encoding human early
CC      mitotic inhibitor 1 (Emil) polypeptide. Emil polypeptides are used in
CC      the method of the invention to inhibit the anaphase-promoting complex
CC      (APC) in a proliferating cell. To this end, the Emil polypeptide is
CC      provided to a cell undergoing mitosis. The method is used to inhibit APC
CC      agents that modulate Emil function or that mimic Emil activity, and the
CC      agents are used for enhancing APC in a proliferating cell. The Emil is
CC      useful for modulating the cycling of cells, e.g. for treating
CC      hyperproliferative conditions, in diseases involving oocyte activation.
CC      is a high rate of cell turnover, and in modulating oocyte activation.
CC      Emil proteins may also be used in screening and research methods for
CC      determining specific analogues, agonists, antagonists and mimetics.
CC      Nucleic acid compositions are useful in identifying homologous or related
CC      genes, in producing the encoded protein, in producing compositions that
CC      modulate the expression or function of its encoded protein, for gene
CC      therapy, mapping functional regions of the protein, and in studying
CC      associated physiological pathways.
XX
XX      Sequence 18 BP; 5 A; 1 C; 10 G; 2 T; 0 other;
SQ
Query Match      1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 2.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      928 GCAGATCTGGAGAGAGG 945
      |||||
Db      1 GTAGATCGGAGGAGG 18
      |||||

RESULT 421
ABQ84276/c
ID      ABQ84276 standard; DNA; 18 BP.
XX
XX      ABQ84276;
AC
XX
XX      20-FEB-2003 (first entry)
DT
XX
XX      Beta-actin reverse PCR primer.
DE
XX
XX      DPP10; dipeptidyl peptidase; prololigopeptidase; enzyme; asthma;
KW      antiinflammatory; antiasthmatic; antipsoriatic; antiarthritic;
KW      antirheumatic; vaccine; gene therapy; inflammatory disease;
KW      inflammatory bowel disease; atopy; rheumatoid arthritis; psoriasis;
KW
```


KW chromosome 2q14; PCR primer; ss.
 XX
 OS Homo sapiens.
 OS Synthetic.
 XX
 XX WO200286113-A2.
 XX
 XX 31-OCT-2002.
 XX
 XX 24-APR-2002; 2002WO-GB01887.
 XX
 XX 24-APR-2001; 2001GB-0010044.
 PR
 PR 24-APR-2001; 2001GB-0010045.
 PR
 PR 12-OCT-2001; 2001GB-0024575.
 PR
 PR 12-OCT-2001; 2001GB-0024594.
 XX
 XX (ISIS-) ISIS INNOVATIONS LTD.
 PA
 XX Cookson WOCM, Moffat MF, Allen M, Lench N;
 XX
 XX WPI; 2003-093132/08.
 DR
 XX New nucleic acid sequence comprising DPP10 mRNA, useful for the
 PT manufacture of a medicament for regulating DPP10 protein expression or
 PT for preventing or treating inflammatory disease e.g., inflammatory
 PT bowel disease -
 XX
 XX Example 2; Page 70; 321pp; English.
 PS
 XX The present invention describes a new isolated nucleic acid sequence (I)
 XX comprising a DPP10 mRNA sequence. DPP10 is a dipeptidyl peptidase (also
 CC known as prolololigopeptidase). (I) has anti-inflammatory, antiasthmatic,
 CC antiproliferative, antitumor and antirheumatic activities, and can be
 CC used in vaccines and gene therapy. A composition comprising (I) can be
 CC used for the manufacture of a medicament for regulating DPP10 expression
 CC or for preventing or treating inflammatory disease e.g., inflammatory
 CC bowel disease, asthma, atopy, rheumatoid arthritis or psoriasis. (I) can
 CC also be used in an assay for detecting or measuring DPP10 in a sample.
 CC A host cell comprising (I) can be used for producing recombinant DPP10
 CC gene products, or in drug screening systems to identify agents for
 CC diagnosis or treatment of individuals having or susceptible to
 CC inflammatory disease. Human DPP10 is located on chromosome 2, more
 CC specifically chromosome 2q14. ABQ84254 to ABQ84612 and ABP55569 to
 CC ABP55629 represent sequences used in the exemplification of the present
 CC invention.
 XX
 XX Sequence 18 BP; 2 A; 7 C; 3 G; 6 T; 0 other;
 SQ
 Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 935 TGGAGAGAGAGTGTGAGC 952
 Db 18 TGGAGAGAGAGTGTGAGC 1
 |||||
 RESULT 422
 ABZ10445/C
 ID ABZ10445 standard; DNA; 18 BP.
 XX
 XX ABZ10445;
 AC
 XX 16-JAN-2003 (first entry)
 DT
 XX Haematopoietic cell proliferation disorder related oligonucleotide #585.
 DE
 XX Human; haematopoietic cell proliferation disorder; cytostatic;
 KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
 KW cytosine methylation state; probe; primer; ss.
 XX
 XX Homo sapiens.
 OS
 OS Synthetic.

XX WO200277272-A2.
 PN
 XX 03-OCT-2002.
 PD
 XX 26-MAR-2002; 2002WO-EP03401.
 XX
 XX 26-MAR-2001; 2001US-278333P.
 PR
 XX (EPIG-) EPIGENOMICS AG.
 PA
 XX Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
 PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Iesche R, Leu E;
 PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;
 PI Pelet C, Schwöpe I, Ziebarth H;
 XX
 XX WPI; 2003-018942/01.
 DR
 XX Detecting and differentiating between hematopoietic cell proliferative
 XX disorders, comprises contacting a target nucleic acid with a reagent
 PT that distinguishes between methylated and non-methylated CpG
 PT dinucleotides -
 PT
 XX Claim 15; SEQ ID 585; 117pp; English.
 PS
 XX The present invention describes a method for detecting and
 XX differentiating between haematopoietic cell proliferative disorders
 CC associated with at least 1 gene and/or their regulatory regions in a
 CC subject. The method comprises contacting a target nucleic acid in a
 CC biological sample obtained from the subject with at least 1 reagent,
 CC which distinguishes between methylated and non-methylated CpG
 CC dinucleotides within the target nucleic acid. AB209861 to AB211118
 CC represent specifically claimed nucleotide sequences from the present
 CC invention. Oligonucleotides from the present invention can be used for
 CC differentiating between healthy haematopoietic cells and proliferative
 CC disorder haematopoietic cells; for differentiating between acute
 CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
 CC determining the cytosine methylation state and/or single nucleotide
 CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
 CC related sequences and their complements; and as primers for the
 CC amplification of haematopoietic cell proliferation disorder related
 CC DNA sequences. The nucleotide sequences from the present invention can
 CC also be used for detecting a predisposition to, differentiation between
 CC subclasses, diagnosis, prognosis, treatment and/or monitoring of
 CC haematopoietic cell proliferative disorders. The present method enables
 CC a highly specific classification of haematopoietic cell proliferative
 CC disorders allowing for improved and informed treatment of patients.
 XX
 XX Sequence 18 BP; 1 A; 1 C; 8 G; 8 T; 0 other;
 SQ
 Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 24 AACCAAAACCCAGCTACGC 41
 Db 18 AACCAAAACCCAGCTACAC 1
 |||||
 RESULT 423
 ABZ10446/C
 ID ABZ10446 standard; DNA; 18 BP.
 XX
 XX ABZ10446;
 AC
 XX 16-JAN-2003 (first entry)
 DT
 XX Haematopoietic cell proliferation disorder related oligonucleotide #586.
 DE
 XX Human; haematopoietic cell proliferation disorder; cytostatic;
 KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
 KW cytosine methylation state; probe; primer; ss.
 XX
 XX Homo sapiens.
 OS
 OS Synthetic.

```

OS Homo sapiens.
OS Synthetic.
XX WO200277272-A2.
XX 03-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-EP03401.
XX
XX 26-MAR-2001; 2001US-278333P.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
XX Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
XX Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;
XX Pellet C, Schwöpe I, Ziebarth H;
XX WPI; 2003-018942/01.
XX
XX Detecting and differentiating between hematopoietic cell proliferative
XX disorders, comprises contacting a target nucleic acid with a reagent
XX that distinguishes between methylated and non-methylated CpG
XX dinucleotides -
XX
XX Claim 15; SEQ ID 586; 117pp; English.
XX
XX The present invention describes a method for detecting and
XX differentiating between hematopoietic cell proliferative disorders
XX associated with at least 1 gene and/or their regulatory regions in a
XX subject. The method comprises contacting a target nucleic acid in a
XX biological sample obtained from the subject with at least 1 reagent,
XX which distinguishes between methylated and non-methylated CpG
XX dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
XX represent specifically claimed nucleotide sequences from the present
XX invention. Oligonucleotides from the present invention can be used: for
XX differentiating between healthy hematopoietic cells and proliferative
XX disorder hematopoietic cells; for differentiating between acute
XX lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
XX determining the cytosine methylation state and/or single nucleotide
XX polymorphisms (SNPs) of hematopoietic cell proliferation disorder
XX related sequences and their complements; and as primers for the
XX amplification of hematopoietic cell proliferation disorder related
XX DNA sequences. The nucleotide sequences from the present invention can
XX also be used for detecting a predisposition to, differentiation between
XX subclasses, diagnosis, prognosis, treatment and/or monitoring of
XX hematopoietic cell proliferative disorders. The present method enables
XX a highly specific classification of hematopoietic cell proliferative
XX disorders allowing for improved and informed treatment of patients.
XX
XX Sequence 18 BP; 1 A; 0 C; 8 G; 9 T; 0 other;
XX
XX Query Match 1.0%; Score 13.2; DB 1; Length 18;
XX Best Local Similarity 83.3%; Pred. No. 2.5e+02;
XX Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 24 AACCAAAACCAGCTACGC 41
XX 18 AACCAAAACCAGCTACAC 1
XX
XX Db
XX
XX RESULT 424
XX ABZ11019/c
XX ID ABZ11019 standard; DNA; 18 BP.
XX
XX AC ABZ11019;
XX
XX 16-JAN-2003 (first entry)
XX
XX Haematopoietic cell proliferation disorder related oligonucleotide #1159.
XX
XX Human; haematopoietic cell proliferation disorder; cytostatic;
XX gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
XX

```

```

KW cytosine methylation state; probe; primer; ss.
XX
XX Homo sapiens.
XX OS Synthetic.
XX
XX WO200277272-A2.
XX
XX 03-OCT-2002.
XX
XX 26-MAR-2002; 2002WO-EP03401.
XX
XX 26-MAR-2001; 2001US-278333P.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
XX Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
XX Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;
XX Pellet C, Schwöpe I, Ziebarth H;
XX WPI; 2003-018942/01.
XX
XX Detecting and differentiating between hematopoietic cell proliferative
XX disorders, comprises contacting a target nucleic acid with a reagent
XX that distinguishes between methylated and non-methylated CpG
XX dinucleotides -
XX
XX Claim 15; Page 44; 117pp; English.
XX
XX The present invention describes a method for detecting and
XX differentiating between hematopoietic cell proliferative disorders
XX associated with at least 1 gene and/or their regulatory regions in a
XX subject. The method comprises contacting a target nucleic acid in a
XX biological sample obtained from the subject with at least 1 reagent,
XX which distinguishes between methylated and non-methylated CpG
XX dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
XX represent specifically claimed nucleotide sequences from the present
XX invention. Oligonucleotides from the present invention can be used: for
XX differentiating between healthy hematopoietic cells and proliferative
XX disorder hematopoietic cells; for differentiating between acute
XX lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
XX determining the cytosine methylation state and/or single nucleotide
XX polymorphisms (SNPs) of hematopoietic cell proliferation disorder
XX related sequences and their complements; and as primers for the
XX amplification of hematopoietic cell proliferation disorder related
XX DNA sequences. The nucleotide sequences from the present invention can
XX also be used for detecting a predisposition to, differentiation between
XX subclasses, diagnosis, prognosis, treatment and/or monitoring of
XX hematopoietic cell proliferative disorders. The present method enables
XX a highly specific classification of hematopoietic cell proliferative
XX disorders allowing for improved and informed treatment of patients.
XX
XX Sequence 18 BP; 1 A; 1 C; 8 G; 8 T; 0 other;
XX
XX Query Match 1.0%; Score 13.2; DB 1; Length 18;
XX Best Local Similarity 83.3%; Pred. No. 2.5e+02;
XX Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
XX
XX QY 24 AACCAAAACCAGCTACGC 41
XX 18 AACCAAAACCAGCTACAC 1
XX
XX Db
XX
XX RESULT 425
XX ABZ11020/c
XX ID ABZ11020 standard; DNA; 18 BP.
XX
XX AC ABZ11020;
XX
XX 16-JAN-2003 (first entry)
XX
XX Haematopoietic cell proliferation disorder related oligonucleotide #1160.
XX

```

KW Human; haematopoietic cell proliferation disorder; cytostatic;
 KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
 KW cytosine methylation state; probe; primer; ss.

OS Homo sapiens.
 OS Synthetic.

PN WO200277272-A2.

XX 03-OCT-2002.

XX 26-MAR-2002; 2002WO-EP03401.

XX 26-MAR-2001; 2001US-278333P.

XX (EPIG-) EPIGENOMICS AG.

XX Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
 PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
 PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;
 PI Pelet C, Schwöpe I, Ziebarth H;

XX WPI; 2003-018942/01.

XX Detecting and differentiating between hematopoietic cell proliferative
 PT disorders, comprises contacting a target nucleic acid with a reagent
 PT that distinguishes between methylated and non-methylated CpG
 PT dinucleotides -

PS Claim 15; Page 44; 117pp; English.

XX The present invention describes a method for detecting and
 CC differentiating between haematopoietic cell proliferative disorders
 CC associated with at least 1 gene and/or their regulatory regions in a
 CC subject. The method comprises contacting a target nucleic acid in a
 CC biological sample obtained from the subject with at least 1 reagent,
 CC which distinguishes between methylated and non-methylated CpG
 CC dinucleotides within the target nucleic acid. AB209861 to AB211118
 CC represent specifically claimed nucleotide sequences from the present
 CC invention. Oligonucleotides from the present invention can be used: for
 CC differentiating between healthy haematopoietic cells and proliferative
 CC disorder haematopoietic cells; for differentiating between acute
 CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
 CC determining the cytosine methylation state and/or single nucleotide
 CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
 CC related sequences and their complements; and as primers for the
 CC amplification of haematopoietic cell proliferation disorder related
 CC DNA sequences. The nucleotide sequences from the present invention can
 CC also be used for detecting a predisposition to, differentiation between
 CC subclasses, diagnosis, prognosis, treatment and/or monitoring of
 CC haematopoietic cell proliferative disorders. The present method enables
 CC a highly specific classification of haematopoietic cell proliferative
 CC disorders allowing for improved and informed treatment of patients.

XX Sequence 18 BP; 1 A; 0 C; 8 G; 9 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 24 AACCAAAACCCAGCTACGC 41

DB 18 AACCAAAACCCAGCTACAC 1

RESULT 426

AB211021

ID AB211021 standard; DNA; 18 BP.

XX AC AB211021;

XX 16-JAN-2003 (first entry)

XX

DE Haematopoietic cell proliferation disorder related oligonucleotide #1161.
 XX Human; haematopoietic cell proliferation disorder; cytostatic;
 KW gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
 KW cytosine methylation state; probe; primer; ss.

OS Homo sapiens.

OS Synthetic.

PN WO200277272-A2.

XX 03-OCT-2002.

XX 26-MAR-2002; 2002WO-EP03401.

XX 26-MAR-2001; 2001US-278333P.

XX (EPIG-) EPIGENOMICS AG.

XX Berlin K, Braun A, Distler J, Guetig D, Howe A, Mueller J;
 PI Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
 PI Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;
 PI Pelet C, Schwöpe I, Ziebarth H;

XX WPI; 2003-018942/01.

XX Detecting and differentiating between hematopoietic cell proliferative
 PT disorders, comprises contacting a target nucleic acid with a reagent
 PT that distinguishes between methylated and non-methylated CpG
 PT dinucleotides -

PS Claim 15; Page 76; 117pp; English.

XX The present invention describes a method for detecting and
 CC differentiating between haematopoietic cell proliferative disorders
 CC associated with at least 1 gene and/or their regulatory regions in a
 CC subject. The method comprises contacting a target nucleic acid in a
 CC biological sample obtained from the subject with at least 1 reagent,
 CC which distinguishes between methylated and non-methylated CpG
 CC dinucleotides within the target nucleic acid. AB209861 to AB211118
 CC represent specifically claimed nucleotide sequences from the present
 CC invention. Oligonucleotides from the present invention can be used: for
 CC differentiating between healthy haematopoietic cells and proliferative
 CC disorder haematopoietic cells; for differentiating between acute
 CC lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
 CC determining the cytosine methylation state and/or single nucleotide
 CC polymorphisms (SNPs) of haematopoietic cell proliferation disorder
 CC related sequences and their complements; and as primers for the
 CC amplification of haematopoietic cell proliferation disorder related
 CC DNA sequences. The nucleotide sequences from the present invention can
 CC also be used for detecting a predisposition to, differentiation between
 CC subclasses, diagnosis, prognosis, treatment and/or monitoring of
 CC haematopoietic cell proliferative disorders. The present method enables
 CC a highly specific classification of haematopoietic cell proliferative
 CC disorders allowing for improved and informed treatment of patients.

XX Sequence 18 BP; 8 A; 8 C; 1 G; 1 T; 0 other;

Query Match 1.0%; Score 13.2; DB 1; Length 18;
 Best Local Similarity 83.3%; Pred. No. 2.5e+02;
 Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

OY 24 AACCAAAACCCAGCTACGC 41

DB 1 AACCAAAACCCAGCTACAC 18

RESULT 427

AB211022

ID AB211022 standard; DNA; 18 BP.

XX AC AB211022;

XX

```

DT 16-JAN-2003 (first entry)
DE Haematopoietic cell proliferation disorder related oligonucleotide #1162.
DE Human; haematopoietic cell proliferation disorder; cytostatic;
DE gene therapy; lymphocytic leukaemia; acute myelogenous leukaemia;
DE cytosine methylation state; probe; primer; ss.
DE Homo sapiens.
DE Synthetic.
DE WO200277272-A2.
DE 03-OCT-2002.
DE 26-MAR-2002; 2002WO-EP03401.
DE 26-MAR-2001; 2001US-278333P.
DE (EPIG-) EPIGENOMICS AG.
DE Berlin K, Braun A, Diastler J, Guetig D, Howe A, Mueller J;
DE Olek A, Piepenbrock C, Adorjan P, Grabs G, Lesche R, Leu E;
DE Lewin A, Lipscher E, Maier S, Model F, Mueller V, Otto T;
DE Pelet C, Schwobe I, Ziebarth H;
DE WPI; 2003-018942/01.
DE Detecting and differentiating between hematopoietic cell proliferative
DE disorders, comprises contacting a target nucleic acid with a reagent
DE that distinguishes between methylated and non-methylated CpG
DE dinucleotides -
DE Claim 15; Page 76; 117pp; English.
DE The present invention describes a method for detecting and
DE differentiating between haematopoietic cell proliferative disorders
DE associated with at least 1 gene and/or their regulatory regions in a
DE subject. The method comprises contacting a target nucleic acid in a
DE biological sample obtained from the subject with at least 1 reagent,
DE which distinguishes between methylated and non-methylated CpG
DE dinucleotides within the target nucleic acid. ABZ09861 to ABZ11118
DE represent specifically claimed nucleotide sequences from the present
DE invention. Oligonucleotides from the present invention can be used: for
DE differentiating between healthy haematopoietic cells and proliferative
DE disorder haematopoietic cells; for differentiating between acute
DE lymphocytic leukaemia and acute myelogenous leukaemia; as probes for
DE determining the cytosine methylation state and/or single nucleotide
DE polymorphisms (SNPs) of haematopoietic cell proliferation disorder
DE related sequences and their complements; and as primers for the
DE amplification of haematopoietic cell proliferation disorder related
DE DNA sequences. The nucleotide sequences from the present invention can
DE also be used for detecting a predisposition to, differentiation between
DE subclasses, diagnosis, prognosis, treatment and/or monitoring of
DE haematopoietic cell proliferative disorders. The present method enables
DE a highly specific classification of haematopoietic cell proliferative
DE disorders allowing for improved and informed treatment of patients.
DE Sequence 18 BP; 9 A; 8 C; 0 G; 1 T; 0 other;
DE
DE Query Match 1.0%; Score 13.2; DB 1; Length 18;
DE Best Local Similarity 83.3%; Pred. No. 2.5e+02;
DE Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
DE
DE QY 24 AACCAACCCAGTACGC 41
DE DB 1 AACCAACCCAGTACGC 18
DE
DE RESULT 428
DE ABC89050/C
DE ID ABC89050 standard; DNA; 13 BP.
DE XX

```

```

AC ABC89050;
XX 21-FEB-2002 (first entry)
XX Oligonucleotide SEQ ID NO 89067 for detecting SNP TSC0022361.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.
XX 18-OCT-2001.
XX 06-APR-2001; 2001WO-IB00713.
XX 07-APR-2000; 2000DE-1019173.
XX (EPIG-) EPIGENOMICS AG.
XX Olek A, Piepenbrock C, Berlin K;
XX WPI; 2001-657177/75.
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX designed to detect single nucleotide polymorphisms and cytosine
XX methylation status -
XX Claim 1; SEQ ID 89067; 29pp + Sequence Listing; German.
XX This invention describes novel oligonucleotide primers or peptide nucleic
XX acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX and cytosine methylation status in chemically pretreated genomic DNA. The
XX oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX range of diseases including immune system, gastrointestinal, respiratory,
XX central nervous system, cardiovascular and metabolic disorders. The
XX oligomers are also used for detecting cell type differentiation.
XX ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
XX ABI00010-ABI92073 represent the oligomers described in the invention.
XX NOTE: The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format from WIPO at
XX ftp.wipo.int/pub/published_pct_sequences.
XX Sequence 13 BP; 12 A; 0 C; 1 G; 0 U; 0 other;
XX
XX Query Match 1.0%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.8e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX QY 1144 TTTTCTCTTTT 1156
XX DB 13 TTTTCTCTTTT 1
XX
XX RESULT 429
XX ABC89051
XX ID ABC89051 standard; DNA; 13 BP.
XX AC ABC89051;
XX 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 89069 for detecting SNP TSC0022361.
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX Homo sapiens.
XX WO200177384-A2.

```

```

XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB00713.
XX PR 07-APR-2000; 2000DE-1019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX PT Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single nucleotide polymorphisms and cytosine
XX PT methylation status -
XX PS Claim 1; SEQ ID 89068; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation.
XX CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
XX CC ABT00010-ABT82073 represent the oligomers described in the invention.
XX CC NOTE: The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences.
XX SQ Sequence 13 BP; 0 A; 1 C; 0 G; 12 T; 0 other;
XX
XX Query Match 1.0%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.8e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 1144 TTTTTCCTTTT 1156
Db 1 TTTTTCCTTTT 13
XX
RESULT 430
ABC99986/c
ID ABC99986 standard; DNA; 13 BP.
XX AC ABC99986;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 100003 for detecting SNP TSC0024859.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB00713.
XX PR 07-APR-2000; 2000DE-1019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX OS Homo sapiens.
XX DR WO200177384-A2.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB00713.
XX PR 07-APR-2000; 2000DE-1019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single nucleotide polymorphisms and cytosine
XX PT methylation status -
XX PS Claim 1; SEQ ID 89068; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation.
XX CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
XX CC ABT00010-ABT82073 represent the oligomers described in the invention.
XX CC NOTE: The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format from WIPO at
XX CC ftp.wipo.int/pub/published_pct_sequences.
XX SQ Sequence 13 BP; 0 A; 1 C; 0 G; 12 T; 0 other;
XX
XX Query Match 1.0%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.8e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
Qy 187 CCGCGCGCCACC 199
Db 13 CCGCGCGCCACC 1
XX
RESULT 431
ABC99987
ID ABC99987 standard; DNA; 13 BP.
XX AC ABC99987;
XX DT 21-FEB-2002 (first entry)
XX DE Oligonucleotide SEQ ID NO 100004 for detecting SNP TSC0024859.
XX SN; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
XX KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
XX KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX OS Homo sapiens.
XX PN WO200177384-A2.
XX PD 18-OCT-2001.
XX PF 06-APR-2001; 2001WO-IB00713.
XX PR 07-APR-2000; 2000DE-1019173.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX OS Homo sapiens.
XX DR WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
XX PT designed to detect single nucleotide polymorphisms and cytosine
XX PT methylation status -
XX PS Claim 1; SEQ ID 100004; 29pp + Sequence Listing; German.
XX CC This invention describes novel oligonucleotide primers or peptide nucleic
XX CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
XX CC and cytosine methylation status in chemically pretreated genomic DNA. The
XX CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
XX CC range of diseases including immune system, gastrointestinal, respiratory,
XX CC central nervous system, cardiovascular and metabolic disorders. The
XX CC oligomers are also used for detecting cell type differentiation.

```

```

CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
CC
XX
SQ Sequence 13 BP; 1 A; 10 C; 2 G; 0 U; 0 other;

  Query Match      1.0%; Score 13; DB 1; Length 13;
  Best Local Similarity 100.0%; Pred. No. 1.8e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 187 CCGCGCGCCGCCACC 199
Db 1 CCGCGCGCCGCCACC 13

RESULT 432
ABF16196
ID ABF16196 standard; DNA; 13 BP.
XX
AC ABF16196;
XX
DT 21-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 116193 for detecting SNP TSC0029109.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
PN WO200177384-A2.
XX
PD 18-OCT-2001.
XX
PF 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
PA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
WPI; 2001-657177/75.
XX
Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single nucleotide polymorphisms and cytosine
methylation status -
XX
Claim 1; SEQ ID 116194; 29pp + Sequence Listing; German.
XX
This invention describes novel oligonucleotide primers or peptide nucleic
acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
and cytosine methylation status in chemically pretreated genomic DNA. The
oligonucleotides are used for diagnosis and/or prognosis of cancer and a
range of diseases including immune system, gastrointestinal, respiratory,
central nervous system, cardiovascular and metabolic disorders. The
oligonucleotides are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
CC
XX
SQ Sequence 13 BP; 5 A; 6 C; 0 G; 2 T; 0 other;

  Query Match      1.0%; Score 13; DB 1; Length 13;
  Best Local Similarity 100.0%; Pred. No. 1.8e+02;
  Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1186 TAGGTGAGTGTTG 1198
Db 13 TAGGTGAGTGTTG 1

RESULT 434
ABH17590/c
ID ABH17590 standard; DNA; 13 BP.
XX
AC ABH17590;
XX
DT 22-FEB-2002 (first entry)
XX
DE Oligonucleotide SEQ ID NO 217567 for detecting SNP TSC0052918.

```

```

XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
OS Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
XX Claim 1; SEQ ID 217567; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABT00010-ABT82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
XX SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 other;
XX
XX Query Match 1.0%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.8e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 314 CAACTCCATACCT 326
XX 13 CAACTCCATACCT 1
XX
XX RESULT 435
XX ABH17591
XX ID ABH17591 standard; DNA; 13 BP.
XX
XX AC ABH17591;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 217568 for detecting SNP TSC0052918.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
XX Claim 1; SEQ ID 217568; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABT00010-ABT82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
XX SQ Sequence 13 BP; 3 A; 0 C; 6 G; 4 T; 0 other;
XX
XX Query Match 1.0%; Score 13; DB 1; Length 13;
XX Best Local Similarity 100.0%; Pred. No. 1.8e+02;
XX Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
XX
XX 314 CAACTCCATACCT 326
XX 13 CAACTCCATACCT 1
XX
XX RESULT 436
XX ABH18096
XX ID ABH18096 standard; DNA; 13 BP.
XX
XX AC ABH18096;
XX
XX 22-FEB-2002 (first entry)
XX
XX Oligonucleotide SEQ ID NO 218073 for detecting SNP TSC0053025.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
XX
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
XX Claim 1; SEQ ID 218073; 29pp + Sequence Listing; German.
XX
XX

```

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC ABT00010-ABT82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

XX Sequence 13 BP; 3 A; 0 C; 5 G; 5 T; 0 other;
 SQ Query Match 1.0%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1184 TATAGTGAGTGT 1196
 DB 1 TATAGTGAGTGT 13
 |||||

RESULT 437

ABH18097/c

ID ABH18097 standard; DNA; 13 BP.

XX AC ABH18097;

XX DT 22-FEB-2002 (first entry)

XX DE Oligonucleotide SEQ ID NO 218074 for detecting SNP TSC0053025.

XX SNP, single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX Homo sapiens.

XX OS WO200177384-A2.

XX PN 18-OCT-2001.

XX PF 06-APR-2001; 2001WO-IB00713.

XX PR 07-APR-2000; 2000DE-1019173.

XX PA (EPIG-) EPIGENOMICS AG.

XX PI Olek A, Piepenbrock C, Berlin K;

XX DR WPI; 2001-657177/75.

XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status

XX Claim 1; SEQ ID 218074; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC ABT00010-ABT82073 represent the oligomers described in the invention.

XX NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 13 BP; 5 A; 5 C; 0 G; 3 T; 0 other;
 SQ Query Match 1.0%; Score 13; DB 1; Length 13;
 Best Local Similarity 100.0%; Pred. No. 1.8e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1184 TATAGTGAGTGT 1196
 DB 13 TATAGTGAGTGT 1
 |||||

RESULT 438

AAV92063

ID AAV92063 standard; RNA; 14 BP.

XX AC AAV92063;

XX DT 18-FEB-1999 (first entry)

XX DE Human C-raf target sequence nucleotide position 2567.

XX Human; C-raf; A-raf; B-raf; hammerhead ribozyme; hairpin ribozyme;
 KW target; substrate; catalyst; modulation; expression; Raf gene;
 KW delivery; screening; identification; synthesis; deprotection;
 KW purification; cancer; inflammation; psoriasis; non-hepatic ascites;
 KW infection; genetic drift; restenosis; rheumatoid arthritis; ss.

XX OS Homo sapiens.

XX PN WO9850530-A2.

XX PD 12-NOV-1998.

XX PF 05-MAY-1998; 98WO-US09249.

XX PR 19-DEC-1997; 97US-0068212.

XX PR 09-MAY-1997; 97US-0046059.

XX PR 09-JUN-1997; 97US-0049002.

XX PR 03-JUL-1997; 97US-0051718.

XX PR 22-AUG-1997; 97US-0056808.

XX PR 02-OCT-1997; 97US-0061321.

XX PR 02-OCT-1997; 97US-0061324.

XX PR 05-NOV-1997; 97US-0064866.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Beaudry A, Beigelman L, Bellon L, Burgin A, Jarvis T;

XX PI Karpeisky A, Kisich K, Matulic-Adamic J, McSwiggen JA;

XX PI Parry T, Reynolds M, Sweedler D, Thompson J, Workman CT;

XX DR WPI; 1999-009494/01.

XX Identifying new catalytic nucleic acid that modulates selected
 PT processes - especially ribozymes that cleave Raf RNA for treating
 PT cancer, restenosis, and also new ribozymes and modified nucleoside
 PT triphosphates used as antiviral agents and synthons

XX Claim 179; Page 156; 259pp; English.

XX A method has been developed for the identification of a nucleic acid
 CC capable of modulating a process in a biological system. The method
 CC comprises: (a) introducing into the system a random library of nucleic
 CC acid catalysts (NAC) having a substrate binding domain (SBD), comprising
 CC a random sequence, and a catalytic domain (CD); and (b) identifying NAC
 CC in systems where modulation has occurred and/or determining the sequence
 CC of at least part of the SBDs in such systems. Nucleic acid molecules
 CC with endonuclease activity and catalytic activity, from the present
 CC invention, are used to modulate gene expression in plant and mammalian
 CC cells and to cleave target nucleic acid, particularly for treating
 CC systemic diseases caused by specific RNA, e.g. cancer, inflammation,
 CC psoriasis, non-hepatic ascites and infection. They may also be used to
 CC detect genetic drift and mutations in diseased cells and to determine

CC c-raf RNA. Specifically NACs with RNA-cleaving activity that modulate
 CC expression of the Raf gene, are used to treat cancer, restenosis,
 CC psoriasis or rheumatoid arthritis, or generally any condition associated
 CC with the level of c-raf. Introduction of sugar/phosphate modifications
 CC increases stability against nuclease and activity. AAV90922 to AAV93877
 CC represent NACs that can be used in the method, specifically for
 CC modulating the expression of a Raf gene.

XX Sequence 14 BP; 3 A; 4 C; 5 G; 2 U; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 14;
 Best Local Similarity 92.3%; Pred. No. 2e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 480 GGACTGCCGAGAC 492

Db 1 GGACUGCCGAGAC 13

RESULT 439

AAT55016

ID AAT55016 standard; RNA; 15 BP.

XX AAT55016;

XX 25-MAR-2003 (updated)

DT 18-APR-1997 (first entry)

XX Human relA hammerhead ribozyme target sequence (nt. position 585).
 DE Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
 KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
 KW intercellular adhesion molecule; rel A; tumour necrosis factor;
 KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
 KW translocation; chronic myelogenous leukaemia; CML; cancer;
 KW Philadelphia chromosome; inflammation; autoimmune disease;
 KW atherosclerosis; myocardial infarction; stroke; restenosis;
 KW transplant rejection; rheumatoid arthritis; psoriasis;
 KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
 KW human immunodeficiency virus; acquired immune deficiency syndrome;
 KW AIDS; ss.

OS Homo sapiens.

XX WO9523225-A2.

XX 31-AUG-1995.

XX 23-FEB-1995; 95WO-IB00156.

XX 30-JAN-1995; 95US-0380734.

XX 23-FEB-1994; 94US-0201109.

XX 29-MAR-1994; 94US-0218934.

XX 04-APR-1994; 94US-0222795.

XX 07-APR-1994; 94US-0224483.

XX 15-APR-1994; 94US-0227958.

XX 15-APR-1994; 94US-0228041.

XX 18-MAY-1994; 94US-0245736.

XX 06-JUL-1994; 94US-0271280.

XX 15-AUG-1994; 94US-0291932.

XX 16-AUG-1994; 94US-0291433.

XX 17-AUG-1994; 94US-0293620.

XX 19-AUG-1994; 94US-0293520.

XX 02-SEP-1994; 94US-0300000.

XX 23-SEP-1994; 94US-0311486.

XX 23-SEP-1994; 94US-0311749.

XX 28-SEP-1994; 94US-0314397.

XX 03-OCT-1994; 94US-0316771.

XX 07-OCT-1994; 94US-0319492.

XX 11-OCT-1994; 94US-0321993.

XX 04-NOV-1994; 94US-0334847.

XX 10-NOV-1994; 94US-0337608.

PR 28-NOV-1994; 94US-0345516.
 PR 16-DEC-1994; 94US-0357577.
 PR 23-DEC-1994; 94US-0363233.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX Stinchcomb DT, Chowrira B, Drenzo A, Draper KG, Dudycz LW;
 PI Grimm S, Karpeisky A, Kisich K, Matulic-adamic J, Mcswiggen JA;
 PI Modak A, Pavco P, Beigleman L, Sullivan SM, Sweedler D;
 PI Thompson JD, Tracz D, Usman N, Wincott FE, Woolf T;
 XX WPI; 1995-351090/45.

DR Ribozymes having modified bases and methods for producing them -
 XX for use in inhibiting disease related genes
 PT Claim 2; Page 228; 407pp; English.

XX The present sequence represents a preferred target sequence for an
 CC enzymatic nucleic acid (i.e. a ribozyme) which cleaves rela
 CC mRNA at the nucleotide base position indicated in the DE line.
 CC The rela gene product is a subunit of the transcriptional
 CC regulator NF-kappaB and is implicated specifically in the induction
 CC of inflammatory responses. Regions of the mRNA that do not form
 CC secondary folding structures and that contain potential hammerhead
 CC and hairpin ribozyme cleavage sites were identified by computer
 CC analysis. Ribozymes directed against these mRNA sequences were
 CC designed and synthesised with modifications that improve their
 CC nuclease resistance. The ribozymes are designed to cleave the
 CC target sequences and thereby inhibit rela expression, making them
 CC potentially useful for treating rheumatoid arthritis, restenosis
 CC and asthma as well as for increasing tolerance to transplanted
 CC tissues. The potential immunosuppressive properties of a ribozyme
 CC that cleaves rela mRNA means that uses are limited to local
 CC delivery, acute indications or ex vivo treatment.
 CC (Updated on 25-MAR-2003 to correct PI field.)

XX Sequence 15 BP; 4 A; 5 C; 5 G; 1 U; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 15;

Best Local Similarity 92.3%; Pred. No. 2.1e+02;

Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1066 CCCATCAGGCAGG 1078

Db 3 CCCAUCAGGCAGG 15

RESULT 440

AAC73458/c

ID AAC73458 standard; DNA; 15 BP.

XX AAC73458;

XX 02-FEB-2001 (first entry)

DE Reverse primer #97 used in multiplexing PCR/SBE assay.

XX Oligonucleotide array; genotyping; single base extension reaction; SBE;
 KW PCR primer; polymorphic locus; single nucleotide polymorphism; ss.
 XX Unidentified.
 XX WO200058516-A2.
 XX 05-OCT-2000.
 XX 27-MAR-2000; 2000WO-US08069.
 XX 26-MAR-1999; 99US-0126473.
 XX 23-JUN-1999; 99US-0140359.
 XX (WHED) WHITEHEAD INST BIOMEDICAL RES.

PA (AFFY-) AFFYMETRIX INC.

XX Fan J, Hirschhorn JN, Huang X, Kaplan P, Lander ES, Lockhart DJ;

PI Ryder T, Sklar P;

XX WPI; 2000-656171/63.

DR Universal array of oligonucleotides tags attached to a solid substrate

XX along with locus-specific tagged oligonucleotides useful in genotyping

PT using single base extension reactions -

XX Example 7; Page 58; 83pp; English.

XX The present invention relates to an oligonucleotide array comprising

XX oligonucleotide tags fixed to a solid substrate. The oligonucleotide

CC array is useful for genotyping a nucleic acid sample at one or more loci

CC via single base extension (SBE) reactions. A pair of primers is used to

CC amplify a polymorphic locus in a sample e.g. a single nucleotide

CC polymorphism (SNP). The present sequence is one of the primers used in

CC the method of the present invention to amplify a polymorphic sample. The

CC amplified nucleic acid product is then used as a template in a SBE

CC reaction with an extension primer. The SBE reaction products are used to

CC form the oligonucleotide array.

XX SQ Sequence 15 BP; 2 A; 5 C; 6 G; 2 T; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 2.1e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 813 GCCGAGCGTCCTG 825

DB 15 GCCGAGCGTCCTG 3

RESULT 441

ABA81582/c

ID ABA81582 standard; DNA; 15 BP.

XX ABA81582;

DT 24-JAN-2002 (first entry)

XX Human phospholipid transfer protein gene ASO primer SEQ ID NO: 31.

XX Human; phospholipid transfer protein; PLTP; SNP; atherosclerosis;

XX single nucleotide polymorphism; high-density lipoprotein metabolism;

XX allele-specific oligonucleotide; PCR primer; ss.

OS Homo sapiens.

XX WO200172761-A2.

PD 04-OCT-2001.

XX 15-MAR-2001; 2001WO-US08283.

XX 24-MAR-2000; 2000US-192127P.

XX (GENA-) GENAISANCE PHARM INC.

PA Chew A, Choi JY, Koshy B;

PI WPI; 2001-662922/76.

XX Genotyping phospholipid transfer protein gene of individual for

XX haplotyping individual's gene, comprises determining identity of

PT nucleotide pair at polymorphic sites for two copies of PLTP gene

PT present in the individual -

XX Claim 15; Page 13; 98pp; English.

XX The present invention relates to a method for haplotyping the human

CC

CC phospholipid transfer protein (PLTP) gene, involving determining the

CC identity of the nucleotide present at one or more of the 25 polymorphic

CC sites within the gene. This can be used to aid drug development for the

CC treatment of diseases associated with different haplotypes of the PLTP

CC gene, possibly including atherosclerosis. The present sequence is an

CC allele-specific primer used for detecting polymorphisms in the PLTP gene.

XX SQ Sequence 15 BP; 1 A; 7 C; 2 G; 4 T; 1 other;

Query Match 1.0%; Score 13; DB 1; Length 15;

Best Local Similarity 86.7%; Pred. No. 2.1e+02;

Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 127 ACGGACAGGACGC 141

DB 15 ASGGATAGGACGC 1

RESULT 442

AAF51701/c

ID AAF51701 standard; DNA; 15 BP.

XX AAF51701;

XX 30-MAR-2001 (first entry)

DT IGF-I oligonucleotide #2661.

XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;

DE cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;

XX IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;

XX growth factor mediated cell proliferation; ichthyosis; serborrhoea; ruba;

XX keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;

XX hyperneovascular condition; hyperplasia; kidney disease;

XX neovascular condition of the retina; ss.

XX Homo sapiens.

XX WO200078341-A1.

PD 28-DEC-2000.

XX 21-JUN-2000; 2000WO-AU00693.

XX 21-JUN-1999; 99US-0140345.

XX (MURD-) MURDOCH CHILDRENS RES INST.

XX Wraight CJ, Werther GA, Edmondson SR;

XX WPI; 2001-041421/05.

DR Ameliorating the effects of a disorder, e.g. psoriasis, by

XX administering UV (ultra-violet) treatment (optional) and an antisense

XX nucleic acid that inhibits or reduces growth factor mediated cell

XX proliferation and/or inflammation -

XX Example 8; Page 78; 201pp; English.

XX The present invention relates to a method for ameliorating the effects

XX of skin disorders. The method comprises contacting the skin with an

XX antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1

XX receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of

XX inhibiting or reducing growth factor mediated cell proliferation,

XX inflammation and/or other disorders. The present sequence is an

XX oligonucleotide which can be used to design the antisense

XX oligonucleotides of the present invention (see AAP45151 and

XX AAP45153-F45161). The method is useful for ameliorating the effects of

XX psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhoea, keloids,

XX keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the

XX skin, a hyperneovascular condition such as a neovascular condition of the

XX retina, brain or skin, growth factor-mediated malignancies, other

CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 4 A; 2 C; 6 G; 3 T; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 160 CGCTGATCCTCAA 172
Db 15 CGCTGATCCTCAA 3

RESULT 443
AAF51702/c
ID AAF51702 standard; DNA; 15 BP.
AC AAF51702;
XX
DT 30-MAR-2001 (first entry)
XX
DE IGF-I oligonucleotide #2662.
XX
KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
KW hyperneovascular condition; hyperplasia; kidney disease;
KW neovascular condition of the retina; ss.
XX
OS Homo sapiens.
XX
XX WO200078341-A1.
XX
PD 28-DEC-2000.
XX
XX 21-JUN-2000; 2000WO-AU00693.
XX
XX 21-JUN-1999; 99US-0140345.
XX
XX (MURD-) MURDOCH CHILDRENS RES INST.
XX
XX Wright CJ, Werther GA, Edmondson SR;
XX
XX WPI; 2001-041421/05.
XX
XX Ameliorating the effects of a disorder, e.g. psoriasis, by
XX administering UV (ultra-violet) treatment (optional) and an antisense
XX nucleic acid that inhibits or reduces growth factor mediated cell
XX proliferation and/or inflammation -
XX
XX Example 8; Page 78; 201pp; English.

CC The present invention relates to a method for ameliorating the effects
CC of skin disorders. The method comprises contacting the skin with an
CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
CC inhibiting or reducing growth factor mediated cell proliferation,
CC inflammation and/or other disorders. The present sequence is an
CC oligonucleotide which can be used to design the antisense
CC oligonucleotides of the present invention (see AAF5151 and
CC AAF5153-F45161). The method is useful for ameliorating the effects of
CC psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea, keloids,
CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
CC skin, a hyperneovascular condition such as a neovascular condition of the
CC retina, brain or skin, growth factor-mediated malignancies, other
CC sclerotic disease, kidney disease, hyperproliferation of the inside of
CC blood vessels or any other hyperplasia.
XX
SQ Sequence 15 BP; 4 A; 2 C; 6 G; 3 T; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 160 CGCTGATCCTCAA 172
Db 14 CGCTGATCCTCAA 2

RESULT 444
ABK98166
ID ABK98166 standard; DNA; 15 BP.
XX
AC ABK98166;
XX
DT 07-OCT-2002 (first entry)
XX
DE Triple helix forming associated oligonucleotide #36.
XX
KW Triple-helix formation; purine-rich target sequence; double-helix DNA;
KW gene expression; regulatory sequence; pathogenic double-stranded DNA;
KW pathogenic bacteria; virus; replication; virulence; cancer;
KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
XX
OS Synthetic.
XX
XX US6403302-B1.
XX
PD 11-JUN-2002.
XX
XX 16-DEC-1993; 93US-0168920.
XX
XX 17-SEP-1992; 92US-0946976.
XX
XX (CALY) CALIFORNIA INST OF TECHNOLOGY.
XX
XX Dervan PB, Beal PA;
XX
XX WPI; 2002-536030/57.
XX
XX A triple-helix comprising a double helical nucleic acid (DHNA) and an
XX oligonucleotide which binds in parallel and antiparallel orientation,
XX respectively, for targeting sequences on alternate strands of DHNA to
XX control gene expression -
XX
XX Example 6; Fig 20A; 108pp; English.

CC The present invention relates to methods and oligonucleotides for
CC forming a triple-helix comprising a double helical nucleic acid
CC comprising first and second substantially complementary strands, and
CC an oligonucleotide bound to a purine-rich target sequence within the
CC double helical nucleic acid, where the oligonucleotide binds in a
CC parallel and antiparallel orientation, respectively, to target
CC sequences on alternate strands of the double helical nucleic acid.
CC The method has therapeutic applications, where gene expression is
CC regulated by selective triple-helix formation within expression
CC regulatory sequences of a target gene. The oligonucleotides can be
CC used to form triple-helices, and are useful to detect the presence or
CC absence of specific sequences within genomic DNA for diagnostic and
CC therapeutic purposes. The oligonucleotides can be selected to
CC specifically bind to pathogenic double-stranded DNA including specific
CC sequences required by pathogenic bacteria or viruses for replication or
CC virulence, reducing their pathogenicity. Alternatively, the
CC oligonucleotide can be chosen to target a unique sequence of the
CC pathogen which is not found in the genome of pathogen's host. The
CC oligonucleotides can be used in cancer treatment by way of triple-helix
CC suppression of specific oncogenes including those of endogenous or
CC viral origin. Such therapeutic oligonucleotides are capable of forming
CC triple-helices with such sequences in cancerous cells containing the
CC activated oncogene, so preferentially killing or repressing the cancer
CC causing cell. The present sequence represents an oligonucleotide
CC used in the methods of the present invention.

XX Sequence 15 BP; 0 A; 1 C; 0 G; 14 T; 0 other;
SQ Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1144 TTTTTCCTTTT 1156
|||||
Db 1 TTTTTCCTTTT 13

RESULT 445
ABK98185
ID ABK98185 standard; DNA; 15 BP.
XX AC ABK98185;
DT 07-OCT-2002 (first entry)
XX Triple helix forming associated oligonucleotide #49.
DE Triple-helix formation; purine-rich target sequence; double-helix DNA;
XX gene expression; regulatory sequence; pathogenic double-stranded DNA;
KW pathogenic bacteria; virus; replication; virulence; cancer;
KW oncogene suppression; cancerous cell; cytostatic; antimicrobial; ss.
XX Synthetic.
OS
XX
XX US6403302-B1.
FN
XX
XX 11-JUN-2002.
PD
XX
XX 16-DEC-1993; 93US-0169920.
PF
XX
XX 17-SEP-1992; 92US-0946976.
PR
XX
XX (CALY) CALIFORNIA INST OF TECHNOLOGY.
PA
XX
XX Dervan PB, Beal PA;
PI
XX
XX WPI; 2002-536030/57.
DR
XX
XX A triple-helix comprising a double helical nucleic acid (DHNA) and an
PT oligonucleotide which binds in parallel and antiparallel orientation,
PT respectively, for targeting sequences on alternate strands of DNA to
PT control gene expression -
XX
XX
XX Example 7; Fig 24A; 108pp; English.

The present invention relates to methods and oligonucleotides for forming a triple-helix comprising a double helical nucleic acid comprising first and second substantially complementary strands, and an oligonucleotide bound to a purine-rich target sequence within the double helical nucleic acid, where the oligonucleotide binds in a parallel and antiparallel orientation, respectively, to target sequences on alternate strands of the double helical nucleic acid. The method has therapeutic applications, where gene expression is controlled by selective triple-helix formation within expression regulatory sequences of a target gene. The oligonucleotides can be used to form triple-helices, and are useful to detect the presence or absence of specific sequences within genomic DNA for diagnostic and therapeutic purposes. The oligonucleotides can be selected to specifically bind to pathogenic double-stranded DNA including specific sequences required by pathogenic bacteria or viruses for replication or virulence, reducing their pathogenicity. Alternatively, the oligonucleotide can be chosen to target a unique sequence of the pathogen which is not found in the genome of pathogen's host. The oligonucleotides can be used in cancer treatment by way of triple-helix suppression of specific oncogenes including those of endogenous or viral origin. Such therapeutic oligonucleotides are capable of forming triple-helices with such sequences in cancerous cells containing the activated oncogene, so preferentially killing or repressing the cancer

CC causing cell. The present sequence represents an oligonucleotide
CC used in the methods of the present invention.
XX
SQ Sequence 15 BP; 0 A; 1 C; 0 G; 14 T; 0 other;
Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

OY 1144 TTTTTCCTTTT 1156
|||||
Db 1 TTTTTCCTTTT 13

RESULT 446
ABK95944/C
ID ABK95944 standard; DNA; 15 BP.
XX AC ABK95944;
DT 24-SEP-2002 (first entry)
XX Human LIPE gene polymorphism detection ASO probe #6.
DE
XX Human; lipase; hormone sensitive; LIPE; isogene; obesity; probe; ss;
KW male sterility; polymorphism; allele-specific oligonucleotide; ASO.
KW
XX Homo sapiens.
OS
XX
XX WO200240502-A2.
FN
XX
XX 23-MAY-2002.
PD
XX
XX 16-NOV-2001; 2001WO-US43518.
PF
XX
XX 16-NOV-2000; 2000US-249302P.
PR
XX
XX (GENA-) GENAISSANCE PHARM INC.
PA
XX
XX Anastasio AE, Bentivegna SC, Chew A, Koshy B, Rounds E;
PI
XX
XX WPI; 2002-519369/55.
DR
XX
XX Novel genetic variants of Lipase, Hormone-Sensitive isogenes, useful
PT for improving efficiency and reliability in drug development for
PT treating diseases associated with LIPE activity, e.g. obesity and male
PT sterility -
XX
XX
XX Claim 15; Page 14; 142pp; English.

The present invention relates to a new polynucleotide comprising a nucleotide sequence which comprises lipase, hormone sensitive (LIPE) isogenes. The invention is useful in screening for drugs targeting LIPE isogenes that are useful for treating obesity and male sterility. The methods of the invention are useful for improving the efficiency and reliability of several steps in the discovery and development of drugs for treating diseases associated with LIPE activity. The polynucleotide is useful in studying the expression and function of LIPE, and in expressing LIPE protein for use in screening for candidate drugs to treat diseases related to LIPE activity. It is also useful in studying the effect of the variation on the biological activity of LIPE as well as on the binding affinity of candidate drugs targeting LIPE for the treatment of obesity and male sterility. The invention is useful for studying the expression of LIPE isogenes in vivo, for in vivo screening and testing of drugs targeted against LIPE protein, and for testing the efficacy of therapeutic agents and compounds for treating obesity and male sterility in a biological system. The present nucleic acid sequence represents one of a collection (ABK95939-ABK95967) of allele-specific oligonucleotide (ASO) probes that were used in the invention to detect polymorphisms in the human LIPE gene.

Sequence 15 BP; 5 A; 4 C; 1 G; 4 T; 1 other;
XX

```
Query Match          1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.1e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 440 GAAAGTTGCTGAAGT 454
Db 15 GATAGTTCGAGT 1

RESULT 447
ABK81414
ID ABR81414 standard; DNA; 15 BP.
AC ABR81414;
XX
XX
DT 13-AUG-2002 (first entry)
XX
XX
XX SCYA20 allele specific oligonucleotide probe #3.
XX
XX Small inducible cytokine subfamily A (Cys-Cys) member 20; SCYA20;
XX polymorphism; haplotype; psoriasis; gene expression; ASO;
XX allele specific oligonucleotide; probe; ss.
XX
XX Homo sapiens.
XX
XX WO200232927-A2.
XX
XX 25-APR-2002.
XX
XX 19-OCT-2001; 2001WO-US46093.
XX
XX 19-OCT-2000; 2000US-241725P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Bieglecki KM, Chew A, Russo DP, Sausker EA;
XX WPI; 2002-435525/46.
XX
XX New genetic variants comprising haplotypes of the small inducible
XX cytokine subfamily A, member 20 (SCYA20) gene, useful in improving the
XX efficiency drug screening protocols for compounds (e.g. antipsoriatic
XX drug) targeting SCYA20
XX
XX Claim 14; Page 13; 62pp; English.
XX
XX The invention describes an isolated polynucleotide, which comprises genes
XX and haplotypes of the small inducible cytokine subfamily A (Cys-Cys),
XX member 20 (SCYA20) gene. The polynucleotide comprises polymorphic sites
XX referred to as P81-9 to designate the order in which they are located in
XX the gene. The polymorphisms and haplotypes of SCYA20 gene are useful for
XX validating whether SCYA20 is a suitable target for drugs to treat
XX psoriasis and disorders associated with its abnormal expression or
XX function, screening for such drugs and reducing bias in clinical trials
XX of such drugs. Haplotype information would be useful in improving the
XX efficiency and output of several steps in the drug discovery and
XX development process, including target validation, identifying lead
XX compounds, early phase clinical trials. The methods are useful in
XX screening for compounds targeting SCYA20 to treat a specific condition
XX or disease predicted to be associated with SCYA20 activity, e.g.
XX psoriasis. This sequence represents an allele specific oligonucleotide
XX (ASO) probe used to identify polymorphisms in the SCYA20 gene.
XX
XX Sequence 15 BP; 2 A; 7 C; 1 G; 4 T; 1 other;

Query Match          1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.1e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 1199 GACCTTCACACCTCC 1213
Db 1 GACCTTCACACCTTC 15
```

```
RESULT 448
ABL52099
ID ABL52099 standard; DNA; 15 BP.
XX
XX ABL52099;
AC
XX
XX 12-JUL-2002 (first entry)
DT
XX
XX Human PER1 allele specific oligonucleotide probe SEQ ID NO:24.
DE
XX
XX Human; period (Drosophila) homologue 1; PER1; polymorphic variant;
XX polymorphic site; genotyping; haplotyping; circadian rhythm regulation;
XX single nucleotide polymorphism; SNP; gene; probe; ss.
XX
XX Homo sapiens.
OS
XX
XX Key Location/Qualifiers
XX misc_feature 8
XX FT /*tag= a
XX FT /note= "polymorphic site indicated by an ambiguity base"
XX
XX WO200222650-A2.
XX
XX 21-MAR-2002.
XX
XX 13-SEP-2001; 2001WO-US28780.
XX
XX 13-SEP-2000; 2000US-232468P.
XX
XX (GENA-) GENAISSANCE PHARM INC.
XX
XX Duda A, Kliem SE, Koshy B;
XX WPI; 2002-393941/42.
XX
XX Novel isolated human period Drosophila homolog 1 polynucleotide, useful
XX for therapeutic purposes, for studying the expression and function of
XX the polynucleotide, and for expressing the homolog
XX
XX Claim 17; Page 14; 162pp; English.
XX
XX The present invention describes an isolated human period (Drosophila)
XX homologue 1, (PER1) polynucleotide (I) comprising a sequence which is a
XX polymorphic variant for a reference sequence (ABL52077) for the PER1 gene
XX or its fragment, or a polymorphic variant of a reference sequence
XX (ABL52078) for a PER1 cDNA or its fragment. The present invention also
XX describes methods for genotyping and haplotyping the PER1 gene of an
XX individual. (I) is useful in studying the expression and function of
XX PER1, and in expressing PER1 protein for use in screening for candidate
XX drugs to treat diseases related to PER1 activity. (I) is useful for
XX therapeutic purposes. A recombinant non-human organism transformed or
XX transduced with (I) can be used for studying expression of the PER1
XX isogenes in vivo, for in vivo screening and testing of drugs targeted
XX against PER1 protein, and for testing the efficacy of therapeutic agents
XX and compounds for disorders associated with circadian rhythm regulation.
XX The present sequence represents an allele specific oligonucleotide probe
XX for human PER1, which is used in the exemplification of the present
XX invention.
XX
XX Sequence 15 BP; 2 A; 5 C; 4 G; 3 T; 1 other;

Query Match          1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 2.1e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 287 CAGCAGCAATCTCTG 301
Db 1 CAGCAGCCTCTCTG 15

RESULT 449
ABK67885/c
```


OS Homo sapiens.
 XX WO200218414-A2.
 XX
 ED 07-MAR-2002.
 XX
 XX 29-AUG-2001; 2001WO-US27098.
 XX
 XX 29-AUG-2000; 2000US-228940P.
 PR
 XX (GENA-) GENAISSANCE PHARM INC.
 PA
 XX Anastasio AE, Finkel K, Kazemi A, Koshy B;
 PI WPI; 2002-304244/34.
 XX
 XX New genetic variants having polymorphisms in the B-Factor, Properdin
 PT (BF) gene, useful for studying the function of BF, and for treating
 PT disorders affected by expression or function of the BF isogene -
 XX
 PS Claim 17; Page 16; 151pp; English.
 XX
 CC The invention relates to single nucleotide polymorphisms in the gene
 CC encoding the human B-factor properdin protein (BF). A method for
 CC haplotyping the BF gene in an individual comprises identifying the
 CC nucleotide at one or more polymorphic sites and determining whether one
 CC of the copies of the gene is defined by one of the BF haplotypes given in
 CC the specification or whether both copies are defined by a haplotype pair.
 CC This method is useful in genotyping, whereby all possible haplotype pairs
 CC can be assigned to specific genotypes. An association between a trait and
 CC a haplotype or haplotype pair of the BF gene can be identified by
 CC comparing the frequency of the haplotype or haplotype pair in a
 CC population exhibiting the trait with the frequency of the haplotype or
 CC haplotype pair in a reference population, where a higher haplotype
 CC frequency in the trait population indicates the trait is associated with
 CC the haplotype or haplotype pair. BF and its corresponding DNA are used
 CC for studying the expression and function of BF, for use in screening for
 CC candidate drugs to treat diseases related to BF activity, such as
 CC diabetes and systemic lupus erythematosus. Sequences ABK63994-ABK64049
 CC represent allele-specific sequencing primers used to detect human BF gene
 CC polymorphisms.
 XX
 SQ Sequence 15 BP; 3 A; 3 C; 8 G; 0 U; 1 other;
 Query Match 1.0%; Score 13; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 2.1e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Oy 129 GGGACAGGGACGCC 143
 Db 1 GGGACAGGGAGGCYC 15
 RESULT 452
 AAS19628
 ID AAS19628 standard; DNA; 15 BP.
 XX AAS19628;
 AC
 XX 26-MAR-2002 (first entry)
 DT
 XX ASO primer #7 to detect human GHRHR gene polymorphisms.
 DE
 XX Human; single nucleotide polymorphism; SNP; GHRHR; chromosome 7p14;
 KW growth hormone releasing hormone receptor; haplotyping; genotyping;
 KW isolated growth hormone deficiency; IGHD; pituitary adenoma; ASO;
 KW allele-specific oligonucleotide; primer; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200179239-A2.
 PN
 XX 25-OCT-2001.
 PD

XX 17-APR-2001; 2001WO-US12453.
 PF
 XX 17-APR-2000; 2000US-197978P.
 XX
 XX (GENA-) GENAISSANCE PHARM INC.
 PA
 XX Chew A, Choi JY, Denton RR, Nandabalan K, Sausker EA;
 PI WPI; 2002-066342/09.
 XX
 XX Genotyping human Growth hormone releasing hormone receptor gene of
 PT individual for determining haplotype of individual by determining
 PT identity of nucleotide pair at specific polymorphic sites for two
 PT copies of gene -
 XX
 XX Claim 16; Page 14; 90pp; English.
 PS
 XX The present invention relates to novel single nucleotide polymorphisms
 CC (SNPs) in the human growth hormone releasing hormone receptor (GHRHR)
 CC gene located on chromosome 7p14, and methods for haplotyping and/or
 CC genotyping the GHRHR gene. The methods of the invention make use of
 CC allele-specific oligonucleotides (ASOs) as probes and primers and/or
 CC primer-extensions oligonucleotides for detecting the GHRHR gene
 CC polymorphisms. The polynucleotides and screened compounds are useful
 CC for the treatment of diseases associated with GHRHR activity, such as
 CC isolated growth hormone deficiency (IGHD) and pituitary adenomas.
 CC AAS19622-AAS19647 represent ASO primers for detecting human GHRHR
 CC gene polymorphisms.
 XX
 SQ Sequence 15 BP; 7 A; 2 C; 5 G; 0 U; 1 other;
 Query Match 1.0%; Score 13; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 2.1e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 Oy 1158 GAAGTAAAGCAGCTA 1172
 Db 1 GAAGTAAAGCAGCTA 15
 RESULT 453
 AAS98667/C
 ID AAS98667 standard; DNA; 15 BP.
 XX AAS98667;
 AC
 XX 26-MAR-2002 (first entry)
 DT
 XX Colony stimulating factor 1 receptor (CSF1R) oligonucleotide #33.
 DE
 XX Colony stimulating factor 1 receptor; CSF1R; polymorphic variant;
 KW cytostatic; gene therapy; malignant histiocytosis; isogene;
 KW myeloid malignancy; inflammatory disorder; transgenic animal;
 KW haplotype; genotype; human; allele specific oligonucleotide; ASO;
 KW probe; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200179225-A2.
 PN
 XX 25-OCT-2001.
 PD
 XX 12-APR-2001; 2001WO-US12044.
 PF
 XX 12-APR-2000; 2000US-196411P.
 PR
 XX (GENA-) GENAISSANCE PHARM INC.
 PA
 XX Chew A, Choi JY, Koshy B;
 PI WPI; 2002-075058/10.
 XX

PT Novel polymorphic variants of colony stimulating factor 1 receptor
 PT useful in studying expression and function of the protein, useful for
 PT screening candidate drugs to treat diseases e.g. inflammatory disorders
 PT
 XX
 PS Claim 15; Page 15; 164pp; English.
 XX
 CC The invention describes a novel isolated polynucleotide (I) comprising a
 CC sequence which is a polymorphic variant (PV) of a reference sequence for
 CC colony stimulating factor 1 receptor (CSF1R) gene, found on the
 CC polypeptide are useful for improving the discovery and development of
 CC drugs for treating diseases associated with CSF1R activity, e.g.,
 CC malignant histiocytosis, myeloid malignancies, and inflammatory disorders
 CC and the haplotypes can be used to validate CSF1R as a candidate target
 CC for treating a specific condition or disease predicted to be associated
 CC with CSF1R activity. Genotyping the CSF1R gene of an individual can also
 CC be used in developing diagnostic tests and therapeutic treatments. (I) is
 CC useful in studying the expression and function of CSF1R, and in
 CC expressing CSF1R protein for use in screening for candidate drugs to
 CC treat diseases related to CSF1R activity and in studying the effect of
 CC the variation on the biological activity of CSF1R as well as on the
 CC binding affinity of candidate drugs targeting CSF1R. Antibodies are
 CC useful in a variety of diagnostic and prognostic formats and therapeutic
 CC methods. A transgenic animal is useful in studying expression of the
 CC CSF1R isogenes in vivo, for in vivo screening and testing of drugs
 CC targeted against CSF1R protein, and for testing the efficacy of
 CC therapeutic agents and compounds. Allele specific oligonucleotides (ASO)
 CC are useful as probes and primers, and for assaying a polymorphism in the
 CC target region. Without requiring any a priori knowledge of the phenotypic
 CC effect of any particular CSF1R or haplotype the invention provides a
 CC method for identifying lead compounds that are more likely to show
 CC efficacy in clinical trials. This sequence is an allele specific
 CC oligonucleotide probe used for detecting CSF1R gene polymorphisms,
 CC described in the method of the invention.
 XX
 SQ Sequence 15 BP; 2 A; 4 C; 4 G; 4 T; 1 other;
 Query Match 1.0%; Score 13; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 2.1e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY .812 AGCCGAGCGTCTCTGA 826
 |||||
 DB 15 AGCCCAAGTCTCTGA 1
 RESULT 454
 AAS94594/c
 ID AAS94594 standard; DNA; 15 BP.
 XX
 AC AAS94594;
 DT 14-FEB-2002 (first entry)
 DE Human PLTP gene allele-specific oligonucleotide sequencing primer #3.
 XX Human; phospholipid transfer protein; PLTP; haplotyping; haplotype pair;
 KW single nucleotide polymorphism; genotyping; gene therapy; drug screening;
 KW binding affinity; atherosclerosis; ss; sequencing primer; PCR primer;
 KW probe.
 XX Homo sapiens.
 OS
 XX WO200172966-A2.
 PN
 XX 04-OCT-2001.
 PD
 XX 26-MAR-2001; 2001WO-US09776.
 PF
 XX 24-MAR-2000; 2000US-192127P.
 PR
 XX (GENA-) GENAISANCE PHARM INC.
 PA

PI Chew A, Choi JY, Koshy B;
 XX WPI; 2002-010724/01.
 XX
 PT New isolated polynucleotide which is polymorphic variant of
 PT phospholipid transfer protein (PLTP) gene, having any one of
 PT polymorphic sites P81-P825, for studying function of PLTP, and
 PT expressing PLTP protein -
 XX
 XX Claim 15; Page 72; 99pp; English.
 PS
 CC The invention relates to single nucleotide polymorphisms in the gene
 CC encoding the human phospholipid transfer protein (PLTP). A method for
 CC haplotyping the PLTP gene in an individual comprises identifying the
 CC nucleotide at one or more polymorphic sites and determining whether one
 CC of the copies of the gene is defined by one of the PLTP haplotypes given
 CC in the specification or whether both copies are defined by a haplotype
 CC pair. This method is useful in genotyping, whereby all possible haplotype
 CC pairs can be assigned to specific genotypes. An association between a
 CC trait and a haplotype or haplotype pair of the PLTP gene can be
 CC identified by comparing the frequency of the haplotype or haplotype pair
 CC in a population exhibiting the trait with the frequency of the haplotype
 CC or haplotype pair in a reference population, where a higher haplotype
 CC frequency in the trait population indicates the trait is associated with
 CC the haplotype or haplotype pair. PLTP and its corresponding DNA are used
 CC for studying the expression and function of PLTP, for use in screening
 CC for candidate drugs to treat diseases related to PLTP activity. The
 CC sequences are also useful for studying the effect of variation on the
 CC biological activity of PLTP as well as on the binding affinity of
 CC candidate drugs targeting PLTP for treating atherosclerosis. Sequences
 CC AAS94566-AAS94691 represent allele-specific oligonucleotide probes,
 CC sequencing primers and PCR primers used for detecting PLTP gene
 CC polymorphisms.
 XX
 SQ Sequence 15 BP; 1 A; 7 C; 2 G; 4 T; 1 other;
 Query Match 1.0%; Score 13; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 2.1e+02;
 Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 127 ACGGGACAGGGACGC 141
 |||||
 DB 15 ASGGGATAGGGACGC 1
 RESULT 455
 ABL42625
 ID ABL42625 standard; DNA; 15 BP.
 XX
 AC ABL42625;
 DT 11-APR-2002 (first entry)
 DE Hairpin beacon target hybridisation oligonucleotide #4.
 XX Hybridisation; thermodynamic; computer readable storage medium;
 KW probe; target; molecular beacon; duplex; hairpin; ss.
 XX Synthetic.
 OS
 XX WO200194611-A2.
 PN
 XX 13-DEC-2001.
 PD
 XX 07-JUN-2001; 2001WO-US18424.
 PF
 XX 07-JUN-2000; 2000US-209778P.
 PR
 XX (UYWA-) UNIV WAYNE STATE.
 PA
 XX Santalucia J, Peyret N;
 PI WPI; 2002-122125/16.
 DR

XX Predicting nucleic acid hybridization thermodynamics based on
 PT hybridization information, thermodynamic parameter, correction data and
 PT first set of data which represents hybridization conditions -
 XX
 PS Disclosure; Fig 8; 100pp; English.
 XX
 CC The present invention describes a method for predicting nucleic acid
 CC hybridisation thermodynamics (HT) comprising providing a database of
 CC thermodynamic parameters (TP), receiving hybridisation information which
 CC represents a sequence, receiving correction data, and a first set of
 CC data which represents hybridisation conditions, and calculating HT
 CC including net HT based on the hybridisation information, TP, the
 CC correction data and the first set of data. Also described are: (1) a
 CC computer-readable storage medium having stored in it, a database of TP
 CC and a computer program which executes the above method; and (2) a system
 CC for predicting nucleic acid HT, comprising a database of TP, units for
 CC receiving hybridisation information which represents at least one
 CC sequence and for receiving correction data, receiving a first set of
 CC data which represents hybridisation conditions and unit for calculating
 CC HT. The method and system are useful to optimise and predict probe-target
 CC hybridisation. The method and system takes into account of single strand
 CC folding thermodynamics to calculate effective hybridisation
 CC thermodynamics not taken into account by prior art methods. ABL42498 to
 CC ABL42626 represent oligonucleotide sequences which are used in the
 CC exemplification of the present invention.
 XX
 SQ Sequence 15 BP; 0 A; 1 C; 4 G; 10 T; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 15;
 Best Local Similarity 100.0%; Pred. No. 2.1e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1146 TTTTTCCTTTTGG 1158
 |||||
 Db 3 TTTTTCCTTTTGG 15

RESULT 456
 AAQ20008
 ID AAQ20008 standard; DNA; 16 BP.
 XX
 AC AAQ20008;
 XX
 DT 01-APR-1992 (first entry)
 XX
 DE Oligonucleotide #4 able to covalently cross-link to target DNA.
 XX
 KW deoxyribonucleic acid; major groove; ethanoamino group;
 KW aziridinylcytosine; cross-linking group; ss.
 OS Synthetic.

Key Location/Qualifiers
 modified_base 8
 /tag= a
 /mod_base= OTHER
 modified_base 14
 /tag= b
 /mod_base= m5c

WO9118997-A.
 12-DEC-1991.
 24-MAY-1991; 91WO-1003680.
 14-JAN-1991; 91US-0640654.
 25-MAY-1990; 90US-0529346.
 (GILE-) GILEAD SCIE INC.

PI Matteucci MD, Krawczyk S;
 XX
 DR WPI; 1992-007480/01.
 XX
 PT New sequence-specific non-photo-activated crosslinking agents -
 PT bind to the major groove of duplex DNA and are esp. useful for
 PT treating latent infections e.g. HIV
 XX
 PS Example 2; Page 21; 42pp; English.
 XX
 CC The 3' end of this oligonucleotide carries 1,3-propanediol. The
 CC oligo is one of four oligonucleotides which were designed to
 CC specifically bind and cross-link to the duplex target sequence
 CC AAQ20004. Oligo #4 with its internal cross-linking group was less
 CC effective than the other oligonucleotides with terminal
 CC cross-linking groups. See also AAQ20005-7.
 XX
 SQ Sequence 16 BP; 0 A; 2 C; 0 G; 14 T; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 16;
 Best Local Similarity 100.0%; Pred. No. 2.3e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1144 TTTTTCCTTTT 1156
 |||||
 Db 1 TTTTTCCTTTT 13

RESULT 457
 AAQ20006
 ID AAQ20006 standard; DNA; 17 BP.
 XX
 AC AAQ20006;
 XX
 DT 01-APR-1992 (first entry)
 XX
 DE Oligonucleotide #2 able to covalently cross-link to target DNA.
 XX
 KW deoxyribonucleic acid; major groove; ethanoamino group;
 KW aziridinylcytosine; cross-linking group; ss.
 OS Synthetic.

Key Location/Qualifiers
 modified_base 17
 /tag= a
 /mod_base= OTHER
 modified_base 8
 /note= "N4N4-ethanocytosine"
 modified_base 14
 /tag= b
 /mod_base= m5c
 modified_base 14
 /tag= c
 /mod_base= m5c

WO9118997-A.
 12-DEC-1991.
 24-MAY-1991; 91WO-1003680.
 14-JAN-1991; 91US-0640654.
 25-MAY-1990; 90US-0529346.
 (GILE-) GILEAD SCIE INC.
 Matteucci MD, Krawczyk S;
 WPI; 1992-007480/01.

New sequence-specific non-photo-activated crosslinking agents -
 bind to the major groove of duplex DNA and are esp. useful for
 treating latent infections e.g. HIV

XX Example 2; Page 20; 42pp; English.

XX The 3' end of this oligonucleotide carries 1,3-propanediol. The

CC oligo is one of four oligonucleotides which were designed to

CC specifically bind and cross-link to the duplex target sequence

CC AAQ20004. Oligo #2 has the covalent cross-linking group, i.e.

CC N4N4-ethanocytosine, at its 3' end. An assay for crosslinked triple

CC helix showed considerable reaction with Oligo #2 and with Oligo #1

CC (see AAQ20005) which has the crosslinking group at the 5' end.

CC The most complete reaction was seen with Oligo #3 (see AAQ20007) having

CC N4N4-ethanocytosine at both the 5' and 3' termini. A control oligo

CC with no cross-linking group showed no reaction. The half-life of the

CC cross-linking reaction for Oligo #2 was ca. 1 hr (1 microm);

CC Oligo #1 showed a rate four times slower. See also AAQ20008.

XX Sequence 17 BP; 0 A; 3 C; 0 G; 14 T; 0 other;

SQ

Query Match 1.0%; Score 13; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 2.5e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1144 TTTTTCCTTTT 1156

Db 1 TTTTTCCTTTT 13

RESULT 458

AAQ33416

ID AAQ33416 standard; cDNA; 17 BP.

XX

AC AAQ33416;

XX

DT 25-MAR-2003 (updated)

DT 06-MAY-1993 (first entry)

XX

DE Polymorphic site recognition probe, Arg-506.

XX

KW Acid sphingomyelinase; ASM; type; 1; 2; PCR; primer; amplify; cryptic;

KW polymerase chain reaction; mutation; R496L; deltaR608; L302; NPD;

KW Niemann-Pick disease; Jewish community; ss.

XX

OS Synthetic.

XX

XX EP520843-A2.

XX

PD 30-DEC-1992.

XX

PF 30-APR-1992; 92EP-0401241.

XX

PR 03-MAY-1991; 91US-0695472.

XX

PA (MOUN) MOUNT SINAI MEDICAL CENT.

XX

PI Desnick RJ, Schuchman EH;

XX

XX WPI; 1993-001632/01.

XX

PT Pure and recombinant acid sphingomyelinase and its nucleic acid -

PT for treatment and diagnosis of Niemann-Pick disease

XX

PS Disclosure; Page 12; 50pp; English.

XX

CC The sequences given in AAQ33414-17 are probes which were used to

CC recognise polymorphic sites within the full length acid sphingo-

CC myelinase (ASM) gene. This was done to determine the population

CC frequency of the different alleles. The template DNA was genomic DNA

CC from normal Caucasian individuals. Certain mutations in the ASM gene

CC ie. R496L, deltaR608 and L302 have been found to correlate with

CC Niemann-Pick disease (NPD). See also AAQ33390-423.

CC (Updated on 25-MAR-2003 to correct PN field.)

XX

XX Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 other;

SQ

Query Match 1.0%; Score 13; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 2.5e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 631 CTCACGAGGCTCT 643

Db 5 CTCACGAGGCTCT 17

RESULT 459

AAQ22208

ID AAQ22208 standard; DNA; 17 BP.

XX

AC AAQ22208;

XX

DT 12-JAN-1996 (first entry)

XX

DE p53 detection probe, (codon 178 ins 1 C).

XX

KW Primer; polymerase chain reaction; amplify; mutant; K-ras; PCR;

KW flanking region; amplification; probe; detection; sputum; diagnosis;

KW benign; malignant; neoplasm; lung; lung cancer; head; neck; ss.

XX

OS Synthetic.

XX

XX WO9513397-A1.

XX

PD 18-MAY-1995.

XX

PF 10-NOV-1994; 94WO-US12947.

XX

PR 12-NOV-1993; 93US-0152313.

XX

PA (UYGO) UNIV JOHNS HOPKINS SCHOOL MED.

XX

PI Sidransky D;

XX

XX WPI; 1995-194114/25.

XX

PT Detecting target nucleic acid in mammalian sputum - particularly for

PT diagnosis of lung neoplasia involving mutation(s) in the K-ras

PT oncogene or p53 tumour suppressor

XX

PS Example 1; Page 36; 122pp; English.

XX

CC The sequences given in AAQ2112-211 are probes which were used in the

CC detection of a mutant p53 gene sequence. The DNA to be detected is

CC amplified using PCR and then these probes which are pref. labeled using

CC 32-P gamma-ATP are used to detect the mutant sequences. The primers and

CC probes given in AAQ2098-219 are used in the method of the invention for

CC detecting mammalian target DNA in sputum samples. Analysis of the

CC target DNA is used to diagnose benign or malignant neoplasms of the

CC lung. It is also useful for screening people at high risk or for

CC monitoring progress of treatment of lung neoplasms. The method is

CC based on the discovery that mutant target DNA associated with lung

CC cancer is present at detectable levels in sputum. Cells shed into

CC sputum from head and neck cancers may also be detected.

XX

XX Sequence 17 BP; 3 A; 9 C; 3 G; 2 T; 0 other;

SQ

Query Match 1.0%; Score 13; DB 1; Length 17;

Best Local Similarity 100.0%; Pred. No. 2.5e+02;

Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 589 CTGCCCCCCCCACCA 601

Db 2 CTGCCCCCCCCACCA 14

RESULT 460

AAT95093

ID AAT95093 standard; DNA; 17 BP.

XX AC AAT95093;
 XX DT 17-FEB-1998 (first entry)
 XX DE Probe for acid sphingomyelinase genomic DNA codon 506 mutation.
 XX DE
 XX DE Prenatal diagnosis; Type A; Type B; Niemann-Pick disease;
 XX DE identification; potential genetic transmitter; detection;
 XX DE recessive mutation; acid sphingomyelinase; Ashkenazi Jew;
 XX DE human; treatment; codon 506 mutation; probe; ss.
 XX OS Synthetic.
 XX OS Homo sapiens.
 XX PN US5686240-A.
 XX PD 11-NOV-1997.
 XX PF 27-MAY-1994; 94US-0250740.
 XX PR 27-MAY-1994; 94US-0250740.
 XX PR 03-MAY-1991; 91US-0695572.
 XX PA (MOUN) MOUNT SINAI SCHOOL MEDICINE.
 XX PI Desnick RJ, Schuchman EH;
 XX PF; 1997-558133/51.
 XX DT Diagnosing Type A or B Niemann-Pick disease - by detecting recessive
 XX PT mutation in acid sphingomyelinase gene
 XX PS Example; Columns 51-52; 58pp; English.
 XX CC The present sequence is a probe for a human acid sphingomyelinase
 XX CC (ASM) genomic DNA codon 506 mutation.
 XX CC Diagnosing Type A or B Niemann-Pick disease (NPD), or identifying a
 XX CC person as having the potential to genetically transmit Type A or B
 XX CC NPD, comprises detecting a recessive mutation in the ASM gene,
 XX CC which results in an alteration of at least 1 amino acid in the ASM
 XX CC amino acid sequence. The method is especially useful for prenatal
 XX CC diagnosis in Ashkenazi Jewish populations. The mutation is
 XX CC Arg496Leu, deltaArg608, Leu302Pro or fsp330, where fsp330 is a
 XX CC frame shift mutation comprising a cytosine deletion in ASM codon
 XX CC 330. The mutations are detected by selectively amplifying mutation
 XX CC containing portions of the ASM gene by PCR using primers
 XX CC complementary and identical to a portion of the ASM cDNA sequence,
 XX CC and sequencing the amplified DNA or subjecting it to a
 XX CC hybridisation assay using mutation specific probes. The ASM type 1
 XX CC sequence, or the cDNA sequence encoding it can also be used in the
 XX CC treatment of NPD.
 XX SQ Sequence 17 BP; 4 A; 6 C; 3 G; 4 T; 0 other;
 Query Match 1.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 631 CTCGAGGAGCTCT 643
 Db 5 CTCGAGGAGCTCT 17
 RESULT 461
 AAV97224/C
 ID AAV97224 standard; RNA; 17 BP.
 XX AC AAV97224;
 XX DT 17-MAR-1999 (first entry)
 XX DE Human EGF-R target sequence nucleotide position 73.

XX KW Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
 KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
 KW cancer; genetic drift; detection; mutation; ss.
 XX OS Homo sapiens.
 XX PN WO9833893-A2.
 XX PD 06-AUG-1998.
 XX PF 14-JAN-1998; 98WO-US00730.
 XX PR 04-DEC-1997; 97US-0985162.
 XX PR 31-JAN-1997; 97US-0036476.
 XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PA (UYAS-) UNIV ASTON.
 XX PI Akhtar S, Fell P, McSwiggen JA;
 XX PF; 1998-437449/37.
 XX DT Enzymatic nucleic acids - which cleave RNA derived from an epidermal
 XX PT growth factor receptor, useful for inhibiting cell proliferation and
 XX PT for treating cancers
 XX PS Claim 5; Page 68; 109pp; English.
 XX CC The present invention describes enzymatic nucleic acid molecules (NAMs)
 XX CC which specifically cleave RNA derived from an epidermal growth factor
 XX CC receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
 XX CC represent specifically claimed target sequence from human EGF-R. AAV98044
 XX CC to AAV98866 and AAV98867 to V9878 represent hammerhead ribozymes and
 XX CC hairpin ribozymes respectively for human EGF-R. The NAMs are useful for
 XX CC cleaving EGF-R RNA in the treatment of a condition associated with EGF-R
 XX CC expression levels e.g. to inhibit cell proliferation in the prevention or
 XX CC treatment of cancers. The NAMs can also be used as diagnostic tools to
 XX CC examine genetic drift and mutations within diseased cells or to detect
 XX CC the presence of EGF-R RNA in a cell.
 XX SQ Sequence 17 BP; 1 A; 8 C; 5 G; 3 U; 0 other;
 Query Match 1.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 Qy 200 CGGACGCCGACGA 212
 Db 17 CGGACGCCGACGA 5
 RESULT 462
 AAV79135
 ID AAV79135 standard; DNA; 17 BP.
 XX AC AAV79135;
 XX DT 03-JAN-2003 (first entry)
 XX DE Human HTPL scanning oligonucleotide SEQ ID 381.
 XX KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 KW human testis expressed patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
 XX OS Homo sapiens.
 XX PN EP1229046-A2.
 XX PD 07-AUG-2002.

```

PF 28-JAN-2002; 2002EP-0001167.
XX
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 23-MAY-2001; 2001US-0864761.
PR 09-OCT-2001; 2001US-0327898.
XX
PA (ABOM-) AEOMICA INC.
XX
PI Zhan J;
XX
DR WPI; 2002-676582/73.
XX
PT Novel isolated human testis expressed Patched like protein (HTPL),
PT useful for identifying agonist and antagonist and specific binding
PT partners, and for treating subjects having defects in HTPL -
XX
PS Example 2; Page 113; 718pp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention.
XX
SQ Sequence 17 BP; 3 A; 7 C; 6 G; 1 T; 0 other;
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 522 CCTGCCGGAGGAG 534
Db 5 CCTGCCGGAGGAG 17
RESULT 463
ID ABV79136
XX ID ABV79136 standard; DNA; 17 BP.
XX AC ABV79136;
XX
DT 03-JAN-2003 (first entry)
XX
DE Human HTPL scanning oligonucleotide SEQ ID 382.
XX
KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
KW human testis expressed Patched like protein; testis; adrenal; liver;
KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
KW prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX
OS Homo sapiens.
XX
PN EP1229046-A2.
XX

```

```

PD 07-AUG-2002.
XX
PF 28-JAN-2002; 2002EP-0001167.
XX
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 23-MAY-2001; 2001US-0864761.
PR 09-OCT-2001; 2001US-0327898.
XX
PA (ABOM-) AEOMICA INC.
XX
PI Zhan J;
XX
DR WPI; 2002-676582/73.
XX
PT Novel isolated human testis expressed Patched like protein (HTPL),
PT useful for identifying agonist and antagonist and specific binding
PT partners, and for treating subjects having defects in HTPL -
XX
PS Example 2; Page 113; 718pp; English.
XX
CC The present invention relates to human testis expressed Patched like
CC protein (HTPL, see ABV78759 to ABV78762 and AB98519 to AB98520). HTPL
CC has two isoforms, with a few single base pair differences between the
CC two. One of the single base pair changes introduces a premature stop
CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
CC shares an overall structure organisation with the Patched protein. The
CC shared structural features strongly imply that HTPL plays a role similar
CC to that of Patched, and is a potential tumour suppressor. HTPL is
CC important in regulating male germ cell development, and the HTPL gene was
CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
CC useful for diagnosing a disorder caused by mutation in HTPL, and in
CC therapy and manufacture of a medicament for treatment or prevention of
CC such disorder associated with decreased expression or activity of human
CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
CC clinically useful diagnostic markers and potential therapeutic agents for
CC male infertility and cancer. The present oligonucleotide was used in an
CC example from the invention.
XX
SQ Sequence 17 BP; 3 A; 6 C; 7 G; 1 T; 0 other;
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.5e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 522 CCTGCCGGAGGAG 534
Db 4 CCTGCCGGAGGAG 16
RESULT 464
AAD33183
ID AAD33183 standard; DNA; 17 BP.
XX
AC AAD33183;
XX
DT 01-JUL-2002 (first entry)
XX
DE LDLR cDNA amplifying RT-PCR primer, LDLR/pl.
XX
KW Phytanic acid; non-insulin dependent diabetes mellitus; NIDDM; obesity;
KW glucose tolerance; food supplement; feed supplement; hyperinsulinaemia;
KW hyperlipidaemia; hypertension; insulin therapy; hypercholesterolaemia;
KW hypertriglyceridaemia; primer; RT-PCR; LDLR; reverse transcription PCR;
KW low-density lipoprotein receptor; ss.
XX
OS Unidentified.

```

XX PN EP117789-A2.
 XX XX 06-FEB-2002.
 XX PF 30-JUL-2001; 2001EP-0118230.
 XX PR 04-AUG-2000; 2000EP-0116948.
 XX PA (ROCH-) ROCHE VITAMINS AG.
 XX PI Fluehmann B, Heim M, Hunziker W, Weber P;
 XX DR WPI; 2002-270864/32.
 XX PT New composition comprising phytanic acid or its derivatives, useful for
 PT treating or preventing non-insulin dependent diabetes mellitus,
 PT impaired glucose tolerance and related obesity -
 XX XX
 XX PS Example 3; Page 9; 29pp; English.
 XX CC The invention relates to the use of phytanic acid or its derivatives
 CC for the treatment or prevention of diabetes mellitus. The invention
 CC also relates to a method for treating or preventing non-insulin
 CC dependent diabetes mellitus (NIDDM) or other conditions associated
 CC with impaired glucose tolerance such as obesity using phytanic acid
 CC or its derivatives. The phytanic acid, their derivatives or their
 CC precursors are useful as pharmaceutical compounds or supplements to
 CC foods or feeds for the treatment or prevention of type II or NIDDM,
 CC hyperlipidaemia, hypercholesterolaemia, hyperinsulinaemia, syndrome X,
 CC hypertension, hypertriglyceridaemia, impaired glucose tolerance and
 CC related obesity. They are also useful in insulin therapy in combination
 CC with known active compounds. The present sequence is low-density
 CC lipoprotein receptor (LDLR) cDNA amplifying reverse transcription PCR
 CC (RT-PCR) primer used in the exemplification of the invention.
 XX XX
 XX SQ Sequence 17 BP; 2 A; 6 C; 6 G; 3 T; 0 other;
 Query Match 1.0%; Score 13; DB 1; Length 17;
 Best Local Similarity 100.0%; Pred. No. 2.5e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 457 GTGTCAGCAGCC 469
 Db 2 GTGTCAGCAGCC 14
 RESULT 465
 AAT05895/c
 ID AAT05895 standard; DNA; 18 BP.
 XX AC AAT05895;
 XX DT 22-AUG-1996 (first entry)
 XX DE Human IL-2 exon 3-specific probe.
 XX KW Interleukin-2; IL-2; interleukin-4; IL-4; splice variant;
 XX KW probe; ss.
 XX OS Synthetic.
 XX PN WO9527052-A1.
 XX PD 12-OCT-1995.
 XX PF 30-MAR-1995; 95WO-US04094.
 XX PR 06-APR-1994; 94US-0224010.
 XX PR 30-MAR-1994; 94US-0219831.
 XX PA (UTMA-) UNIV MARYLAND BALTIMORE.
 XX XX

PI Alms W, White B;
 XX DR WPI; 1995-358629/46.
 XX PT New human interleukin alternative splice variants - expressed by
 PT exon(s) 1, 3 and 4 of IL-4 or IL-2, used for regulating the activity
 PT of corresp. interleukin(s)
 XX PS Example 6; Page 29; 58pp; English.
 XX CC Cytokine-specific probes were used to screen products obtd. by
 CC RT-PCR amplification (see AAT05878-93) of cellular RNA from human
 CC peripheral blood mononuclear cells stimulated with an anti-CD3 Mab.
 CC Probes were human IL-2 exon 2-specific (AAT05894), human IL-2 exon
 CC 3-specific (AAT05895), human IL-3 exon 1/exon 3 junction-specific
 CC (AAT05896), human IL-5 exon 1/exon 3 junction-specific (AAT05897) and
 CC human GM-CSF exon 1/exon 3 junction-specific (AAT05898). Novel splice
 CC variants of IL-4 (AAT05899) and IL-2 (AAT05900) lacking exon 2 were
 CC identified.
 XX SQ Sequence 18 BP; 4 A; 4 C; 6 G; 4 T; 0 other;
 Query Match 1.0%; Score 13; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2.7e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
 QY 379 CTTCTCCAGAGG 391
 Db 13 CTTCTCCAGAGG 1
 RESULT 466
 AAZ31808
 ID AAZ31808 standard; DNA; 18 BP.
 XX AC AAZ31808;
 XX DT 24-JAN-2000 (first entry)
 XX DE Human G-alpha-13 antisense inhibitor ISIS# 20763.
 XX KW G-alpha-13; human; inhibitor; cancer; antisense compound; therapy; ss.
 XX OS Synthetic.
 XX OS Homo sapiens.
 XX PN US5981732-A.
 XX PD 09-NOV-1999.
 XX PF 04-DEC-1998; 98US-0205860.
 XX PR 04-DEC-1998; 98US-0205860.
 XX PA (ISIS-) ISIS PHARM INC.
 XX PI Cowser LM;
 XX DR WPI; 1999-633376/54.
 XX PT Antisense compound inhibiting expression of human G-alpha-13 -
 PS Claim 11; Column 39; 38pp; English.
 XX CC This sequence represents an antisense inhibitor of the invention, and
 CC inhibits the expression of the human G-alpha-13 protein. The antisense
 CC compounds of the invention are of 8 to 30 nucleobases in length, that
 CC inhibits the expression of the human G-alpha-13. The antisense compound
 CC is useful for treating an animal, particularly humans, having or being
 CC prone to a disease or condition associated with the expression of
 CC G-alpha-13, such as cancer.
 XX SQ Sequence 18 BP; 4 A; 7 C; 6 G; 1 T; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2.7e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 718 GCCACGACGAGG 730
 |||||
 DB 4 GCCACGACGAGG 16

RESULT 467
 AAZ74428/c
 ID AAZ74428 standard; DNA; 18 BP.
 XX
 AC AAZ74428;
 XX
 DT 10-SEP-2001 (first entry)
 XX
 DE Human biallelic marker downstream amplification primer SEQ ID NO:8784.
 XX
 KW Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9954500-A2.
 XX
 PD 28-OCT-1999.
 XX
 PF 21-APR-1999; 99WO-IB00822.
 XX
 PR 21-APR-1998; 98US-0082614.
 PR 23-NOV-1998; 98US-0109732.
 XX
 PA (GEST) GENSET.
 XX
 PI Cohen D, Blumenfeld M, Chumakov I;
 XX
 DR WPI; 2000-013267/01.
 XX
 PT Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome -
 XX
 PS Claim 8; Page 2103; 2745pp; English.
 XX
 CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
 CC invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the
 CC invention have a variety of uses: they can be used for high density
 CC mapping of the human genome, and in complex association studies and
 CC haplotyping studies which are useful in determining the genetic basis
 CC for disease states. Compositions and methods of the invention can also
 CC be useful for the identification of the targets for the development of
 CC pharmaceutical agents and diagnostic methods, as well as the
 CC characterisation of the differential efficacious responses to and side
 CC effects from pharmaceutical agents acting on a disease as well as other
 CC treatment.
 CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297
 CC and 3367, are not actually given a sequence in the Sequence Listing
 CC from the present invention.
 XX
 SQ Sequence 18 BP; 10 A; 2 C; 6 G; 0 U; 0 other;

Query Match 1.0%; Score 13; DB 1; Length 18;
 Best Local Similarity 100.0%; Pred. No. 2.7e+02;
 Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1140 TGCCTTTTCT 1152
 |||||

Db 17 TGCCTTTTCT 5

RESULT 468
 AAZ26911/c
 ID AAZ26911 standard; DNA; 18 BP.
 XX
 AC AAZ26911;
 XX
 DT 21-DEC-2001 (first entry)
 XX
 DE Fluorescent oligonucleotide target for electronic hybridisation.
 XX
 KW Capture probe; hybridisation; electronics; photonics;
 KW nanotechnology; ss.
 XX
 OS Synthetic.
 XX
 FH Key Location/Qualifiers
 FT modified_base 1
 FT /*tag= a
 FT /mod_base= "OTHER"
 FT /note= "fluorescent dye with 493 nm absorption and
 FT 503 nm emission"
 XX
 PN WO200153799-A1.
 XX
 PD 26-JUL-2001.
 XX
 PF 12-JAN-2001; 2001WO-US00926.
 XX
 PR 24-JAN-2000; 2000US-0498855.
 XX
 PA (NANO-) NANOGEN INC.
 XX
 PI Edman CF, Heller MJ, Gurtner C, Formosa R;
 XX
 DR WPI; 2001-607116/69.
 XX
 FT Device for photoelectric transport of charged materials in liquid
 FT environment for micro- and opto- electronic devices, has a substrate
 FT generating light induced current, conductor, permeation layer and light
 FT source to illuminate substrate -
 XX
 PS Disclosure; Page 60; 119pp; English.
 XX
 CC The present sequence is that of fluorescent target oligonucleotide
 CC T2, which was used to demonstrate an electron hybridisation method
 CC of the invention. Mn2O3 stabilised n-type silicon photoelectrodes
 CC coated with a streptavidin-agarose permeation layer were shown to
 CC constitute a simple platform for rapid manipulation of DNA
 CC oligonucleotides by electron hybridisation. In this process, a
 CC set of unlabelled oligonucleotides (capture strands) are first
 CC targeted to specific locations and anchored. A second set of
 CC fluorescent labeled oligonucleotides (target strands) is then
 CC targeted to the same locations and actively hybridised to the
 CC capture strands. In the example provided, 2 sets of biotinylated
 CC capture probes, C1 (see AAZ26908) and C2 (see AAZ26909), were
 CC successively transported and anchored to 4 different locations on a
 CC streptavidin-agarose and Mn2O3 coated amorphous silicon substrate.
 CC 2 Fluorescence labeled target sequences, T1 (see AAZ26910) and
 CC T2 (present sequence), were then transported to a location with
 CC complementary capture probes and a location with non-complementary
 CC capture probes. This step produced 2 clearly detectable
 CC fluorescence signals at the 2 locations with matching sequences.
 CC The ratio between signal and non-specific background was better
 CC than 4. The method allows for detection of DNA oligonucleotides in
 CC an extremely short time. The invention generally provides systems
 CC and devices for photoelectrophoretic transport and hybridisation of
 CC oligonucleotides. The techniques of the invention have wide use in
 CC manufacture of micro electronic and opto electronic devices.
 CC Self-assembly fabrication techniques based on DNA polymers enables
 CC micron, sub-micron or nanoscale devices to be fabricated.

```

XX SQ Sequence 18 BP; 5 A; 6 C; 3 G; 4 T; 0 other;
Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 84 ATAGCAGTTCCTAC 96
Db 17 ATAGCAGTTCCTAC 5

RESULT 469
AADI5912/c
ID AAD15912 standard; RNA; 18 BP.
XX AAD15912;
AC
XX
DT 15-NOV-2001 (first entry)
XX
DE Y strand RNA oligonucleotide #6.
XX
KW Nucleic acid activity modulator; targeting portion; reactive portion;
XX ss.
XX Unidentified.
XX
FH Key Location/Qualifiers
FT misc_feature 9 /*tag= a
FT FT /note= "Optionally absent"
PN
XX US626241-B1.
PD 17-JUL-2001.
XX
XX 03-FEB-1995; 95US-0383666.
XX
XX 01-JUL-1992; 92US-0854634.
XX 13-AUG-1990; 90US-0566977.
XX 11-JAN-1991; 91US-0463358.
XX 11-JAN-1991; 91WO-US00243.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Cook PD, Ecker DJ, Guinosso CJ, Acevedo OL, Kawasaki A;
XX Ramasamy K;
XX WPI; 2001-528597/58.
XX
XX New heterocycle derivatives, useful for modulating the activity of RNA
XX and DNA -
XX
XX Example 136; Column 66; 54pp; English.
XX
XX The present invention relates to compositions and methods for modulating
XX the activity of RNA and DNA. The compositions comprise a targeting
XX portion specifically hybridisable with a preselected nucleotide sequence
XX of RNA. The composition further provides a reactive portion capable of
XX catalysing, alkylating, or otherwise effecting the cleavage of RNA,
XX especially of its phosphodiester bonds. The compositions are useful for
XX modulating the activity of RNA and DNA. The present sequence is
XX Y strand RNA oligonucleotide used in the exemplification of the
XX invention.
XX
XX Sequence 18 BP; 5 A; 3 C; 8 G; 1 U; 1 other;
Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 92.9%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1057 CCTGGCCTTCCCAT 1070
Db 17 ATAGCAGTTCCTAC 5

RESULT 471
AAQ68252/c
ID AAQ68252 standard; DNA; 16 BP.
XX AAQ68252;
AC
XX
DT 25-MAR-2003 (updated)

```

```

Db 18 CCTGGCCTTCCCAT 5

RESULT 470
ABK41151/c
ID ABK41151 standard; DNA; 18 BP.
XX
AC ABK41151;
XX
DT 21-MAY-2002 (first entry)
XX
XX Human obesity-associated biallelic marker downstream PCR primer #57.
XX
XX Human; obesity associated-biallelic marker; chromosome 10; obesity; ss;
XX drug response; hyperuricaemia; digestive pathology; hypertension; cancer;
XX hepatic function disorder; cardiovascular disease; hyperlipidaemia; PCR;
XX insulin disorder; atheromatous disease; cardiac insufficiency; primer.
XX
XX Homo sapiens.
XX
XX W0200206525-A2.
XX
XX 24-JAN-2002.
XX
XX 28-JUN-2001; 2001WO-IB01477.
XX
XX 18-JUL-2000; 2000US-219704P.
XX
XX (GEST ) GENSET.
XX
XX Cohen D, Blumenfeld M, Chumakov I, Abderrahim H, Bihain B;
XX WPI; 2002-155043/20.
XX
XX Set of novel map-related biallelic markers, preferably located on
XX obesity disorder-associated chromosomal regions on chromosomes 3, 10
XX and 19, useful, for e.g. detecting statistical correlations between
XX marker allele and a phenotype -
XX
XX Example 2; Page 274; 31pp; English.
XX
XX The invention relates to a set of novel map-related biallelic markers,
XX preferably located on obesity disorder-associated chromosomal regions on
XX chromosomes 3, 10 and 19. The markers are useful for genotyping or
XX estimating the frequency of an allele in a population, for detecting an
XX association between a genotype or haplotype and a phenotype, e.g. a
XX disease involving drug responses, obesity or disorders related to
XX obesity, such as hyperuricaemia, digestive pathology, hepatic function
XX disorders, cancer, cardiovascular disease, hypertension, hyperlipidaemia,
XX insulin disorders, atheromatous disease and cardiac insufficiency. The
XX markers are useful for detecting a statistical correlation between a
XX biallelic marker allele and a phenotype. This sequence represents a PCR primer used to
XX amplify a human obesity-associated biallelic marker.
XX
XX Sequence 18 BP; 6 A; 3 C; 5 G; 4 T; 0 other;
Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 2.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 325 CTGCATCATCTCG 337
Db 18 CTGCATCATCTCG 6

RESULT 471
AAQ68252/c
ID AAQ68252 standard; DNA; 16 BP.
XX
AC AAQ68252;
XX
DT 25-MAR-2003 (updated)

```


CC detect each polymorphism. When the MMS show considerable polymorphism
 CC (ie. a difference in the number of repeats) between individuals, the
 CC markers can be particularly informative. The MMS can be ideal for
 CC linkage studies. Kits comprise at least 4 groups, of at least 3 sets,
 CC each comprising labelled primers for PCR amplification of the DNA.
 CC Group 11 primer pairs are shown in AAQ95841-82. The published size range
 CC of the D5S425 allele is 224-248 bp, and the degree of heterozygosity
 CC in the population is about 77%.

XX SQ Sequence 16 BP; 2 A; 8 C; 3 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 2.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 459 GGTGAGCAGCCTGCAG 474

Db 16 GGTGAGCAGCCTGCAG 1

RESULT 474

AAAT43025

ID AAT43025 standard; DNA; 16 BP.

XX AC AAT43025;

XX 19-JUN-1997 (first entry)

XX Juvenile glaucoma marker afm350yh1 upstream amplification primer.

XX Microsatellite; genetic marker; screening; detection; PCR primer;

XX polymerase chain reaction; juvenile glaucoma; predisposition; ss.

XX OS Synthetic.

XX FH Key Location/Qualifiers

FT modified_base 1

FT /*tag= a

FT /note= "linked to JOE fluorochrome label"

XX W09633287-A1.

XX 24-OCT-1996.

XX 18-APR-1996; 96WO-FR00592.

XX 18-APR-1995; 95FR-0004590.

XX (INRM) INSERM INST NAT SANTE & RECH MEDICALE.

XX Bach JF, Garchon HJ;

XX WPI; 1996-485791/48.

XX Detecting pre-disposition to juvenile glaucoma - from presence of

XX specific microsatellite markers on chromosome 1q21q31, also DNA

XX from the region defined by these markers.

XX Example; Page 7; 25pp; French.

XX Predisposition to juvenile glaucoma is detected by characterising

XX the following microsatellite markers on chromosome 1q21q31 associated

XX with occurrence of juvenile glaucoma: afm350yh1; afm122xa3; ngal;

XX afm21; afm248wg5; afm278ye5; afm212xb10; afm157xe7 and NGA5. An

XX oligonucleotide primer of the present sequence was used with a

XX primer having the sequence given in AAT43026 to amplify the afm350yh1

XX marker. Apart from detecting predisposition to disease, the

XX microsatellites should allow localisation, and thus isolation, of

XX the gene involved in juvenile glaucoma.

XX SQ Sequence 16 BP; 2 A; 9 C; 1 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 2.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1042 TCTTCCACGACAGCC 1057

Db 1 TCTTCCACGACAGCC 16

RESULT 475

AAAX18366

ID AAX18366 standard; DNA; 16 BP.

XX AC AAX18366;

XX 11-MAY-1999 (first entry)

XX RT-PCR primer of the invention SEQ ID 7.

XX RT-PCR primer; DNA sequence determination; gene sequence analysis; ss.

XX OS Synthetic.

XX JPI1032765-A.

XX 09-FEB-1999.

XX 18-JUL-1997; 97JP-0208312.

XX 18-JUL-1997; 97JP-0208312.

XX (TAKI) TAKARA SHUZO CO LTD.

XX WPI; 1999-183822/16.

XX Peptides having at least two new nucleotides - useful as primers in

XX RT-PCR

XX Disclosure; Page 10; 19pp; Japanese.

XX This sequence represents a primer of the invention. The invention relates

XX to sequences of at least two nucleotides of formula:

XX (X)m5'-(alpha)n-beta-N3'; or (X)m5'-(gamma)k-delta-N3'; where

XX X = a labelled compound and/or a nucleotide with voluntary sequence;

XX m = 0 or 1; alpha = thymine; n = a natural number indicating the repetition

XX of alpha; beta, delta = V or N; V = adenine, guanine or cytosine;

XX N = adenine, guanine, cytosine or thymine; gamma = thymine;

XX k = natural number of 3 or over indicating the repetition of gamma, in

XX which thymine expressed by gamma is composed of 1/3 or less of adenine,

XX guanine and/or cytosine. The new nucleotides are useful as primers for

XX RT-PCR and determination of base sequences. The new sequences allow for

XX reproductive and highly efficient analysis of gene sequences.

XX SQ Sequence 16 BP; 1 A; 0 C; 1 G; 14 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 16;

Best Local Similarity 87.5%; Pred. No. 2.5e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTTCGA 1159

Db 1 TTTTTCCTTTTTCGA 16

RESULT 476

AAAC63258/C

ID AAC63258 standard; DNA; 16 BP.

XX AC AAC63258;

XX 06-FEB-2001 (first entry)

XX Oligonucleotide #31 used in a method for primer selection.

XX DE

XX

KW PCR primer; nucleic acid amplification; melting temperature; T_m; ss.
 XX Homo sapiens.
 OS WO200060123-A2.
 XX 12-OCT-2000.
 PD
 XX 05-APR-2000; 2000WO-US08962.
 PF
 XX 06-APR-1999; 99US-0127891.
 PR
 XX (GENO-) GENOME TECHNOLOGIES LLC.
 PA
 XX Senapathy P;
 PI
 XX WPI; 2000-656235/63.
 DR
 XX Determining T_m range for several degenerate primers with a
 PT fixed-sequence and a degenerate-sequence portion for use in polymerase
 PT chain reaction amplification by identifying a specific sequence in the
 PT nucleic acid template -
 XX
 PS Disclosure; Fig 3B; 34pp; English.
 XX The present invention relates to a method for selecting PCR primers for
 CC nucleic acid amplification. The method comprises determining the melting
 CC temperature (T_m) range for degenerate oligonucleotide primers with a
 CC fixed-sequence portion (FS) and a degenerate-sequence portion (DS) by
 CC searching known portion of a nucleic acid template for a sequence
 CC complementary to a desired FS of a primer. Nucleotide base pairs flanking
 CC or interspersed between the sequence complementary to a DS of one of the
 CC primers are detected and T_m is calculated. The method of the present
 CC invention allows primers which produce more efficient DNA amplification
 CC to be produced. The present sequence is a primer used in the method of
 CC the present invention.
 XX
 SQ Sequence 16 BP; 0 A; 4 C; 11 G; 1 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 191 CGGCCACCCGGACGC 206
 DB 16 CGGCCCGCCGGACCC 1
 RESULT 477
 AAC63300
 ID AAC63300 standard; DNA; 16 BP.
 XX
 AC AAC63300;
 XX
 XX 06-FEB-2001 (first entry)
 DT
 XX Oligonucleotide #73 used in a method for primer selection.
 DE
 XX PCR primer; nucleic acid amplification; melting temperature; T_m; ss.
 KW Homo sapiens.
 OS
 XX WO200060123-A2.
 PN
 XX 12-OCT-2000.
 PD
 XX 05-APR-2000; 2000WO-US08962.
 PF
 XX 06-APR-1999; 99US-0127891.
 PR
 XX (GENO-) GENOME TECHNOLOGIES LLC.
 PA
 XX Senapathy P;
 PI

XX WPI; 2000-656235/63.
 DR
 XX Determining T_m range for several degenerate primers with a
 PT fixed-sequence and a degenerate-sequence portion for use in polymerase
 PT chain reaction amplification by identifying a specific sequence in the
 PT nucleic acid template -
 XX
 PS Disclosure; Fig 3B; 34pp; English.
 XX The present invention relates to a method for selecting PCR primers for
 CC nucleic acid amplification. The method comprises determining the melting
 CC temperature (T_m) range for degenerate oligonucleotide primers with a
 CC fixed-sequence portion (FS) and a degenerate-sequence portion (DS) by
 CC searching known portion of a nucleic acid template for a sequence
 CC complementary to a desired FS of a primer. Nucleotide base pairs flanking
 CC or interspersed between the sequence complementary to a DS of one of the
 CC primers are detected and T_m is calculated. The method of the present
 CC invention allows primers which produce more efficient DNA amplification
 CC to be produced. The present sequence is a primer used in the method of
 CC the present invention.
 XX
 SQ Sequence 16 BP; 1 A; 9 C; 6 G; 0 U; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 191 CGGCCACCCGGACGC 206
 DB 1 CGGCCCGCCGGACGC 16
 RESULT 478
 AAA46382
 ID AAA46382 standard; DNA; 16 BP.
 XX
 AC AAA46382;
 XX
 XX 04-SEP-2000 (first entry)
 DT
 XX PCR primer used for screening for ESP carrying fragments.
 DE
 XX Polymorphism; endonuclease site polymorphism; ESP; genetic marker;
 KW restriction endonuclease; high throughput genetic analysis;
 KW animal breeding; plant breeding; PCR primer; ss.
 XX
 OS Zea sp.
 XX
 XX WO200028081-A2.
 PN
 XX 18-MAY-2000.
 PD
 XX 09-NOV-1999; 99WO-IB01958.
 PF
 XX 09-NOV-1999; 98US-0107293.
 PR
 XX (METH-) METHEXIS NV.
 PA
 XX Zabeau M, Stanssens P;
 PI
 XX WPI; 2000-376586/32.
 DR
 XX Novel method for restricted amplicon analysis of endonuclease site
 PT polymorphisms resulting in loss of restriction sites, useful for
 PT multiplex genotyping -
 XX
 PS Example 2; Page 34; 67pp; English.
 XX The specification describes methods for genotyping polymorphisms that
 CC result in the gain or loss of an endonuclease site polymorphisms (ESPs).
 CC The method comprises deriving a set of concomitantly amplifiable target
 CC DNA fragments from sample DNA, treating the target DNA fragments with a

CC probe restriction endonuclease reagent, amplifying the DNA fragments,
 CC and analysing the DNA to determine which target fragments have been, and
 CC have not been, amplified. Target DNA fragments which have been amplified
 CC lack a recognition site for the probe restriction endonuclease reagent,
 CC and target fragments having a recognition site for the probe restriction
 CC endonuclease reagent are not amplified. The method is capable of
 CC diagnosing the immense number of genetic markers that are needed to
 CC unravel complex traits. The method is useful for high throughput genetic
 CC analysis in pharmacogenomics, and in animal and plant breeding to
 CC identify genes involved in quantitative agronomic traits. The methods
 CC are also useful to monitor mutations in specific genes or loci in
 CC addition to scanning the entire genome. The present sequence represents
 CC a PCR primer used in the course of the invention, for genetic analysis
 CC of Corr.

SQ Sequence 16 BP; 3 A; 4 C; 5 G; 4 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 87.5%; Pred. No. 2.5e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 739 CTGCGCATGTGTGCTG 754
 Db 1 CTGACCGATGTGCG 16

RESULT 479
 AAF73460
 ID AAF73460 standard; DNA; 16 BP.
 XX AC AAF73460;
 XX DT 08-MAY-2001 (first entry)
 XX DE HGF nucleic acid ligand SEQ ID NO: 10.
 XX KW Hepatocyte growth factor/ scatter factor; HGF; c-met; integrin; stroke;
 XX KW cell adhesion; cell migration; nucleic acid ligand; thrombosis; cancer;
 XX KW hypertension; arteriosclerosis; myocardial infarction; restenosis;
 XX KW rheumatoid arthritis; macular degeneration; endometriosis; psoriasis;
 XX KW osteoporosis; DNA-RNA hybrid; ss.

OS Synthetic.
 XX FH Key Location/Qualifiers
 XX FT misc_RNA 5..16 /tag= a
 XX FT modified_base 1..16 /tag= b
 XX FT /mod_base= "OTHER"
 XX FT /note= "all bases are 2'OMe"

XX PN WO200109159-A1.
 XX PD 08-FEB-2001.
 XX PF 24-JUL-2000; 2000WO-US20139.
 XX PR 29-JUL-1999; 99US-0364539.
 XX PR 29-JUL-1999; 99US-0364543.
 XX PA (NEXS-) NEXSTAR PHARM INC.
 XX PI Ruckman J, Gold L, Stephens A, Janjic N, Rabin R, Lochrie M;
 XX DR WPI; 2001-103180/11.

XX FT Isolation of nucleic acid ligands to hepatocyte growth factor, its
 XX FT receptor c-met and integrins, useful for treating tumors, deep vein
 XX FT thrombosis and diabetic retinopathy -
 XX PS Example 1; Fig 2; 226pp; English.

CC The present invention provides nucleic acid ligands to hepatocyte growth
 CC factor/scatter factor (HGF), its receptor c-met and integrins. Integrins
 CC are involved in cell adhesion and migration, and HGF is a cytokine
 CC involved in cell proliferation and migration. The ligands of the
 CC invention are useful in the treatment of diseases such as cancer,
 CC thrombosis, hypertension, arteriosclerosis, myocardial infarction,
 CC rheumatoid arthritis, macular degeneration, endometriosis, psoriasis,
 CC stroke, osteoporosis and restenosis. The present sequence is an example
 CC of a ligand of the invention.

SQ Sequence 16 BP; 1 A; 4 C; 7 G; 2 T; 2 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 16;
 Best Local Similarity 75.0%; Pred. No. 2.5e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

OY 297 GTCTGCTGTGGGGCT 312
 Db 1 GTCTGCTGTGGGGCT 16

RESULT 480
 ABL95939
 ID ABL95939 standard; DNA; 16 BP.

XX AC ABL95939;
 XX DT 19-JUN-2002 (first entry)
 XX DE Probe #23 for assaying nucleic acids.
 XX KW Probe: polymorphism detection; mutation detection;
 XX KW disease diagnosis; microbial identification; ss.

OS Unidentified.

XX PN WO200208414-A1.

XX PD 31-JAN-2002.

XX PF 27-JUN-2001; 2001WO-IB01147.

XX PR 27-JUN-2000; 2000JP-0193133.

XX PR 03-AUG-2000; 2000JP-0226115.

XX PR 26-SEP-2000; 2000JP-0292483.

XX PA (NAAD-) NAT INST ADVANCED IND SCI & TECHNOLOGY.

XX PA (KANK-) KANKYO ENG CO LTD.

XX PI Kurane R, Kanagawa T, Kamagata Y, Torimura M, Kurata S, Yamada K;
 XX PI Yokomaku T;

XX DR WPI; 2002-195876/25.

XX FT Fluorescently-labeled nucleic acid probes for assaying nucleic acids
 XX FT and their polymorphism and mutation, particularly useful in science and
 XX FT medicine for e.g. analytical applications, disease diagnosis and
 XX FT microbial identification -

XX PS Example 22; Page 76; 152pp; Japanese.

XX CC The present invention relates to nucleic acid probes, which are useful
 XX CC for assaying nucleic acids by hybridising with a target nucleic acid, in
 XX CC which a single-stranded oligonucleotide is labelled with a fluorescent
 XX CC substance and a quencher in a manner that the fluorescence intensity of
 XX CC the hybridisation reaction system is increased after completion of the
 XX CC hybridisation but no stem loop structure is formed. The probes are useful
 XX CC for assaying nucleic acids and their polymorphism and mutation,
 XX CC particularly useful for e.g. analytical applications, disease diagnosis
 XX CC and microbial identification. The present sequence was used to illustrate
 XX CC the invention.

XX SQ Sequence 16 BP; 0 A; 6 C; 2 G; 8 T; 0 other;

```

Query Match          0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1214 CCTTCCTGCTACATTT 1229
DB 1 CCTTCCTGCTGCTTT 16

RESULT 481
ID ABX94194 standard; DNA; 16 BP.
XX AC
XX ABX94194;
XX
DT 10-JUN-2003 (first entry)
XX
DE Human SCCA2 gene, PCR primer #2.
XX
KW Bronchial asthma attack; SCCA1; SCCA2; gene expression; risk of attack;
KW PCR; primer; ss.
XX
OS Homo sapiens.
XX
XX WO2003014395-A1.
XX
XX 20-FEB-2003.
XX
PF 02-AUG-2002; 2002WO-JP07918.
XX
PR 07-AUG-2001; 2001JP-0239857.
XX
PA (GENO-) GENOX RES INC.
XX
PI Ohtani N, Matsui K, Yoshida N, Sugita Y, Hamasaki Y, Izuha K;
XX
DR WPI; 2003-248304/24.
XX
PT Method for examining bronchial asthma based on SCCA1 and SCCA2 as
PT allergy-associated genes, useful in assessing risk of attacks with
PT their expression levels as indication -
XX
PS Example 2; Page 20; 44pp; Japanese.
XX
CC The present invention relates to a method of examining attacks of
CC bronchial asthma by using SCCA1 and/or SCCA2 as the indicator genes.
CC The method comprises determining the expression levels of the
CC indicator genes in the biological sample from a patient, and comparing
CC the expression level with that in the sample of a healthy individual.
CC The method is useful for examining bronchial asthma, which is useful
CC in assessing the risk of attacks with SCCA1 and SCCA2 gene expression
CC levels as indication. The method is cheap and capable of operating in
CC high throughput, even for bedside diagnosis. The present sequence
CC represents a PCR primer used in the examples of the present invention.
XX
SQ Sequence 16 BP; 3 A; 6 C; 4 G; 3 T; 0 other;

Query Match          0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 828 GCAGCTGAGCTTTCA 843
DB 1 GCAGCTGAGCTTTCA 16

RESULT 482
ID ABX94515 standard; DNA; 16 BP.
XX AC
XX ABX94515;
XX

```

```

DT 10-JUN-2003 (first entry)
XX
DE 23S rDNA helix 54 region probe SEQ ID 33.
XX
KW Diagnostic; Gram-positive bacterium; high G+C content; amplification;
KW mycobacterial infection; PCR; primer; probe; detection; ss.
XX
OS Corynebacterium jeikeium.
XX
PN WO200297126-A2.
XX
PD 05-DEC-2002.
XX
PF 09-APR-2002; 2002WO-EP03956.
XX
PR 03-MAY-2001; 2001DE-1021505.
XX
PA (HAIN-) HAIN LIFESCIENCE GMBH.
XX
PI Weizenegger M;
XX
DR WPI; 2003-140491/13.
XX
CC Detecting and identifying Gram-positive bacteria of high G/C content,
CC useful particularly for diagnosis of mycobacterial infection, by
CC specific amplification and hybridization -
XX
PS Claim 1b; Figure 2B; 34pp; German.
XX
CC This invention describes a novel method for the diagnostic detection
CC and/or identification of Gram-positive bacteria that have a high G+C
CC content, especially Mycobacteria. The method comprises subjecting a
CC sample to nucleic acid amplification using the PCR primers represented in
CC ABX94483-ABX94492. The amplification mixture, or part of it, is then
CC tested for hybridisation to at least one of the probes represented in
CC ABX94493-ABX94524 which can be immobilised on a solid phase or used in
CC kit form. The specified primers/probes provide highly specific detection
CC of particular Gram positive bacteria, which are difficult to
CC differentiate by morphological or biochemical tests and/or those which
CC take a long time to test because of their slow growth.
XX
SQ Sequence 16 BP; 4 A; 6 C; 4 G; 2 T; 0 other;

Query Match          0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 87.5%; Pred. No. 2.5e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 598 ACCAGCCTGAGCCTG 613
DB 1 ACCAGCCTGAGCCTG 16

RESULT 483
ID AAT53533/c
XX
XX AAT53533 standard; RNA; 17 BP.
XX
AC AAT53533;
XX
DT 25-MAR-2003 (updated)
DT 27-MAR-1997 (first entry)
XX
DE Rat ICAM hammerhead ribozyme target sequence (nt. position 1006).
XX
KW Enzymatic nucleic acid; ribozyme; trans cleavage; inhibition;
KW gene expression; downregulation; interleukin-5; IL-5; ICAM-1;
KW intercellular adhesion molecule; rel A; tumour necrosis factor;
KW TNF-alpha; respiratory syncytial virus; RSV; bcr-abl; oncogene;
KW translocation; chronic myelogenous leukaemia; CML; cancer;
KW Philadelphia chromosome; inflammation; autoimmune disease;
KW atherosclerosis; myocardial infarction; stroke; restenosis;
KW transplant rejection; rheumatoid arthritis; psoriasis;
KW myocardial ischaemia; Kawasaki disease; septic shock; HIV;
KW human immunodeficiency virus; acquired immune deficiency syndrome;

```


PS Claim 2; Page 204; 407pp; English.

XX The present sequence represents a preferred target sequence for

CC an enzymatic nucleic acid (i.e. a ribozyme) which cleaves ICAM-1

CC mRNA at the nucleotide base position indicated in the DE line.

CC Regions of the mRNA that do not form secondary folding

CC structures and that contain potential hammerhead and hairpin

CC ribozyme cleavage sites were identified by computer analysis.

CC Ribozymes directed against these mRNA sequences were designed and

CC synthesised with modifications that improve their nuclease

CC resistance. The ribozymes cleave the ICAM-1 target sequences and

CC thereby inhibit ICAM-1 expression, making them useful for reducing

CC transplant rejection and alleviating symptoms in patients with

CC rheumatoid arthritis, asthma and other inflammatory disorders.

CC (Updated on 25-MAR-2003 to correct PI field.)

XX SQ Sequence 17 BP; 4 A; 3 C; 7 G; 3 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 334 CTTGGTGATGATGACCA 349

DB 17 CTTGGTGATGATGACCA 2

RESULT 485

AAAT81190

ID AAT81190 standard; RNA; 17 BP.

AC AAT81190;

XX 29-SEP-1997 (first entry)

DT Human c-myb hammerhead ribozyme target sequence (nt. position 1276).

DE Enzymatic nucleic acid; hammerhead; ribozyme; cleavage; human;

XX smooth muscle cell; hyperproliferation; restenosis; cancer;

KW c-myb; coronary angioplasty; ss.

OS Homo sapiens.

XX WO9531541-A2.

PN 23-NOV-1995.

XX 18-MAY-1995; 95WO-US06368.

XX 13-JAN-1995; 95US-0373124.

PR 18-MAY-1994; 94US-0245466.

XX (RIBO-) RIBOZYME PHARM INC.

PA Draper K, Jarvis T, McSwiggen J, Stinchcomb DT;

PI WPI; 1996-010927/01.

DR New enzymatic nucleic acid molecules - which cleave RNA produced by

PT e.g. c-myb, for treating restenosis or cancer

XX Claim 1; Page 68; 128pp; English.

PS The present sequence represents the preferred target sequence for an

CC enzymatic nucleic acid, especially a hammerhead ribozyme, which cleaves

CC the human c-myb sequence at the base position indicated in the

CC descriptor line. The c-myb sequence was screened for optimal ribozyme

CC target sites using a computer folding algorithm, and regions of the mRNA

CC which did not form secondary folding structures and contained potential

CC ribozyme cleavage sites were identified. Ribozymes were synthesised and

CC their activities optimised by either varying the length of the binding

CC arms or by modification to prevent degradation by nucleases.

CC the ribozymes cleave the c-myb sequence and can be used to prevent

CC smooth muscle cell hyperproliferation in restenosis, especially after

CC coronary angioplasty, and in cancers.

XX Sequence 17 BP; 1 A; 8 C; 3 G; 5 U; 0 other;

SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 62.5%; Pred. No. 2.7e+02;

Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 795 CTTGGCTGCTCCCTG 810

DB 2 CCGGCGUCCUACUG 17

RESULT 486

AAAX75174

ID AAX75174 standard; RNA; 17 BP.

AC AAX75174;

XX 28-JUL-1999 (first entry)

DT Mouse flt-1 VEGF receptor hammerhead ribozyme substrate #702.

DE Vascular endothelial growth factor receptor; VEGF receptor; flt-1;

XX flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;

XX tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;

KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;

XX foetal liver kinase 1; ss.

OS Mus sp.

XX WO9715662-A2.

PN 01-MAY-1997.

XX 25-OCT-1996; 96WO-US17480.

XX 11-JAN-1996; 96US-0584040.

PR 26-OCT-1995; 95US-0005974.

XX (CHIR) CHIRON CORP.

PA (RIBO-) RIBOZYME PHARM INC.

XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

PI WPI; 1997-259017/23.

DR Nucleic acid molecule modulating VEGF receptor(s) gene expression or

PT mRNA stability - useful for treating e.g. tumour angiogenesis,

PT psoriasis, rheumatoid arthritis, etc., in a human patient

XX Claim 4; Page 176; 218pp; English.

PS The present invention describes nucleic acid molecules which modulate

CC the synthesis, expression and/or stability of a mRNA encoding 1 or more

CC receptors of vascular endothelial growth factor (VEGF). A patient

CC (preferably human) having a condition associated with the level of the

CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing

CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour

CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can

CC be treated by administering the nucleic acid molecule or the expression

CC vector to the patient. AAX75174 to AAX75752 represent specific examples

CC of nucleic acid molecules from the present invention.

XX Sequence 17 BP; 3 A; 7 C; 2 G; 5 U; 0 other;

SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 56.2%; Pred. No. 2.7e+02;

Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 47 CTTAGCATCTCTCA 62

1:: |||:: |||


```

PN WO9710328-A2.
XX
PD 20-MAR-1997.
XX
PF 12-JUL-1996; 96WO-US11689.
XX
PR 13-JUL-1995; 95US-0001135.
XX
PA (DOWC) DOWELANCO.
XX
PI (RIBO-) RIBOZYME PHARM INC.
XX
PI Edington BE, Folkerts O, Guo L, McSwiggen JA, Merlo DU;
PI Merlo PAO, Skokut TA, Young SA, Zwick MG;
XX
DR WPI; 1997-202224/18.
XX
PT Ribozyme which modulates plant gene expression - preferably
PT modulates expression of DELTA-9 desaturase or granule bound starch
PT synthase in maize or canola
XX
PS Claim 41; Page 73; 155pp; English.
XX
CC The present invention describes an enzymatic nucleic acid molecule (I)
CC with RNA cleaving activity, which modulates the expression of a plant
CC gene. Also described is a gene comprising a cDNA sequence encoding maize
CC Delta-9 desaturase. (I) can be used to modulate expression of a gene,
CC preferably Delta-9 desaturase or a granule bound starch synthase (GBSS)
CC gene, in a plant (preferably a maize or canola plant). (I) can be used
CC to modulate caffeine synthesis in a coffee plant, nicotine production in
CC a tobacco plant, fruit ripening processes in an apple, tomato, pear,
CC plum or peach plant, flower pigmentation in a rose, petunia,
CC chrysanthemum or marigold plant or lignin production in a tobacco,
CC aspen, poplar or pine plant.
XX
SQ Sequence 17 BP; 1 A; 6 C; 6 G; 4 U; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.7e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 891 GTCGGGTACAGCGTG 906
DB 1 GCUGCGGUUCAGCCUG 16
RESULT 490
AAV97672
ID AAV97672 standard; RNA; 17 BP.
AC AAV97672;
XX
DT 17-MAR-1999 (first entry)
XX
DE Human EGF-R target sequence nucleotide position 3888.
XX
KW Human; epidermal growth factor receptor; EGFR; EGF-R; target sequence;
KW hammerhead ribozyme; hairpin ribozyme; inhibition; cell proliferation;
KW cancer; genetic drift; detection; mutation; ss.
XX
OS Homo sapiens.
XX
FN WO9833893-A2.
XX
PD 06-AUG-1998.
XX
PF 14-JAN-1998; 98WO-US00730.
XX
PR 04-DEC-1997; 97US-0985162.
XX
PR 31-JAN-1997; 97US-0036476.
XX
XX (RIBO-) RIBOZYME PHARM INC.
PA (UYAS-) UNIV ASTON.
XX
PI Akhtar S, Fell P, McSwiggen JA;
XX
DR WPI; 1998-437449/37.
XX
PT Enzymatic nucleic acids - which cleave RNA derived from an epidermal
PT growth factor receptor, useful for inhibiting cell proliferation and
PT for treating cancers
XX
PS Claim 5; Page 77; 109pp; English.
XX
CC The present invention describes enzymatic nucleic acid molecules (NAMs)
CC which specifically cleave RNA derived from an epidermal growth factor
CC receptor (EGF-R) gene. AAV97221 to AAV98043 and AAV98979 to AAV99090
CC represent specifically claimed target sequence from human EGF-R. AAV98044
CC to AAV98865 and AAV98867 to V9878 represent hammerhead ribozymes and
CC hairpin ribozymes respectively for human EGF-R. The NAMs are useful for
CC cleaving EGF-R RNA in the treatment of a condition associated with EGFR
CC expression levels e.g. to inhibit cell proliferation in the prevention or
CC treatment of cancers. The NAMs can also be used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of EGF-R RNA in a cell.
XX
SQ Sequence 17 BP; 3 A; 8 C; 3 G; 3 U; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.7e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
QY 574 CAGCAGGCCCTCCGTC 589
DB 1 CAGCAGGCCCTCCGTC 16
RESULT 491
AAV94931
ID AAV94931 standard; RNA; 17 BP.
AC AAV94931;
XX
DT 24-FEB-1999 (first entry)
XX
DE Mouse IL-2 receptor g-chain substrate position 403.
XX
KW Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;
KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;
KW autoimmune disease; psoriasis; allergy; inflammatory disease;
KW graft rejection; ss.
XX
OS Mus sp.
XX
FN WO9824913-A2.
XX
PD 11-JUN-1998.
XX
PF 02-DEC-1997; 97WO-US21748.
XX
PR 03-DEC-1996; 96US-0758306.
XX
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI McSwiggen JA, Stinchcomb DT;
XX
DR WPI; 1998-333332/29.
XX
PT Ribozymes targeted to interleukin 2 - useful for treating e.g.
PT cancer, autoimmune disease and allergies
XX
PS Claim 4; Page 41; 61pp; English.
XX
CC The present sequence invention describes ribozymes targeted to modulate
CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded
CC RNA. AAV93889 to AAV94574 represent specifically claimed ribozymes, and
CC AAV94575 to AAV95260 represent specifically claimed substrate sequences

```


CC from the present invention. The ribozymes can be used for the treatment
 CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis,
 CC allergy and other inflammatory conditions. The ribozymes are also used
 CC to induce tolerance in a recipient to alloantigen from a donor.

XX SQ Sequence 17 BP; 3 A; 8 C; 4 G; 2 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 2.7e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 625 GACGAGTCGAGGAC 640
 Db 1 GUCCAGCUCGAGGAC 16

RESULT 492

AAV94898

ID AAV94898 standard; RNA; 17 BP.

XX AC AAV94898;

DT 24-FEB-1999 (first entry)

DE Mouse IL-2 receptor g-chain substrate position 248.

XX Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;
 KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;
 KW autoimmune disease; psoriasis; allergy; inflammatory disease;
 KW graft rejection; ss.

XX OS Mus sp.

XX PN WO9824913-A2.

XX PD 11-JUN-1998.

XX PF 02-DEC-1997; 97WO-US21748.

XX PR 03-DEC-1996; 96US-0758306.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI McSwiggen JA, Stinchcomb DT;

XX DR WPI; 1998-333332/29.

XX PT Ribozymes targeted to interleukin 2 - useful for treating e.g.
 PT cancer, autoimmune disease and allergies

XX PS Claim 4; Page 41; 61pp; English.

XX The present sequence invention describes ribozymes targeted to modulate
 CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded
 CC RNA. AAV93889 to AAV94574 represent specifically claimed ribozymes, and
 CC AAV94575 to AAV95260 represent specifically claimed substrate sequences
 CC from the present invention. The ribozymes can be used for the treatment
 CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis,
 CC allergy and other inflammatory conditions. The ribozymes are also used
 CC to induce tolerance in a recipient to alloantigen from a donor.

XX SQ Sequence 17 BP; 4 A; 7 C; 4 G; 2 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 75.0%; Pred. No. 2.7e+02;
 Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

Qy 227 CTCAGCCTCAGGCATC 242

Db 1 CUGAGCCUCAGGCAAC 16

RESULT 493

AAV39410

ID AAV39410 standard; DNA; 17 BP.

XX AC AAV39410;

DT 21-SEP-1998 (first entry)

DE Humanised anti-HM1.24 antibody PCR primer SEQ ID NO:72.

XX Mouse; human; humanised; anti-HM1.24 antibody; myeloma; FR; CDR;
 KW framework region; complementarity determining region; antigenicity;
 KW PCR primer; ss.

XX OS Synthetic.

XX OS Mus sp.

XX OS Homo sapiens.

XX PN WO9814580-A1.

XX PD 09-APR-1998.

XX PF 03-OCT-1997; 97WO-JP03553.

XX PR 04-OCT-1996; 96JP-0264756.

XX PA (CHUS) CHUGAI SEIYAKU KK.

XX PI Koishihara Y, Kosaka M, Ohtomo T, Ono K, Tsuchiya M;

XX PI Yoshimura Y;

XX DR WPI; 1998-286421/25.

XX PT Humanised anti-HM1.24 antibody - for treatment of myeloma

XX PS Example 9; Page 140; 210pp; Japanese.

XX A humanised anti-HM1.24 antibody has been developed which comprises
 CC human L and H chain C regions, and L and/or H chain V regions
 CC containing material originating in mouse anti-HM1.24 antibody. The V
 CC regions contain framework (FR) regions of human origin and
 CC complementarity determining regions (CDR) of mouse origin, leading to
 CC a reshaped humanised antibody. The C regions are human Ck (L-chain) and
 CC human C gamma (especially C gamma 1) (H-chain). The FR regions of the
 CC L chain V region are derived from human subtype HSG1 (e.g. from human
 CC antibody RE1) and the FR regions of the H chain V region are derived
 CC from human subtype HSG1 (e.g. FR1-3 from human antibody HG3 and FR4
 CC from human antibody JH6). The present sequence represents a PCR primer
 CC used in an example from the present invention. The antibodies are used
 CC for the treatment of myeloma, especially by injection, intravenously,
 CC intramuscularly or subcutaneously. The antibodies are used at 0.01-1000
 CC (especially 5-100) mg/kg body weight. The humanised antibody has low
 CC antigenicity and is therefore effective therapeutically in humans.

XX SQ Sequence 17 BP; 5 A; 7 C; 4 G; 1 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 870 CCCACAGCCCAAGTTC 885

Db 2 CCCCAAGCCCAAGGTC 17

RESULT 494

AAA20491

ID AAA20491 standard; RNA; 17 BP.

XX AC AAA20491;

DT 19-JUN-2000 (first entry)

DE Integrin alpha 6 subunit substrate sequence SEQ ID NO:3717.

XX PA (RIBO-) RIBOZYME PHARM INC.
 XX PI Blatt L, Zwick M, Pavco P, McSwiggen J;
 XX DR WPI; 2000-647423/62.
 XX
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor
 PT protein, interferon alpha and erythropoietin -
 XX
 XX Claim 37; Page 80; 164pp; English.
 XX
 XX The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA
 CC transcription factor gene, IRF-2 and/or the CAAT Displacement
 CC Protein (CDP). Inhibition of the repressors removes prevents
 CC inhibition (and consequently increases expression of) genes involved in
 CC the production of erythropoietin, granulocyte colony stimulating factor
 CC protein and interferon alpha.
 XX
 XX Sequence 17 BP; 0 A; 9 C; 3 G; 5 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 145 CTCGGCTCCGCTCCGC 160
 DB 2 CTCGGCTCTCTCCGC 17
 RESULT 497
 AAF02789
 ID AAF02789 standard; DNA; 17 BP.
 XX
 XX AAF02789;
 DT 16-FEB-2001 (first entry)
 XX
 XX Hammerhead ribozyme substrate #1084.
 DE
 XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200061729-A2.
 PN
 XX 19-OCT-2000.
 PD
 XX 11-APR-2000; 2000WO-US09721.
 PF
 XX 12-APR-1999; 99US-0129390.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Zwick M, Pavco P, McSwiggen J;
 PI WPI; 2000-647423/62.
 DR
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor
 PT protein, interferon alpha and erythropoietin -
 XX
 XX Claim 37; Page 80; 164pp; English.
 XX
 XX The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA
 CC transcription factor gene, IRF-2 and/or the CAAT Displacement
 CC Protein (CDP). Inhibition of the repressors removes prevents

CC inhibition (and consequently increases expression of) genes involved in
 CC the production of erythropoietin, granulocyte colony stimulating factor
 CC protein and interferon alpha.
 XX
 XX Sequence 17 BP; 0 A; 9 C; 4 G; 4 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 147 CGGCTCCGCTCCGCGC 162
 DB 1 CGGCTCTCTCCGCGC 16
 RESULT 498
 AAF03345
 ID AAF03345 standard; DNA; 17 BP.
 XX
 XX AAF03345;
 AC
 XX 16-FEB-2001 (first entry)
 DT
 XX Hammerhead ribozyme substrate #1640.
 DE
 XX Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 KW interferon alpha; ss.
 XX
 XX Homo sapiens.
 OS
 XX WO200061729-A2.
 PN
 XX 19-OCT-2000.
 PD
 XX 11-APR-2000; 2000WO-US09721.
 PF
 XX 12-APR-1999; 99US-0129390.
 PR
 XX (RIBO-) RIBOZYME PHARM INC.
 PA
 XX Blatt L, Zwick M, Pavco P, McSwiggen J;
 PI WPI; 2000-647423/62.
 DR
 XX Enzymatic and antisense nucleic acid inhibition of repressor genes,
 PT useful for producing e.g. granulocyte colony stimulating factor
 PT protein, interferon alpha and erythropoietin -
 XX
 XX Claim 37; Page 93; 164pp; English.
 XX
 XX The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA
 CC transcription factor gene, IRF-2 and/or the CAAT Displacement
 CC Protein (CDP). Inhibition of the repressors removes prevents
 CC inhibition (and consequently increases expression of) genes involved in
 CC the production of erythropoietin, granulocyte colony stimulating factor
 CC protein and interferon alpha.
 XX
 XX Sequence 17 BP; 2 A; 1 C; 2 G; 12 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1144 TTTTCTTTTGTGGA 1159
 DB 2 TTTTCTTTTGTGGA 17
 RESULT 499
 AAF05405/c
 ID AAF05405 standard; DNA; 17 BP.

```

XX AAF05405;
XX AC
XX DT 16-FEB-2001 (first entry)
XX DE
XX DE Hammerhead ribozyme substrate #2624.
XX KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX KW interferon alpha; ss.
XX OS Homo sapiens.
XX PN WO200061729-A2.
XX PD 19-OCT-2000.
XX PF 11-APR-2000; 2000WO-US09721.
XX PR 12-APR-1999; 99US-0129390.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Zwick M, Pavco P, McSwiggen J;
XX DR WPI; 2000-647423/62.
XX CC Enzymatic and antisense nucleic acid inhibition of repressor genes,
XX CC useful for producing e.g. granulocyte colony stimulating factor
XX CC protein, interferon alpha and erythropoietin -
XX CC Claim 18; Page 116; 164pp; English.
XX CC The present invention relates to enzymatic and antisense nucleic acid
XX CC molecules that act as inhibitors of the expression of repressor genes
XX CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA
XX CC transcription factor gene, IRF-2 and/or the CAAT Displacement
XX CC Protein (CDP). Inhibition of the repressors removes prevents
XX CC inhibition (and consequently increases expression of) genes involved in
XX CC the production of erythropoietin, granulocyte colony stimulating factor
XX CC protein and interferon alpha.
XX CC Sequence 17 BP; 3 A; 6 C; 3 G; 5 T; 0 other;
SQ
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.7e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1248 GGCCATGTGAGGCCAG 1263
DB 17 GGACATGTAAGGCCAG 2
RESULT 500
AAF05437/C
ID AAF05437 standard; DNA; 17 BP.
XX AC
XX AC AAF05437;
XX DT 16-FEB-2001 (first entry)
XX DE Hammerhead ribozyme substrate #2656.
XX KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX KW interferon alpha; ss.
XX OS Homo sapiens.
XX PN WO200061729-A2.
XX PD 19-OCT-2000.
XX PF 11-APR-2000; 2000WO-US09721.
XX

```

```

PR 12-APR-1999; 99US-0129390.
XX (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Zwick M, Pavco P, McSwiggen J;
XX DR WPI; 2000-647423/62.
XX CC Enzymatic and antisense nucleic acid inhibition of repressor genes,
XX CC useful for producing e.g. granulocyte colony stimulating factor
XX CC protein, interferon alpha and erythropoietin -
XX CC Claim 18; Page 116; 164pp; English.
XX CC The present invention relates to enzymatic and antisense nucleic acid
XX CC molecules that act as inhibitors of the expression of repressor genes
XX CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA
XX CC transcription factor gene, IRF-2 and/or the CAAT Displacement
XX CC Protein (CDP). Inhibition of the repressors removes prevents
XX CC inhibition (and consequently increases expression of) genes involved in
XX CC the production of erythropoietin, granulocyte colony stimulating factor
XX CC protein and interferon alpha.
XX CC Sequence 17 BP; 10 A; 1 C; 1 G; 5 T; 0 other;
SQ
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.7e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1114 TTCTGTTTAAATGAAA 1129
DB 17 TTCTGTTTAAATGAAA 2
RESULT 501
AAF06984
ID AAF06984 standard; DNA; 17 BP.
XX AC
XX AC AAF06984;
XX DT 16-FEB-2001 (first entry)
XX DE Hammerhead ribozyme substrate #3241.
XX KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
XX KW interferon alpha; ss.
XX OS Homo sapiens.
XX PN WO200061729-A2.
XX PD 19-OCT-2000.
XX PF 11-APR-2000; 2000WO-US09721.
XX PR 12-APR-1999; 99US-0129390.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Blatt L, Zwick M, Pavco P, McSwiggen J;
XX DR WPI; 2000-647423/62.
XX CC Enzymatic and antisense nucleic acid inhibition of repressor genes,
XX CC useful for producing e.g. granulocyte colony stimulating factor
XX CC protein, interferon alpha and erythropoietin -
XX CC Claim 54; Page 131; 164pp; English.
XX CC The present invention relates to enzymatic and antisense nucleic acid
XX CC molecules that act as inhibitors of the expression of repressor genes
XX CC encoding the TR2 Orphan receptor, EAR3/COUP-TF-1, the GATA
XX CC transcription factor gene, IRF-2 and/or the CAAT Displacement

```

CC Protein (CDP). Inhibition of the repressors removes prevents
 CC inhibition (and consequently increases expression of) genes involved in
 CC the production of erythropoietin, granulocyte colony stimulating factor
 CC protein and interferon alpha.

XX SQ Sequence 17 BP; 6 A; 1 C; 5 G; 5 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 439 ACAAGATGCTGAAGT 454
 |||||
 Db 2 AGGAATTGCTGAAGT 17

RESULT 502

AAAF07122
 ID AAF07122 standard; DNA; 17 BP.

XX AC AAF07122;
 XX DT 16-FEB-2001 (first entry)

XX DE Hammerhead ribozyme substrate #3379.

XX KW Ribozyme; erythropoietin; granulocyte colony stimulating factor;
 XX KW interferon alpha; ss.

XX OS Homo sapiens.

XX FN WO200061729-A2.

XX PD 19-OCT-2000.

XX PF 11-APR-2000; 2000WO-US09721.

XX PR 12-APR-1999; 99US-0129390.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Blatt L, Zwick M, Pavco P, McSwiggen J;

XX DR WPI; 2000-647423/62.

XX PT Enzymatic and antisense nucleic acid inhibition of repressor genes,
 useful for producing e.g. granulocyte colony stimulating factor
 PT protein, interferon alpha and erythropoietin -

XX PS Claim 54; Page 133; 164pp; English.

XX CC The present invention relates to enzymatic and antisense nucleic acid
 CC molecules that act as inhibitors of the expression of repressor genes
 CC encoding the TR2 Orphan receptor, ERX3/COUP-TF-1, the GATA
 CC transcription factor gene, IRF-2 and/or the CAAT Displacement
 CC Protein (CDP). Inhibition of the repressors removes prevents
 CC inhibition (and consequently increases expression of) genes involved in
 CC the production of erythropoietin, granulocyte colony stimulating factor
 CC protein and interferon alpha.

XX SQ Sequence 17 BP; 5 A; 6 C; 5 G; 1 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 394 GCAGCAATGCCCGGC 409
 |||||
 Db 1 GCAGCAATGCCCGGC 16

RESULT 503

AAC70618/c

ID AAC70618 standard; DNA; 17 BP.
 XX AC AAC70618;
 XX DT 09-FEB-2001 (first entry)
 XX DE Single nucleotide polymorphism PCR primer #299.

XX KW Single nucleotide polymorphism; SNP; human; genetic disease;
 XX KW disease susceptibility; cardiovascular system; endocrine system;
 XX KW neurological system; forensic testing; paternity testing; PCR primer; ss.

XX OS Homo sapiens.

XX FN WO200058519-A2.

XX PD 05-OCT-2000.

XX PF 30-MAR-2000; 2000WO-US08440.

XX PR 31-MAR-1999; 99US-0127248.

XX PA (WHED) WHITEHEAD INST BIOMEDICAL RES.
 XX PA (AFFY-) AFFYMETRIX INC.

XX PI Altschuler D, Cargill M, Daley GQ, Ireland JS, Lander ES;
 XX PI Lipshutz RJ, Patil N, Sklar P;

XX DR WPI; 2000-611722/58.

XX CC Nucleic acid selected from one of 106 genes comprising single
 CC nucleotide polymorphisms, allele-specific oligonucleotides to the genes
 CC are useful for phenotypic correlations, forensics, paternity testing,
 CC medicine and genetic analysis -

XX PS Claim 8; Fig 5; 214pp; English.

XX CC The present invention is concerned with a number of human single
 CC nucleotide polymorphisms (SNPs) which the inventors identified in human
 CC genes. These SNPs can be used in disease diagnosis and prediction of an
 CC individual's susceptibility to disease, in forensic and paternity testing
 CC and in genetic mapping. In particular, the SNPs of the invention can be
 CC used to diagnose susceptibility to diseases of the cardiovascular,
 CC endocrine and neurological systems, such as coronary artery disease,
 CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
 CC diseases.

XX SQ Sequence 17 BP; 6 A; 7 C; 3 G; 1 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 259 CTCCTGGGCTGGCTGA 274
 |||||
 Db 16 CTCCTGGGCTGGGCTGA 1

RESULT 504

AAC70621/c
 ID AAC70621 standard; DNA; 17 BP.

XX AC AAC70621;

XX DT 09-FEB-2001 (first entry)

XX DE Single nucleotide polymorphism PCR primer #301.

XX KW Single nucleotide polymorphism; SNP; human; genetic disease;
 XX KW disease susceptibility; cardiovascular system; endocrine system;
 XX KW neurological system; forensic testing; paternity testing; PCR primer; ss.

XX OS Homo sapiens.

XX WO200058519-A2.
 PN 05-OCT-2000.
 PD 30-MAR-2000; 2000WO-US08440.
 XX 31-MAR-1999; 99US-0127248.
 XX (WHEED) WHITEHEAD INST BIOMEDICAL RES.
 PA (AFFY-) AFFYMETRIX INC.
 PI Altshuler D, Cargill M, Daley GQ, Ireland JS, Lander ES;
 PI Lipshutz RJ, Patil N, Sklar P;
 XX WPI; 2000-611722/58.
 XX Nucleic acid selected from one of 106 genes comprising single
 PT nucleotide polymorphisms, allele-specific oligonucleotides to the genes
 PT are useful for phenotypic correlations, forensics, paternity testing,
 PT medicine and genetic analysis -
 XX Claim 8; Fig 5; 214pp; English.
 XX The present invention is concerned with a number of human single
 CC nucleotide polymorphisms (SNPs) which the inventors identified in human
 CC genes. These SNPs can be used in disease diagnosis and prediction of an
 CC individual's susceptibility to disease, in forensic and paternity testing
 CC and in genetic mapping. In particular, the SNPs of the invention can be
 CC used to diagnose susceptibility to diseases of the cardiovascular,
 CC endocrine and neurological systems, such as coronary artery disease,
 CC schizophrenia, cancer, autoimmune diseases, Alzheimer's and Parkinson's
 CC diseases.
 XX Sequence 17 BP; 6 A; 7 C; 3 G; 1 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. NO. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 259 CTCCTGGGCTGGCTGA 274
 DB |||||||
 16 CTCCTGGGCTGGCTGA 1
 RESULT 505
 AAA25453
 ID AAA25453 standard; DNA; 17 BP.
 XX AAA25453;
 AC 19-JUL-2000 (first entry)
 DT Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1951.
 DE Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
 KW gene expression modification; cancer; phosphorothioate; endonuclease;
 KW anticancer; breast cancer; endometrium cancer; ss.
 XX Homo sapiens.
 OS WO9954459-A2.
 PN 28-OCT-1999.
 PD 19-APR-1999; 99WO-US08547.
 PF 20-APR-1998; 98US-0082404.
 XX 23-JUN-1998; 98US-0103636.
 PR (RIBO-) RIBOZYME PHARM INC.
 PA Thompson JD, Beigelman L, McSwiggen JA, Karpeisky A, Bellon L;
 PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerli P;

PI Thompson JD, Beigelman L, McSwiggen JA, Karpeisky A, Bellon L;
 PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerli P;
 XX Matulic-Adamic J;
 DR WPI; 2000-013248/01.
 XX New nucleic acids that interact, and optionally cleave, target
 PT sequences, used to treat cancer -
 XX Claim 77; Page 79; 148pp; English.
 XX The present invention describes nucleic acids (A) that interact stably
 CC with a target sequence and contain at least one phosphorodithioate
 CC link, having endonuclease activity. (A), and more generally any
 CC catalytic nucleic acid (A') that modulates expression of the oestrogen
 CC receptor gene, are used to treat cancer (particularly of breast or
 CC endometrium), in vivo or by transforming cells ex vivo and implanting
 CC treated cells, or for other conditions associated with levels of
 CC oestrogen receptor. Because of the high selectivity for targeted RNA, (A)
 CC can also be used to correlate inhibition of gene expression with
 CC alterations in phenotype, particularly for identification of therapeutic
 CC targets, and as research reagents (for RNA, in the same way that
 CC restriction endonucleases are used with DNA). The combination of
 CC modifications in (A) improves resistance to nucleases, binding affinity
 CC and/or activity. AAA23503 to AAA24747 represent oestrogen receptor
 CC hammerhead ribozyme sequences, and AAA24748 to AAA25992 represent their
 CC corresponding target sequences. AAA25993 to AAA26105 represent oestrogen
 CC receptor hairpin ribozyme sequences, and AAA26107 to AAA26218 represent
 CC their corresponding target sequences. AAA26219 to AAA26271 represent
 CC other ribozyme sequences and antisense oligonucleotides used in the
 CC exemplification of the present invention.
 XX Sequence 17 BP; 1 A; 0 C; 1 G; 15 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. NO. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1144 TTTTCTTTCTTTTGTGA 1159
 DB |||||||
 2 TTTTCTTTCTTTTGTGA 17
 RESULT 506
 AAA25454
 ID AAA25454 standard; DNA; 17 BP.
 XX AAA25454;
 AC 19-JUL-2000 (first entry)
 DT Oestrogen receptor hammerhead ribozyme target sequence SEQ ID NO:1952.
 DE Oestrogen receptor; c-raf; k-ras; bcl-2; ribozyme; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; antisense oligonucleotide;
 KW gene expression modification; cancer; phosphorothioate; endonuclease;
 KW anticancer; breast cancer; endometrium cancer; ss.
 XX Homo sapiens.
 OS WO9954459-A2.
 PN 28-OCT-1999.
 PD 19-APR-1999; 99WO-US08547.
 PF 20-APR-1998; 98US-0082404.
 XX 23-JUN-1998; 98US-0103636.
 PR (RIBO-) RIBOZYME PHARM INC.
 PA Thompson JD, Beigelman L, McSwiggen JA, Karpeisky A, Bellon L;
 PI Reynolds M, Zwick M, Jarvis T, Woolf T, Haeblerli P;


```

PR 01-JUN-2000; 2000US-208538P.
PR 30-OCT-2000; 2000US-244989P.
XX (UYDE ) UNIV DELAWARE.
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification -
XX
XX Claim 7; Page 252; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention.
XX
XX Sequence 17 BP; 3 A; 7 C; 3 G; 4 T; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.7e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 974 TCACCTTGACCAATCCC 989
Db 1 TCATCTGACCAATCCC 16
XX
RESULT 509
ABR81248
ID ABR81248 standard; DNA; 17 BP.
XX
XX ABR81248;
XX
XX 24-JAN-2002 (first entry)
XX
XX PSEN1 mutation correcting oligonucleotide SEQ ID NO: 4094.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
XX antileptic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US09761.
XX
XX 27-MAR-2000; 2000US-192176P.
XX

```

```

PR 27-MAR-2000; 2000US-192179P.
PR 01-JUN-2000; 2000US-208538P.
PR 30-OCT-2000; 2000US-244989P.
XX (UYDE ) UNIV DELAWARE.
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification -
XX
XX Claim 7; Page 265; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CFTR, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VIII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APC), presenilin-1 (PSEN1) and
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention.
XX
XX Sequence 17 BP; 0 A; 2 C; 9 G; 6 T; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.7e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1235 TGGTGTGGACGTGGC 1250
Db 1 TGGTGTGGTGTGGTGGC 16
XX
RESULT 510
ABR81249/c
ID ABR81249 standard; DNA; 17 BP.
XX
XX ABR81249;
XX
XX 24-JAN-2002 (first entry)
XX
XX PSEN1 mutation correcting oligonucleotide SEQ ID NO: 4095.
XX
XX Human; gene therapy; adenosine deaminase deficiency; p53; beta-globin;
XX retinoblastoma; BRCA1; BRCA2; CFTR; cystic fibrosis; cancer; Factor V;
XX cyclin-dependent kinase inhibitor 2A; CDKN2A; melanoma; APC; HBA1; HBA2;
XX adenomatous polyposis of the colon; Factor VII; Factor IX; thrombosis;
XX haemophilia; alpha thalassaemia; haemoglobin alpha locus 1; MLH1; APOE;
XX mismatch repair; MSH2; MSH6; hyperlipidaemia; apolipoprotein E; LDLR;
XX familial hypercholesterolaemia; UGT1; syndrome; APP; PSEN1; antisense;
XX UDP-glucuronosyltransferase; amyloid precursor protein; presenilin-1;
XX Alzheimer's disease; cytostatic; antisickling; antianaemic; haemostatic;
XX antileptic; ss.
XX
XX Homo sapiens.
XX
XX WO200173002-A2.
XX
XX 04-OCT-2001.
XX
XX 27-MAR-2001; 2001WO-US09761.
XX
XX 27-MAR-2000; 2000US-192176P.
XX

```



```

PR 27-MAR-2000; 2000US-192176P.
PR 27-MAR-2000; 2000US-192179P.
PR 01-JUN-2000; 2000US-208538P.
PR 30-OCT-2000; 2000US-244989P.
XX (UYDE ) UNIV DELAWARE.
XX Kmiec EB, Gamper HB, Rice MC;
XX WPI; 2001-639230/73.
XX
XX Oligonucleotide for targeted alterations of genetic sequences and for
XX treating cystic fibrosis, comprises at least one mismatch and chemical
XX modification -
XX
XX Claim 7; Page 265; 294pp; English.
XX
XX The present invention provides single-stranded oligonucleotides which can
XX be used for the targeted alteration of genomic sequences, where the
XX oligonucleotide has at least one mismatch compared with the genomic
XX sequence to be altered. In particular, these sequences are directed at
XX the following genes: adenosine deaminase, p53, beta-globin,
XX retinoblastoma, BRCA1, BRCA2, CTRF, cyclin-dependent kinase inhibitor 2A
XX (CDKN2A), APC, Factor V, Factor VII, Factor IX, haemoglobin alpha locus
XX 1 (HBA1), haemoglobin alpha locus 2 (HBA2), MLH1, MSH2, MSH6,
XX apolipoprotein E (APOE), LDL receptor (LDLR), UDP-glucuronosyltransferase
XX (UGT1), amyloid precursor protein (APP), presenilin-1 (PSEN1) and
XX presenilin-2 (PSEN2). These can be used in the gene therapy of diseases
XX such as cancer, adenosine deaminase deficiency, cystic fibrosis,
XX haemophilia, hypercholesterolaemia, thalassaemia, sickle cell anaemia,
XX Alzheimer's disease, melanoma, adenomatous polyposis of the colon and
XX various syndromes. The present sequence is one of the gene correcting
XX oligonucleotides of the invention.
XX
XX Sequence 17 BP; 6 A; 9 C; 2 G; 0 U; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.7e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1235 TGGTCTGGACGTGGC 1250
XX ||||| ||||| |||||
XX Db 17 TGGTGGTGGTGGTGGC 2
XX
XX RESULT 511
XX ABK03155/c
XX ID ABK03155 standard; RNA; 17 BP.
XX
XX AC ABK03155;
XX
XX DT 12-MAR-2002 (first entry)
XX
XX DE Human CD20 Inozyme #106.
XX
XX KW Human; ss; antisense therapy; cytostatic; antiinflammatory; haemostatic;
XX cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
XX muscular; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
XX DNazyme; inozyme; G-cleaver; amberzyme; zinczyme; lymphoma; leukaemia;
XX B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
XX human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
XX MCL; immunocytoma; IMC; immune thrombocytopenia; stroke; dementia;
XX inflammatory arthropathy; central nervous system injury;
XX cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
XX chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
XX Parkinson's disease; ataxia; Huntington's disease;
XX Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
XX
XX OS Homo sapiens.
XX OS Synthetic.
XX
XX PN WO200159103-A2.
XX

```

```

PD 16-AUG-2001.
XX 09-FEB-2001; 2001WO-US04273.
XX
XX 11-FEB-2000; 2000US-181797P.
XX 28-FEB-2000; 2000US-185516P.
XX 06-MAR-2000; 2000US-187128P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (CHOW/) CHOWRIRA B M.
XX Blatt L, McSwiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX constructs, which down regulate expression of a CD20 gene or neurite
XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
XX and central nervous system injury -
XX
XX Claim 30; Page 147; 200pp; English.
XX
XX The invention relates to a nucleic acid molecule which down regulates
XX expression of a CD20 gene and a nucleic acid molecule which down
XX regulates expression of a neurite growth inhibitor gene (NOGO).
XX The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
XX possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN
XX motif) or an amberzyme (cleaving RNA with an NGN triplet), a zinczyme
XX (cleaving RNA with a VGY motif). The CD20-targeting nucleic acid is used
XX to cleave RNA of CD20 in the presence of a divalent cation that is
XX preferably Mg2+. Furthermore, it may be contacted with a cell to reduce
XX CD20 activity of the cell and treat a patient having a condition
XX associated with the level of CD20. The treatment may further comprise the
XX use of one or more therapies. In particular, the CD20 targeting
XX nucleic acid may be used to treat lymphoma, leukaemia, B-cell
XX lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
XX low-grade or follicular NHL, lymphocytic leukaemia, HIV (human
XX immunodeficiency virus) associated NHL, mantle-cell lymphoma (MCL),
XX immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
XX thrombocytopenia, and inflammatory arthropathy. The NOGO-targeting
XX nucleic acid is used to cleave RNA of the NOGO gene in the presence of a
XX divalent cation that is preferably Mg2+. Furthermore, the nucleic acid
XX may be contacted with a cell to reduce NOGO activity of the cell and
XX treat a patient having a condition associated with the level of NOGO. The
XX treatment may further comprise the use of one or more therapies.
XX In particular, the NOGO-targeting nucleic acid may be used to treat
XX central nervous system (CNS) injury and cerebrovascular accident (CVA,
XX stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
XX chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
XX Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob
XX disease, muscular dystrophy, and/or other neurodegenerative disease
XX states which respond to the modulation of NOGO expression. The
XX present sequence is an inozyme of the invention.
XX
XX Sequence 17 BP; 1 A; 4 C; 4 G; 8 U; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.7e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 385 CCAGAGGTGGCAGCAA 400
XX ||||| ||||| |||||
XX Db 17 CCAGAAATGGCAGCAA 2
XX
XX RESULT 512
XX ABK03627/c
XX ID ABK03627 standard; RNA; 17 BP.
XX
XX AC ABK03627;

```

XX 12-WAR-2002 (first entry)
XX Human CD20 DNazyme #81.
XX Human; ss: antisense therapy; cytostatic; antiinflammatory; haemostatic;
XX cerebroprotective; neurotropic; neuroprotective; antiparkinsonian;
XX musclar; CD20; neurite growth inhibitor gene; NOGO; hammerhead ribozyme;
XX DNazyme; inozyme; G-cleaver; amberyne; zinzyme; lymphoma; leukaemia;
XX B-cell lymphoma; non-Hodgkin's lymphoma; NHL; lymphocytic leukaemia;
XX human immunodeficiency virus; HIV associated NHL; mantle-cell lymphoma;
XX MCL; immunocytoma; IWC; immune thrombocytopenia; stroke; dementia;
XX inflammatory arthropathy; central nervous system injury;
XX cerebrovascular accident; CVA; Alzheimer's disease; multiple sclerosis;
XX chemotherapy-induced neuropathy; amyotrophic lateral sclerosis; ALS;
XX Parkinson's disease; ataxia; Huntington's disease;
XX Creutzfeldt-Jakob disease; muscular dystrophy; neurodegenerative disease.
OS Homo sapiens.
OS Synthetic.
XX WO200159103-A2.
XX 16-AUG-2001.
XX 09-FEB-2001; 2001WO-US04273.
XX 11-FEB-2000; 2000US-181797P.
XX 28-FEB-2000; 2000US-185516P.
XX 06-MAR-2000; 2000US-187128P.
XX (RIBO-) RIBOZYME PHARM INC.
XX (BLAT/) BLATT L.
XX (MCSW/) MCSWIGGEN J.
XX (CHOW/) CHOWRIRA B M.
XX Blatt L, McSwiggen J, Chowrira BM;
XX WPI; 2001-607195/69.
XX Nucleic acid molecules, e.g., enzymatic nucleic acids and antisense
XX constructs, which down regulate expression of a CD20 gene or neurite
XX growth inhibitor gene useful for treating, e.g., lymphoma, leukemia,
XX and central nervous system injury -
XX Claim 30; Page 160; 200pp; English.
XX The invention relates to a nucleic acid molecule which down regulates
XX expression of a CD20 gene and a nucleic acid molecule which down
XX regulates expression of a neurite growth inhibitor gene (NOGO).
XX The nucleic acids may be enzymatic nucleic acids (e.g. a ribozyme or a
XX DNazyme) an inozyme (an endolytic nucleic acid cleaving an RNA molecule
XX possessing an NCH motif), a G-cleaver (cleaving RNA with a NYN
XX motif) or an amberyne (cleaving RNA with an NGN triplet), a zinzyme
XX (cleaving RNA with a YGY motif). The CD20-targetting nucleic acid is used
XX to cleave RNA of CD20 in the presence of a divalent cation that is
XX preferably Mg²⁺. Furthermore, it may be contacted with a cell to reduce
XX CD20 activity of the cell and treat a patient having a condition
XX associated with the level of CD20. The treatment may further comprise the
XX use of one or more therapies. In particular, the CD20 targeting
XX nucleic acid may be used to treat lymphoma, leukaemia, B-cell
XX lymphoma, low-grade or follicular non-Hodgkin's lymphoma (NHL), bulky
XX immunodeficiency virus associated NHL, mantle-cell lymphoma (MCL),
XX immunocytoma (IMC), small B-cell lymphocytic lymphoma, immune
XX thrombocytopenia, and inflammatory arthropathy. The NOGO-targetting
XX nucleic acid is used to cleave RNA of the NOGO gene in the presence of a
XX divalent cation that is preferably Mg²⁺. Furthermore, the nucleic acid
XX may be contacted with a cell to reduce NOGO activity of the cell and
XX treat a patient having a condition associated with the level of NOGO. The
XX treatment may further comprise the use of one or more therapies.
XX In particular, the NOGO-targetting nucleic acid may be used to treat
XX central nervous system (CNS) injury and cerebrovascular accident (CVA),

CC stroke), Alzheimer's disease, dementia, multiple sclerosis (MS),
CC chemotherapy-induced neuropathy, amyotrophic lateral sclerosis (ALS),
CC Parkinson's disease, ataxia, Huntington's disease, Creutzfeldt-Jakob.
CC disease, muscular dystrophy, and/or other neurodegenerative disease
CC states which respond to the modulation of NOGO expression. The
CC present sequence is a DNazyme molecule of the invention.
XX Sequence 17 BP; 4 A; 3 C; 2 G; 8 U; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 437 TCAGAAAGTTCGTGAA 452
DB 17 TAAGAAAGTTGCTCAA 2
RESULT 513
ABV80570/c
ID ABV80570 standard; DNA; 17 BP.
XX AC ABV80570;
XX DT 03-JAN-2003 (first entry)
XX DE Human HTPL scanning oligonucleotide SEQ ID 1816.
XX Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
XX human testis expressed Patched like protein; testis; adrenal; liver;
XX male germ cell development; bone marrow; brain; kidney; lung; placenta;
XX prostate; skeletal muscle; colon; male infertility; cancer; ss.
XX Homo sapiens.
XX EP1229046-A2.
XX 07-AUG-2002.
XX 28-JAN-2002; 2002EP-0001167.
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 23-MAY-2001; 2001US-0864761.
XX 09-OCT-2001; 2001US-0327898.
XX (AEOM-) AEOMICA INC.
XX Zhan J;
XX WPI; 2002-676592/73.
XX Novel isolated human testis expressed Patched like protein (HTPL),
XX useful for identifying agonist and antagonist and specific binding
XX partners, and for treating subjects having defects in HTPL -
XX Example 2; Page 301; 718pp; English.
XX The present invention relates to human testis expressed Patched like
XX protein (HTPL), see ABV78759 to ABV78762 and AB988519 to AB988520. HTPL
XX has two isoforms, with a few single base pair differences between the
XX two. One of the single base pair changes introduces a premature stop
XX codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL
XX shares an overall structure organisation with the Patched protein. The
XX shared structural features strongly imply that HTPL plays a role similar
XX to that of Patched, and is a potential tumour suppressor. HTPL is
XX important in regulating male germ cell development, and the HTPL gene was
XX mapped to human chromosome 10p12.1. HTPL and its coding sequence are
XX useful for diagnosing a disorder caused by mutation in HTPL, and in

CC to that of Patched, and is a potential tumour suppressor. HTPL is
 CC important in regulating male germ cell development, and the HTPL gene was
 CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in
 CC therapy and manufacture of a medicament for treatment or prevention of
 CC such disorder associated with decreased expression or activity of human
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
 CC clinically useful diagnostic markers and potential therapeutic agents for
 CC male infertility and cancer. The present oligonucleotide was used in an
 CC example from the invention.

XX Sequence 17 BP; 2 A; 4 C; 2 G; 9 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1137 CTATGCTTTTCT 1152

Db 2 CTATGCTTTTCT 17

RESULT 516

ABV82839

ID ABV82839 standard; DNA; 17 BP.

XX AC ABV82839;

XX DT 03-JAN-2003 (first entry)

XX DE Human HTPL scanning oligonucleotide SEQ ID 4085.

XX KW Human; gene therapy; tumour suppressor; HTPL; chromosome 10p12.1;
 KW human testis expressed Patched like protein; testis; adrenal; liver;
 KW male germ cell development; bone marrow; brain; kidney; lung; placenta;
 KW prostate; skeletal muscle; colon; male infertility; cancer; ss.

XX OS Homo sapiens.

XX PN EF1229046-A2.

XX PD 07-AUG-2002.

XX PF 28-JAN-2002; 2002EP-0001167.

XX PR 30-JAN-2001; 2001WO-US000663.

XX PR 30-JAN-2001; 2001WO-US000664.

XX PR 30-JAN-2001; 2001WO-US000665.

XX PR 30-JAN-2001; 2001WO-US000667.

XX PR 30-JAN-2001; 2001WO-US000668.

XX PR 23-MAY-2001; 2001WO-US000669.

XX PR 09-OCT-2001; 2001US-0327898.

XX PA (AEOM-) AEOMICA INC.

XX PI Zhan J;

XX DR WPI; 2002-676582/73.

XX PT Novel isolated human testis expressed Patched like protein (HTPL),
 PT useful for identifying agonist and antagonist and antagonist and specific binding
 PT partners, and for treating subjects having defects in HTPL -

XX PS Example 2; Page 599; 718pp; English.

XX The present invention relates to human testis expressed Patched like
 CC protein (HTPL, see ABV78759 to ABV78762 and ABV8519 to ABV8520). HTPL
 CC has two isoforms, with a few single base pair differences between the
 CC two. One of the single base pair changes introduces a premature stop
 CC codon in HTPL-S (S for short) compared to HTPL-L (L for long). HTPL

CC shares an overall structure organisation with the Patched protein. The
 CC shared structural features strongly imply that HTPL plays a role similar
 CC to that of Patched, and is a potential tumour suppressor. HTPL is
 CC important in regulating male germ cell development, and the HTPL gene was
 CC mapped to human chromosome 10p12.1. HTPL and its coding sequence are
 CC useful for diagnosing a disorder caused by mutation in HTPL, and in
 CC therapy and manufacture of a medicament for treatment or prevention of
 CC such disorder associated with decreased expression or activity of human
 CC HTPL. Such disorders include disorders of testis, or adrenal, adult and
 CC foetal liver, bone marrow, brain, kidney, lung, placenta, prostate,
 CC skeletal muscle or colon function. HTPL proteins and nucleic acids are
 CC clinically useful diagnostic markers and potential therapeutic agents for
 CC male infertility and cancer. The present oligonucleotide was used in an
 CC example from the invention.

XX Sequence 17 BP; 3 A; 3 C; 2 G; 9 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1137 CTATGCTTTTCT 1152

Db 1 CTATGCTTTTCT 16

RESULT 517

ABV89507

ID ABV89507 standard; DNA; 17 BP.

XX AC ABV89507;

XX DT 23-DEC-2002 (first entry)

XX DE Human POSHL1 scanning oligonucleotide SEQ ID NO 220.

XX KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.

XX OS Homo sapiens.

XX PN EP1239051-A2.

XX PD 11-SEP-2002.

XX PF 28-JAN-2002; 2002EP-0001165.

XX PR 30-JAN-2001; 2001WO-US000663.

XX PR 30-JAN-2001; 2001WO-US000664.

XX PR 30-JAN-2001; 2001WO-US000665.

XX PR 30-JAN-2001; 2001WO-US000666.

XX PR 30-JAN-2001; 2001WO-US000667.

XX PR 30-JAN-2001; 2001WO-US000668.

XX PR 30-JAN-2001; 2001WO-US000669.

XX PR 23-MAY-2001; 2001WO-US000670.

XX PR 10-OCT-2001; 2001US-0328205.

XX PA (AEOM-) AEOMICA INC.

XX PI Shannon M;

XX DR WPI; 2002-684061/74.

XX PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
 PT POSHL-1, useful for treating disorders associated with decreased
 PT expression or activity of human POSHL1 -

XX PS Example 2; SEQ ID NO 220; 60pp + Sequence Listing; English.

XX The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino

CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
 CC (S1) having 95% deviations especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention.
 CC Note: The present sequence did not form part of the printed
 CC specification, but is based on sequence information supplied to Derwent
 CC by the European Patent Office.

SQ Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 160 CGCTGATCCTCAAGGT 175
 Db 2 CGCTGCTCTCCAGGT 17
 ||||| ||||| |||||

RESULT 518
 ABV89508
 ID ABV89508 standard; DNA; 17 BP.
 XX AC ABV89508;
 XX DT 23-DEC-2002 (first entry)
 XX DE Human POSHL1 scanning oligonucleotide SEQ ID NO 221.
 XX KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.
 XX OS Homo sapiens.
 XX PN EP1239051-A2.
 XX PD 11-SEP-2002.

XX 28-JAN-2002; 2002EP-0001165.
 XX 30-JAN-2001; 2001WO-US00663.
 XX 30-JAN-2001; 2001WO-US00664.
 XX 30-JAN-2001; 2001WO-US00665.
 XX 30-JAN-2001; 2001WO-US00666.
 XX 30-JAN-2001; 2001WO-US00667.
 XX 30-JAN-2001; 2001WO-US00668.
 XX 30-JAN-2001; 2001WO-US00669.
 XX 23-MAY-2001; 2001WO-US00670.
 XX 10-OCT-2001; 2001US-0328205.
 XX (AEOM-) AEOMICA INC.
 XX Shannon M;
 XX WPI; 2002-684061/74.

XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
 XX POSHL-1, useful for treating disorders associated with decreased
 XX expression or activity of human POSHL1 -

PS Example 2; SEQ ID NO 221; 60pp + Sequence Listing; English.

XX The invention relates to an isolated SH3 domain (POSH)-like signalling
 CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
 CC acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
 CC (S1) having 95% deviations, especially conservative substitutions or a
 CC fragment of the sequences comprising at least 8 contiguous amino acids.
 CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
 CC adaptor protein that interacts with rho family small GTPases as well as
 CC downstream components of the signal transduction pathway. (I) is useful
 CC for identifying a specific binding partner. (I) and nucleic acids (II)
 CC encoding (I) are useful for diagnosing, monitoring disease and treating
 CC caused by altered expression of human POSHL1 including diagnosing and
 CC treating cancer, they useful in the development of vaccines and (II) is
 CC useful in gene therapy. (II) is useful for constructing microarrays which
 CC are useful for measuring and for surveying gene expression and creating
 CC transgenic non-human animals capable of producing the proteins. The
 CC present sequence is that of a scanning oligonucleotide useful in examples
 CC of the invention.
 CC Note: The present sequence did not form part of the printed
 CC specification, but is based on sequence information supplied to Derwent
 CC by the European Patent Office.

SQ Sequence 17 BP; 1 A; 7 C; 5 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 160 CGCTGATCCTCAAGGT 175
 Db 1 CGCTGCTCTCCAGGT 16
 ||||| ||||| |||||

RESULT 519
 ABV90534
 ID ABV90534 standard; DNA; 17 BP.
 XX AC ABV90534;
 XX DT 23-DEC-2002 (first entry)
 XX DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1247.
 XX KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
 KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
 KW gene therapy; transgenic; ss.

XX OS Homo sapiens.
 XX PN EP1239051-A2.
 XX PD 11-SEP-2002.
 XX 28-JAN-2002; 2002EP-0001165.
 XX 30-JAN-2001; 2001WO-US00663.
 XX 30-JAN-2001; 2001WO-US00664.
 XX 30-JAN-2001; 2001WO-US00665.
 XX 30-JAN-2001; 2001WO-US00666.
 XX 30-JAN-2001; 2001WO-US00667.
 XX 30-JAN-2001; 2001WO-US00668.
 XX 30-JAN-2001; 2001WO-US00669.
 XX 23-MAY-2001; 2001WO-US00670.
 XX 10-OCT-2001; 2001US-0328205.

XX (AEOM-) AEOMICA INC.
 XX Shannon M;
 XX WPI; 2002-684061/74.

PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
PT POSHL-1, useful for treating disorders associated with decreased
PT expression or activity of human POSHL1 -
XX
XX
XX Example 2; SEQ ID NO 1247; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, AB88399), a sequence having 85% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they are useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention.
CC Note: The present sequence did not form part of the printed
CC specification, but is based on sequence information supplied to Derwent
CC by the European Patent Office.
XX
XX
SQ Sequence 17 BP; 4 A; 9 C; 2 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 570 GCTCCAGCAGGCCCTC 585
DB 2 GCTCCAGCAGGCCCTC 17

RESULT 520
ABV90535
ID ABV90535 standard; DNA; 17 BP.
XX
AC ABV90535;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1248.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
XX EP1239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-0001165.
XX
XX 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 23-MAY-2001; 2001US-0864761.
PR 10-OCT-2001; 2001US-0328205.
XX
XX (ABOM-) AEOMICA INC.
PA
XX

PI Shannon M;
XX
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
PT POSHL-1, useful for treating disorders associated with decreased
PT expression or activity of human POSHL1 -
XX
XX Example 2; SEQ ID NO 1248; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (S1, AB88399), a sequence having 85% sequence identity to (S1),
CC (S1) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they are useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention.
CC Note: The present sequence did not form part of the printed
CC specification, but is based on sequence information supplied to Derwent
CC by the European Patent Office.
XX
XX
SQ Sequence 17 BP; 3 A; 9 C; 2 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 570 GCTCCAGCAGGCCCTC 585
DB 1 GCTCCAGCAGGCCCTC 16

RESULT 521
ABV90546/c
ID ABV90546 standard; DNA; 17 BP.
XX
AC ABV90546;
XX
DT 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1259.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
XX EP1239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-0001165.
XX
XX 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 23-MAY-2001; 2001US-0864761.
XX
XX

```
PR 10-OCT-2001; 2001US-0328205.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
DR WPI; 2002-684061/74.
XX
XX
PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
PT POSHL-1, useful for treating disorders associated with decreased
PT expression or activity of human POSHL1 -
XX
PS Example 2; SEQ ID NO 1259; 60pp + Sequence Listing; English.
XX
CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (SI, AB83999), a sequence having 65% sequence identity to (SI),
CC (SI) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they are useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention.
CC Note: The present sequence did not form part of the printed
CC specification, but is based on sequence information supplied to Derwent
CC by the European Patent Office.
XX
SQ Sequence 17 BP; 3 A; 8 C; 2 G; 4 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 268 TGGCTGATCACAAGAGG 283
DB 17 TGGGTGATCACAAGAGG 2
RESULT 522
ABV90554/C
XX ID ABV90554 standard; DNA; 17 BP.
XX AC ABV90554;
XX
XX 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1267.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
XX EP1239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-0001165.
XX
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR
PR 10-OCT-2001; 2001US-0328205.
XX
PA (AEOM-) AEOMICA INC.
XX
PI Shannon M;
XX
DR WPI; 2002-684061/74.
XX
XX
PT Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
PT POSHL-1, useful for treating disorders associated with decreased
PT expression or activity of human POSHL1 -
XX
PS Example 2; SEQ ID NO 1267; 60pp + Sequence Listing; English.
XX
CC The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (SI, AB83999), a sequence having 65% sequence identity to (SI),
CC (SI) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they are useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention.
CC Note: The present sequence did not form part of the printed
CC specification, but is based on sequence information supplied to Derwent
CC by the European Patent Office.
XX
SQ Sequence 17 BP; 4 A; 7 C; 4 G; 2 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 261 CCTGGGCTGGCTGATC 276
DB 16 CATGGGCTGGGCTGATC 1
RESULT 523
ABV91053/C
XX ID ABV91053 standard; DNA; 17 BP.
XX AC ABV91053;
XX
XX 23-DEC-2002 (first entry)
XX
DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1766.
XX
KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
OS Homo sapiens.
XX
XX EP1239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-0001165.
XX
PR 30-JAN-2001; 2001WO-US00663.
```

```

PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 23-MAY-2001; 2001US-0864761.
PR 10-OCT-2001; 2001US-0328205.
XX (AEOM-) ABOMICA INC.
XX Shannon M;
XX WPI; 2002-684061/74.
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
XX POSHL-1, useful for treating disorders associated with decreased
XX expression or activity of human POSHL1 -
XX Example 2; SEQ ID NO 1766; 60pp + Sequence Listing; English.
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
XX protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
XX acids (S1, AB983999), a sequence having 55% sequence identity to (S1),
XX (S1) having 95% deviations, especially conservative substitutions or a
XX fragment of the sequences comprising at least 8 contiguous amino acids.
XX Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
XX adaptor protein that interacts with Rho family small GTPases as well as
XX for identifying a specific binding partner. (I) is useful
XX encoding (I) are useful for diagnosing, monitoring disease and treating
XX caused by altered expression of human POSHL1 including diagnosing and
XX treating cancer, they are useful in the development of vaccines and (II) is
XX useful in gene therapy. (II) is useful for constructing microarrays which
XX are useful for measuring and for surveying gene expression and creating
XX transgenic non-human animals capable of producing the proteins. The
XX present sequence is that of a scanning oligonucleotide useful in examples
XX of the invention.
XX Note: The present sequence did not form part of the printed
XX specification, but is based on sequence information supplied to Derwent
XX by the European Patent Office.
XX Sequence 17 BP; 5 A; 3 C; 5 G; 4 T; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 906 GGCCCTGGTCTTAAG 921
Db 17 GACCCCTGTCTTAAG 2
RESULT 524
ABV91054/c
ID ABV91054 standard; DNA; 17 BP.
XX AC ABV91054;
XX DT 23-DEC-2002 (first entry)
XX DE Human POSHL1 scanning oligonucleotide SEQ ID NO 1767.
XX KW Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
XX Rho GTPase; signal transduction; gene expression; cancer; vaccine;
XX KW gene therapy; transgenic; ss.
XX OS Homo sapiens.
XX XX EP1239051-A2.
XX PD 11-SEP-2002.

```

```

XX PF 28-JAN-2002; 2002EP-0001165.
XX PR 30-JAN-2001; 2001WO-US00663.
XX PR 30-JAN-2001; 2001WO-US00664.
XX PR 30-JAN-2001; 2001WO-US00665.
XX PR 30-JAN-2001; 2001WO-US00666.
XX PR 30-JAN-2001; 2001WO-US00667.
XX PR 30-JAN-2001; 2001WO-US00668.
XX PR 30-JAN-2001; 2001WO-US00669.
XX PR 30-JAN-2001; 2001WO-US00670.
XX PR 23-MAY-2001; 2001US-0864761.
XX PR 10-OCT-2001; 2001US-0328205.
XX (AEOM-) ABOMICA INC.
XX Shannon M;
XX WPI; 2002-684061/74.
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
XX POSHL-1, useful for treating disorders associated with decreased
XX expression or activity of human POSHL1 -
XX Example 2; SEQ ID NO 1767; 60pp + Sequence Listing; English.
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
XX protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
XX acids (S1, AB983999), a sequence having 55% sequence identity to (S1),
XX (S1) having 95% deviations, especially conservative substitutions or a
XX fragment of the sequences comprising at least 8 contiguous amino acids.
XX Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
XX adaptor protein that interacts with Rho family small GTPases as well as
XX for identifying a specific binding partner. (I) is useful
XX encoding (I) are useful for diagnosing, monitoring disease and treating
XX caused by altered expression of human POSHL1 including diagnosing and
XX treating cancer, they are useful in the development of vaccines and (II) is
XX useful in gene therapy. (II) is useful for constructing microarrays which
XX are useful for measuring and for surveying gene expression and creating
XX transgenic non-human animals capable of producing the proteins. The
XX present sequence is that of a scanning oligonucleotide useful in examples
XX of the invention.
XX Note: The present sequence did not form part of the printed
XX specification, but is based on sequence information supplied to Derwent
XX by the European Patent Office.
XX Sequence 17 BP; 4 A; 3 C; 5 G; 5 T; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 906 GGCCCTGGTCTTAAG 921
Db 16 GACCCCTGTCTTAAG 1
RESULT 525
ABQ63634/c
ID ABQ63634 standard; DNA; 17 BP.
XX AC ABQ63634;
XX XX 20-AUG-2002 (first entry)
XX DE Human KTM01a portion (ABQ63232) probe # 347.
XX KW Human; KTM01a; KTM01; kidney tumour overexpressed membrane; cytostatic;
XX gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
XX KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX OS Homo sapiens.

```



```
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX WO200211674-A2.
XX
PD 14-FEB-2002.
XX
PF 09-AUG-2001; 2001WO-US24970.
XX
PR 09-AUG-2000; 2000US-224383P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (SYNT) SYNTEX USA LLC.
PA (THOM/) THOMPSON J.
XX
PI Thompson J, McSwiggen J, McKenzie T, Ayers D, Szymkowski DE;
PI Grupe A;
XX
DR WPI; 2002-217145/27.
XX
PT Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PT pulmonary disease (COPD), chronic bronchitis and asthma
XX
PS Claim 4; Page 57; 152pp; English.
XX
CC The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention.
XX
SQ Sequence 17 BP; 4 A; 3 C; 7 G; 3 U; 0 other;
XX
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 2.7e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
QY 4 CAGGCAGTTGAGGTGG 19
Db 1 CAGACAGUUGAGCUGG 16
RESULT 528
ABK56045/c
ID ABK56045 standard; RNA; 17 BP.
XX
AC ABK56045;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #416.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
```

```
OS Homo sapiens.
XX WO200211674-A2.
XX
PD 14-FEB-2002.
XX
PF 09-AUG-2001; 2001WO-US24970.
XX
PR 09-AUG-2000; 2000US-224383P.
XX
PA (RIBO-) RIBOZYME PHARM INC.
PA (SYNT) SYNTEX USA LLC.
PA (THOM/) THOMPSON J.
XX
PI Thompson J, McSwiggen J, McKenzie T, Ayers D, Szymkowski DE;
PI Grupe A;
XX
DR WPI; 2002-217145/27.
XX
PT Enzymatic polynucleotide that down regulates expression of chloride
PT channel calcium activated gene, useful for treating Chronic obstructive
PT pulmonary disease (COPD), chronic bronchitis and asthma
XX
PS Claim 4; Page 60; 152pp; English.
XX
CC The invention relates to enzymatic nucleic acid molecules that down
CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
CC by cleaving RNA derived from the genes. The nucleic acid sequences are
CC useful as pharmaceutical agents for treating conditions such as chronic
CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
CC that are related to or will respond to the levels of CLCA1 in a cell or
CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
CC hence, are useful for treatment of a patient having a condition
CC associated with the level of CLCA1, where the invention further comprises
CC the use of one or more therapies under conditions suitable for the
CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
CC nucleic acids of the invention are also used as diagnostic tools to
CC examine genetic drift and mutations within diseased cells or to detect
CC the presence of CLCA1 RNA in a cell. This sequence represents an
CC enzymatic nucleic acid molecule of the invention.
XX
SQ Sequence 17 BP; 5 A; 7 C; 3 G; 2 U; 0 other;
XX
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 660 GGTGGGGGACTTGGCC 675
Db 16 GGTGGGTGATTGGCC 1
RESULT 529
ABK56620/c
ID ABK56620 standard; RNA; 17 BP.
XX
AC ABK56620;
XX
DT 02-JUL-2002 (first entry)
XX
DE Human CLCA1 gene enzymatic nucleic acid #991.
XX
KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
KW acetylcysteine.
XX
OS Homo sapiens.
XX WO200211674-A2.
XX
```

XX PD 14-FEB-2002.
XX XX
XX PF 09-AUG-2001; 2001WO-US24970.
XX XX
XX PR 09-AUG-2000; 2000US-224383P.
XX XX
XX PR 09-AUG-2000; 2000US-224383P.
XX XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (SYNT) SYNTAX USA LLC.
XX PA (THOM/) THOMPSON J.
XX XX
XX PI Thompson J, McSwiggen J, McKenzie T, Ayers D, Szymkowski DE;
XX PI Grupe A;
XX XX
XX DR WPI; 2002-217145/27.
XX XX
XX PT Enzymatic polynucleotide that down regulates expression of chloride
XX PT channel calcium activated gene, useful for treating Chronic obstructive
XX PT pulmonary disease (COPD), chronic bronchitis and asthma -
XX PS Claim 4; Page 76; 152pp; English.
XX CC The invention relates to enzymatic nucleic acid molecules that down
XX CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
XX CC by cleaving RNA derived from the genes. The nucleic acid sequences are
XX CC useful as pharmaceutical agents for treating conditions such as chronic
XX CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
XX CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
XX CC that are related to or will respond to the levels of CLCA1 in a cell or
XX CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
XX CC hence, are useful for treatment of a patient having a condition
XX CC associated with the level of CLCA1, where the invention further comprises
XX CC the use of one or more therapies under conditions suitable for the
XX CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
XX CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
XX CC nucleic acids of the invention are also used as diagnostic tools to
XX CC examine genetic drift and mutations within diseased cells or to detect
XX CC the presence of CLCA1 RNA in a cell. This sequence represents an
XX CC enzymatic nucleic acid molecule of the invention.
XX SQ Sequence 17 BP; 7 A; 4 C; 3 G; 3 U; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.7e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1149 TTCCTTTTGGAGTAA 1164
XX DB |||||
XX 17 TTCGTTTGGAGTCA 2
XX
XX RESULT 530
XX ABK56621/c
XX ID ABK56621 standard; RNA; 17 BP.
XX XX
XX AC ABK56621;
XX XX
XX DT 02-JUL-2002 (first entry)
XX XX
XX DE Human CLCA1 gene enzymatic nucleic acid #992.
XX XX
XX KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
XX KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
XX KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
XX KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
XX KW acetylcysteine.
XX OS Homo sapiens.
XX XX
XX PN WO200211674-A2.
XX XX
XX PD 14-FEB-2002.
XX XX

PF 09-AUG-2001; 2001WO-US24970.
XX XX
XX PR 09-AUG-2000; 2000US-224383P.
XX XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PA (SYNT) SYNTAX USA LLC.
XX PA (THOM/) THOMPSON J.
XX XX
XX PI Thompson J, McSwiggen J, McKenzie T, Ayers D, Szymkowski DE;
XX PI Grupe A;
XX XX
XX DR WPI; 2002-217145/27.
XX XX
XX PT Enzymatic polynucleotide that down regulates expression of chloride
XX PT channel calcium activated gene, useful for treating Chronic obstructive
XX PT pulmonary disease (COPD), chronic bronchitis and asthma -
XX PS Claim 4; Page 76; 152pp; English.
XX CC The invention relates to enzymatic nucleic acid molecules that down
XX CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
XX CC by cleaving RNA derived from the genes. The nucleic acid sequences are
XX CC useful as pharmaceutical agents for treating conditions such as chronic
XX CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
XX CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
XX CC that are related to or will respond to the levels of CLCA1 in a cell or
XX CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
XX CC hence, are useful for treatment of a patient having a condition
XX CC associated with the level of CLCA1, where the invention further comprises
XX CC the use of one or more therapies under conditions suitable for the
XX CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
XX CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
XX CC nucleic acids of the invention are also used as diagnostic tools to
XX CC examine genetic drift and mutations within diseased cells or to detect
XX CC the presence of CLCA1 RNA in a cell. This sequence represents an
XX CC enzymatic nucleic acid molecule of the invention.
XX SQ Sequence 17 BP; 7 A; 5 C; 2 G; 3 U; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
XX Best Local Similarity 87.5%; Pred. No. 2.7e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1149 TTCCTTTTGGAGTAA 1164
XX DB |||||
XX 16 TTCGTTTGGAGTCA 1
XX
XX RESULT 531
XX ABK57130
XX ID ABK57130 standard; RNA; 17 BP.
XX XX
XX AC ABK57130;
XX XX
XX DT 02-JUL-2002 (first entry)
XX XX
XX DE Human CLCA1 gene enzymatic nucleic acid #1501.
XX XX
XX KW Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
XX KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
XX KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
XX KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
XX KW acetylcysteine.
XX OS Homo sapiens.
XX XX
XX PN WO200211674-A2.
XX XX
XX PD 14-FEB-2002.
XX XX
XX PF 09-AUG-2001; 2001WO-US24970.
XX XX
XX PR 09-AUG-2000; 2000US-224383P.
XX XX

XX (RIBO-) RIBOZYME PHARM INC.
 PA (SYNT) SYNTAX USA LLC.
 PA (THOM/) THOMPSON J.
 XX Thompson J, McSwiggen J, McKenzie T, Ayers D, Szymkowski DE;
 PI Grupe A;
 XX WPI; 2002-217145/27.
 XX Enzymatic polynucleotide that down regulates expression of chloride
 PT channel calcium activated gene, useful for treating Chronic obstructive
 PT pulmonary disease (COPD), chronic bronchitis and asthma
 XX Claim 4; Page 96; 152pp; English.
 XX The invention relates to enzymatic nucleic acid molecules that down
 CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
 CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of CLCA1 in a cell or
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
 CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of CLCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of CLCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention.
 XX Sequence 17 BP; 4 A; 3 C; 6 G; 4 U; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 2.7e+02;
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
 QY 3 GCAGGCAGTTGAGGTG 18
 DB |||||:::|:
 2 GCAGACAGUUGAGCUG 17
 RESULT 532
 ABK57404/C
 ID ABK57404 standard; RNA; 17 BP.
 XX AC ABK57404;
 XX DT 02-JUL-2002 (first entry)
 XX Human CLCA1 gene enzymatic nucleic acid #1775.
 XX Human; chloride channel calcium activated 1; CLCA1; ss; antiasthmatic;
 KW antiinflammatory; chronic obstructive pulmonary disease; COPD; asthma;
 KW chronic bronchitis; cystic fibrosis; obstructive bowel syndrome;
 KW oxygen therapy; bronchodilator; corticosteroid; vaccination; mucokinetic;
 KW acetylcysteine.
 XX Homo sapiens.
 OS WO200211674-A2.
 PN 14-FEB-2002.
 XX 09-AUG-2001; 2001WO-US24970.
 XX 09-AUG-2000; 2000US-224383P.
 XX (RIBO-) RIBOZYME PHARM INC.
 PA (SYNT) SYNTAX USA LLC.

PA (THOM/) THOMPSON J.
 XX Thompson J, McSwiggen J, McKenzie T, Ayers D, Szymkowski DE;
 PI Grupe A;
 XX WPI; 2002-217145/27.
 XX Enzymatic polynucleotide that down regulates expression of chloride
 PT channel calcium activated gene, useful for treating Chronic obstructive
 PT pulmonary disease (COPD), chronic bronchitis and asthma
 XX Claim 4; Page 112; 152pp; English.
 XX The invention relates to enzymatic nucleic acid molecules that down
 CC regulate expression of chloride channel calcium activated 1 (CLCA1) genes
 CC by cleaving RNA derived from the genes. The nucleic acid sequences are
 CC useful as pharmaceutical agents for treating conditions such as chronic
 CC obstructive pulmonary disease (COPD), chronic bronchitis, asthma, cystic
 CC fibrosis, obstructive bowel syndrome and any other diseases or conditions
 CC that are related to or will respond to the levels of CLCA1 in a cell or
 CC tissue. The sequences are useful for reducing CLCA1 activity in a cell,
 CC hence, are useful for treatment of a patient having a condition
 CC associated with the level of CLCA1, where the invention further comprises
 CC the use of one or more therapies under conditions suitable for the
 CC treatment, for example, oxygen therapy, bronchodilators, corticosteroids,
 CC antibacterials, vaccinations, acetylcysteine and mucokinetic agents. The
 CC nucleic acids of the invention are also used as diagnostic tools to
 CC examine genetic drift and mutations within diseased cells or to detect
 CC the presence of CLCA1 RNA in a cell. This sequence represents an
 CC enzymatic nucleic acid molecule of the invention.
 XX Sequence 17 BP; 8 A; 5 C; 2 G; 2 U; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1146 TTTTCTTTTGGGAG 1161
 DB |||||:::|:
 16 TTGTCGTTTGGAG 1
 RESULT 533
 ABN01790/C
 ID ABN01790 standard; DNA; 17 BP.
 XX AC ABN01790;
 XX DT 29-MAY-2002 (first entry)
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1782.
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 OS WO200192524-A2.
 PN 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US16981.
 XX 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.

```
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX Disclosure; SEQ ID 1782; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX Sequence 17 BP; 5 A; 6 C; 5 G; 1 T; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 547 CTGCTGGCAGGCTGC 562
DB 17 CTGCTGGCAGGCTGC 2
RESULT 534
ABN01792/c
ID ABN01792 standard; DNA; 17 BP.
XX ABN01792;
AC ABN01792;
XX 29-MAY-2002 (first entry)
DE Human GDMLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1784.
XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX Homo sapiens.
OS
XX WO200192524-A2.
XX
```

```
PD 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US16981.
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 05-FEB-2001; 2001US-266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMLP-1 -
XX Disclosure; SEQ ID 1784; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX Sequence 17 BP; 5 A; 6 C; 5 G; 1 T; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 546 CCTGCTGGCAGGCTGC 561
DB 16 CCTGCTGGCAGGCTGC 1
RESULT 535
ABN01897
ID ABN01897 standard; DNA; 17 BP.
XX ABN01897;
AC ABN01897;
```

XX DT 29-MAY-2002 (first entry)

XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1889.

XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;

XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

XX KW skeletal muscle disorder; amplicon; screening; ss.

XX OS Homo sapiens.

XX PN WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US16981.

XX PR 26-MAY-2000; 2000US-207456P.

XX PR 21-SEP-2000; 2000US-234687P.

XX PR 27-SEP-2000; 2000US-236359P.

XX PR 04-OCT-2000; 2000GB-0024263.

XX PR 30-JAN-2001; 2001WO-US00661.

XX PR 30-JAN-2001; 2001WO-US00662.

XX PR 30-JAN-2001; 2001WO-US00663.

XX PR 30-JAN-2001; 2001WO-US00664.

XX PR 30-JAN-2001; 2001WO-US00665.

XX PR 30-JAN-2001; 2001WO-US00666.

XX PR 30-JAN-2001; 2001WO-US00667.

XX PR 30-JAN-2001; 2001WO-US00668.

XX PR 30-JAN-2001; 2001WO-US00669.

XX PR 05-FEB-2001; 2001US-266860P.

XX PA (AEOM-) AEOMICA INC.

XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;

XX PI WPI; 2002-179446/23.

XX DR New polypeptide, for raising antibodies that recognize hGDMPLP-1

XX PT proteins, or as specific biomolecule capture probes for

XX PT surface-enhanced laser desorption/ionization, comprises human

XX PT myosin-like protein hGDMPLP-1 -

XX PS Disclosure; SEQ ID 1889; 214pp; English.

XX CC The present invention describes a human genome-derived myosin-like

XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of

XX CC hGDMPLP-1 can be used in gene therapy and vaccine production. The

XX CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise

XX CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification

XX CC substrates, to provide initial substrates for the recombinant engineering

XX CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and

XX CC biomolecule capture probes for surface-enhanced laser desorption

XX CC ionisation, as therapeutic supplement in patients having specific

XX CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement

XX CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for

XX CC diagnosing a disorder associated with the expression of hGDMPLP-1, in

XX CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to

XX CC chromosome 22. The present sequence represents an oligomer used in the

XX CC screening of the hGDMPLP-1 sequence in the exemplification of the present

XX CC invention.

XX CC N.B. The sequence data for this patent did not form part of the printed

XX CC specification, but was obtained in electronic format directly from WIPO

XX CC at ftp.wipo.int/pub/published_pct_sequence.

XX SQ Sequence 17 BP; 3 A; 5 C; 7 G; 2 T; 0 other;

XX Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 660 GGTGGGACTTGCC 675

Db 2 GGTGGGACTTGCC 17

RESULT 536

ABN01898

ID ABN01898 standard; DNA; 17 BP.

XX AC ABN01898;

XX DT 29-MAY-2002 (first entry)

XX DE Human GDMPLP-1 17-mer scanning SEQ ID NO:4 sequence SEQ ID NO:1890.

XX KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;

XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

XX KW skeletal muscle disorder; amplicon; screening; ss.

XX OS Homo sapiens.

XX PN WO200192524-A2.

XX PD 06-DEC-2001.

XX PF 25-MAY-2001; 2001WO-US16981.

XX PR 26-MAY-2000; 2000US-207456P.

XX PR 21-SEP-2000; 2000US-234687P.

XX PR 27-SEP-2000; 2000US-236359P.

XX PR 04-OCT-2000; 2000GB-0024263.

XX PR 30-JAN-2001; 2001WO-US00661.

XX PR 30-JAN-2001; 2001WO-US00662.

XX PR 30-JAN-2001; 2001WO-US00663.

XX PR 30-JAN-2001; 2001WO-US00664.

XX PR 30-JAN-2001; 2001WO-US00665.

XX PR 30-JAN-2001; 2001WO-US00666.

XX PR 30-JAN-2001; 2001WO-US00667.

XX PR 30-JAN-2001; 2001WO-US00668.

XX PR 30-JAN-2001; 2001WO-US00669.

XX PR 05-FEB-2001; 2001US-266860P.

XX PA (AEOM-) AEOMICA INC.

XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;

XX PI WPI; 2002-179446/23.

XX DR New polypeptide, for raising antibodies that recognize hGDMPLP-1

XX PT proteins, or as specific biomolecule capture probes for

XX PT surface-enhanced laser desorption/ionization, comprises human

XX PT myosin-like protein hGDMPLP-1 -

XX PS Disclosure; SEQ ID 1890; 214pp; English.

XX CC The present invention describes a human genome-derived myosin-like

XX CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of

XX CC hGDMPLP-1 can be used in gene therapy and vaccine production. The

XX CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise

XX CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification

XX CC substrates, to provide initial substrates for the recombinant engineering

XX CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and

XX CC biomolecule capture probes for surface-enhanced laser desorption

XX CC ionisation, as therapeutic supplement in patients having specific

XX CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement

XX CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for

XX CC diagnosing a disorder associated with the expression of hGDMPLP-1, in

XX CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to

XX CC chromosome 22. The present sequence represents an oligomer used in the

XX CC screening of the hGDMPLP-1 sequence in the exemplification of the present

XX CC invention.

XX CC N.B. The sequence data for this patent did not form part of the printed

XX CC specification, but was obtained in electronic format directly from WIPO

XX CC at ftp.wipo.int/pub/published_pct_sequence.

XX SQ Sequence 17 BP; 3 A; 5 C; 7 G; 2 T; 0 other;

XX Query Match 0.9%; Score 12.8; DB 1; Length 17;

CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMPLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 660 GGTGGGACCTGGCC 675

Db 1 GGTGGGACCTGGCC 16

RESULT 537

ABN06164
ID ABN06164 standard; DNA; 17 BP.

AC ABN06164;

XX 29-MAY-2002 (first entry)

XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6156.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US16981.

XX 26-MAY-2000; 2000US-207456P.

XX 21-SEP-2000; 2000US-234687P.

XX 27-SEP-2000; 2000US-236359P.

XX 04-OCT-2000; 2000GB-0024263.

XX 30-JAN-2001; 2001WO-US00661.

XX 30-JAN-2001; 2001WO-US00662.

XX 30-JAN-2001; 2001WO-US00663.

XX 30-JAN-2001; 2001WO-US00664.

XX 30-JAN-2001; 2001WO-US00665.

XX 30-JAN-2001; 2001WO-US00666.

XX 30-JAN-2001; 2001WO-US00667.

XX 30-JAN-2001; 2001WO-US00668.

XX 30-JAN-2001; 2001WO-US00669.

XX 30-JAN-2001; 2001WO-US00670.

XX 05-FEB-2001; 2001US-266860P.

XX (AEOM-) AEOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;

XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMPLP-1
XX proteins, or as specific biomolecule capture probes for
XX surface-enhanced laser desorption/ionization, comprises human
XX myosin-like protein hGDMPLP-1 -

XX Disclosure; SEQ ID 6156; 214pp; English.

XX The present invention describes a human genome-derived myosin-like

CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMPLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMPLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMPLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 3 A; 6 C; 6 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 255 CGACCTCTGGGCTGG 270

Db 2 CGACCTCAGGGCTGG 17

RESULT 538

ABN06167

ID ABN06167 standard; DNA; 17 BP.

AC ABN06167;

XX 29-MAY-2002 (first entry)

XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6159.

XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US16981.

XX 26-MAY-2000; 2000US-207456P.

XX 21-SEP-2000; 2000US-234687P.

XX 27-SEP-2000; 2000US-236359P.

XX 04-OCT-2000; 2000GB-0024263.

XX 30-JAN-2001; 2001WO-US00661.

XX 30-JAN-2001; 2001WO-US00662.

XX 30-JAN-2001; 2001WO-US00663.

XX 30-JAN-2001; 2001WO-US00664.

XX 30-JAN-2001; 2001WO-US00665.

XX 30-JAN-2001; 2001WO-US00666.

XX 30-JAN-2001; 2001WO-US00667.

XX 30-JAN-2001; 2001WO-US00668.

XX 30-JAN-2001; 2001WO-US00669.

XX 30-JAN-2001; 2001WO-US00670.

XX 05-FEB-2001; 2001US-266860P.

XX (AEOM-) AEOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMPLP-1 -
 XX Disclosure; SEQ ID 6159; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
 CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMPLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMPLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMPLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. NO. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 257 ACCTCTGGGCTGGCT 272
 Db 1 ACCTCAGGGCTGGCT 16
 RESULT 539
 ID AEN06274 standard; DNA; 17 BP.
 XX AEN06274;
 XX 29-MAY-2002 (first entry)
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6266.
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 XX WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US16981.
 XX 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.

PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 05-FEB-2001; 2001WO-266860P.
 XX (AEN06274) AEN06274 INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMPLP-1 -
 XX Disclosure; SEQ ID 6266; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
 CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMPLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMPLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMPLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX Sequence 17 BP; 2 A; 8 C; 5 G; 2 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. NO. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 371 GGCCCGAGCTTCCTCC 386
 Db 2 GGCCCGAGCTTCCTCC 17
 RESULT 540
 ID AEN06275 standard; DNA; 17 BP.
 XX AEN06275;
 XX 29-MAY-2002 (first entry)
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6267.
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.

XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US16981.
XX PR 26-MAY-2000; 2000US-207456P.
XX PR 21-SEP-2000; 2000US-234687P.
XX PR 27-SEP-2000; 2000US-236359P.
XX PR 04-OCT-2000; 2000GB-0024263.
XX PR 30-JAN-2001; 2001WO-US00661.
XX PR 30-JAN-2001; 2001WO-US00662.
XX PR 30-JAN-2001; 2001WO-US00663.
XX PR 30-JAN-2001; 2001WO-US00664.
XX PR 30-JAN-2001; 2001WO-US00665.
XX PR 30-JAN-2001; 2001WO-US00666.
XX PR 30-JAN-2001; 2001WO-US00667.
XX PR 30-JAN-2001; 2001WO-US00668.
XX PR 30-JAN-2001; 2001WO-US00669.
XX PR 05-FEB-2001; 2001US-266860P.
XX PA (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
XX WPI; 2002-179446/23.
XX DR New polypeptide, for raising antibodies that recognize hGDMLP-1
XX PT proteins, or as specific biomolecule capture probes for
XX PT surface-enhanced laser desorption/ionization, comprises human
XX PT myosin-like protein hGDMLP-1 -
XX PS Disclosure; SEQ ID 6267; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX CC hGDMLP-1 can be used in gene therapy and vaccine production. The
XX CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX CC substrates, to provide initial substrates for the recombinant engineering
XX CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
XX CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
XX CC be used as immunogens to raise antibodies that specifically recognise
XX CC hGDMLP-1 proteins, as standards in assays used to determine the
XX CC concentration and/or amount specifically of hGDMLP proteins, as specific
XX CC biomolecule capture probes for surface-enhanced laser desorption
XX CC ionisation, as therapeutic supplement in patients having specific
XX CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
XX CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
XX CC diagnosing a disorder associated with the expression of hGDMLP-1, in
XX CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
XX CC chromosome 22. The present sequence represents an oligomer used in the
XX CC screening of the hGDMLP-1 sequence in the exemplification of the present
XX CC invention.
XX CC N.B. The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence.
XX SQ Sequence 17 BP; 2 A; 7 C; 5 G; 3 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e-02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 371 GGGCCAGCTTCCTCC 386
||||| ||||| |||||
Db 1 GGGCCAGCTTCCTCC 16

RESULT 541
ABN06515
ID ABN06515 standard; DNA; 17 BP.
XX AC ABN06515;
XX DT 29-MAY-2002 (first entry)
XX DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6507.
XX KW Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
XX KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX KW skeletal muscle disorder; amplicon; screening; ss.
XX OS Homo sapiens.
XX PN WO200192524-A2.
XX PD 06-DEC-2001.
XX PF 25-MAY-2001; 2001WO-US16981.
XX PR 26-MAY-2000; 2000US-207456P.
XX PR 21-SEP-2000; 2000US-234687P.
XX PR 27-SEP-2000; 2000US-236359P.
XX PR 04-OCT-2000; 2000GB-0024263.
XX PR 30-JAN-2001; 2001WO-US00661.
XX PR 30-JAN-2001; 2001WO-US00662.
XX PR 30-JAN-2001; 2001WO-US00663.
XX PR 30-JAN-2001; 2001WO-US00664.
XX PR 30-JAN-2001; 2001WO-US00665.
XX PR 30-JAN-2001; 2001WO-US00666.
XX PR 30-JAN-2001; 2001WO-US00667.
XX PR 30-JAN-2001; 2001WO-US00668.
XX PR 30-JAN-2001; 2001WO-US00669.
XX PR 05-FEB-2001; 2001US-266860P.
XX PA (AEOM-) AEOMICA INC.
XX PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon MB;
XX WPI; 2002-179446/23.
XX DR New polypeptide, for raising antibodies that recognize hGDMLP-1
XX PT proteins, or as specific biomolecule capture probes for
XX PT surface-enhanced laser desorption/ionization, comprises human
XX PT myosin-like protein hGDMLP-1 -
XX PS Disclosure; SEQ ID 6507; 214pp; English.
XX CC The present invention describes a human genome-derived myosin-like
XX CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
XX CC hGDMLP-1 can be used in gene therapy and vaccine production. The
XX CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
XX CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
XX CC substrates, to provide initial substrates for the recombinant engineering
XX CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
XX CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
XX CC be used as immunogens to raise antibodies that specifically recognise
XX CC hGDMLP-1 proteins, as standards in assays used to determine the
XX CC concentration and/or amount specifically of hGDMLP proteins, as specific
XX CC biomolecule capture probes for surface-enhanced laser desorption
XX CC ionisation, as therapeutic supplement in patients having specific
XX CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
XX CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
XX CC diagnosing a disorder associated with the expression of hGDMLP-1, in
XX CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
XX CC chromosome 22. The present sequence represents an oligomer used in the
XX CC screening of the hGDMLP-1 sequence in the exemplification of the present
XX CC invention.
XX CC N.B. The sequence data for this patent did not form part of the printed
XX CC specification, but was obtained in electronic format directly from WIPO
XX CC at ftp.wipo.int/pub/published_pct_sequence.

CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 5 A; 6 C; 4 G; 2 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 775 GTAGCAATCTCCACCA 790
Db 2 GCAGGAATCTCCACCA 17
RESULT 542
ABN06516
ID ABN06516 standard; DNA; 17 BP.
XX
AC ABN06516;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:6508.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
XX
PR 21-SEP-2000; 2000US-234687P.
XX
PR 27-SEP-2000; 2000US-236353P.
XX
PR 04-OCT-2000; 2000GB-0024283.
XX
PR 30-JAN-2001; 2001WO-US00661.
XX
PR 30-JAN-2001; 2001WO-US00662.
XX
PR 30-JAN-2001; 2001WO-US00663.
XX
PR 30-JAN-2001; 2001WO-US00664.
XX
PR 30-JAN-2001; 2001WO-US00665.
XX
PR 30-JAN-2001; 2001WO-US00666.
XX
PR 30-JAN-2001; 2001WO-US00667.
XX
PR 30-JAN-2001; 2001WO-US00668.
XX
PR 30-JAN-2001; 2001WO-US00669.
XX
PR 05-FEB-2001; 2001US-266860P.
XX
FA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMPLP-1.
XX
PS Disclosure; SEQ ID 6508; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise

CC hGDMPLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMPLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMPLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 5 A; 7 C; 3 G; 2 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 775 GTAGCAATCTCCACCA 790
Db 1 GCAGGAATCTCCACCA 16
RESULT 543
ABN08389/C
ID ABN08389 standard; DNA; 17 BP.
XX
AC ABN08389;
XX
DT 29-MAY-2002 (first entry)
XX
DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8381.
XX
KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
PN WO200192524-A2.
XX
PD 06-DEC-2001.
XX
PF 25-MAY-2001; 2001WO-US16981.
XX
PR 26-MAY-2000; 2000US-207456P.
XX
PR 21-SEP-2000; 2000US-234687P.
XX
PR 27-SEP-2000; 2000US-236353P.
XX
PR 04-OCT-2000; 2000GB-0024283.
XX
PR 30-JAN-2001; 2001WO-US00661.
XX
PR 30-JAN-2001; 2001WO-US00662.
XX
PR 30-JAN-2001; 2001WO-US00663.
XX
PR 30-JAN-2001; 2001WO-US00664.
XX
PR 30-JAN-2001; 2001WO-US00665.
XX
PR 30-JAN-2001; 2001WO-US00666.
XX
PR 30-JAN-2001; 2001WO-US00667.
XX
PR 30-JAN-2001; 2001WO-US00668.
XX
PR 30-JAN-2001; 2001WO-US00669.
XX
PR 05-FEB-2001; 2001US-266860P.
XX
FA (AEOM-) AEOMICA INC.
XX
PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX
DR WPI; 2002-179446/23.
XX
PT New polypeptide, for raising antibodies that recognize hGDMPLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMPLP-1.
XX
PS Disclosure; SEQ ID 6508; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise

PT myosin-like protein hGDMPLP-1 -
XX Disclosure; SEQ ID 8381; 214pp; English.
XX
CC The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMPLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMPLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMPLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 5 A; 4 C; 7 G; 1 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 566 CACTGCTCCAGCAGC 581
Db 17 CTCTGCTCCAGCTGCG 2
RESULT 544
ABN08392/c
ID ABN08392 standard; DNA; 17 BP.
XX AC ABN08392;
XX
XX
DT 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:8384.
DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US16981.
XX
XX 26-MAY-2000; 2000US-207456P.
XX
XX 21-SEP-2000; 2000US-234687P.
XX
XX 27-SEP-2000; 2000US-236359P.
XX
XX 04-OCT-2000; 2000GB-0024263.
XX
XX 30-JAN-2001; 2001WO-US00661.
XX
XX 30-JAN-2001; 2001WO-US00662.
XX
XX 30-JAN-2001; 2001WO-US00663.
XX
XX 30-JAN-2001; 2001WO-US00664.
XX
XX 30-JAN-2001; 2001WO-US00665.
XX
XX 30-JAN-2001; 2001WO-US00666.
XX
XX 30-JAN-2001; 2001WO-US00667.
XX
XX 30-JAN-2001; 2001WO-US00668.
XX
XX 30-JAN-2001; 2001WO-US00669.
XX
XX 30-JAN-2001; 2001WO-US00670.
XX
XX 05-FEB-2001; 2001US-266860P.
XX
XX (ABOM-) ABOMICA INC.
XX
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1
XX proteins, or as specific biomolecule capture probes for
XX surface-enhanced laser desorption ionization, comprises human
XX myosin-like protein hGDMPLP-1 -
XX Disclosure; SEQ ID 8384; 214pp; English.
XX
XX The present invention describes a human genome-derived myosin-like
XX protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
XX hGDMPLP-1 can be used in gene therapy and vaccine production. The
XX hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
XX and quantify hGDMPLP-1 nucleic acids in samples, as amplification
XX substrates, to provide initial substrates for the recombinant engineering
XX of hGDMPLP-1 protein variants having desired phenotypic improvements, and
XX for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
XX be used as immunogens to raise antibodies that specifically recognise
XX hGDMPLP-1 proteins, as standards in assays used to determine the
XX concentration and/or amount specifically of hGDMPLP proteins, as specific
XX biomolecule capture probes for surface-enhanced laser desorption
XX ionisation, as therapeutic supplement in patients having specific
XX deficiency in hGDMPLP-1 production, and in vaccines or for replacement
XX therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
XX diagnosing a disorder associated with the expression of hGDMPLP-1, in
XX particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
XX chromosome 22. The present sequence represents an oligomer used in the
XX screening of the hGDMPLP-1 sequence in the exemplification of the present
XX invention.
XX N.B. The sequence data for this patent did not form part of the printed
XX specification, but was obtained in electronic format directly from WIPO
XX at ftp.wipo.int/pub/published_pct_sequence.
XX
SQ Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 564 CACACTGCTCCAGCAGC 579
Db 16 CACTCTGCTCCAGCTG 1
RESULT 545
ABN09587/c
ID ABN09587 standard; DNA; 17 BP.
XX AC ABN09587;
XX
XX 29-MAY-2002 (first entry)
XX
XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9579.
DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
KW skeletal muscle disorder; amplicon; screening; ss.
XX
OS Homo sapiens.
XX
XX WO200192524-A2.
XX
XX 06-DEC-2001.
XX
XX 25-MAY-2001; 2001WO-US16981.
XX

XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 05-FEB-2001; 2001US-266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMPLP-1 -
XX Disclosure; SEQ ID 9579; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMPLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMPLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMPLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1041 CTCCTCCACGACG 1056
Db 17 CTTTCCCTCGACG 2
RESULT 546
ABN09588/c
ID ABN09588 standard; DNA; 17 BP.
XX AC ABN09588;
XX 29-MAY-2002 (first entry)
XX

DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:9580.
XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
XX skeletal muscle disorder; amplicon; screening; ss.
OS Homo sapiens.
XX W0200192524-A2.
XX 06-DEC-2001.
XX 25-MAY-2001; 2001WO-US16981.
XX 26-MAY-2000; 2000US-207456P.
PR 21-SEP-2000; 2000US-234687P.
PR 27-SEP-2000; 2000US-236359P.
PR 04-OCT-2000; 2000GB-0024263.
PR 30-JAN-2001; 2001WO-US00661.
PR 30-JAN-2001; 2001WO-US00662.
PR 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 05-FEB-2001; 2001US-266860P.
XX (AEOM-) AEOMICA INC.
XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
XX WPI; 2002-179446/23.
XX New polypeptide, for raising antibodies that recognize hGDMPLP-1
PT proteins, or as specific biomolecule capture probes for
PT surface-enhanced laser desorption/ionization, comprises human
PT myosin-like protein hGDMPLP-1 -
XX Disclosure; SEQ ID 9580; 214pp; English.
XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMPLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMPLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMPLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.
XX Sequence 17 BP; 5 A; 3 C; 7 G; 2 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1041 CTCCTCCACGACG 1056
Db 17 CTTTCCCTCGACG 2
RESULT 546
ABN09588/c
ID ABN09588 standard; DNA; 17 BP.
XX AC ABN09588;
XX 29-MAY-2002 (first entry)
XX

QY 1041 CTCTCCACGACG 1056
 Db 16 CTTTCCCTCGACG 1

RESULT 547
 ABN10235
 ID ABN10235 standard; DNA; 17 BP.
 XX
 AC ABN10235;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10227.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US16981.
 XX
 PR 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 05-FEB-2001; 2001US-266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX
 DR WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMPLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMPLP-1 -
 XX
 PS Disclosure; SEQ ID 10227; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
 CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMPLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMPLP-1 proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to

CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMPLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX
 SQ Sequence 17 BP; 2 A; 8 C; 2 G; 5 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 253 ACCGACCTCTGGGCT 268
 Db 2 ACCTACCTCTGGGCT 17
 RESULT 548
 ABN10238
 ID ABN10238 standard; DNA; 17 BP.
 XX
 AC ABN10238;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10230.
 XX
 KW Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192524-A2.
 XX
 PD 06-DEC-2001.
 XX
 PF 25-MAY-2001; 2001WO-US16981.
 XX
 PR 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 05-FEB-2001; 2001US-266860P.
 XX
 PA (AEOM-) AEOMICA INC.
 XX
 PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX
 DR WPI; 2002-179446/23.
 XX
 PT New polypeptide, for raising antibodies that recognize hGDMPLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMPLP-1 -
 XX
 PS Disclosure; SEQ ID 10230; 214pp; English.
 XX
 CC The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
 CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMPLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMPLP-1 proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to

CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.

XX Sequence 17 BP; 2 A; 6 C; 4 G; 5 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 255 CGACTCTCTGGCTGG 270

Db 1 CTACTCTCTGGCTGG 16

RESULT 549

ABN10239

ID ABN10239 standard; DNA; 17 BP.

AC ABN10239;

DT 29-MAY-2002 (first entry)

DE Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10231.

XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.

OS Homo sapiens.

XX WO200192524-A2.

FN 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US16981.

XX 26-MAY-2000; 2000US-207456P.

PR 21-SEP-2000; 2000US-234687P.

PR 27-SEP-2000; 2000US-236359P.

PR 04-OCT-2000; 2000GB-0024263.

PR 30-JAN-2001; 2001WO-US00661.

PR 30-JAN-2001; 2001WO-US00662.

PR 30-JAN-2001; 2001WO-US00663.

PR 30-JAN-2001; 2001WO-US00664.

PR 30-JAN-2001; 2001WO-US00665.

PR 30-JAN-2001; 2001WO-US00666.

PR 30-JAN-2001; 2001WO-US00667.

PR 30-JAN-2001; 2001WO-US00668.

PR 30-JAN-2001; 2001WO-US00669.

PR 05-FEB-2001; 2001WO-US00670.

DR WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption ionization, comprises human
 PT myosin-like protein hGDMLP-1 -

XX Disclosure; SEQ ID 10231; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
 CC hGDMLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMLP-1 sequence in the exemplification of the present
 CC invention.

CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.

XX Sequence 17 BP; 2 A; 5 C; 4 G; 6 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 257 ACCTCTCTGGCTGGCT 272

Db 2 ACCTCTCTGGCTGGAT 17

RESULT 550

ABN10240

ID ABN10240 standard; DNA; 17 BP.

AC ABN10240;

DT 29-MAY-2002 (first entry)

XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10232.

XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.

OS Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US16981.

XX 26-MAY-2000; 2000US-207456P.

PR 21-SEP-2000; 2000US-234687P.

PR 27-SEP-2000; 2000US-236359P.

PR 04-OCT-2000; 2000GB-0024263.

PR 30-JAN-2001; 2001WO-US00661.

PR 30-JAN-2001; 2001WO-US00662.

PR 30-JAN-2001; 2001WO-US00663.

PA (AEOM-) AEOMICA INC.

PI Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX

PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 05-FEB-2001; 2001US-266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 DR New polypeptide, for raising antibodies that recognize hGDMPLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMPLP-1 -
 XX Disclosure; SEQ ID 10232; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
 CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMPLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMPLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMPLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX Sequence 17 BP; 2 A; 6 C; 4 G; 5 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 257 ACCTCTGGGCTGGCT 272
 Db |||||
 1 ACCTCTGGCTGGAT 16
 RESULT 551
 ABN10735/c
 XX AC ABN10735 standard; DNA; 17 BP.
 XX AC ABN10735;
 XX 29-MAY-2002 (first entry)
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10727.
 XX Human; genome-derived myosin-like protein 1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 XX

PN WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US16981.
 XX 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 05-FEB-2001; 2001US-266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 XX WPI; 2002-179446/23.
 DR New polypeptide, for raising antibodies that recognize hGDMPLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMPLP-1 -
 XX Disclosure; SEQ ID 10727; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
 CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMPLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMPLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMPLP-1 may be used for
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMPLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX Sequence 17 BP; 1 A; 5 C; 8 G; 3 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 636 GGAGCTCTGCATCCCC 651
 Db |||||
 17 GGAGCCCCGATCCCC 2
 RESULT 552
 ABN10736/c
 ID ABN10736 standard; DNA; 17 BP.

XX ABN10736;
 XX 29-MAY-2002 (first entry)
 XX Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10728.
 DE Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 OS
 XX WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US16981.
 XX 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 30-JAN-2001; 2001WO-US00670.
 PR 05-FEB-2001; 2001US-266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMPLP-1 -
 XX Disclosure; SEQ ID 10728; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
 CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMPLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMPLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption
 CC ionisation, as therapeutic supplement in patients having specific
 CC deficiency in hGDMPLP-1 production, and in vaccines or for replacement
 CC therapy. The polynucleotide sequences encoding hGDMPLP-1, in
 CC diagnosing a disorder associated with the expression of hGDMPLP-1, in
 CC particular heart and skeletal muscle disorders. hGDMPLP-1 is localised to
 CC chromosome 22. The present sequence represents an oligomer used in the
 CC screening of the hGDMPLP-1 sequence in the exemplification of the present
 CC invention.
 CC N.B. The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pct_sequence.
 XX Sequence 17 BP; 1 A; 5 C; 8 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 636 GGAGCTCTGCATCCCC 651
 Db 16 GGAGCCCCAGCATCCCC 1
 ||||| |||||
 RESULT 553
 ABN10737/c
 ID ABN10737 standard; DNA; 17 BP.
 XX
 AC ABN10737;
 XX
 DT 29-MAY-2002 (first entry)
 XX
 DE Human GDMPLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10729.
 XX Human; genome-derived myosin-like protein 1; GDMPLP-1; hGDMPLP-1; heart;
 KW muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;
 KW skeletal muscle disorder; amplicon; screening; ss.
 XX Homo sapiens.
 OS
 XX WO200192524-A2.
 XX 06-DEC-2001.
 XX 25-MAY-2001; 2001WO-US16981.
 XX 26-MAY-2000; 2000US-207456P.
 PR 21-SEP-2000; 2000US-234687P.
 PR 27-SEP-2000; 2000US-236359P.
 PR 04-OCT-2000; 2000GB-0024263.
 PR 30-JAN-2001; 2001WO-US00661.
 PR 30-JAN-2001; 2001WO-US00662.
 PR 30-JAN-2001; 2001WO-US00663.
 PR 30-JAN-2001; 2001WO-US00664.
 PR 30-JAN-2001; 2001WO-US00665.
 PR 30-JAN-2001; 2001WO-US00666.
 PR 30-JAN-2001; 2001WO-US00667.
 PR 30-JAN-2001; 2001WO-US00668.
 PR 30-JAN-2001; 2001WO-US00669.
 PR 05-FEB-2001; 2001US-266860P.
 XX (AEOM-) AEOMICA INC.
 XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;
 PI WPI; 2002-179446/23.
 XX New polypeptide, for raising antibodies that recognize hGDMPLP-1
 PT proteins, or as specific biomolecule capture probes for
 PT surface-enhanced laser desorption/ionization, comprises human
 PT myosin-like protein hGDMPLP-1 -
 XX Disclosure; SEQ ID 10729; 214pp; English.
 XX The present invention describes a human genome-derived myosin-like
 CC protein 1 (hGDMPLP-1). The protein and polynucleotide sequences of
 CC hGDMPLP-1 can be used in gene therapy and vaccine production. The
 CC hGDMPLP-1 nucleic acids can be used as probes to detect, characterise
 CC and quantify hGDMPLP-1 nucleic acids in samples, as amplification
 CC substrates, to provide initial substrates for the recombinant engineering
 CC of hGDMPLP-1 protein variants having desired phenotypic improvements, and
 CC for expressing the proteins. The hGDMPLP-1 proteins or polypeptides may
 CC be used as immunogens to raise antibodies that specifically recognise
 CC hGDMPLP-1 proteins, as standards in assays used to determine the
 CC concentration and/or amount specifically of hGDMPLP proteins, as specific
 CC biomolecule capture probes for surface-enhanced laser desorption

CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.

SQ Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 368 TGGGGGCCCGAGCTTC 383

DB 17 TGGGAGCCCGAGCATCC 2

RESULT 554

ID ABN10738/c

AC ABN10738 standard; DNA; 17 BP.

XX ABN10738;

XX 29-MAY-2002 (first entry)

XX Human GDMLP-1 17-mer scanning SEQ ID NO:5 sequence SEQ ID NO:10730.

XX Human; genome-derived myosin-like protein 1; GDMLP-1; hGDMLP-1; heart;

XX muscle; myosin; chromosome 22; gene therapy; vaccine; heart disease;

XX skeletal muscle disorder; amplicon; screening; ss.

XX Homo sapiens.

XX WO200192524-A2.

XX 06-DEC-2001.

XX 25-MAY-2001; 2001WO-US16981.

XX 26-MAY-2000; 2000US-207456P.

XX 21-SEP-2000; 2000US-234687P.

XX 27-SEP-2000; 2000US-236359P.

XX 04-OCT-2000; 2000GB-0024263.

XX 30-JAN-2001; 2001WO-US00661.

XX 30-JAN-2001; 2001WO-US00662.

XX 30-JAN-2001; 2001WO-US00663.

XX 30-JAN-2001; 2001WO-US00664.

XX 30-JAN-2001; 2001WO-US00665.

XX 30-JAN-2001; 2001WO-US00666.

XX 30-JAN-2001; 2001WO-US00667.

XX 30-JAN-2001; 2001WO-US00668.

XX 30-JAN-2001; 2001WO-US00669.

XX 05-FEB-2001; 2001WO-US00670.

XX (AEOM-) AEOMICA INC.

XX Gu Y, Ji Y, Penn SG, Hanzel DK, Rank DR, Chen W, Shannon ME;

XX WPI; 2002-179446/23.

XX New polypeptide, for raising antibodies that recognize hGDMLP-1

XX proteins, or as specific biomolecule capture probes for

XX surface-enhanced laser desorption/ionization, comprises human

XX myosin-like protein hGDMLP-1 -

XX Disclosure; SEQ ID 10730; 214pp; English.

XX The present invention describes a human genome-derived myosin-like
CC protein 1 (hGDMLP-1). The protein and polynucleotide sequences of
CC hGDMLP-1 can be used in gene therapy and vaccine production. The
CC hGDMLP-1 nucleic acids can be used as probes to detect, characterise
CC and quantify hGDMLP-1 nucleic acids in samples, as amplification
CC substrates, to provide initial substrates for the recombinant engineering
CC of hGDMLP-1, protein variants having desired phenotypic improvements, and
CC for expressing the proteins. The hGDMLP-1 proteins or polypeptides may
CC be used as immunogens to raise antibodies that specifically recognise
CC hGDMLP-1 proteins, as standards in assays used to determine the
CC concentration and/or amount specifically of hGDMLP proteins, as specific
CC biomolecule capture probes for surface-enhanced laser desorption
CC ionisation, as therapeutic supplement in patients having specific
CC deficiency in hGDMLP-1 production, and in vaccines or for replacement
CC therapy. The polynucleotide sequences encoding hGDMLP-1 may be used for
CC diagnosing a disorder associated with the expression of hGDMLP-1, in
CC particular heart and skeletal muscle disorders. hGDMLP-1 is localised to
CC chromosome 22. The present sequence represents an oligomer used in the
CC screening of the hGDMLP-1 sequence in the exemplification of the present
CC invention.
CC N.B. The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pct_sequence.

SQ Sequence 17 BP; 2 A; 5 C; 7 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 368 TGGGGGCCCGAGCTTC 383

DB 16 TGGGAGCCCGAGCATCC 1

RESULT 555

ABK17830

ID ABK17830 standard; RNA; 17 BP.

XX ABK17830;

XX 09-APR-2002 (first entry)

XX Human ERG hammerhead ribozyme target sequence, Seq ID No 477.

XX Human, hammerhead ribozyme; cytostatic; antitumour; antidiabetic;

XX ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;

XX vulvar; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;

XX tumour angiogenesis; diabetic retinopathy; macular degeneration;

XX neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;

XX angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;

XX Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;

XX Osler-Weber-rendu syndrome, leukaemia; osteoporosis; incozyme;

XX Homo sapiens.

XX WO200188124-A2.

XX 22-NOV-2001.

XX 16-MAY-2001; 2001WO-US15866.

XX 16-MAY-2000; 2000US-0572021.

XX (RIBO-) RIBOZYME PHARM INC.

XX (GLAX) GLAXO GROUP LTD.

XX Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin F, Randi AM;

XX WPI; 2002-082995/11.

XX

XX WO2001188124-A2.
 XX 22-NOV-2001.
 XX 16-MAY-2001; 2001WO-US15866.
 XX 16-MAY-2000; 2000US-0572021.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (GLAX) GLAXO GROUP LTD.
 XX Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin F, Randi AM;
 XX WPI; 2002-082995/11.
 XX Novel polynucleotide which down regulates expression of Ets-related
 XX gene, useful for treating cancer, diabetic retinopathy, macular
 XX degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber
 XX syndrome -
 XX Claim 4; Page 77; 149pp; English.
 XX The invention relates to a nucleic acid molecule (I) which down regulates
 XX expression of an Ets-related gene (ERG). (I) is useful for treating
 XX conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 XX tumour angiogenesis, diabetic retinopathy, macular degeneration, verruca
 XX vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 XX Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 XX syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 XX treating a patient having a condition associated with the level of ERG,
 XX by contacting cells of the patient with (I) under conditions suitable for
 XX the treatment. The method comprises the use of one or more therapies
 XX under conditions suitable for the treatment. Leukaemia or tumour
 XX angiogenesis is treated by administering (I) to the patient in
 XX conjunction with one or more of other therapies such as radiation or
 XX chemotherapy treatment. (I) is useful for reducing ERG activity in a
 XX cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 XX ERG gene, by contacting (I) with RNA, in the presence of a divalent
 XX cation such as Mg2+. (I) is useful for diagnosis of conditions and
 XX diseases related to the expression of ERG, and as diagnostic tool to
 XX examine genetic drift and mutations within diseased cells or to detect
 XX the presence of ERG RNA in a cell. (I) is useful for specifically
 XX targeting genes that share homology with ERG gene or ERG fusion genes.
 XX ABK17354-ABK22719 represent nucleic acids, including antisense and
 XX enzymatic nucleic acid molecules which regulate expression of ERG, and
 XX related PCR primers of the invention.
 XX Sequence 17 BP; 5 A; 5 C; 4 G; 3 U; 0 other;
 XX
 XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
 XX Best Local Similarity 75.0%; Pred. No. 2.7e+02;
 XX Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 714 TGTGGCCGACGACGACG 729
 XX :|||
 XX Db 1 UGUGGCCCAUCACACAG 16
 XX
 XX RESULT 558
 XX ABK18805/C
 XX ID ABK18805 standard; RNA; 17 BP.
 XX AC ABK18805;
 XX XX
 XX 09-APR-2002 (first entry)
 XX
 XX Human ERG DNazyme target sequence Seq ID No 1452.
 XX
 XX Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;
 XX ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;
 XX vulnery; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;

KW tumour angiogenesis; diabetic retinopathy; macular degeneration;
 KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;
 KW angiofibroma of tuberous sclerosis; port-wine stain; wound healing;
 KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;
 KW Osler-Weber-rendu syndrome, leukaemia; osteoporosis; DNazyme; inozyme;
 KW amberzyme.
 XX Homo sapiens.
 XX WO2001188124-A2.
 XX 22-NOV-2001.
 XX 16-MAY-2001; 2001WO-US15866.
 XX 16-MAY-2000; 2000US-0572021.
 XX (RIBO-) RIBOZYME PHARM INC.
 XX (GLAX) GLAXO GROUP LTD.
 XX Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin F, Randi AM;
 XX WPI; 2002-082995/11.
 XX Novel polynucleotide which down regulates expression of Ets-related
 XX gene, useful for treating cancer, diabetic retinopathy, macular
 XX degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber
 XX syndrome -
 XX Claim 4; Page 92; 149pp; English.
 XX The invention relates to a nucleic acid molecule (I) which down regulates
 XX expression of an Ets-related gene (ERG). (I) is useful for treating
 XX conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,
 XX tumour angiogenesis, diabetic retinopathy, macular degeneration, verruca
 XX neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca
 XX vulgaris, angiofibroma of tuberous sclerosis, port-wine stains, Sturge
 XX Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu
 XX syndrome, leukaemia, osteoporosis and wound healing. (I) is useful for
 XX treating a patient having a condition associated with the level of ERG,
 XX by contacting cells of the patient with (I) under conditions suitable for
 XX the treatment. The method comprises the use of one or more therapies
 XX under conditions suitable for the treatment. Leukaemia or tumour
 XX angiogenesis is treated by administering (I) to the patient in
 XX conjunction with one or more of other therapies such as radiation or
 XX chemotherapy treatment. (I) is useful for reducing ERG activity in a
 XX cell, by contacting the cell with (I). (I) is useful for cleaving RNA of
 XX ERG gene, by contacting (I) with RNA, in the presence of a divalent
 XX cation such as Mg2+. (I) is useful for diagnosis of conditions and
 XX diseases related to the expression of ERG, and as diagnostic tool to
 XX examine genetic drift and mutations within diseased cells or to detect
 XX the presence of ERG RNA in a cell. (I) is useful for specifically
 XX targeting genes that share homology with ERG gene or ERG fusion genes.
 XX ABK17354-ABK22719 represent nucleic acids, including antisense and
 XX enzymatic nucleic acid molecules which regulate expression of ERG, and
 XX related PCR primers of the invention.
 XX Sequence 17 BP; 5 A; 7 C; 2 G; 3 U; 0 other;
 XX
 XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
 XX Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 824 TGATGCAGCTGAGCT 839
 XX :|||
 XX Db 17 TGATGCAGCTGAGCTT 2
 XX
 XX RESULT 559
 XX ABK19286
 XX ID ABK19286 standard; RNA; 17 BP.
 XX AC ABK19286;

XX DT 09-APR-2002 (first entry)

XX DE Human ERG Amberzyme target sequence Seq ID No 1933.

XX KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;

XX KW Ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;

XX KW vulvar; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;

XX KW tumour angiogenesis; diabetic retinopathy; macular degeneration;

XX KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;

XX KW angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;

XX KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;

XX KW Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNAzyme; inozyme;

XX KW amberzyme.

XX OS Homo sapiens.

XX PN WO200188124-A2.

XX PD 22-NOV-2001.

XX PF 16-MAY-2001; 2001WO-US15866.

XX PR 16-MAY-2000; 2000US-0572021.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PA (GLAX) GLAXO GROUP LTD.

XX PI Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin F, Randi AM;

XX PI WPI; 2002-082995/11.

XX DR Novel polynucleotide which down regulates expression of Ets-related

XX PT gene, useful for treating cancer, diabetic retinopathy, macular

XX PT degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber

XX PT syndrome

XX PS Claim 4; Page 124; 149pp; English.

XX CC The invention relates to a nucleic acid molecule (I) which down regulates

XX CC expression of an Ets-related gene (ERG). (I) is useful for treating

XX CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,

XX CC tumour angiogenesis, diabetic retinopathy, macular degeneration,

XX CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca

XX CC vulgaris, angiofibroma of tuberosus sclerosis, port-wine stains, Sturge

XX CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu

XX CC treating a patient having a condition associated with the level of ERG,

XX CC by contacting cells of the patient with (I) under conditions suitable for

XX CC the treatment. The method comprises the use of one or more therapies

XX CC under conditions suitable for the treatment. Leukaemia or tumour

XX CC angiogenesis is treated by administering (I) to the patient in

XX CC conjunction with one or more of other therapies such as radiation or

XX CC chemotherapy treatment. (I) is useful for reducing ERG activity in a

XX CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of

XX CC ERG gene, by contacting (I) with RNA, in the presence of a divalent

XX CC cation such as Mg2+. (I) is useful for diagnosis of conditions and

XX CC diseases related to the expression of ERG, and as diagnostic tool to

XX CC examine genetic drift and mutations within diseased cells or to detect

XX CC the presence of ERG RNA in a cell. (I) is useful for specifically

XX CC targeting genes that share homology with ERG gene or ERG fusion genes.

XX CC ABK17354-ABK22719 represent nucleic acids, including antisense and

XX CC enzymatic nucleic acid molecules which regulate expression of ERG, and

XX CC related PCR primers of the invention.

SQ Sequence 17 BP; 8 A; 5 C; 3 G; 1 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 81.2%; Pred. No. 2.7e+02;

Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

66 ACCACATAGGATGAA 81

||||||| | | | | |

Db 2 ACCACAGAGAUGAA 17

RESULT 560

ABK19333/c

ID ID ABK19333 standard; RNA; 17 BP.

XX AC ABK19333;

XX DT 09-APR-2002 (first entry)

XX DE Human ERG Amberzyme target sequence Seq ID No 1980.

XX KW Human; hammerhead ribozyme; cytostatic; antitumour; antidiabetic;

XX KW ophthalmological; antiarthritic; antipsoriatic; virucide; osteopathic;

XX KW vulvar; cancer; lymphoma; Ewing's sarcoma; melanoma; psoriasis;

XX KW tumour angiogenesis; diabetic retinopathy; macular degeneration;

XX KW neovascular glaucoma; myopic degeneration; arthritis; verruca vulgaris;

XX KW angiofibroma of tuberosus sclerosis; port-wine stain; wound healing;

XX KW Sturge Weber syndrome; Kippel-Trenaunay-Weber syndrome; leukaemia; ss;

XX KW Osler-Weber-rendu syndrome; leukaemia; osteoporosis; DNAzyme; inozyme;

XX KW amberzyme.

XX OS Homo sapiens.

XX PN WO200188124-A2.

XX PD 22-NOV-2001.

XX PF 16-MAY-2001; 2001WO-US15866.

XX PR 16-MAY-2000; 2000US-0572021.

XX XX (RIBO-) RIBOZYME PHARM INC.

XX PA (GLAX) GLAXO GROUP LTD.

XX PI Jarvis T, Von Carlowitz I, McSwiggen JA, McLaughlin F, Randi AM;

XX PI WPI; 2002-082995/11.

XX DR Novel polynucleotide which down regulates expression of Ets-related

XX PT gene, useful for treating cancer, diabetic retinopathy, macular

XX PT degeneration, arthritis, psoriasis, verruca vulgaris and Sturge Weber

XX PT syndrome

XX PS Claim 4; Page 126; 149pp; English.

XX CC The invention relates to a nucleic acid molecule (I) which down regulates

XX CC expression of an Ets-related gene (ERG). (I) is useful for treating

XX CC conditions selected from cancer, lymphoma, Ewing's sarcoma, melanoma,

XX CC tumour angiogenesis, diabetic retinopathy, macular degeneration,

XX CC neovascular glaucoma, myopic degeneration, arthritis, psoriasis, verruca

XX CC vulgaris, angiofibroma of tuberosus sclerosis, port-wine stains, Sturge

XX CC Weber syndrome, Kippel-Trenaunay-Weber syndrome, Osler-Weber-rendu

XX CC treating a patient having a condition associated with the level of ERG,

XX CC by contacting cells of the patient with (I) under conditions suitable for

XX CC the treatment. The method comprises the use of one or more therapies

XX CC under conditions suitable for the treatment. Leukaemia or tumour

XX CC angiogenesis is treated by administering (I) to the patient in

XX CC conjunction with one or more of other therapies such as radiation or

XX CC chemotherapy treatment. (I) is useful for reducing ERG activity in a

XX CC cell, by contacting the cell with (I). (I) is useful for cleaving RNA of

XX CC ERG gene, by contacting (I) with RNA, in the presence of a divalent

XX CC cation such as Mg2+. (I) is useful for diagnosis of conditions and

XX CC diseases related to the expression of ERG, and as diagnostic tool to

XX CC examine genetic drift and mutations within diseased cells or to detect

XX CC the presence of ERG RNA in a cell. (I) is useful for specifically

XX CC targeting genes that share homology with ERG gene or ERG fusion genes.

XX CC ABK17354-ABK22719 represent nucleic acids, including antisense and

XX CC enzymatic nucleic acid molecules which regulate expression of ERG, and

XX CC related PCR primers of the invention.

CC respect to the genetic sequence to be altered and further comprises
 CC chemical modifications of the oligonucleotide. The chemical modifications
 CC consist of o-methyl modification, an LNA modification, two or more
 CC phosphorothioate linkages on a terminus, or a combination of any two or
 CC more of these modifications. The oligonucleotides are useful for
 CC directing repair or alteration of plant genetic information. The
 CC oligonucleotides are particularly useful for creating plants with desired
 CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
 CC nutritional value (e.g. altering amino acid content of plants or
 CC conferring amino acid over production), herbicide resistance (e.g.
 CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
 CC resistance, porphyrin herbicide resistance or triazine resistance),
 CC disease resistance, modified oil production, modified starch production
 CC (e.g. increased starch or production of waxy starch), altered floral
 CC morphology (e.g. male-sterile plants) or modified fatty acid content
 CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
 CC The oligonucleotides are also useful for producing albino mutants for the
 CC analysis of photosynthetic processes. This sequence represents a genome
 CC altering oligonucleotide of the invention.

XX Sequence 17 BP; 4 A; 5 C; 3 G; 5 T; 0 other;
 SQ

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 164 GATCCTCAAGTCTCG 179

DB 1 GATCCTCTAGATCTCG 16

RESULT 563

ABK25527/C

ID ABK25527 standard; DNA; 17 BP.

XX

AC ABK25527;

XX

DT 09-APR-2002 (first entry)

XX

DE Male-sterile plant producing genome altering oligonucleotide #427.

XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
 KW o-methyl modification; LNA modification; phosphorothioate linkage;
 KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
 KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;
 KW amino acid over production; herbicide resistance; glyphosate resistance;
 KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
 KW porphyrin herbicide resistance; triazine resistance; disease resistance;
 KW modified oil production; modified starch production; waxy starch;
 KW altered floral morphology; male-sterile plant; albino mutant;
 KW increased fatty acid content; reduced palmitate production; albino plant;
 KW increased stearate production; reduced linolenic acid production;
 KW photosynthetic process.

XX

OS Oryza sativa.

OS Synthetic.

XX

FN WO200192512-A2.

XX

PD 06-DEC-2001.

XX

PF 01-JUN-2001; 2001WO-US17672.

XX

PR 01-JUN-2000; 2000US-208538P.

PR 30-OCT-2000; 2000US-244989P.

PR 27-WAR-2001; 2001US-0819875.

XX

PA (UYDE) UNIV DELAWARE.

XX

PI Kmiec EB, Gamper HB, Rice MC, Kim J;

XX

DR WPI; 2002-106307/14.

XX

PT New oligonucleotides with modified nuclease-resistant termini, useful
 PT for creating plants with desired phenotypes, e.g. stress tolerance,
 PT improved nutritional value, herbicide or disease resistance, or
 PT modified oil production -

XX Claim 7; Page 94; 220pp; English.

XX The invention relates to an oligonucleotide for targeted alteration of a
 CC genetic sequence, which comprises a single-stranded oligonucleotide
 CC having a DNA domain. The DNA domain has at least one mismatch with
 CC respect to the genetic sequence to be altered and further comprises
 CC chemical modifications of the oligonucleotide. The chemical modifications
 CC consist of o-methyl modification, an LNA modification, two or more
 CC phosphorothioate linkages on a terminus, or a combination of any two or
 CC more of these modifications. The oligonucleotides are useful for
 CC directing repair or alteration of plant genetic information. The
 CC oligonucleotides are particularly useful for creating plants with desired
 CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
 CC nutritional value (e.g. altering amino acid content of plants or
 CC conferring amino acid over production), herbicide resistance (e.g.
 CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
 CC resistance, porphyrin herbicide resistance or triazine resistance),
 CC disease resistance, modified oil production, modified starch production
 CC (e.g. increased starch or production of waxy starch), altered floral
 CC morphology (e.g. male-sterile plants) or modified fatty acid content
 CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
 CC The oligonucleotides are also useful for producing albino mutants for the
 CC analysis of photosynthetic processes. This sequence represents a genome
 CC altering oligonucleotide of the invention.

XX Sequence 17 BP; 5 A; 3 C; 5 G; 4 T; 0 other;
 SQ

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 164 GATCCTCAAGTCTCG 179

DB 17 GATCCTCTAGATCTCG 2

RESULT 564

ABK25528

ID ABK25528 standard; DNA; 17 BP.

XX

AC ABK25528;

XX

DT 09-APR-2002 (first entry)

XX

DE Male-sterile plant producing genome altering oligonucleotide #428.

XX Chromosomal genomic alteration; genome altering oligonucleotide; PCR; ss;
 KW o-methyl modification; LNA modification; phosphorothioate linkage;
 KW DNA repair; DNA alteration; environmental tolerance; hygromycin-B;
 KW abiotic stress tolerance; improved nutritional value; hygromycin; primer;
 KW amino acid over production; herbicide resistance; glyphosate resistance;
 KW imidazolinone herbicide resistance; sulphonylurea herbicide resistance;
 KW porphyrin herbicide resistance; triazine resistance; disease resistance;
 KW modified oil production; modified starch production; waxy starch;
 KW altered floral morphology; male-sterile plant; albino mutant;
 KW increased fatty acid content; reduced palmitate production; albino plant;
 KW increased stearate production; reduced linolenic acid production;
 KW photosynthetic process.

XX

OS Oryza sativa.

OS Synthetic.

XX

FN WO200192512-A2.

XX

PD 06-DEC-2001.

XX

PF 01-JUN-2001; 2001WO-US17672.

XX

PR 01-JUN-2000; 2000US-208538P.
 PR 30-OCT-2000; 2000US-244989P.
 PR 27-MAR-2001; 2001US-0818875.
 XX
 XX (UYDE) UNIV DELAWARE.
 XX Kmiec EB, Gamper HB, Rice MC, Kim J;
 XX WPI; 2002-106307/14.
 XX
 XX New oligonucleotides with modified nuclease-resistant termini, useful
 PT for creating plants with desired phenotypes, e.g. stress tolerance,
 PT improved nutritional value, herbicide or disease resistance, or
 PT modified oil production
 XX
 XX Claim 7; Page 94; 220pp; English.
 XX
 CC The invention relates to an oligonucleotide for targeted alteration of a
 CC genetic sequence, which comprises a single-stranded oligonucleotide
 CC having a DNA domain. The DNA domain has at least one mismatch with
 CC respect to the genetic sequence to be altered and further comprises
 CC chemical modifications of the oligonucleotide. The chemical modifications
 CC consist of o-methyl modification, an DNA modification, two or more
 CC phosphorothioate linkages on a terminus, or a combination of any two or
 CC more of these modifications. The oligonucleotides are useful for
 CC directing repair or alteration of plant genetic information. The
 CC oligonucleotides are particularly useful for creating plants with desired
 CC phenotypes, e.g. environmental or abiotic stress tolerance, improved
 CC nutritional value (e.g. altering amino acid content of plants or
 CC conferring amino acid over production), herbicide resistance (e.g.
 CC glyphosate resistance, imidazolinone and sulphonylurea herbicide
 CC resistance, porphyric herbicide resistance or triazine resistance),
 CC disease resistance, modified oil production, modified starch production
 CC (e.g. increased starch or production of waxy starch), altered floral
 CC morphology (e.g. male-sterile plants) or modified fatty acid content
 CC (e.g. reduced palmitate, increased stearate or reduced linolenic acid).
 CC The oligonucleotides are also useful for producing albino mutants for the
 CC analysis of photosynthetic processes. This sequence represents a genome
 CC altering oligonucleotide of the invention.
 XX
 XX Sequence 17 BP; 4 A; 5 C; 3 G; 5 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 164 GATCCTCAAGTCTCG 179
 Db 1 GATCCTCTAGATCTCG 16
 RESULT 565
 ABL31073
 ID ABL31073 standard; DNA; 17 BP.
 XX
 AC ABL31073;
 XX
 XX 21-MAR-2002 (first entry)
 XX Human HLA genotyping oligonucleotide SEQ ID NO 562.
 XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
 KW immunogenetic; transplantation; genetic disease; ss.
 XX Homo sapiens.
 XX WO200192572-A1.
 XX
 XX 06-DEC-2001.
 XX
 XX 01-JUN-2001; 2001WO-JP04662.
 XX
 XX 01-JUN-2000; 2000JP-0164798.
 XX Claim 10; Page 293; 345pp; Japanese.

XX (NISN) NISSHINO IND INC.
 PA (SYST-) SYSTEM RES INC.
 XX
 XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 XX
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 PT of individuals e.g. by determining immunogenetic differences when
 PT transplanting between them -
 XX
 XX Claim 10; Page 199; 345pp; Japanese.
 XX
 CC The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals.
 XX
 XX Sequence 17 BP; 1 A; 7 C; 6 G; 3 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 803 GCTCCTCGAGCCGAG 818
 Db 1 GCTGCTGCGCCGAG 16
 RESULT 566
 ABL31564
 ID ABL31564 standard; DNA; 17 BP.
 XX
 AC ABL31564;
 XX
 XX 21-MAR-2002 (first entry)
 XX Human HLA genotyping oligonucleotide SEQ ID NO 1053.
 XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
 KW immunogenetic; transplantation; genetic disease; ss.
 XX Homo sapiens.
 XX WO200192572-A1.
 XX
 XX 06-DEC-2001.
 XX
 XX 01-JUN-2001; 2001WO-JP04662.
 XX
 XX 01-JUN-2000; 2000JP-0164798.
 XX
 XX (NISN) NISSHINO IND INC.
 PA (SYST-) SYSTEM RES INC.
 XX
 XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 XX
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 PT of individuals e.g. by determining immunogenetic differences when
 PT transplanting between them -
 XX
 XX Claim 10; Page 293; 345pp; Japanese.

XX The invention relates to a typing kit for judging human leukocyte antigen
CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
CC genes e.g. belonging to HLA class I antigens on human genome and
CC containing gene polymorphisms as alloantigens have been immobilised as
CC primers for amplification of cleaved nucleic acids relating to gene
CC polymorphisms. The method is useful for judging HLA genotypes of
CC individuals by determining immunogenetic differences before transplanting
CC between them, providing genetic information to decide compatibility of
CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC diagnosis of genetic diseases and identifying individuals.
XX
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 531 GGAGCAGCTGGGTGCC 546
Db 1 GGAGCAGCTGAGAGCC 16
RESULT 567
ABL31655
ID ABL31655 standard; DNA; 17 BP.
XX
AC ABL31655;
XX
DT 21-MAR-2002 (first entry)
DE Human HLA genotyping oligonucleotide SEQ ID NO 1144.
XX
KW Human; human leukocyte antigen; HLA; genotype; polymorphism;
KW immunogenetic; transplantation; genetic disease; ss.
XX
OS Homo sapiens.
XX
PN WC200192572-A1.
XX
PD 06-DEC-2001.
XX
PF 01-JUN-2001; 2001WO-JP04662.
XX
PR 01-JUN-2000; 2000JP-0164798.
XX
PA (NIN) NISSHINBO IND INC.
PA (SYST-) SYSTEM RES INC.
XX
PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX WPI; 2002-122074/16.
XX
PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
PT of individuals e.g. by determining immunogenetic differences when
PT transplanting between them -
XX
PS Claim 10; Page 310; 345pp; Japanese.
XX
CC The invention relates to a typing kit for judging human leukocyte antigen
CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
CC genes e.g. belonging to HLA class I antigens on human genome and
CC containing gene polymorphisms as alloantigens have been immobilised as
CC primers for amplification of cleaved nucleic acids relating to gene
CC polymorphisms. The method is useful for judging HLA genotypes of
CC individuals by determining immunogenetic differences before transplanting
CC between them, providing genetic information to decide compatibility of
CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC diagnosis of genetic diseases and identifying individuals.

XX
SQ Sequence 17 BP; 5 A; 8 C; 3 G; 1 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 195 CCACCCGACGCGGAC 210
Db 2 CCACCCGACGCGGAC 17
RESULT 568
ABL31671
ID ABL31671 standard; DNA; 17 BP.
XX
AC ABL31671;
XX
DT 21-MAR-2002 (first entry)
DE Human HLA genotyping oligonucleotide SEQ ID NO 1160.
XX
KW Human; human leukocyte antigen; HLA; genotype; polymorphism;
KW immunogenetic; transplantation; genetic disease; ss.
XX
OS Homo sapiens.
XX
PN WC200192572-A1.
XX
PD 06-DEC-2001.
XX
PF 01-JUN-2001; 2001WO-JP04662.
XX
PR 01-JUN-2000; 2000JP-0164798.
XX
PA (NIN) NISSHINBO IND INC.
PA (SYST-) SYSTEM RES INC.
XX
PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX WPI; 2002-122074/16.
XX
PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
PT of individuals e.g. by determining immunogenetic differences when
PT transplanting between them -
XX
PS Claim 10; Page 313; 345pp; Japanese.
XX
CC The invention relates to a typing kit for judging human leukocyte antigen
CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
CC genes e.g. belonging to HLA class I antigens on human genome and
CC containing gene polymorphisms as alloantigens have been immobilised as
CC primers for amplification of cleaved nucleic acids relating to gene
CC polymorphisms. The method is useful for judging HLA genotypes of
CC individuals by determining immunogenetic differences before transplanting
CC between them, providing genetic information to decide compatibility of
CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC diagnosis of genetic diseases and identifying individuals.
XX
SQ Sequence 17 BP; 4 A; 4 C; 7 G; 2 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 531 GGAGCAGCTGGGTGCC 546
Db 1 GGAGCAGCTGAGAGCC 16
RESULT 569

DR WPI; 2003-313353/30.

XX New isolated nucleic acid, useful for treating viral diseases

PT associated with tumors and cell degeneration, also related

PT polypeptides, antibodies and transfected cells

XX Disclosure; Page 203; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,

XX given in the specification, a sequence containing at least 15

CC consecutive nucleotides from the 17 mer sequence, a sequence with, after

CC optimal alignment, at least 80 % identity to the 17 mer sequence, a

CC sequence that hybridizes to them under highly stringent conditions, or

CC the complement of any of them, or the corresponding RNA. The novel

CC isolated nucleic acids of the invention are useful as probes and primers

CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,

CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,

CC and for production of recombinant polypeptides. Any of the nucleic acids,

CC polypeptides, vectors containing the nucleic acids, cells containing the

CC vector or antibodies directed against the polypeptides are useful for

CC preparation of pharmaceuticals for prevention and/or treatment of viral

CC diseases that are characterised by development of tumours or cell

CC degeneration, specifically cancer but also Alzheimer's disease and

CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in

CC patient samples is useful for diagnosis and/or prognosis of these

CC diseases. The polypeptides can also be used to generate antibodies, and

CC both the polypeptide and antibodies are useful as components of protein

CC chips. The nucleic acid sequences of the invention can be used in gene

CC therapy. This polynucleotide sequence represents a tumour suppression

CC related human fukutin oligonucleotide of the invention.

XX

XX Sequence 17 BP; 2 A; 3 C; 1 G; 11 T; 0 other;

XX

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1139 ATGCGCTTTTTCCTT 1154

DB 2 ATCGCTTTTTCCTT 17

RESULT 572

ABT35849/C

ID ABT35849 standard; DNA; 17 BP.

AC

AC ABT35849;

XX

XX 12-JUN-2003 (first entry)

XX

XX Tumour suppression related human fukutin oligo SEQ ID No 1486.

DE

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;

XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;

KW schizophrenia; protein chip; gene therapy; tumour suppression;

KW human fukutin; ds.

XX

OS Homo sapiens.

XX

XX WO2003025175-A2.

EN

XX 27-MAR-2003.

PD

XX 17-SEP-2002; 2002WO-IB04208.

XX

XX 17-SEP-2001; 2001FR-0011978.

XX

XX (MOLE-) MOLECULAR ENGINES LAB.

PA

XX Telerman A, Amson R, Tuijnder M;

XX

XX WPI; 2003-313353/30.

XX

XX New isolated nucleic acid, useful for treating viral diseases

PT associated with tumors and cell degeneration, also related

PT polypeptides, antibodies and transfected cells

PT New isolated nucleic acid, useful for treating viral diseases

PT associated with tumors and cell degeneration, also related

XX polypeptides, antibodies and transfected cells

PS Disclosure; Page 206; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,

XX given in the specification, a sequence containing at least 15

CC consecutive nucleotides from the 17 mer sequence, a sequence with, after

CC optimal alignment, at least 80 % identity to the 17 mer sequence, a

CC sequence that hybridizes to them under highly stringent conditions, or

CC the complement of any of them, or the corresponding RNA. The novel

CC isolated nucleic acids of the invention are useful as probes and primers

CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,

CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,

CC and for production of recombinant polypeptides. Any of the nucleic acids,

CC polypeptides, vectors containing the nucleic acids, cells containing the

CC vector or antibodies directed against the polypeptides are useful for

CC preparation of pharmaceuticals for prevention and/or treatment of viral

CC diseases that are characterised by development of tumours or cell

CC degeneration, specifically cancer but also Alzheimer's disease and

CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in

CC patient samples is useful for diagnosis and/or prognosis of these

CC diseases. The polypeptides can also be used to generate antibodies, and

CC both the polypeptide and antibodies are useful as components of protein

CC chips. The nucleic acid sequences of the invention can be used in gene

CC therapy. This polynucleotide sequence represents a tumour suppression

CC related human fukutin oligonucleotide of the invention.

XX

XX Sequence 17 BP; 4 A; 6 C; 4 G; 3 T; 0 other;

XX

Query Match 0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 2.7e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GGCAGTTGAGGTGGAT 21

DB 17 GGCAGTTGAGGTGGAT 2

RESULT 573

ABT36006

ID ABT36006 standard; DNA; 17 BP.

AC

AC ABT36006;

XX

XX 12-JUN-2003 (first entry)

XX

XX Tumour suppression related human fukutin oligo SEQ ID No 1643.

DE

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;

XX antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;

KW schizophrenia; protein chip; gene therapy; tumour suppression;

KW human fukutin; ds.

XX

OS Homo sapiens.

XX

XX WO2003025175-A2.

EN

XX 27-MAR-2003.

PD

XX 17-SEP-2002; 2002WO-IB04208.

XX

XX 17-SEP-2001; 2001FR-0011978.

XX

XX (MOLE-) MOLECULAR ENGINES LAB.

PA

XX Telerman A, Amson R, Tuijnder M;

XX

XX WPI; 2003-313353/30.

XX

XX New isolated nucleic acid, useful for treating viral diseases

PT associated with tumors and cell degeneration, also related

PT polypeptides, antibodies and transfected cells

```
PT polypeptides, antibodies and transfected cells
XX
PS Disclosure; Page 225; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15
CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
CC sequence that hybridizes to them under highly stringent conditions, or
CC the complement of any of them, or the corresponding RNA. The novel
CC isolated nucleic acids of the invention are useful as probes and primers
CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
CC and for production of recombinant polypeptides. Any of the nucleic acids,
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention.
XX
SQ Sequence 17 BP; 6 A; 2 C; 5 G; 4 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 429 GAGCAGGTCAGAAAG 444
DB 1 GATCATGTTTCAGAAAG 16
|||||
RESULT 574
ABT37187
ID ABT37187 standard; DNA; 17 BP.
XX
AC ABT37187;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 2824.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB04208.
XX
PR 17-SEP-2001; 2001FR-0011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases
PT associated with tumors and cell degeneration, also related
PT polypeptides, antibodies and transfected cells -
XX
```

```
PS Disclosure; Page 363; 720pp; French.
XX
CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
CC given in the specification, a sequence containing at least 15
CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
CC sequence that hybridizes to them under highly stringent conditions, or
CC the complement of any of them, or the corresponding RNA. The novel
CC isolated nucleic acids of the invention are useful as probes and primers
CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
CC and for production of recombinant polypeptides. Any of the nucleic acids,
CC vector or antibodies directed against the polypeptides are useful for
CC preparation of pharmaceuticals for prevention and/or treatment of viral
CC diseases that are characterised by development of tumours or cell
CC degeneration, specifically cancer but also Alzheimer's disease and
CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
CC patient samples is useful for diagnosis and/or prognosis of these
CC diseases. The polypeptides can also be used to generate antibodies, and
CC both the polypeptide and antibodies are useful as components of protein
CC chips. The nucleic acid sequences of the invention can be used in gene
CC therapy. This polynucleotide sequence represents a tumour suppression
CC related human fukutin oligonucleotide of the invention.
XX
SQ Sequence 17 BP; 8 A; 2 C; 5 G; 2 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 273 GATCAAGAGGAGCA 288
DB 1 GATCCAGAGGAGGAA 16
|||||
RESULT 575
ABT37634
ID ABT37634 standard; DNA; 17 BP.
XX
AC ABT37634;
XX
DT 12-JUN-2003 (first entry)
XX
DE Tumour suppression related human fukutin oligo SEQ ID No 3271.
XX
KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
KW schizophrenia; protein chip; gene therapy; tumour suppression;
KW human fukutin; ds.
XX
OS Homo sapiens.
XX
PN WO2003025175-A2.
XX
PD 27-MAR-2003.
XX
PF 17-SEP-2002; 2002WO-IB04208.
XX
PR 17-SEP-2001; 2001FR-0011978.
XX
PA (MOLE-) MOLECULAR ENGINES LAB.
XX
PI Telerman A, Amson R, Tuijnder M;
XX
DR WPI; 2003-313353/30.
XX
PT New isolated nucleic acid, useful for treating viral diseases
PT associated with tumors and cell degeneration, also related
PT polypeptides, antibodies and transfected cells -
XX
PS Disclosure; Page 416; 720pp; French.
XX
```

CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15
 CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
 CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
 CC sequence that hybridizes to them under highly stringent conditions, or
 CC the complement of any of them, or the corresponding RNA. The novel
 CC isolated nucleic acids of the invention are useful as probes and primers
 CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
 CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
 CC and for production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention.
 XX
 SQ Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 164 GATCCTCAAGTCTCG 179
 ||||| |||||
 Db 1 GATCCCAAGTCTCG 16

RESULT 576
 ABT37805/c
 ID ABT37805 standard; DNA; 17 BP.
 XX
 AC ABT37805;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID No 3442.
 XX
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB04208.
 XX
 PR 17-SEP-2001; 2001FR-0011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases
 PT associated with tumors and cell degeneration, also related
 PT polypeptides, antibodies and transfected cells -
 XX
 PS Disclosure; Page 436; 720pp; French.
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15

CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
 CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
 CC sequence that hybridizes to them under highly stringent conditions, or
 CC the complement of any of them, or the corresponding RNA. The novel
 CC isolated nucleic acids of the invention are useful as probes and primers
 CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
 CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
 CC and for production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention.
 XX
 SQ Sequence 17 BP; 6 A; 2 C; 4 G; 5 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 983 CAGTCCCATTCAGATC 998
 ||||| |||||
 Db 16 CAGTCCCATTAAGATC 1

RESULT 577
 ABT38097/c
 ID ABT38097 standard; DNA; 17 BP.
 XX
 AC ABT38097;
 XX
 DT 12-JUN-2003 (first entry)
 XX
 DE Tumour suppression related human fukutin oligo SEQ ID No 3734.
 XX
 KW Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.
 XX
 OS Homo sapiens.
 XX
 PN WO2003025175-A2.
 XX
 PD 27-MAR-2003.
 XX
 PF 17-SEP-2002; 2002WO-IB04208.
 XX
 PR 17-SEP-2001; 2001FR-0011978.
 XX
 PA (MOLE-) MOLECULAR ENGINES LAB.
 XX
 PI Telerman A, Amson R, Tuijnder M;
 XX
 DR WPI; 2003-313353/30.
 XX
 PT New isolated nucleic acid, useful for treating viral diseases
 PT associated with tumors and cell degeneration, also related
 PT polypeptides, antibodies and transfected cells -
 XX
 PS Disclosure; Page 470; 720pp; French.
 XX
 CC The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15
 CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
 CC optimal alignment, at least 80 % identity to the 17 mer sequence, a

CC sequence that hybridizes to them under highly stringent conditions, or
 CC the complement of any of them, or the corresponding RNA. The novel
 CC isolated nucleic acids of the invention are useful as probes and primers
 CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
 CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
 CC and for production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention.

XX SQ Sequence 17 BP; 2 A; 5 C; 6 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1066 CCCATCAGGCGGCTC 1081
 |||||
 Db 16 CCCATCAGGAGATC 1

RESULT 578
 ABT39257/c
 ID ABT39257 standard; DNA; 17 BP.
 XX AC ABT39257;
 XX DT 12-JUN-2003 (first entry)

DE Tumour suppression related human fukutin oligo SEQ ID No 4894.

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.

XX OS Homo sapiens.
 XX PN WO2003025175-A2.
 XX PD 27-MAR-2003.

XX PF 17-SEP-2002; 2002WO-IB04208.

XX PR 17-SEP-2001; 2001FR-0011978.

XX PA (MOLE-) MOLECULAR ENGINES LAB.

XX PI Telerman A, Amson R, Tuijnder M;

XX DR WPI; 2003-313353/30.

XX PT New isolated nucleic acid, useful for treating viral diseases
 PT associated with tumors and cell degeneration, also related
 PT polypeptides, antibodies and transfected cells -

XX PS Disclosure; Page 606; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15
 CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
 CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
 CC sequence that hybridizes to them under highly stringent conditions, or
 CC the complement of any of them, or the corresponding RNA. The novel

CC isolated nucleic acids of the invention are useful as probes and primers
 CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
 CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
 CC and for production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention.

XX SQ Sequence 17 BP; 7 A; 3 C; 3 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 855 ATACCGCTTTCAGGTC 870
 |||||
 Db 16 ATACTGCTTTCAGATC 1

RESULT 579
 ABT39551
 ID ABT39551 standard; DNA; 17 BP.
 XX AC ABT39551;
 XX DT 12-JUN-2003 (first entry)

DE Tumour suppression related human fukutin oligo SEQ ID No 5188.

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.

XX OS Homo sapiens.

XX PN WO2003025175-A2.

XX PD 27-MAR-2003.

XX PF 17-SEP-2002; 2002WO-IB04208.

XX PR 17-SEP-2001; 2001FR-0011978.

XX PA (MOLE-) MOLECULAR ENGINES LAB.

XX PI Telerman A, Amson R, Tuijnder M;

XX DR WPI; 2003-313353/30.

XX PT New isolated nucleic acid, useful for treating viral diseases
 PT associated with tumors and cell degeneration, also related
 PT polypeptides, antibodies and transfected cells -

XX PS Disclosure; Page 640; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15
 CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
 CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
 CC sequence that hybridizes to them under highly stringent conditions, or
 CC the complement of any of them, or the corresponding RNA. The novel
 CC isolated nucleic acids of the invention are useful as probes and primers
 CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,

CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
 CC and for production of recombinant polypeptides. Any of the nucleic acids,
 CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the nucleic acids, cells containing the
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention.

XX SQ Sequence 17 BP; 2 A; 3 C; 1 G; 11 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1139 ATGCCTTTTTCCTT 1154
 || |||||
 Db 2 ATCACTTTTTCCTT 17

RESULT 580

ABT39720

ID ABT39720 standard; DNA; 17 BP.

XX AC

XX ABT39720;

XX DT

DE 12-JUN-2003 (first entry)

XX DE

XX Tumour suppression related human fukutin oligo SEQ ID No 5357.

XX Cytostatic; virucide; neuroprotective; nootropic; neuroleptic; gene chip;
 KW antisense; sense; tumour; cell degeneration; cancer; Alzheimer's disease;
 KW schizophrenia; protein chip; gene therapy; tumour suppression;
 KW human fukutin; ds.

XX OS Homo sapiens.

XX WO2003025175-A2.

XX 27-MAR-2003.

XX 17-SRP-2002; 2002WO-IB04208.

XX 17-SEP-2001; 2001FR-0011978.

XX (MOLE-) MOLECULAR ENGINES LAB.

XX Telerman A, Amson R, Tuijnder M;

XX WPI; 2003-313353/30.

XX New isolated nucleic acid, useful for treating viral diseases

XX associated with tumors and cell degeneration, also related

XX polypeptides, antibodies and transfected cells -

XX Disclosure; Page 660; 720pp; French.

XX The invention relates to a novel isolated 17 mer nucleic acid sequence,
 CC given in the specification, a sequence containing at least 15
 CC consecutive nucleotides from the 17 mer sequence, a sequence with, after
 CC optimal alignment, at least 80 % identity to the 17 mer sequence, a
 CC sequence that hybridizes to them under highly stringent conditions, or
 CC the complement of any of them, or the corresponding RNA. The novel
 CC isolated nucleic acids of the invention are useful as probes and primers
 CC for detecting, identifying, quantifying and/or amplifying a nucleic acid,
 CC e.g. as one component of a gene chip, in vitro as (anti)sense reagents,
 CC and for production of recombinant polypeptides. Any of the nucleic acids,

CC polypeptides, vectors containing the nucleic acids, cells containing the
 CC vector or antibodies directed against the polypeptides are useful for
 CC preparation of pharmaceuticals for prevention and/or treatment of viral
 CC diseases that are characterised by development of tumours or cell
 CC degeneration, specifically cancer but also Alzheimer's disease and
 CC schizophrenia. Analysis of the expression of the 17 mer nucleic acids in
 CC patient samples is useful for diagnosis and/or prognosis of these
 CC diseases. The polypeptides can also be used to generate antibodies, and
 CC both the polypeptide and antibodies are useful as components of protein
 CC chips. The nucleic acid sequences of the invention can be used in gene
 CC therapy. This polynucleotide sequence represents a tumour suppression
 CC related human fukutin oligonucleotide of the invention.

XX SQ Sequence 17 BP; 4 A; 2 C; 5 G; 6 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 435 GTTCAGAAAGTTGCTG 450
 || |||||
 Db 1 GATCAGATAGTTGCTG 16

RESULT 581

ACA06264

ID ACA06264 standard; RNA; 17 BP.

XX AC

XX ACA06264;

XX DT

DE 03-JUN-2003 (first entry)

XX NFKB sub-unit modulating inozyme substrate #83.

XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberyzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapeutic; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 ss.

XX OS Homo sapiens.

XX US2002177568-A1.

XX 29-NOV-2002.

XX 23-MAY-2001; 2001US-0864785.

XX 15-AUG-1994; 94US-0291932.

XX 07-DEC-1992; 92US-0987132.

XX 18-MAY-1994; 94US-0245466.

XX 23-DEC-1996; 96US-0777916.

XX (STIN/) STINCHCOMB D T.

XX (MCSW/) MCSWIGGEN J.

XX (DRAP/) DRAPER K G.

XX Stinchcomb DT, Mcswiggen J, Draper KG;

XX WPI; 2003-340953/32.

XX Novel enzymatic nucleic acid molecules which down regulates expression
 PT of a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases -

```

XX PS Claim 3; Page 28; 72pp; English.
XX
CC The invention describes an enzymatic nucleic acid molecule (I) which down
CC regulates expression of a sequence encoding a subunit of nuclear factor
CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
CC configuration. The enzymatic nucleic acid molecule is adapted to treat
CC cancer and is useful for down-regulating REL-A activity in a cell for
CC treating a patient having a condition associated with the level of REL-A.
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC the presence of a divalent cation, especially Mg2+. The enzymatic and
CC antisense nucleic acid molecules are useful for treating breast, lung,
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC multidrug resistant cancer. The method involves use of other drug
CC therapies such as monoclonal antibodies, docetaxel, cisplatin, methotrexate,
CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
CC gencitabine or radiation therapy. The enzymatic and antisense nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischaemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel
CC enzymatic nucleic acid molecule.
XX
SQ Sequence 17 BP; 3 A; 4 C; 8 G; 2 U; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 2.7e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
Qy 479 AGGACTGCGGAGCGG 494
Db 1 AGGACUGCGCGGAGCGG 16
RESULT 582
ACA06326
ID ACA06326 standard; RNA; 17 BP.
AC ACA06326;
XX
DT 03-JUN-2003 (first entry)
XX
DE NFkB sub-unit modulating inozyme substrate #145.
XX
KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
KW gencitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection;
KW ss.
XX
OS Homo sapiens.
XX
PN US2002177568-A1.
XX
PD 28-NOV-2002.
XX
PF 23-MAY-2001; 2001US-0864785.
XX
PR 15-AUG-1994; 94US-0291932.

```

```

PR 07-DEC-1992; 92US-0987132.
PR 18-MAY-1994; 94US-0245466.
PR 23-DEC-1996; 96US-0777916.
XX
PA (STIN/) STINCHCOMB D T.
PA (MCSW/) MCSWIGGEN J.
PA (DRAP/) DRAPER K G.
XX
PI Stinchcomb DT, Mcswiggen J, Draper KG;
XX
XX WPI; 2003-340953/32.
XX
XX Novel enzymatic nucleic acid molecules which down regulates expression
XX of a sequence encoding a subunit of nuclear factor kappa B useful for
XX treating cancer, inflammatory disorders and autoimmune diseases -
XX
XX Claim 3; Page 29; 72pp; English.
XX
XX The invention describes an enzymatic nucleic acid molecule (I) which down
XX regulates expression of a sequence encoding a subunit of nuclear factor
XX kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
XX configuration. The enzymatic nucleic acid molecule is adapted to treat
XX cancer and is useful for down-regulating REL-A activity in a cell, for
XX treating a patient having a condition associated with the level of REL-A.
XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
XX the presence of a divalent cation, especially Mg2+. The enzymatic and
XX antisense nucleic acid molecules are useful for treating breast, lung,
XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
XX multidrug resistant cancer. The method involves use of other drug
XX therapies such as monoclonal antibodies, docetaxel, cisplatin, methotrexate,
XX cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
XX gencitabine or radiation therapy. The enzymatic and antisense nucleic
XX acid molecules are also useful for treating inflammatory disease such as
XX rheumatoid arthritis, restenosis, lupus, multiple sclerosis, transplant/graft
XX rejection, gene therapy applications, ischaemia/reperfusion injury
XX (central nervous system (CNS) and myocardial), glomerulonephritis,
XX sepsis, allergic airway inflammation, inflammatory bowel disease or
XX infection. This sequence represents the substrate of a novel
XX enzymatic nucleic acid molecule.
XX
SQ Sequence 17 BP; 0 A; 11 C; 3 G; 3 U; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 2.7e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;
Qy 581 CCCTCCGCTGTGCCGCC 596
Db 1 CCCUCCGCCGCGCGCC 16
RESULT 583
ACA06585/c
ID ACA06585 standard; RNA; 17 BP.
XX
AC ACA06585;
XX
XX 03-JUN-2003 (first entry)
XX
XX NFkB sub-unit modulating inozyme substrate #404.
XX
XX Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
XX G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
XX lung cancer; prostate cancer; colorectal cancer; brain cancer;
XX oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
XX cervical cancer; head and neck cancer; ovarian cancer; melanoma;
XX lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
XX chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
XX cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
XX gencitabine; radiation therapy; inflammatory disease; asthma; diabetes;
XX rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
XX gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
XX transplant/graft rejection; reperfusion injury; glomerulonephritis;
XX allergic airway inflammation; inflammatory bowel disease; infection;
XX ss.
XX
OS Homo sapiens.
XX
PN US2002177568-A1.
XX
PD 28-NOV-2002.
XX
PF 23-MAY-2001; 2001US-0864785.
XX
PR 15-AUG-1994; 94US-0291932.

```


KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 KW ss.
 XX Homo sapiens.
 XX OS
 XX US2002177568-A1.
 XX
 XX 28-NOV-2002.
 XX
 XX 23-MAY-2001; 2001US-0864785.
 XX
 XX 15-AUG-1994; 94US-0291932.
 XX 07-DEC-1992; 92US-0987132.
 XX 18-MAY-1994; 94US-0245466.
 XX 23-DEC-1996; 96US-0777916.
 XX
 XX (STIN/) STINCHOMB D T.
 XX (MCSW/) MCSWIGGEN J.
 XX (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 XX WPI; 2003-340953/32.
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression
 XX of a sequence encoding a subunit of nuclear factor kappa B useful for
 XX treating cancer, inflammatory disorders and autoimmune diseases -
 XX
 XX Claim 3; Page 33; 72pp; English.
 XX
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 XX regulates expression of a sequence encoding a subunit of nuclear factor
 XX kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 XX configuration. The enzymatic nucleic acid molecule is adapted to treat
 XX cancer and is useful for down-regulating REL-A activity in a cell, for
 XX treating a patient having a condition associated with the level of REL-A.
 XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 XX the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 XX antisense nucleic acid molecules are useful for treating breast, lung,
 XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 XX multidrug resistant cancer. The method involves use of other drug
 XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 XX chemotherapies including paclitaxel, docetaxel, cisplatin, methotrexate,
 XX cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 XX gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 XX acid molecules are also useful for treating inflammatory disease such as
 XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 XX rejection, gene therapy applications, ischaemia/reperfusion injury
 XX (central nervous system (CNS) and myocardial), glomerulonephritis,
 XX sepsis, allergic airway inflammation, inflammatory bowel disease or
 XX infection. This sequence represents the substrate of a novel
 XX enzymatic nucleic acid molecule.
 XX
 XX Sequence 17 BP; 3 A; 6 C; 6 G; 2 U; 0 other;
 XX
 XX Query Match 0.9%; Score 12.8; DB 1; Length 17;
 XX Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 XX
 XX QY 570 GTCACGAGGCGCTC 585
 XX ||| ||||| ||||| |||||
 XX Db 17 GCTGACGAGGCGCTC 2
 XX
 XX RESULT 584
 XX ACA06587
 XX ID ACA06587 standard; RNA; 17 BP.
 XX

AC ACA06587;
 XX 03-JUN-2003 (first entry)
 DT
 DE NFKB sub-unit modulating inozyme substrate #406.
 XX
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapies; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 KW ss.
 XX Homo sapiens.
 XX OS
 XX US2002177568-A1.
 XX
 XX 28-NOV-2002.
 XX
 XX 23-MAY-2001; 2001US-0864785.
 XX
 XX 15-AUG-1994; 94US-0291932.
 XX 07-DEC-1992; 92US-0987132.
 XX 18-MAY-1994; 94US-0245466.
 XX 23-DEC-1996; 96US-0777916.
 XX
 XX (STIN/) STINCHOMB D T.
 XX (MCSW/) MCSWIGGEN J.
 XX (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 XX WPI; 2003-340953/32.
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression
 XX of a sequence encoding a subunit of nuclear factor kappa B useful for
 XX treating cancer, inflammatory disorders and autoimmune diseases -
 XX
 XX Claim 3; Page 33; 72pp; English.
 XX
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 XX regulates expression of a sequence encoding a subunit of nuclear factor
 XX kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 XX configuration. The enzymatic nucleic acid molecule is adapted to treat
 XX cancer and is useful for down-regulating REL-A activity in a cell, for
 XX treating a patient having a condition associated with the level of REL-A.
 XX (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 XX the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 XX antisense nucleic acid molecules are useful for treating breast, lung,
 XX prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 XX cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 XX multidrug resistant cancer. The method involves use of other drug
 XX therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 XX chemotherapies including paclitaxel, docetaxel, cisplatin, methotrexate,
 XX cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 XX gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 XX acid molecules are also useful for treating inflammatory disease such as
 XX rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 XX obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 XX rejection, gene therapy applications, ischaemia/reperfusion injury
 XX (central nervous system (CNS) and myocardial), glomerulonephritis,
 XX sepsis, allergic airway inflammation, inflammatory bowel disease or
 XX infection. This sequence represents the substrate of a novel
 XX enzymatic nucleic acid molecule.

SQ Sequence 17 BP; 2 A; 6 C; 5 G; 4 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 68.8%; Pred. No. 2.7e+02;
 Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 822 CCTGATGCGAGCTGAAG 837
 ||| :|||:|
 Db 1 CCUGGUGGAGGUGCAG 16

RESULT 585
 ACA06653/c
 ID ACA06653 standard; RNA; 17 BP.
 XX
 AC ACA06653;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFKB sub-unit modulating inozyme substrate #472.

Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 lung cancer; prostate cancer; colorectal cancer; brain cancer;
 oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 chemotherapeutic; paclitaxel; docetaxel; cisplatin; methotrexate;
 cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 rheumatoid arthritis; restenosis; Crohn's disease; obesity; diabetes;
 gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 transplant/graft rejection; reperfusion injury; glomerulonephritis;
 allergic airway inflammation; inflammatory bowel disease; infection;
 ss.

OS Homo sapiens.
 XX
 PN US2002177568-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 23-MAY-2001; 2001US-0864785.
 XX
 PR 15-AUG-1994; 94US-0291932.
 PR 07-DEC-1992; 92US-0987132.
 PR 18-MAY-1994; 94US-0245466.
 PR 23-DEC-1996; 96US-0777916.
 XX
 PA (STIN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 PI Stinchcomb DT, Mcswiggen J, Draper KG;
 DR WPI; 2003-340953/32.
 XX
 PT Novel enzymatic nucleic acid molecules which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B useful for treating cancer, inflammatory disorders and autoimmune diseases -

Claim 3; Page 34; 72pp; English.

The invention describes an enzymatic nucleic acid molecule (I) which down regulates expression of a sequence encoding a subunit of nuclear factor kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme configuration. The enzymatic nucleic acid molecule is adapted to treat cancer and is useful for down-regulating REL-A activity in a cell, for treating a patient having a condition associated with the level of REL-A. (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in the presence of a divalent cation, especially Mg²⁺. The enzymatic and antisense nucleic acid molecules are useful for treating breast, lung, prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,

CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapeutic including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel
 CC enzymatic nucleic acid molecule.
 XX
 SQ Sequence 17 BP; 2 A; 9 C; 3 G; 3 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 87.5%; Pred. No. 2.7e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 528 GGAGGAGGAGCTGGGT 543
 ||||| :|||:|
 Db 17 GGAGGAGGAGCTGGGT 2

RESULT 586
 ACA06814/c
 ID ACA06814 standard; RNA; 17 BP.
 XX
 AC ACA06814;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFKB sub-unit modulating inozyme substrate #633.

Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 lung cancer; prostate cancer; colorectal cancer; brain cancer;
 oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 chemotherapeutic; paclitaxel; docetaxel; cisplatin; methotrexate;
 cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 rheumatoid arthritis; restenosis; Crohn's disease; obesity; diabetes;
 gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 transplant/graft rejection; reperfusion injury; glomerulonephritis;
 allergic airway inflammation; inflammatory bowel disease; infection;
 ss.

OS Homo sapiens.
 XX
 PN US2002177568-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 23-MAY-2001; 2001US-0864785.
 XX
 PR 15-AUG-1994; 94US-0291932.
 PR 07-DEC-1992; 92US-0987132.
 PR 18-MAY-1994; 94US-0245466.
 PR 23-DEC-1996; 96US-0777916.
 XX
 PA (STIN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 PI Stinchcomb DT, Mcswiggen J, Draper KG;
 DR WPI; 2003-340953/32.
 XX
 PT Novel enzymatic nucleic acid molecules which down regulates expression

CC of cancer proliferation and metastasis. The present sequence represents
CC a PCR primer for human CBFA1 type II, which is used in an example from
CC the present invention.

XX Sequence 17 BP; 4 A; 8 C; 3 G; 2 T; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 679 GTGGTATTGGAGCC 694
DB 16 GTGGTATCTGGGGCC 1

RESULT 592
ABZ60572/c
ID ABZ60572 standard; RNA; 17 BP.
XX AC ABZ60572;
XX DT 21-MAR-2003 (first entry)
XX DE Human K-Ras DNzyme substrate #684.
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX DR WPI; 2003-140484/13.

PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX Claim 58; Page 98; 185pp; English.
XX The invention relates to a novel short interfering RNA (siRNA) nucleic
XX acid molecule or an enzymatic nucleic acid molecule, that modulates
XX expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX acid molecule of the invention has cytostatic, anti-HIV, and
XX anti-rheumatic activity. The nucleic acid molecules are useful for
XX reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
XX acids are also useful for treating breast, ovarian, colorectal, lung,
XX prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
XX The sequences shown in ABZ60520 - ABZ60524, ABZ60530 - ABZ60531,
XX represent substrate/target sequences for the human ribozymes of the invention.

XX Sequence 17 BP; 2 A; 6 C; 5 G; 4 U; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1013 ACCTGAGATGGTGCCA 1028

DB 17 AGCTGAGATGGGCCA 2

RESULT 593
ABZ61171
ID ABZ61171 standard; RNA; 17 BP.
XX AC ABZ61171;
XX DT 21-MAR-2003 (first entry)
XX DE Human K-Ras DNzyme substrate #1283.

XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX DR WPI; 2003-140484/13.

PT Novel short interfering RNA and enzymatic nucleic acid useful for
PT treating cancer, modulates the expression of a nucleic acid encoding
PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX Claim 58; Page 109; 185pp; English.

XX The invention relates to a novel short interfering RNA (siRNA) nucleic
XX acid molecule or an enzymatic nucleic acid molecule, that modulates
XX expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX acid molecule of the invention has cytostatic, anti-HIV, and
XX anti-rheumatic activity. The nucleic acid molecules are useful for
XX reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
XX acids are also useful for treating breast, ovarian, colorectal, lung,
XX prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
XX The sequences shown in ABZ60520 - ABZ60524, ABZ60530 - ABZ60531,
XX represent substrate/target sequences for the human ribozymes of the invention.

XX Sequence 17 BP; 7 A; 4 C; 5 G; 1 U; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 279 AGAGGAGCAGCAGCA 294
DB 2 AAGGAGCAGCAGCA 17

RESULT 594
ABZ61760/c
ID ABZ61760 standard; RNA; 17 BP.
XX AC ABZ61760;
XX DT 21-MAR-2003 (first entry)

```

XX DE Human H-Ras DNazyme target #551.
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
XX KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX XX
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX XX
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX XX
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX XX
XX DR WPI; 2003-140484/13.
XX XX
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
XX PT treating cancer, modulates the expression of a nucleic acid encoding
XX PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX XX
XX PS Claim 58; Page 121; 185pp; English.
XX XX
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
XX CC acid molecule or an enzymatic nucleic acid molecule, that modulates
XX CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX CC acid molecule of the invention has cytostatic, anti-HIV, and
XX CC anti-rheumatic activity. The nucleic acid molecules are useful for
XX CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
XX CC acids are also useful for treating breast, ovarian, colorectal, lung,
XX CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
XX CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
XX CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
XX CC sequences for the human ribozymes of the invention.
XX SQ Sequence 17 BP; 5 A; 2 C; 8 G; 2 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 693 CCAGCGCGCCCTCCTT 708
DB 16 CCAGCAGCCCTTCCTT 1

RESULT 595
ABZ61761/c
ID ABZ61761 standard; RNA; 17 BP.
XX AC ABZ61761;
XX XX
XX DT 21-MAR-2003 (first entry)
XX DE Human H-Ras DNazyme target #552.
XX XX
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
XX KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX XX

```

```

PD 05-DEC-2002.
XX XX
XX PF 29-MAY-2002; 2002WO-US16840.
XX XX
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX XX
XX PI Mcswiggen J;
XX XX
XX DR WPI; 2003-140484/13.
XX XX
XX PT Novel short interfering RNA and enzymatic nucleic acid useful for
XX PT treating cancer, modulates the expression of a nucleic acid encoding
XX PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
XX XX
XX PS Claim 58; Page 121; 185pp; English.
XX XX
XX CC The invention relates to a novel short interfering RNA (siRNA) nucleic
XX CC acid molecule or an enzymatic nucleic acid molecule, that modulates
XX CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
XX CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
XX CC acid molecule of the invention has cytostatic, anti-HIV, and
XX CC anti-rheumatic activity. The nucleic acid molecules are useful for
XX CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
XX CC acids are also useful for treating breast, ovarian, colorectal, lung,
XX CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
XX CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
XX CC ABZ66520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
XX CC sequences for the human ribozymes of the invention.
XX SQ Sequence 17 BP; 3 A; 4 C; 8 G; 2 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 2.7e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 570 GCTCCAGCAGCCCTTC 585
DB 16 GCTCCAGCAGCCCTTC 1

RESULT 596
ABZ64859
ID ABZ64859 standard; RNA; 17 BP.
XX AC ABZ64859;
XX XX
XX DT 21-MAR-2003 (first entry)
XX DE Human HER2 DNazyme substrate #316.
XX XX
XX KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
XX KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
XX KW anti-rheumatic; cancer; AIDS; ss.
XX OS Homo sapiens.
XX PN WO200297114-A2.
XX PD 05-DEC-2002.
XX XX
XX PF 29-MAY-2002; 2002WO-US16840.
XX PR 29-MAY-2001; 2001US-294140P.
XX PR 06-JUN-2001; 2001US-296249P.
XX PR 10-SEP-2001; 2001US-318471P.
XX XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX PI Mcswiggen J;
XX XX

```

XX WPI; 2003-140484/13.
 XX Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
 XX
 PS Claim 4; Page 139; 185pp; English.
 XX The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytostatic, anti-HIV, and
 CC anti-rheumatic activity. The nucleic acid molecules are useful for
 CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
 CC acids are also useful for treating breast, ovarian, colorectal, lung,
 CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
 CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
 CC ABZ6520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
 CC sequences for the human ribozymes of the invention.
 XX
 SQ Sequence 17 BP; 2 A; 10 C; 3 G; 2 U; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 2.7e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 589 CTGCCCCCACCAGCC 604
 | : | | | | | | | | | |
 Db 2 CUGCCCCGCCAGCC 17
 RESULT 597
 ABZ64966
 ID ABZ64966 standard; RNA; 17 BP.
 XX
 AC ABZ64966;
 XX
 DT 21-MAR-2003 (first entry)
 XX
 DE Human HER2 DNzyme substrate #423.
 XX
 XX Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 XX enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytostatic; anti-HIV;
 XX anti-rheumatic; cancer; AIDS; ss.
 OS
 OS Homo sapiens.
 XX
 PN WO200297114-A2.
 XX
 PD 05-DEC-2002.
 XX
 PF 29-MAY-2002; 2002WO-US16840.
 XX
 PR 29-MAY-2001; 2001US-294140P.
 PR 06-JUN-2001; 2001US-296249P.
 PR 10-SEP-2001; 2001US-318471P.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Mcswiggen J;
 XX
 DR WPI; 2003-140484/13.
 XX
 PT Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
 XX
 PS Claim 4; Page 141; 185pp; English.
 XX
 CC The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates

CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytostatic, anti-HIV, and
 CC anti-rheumatic activity. The nucleic acid molecules are useful for
 CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
 CC acids are also useful for treating breast, ovarian, colorectal, lung,
 CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.
 CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
 CC ABZ6520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
 CC sequences for the human ribozymes of the invention.
 XX
 SQ Sequence 17 BP; 4 A; 2 C; 8 G; 3 U; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 17;
 Best Local Similarity 81.2%; Pred. No. 2.7e+02;
 Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
 QY 475 GGGGAGGAGTCCGAG 490
 | : | | | | | | | | | |
 Db 1 GUGGAGGAGUCCGAG 16
 RESULT 598
 AAQ70348
 ID AAQ70348 standard; DNA; 18 BP.
 XX
 AC AAQ70348;
 XX
 DT 25-MAR-2003 (updated)
 DT 15-FEB-1995 (first entry)
 XX
 DE Antisense oligonucleotide for mouse FGF.
 XX
 XX Fibroblast growth factor; hybridisation; laser procedures;
 XX vascular smooth muscle cell; proliferation;
 XX SMC; vascular stenosis; post angioplasty restenosis;
 XX atherosclerosis; cardiac hypertrophy; organ transplant; ss.
 XX
 OS Synthetic.
 XX
 PN WO9415945-A1.
 XX
 PD 21-JUL-1994.
 XX
 PF 28-DEC-1993; 93WO-US12600.
 XX
 PR 31-DEC-1992; 92US-0999706.
 XX
 PA (TEXA-) TEXAS BIOTECHNOLOGY CORP.
 XX
 PI Denner LA, Dixon RAF, Rege AA, Dixon RA;
 XX
 DR WPI; 1994-249123/30.
 XX
 PT New anti-sense polynucleotide(s) to fibroblast growth factor
 PT receptor - used for inhibiting vascular smooth muscle cell
 PT proliferation, partic. for treating restenosis
 XX
 PS Claim 3; Page 9; 53pp; English.
 XX
 CC The sequence is an antisense molecule directed against position -9
 CC to +9, relative to the start codon of the gene for
 CC mouse fibroblast growth factor 1. The polynucleotide can be used for
 CC inhibiting vascular smooth muscle cell proliferation and for treating
 CC a disease e.g. vascular stenosis, post angioplasty restenosis,
 CC atherectomy, atherosclerosis, atrial venous shunt failure, cardiac
 CC hypertrophy, vascular surgery and organ transplant.
 CC See also AAQ70333-60.
 CC (Updated on 25-MAR-2003 to correct PN field.)
 XX
 SQ Sequence 18 BP; 3 A; 9 C; 2 G; 4 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;

Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 870 CCCACACCCAGTTC 885
|||||
Db 2 CCCACATCCAGTTC 17

RESULT 599

AAQ86978/c
ID AAQ86978 standard; DNA; 18 BP.

XX AC
XX AAQ86978;

DT 17-JAN-1996 (first entry)

XX Primer 1 to amplify MRSA target DNA.

XX MRSA; methicillin resistant Staphylococcus aureus; probe;
KW hybridisation; meca; MRSP; Staphylococcus epidermis; primer; PCR;
KW Polymerase chain reaction; ss.

XX Staphylococcus aureus.

OS DE4338119-Al.

XX 11-MAY-1995.

PD 08-NOV-1993; 93DE-4338119.

XX 08-NOV-1993; 93DE-4338119.

PR (FARB) BAYER AG.

XX Endermann R, Springer W;

XX WPI; 1995-180108/24.

XX Detection of methicillin resistant Staphylococcus - using an

PT oligo:nucleotide derived from the meca gene

XX Claim 3; Page 11; 14pp; German.

XX Primer 1 and 2 (AAQ86978-79) were used to amplify a target nucleotide

CC sequence from methicillin resistant S. aureus (MRSA). The target

CC is detected with a probe specifically derived from the meca gene of

CC S. aureus and S. epidermidis. The meca gene product has no homology

CC with known PBPs (penicillin-binding proteins). The new probes allow

CC for the rapid identification of all MRSA, eradicating need for labour

CC intensive in vitro cultivation and physiological assays.

XX Sequence 18 BP; 7 A; 1 C; 4 G; 6 T; 0 other;

SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;

CC Best Local Similarity 87.5%; Pred. No. 2.9e+02;

XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 321 ATACCTGCATCATCT 336

Db 18 ATACTGCATCATCTT 3

RESULT 600

AAAT50704/c

ID AAT50704 standard; RNA; 18 BP.

XX AC

XX AAT50704;

XX 07-MAR-1997 (first entry)

XX Rabbit CERP hairpin ribozyme target sequence #191.

XX Hairpin ribozyme; cholesterol ester transfer protein; mRNA cleavage;

XX

KW neutral lipid transfer; plasma lipoprotein; atherosclerosis; atherectomy;
KW reverse cholesterol transport; high density lipoprotein; therapy; CERP;
KW familial hypercholesterolaemia; dyslipidaemia; hypolipoproteinaemia;
KW peripheral vascular disease; hyperbetalipoproteinaemia; RCT; inhibitor;
KW angioplastic restenosis; low density lipoprotein; diabetes; HDL; rabbit;
KW LDL; ss.

XX Oryctolagus cuniculus.

XX WO9620279-Al.

XX 04-JUL-1996.

XX 11-DEC-1995; 95WO-US16000.

XX 23-DEC-1994; 94US-0363240.

XX (RIBO-) RIBOZYME PHARM INC.

XX (WARN) WARNER LAMBERT CO.

XX Bisgaier C, Couture L, McSwiggen J, Pape M, Stinchcomb D;

XX WPI; 1996-321852/32.

XX New ribozyme(s) for cleaving cholesterol ester transfer protein mRNA

XX - useful for preventing or treating initial development, progression

XX or regression of vascular diseases, esp. familial

XX hypercholesterolaemia

XX Claim 4; Page 55; 72pp; English.

XX AAT50699-T50754 represent target sequences for the rabbit cholesterol

CC ester transfer protein (CERP) hairpin ribozymes (see AAT50643-T50698).

CC CERP is a 74 kD glycoprotein that facilitates neutral lipid transfer

CC between plasma lipoproteins. The numbering of the targets refers to the

CC position of the cleavage site in full length CERP. The ribozyme then

CC binds to 4-6 nucleotides 5', and a variable number 3' of this site. The

CC ribozymes are able to cleave mRNA from the gene encoding CERP, thereby

CC blocking synthesis and/or expression of the mRNA. By inhibiting CERP,

CC the reverse cholesterol transport (RCT) pathway can be inhibited (or

CC eliminated) thereby preventing the reduction in size density of the high

CC density lipoproteins (HDL), prolonging HDL half life, and therefore

CC increasing HDL levels. The ribozymes can be used to treat conditions

CC associated with abnormal levels of CERP, specifically atherosclerosis,

CC peripheral vascular disease, hyperbetalipoproteinaemia, dyslipidaemia,

CC familial hypercholesterolaemia, hypolipoproteinaemia, vascular

CC complications of diabetes, transplant, atherectomy and angioplastic

CC restenosis. By inhibiting CERP, the levels of HDL and low density

CC lipoproteins (LDL), and the HDL:LDL ratio are favourably altered (a

CC decrease in LDL levels, and a corresponding increase in HDL levels). The

CC ribozymes can also be used diagnostically to study genetic drift and

CC mutations in diseased cells, and to detect CERP mRNA. As the ribozymes

CC target specific regions of the CERP gene, they have low non-specific

CC activity.

XX Sequence 18 BP; 5 A; 9 C; 2 G; 2 U; 0 other;

SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;

CC Best Local Similarity 87.5%; Pred. No. 2.9e+02;

XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 924 GATGGCAGATCTGGAG 939

Db 18 GGTGGCTGATCTGGAG 3

RESULT 601

AAT28333/c

ID AAT28333 standard; DNA; 18 BP.

XX AC

XX AAT28333;

XX 20-NOV-1996 (first entry)


```

XX DE Multi-G oligonucleotide hu SCR (I2G2).
XX DE
XX DE
XX DE
XX DE Multi-G oligonucleotide; antisense sequence; c-myc; nuclease resistant;
XX DE phosphorothioate linkage; phosphorothioate linkage; inhibitor; therapy;
XX DE cell proliferation; smooth muscle cell; proliferation protein;
XX DE vascular restenosis; arterial restenosis; ss.
XX OS Synthetic.
XX OS
XX OS
XX OS Key Location/Qualifiers
XX OS modified_base 6 /*tag= a
XX FT /mod_base= i
XX FT
XX FT modified_base 7
XX FT /*tag= b
XX FT /mod_base= i
XX FT
XX FT
XX FT
XX FT WO9611266-A2.
XX FN
XX FN
XX FN 18-APR-1996.
XX PD
XX PD
XX PD 03-OCT-1995; 95WO-US12770.
XX PF
XX PF
XX PF 05-OCT-1994; 94US-0318458.
XX PR
XX PR (AMGE-) AMGEN INC.
XX PA
XX PA Burgess TL, Farrell CL, Fisher EF;
XX PI WPI; 1996-209848/21.
XX DR
XX DR
XX DR New modified oligo:nucleotide(s) contg. consecutive guanine residues
XX PT - inhibit proliferation of smooth muscle cells, esp. to prevent
XX PT arterial restenosis
XX PT
XX PS Example 1; Page 46; 67pp; English.
XX PS
XX CC AAT28317-T28347 represent multi-G oligonucleotides. AAT28332-T28335 are
XX CC multi-G oligonucleotides with inosine substitutions. These sequences
XX CC are oligonucleotides of the invention. These sequences can be modified
XX CC to become more nuclease resistant, using phosphorothioate,
XX CC phosphorodithioate, or 3'-carbon modified links. To screen for modified
XX CC multi-G sequences that inhibit cell proliferation, cultured smooth
XX CC muscle cells that are arrested in the G0 phase, are induced to
XX CC proliferate in the presence of the multi-G sequence. The cultured smooth
XX CC muscle cells used in this method are attached to a solid support, and
XX CC growth arrest is achieved on a starvation medium, followed by transfer to
XX CC a normal growth medium to induce proliferation. The compounds that
XX CC provide over 50% inhibition at a set dosage are selected as being useful
XX CC for inhibiting vascular restenosis. The multi-G oligonucleotides are
XX CC used to inhibit proliferation of smooth muscle cells, such as to prevent
XX CC arterial restenosis. These sequences are not antisense sequences, but
XX CC are thought to work in a similar way. The sequences are thought to act
XX CC by binding to proteins involved in the proliferation process. Compounds
XX CC containing these multi-G oligonucleotides are not toxic, and their effect
XX CC on cell proliferation is fully reversible.
XX SQ Sequence 18 BP; 0 A; 5 C; 7 G; 4 T; 2 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

Qy 886 CAGGAGCTGCGGTACAGC 903
Dy 18 CAGGAGCGCCCNACAGC 1

RESULT 602
AAT30032
ID AAT30032 standard; DNA; 18 BP.
XX

```

```

AC AAT30032;
XX
XX 19-AUG-1996 (first entry)
XX
XX NER PCR primer ES11.
XX
XX NER receptor; potentiator; steroid hormone receptor;
XX G-protein coupled receptor; nerve growth factor; Alzheimer disease;
XX ocular hypertension; schizophrenia; distonia; tardive dyskinesia;
XX Gilles de la Tourette syndrome; polymerase chain reaction; PCR;
XX primer; ss.
XX
XX OS Synthetic.
XX OS
XX OS Key Location/Qualifiers
XX OS misc_difference 1..18
XX FT /*tag= a
XX FT /note= "sequence differs from ES11 sequence on
XX FT pages 32 and 52 (see also AAT30035)"
XX FT
XX FN WO9613257-A1.
XX PD
XX PD 09-MAY-1996.
XX PF
XX PF 24-OCT-1995; 95WO-US13931.
XX PR
XX PR 27-OCT-1994; 94US-0330518.
XX PA (MEDI-) MEDICAL COLLEGE PENNSYLVANIA.
XX PA (MERI) MERCK & CO INC.
XX
XX PI Friedman E, Holloway MK, Rodan GA, Schmidt A, Vogel RL;
XX WPI; 1996-239256/24.
XX
XX PT Use of steroid hormone receptor NER activators - for potentiating
XX PT activity of modulator of G-protein coupled receptor
XX PS Example 1; Page 31; 63pp; English.
XX PS
XX CC Primer ES11 (AAT30032) is based on the conserved amino acids
XX CC CEGCKA(G) of the DNA binding domain of a typical nuclear receptor.
XX CC It was used with antisense primer ES15 (AAT30034) for the PCR
XX CC amplification of human CDNA prep. from osteosarcoma SAOS-2/B10
XX CC cells. A second round of PCR utilised primers ES12 (AAT30033) and
XX CC ES15. A product was obtd. that was used to screen the osteosarcoma
XX CC library, resulting in isolation of a clone (AAT30031) coding for
XX CC a novel steroid hormone receptor, NER (AAR98140).
XX SQ Sequence 18 BP; 3 A; 3 C; 7 G; 3 T; 2 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 2.9e+02;
Matches 14; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 303 TGTGGGGGCTGCAACTCC 320
Dy 1 TGTGGGGGCTGCAARGSC 18

RESULT 603
AAX75628
ID AAX75628 standard; RNA; 18 BP.
XX
XX AAX75628;
XX
XX 28-JUL-1999 (first entry)
XX
XX Mouse flt-1 VEGF receptor hairpin ribozyme substrate #87.
XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
XX flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
XX tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
XX

```

KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.

OS Mus sp.

XX WO9715662-A2.

XX PN 01-MAY-1997.

XX PF 25-OCT-1996; 96WO-US17480.

XX PR 11-JAN-1996; 96US-0584040.

XX PR 26-OCT-1995; 95US-0005974.

XX PA (CHIR) CHIRON CORP.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

XX DR WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient

XX PS Claim 4; Page 188; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.

SQ Sequence 18 BP; 2 A; 5 C; 6 G; 5 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 56.2%; Pred. No. 2.9e+02;
 Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1311 GTAGCCAGCGCTTTT 1326

Db 1 GGAGCCAGCGCUUUU 16

RESULT 604

AAX70294

ID AAX70294 standard; RNA; 18 BP.

XX AC AAX70294;

XX DT 28-JUL-1999 (first entry)

XX DE Human flt1 VEGF receptor hairpin ribozyme substrate #62.

XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
 KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.

XX OS Homo sapiens.

XX PN WO9715662-A2.

XX PD 01-MAY-1997.

XX PF 25-OCT-1996; 96WO-US17480.

XX

PR 11-JAN-1996; 96US-0584040.
 PR 26-OCT-1995; 95US-0005974.

XX (CHIR) CHIRON CORP.

XX (RIBO-) RIBOZYME PHARM INC.

XX PI Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

XX DR WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient

XX PS Claim 4; Page 94; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour
 CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX67275 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.

SQ Sequence 18 BP; 2 A; 4 C; 6 G; 6 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 56.2%; Pred. No. 2.9e+02;
 Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1311 GTAGCCAGCGCTTTT 1326

Db 1 GGAGCCAGCGCUUUU 16

RESULT 605

AAX62734/c

ID AAX62734 standard; RNA; 18 BP.

XX AC AAX62734;

XX DT 16-JUL-1999 (first entry)

XX DE Granule bound starch synthase hairpin substrate SEQ ID NO:609.

XX Maize; corn; Zea mays; delta-9 desaturase; GBSS; target; substrate;
 KW granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;
 KW modulation; gene expression; transgenic plant; cleavage; canola plant;
 KW caffeine synthesis; coffee plant; nicotine production; tobacco;
 KW fruit ripening; flower pigmentation; lignin production; ss.

XX OS Zea mays.

XX PN WO9710328-A2.

XX PD 20-MAR-1997.

XX PF 12-JUL-1996; 96WO-US11689.

XX PR 13-JUL-1995; 95US-0001135.

XX PA (DOWC) DOWELANCO.

XX PA (RIBO-) RIBOZYME PHARM INC.

XX PI Edington BE, Folkerts O, Guo L, McSwiggen JA, Merlo DJ;

XX PI Merlo PAO, Skokut TA, Young SA, Zwick MG;

XX DR WPI; 1997-202224/18.

XX PT Ribozyme which modulates plant gene expression - preferably

modulates expression of DELTA-9 desaturase or granule bound starch synthase in maize or canola

Claim 42; Page 84; 155pp; English.

The present invention describes an enzymatic nucleic acid molecule (I) with RNA cleaving activity, which modulates the expression of a plant gene. Also described is a gene comprising a cDNA sequence encoding maize Delta-9 desaturase. (I) can be used to modulate expression of a gene, preferably Delta-9 desaturase or a granule bound starch synthase (GBSS) gene, in a plant (preferably a maize or canola plant). (I) can be used to modulate caffeine synthesis in a coffee plant, nicotine production in a tobacco plant, fruit ripening processes in an apple, tomato, pear, plum or peach plant, flower pigmentation in a rose, petunia, chrysanthemum or marigold plant or lignin production in a tobacco, aspen, poplar or pine plant.

Sequence 18 BP; 4 A; 6 C; 5 G; 3 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

OY 884 TCACGAGCTGCGGTA 899
||| |||||
D 16 TCACGAGCTGCGGGA 1

RESULT 606
AA62754
ID AA62754 standard; RNA; 18 BP.
AC AA62754;
XX
DT 16-JUL-1999 (first entry)
XX
DE Granule bound starch synthase hairpin substrate SEQ ID NO:629.
XX
KW Maize; corn; Zea mays; delta-9 desaturase; GBSS; target; substrate;
KW granule bound starch synthase; hammerhead ribozyme; hairpin ribozyme;
KW modulation; gene expression; transgenic plant; cleavage; canola plant;
KW caffeine synthesis; coffee plant; nicotine production; tobacco;
KW fruit ripening; flower pigmentation; lignin production; ss.
XX
OS Zea mays.
XX
FN WO9710328-A2.
XX
PD 20-MAR-1997.
XX
PF 12-JUL-1996; 96WO-US11689.
XX
PR 13-JUL-1995; 95US-0001135.
XX
PA (DOWC) DOWELANCO.
PA (RIBO-) RIBOZYME PHARM INC.
XX
PI Edington BE, Folkerts O, Guo L, McSwiggen JA, Merlo DJ;
PI Merlo PAO, Skokut TA, Young SA, Zwick WG;
XX
DR WPI; 1997-202224/18.
XX
PT Ribozyme which modulates plant gene expression - preferably
PT modulates expression of DELTA-9 desaturase or granule bound starch
PT synthase in maize or canola
XX
PS Claim 42; Page 84; 155pp; English.
XX
CC The present invention describes an enzymatic nucleic acid molecule (I) with RNA cleaving activity, which modulates the expression of a plant gene. Also described is a gene comprising a cDNA sequence encoding maize Delta-9 desaturase. (I) can be used to modulate expression of a gene, preferably Delta-9 desaturase or a granule bound starch synthase (GBSS) gene, in a plant (preferably a maize or canola plant). (I) can be used to modulate caffeine synthesis in a coffee plant, nicotine production in a tobacco plant, fruit ripening processes in an apple, tomato, pear, plum or peach plant, flower pigmentation in a rose, petunia, chrysanthemum or marigold plant or lignin production in a tobacco, aspen, poplar or pine plant.

gene, in a plant (preferably a maize or canola plant). (I) can be used to modulate caffeine synthesis in a coffee plant, nicotine production in a tobacco plant, fruit ripening processes in an apple, tomato, pear, plum or peach plant, flower pigmentation in a rose, petunia, chrysanthemum or marigold plant or lignin production in a tobacco, aspen, poplar or pine plant.

Sequence 18 BP; 2 A; 7 C; 5 G; 4 U; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 68.8%; Pred. No. 2.9e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

OY 220 CGAGCTCTCTCAGCTC 235
||| |||||
D 2 CGUGCUGCUCAGCCUC 17

RESULT 607
AAT94805
ID AAT94805 standard; DNA; 18 BP.
XX
AC AAT94805;
XX
DT 19-FEB-1998 (first entry)
XX
DE Human leukocyte antigen class I gene URSTO probe 531-548.
XX
KW Human leukocyte antigen; HLA; probe; tissue transplantation;
KW MHC gene; major histocompatibility complex; paternity test;
KW forensic medicine; haematological malignancy; inherited disorder;
KW adoptive immunotherapy; identification; ss.
XX
OS Synthetic.
OS Homo sapiens.
XX
FN WO9720197-A2.
XX
PD 05-JUN-1997.
XX
PF 29-NOV-1996; 96WO-GB02959.
XX
PR 29-NOV-1995; 95GB-0024381.
XX
PA (NOLA-) NOLAN BONE MARROW TRUST ANTHONY.
XX
PI Arguello R, Avakian H, Madrigal A;
XX
DR WPI; 1997-310717/28.
XX
PT Identifying unknown allele(s) of a polyallelic gene using panel of
PT probes each recognising a sequence motif present in some allele(s) -
PT useful for donor matching in tissue transplantation
XX
PS Claim 5; Page 19; 64pp; English.
XX
CC A novel method has been developed for identifying an unknown allele of a
CC polyallelic gene. The method involves: (a) contacting the unknown allele
CC with a panel of probes, each of which recognises a sequence motif that
CC is present in some alleles of the polyallelic gene but not in others;
CC (b) observing which probes recognise the unknown allele so as to obtain
CC a fingerprint of the unknown allele; and (c) comparing the fingerprint
CC with fingerprints of known alleles. The present sequence represents a
CC specifically claimed probe for use in the method where the polyallelic
CC gene is a human leukocyte antigen class I gene. The method can be used
CC for genes such as mammalian MHC genes, specifically the HLA class I and
CC II genes, the T cell receptor genes in mammals, TAP, LMP, ras,
CC nonclassical HLA class I genes, human complement factor genes C4 and C2,
CC Bf in the HLA complex, and genes located in mitochondrial DNA, bacterial
CC chromosomes and viral DNA. The method is particularly useful for
CC matching the alleles of the HLA genes in a prospective donor and a
CC prospective recipient in tissue or organ transplantations. The method
CC can also be used in paternity testing, in forensic medicine, as a

CC follow up technique in treatment of haematological malignancies or
 CC inherited disorders, in adoptive immunotherapy, and in identification
 CC of bacteria and viruses. The method can provide for the identification
 CC of alleles of the polyallelic genes using a limited number of selected
 CC recurring motif probes.
 XX
 SQ Sequence 18 BP; 5 A; 4 C; 7 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 531 GGAGCAGCTGGTGGCC 546
 Db 1 GGAGCAGCTGGAGCC 16

RESULT 608
 AAT76410
 ID AAT76410 standard; DNA; 18 BP.
 XX
 AC AAT76410;
 XX
 DT 15-SEP-1997 (first entry)
 XX
 DE Human endothelin-1 antisense oligonucleotide.

XX Asthma; airway epithelium; adenosine free; cystic fibrosis;
 KW chronic obstructive pulmonary disease; bronchitis; ss.
 KW
 XX Synthetic.

OS
 XX WO9640162-Al.
 PN
 XX

PD 19-DEC-1996.
 XX
 PF 06-JUN-1996; 96WO-US09306.
 XX
 PR 07-JUN-1995; 95US-0474497.
 XX

PA (UYEC-) UNIV EAST CAROLINA.

PI Metzger WJ, Nyce JW;

XX WPI; 1997-051871/05.

DR
 XX Treatment of airway diseases such as asthma - by topically applying
 PT adenosine-free antisense oligonucleotide to airway epithelium of
 PT subject

XX Claim 5; Page 38; 71pp; English.

XX A method for treating airway disease in a subject has been produced,
 CC which involves the topical administration of an essentially adenosine
 CC free antisense oligonucleotide (ON) to the airway epithelium of the
 CC subject. The present sequence is an antisense oligonucleotide
 CC specific for the human endothelin-1. The method can be used to treat
 CC airway diseases such as cystic fibrosis, asthma, chronic obstructive
 CC pulmonary disease, bronchitis and other airway diseases characterised
 CC by an inflammatory response. By eliminating adenosine from the
 CC antisense ON, its liberation upon antisense degradation is prevented,
 CC thereby preventing adenosine-induced bronchoconstriction in patients
 CC with hyper-reactive airways.

SQ Sequence 18 BP; 0 A; 4 C; 3 G; 11 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1143 CTTTTCCTTTTGG 1158
 Db 1 CTTCTGTCTTTTGG 16

RESULT 609
 AAX10189
 ID AAX10189 standard; DNA; 18 BP.
 XX
 AC AAX10189;

XX
 DT 24-MAR-1999 (first entry)

XX Human biallelic polymorphic marker downstream primer #495.
 DE
 XX Polymorphism; biallelic; human; forensic; paternity testing; disease;
 KW detection; phenotypic typing; characteristic; infection; hereditary;
 KW autoimmune disease; cancer; inflammation; drug; therapy; medicament;
 KW treatment; marker; primer; ss.

XX Synthetic.

OS Homo sapiens.

XX WO9820165-A2.

XX 14-MAY-1998.

XX 05-NOV-1997; 97WO-US20313.

XX 06-NOV-1996; 96US-0030455.

XX (WHED) WHITEHEAD INST BIOMEDICAL RES.

XX Hudson T, Lander ES, Wang D;

XX WPI; 1998-286974/25.

XX New isolated nucleic acid segments from the human genome - used for
 PT determining polymorphic forms for use in e.g. forensics, paternity
 PT testing or phenotypic typing for disease
 XX Claim 16; Page 212; 310pp; English.

XX AAX09121-X10268 are allele-specific oligonucleotide primers used in the
 CC isolation of various biallelic polymorphic markers found in the human
 CC genome (represented in AAX10269-X12937). These primers can be used in a
 CC method for determining polymorphic forms in an individual for use in
 CC e.g. forensics, paternity testing or for phenotypic typing for diseases
 CC such as agammaglobulinemia, diabetes insipidus, Lesch-Nyhan syndrome,
 CC muscular dystrophy, Wiskott-Aldrich syndrome, Fabry's disease, familial
 CC hypercholesterolemia, polycystic kidney disease, hereditary
 CC spherocytosis, von Willebrand's disease, tuberculous sclerosis, hereditary
 CC haemorrhagic telangiectasia, familial colonic polyposis, Ehlers-Danlos
 CC syndrome, osteogenesis imperfecta, acute intermittent porphyria,
 CC autoimmune diseases, inflammation, cancer, diseases of the nervous
 CC system, infection by pathogenic microorganisms, and characteristics such
 CC as longevity, appearance (e.g. baldness, obesity), strength, speed,
 CC endurance, fertility, and susceptibility or receptivity to particular
 CC drugs or therapeutic treatments. The isolated polymorphic nucleic acid
 CC segments can also be used to produce medicaments for the treatment or
 CC prophylaxis of such diseases.

SQ Sequence 18 BP; 5 A; 6 C; 4 G; 3 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1285 CATACAGTGTCTCAGC 1300
 Db 3 CATACATGGCTCAGC 18

RESULT 610
 AAV95056
 ID AAV95056 standard; RNA; 18 BP.

```

XX AC AAV95056;
XX XX
XX DT 24-FEB-1999 (first entry)
XX DE Mouse IL-2 receptor g-chain substrate position 399.
XX XX
XX KW Human; IL-2 receptor g-chain; interleukin 2 receptor gamma chain;
XX KW hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;
XX KW autoimmune disease; psoriasis; allergy; inflammatory disease;
XX KW graft rejection; ss.
XX OS Mus sp.
XX XX
XX PN WO9824913-A2.
XX XX
XX PD 11-JUN-1998.
XX XX
XX PF 02-DEC-1997; 97WO-US21748.
XX XX
XX PR 03-DEC-1996; 96US-0758306.
XX XX
XX PA (RIBO-) RIBOZYME PHARM INC.
XX XX
XX PI McSwiggen JA, Stinchcomb DT;
XX XX
XX DR WPI; 1998-333332/29.
XX XX
XX PT Ribozymes targeted to interleukin 2 - useful for treating e.g.
XX PT cancer, autoimmune disease and allergies
XX XX
XX PS Claim 4; Page 44; 61pp; English.
XX XX
XX CC The present sequence invention describes ribozymes targeted to modulate
XX CC the synthesis and/or expression of interleukin (IL)-2R gamma encoded
XX CC RNA. AAV93889 to AAV94574 represent specifically claimed ribozymes, and
XX CC AAV94575 to AAV95260 represent specifically claimed substrate sequences
XX CC from the present invention. The ribozymes can be used for the treatment
XX CC of, e.g. graft rejection, autoimmune disease, cancer, psoriasis,
XX CC allergy and other inflammatory conditions. The ribozymes are also used
XX CC to induce tolerance in a recipient to alloantigen from a donor.
XX SQ
XX Sequence 18 BP; 3 A; 7 C; 4 G; 4 U; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 18;
XX Best Local Similarity 81.2%; Pred. No. 2.9e+02;
XX Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 625 GACCAGCTCCAGGAC 640
XX DB |||||:|||||
XX 3 GUCCAGCUCCAGGACC 18

RESULT 611
AAV54165
ID AAV54165 standard; cDNA; 18 BP.
XX AC AAV54165;
XX XX
XX DT 21-DEC-1998 (first entry)
XX DE Nucleotide sequence PCR primer 2.
XX XX
XX KW PCR; primer; amplification; apoptosis; antibody; inhibition; ss;
XX KW immunohistological staining.
XX OS Synthetic.
XX XX
XX PN WO9839437-A1.
XX XX
XX PD 11-SEP-1998.
XX XX
XX PF 05-MAR-1998; 98WO-JP00905.

```

```

XX XX
XX PR 05-MAR-1997; 97JP-0050302.
XX PA (KYOW ) KYOWA HAKKO KOGYO KK.
XX PI Sakaki Y;
XX DR WPI; 1998-495844/42.
XX XX
XX PT Novel apoptosis-related DNAs and proteins - for diagnosis,
XX PT preventing or treating diseases associated with apoptosis.
XX PS Example 1; Page 47; 70pp; Japanese.
XX XX
XX CC This is the nucleotide sequence of a PCR primer used in the method
XX CC of the invention, involving the use of novel apoptosis-related DNAs
XX CC and proteins. The inventions can be used as diagnostic reagents for
XX CC apoptosis e.g. (monoclonal) antibodies for the protein, as a reagent
XX CC in immunohistological staining, as apoptosis inhibitors. It can also
XX CC be used for treatment of apoptosis-related diseases.
XX SQ
XX Sequence 18 BP; 1 A; 0 C; 2 G; 15 T; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 18;
XX Best Local Similarity 87.5%; Pred. No. 2.9e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 1144 TTTTCTCTTTTGA 1159
XX DB |||||:|||||
XX 3 TTTTCTCTTTTGA 18

RESULT 612
AAV35391
ID AAV35391 standard; DNA; 18 BP.
XX AC AAV35391;
XX XX
XX DT 13-OCT-1998 (first entry)
XX XX
XX DE HIV-1 gag protein DNA primer #4.
XX XX
XX KW Hypervariable region; ENV protein; vaccinia virus; gag gene; retrovirus;
XX KW vaccines; infection; protection; primer; ss.
XX OS Synthetic.
XX XX
XX PN WO9822596-A1.
XX PD 28-MAY-1998.
XX XX
XX PF 19-NOV-1997; 97WO-JP04216.
XX XX
XX PR 19-NOV-1996; 96JP-0323412.
XX PA (NINA-) JAPAN NAT INST INFECTIOUS DISEASES.
XX PA (JAPG ) NIPPON ZEON KK.
XX XX
XX PI Kojima A, Kurata T, Yasuda A;
XX XX
XX DR WPI; 1998-312481/27.
XX XX
XX PT Recombinant vaccinia virus containing fusion H1B gag gene - for
XX PT production in host cells of gag protein for use as vaccine
XX XX
XX PS Example 1; Page 64; 84pp; Japanese.
XX XX
XX CC AAV35388-V35414 are primers used in a method which results in a
XX CC recombinant vaccinia virus comprising of a gag gene from a retrovirus
XX CC such as HIV-1 or HIV-2, fused to a DNA fragment containing an epitope
XX CC region (30-300 bases in length) of a retroviral gene other than the gag
XX CC gene. The gag gene may be altered so as to produce a gag protein modified
XX CC from the natural sequence by the addition, deletion or substitution of at

```


CC AAZ41220, and AAY52701 to AAY52706, represent sequences used in the
 CC exemplification of the present invention.

XX Sequence 18 BP; 1 A; 6 C; 4 G; 7 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 257 ACCTCTGGGCTGGCT 272
 | | | | | | | | | |
 Db 3 ATCTCTGGGCTGTCT 18

RESULT 615

AAZ22129
 ID AAZ22129 standard; DNA; 18 BP.

AC AAZ22129;

XX 26-NOV-1999 (first entry)

DE Human c-IAP-2 mRNA inhibiting antisense oligo ISIS #23438.

XX Cellular Inhibitor of Apoptosis-2; antisense; diagnostic; therapeutic;
 KW c-IAP-2; prophylaxis; infection; inflammation; tumor formation; ss.

XX Synthetic.

OS Homo sapiens.

XX US5958771-A.

XX 28-SEP-1999.

PF 03-DEC-1998; 98US-0205144.

PR 03-DEC-1998; 98US-0205144.

XX (ISIS-) ISIS PHARM INC.

XX Bennett CF, Cowsett LM, Ackermann EU;

XX WPI; 1999-561046/47.

PT Antisense compounds complementary to Cellular Inhibitor of Apoptosis-2
 XX useful for e.g. diagnostics, therapeutics, and as research reagents -

PS Claim 3; Column 39; 33pp; English.

XX The invention provides antisense compounds of 8-30 nucleotides that
 CC inhibit the expression of human Cellular Inhibitor of Apoptosis-2
 CC (c-IAP-2). The antisense compounds may be used for diagnostics,
 CC therapeutics (for modulating the expression of c-IAP-2), prophylaxis
 CC (e.g. to prevent or delay infection, inflammation, or tumor formation),
 CC as research reagents (e.g. to distinguish between members of a
 CC biological pathway) and in kits. Sequences AAZ22103-142 represent
 CC phosphorothioate oligonucleotides used for antisense inhibition of
 CC cellular inhibitor of apoptosis-2.

XX Sequence 18 BP; 1 A; 6 C; 4 G; 7 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 257 ACCTCTGGGCTGGCT 272
 | | | | | | | | | |
 Db 3 ATCTCTGGGCTGTCT 18

RESULT 616

AAZ21232/c

ID AAZ21232 standard; DNA; 18 BP.

XX
 AC AAZ21232;

XX 22-NOV-1999 (first entry)

XX Human CG1CE PCR primer SEQ ID NO:8.

XX CG1CE; Best's macular dystrophy; mutation; diagnosis; detection;
 KW BMD; age-related macular dystrophy; PCR primer; ss.

XX Synthetic.

OS Homo sapiens.

XX WO9943695-A1.

XX 02-SEP-1999.

XX 22-FEB-1999; 99WO-US03790.

XX 25-FEB-1998; 98US-0075941.

XX 18-DEC-1998; 98US-0112926.

XX (MERI) MERCK & CO INC.

XX (UYUP-) UNIV UPPSALA.

XX Petrukhin K, Caskey CT, Metzker M, Wadelius C;

XX WPI; 1999-540560/45.

XX Human and mouse polynucleotides encoding CG1CE polypeptides -

XX Disclosure; Page 17; 67pp; English.

XX The present invention describes human and mouse CG1CE polynucleotides
 CC and proteins. When the CG1CE gene is mutated it is responsible for
 CC Best's macular dystrophy (BMD). Polynucleotides encoding CG1CE are
 CC useful for diagnosing whether a patient carries a mutation in the
 CC CG1CE gene. Normal and mutated CG1CE proteins are useful for
 CC identifying activators and/or inhibitors of these proteins, in order
 CC to treat BMD. The CG1CE gene offers a simpler and cheaper method of
 CC diagnosing BMD without the need for the presence of the patient. The
 CC gene may also be useful to discovering the genetic cause of age-related
 CC macular dystrophy. The present sequence represents a PCR primer for
 CC the human CG1CE cDNA sequence.

XX Sequence 18 BP; 1 A; 6 C; 3 G; 8 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 269 GCGTCATCAACAGGGA 284

Db 18 GCGTCATCAACAGGGA 3

RESULT 617

AAZ54203

ID AAZ54203 standard; DNA; 18 BP.

XX AAZ54203;

XX 05-JUL-1999 (first entry)

XX Human endothelin-1 antisense oligonucleotide fragment.

XX Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; impeded respiration;
 KW respiratory distress syndrome; pain; cystic fibrosis;
 KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;

KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.
 XX Synthetic.
 OS WO9913886-A1.
 PN 25-MAR-1999.
 PD 17-SEP-1998; 98WO-US19419.
 XX 09-JUN-1998; 98US-0093972.
 PR 17-SEP-1997; 97US-0059160.
 XX (UYEC-) UNIV EAST CAROLINA.
 PA Nyce JW;
 XX WPI; 1999-229400/19.
 DR New antisense oligonucleotides used in treatment of, e.g. pulmonary
 XX vasoconstriction
 PT Disclosure; Page 58; 120pp; English.
 PS The specification describes antisense oligonucleotides (AA52869-X55271)
 CC directed against at least 2 mRNAs selected from target genes, coding and
 CC non-coding regions of RNAs corresponding to target genes, gene
 CC initiation codons, genomic flanking regions, intron-exon borders, the
 CC 5'-end, the 3'-end and the juxta-section between coding and non-coding
 CC regions and all segments of RNAs encoding proteins associated with one
 CC or more diseases, conditions or mixtures. The antisense oligonucleotides
 CC may be derived from sequences AA5272-74. These multiple target
 CC oligonucleotides (specifically AA55180-271) can be used for the
 CC antisense treatment of diseases and conditions. Typical diseases and
 CC conditions are those associated with impaired respiration and
 CC inflammation, including lung diseases, pulmonary vasoconstriction,
 CC asthma, allergic rhinitis, acute asthma, allergies, asthma, impaired
 CC respiration, respiratory distress syndrome, pain, cystic fibrosis,
 CC pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic
 CC obstructive pulmonary disease (COPD), and cancers such as leukemias,
 CC lymphomas, carcinomas e.g. colon cancer, breast cancer, lung cancer,
 CC pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma,
 CC hepatic metastases, as well as all types of cancers which may metastasize
 CC or have metastasized to the lungs, including breast and prostate cancer.
 XX Sequence 18 BP; 0 A; 4 C; 3 G; 11 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1143 CTTTTCCTTTTGG 1158
 |||||
 Db 1 CTTCTGCTTTTGG 16
 RESULT 618
 AAX54193
 ID AAX54193 standard; DNA; 18 BP.
 XX AAX54193;
 AC 05-JUL-1999 (first entry)
 XX Human endothelin-1 antisense oligonucleotide fragment.
 DE Antisense oligonucleotide; multiple target; antisense treatment;
 KW impaired respiration; inflammation; lung disease;
 KW pulmonary vasoconstriction; inflammation; allergic rhinitis;
 KW acute asthma; allergy; asthma; impaired respiration;
 KW respiratory distress syndrome; pain; cystic fibrosis;

KW pulmonary hypertension; pulmonary vasoconstriction; emphysema;
 KW chronic obstructive pulmonary disease; leukemia; lymphoma; carcinoma;
 KW colon cancer; breast cancer; lung cancer; pancreatic cancer;
 KW hepatocellular carcinoma; kidney cancer; melanoma; hepatic metastasis;
 KW prostate cancer; ss.
 XX Synthetic.
 OS WO9913886-A1.
 PN 25-MAR-1999.
 PD 17-SEP-1998; 98WO-US19419.
 XX 09-JUN-1998; 98US-0093972.
 PR 17-SEP-1997; 97US-0059160.
 XX (UYEC-) UNIV EAST CAROLINA.
 PA Nyce JW;
 XX WPI; 1999-229400/19.
 DR New antisense oligonucleotides used in treatment of, e.g. pulmonary
 XX vasoconstriction
 PT Disclosure; Page 57; 120pp; English.
 PS The specification describes antisense oligonucleotides (AA52869-X55271)
 CC directed against at least 2 mRNAs selected from target genes, coding and
 CC non-coding regions of RNAs corresponding to target genes, gene
 CC initiation codons, genomic flanking regions, intron-exon borders, the
 CC 5'-end, the 3'-end and the juxta-section between coding and non-coding
 CC regions and all segments of RNAs encoding proteins associated with one
 CC or more diseases, conditions or mixtures. The antisense oligonucleotides
 CC may be derived from sequences AA5272-74. These multiple target
 CC oligonucleotides (specifically AA55180-271) can be used for the
 CC antisense treatment of diseases and conditions. Typical diseases and
 CC conditions are those associated with impaired respiration and
 CC inflammation, including lung diseases, pulmonary vasoconstriction,
 CC asthma, allergic rhinitis, acute asthma, allergies, asthma, impaired
 CC respiration, respiratory distress syndrome, pain, cystic fibrosis,
 CC pulmonary hypertension, pulmonary vasoconstriction, emphysema, chronic
 CC obstructive pulmonary disease (COPD), and cancers such as leukemias,
 CC lymphomas, carcinomas e.g. colon cancer, breast cancer, lung cancer,
 CC pancreatic cancer, hepatocellular carcinoma, kidney cancer, melanoma,
 CC hepatic metastases, as well as all types of cancers which may metastasize
 CC or have metastasized to the lungs, including breast and prostate cancer.
 XX Sequence 18 BP; 0 A; 4 C; 3 G; 11 T; 0 other;
 SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1143 CTTTTCCTTTTGG 1158
 |||||
 Db 1 CTTCTGCTTTTGG 16
 RESULT 619
 AAX26160/c
 ID AAX26160 standard; DNA; 18 BP.
 XX AAX26160;
 AC 21-MAY-1999 (first entry)
 XX Primer for cDNA synthesis.
 DE Replication-competent; Sabin type 1 poliovirus vector; cloning site;
 KW 3C-protease cleavage site; mucosal vaccine; infectious disease; AIDS;
 KW human immunodeficiency virus type 1; HIV-1; small pox; poliomyelitis;

KW Hepatitis C; acquired immunodeficiency syndrome; Mahoney vector; viral;
 KW primer; ss.
 XX
 OS Synthetic.
 XX
 FN WO9907859-A1.
 XX
 PD 18-FEB-1999.
 XX
 PF 07-AUG-1998; 98WO-KR00242.
 XX
 XX 07-AUG-1997; 97KR-0037812.
 PR (ALTW-) ALTWELL BIOTECH INC.
 XX
 PA Bae YS, Jung HR;
 XX
 PI WPI; 1999-167434/14.
 DR
 XX New replication-competent recombinant Sabin type 1 poliovirus vector
 PT - useful for developing mucosal vaccines against HIV-type 1, small
 PT pox, poliomyelitis and hepatitis C
 XX
 XX Disclosure; Page 58; 64pp; English.
 PS
 XX The invention relates to a replication-competent recombinant Sabin type 1
 CC poliovirus vector encoding a multiple cloning site and 3C-protease
 CC cleavage site between the two end N-terminal residues. This comprises a
 CC vector containing an exogenous vaccine gene at the multiple cloning site.
 CC A method of production of both vectors is also provided. The recombinant
 CC vectors are useful for developing various mucosal vaccines against a
 CC number of infectious diseases, including human immunodeficiency virus
 CC type 1 (HIV-1) (which causes acquired immunodeficiency syndrome (AIDS)),
 CC small pox, poliomyelitis and Hepatitis C. The poliovirus-mediated mucosal
 CC vaccine vectors overcome the disadvantages exhibited by Mahoney vectors
 CC by being safe to humans, replicable (having equal replication ability to
 CC that of the wild type) vectors, where the introduced vaccine genes are
 CC stably maintained during viral passages.
 XX
 SQ Sequence 18 BP; 1 A; 10 C; 4 G; 3 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. NO. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 302 CTGTGGGGGGCTGCAAC 317
 Db 17 CGGTGGGGGGCGGCAAC 2
 RESULT 620
 ID AAV81061 standard; DNA; 18 BP.
 XX
 AC AAV81061;
 XX
 DT 03-MAR-1999 (first entry)
 XX
 DE De-immunised 708 Vx constructing flanking primer DIVK7.
 XX
 KW Non-immunogenic; epitope; T-cell; immunogenicity; immune system; SK;
 KW immunoglobulin; therapeutic; streptokinase; de-immunised; 708;
 KW primer; ss.
 XX
 OS Synthetic.
 XX
 FN WO9852976-A1.
 XX
 PD 26-NOV-1998.
 XX
 PF 21-MAY-1998; 98WO-GB01473.
 XX
 PA 14-APR-1998; 98GB-0007751.
 PR

PR 21-MAY-1997; 97GB-0010480.
 PR 31-JUL-1997; 97GB-0016197.
 PR 28-NOV-1997; 97GB-0025270.
 PR 02-DEC-1997; 97US-0067235.
 XX
 PA (BIOV-) BIOVATION LTD.
 XX
 PI Carr EJ;
 XX
 DR WPI; 1999-045301/04.
 XX
 XX Reducing immunogenicity of proteins - by modifying the amino acid
 PT sequence of the protein to eliminate potential epitopes for T-cells
 PT of a given species
 XX
 PS Example 3; Fig 16; 77pp; English.
 XX
 CC The invention relates to a method for the production of non-immunogenic
 CC proteins. The method comprises determining at least part of the amino
 CC acid sequence of the protein; (b) identifying in the amino acid sequence
 CC one or more potential epitopes for T-cells (T-cell epitopes) of the
 CC given species; and (c) modifying the amino acid sequence to eliminate at
 CC least one of the T-cell epitopes identified in step (b) thereby to
 CC eliminate or reduce the immunogenicity of the protein when exposed to the
 CC immune system of the given species. A method of analysing a pre-existing
 CC protein to predict the basis for immunogenic responses is also provided.
 CC The methods can be used particularly for reducing the immunogenicity of
 CC immunoglobulins or therapeutic proteins, e.g. Streptokinase (SK). The
 CC products can be used for diagnosis and therapy. Sequences AAV81047-68
 CC represent oligonucleotides used for the construction of de-immunised 708
 CC Vh and Vk.
 XX
 SQ Sequence 18 BP; 2 A; 5 C; 4 G; 7 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. NO. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 991 TTCAGATCCGCTTGG 1006
 Db 2 TTCAGCTCCAGCTTGG 17
 RESULT 621
 ID AAZ73148 standard; DNA; 18 BP.
 XX
 AC AAZ73148;
 XX
 DT 10-SEP-2001 (first entry)
 XX
 DE Human biallelic marker upstream amplification primer SEQ ID NO:7504.
 XX
 KW Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO9954500-A2.
 XX
 PD 28-OCT-1999.
 XX
 PF 21-APR-1999; 99WO-IB00822.
 XX
 PR 21-APR-1998; 98US-0082614.
 PR 23-NOV-1998; 98US-0109732.
 XX
 PA (GEST) GENSET.
 PI Cohen D, Blumenfeld M, Chumakov I;

XX WPI; 2000-013267/01.
 DR Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome -
 XX
 XX Claim 9; Page 1830; 2745pp; English.
 XX
 CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
 CC invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the
 CC invention have a variety of uses: they can be used for high density
 CC mapping of the human genome, and in complex association studies and
 CC haplotyping studies which are useful in determining the genetic basis
 CC for disease states. Compositions and methods of the invention can also
 CC be useful for the identification of the targets for the development of
 CC pharmaceutical agents and diagnostic methods, as well as the
 CC characterisation of the differential efficacious responses to and side
 CC effects from pharmaceutical agents acting on a disease as well as other
 CC treatment.
 CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297
 CC and 3367, are not actually given a sequence in the Sequence Listing
 CC from the present invention.
 XX
 SQ Sequence 18 BP; 4 A; 4 C; 4 G; 6 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 850 TCAGCATACCGCTTGG 865
 Db 3 TCAGCATACCGCTTGG 18
 RESULT 622
 AAZ76819
 ID AAZ76819 standard; DNA; 18 BP.
 XX AAZ76819;
 AC
 XX 10-SEP-2001 (first entry)
 DT
 DE Human biallelic marker downstream amplification primer SEQ ID NO:11175.
 XX
 KW Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO9954500-A2.
 FN
 XX 28-OCT-1999.
 PD
 XX 21-APR-1999; 99WO-1B00822.
 PF
 XX 21-APR-1998; 98US-0082614.
 PR
 XX 23-NOV-1998; 98US-0109732.
 XX
 XX (GEST) GENSET.
 PA
 XX Cohen D, Blumenfeld M, Chumakov I;
 PI
 XX WPI; 2000-013267/01.
 DR
 XX Novel biallelic markers used to construct a high density disequilibrium
 PT map of the human genome -
 XX
 XX Claim 9; Page 2613; 2745pp; English.

XX
 CC AAZ65654 to AAZ69578 represent human biallelic markers from the present
 CC invention, which contain a polymorphic base at position 24 of their
 CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
 CC primers for the biallelic markers. The biallelic markers of the
 CC invention have a variety of uses: they can be used for high density
 CC mapping of the human genome, and in complex association studies and
 CC haplotyping studies which are useful in determining the genetic basis
 CC for disease states. Compositions and methods of the invention can also
 CC be useful for the identification of the targets for the development of
 CC pharmaceutical agents and diagnostic methods, as well as the
 CC characterisation of the differential efficacious responses to and side
 CC effects from pharmaceutical agents acting on a disease as well as other
 CC treatment.
 CC N.B. The SEQ ID NOS 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297
 CC and 3367, are not actually given a sequence in the Sequence Listing
 CC from the present invention.
 XX
 SQ Sequence 18 BP; 8 A; 5 C; 4 G; 1 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 955 AGACTGACGAGCTGAC 970
 Db 3 ACACAGCAGGACTGAC 18
 RESULT 623
 AAF19759
 ID AAF19759 standard; DNA; 18 BP.
 XX AAF19759;
 AC
 XX 14-MAR-2001 (first entry)
 DT
 DE Human endothelin-1 polynucleotide fragment #1326.
 XX
 KW Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
 KW human; airway disorder; bronchoconstriction; lung inflammation;
 KW surfactant depletion; respiratory; bronchodilator; anti-inflammatory;
 KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytostatic;
 KW respiratory obstruction; pulmonary obstruction; impeded respiration;
 KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
 KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
 KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
 KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
 KW cancer; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200062736-A2.
 FN
 XX 26-OCT-2000.
 PD
 XX 24-MAR-2000; 2000WO-US08020.
 PF
 XX 06-APR-1999; 99US-0127958.
 PR
 XX (UYEC-) UNIV EAST CAROLINA.
 PA
 XX (NYCE/) NYCE J W.
 XX
 XX Nyce JW;
 PI
 XX WPI; 2000-679539/66.
 DR
 XX Low adenosine (A) content antisense oligonucleotides which do not
 PT trigger adenosine receptors during metabolism, useful e.g. for treating
 PT cancers and respiratory obstructions -
 XX
 XX Claim 14; Page 241; 1592pp; English.

CC The present invention describes low adenosine (A) content antisense
CC oligonucleotides and compositions (I) comprising them. In the antisense
CC oligonucleotides the A is replaced by a 'Universal' or alternative base.
CC (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
CC immunosuppressive, antiasthmatic, hypotensive and cytoskeletal activities.
CC The antisense oligonucleotides and (I) can be used to down-regulate the
CC expression and/or activity of target polypeptides associated with
CC lung/respiratory disorders and malignancies, such as stimulating and
CC activating peptide factors and transmitters, transcription factors,
CC immunoglobulins and antibodies, antibody receptors, cytokines and
CC chemokines, endogenously produced specific and non-specific enzymes,
CC binding proteins, adenosine molecules and their receptors, cytokine and
CC chemokine receptors, adenosine molecules and their receptors, cytokine and
CC nervous system (CNS) and peripheral nervous and non-nervous system
CC receptors, CNS and peripheral nervous and non-nervous system peptide
CC transmitters, defensins, growth factors, vasoactive peptides and
CC receptors, binding proteins and malignancy associated proteins. The
CC antisense oligonucleotides may be used in this way to treat disorders
CC including respiratory obstruction (especially pulmonary obstruction
CC and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
CC and/or surfactant hypoproduction which are associated with a disease or
CC condition selected from pulmonary vasoconstriction, inflammation,
CC allergies, asthma, impeded respiration, respiratory distress syndrome
CC (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
CC hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
CC pulmonary transplantation rejection, pulmonary infections, bronchitis,
CC and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
CC fragments and antisense oligonucleotides used in the exemplification of
CC the present invention.

XX SQ Sequence 18 BP; 0 A; 4 C; 3 G; 11 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1143 CTTTCTCTCTTTTGG 1158
Db 1 CTTCTCTCTTTTGG 16

RESULT 624
AAF19769
ID AAF19769 standard; DNA; 18 BP.

XX AC AAF19769;
XX DT 14-MAR-2001 (first entry)

XX Human endothelin-1 polynucleotide fragment #1336.

XX Low adenosine antisense oligonucleotide; phosphorothioate; allergy;
KW human; airway disorder; bronchoconstriction; lung inflammation;
KW surfactant depletion; respiratory; bronchodilator; antiinflammatory;
KW immunosuppressive; antiasthmatic; analgesic; hypotensive; cytoskeletal;
KW respiratory obstruction; pulmonary obstruction; impeded respiration;
KW surfactant hypoproduction; pulmonary vasoconstriction; asthma; RDS;
KW respiratory distress syndrome; pain; cystic fibrosis; allergic rhinitis;
KW pulmonary hypertension; emphysema; pulmonary transplantation rejection;
KW chronic obstructive pulmonary disease; pulmonary infection; bronchitis;
KW cancer; ss.

XX OS Homo sapiens.
XX PN WO200062736-A2.
XX PD 26-OCT-2000.
XX 24-MAR-2000; 2000WO-US08020.
XX 06-APR-1999; 99US-0127958.
XX (UYEC-) UNIV EAST CAROLINA.

PA (NYCE/) NYCE J W.
XX NYce JW;
XX WPI; 2000-679539/66.

XX Low adenosine (A) content antisense oligonucleotides which do not
XX trigger adenosine receptors during metabolism, useful e.g. for treating
XX cancers and respiratory obstructions -
PS Claim 14; Page 242; 1592pp; English.

XX The present invention describes low adenosine (A) content antisense
XX oligonucleotides and compositions (I) comprising them. In the antisense
XX oligonucleotides the A is replaced by a 'Universal' or alternative base.
XX (I) can have respiratory, bronchodilator, antiinflammatory, analgesic,
XX immunosuppressive, antiasthmatic, hypotensive and cytoskeletal activities.
XX The antisense oligonucleotides and (I) can be used to down-regulate the
XX expression and/or activity of target polypeptides associated with
XX lung/respiratory disorders and malignancies, such as stimulating and
XX activating peptide factors and transmitters, transcription factors,
XX immunoglobulins and antibodies, antibody receptors, cytokines and
XX chemokines, endogenously produced specific and non-specific enzymes,
XX binding proteins, adenosine molecules and their receptors, cytokine and
XX chemokine receptors, adenosine molecules and their receptors, cytokine and
XX nervous system (CNS) and peripheral nervous and non-nervous system
XX receptors, CNS and peripheral nervous and non-nervous system peptide
XX transmitters, defensins, growth factors, vasoactive peptides and
XX receptors, binding proteins and malignancy associated proteins. The
XX antisense oligonucleotides may be used in this way to treat disorders
XX including respiratory obstruction (especially pulmonary obstruction
XX and/or bronchoconstriction) and/or lung inflammation, allergy(ies)
XX and/or surfactant hypoproduction which are associated with a disease or
XX condition selected from pulmonary vasoconstriction, inflammation,
XX allergies, asthma, impeded respiration, respiratory distress syndrome
XX (RDS), pain, cystic fibrosis (CF), allergic rhinitis (AR), pulmonary
XX hypertension, emphysema, chronic obstructive pulmonary disease (COPD),
XX pulmonary transplantation rejection, pulmonary infections, bronchitis,
XX and/or cancer. AAF18434 to AAF21543 represent human polynucleotide
XX fragments and antisense oligonucleotides used in the exemplification of
XX the present invention.

SQ Sequence 18 BP; 0 A; 4 C; 3 G; 11 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1143 CTTTCTCTCTTTTGG 1158
Db 1 CTTCTCTCTTTTGG 16

RESULT 625
AAA86618/c
ID AAA86618 standard; DNA; 18 BP.

XX AC AAA86618;
XX DT 04-DEC-2000 (first entry)

XX Cdc 2 kinase hammerhead ribozyme recogniton site #49.
XX Ribozyme; hairpin; hammerhead; gene therapy; vasotropic;
XX restenosis; ss.

XX OS Mammalia.
XX PN WO200032765-A2.
XX 08-JUN-2000.
XX 06-DEC-1999; 99WO-US28772.

XX 04-DEC-1998; 98US-0110954.
 PR (IMMU-) IMMUSOL INC.
 PA Tritz R, Welch PJ, Barber JR, Robbins JM;
 XX WPI; 2000-412314/35.
 DR
 XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
 PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
 PCNA and Cyclin B1
 PT Example 1; Page 19; 109pp; English.
 PS
 XX The present invention relates to a hairpin or hammerhead ribozyme,
 CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
 CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
 CC Representative examples of ribozyme recognition sites are given in
 CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
 CC inhibiting restenosis by introduction of the ribozyme into cells.
 CC The ribozyme is resistant to endonuclease activity and hence is
 CC efficient in restenosis treatment.
 XX Sequence 18 BP; 4 A; 3 C; 5 G; 6 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. NO. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 600 CAGCCTGAAGCCTGAC 615
 DB 18 CATCCTGAAGACTGAC 3
 RESULT 626
 AAA86619/c
 ID AAA86619 standard; DNA; 18 BP.
 AC AAA86619;
 XX
 DT 04-DEC-2000 (first entry)
 DE Cdc 2 kinase hammerhead ribozyme recognitoins site #50.
 XX
 KW Ribozyme; hairpin; hammerhead; gene therapy; vasotropic;
 KW restenosis; ss.
 XX Mammalia.
 OS
 XX WO200032765-A2.
 PN
 XX 08-JUN-2000.
 PD
 XX 06-DEC-1999; 99WO-US28772.
 PF
 XX 04-DEC-1998; 98US-0110954.
 PR
 XX (IMMU-) IMMUSOL INC.
 PA
 XX Tritz R, Welch PJ, Barber JR, Robbins JM;
 PI WPI; 2000-412314/35.
 DR
 XX New hairpin and hammerhead ribozyme for inhibiting restenosis, cleaves
 PT RNA encoding a cyclin or cell-cycle dependent kinase other than CDK1,
 PCNA and Cyclin B1
 PT Example 1; Page 19; 109pp; English.
 PS
 XX The present invention relates to a hairpin or hammerhead ribozyme,
 CC designed to cleave RNA encoding a cyclin or cell-cycle dependent kinase
 CC other than cell-cycle dependent kinases CDK1, PCNA and Cyclin B1.
 CC

CC Representative examples of ribozyme recognition sites are given in
 CC AAA82415 to AAA86787. The ribozyme of the invention is useful for
 CC inhibiting restenosis by introduction of the ribozyme into cells.
 CC The ribozyme is resistant to endonuclease activity and hence is
 CC efficient in restenosis treatment.
 XX Sequence 18 BP; 3 A; 3 C; 6 G; 6 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. NO. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 600 CAGCCTGAAGCCTGAC 615
 DB 16 CATCCTGAAGACTGAC 1
 RESULT 627
 AAA29110/c
 ID AAA29110 standard; DNA; 18 BP.
 XX
 AC AAA29110;
 XX
 DT 12-SEP-2000 (first entry)
 DE Primer 1 for eosinophil peroxidase gene promoter amplification.
 XX
 KW Eosinophil; promoter; peroxidase; heterologous protein expression;
 KW major basic protein; granule ribonuclease; transgenic animal model;
 KW tissue-specific; primer; ss.
 XX
 OS Mus musculus.
 XX
 PN WO200034304-A1.
 XX
 PD 15-JUN-2000.
 XX
 PF 09-DEC-1999; 99WO-US29162.
 XX
 PR 11-DEC-1998; 98US-0210342.
 XX
 PA (MAYO-) MAYO FOUND MEDICAL EDUCATION & RES.
 XX
 XX Lee JJ, Lee NA, Macias MP;
 XX WPI; 2000-423368/36.
 DR
 XX New nucleotide comprising an eosinophil-specific promoter for
 PT expression of proteins such as cell toxins or eosinophil peroxidase in
 PT eosinophils and for ablating the eosinophil lineage from transgenic
 PT mammals
 XX
 PS Disclosure; Page 6; 40pp; English.
 XX
 CC AAA29110-11 are primers, which can be used to clone an
 CC eosinophil-specific promoter (e.g. AAA29109) from the 5' flanking
 CC sequences of genomic eosinophil peroxidase gene. The promoter is useful
 CC for manipulating expression of heterologous proteins such as murine or
 CC human major basic proteins, eosinophil peroxidase, human granule
 CC ribonuclease, ribozyme, cell toxin and reporter proteins such as
 CC beta-galactosidase, within eosinophils. Transgenic animals are useful for
 CC producing large quantities of eosinophils and as animal models for
 CC pulmonary pathologies such as asthma, using eosinophil-specific
 CC expression of transgenes. Discovery of the promoter is advantageous
 CC because eosinophil-specific expression of proteins is not toxic to the
 CC eosinophil and absence of eosinophil does not affect survival of the
 CC animal.
 XX
 XX Sequence 18 BP; 3 A; 5 C; 7 G; 3 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. NO. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 627 CCAGCTCCAGGAGCTC 642
 |||||
 Db 17 CCAGCTCCAGGGGATC 2

RESULT 628
 AAA12057
 ID AAA12057 standard; DNA; 18 BP.
 XX
 AC AAA12057;
 XX
 DT 14-AUG-2000 (first entry)
 XX
 DE Murine promoter OBHrel D4 HRE binding site primer.
 XX
 KW HRE; hypoxia response element; hypoxia-inducible factor; HIF; vasotropic;
 KW cardiant; cycostatic; antiarthritic; gene therapy; ischaemia; arthritis;
 KW cardiovascular disease; peripheral arterial disease; cancer; primer
 KW phosphoglycerate kinase; PGK; murine; promoter; OBHrel; ss.
 XX
 OS Mus sp.
 XX WO200017371-A1.
 XX
 XX 30-MAR-2000.
 XX
 XX 22-SEP-1999; 99WO-GB03181.
 XX
 XX 23-SEP-1998; 98WO-GB02885.
 PR 28-JAN-1999; 99GB-0001906.
 PR 16-FEB-1999; 99GB-0003538.
 XX
 XX (OXFO-) OXFORD BIOMEDICA UK LTD.
 XX
 XX Binley KM, Naylor S;
 XX WPI; 2000-283595/24.
 XX
 XX Novel polynucleotide constructs comprising at least two repeats of a
 PT hypoxia response element useful for driving expression of nucleic acids
 PT of interest in a cell under hypoxic conditions -
 XX
 XX Example 21; Page 109; 155pp; English.
 XX
 XX This invention describes novel polynucleotide comprising at least 2
 CC repeats of a hypoxia response element (HRE), where the hypoxia-inducible
 CC factor (HIF) consensus binding sites within each of the 2 repeats are
 CC separated by a spacer of at least 20 contiguous nucleotides. The products
 CC of the invention have vasotropic, cardiant, cycostatic and antiarthritic
 CC activity and can be used for gene therapy. The polynucleotides are useful
 CC for delivering nucleic acids of interest to mammalian cells. Lentiviral
 CC vectors are responsive to hypoxic agents and to agents that mimic
 CC hypoxia. This regulation can be harnessed in vitro to enhance the
 CC production of the vector and can be used in vivo to regulate gene
 CC expression in response to a physiological signal. The vectors have
 CC utility in disease, where ischaemia, including hypoxia, is a feature,
 CC e.g. cardiovascular disease, peripheral arterial disease, cancer and
 CC arthritis. The novel regulatory construct is capable of driving very high
 CC levels of transcription under conditions of hypoxia whilst providing only
 CC low basal levels of transcription under normal oxygen conditions. The
 CC polynucleotide construct targets cells within a tumor mass that are under
 CC conditions of hypoxia without affecting normal surrounding tissue. This
 CC sequence represents a murine phosphoglycerate kinase (PGK) promoter
 CC OBHrel HRE binding site primer which is described in the method of the
 CC invention.
 XX
 SQ Sequence 18 BP; 3 A; 4 C; 8 G; 3 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1235 TGGTGCTGAGCTGGC 1250
 |||||
 Db 2 TCGTGCGAGGAGCTGGC 17

RESULT 629
 AAA33637
 ID AAA33637 standard; DNA; 18 BP.
 XX
 AC AAA33637;
 XX
 DT 28-JUL-2000 (first entry)
 XX
 DE Low adenosine antisense oligonucleotide SEQ ID NO:1326.
 XX
 KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cyostatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX
 OS Homo sapiens.
 XX
 XX WO200009525-A2.
 XX
 XX 24-FEB-2000.
 XX
 XX 03-AUG-1999; 99WO-US17712.
 XX
 XX 03-AUG-1998; 98US-0095212.
 XX
 XX (UYEC-) UNIV EAST CAROLINA.
 XX
 XX Nyce JW;
 XX WPI; 2000-205971/18.
 XX
 XX New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers -
 XX
 XX Claim 18; Page 430; 1343pp; English.
 XX
 XX The present invention describes a new composition comprising an
 CC antisense oligonucleotide (ON) with low adenosine (up to 15%), which
 CC targets nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antiasthmatic, cyostatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies,
 CC asthma, impeded respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasize to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of
 CC the ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences
 CC differ from the previously named sequences. SEQ ID NO:11 to 1680
 CC (AAA32323 to AAA33992) are specifically claimed ONs from the present
 CC invention. N.B. Sequences given in the disclosure of the present
 CC invention do not match up with their corresponding SEQ ID NO: sequences
 CC given in the sequence listing.
 XX

SQ Sequence 18 BP; 0 A; 4 C; 3 G; 11 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1143 CTTTTCCTTTTGG 1158
 |||||
 Db 1 CTTCTGCTTTTGG 16

RESULT 630
 AAA33647
 ID AAA33647 standard; DNA; 18 BP.
 XX
 AC AAA33647;
 XX
 DT 28-JUL-2000 (first entry)
 XX
 DE Low adenosine antisense oligonucleotide SEQ ID NO:1336.
 XX
 KW Human; adenosine receptor; low adenosine antisense oligonucleotide;
 KW phosphorothioate; impaired respiration; inflammation; allergy;
 KW allergic disease; bronchoconstriction; inhibitor; antiinflammatory;
 KW antiallergic; antiasthmatic; cytotatic; analgesic; impaired airway;
 KW lung disease; ischaemic condition; pulmonary vasoconstriction; asthma;
 KW respiratory distress syndrome; pain; cystic fibrosis; emphysema;
 KW pulmonary hypertension; chronic obstructive pulmonary disease; COPD;
 KW cancer; leukaemia; lymphoma; carcinoma; metastasis; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200009525-A2.
 XX
 PD 24-FEB-2000.
 XX
 PF 03-AUG-1999; 99WO-US17712.
 XX
 PR 03-AUG-1998; 98US-0095212.
 XX
 PA (UYEC-) UNIV EAST CAROLINA.
 XX
 PI Nyce JW;
 XX
 DR WPI; 2000-205971/18.
 XX
 PT New antisense oligonucleotides useful for treating e.g. pulmonary
 PT vasoconstriction, inflammation, allergies, asthma, hypertension,
 PT bronchitis, emphysema, respiratory distress syndrome, ischemia or
 PT cancers -
 XX
 PS Claim 18; Page 431; 1343pp; English.
 XX
 CC The present invention describes a new composition comprising an
 CC antisense oligonucleotide (ON) with low adenosine (up to 15%), which
 CC targets nucleic acids involved in bronchoconstriction, allergies, and/or
 CC inflammation. The ON can have antiinflammatory, antiallergic,
 CC antisthmatic, cytotatic and analgesic activities. The compositions are
 CC useful for the treatment of diseases associated with inflammation,
 CC impaired airways, including lung disease and diseases whose secondary
 CC effects afflict the lungs of a subject. They can be used for treating
 CC e.g. ischaemic conditions, pulmonary vasoconstriction, allergies,
 CC asthma, impeded respiration, respiratory distress syndrome, pain, cystic
 CC fibrosis, pulmonary hypertension, emphysema, chronic obstructive
 CC pulmonary disease (COPD), and cancers such as leukaemias, lymphomas,
 CC carcinomas, and cancers which may metastasise to the lungs, including
 CC breast and prostate cancer. The reduction of the adenosine content of
 CC the ONs reduces side effects. The A-containing ONs break down with the
 CC release of deoxyadenosine which activates adenosine receptors causing
 CC bronchoconstriction and inflammation. AAA32313 to AAA35312 represent the
 CC nucleotide sequences given in the sequence listing from the present
 CC invention, which correspond to SEQ ID NO:1 to 2815, and then the last
 CC 185 sequences are also called SEQ ID NO:1 to 185, but the sequences

CC differ from the previously named sequences. SEQ ID NO:11 to 1680
 CC (AAA32323 to AAA33992) are specifically claimed ONs from the present
 CC invention. N.B. Sequences given in the disclosure of the present
 CC invention do not match up with their corresponding SEQ ID NO: sequences
 CC given in the sequence listing.

SQ Sequence 18 BP; 0 A; 4 C; 3 G; 11 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1143 CTTTTCCTTTTGG 1158
 |||||
 Db 1 CTTCTGCTTTTGG 16

RESULT 631
 AAZ90647
 ID AAZ90647 standard; DNA; 18 BP.
 XX
 AC AAZ90647;
 XX
 DT 13-JUN-2000 (first entry)
 XX
 DE Human adipose tissue gene amplifying primer #8.
 XX
 KW Adipose tissue; obesity; diabetes; hyperlipemia; hypertension; human;
 KW arteriosclerosis; hyperuricemia; sleep apnea syndrome; PCR primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN JP20000037190-A.
 XX
 PD 08-FEB-2000.
 XX
 PF 23-JUL-1998; 98JP-0225228.
 XX
 PR 23-JUL-1998; 98JP-0225228.
 XX
 PA (NISH) JAPAN TOBACCO INC.
 XX
 DR WPI; 2000-306578/27.
 XX
 PT A physiologically active protein specifically derived from mammal
 PT tissue -
 XX
 PS Example 2; Page 18; 50pp; Japanese.
 XX
 CC The invention relates to identification of genes and proteins of adipose
 CC tissue relating to obesity, particularly complications of visceral
 CC obesity including diabetes, hyperlipemia, hypertension,
 CC arteriosclerosis, hyperuricemia and sleep apnea syndrome. The genes
 CC (AAZ90631-633) and the proteins (AAZ97598-Y67600) are used in the genetic
 CC diagnosis, prevention and treatment of adipose tissue related diseases.
 CC Sequences AAZ90640-51 represent PCR primers amplifying the human adipose
 CC tissue genes.
 XX
 SQ Sequence 18 BP; 1 A; 0 C; 2 G; 15 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTGG 1159
 |||||
 Db 3 TTTTTCCTTTTGA 18

RESULT 632
 AAH47994/C
 ID AAH47994 standard; DNA; 18 BP.
 XX


```
XX Human; Akt-3; protein kinase; cytostatic; antiinflammatory; infection;
KW antisense therapy; inflammation; tumour; ss.
XX Homo sapiens.
OS US6187586-B1.
XX FN
XX PD 13-FEB-2001.
XX PF 29-DEC-1999; 99US-0474922.
XX PR 29-DEC-1999; 99US-0474922.
XX PA (ISIS-) ISIS PHARM INC.
XX PI Monia BP, Cowsert LM, Roth RA;
XX WPI; 2001-264979/27.
XX New antisense compounds targeting nucleic acids encoding human Akt-3
PT useful for treating a disease or condition associated with Akt-3
PT expression, or in preventing or delaying inflammation or tumor
PT formation
XX Claim 1; Column 40; 37pp; English.
XX The present sequence is one of a number of antisense compounds of up to
CC 30 nucleobases in length targeted to a nucleic acid encoding human Akt-3.
CC The antisense compounds are useful for inhibiting the expression of human
CC Akt-3 in human cells or tissues. They are also useful for modulating the
CC expression of Akt-3, and for treating a human or an animal suspected of
CC having, or being prone to, a disease or condition associated with Akt-3
CC expression. The antisense compounds may also be used as research
CC reagents, in kits and in diagnostics, e.g. to elucidate the function of a
CC particular gene or to distinguish between functions of various members of
CC a biological pathway; and as a prophylactic, e.g. to prevent or delay
CC infection, inflammation or tumour formation.
XX Sequence 18 BP; 5 A; 5 C; 4 G; 4 T; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 375 CCAGCTTCCTCCAGAG 390
DB 2 CCAGTTTACTCCAGAG 17
RESULT 637
AAF74480/c
ID AAF74480 standard; DNA; 18 BP.
XX AAF74480;
AC AAF74480;
XX 09-MAY-2001 (first entry)
DT Clone 21399247.0.1 PRO5 sequencing primer SEQ ID NO:66.
DE Human; PRO; PROX; cytostatic; immunomodulatory; reproduction;
XX gene therapy; cell proliferation; differentiation disorder; cancer;
KW immune associated disorder; gestational disease; pre-clampsia;
XX PCR primer; sequencing primer; ss.
XX Homo sapiens.
OS WO200110902-A2.
XX FN
XX PD 15-FEB-2001.
XX PF 11-AUG-2000; 2000WO-US21857.
XX WPI; 2001-147509/15.
XX Shimkets RA, Fernandes E;
XX WPI; 2001-147509/15.
```

```
PR 11-AUG-1999; 99US-0148433.
PR 10-AUG-2000; 2000US-0148433.
XX (CURA-) CURAGEN CORP.
XX Shimkets RA, Fernandes E;
XX WPI; 2001-147509/15.
DR Nucleic acids encoding secreted polypeptides, designated PROX
XX polypeptides, useful for treating a syndrome associated with a
PT PROX-associated disorder, e.g. cancer -
XX Example 9; Page 125; 166pp; English.
XX The present invention describes isolated nucleic acids encoding secreted
CC polypeptides, designated PROX polypeptides (i.e. a PRO polypeptide where
CC X is an integer from 1 to 17). PROX polypeptides have cytosstatic,
CC immunomodulatory and reproduction activities, and can be used in gene
CC therapy, and as PROX antagonists and PROX agonists. PROX polypeptides,
CC nucleic acids and antibodies are useful in the manufacture of a
CC medicament for treating a syndrome associated with a PROX-associated
CC disorder, e.g. a cell proliferation and/or differentiation disorder
CC (e.g. cancer or immune associated disorders) and a gestational disease
CC (e.g. pre-clampsia). They are also used for screening for a modulator of
CC activity or of latency or predisposition to a PROX-associated disorder.
CC AAF74432 to AAF74448 encode the specifically claimed human PROX
CC polypeptides PRO1 to PRO17 given in AAB70531 to AAB70547. The present
CC sequence represents a primer used in an example from the present
CC invention.
XX Sequence 18 BP; 4 A; 5 C; 7 G; 2 T; 0 other;
SQ Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1292 TTGCTCAGCCGTGGCC 1307
DB 18 TTGCTCAGCCCGTCC 3
RESULT 638
AAF74483
ID AAF74483 standard; DNA; 18 BP.
XX AAF74483;
AC AAF74483;
XX 09-MAY-2001 (first entry)
DT Clone 21399247.0.1 PRO5 sequencing primer SEQ ID NO:69.
DE Human; PRO; PROX; cytostatic; immunomodulatory; reproduction;
XX gene therapy; cell proliferation; differentiation disorder; cancer;
KW immune associated disorder; gestational disease; pre-clampsia;
XX PCR primer; sequencing primer; ss.
XX Homo sapiens.
OS WO200110902-A2.
XX FN
XX PD 15-FEB-2001.
XX PF 11-AUG-2000; 2000WO-US21857.
XX WPI; 2001-147509/15.
XX Shimkets RA, Fernandes E;
XX WPI; 2001-147509/15.
```

XX Nucleic acids encoding secreted polypeptides, designated PROX
PT polypeptides, useful for treating a syndrome associated with a
PT PROX-associated disorder, e.g. cancer -
XX Example 9; Page 126; 166pp; English.
XX
CC The present invention describes isolated nucleic acids encoding secreted
CC polypeptides, designated PROX polypeptides (i.e. a PRO polypeptide where
CC X is an integer from 1 to 17). PROX polypeptides have cytosolic,
CC immunomodulatory and reproduction activities, and can be used in gene
CC therapy, and as PROX antagonists and PROX agonists. PROX polypeptides,
CC nucleic acids and antibodies are useful in the manufacture of a
CC medicament for treating a syndrome associated with a PROX-associated
CC disorder, e.g. a cell proliferation and/or differentiation disorder
CC (e.g. cancer or immune associated disorders) and a gestational disease
CC (e.g. pre-clampsia). They are also used for screening for a modulator of
CC activity or of latency or predisposition to a PROX-associated disorder.
CC AAF74432 to AAF74448 encode the specifically claimed human PROX
CC polypeptides PRO1 to PRO17 given in AAB70531 to AAB70547. The present
CC sequence represents a primer used in an example from the present
CC invention.
XX
XX Sequence 18 BP; 2 A; 7 C; 5 G; 4 T; 0 other;
SQ
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1292 TTGCTCAGCTGGCC 1307
Db 1 TTGCTCAGCTGGCTCC 16
RESULT 639
AAF68906
ID AAF68906 standard; DNA; 18 BP.
XX
XX AAF68906;
XX
XX 12-APR-2001 (first entry)
DT
DE COXII probe #12.
XX Mitochondria; cytochrome C oxidase; COX; Alzheimer's disease;
XX probe; ss.
XX Homo sapiens.
XX US6171859-B1.
PN
XX 09-JAN-2001.
PD
XX 30-MAR-1995; 95US-0413740.
PF
XX 30-MAR-1994; 94US-0219842.
PR
XX (MITO-) MITOKOR.
PA
XX Herrnstadt C, Parker WD;
PI
XX WPI; 2001-136875/14.
DR
XX Targeting conjugate molecule to mitochondria having defective
PT cytochrome C oxidase activity for diagnosing Alzheimer's disease,
PT involves contacting mitochondria with a conjugate of targeting molecule
PT and toxin -
XX Disclosure; Columns 21-22; 88pp; English.
XX
XX The present invention relates to a method for selectively accumulating
CC a mitochondrial disabling or destructive amount of a conjugate molecule
CC in mitochondria having defective cytochrome C oxidase (COX) activity or

CC displaying increased membrane potential. The method involves contacting
CC mitochondria with a conjugate molecule comprising a targeting molecule
CC conjugated to a toxin, where the conjugate or targeting molecule selected
CC accumulates in the mitochondria. The method is useful for diagnosis of
CC Alzheimer's disease (AD), especially sporadic AD. The present sequence
CC is a probe used in the method of the present invention.
XX
XX Sequence 18 BP; 3 A; 9 C; 3 G; 3 T; 0 other;
SQ
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 590 TGCCCCCACCAGCCT 605
Db 1 TGCCCCCACCATCCT 16
RESULT 640
AAH49174
ID AAH49174 standard; DNA; 18 BP.
XX
XX AAH49174;
XX 26-NOV-2001 (first entry)
DT
DE Human procalcitonin pCT PCR primer 1101.
XX
XX Procalcitonin; pCT; antitumor; antiseptis; antiinflammatory; tumor;
XX sepsis; systemic inflammatory response syndrome; PCR primer; ss.
XX Homo sapiens.
XX EP1111050-A2.
PN
XX 27-JUN-2001.
PD
XX 24-NOV-2000; 2000EP-0125719.
PF
XX 22-DEC-1999; 99DE-1062434.
PR
XX 03-APR-2000; 2000DE-1016278.
PR
XX 08-JUN-2000; 2000DE-1027954.
XX
XX (DADB-) DADE BEHRING MARBURG GMBH.
XX Althaus H, Hauser HP;
PI
XX WPI; 2001-572431/65.
DR
XX New, preferably recombinant, human procalcitonin, useful for diagnosis
PT and treatment of sepsis, tumors and systemic inflammatory response
PT syndrome -
XX Example 1; Page 22; 36pp; German.
PS
XX This invention describes novel isolated, preferably recombinant,
CC polypeptides (I) containing the amino acid sequence for human
CC procalcitonin (hpCT). The products of the invention have antitumor,
CC antiseptis and antiinflammatory activity. (I) (also antibodies (Ab)
CC raised against it) are used: (i) for diagnosis and treatment of tumors,
CC sepsis and systemic inflammatory response syndrome; (ii) to raise Ab;
CC (iii) for quantitative or qualitative detection and analysis, especially
CC of hpCT and antibodies against it; (iv) as controls or standards for
CC assays; and (v) for affinity chromatography. Isolated (I) can be produced
CC inexpensively in large amounts by recombinant expression. Solutions of
CC (I) that contain a polyethoxylated sterol ester have good storage
CC stability. This sequence represents a PCR primer used in the
CC amplification of human procalcitonin pCT.
XX
XX Sequence 18 BP; 3 A; 2 C; 6 G; 7 T; 0 other;
SQ
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 833 TGAAGCTTTCAGATGG 848
 |||||
 2 TGAAGCTTTCAGATGG 17

Db

RESULT 641
 ABZ72206/c
 ID ABZ72206 standard; DNA; 18 BP.

XX AC ABZ72206;
 XX DT 03-APR-2003 (first entry)
 XX DE Gene 216 SSCP sequencing primer SEQ ID NO 178.
 XX KW Human; Gene 216; chromosome 20p13-p12; antiasthmatic; anorectic;
 KW antiinflammatory; gastrointestinal; gene therapy; vaccine; asthma;
 KW obesity; inflammatory bowel disease; primer; ss.
 XX OS Synthetic.
 XX XN WO200178894-A2.
 XX PD 25-OCT-2001.
 XX PF 13-APR-2001; 2001WO-US12245.
 XX PR 13-APR-2000; 2000US-0548797.
 XX PA (GENO-) GENOME THERAPEUTICS CORP.
 XX PI Keith T;
 XX WPI; 2001-639428/73.

Isolated genes (Gene 216) from human chromosome 20p13-p12 and the proteins they encode, useful for the prevention, diagnosis and treatment of asthma, obesity and inflammatory bowel disease -

Example 10; Page 150; 520pp; English.

The invention relates to isolated genes (Gene 216) from human chromosome 20p13-p12 and the proteins they encode. The nucleic acids and proteins may be used in the prevention, diagnosis and treatment of diseases associated with inappropriate gene 216 expression. For example, the nucleic acids (or vectors) and proteins may be used to treat disorders associated with decreased expression by rectifying mutations or deletions in a patient's genome that affect the activity of gene 216 by expressing inactive proteins or to supplement the patients own production of Gene 216 proteins. Additionally, the nucleic acids may be used to produce the secreted Gene 216 protein, by inserting the nucleic acids into a host cell and culturing the cell to express the protein. The nucleic acids and complementary sequences may also be used as DNA probes in diagnostic assays to detect and quantitate the presence of similar nucleic acid sequences in samples and therefore which patients may be in need of restorative therapy. The Gene 216 protein may also be used as antigens in the production of antibodies against gene 216 and in assays to identify modulators of Gene 216 expression and activity. The anti-Gene 216 antibodies and antagonists may also be used to down regulate expression and activity. The anti-Gene 216 antibodies may also be used as diagnostic agents for detecting the presence of Gene 216 proteins in samples (e.g. by enzyme linked immunosorbant assay or ELISA). Disorders that may be prevented, diagnosed and/or treated by the above methods include, for example asthma, obesity and inflammatory bowel disease. The present invention is that of a Gene 216 related primer used in examples of the invention. The primers are used in the physical mapping of the gene (ABZ72067-ABZ72088), polymorphism identification using single strand conformational polymorphism (SSCP) analysis (ABZ72091-ABZ72184), sequencing (ABZ72185-ABZ72268) and genotyping (ABZ72317-ABZ72362).

XX SQ Sequence 18 BP; 2 A; 7 C; 3 G; 6 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 725 AGCAGGGGGCTGGCT 740
 |||||
 16 AGCAGGGGGCTGGCT 1

Db

RESULT 642
 ABT11916
 ID ABT11916 standard; DNA; 18 BP.
 XX AC ABT11916;
 XX DT 19-DEC-2002 (first entry)
 XX DE Neublabin DNA related PCR primer.
 XX KW Nootropic; neuroprotective; antiparkinsonian; anticonvulsant; analgesic;
 KW tranquiliser; antidiabetic; ophthalmological; neurodegenerative disorder;
 KW neublabin; ischemic neuronal damage; traumatic brain injury; diabetes;
 KW peripheral neuropathy; neuropathic pain; Alzheimer's disease; glaucoma;
 KW Huntington's disease; parkinson's disease; amyotrophic lateral sclerosis;
 KW memory impairment; renal disease; PCR; primer; ss.
 XX OS Unidentified.
 XX XN WO200272826-A2.
 XX PD 19-SEP-2002.
 XX PF 12-MAR-2002; 2002WO-EP02691.
 XX PR 12-MAR-2001; 2001US-0804615.
 XX PA (BIOJ) BIOGEN INC.
 XX PA (NSGE-) NS GENE AS.
 XX PI Sah DWY, Johansen TE, Rossomando A;
 XX WPI; 2002-713515/77.

New truncated neublabin polypeptides lacking one or more amino-terminal amino acids of a mature neublabin polypeptide useful for treating neurodegenerative disorders, e.g. peripheral neuropathy, neuropathic pain, brain injury -

Disclosure; Fig 8; 138pp; English.

The invention relates to a truncated neublabin polypeptide comprising an amino acid terminus that lacks one or more amino-terminal amino acids of a mature neublabin polypeptide. The polypeptides and nucleic acids are useful for treating neurodegenerative disorders such as ischemic neuronal damage, traumatic brain injury, peripheral neuropathy, neuropathic pain, Alzheimer's disease, Huntington's disease, Parkinson's disease, amyotrophic lateral sclerosis, memory impairment, diabetes, renal diseases, or glaucoma by moderating metabolism, growth, differentiation or survival of a nerve or neuronal cell. This polynucleotide sequence is a neublabin PCR primer of the invention.

XX SQ Sequence 18 BP; 1 A; 6 C; 9 G; 2 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 716 TGGCCCCGATGAGGG 731
 |||||
 3 TGGCCCCGATGAGGG 18

Db

RESULT 643
ABQ65394
ID ABQ65394 standard; DNA; 18 BP.
XX AC ABQ65394;
XX DT 20-AUG-2002 (first entry)
XX DE Human gene methylation status determination oligo SEQ ID NO: 6.
XX DE Toxicological diagnosis; DNA methylation; methylation status;
KW toxic response; human; ds.
XX OS Homo sapiens.
XX PN WO200240710-A2.
XX PD 23-MAY-2002.
XX PF 08-NOV-2001; 2001WO-EP12951.
XX PR 14-NOV-2000; 2000DE-1056802.
XX PA (EPIG-) EPIGENOMICS AG.
XX PI Olek A, Piepenbrock C, Berlin K;
XX DR WPI; 2002-463571/49.
XX XX Toxicological diagnosis, useful for diagnosis and prognosis of adverse
PT reactions, based on effect of test compounds on methylation status of
PT selected genes, involves determining changes in DNA methylation status
PT -
XX XX Example 3; Page 107; 113pp; German.
XX CC The present invention relates to a method of toxicological diagnosis,
CC involving taking a DNA-containing sample from an organism or cell culture
CC that has been treated with a test compound and determining any changes in
CC the DNA methylation status or pattern caused by said test compound. The
CC method is used for diagnosis and prognosis of adverse toxic responses in
CC individuals. The present sequence is a human sequence used to demonstrate
CC the method of the invention.
XX SQ Sequence 18 BP; 2 A; 1 C; 4 G; 11 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 1144 TTTTTCCTTTTGGG 1159
Db 2 TTTTTCCTTTTAGA 17
RESULT 644
ABK11324
ID ABK11324 standard; DNA; 18 BP.
XX AC ABK11324;
XX DT 05-JUN-2002 (first entry)
XX DE Arabidopsis Acyl coenzyme A thioesterase 4 PCR primer ACH4-sEcoRI.
XX ss; PCR; ACH4; Acyl coenzyme A thioesterase; plant; transgenic;
KW lipid oxidation; regulation of Coenzyme A; fatty acid metabolism;
KW primer; ACH4-sEcoRI.
XX OS Arabidopsis thaliana.
XX PN WO200208433-A2.
XX PT

PD 31-JAN-2002.
XX PF 19-JUL-2001; 2001WO-US22907.
XX PR 21-JUL-2000; 2000US-220028P.
XX PR 16-JUL-2001; 2001US-0906408.
XX PA (TILT/) TILTON G B.
PA (SHOC/) SHOCKEY J M.
PA (BROW/) BROWSE J A.
XX Tilton GB, Shockeey JM, Browse JA;
PI WPI; 2002-241573/29.
XX DR Novel acyl coenzyme A thioesterase gene useful for altering a phenotype
XX of a plant, making a transgenic plant and for producing variants of
PT acyl-CoA thioesterases -
XX PS Example 1; Page 47; 78pp; English.
XX CC The invention relates to an isolated acyl coenzyme A thioesterase (ACH)
CC encoding nucleic acid, encoding one of ACH1, ACH2, ACH4 or ACH5. ACH
CC enzymes have a role in lipid oxidation, regulation of Coenzyme A pools
CC and in fatty acid metabolism. Also include are a host cell
CC transfected with the nucleic acid, a transgenic plant transfected with
CC the nucleic acid (including its seed or oil) and ACH antisense
CC molecules. The ACH nucleic acid is useful for altering a phenotype of a
CC plant and for making a transgenic plant, by transfecting the
CC plant tissue with the ACH nucleic acid under conditions such that a
CC transgenic plant is generated. The ACH nucleic acid is also useful for
CC producing variants of acyl-CoA thioesterases. The present sequence
CC is a PCR primer used to amplify Arabidopsis ACH4 encoding sequences.
XX SQ Sequence 18 BP; 6 A; 7 C; 2 G; 3 T; 0 other;
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 643 TGCATCCCCCAAGACC 658
Db 2 TGAATTCCTCCCAAGACC 17
RESULT 645
ABL40174/c
ID ABL40174 standard; DNA; 18 BP.
XX AC ABL40174;
XX DT 21-MAY-2002 (first entry)
XX DE Mouse reelin protein CR-50 epitope region PCR primer SEQ ID NO:11.
XX KW Mouse; reelin protein CR-50 epitope region; elucidation; neuron;
KW cerebral disturbance; reelin protein; neuroprotective; PCR primer; ss.
XX OS Mus musculus.
XX PN JP2002017361-A.
XX PD 22-JAN-2002.
XX PF 04-JUL-2000; 2000JP-0202801.
XX PR 04-JUL-2000; 2000JP-0202801.
XX PA (RIKA) RIKAGAKU KENKYUSHO.
XX XX WPI; 2002-221707/28.
XX PT Reelin protein CR-50 epitope region, useful for diagnosis and treatment

PT of cerebral disturbance -
 XX
 PS Example 2; Page 7; 16pp; Japanese.
 XX
 CC The present invention describes the mouse reelin protein CR-50 epitope
 CC region, which contains the CR-50 antibody recognition site and is free
 CC from F-spondin domains and repetitive sites. Also described are: (1) an
 CC expression vector comprising a polynucleotide encoding a reelin protein
 CC epitope region; (2) host cells with transfected the expression vector;
 CC (3) polypeptides prepared by culture of the host cells; and (4)
 CC polynucleotides comprising the 351 base sequence given in ABL40165 which
 CC encodes the 117 amino acid sequence given in ABB06244; and (5) use of
 CC the polynucleotide for diagnosis and/or treatment of diseases caused by
 CC abnormal positioning of neural cells, and stimulation of association of
 CC reelin protein. The mouse reelin protein CR-50 epitope region has
 CC neuroprotective activity, and can be used in the diagnosis and treatment
 CC of cerebral disturbance due to an abnormal reelin gene and positioning
 CC of neurons. The present sequence represents a PCR primer for the mouse
 CC reelin protein CR-50 epitope region, which is used in an example from
 CC the present invention.
 XX
 SQ Sequence 18 BP; 4 A; 5 C; 6 G; 3 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1019 GATGGTGCCAAAGTGC 1034
 Db |||||
 18 GATGGTGCCACACTGC 3
 RESULT 646
 ABA05859/c
 ID ABA05859 standard; DNA; 18 BP.
 XX
 AC ABA05859;
 XX
 DT 15-MAR-2002 (first entry)
 XX
 DE Corynebacterium thrE gene vector construction PCR primer #4.
 XX
 KW Coryneform bacteria; L-threonine production; fermentation;
 XX animal nutrition; medicine; pharmaceutical industry; PCR primer; ss.
 XX
 OS Corynebacterium glutamicum.
 XX
 PN DE10102823-A1.
 XX
 PD 29-NOV-2001.
 XX
 PF 23-JAN-2001; 2001DE-1002823.
 XX
 PR 27-MAY-2000; 2000DE-1026494.
 XX
 PA (DEGS) DEGUSSA AG.
 XX
 PI Rieping M;
 XX
 XX WPI; 2002-115532/16.
 XX
 XX Fermentative production of L-threonine, useful in animal nutrition,
 XX comprises culturing enterobacterium with increased thrE gene activity
 PT
 PT
 PS Example 2; Page 6; 23pp; German.
 XX
 XX The present invention relates to the fermentative production of
 CC L-threonine using an Enterobacterium, particularly one already capable of
 CC producing L-threonine, in which activity of the thrE gene sequence (or
 CC sequences) is increased by overexpression. L-threonine is useful in
 CC animal nutrition, human medicine and the pharmaceutical industry. The
 CC present sequence is a PCR primer used to isolate the Corynebacterium

CC glutamicum thrE gene.
 XX
 SQ Sequence 18 BP; 0 A; 6 C; 5 G; 7 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 278 AAGAGGAAGCAGCAGC 293
 Db |||||
 18 AAGAGGAACCGCAGC 3
 RESULT 647
 ABL30619
 ID ABL30619 standard; DNA; 18 BP.
 XX
 AC ABL30619;
 XX
 DT 21-MAR-2002 (first entry)
 XX
 DE Human HLA genotyping oligonucleotide SEQ ID NO 108.
 XX
 KW Human; human leukocyte antigen; HLA; genotype; polymorphism;
 XX immunogenetic; transplantation; genetic disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192572-A1.
 XX
 PD 06-DEC-2001.
 XX
 PF 01-JUN-2001; 2001WO-JP04662.
 XX
 PR 01-JUN-2000; 2000JP-0164798.
 XX
 PA (NISN) NISSHINBO IND INC.
 XX (SYST-) SYSTEM RES INC.
 XX
 PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 XX
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 PT of individuals e.g. by determining immunogenetic differences when
 PT transplanting between them -
 XX
 PS Claim 10; Page 113; 345pp; Japanese.
 XX
 CC The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals.
 XX
 SQ Sequence 18 BP; 2 A; 7 C; 6 G; 3 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 803 GCTCCCTGCAGCGAG 818
 Db |||||
 1 GCTCCCTGCAGCGAG 16

Thu Jan 8 16:51:54 2004

```

RESULT 648
ABL30631/c
ID ABL30631 standard; DNA; 18 BP.
XX
XX
AC ABL30631;
XX
XX
DT 21-MAR-2002 (first entry)
XX
XX
DE Human HLA genotyping oligonucleotide SEQ ID NO 120.
XX
XX
KW Human; human leukocyte antigen; HLA; genotype; polymorphism;
KW immunogenetic; transplantation; genetic disease; ss.
XX
XX
OS Homo sapiens.
XX
XX
FN WO200192572-A1.
XX
XX
PD 06-DEC-2001.
XX
XX
PF 01-JUN-2001; 2001WO-JP04662.
XX
XX
PR 01-JUN-2000; 2000JP-0164798.
XX
XX
PA (NISR ) NISSHINBO IND INC.
PA (SYST-) SYSTEM RES INC.
XX
XX
PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX
XX
WPI; 2002-122074/16.
XX
XX
PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
PT of individuals e.g. by determining immunogenetic differences when
PT transplanting between them -
XX
XX
PS Claim 10; Page 123; 345pp; Japanese.
XX
XX
CC The invention relates to a typing kit for judging human leukocyte antigen
CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
CC genes e.g. belonging to HLA class I antigens on human genome and
CC containing gene polymorphisms as alloantigens have been immobilised as
CC primers for amplification of cleaved nucleic acids relating to gene
CC polymorphisms. The method is useful for judging HLA genotypes of
CC individuals by determining immunogenetic differences before transplanting
CC between them, providing genetic information to decide compatibility of
CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC diagnosis of genetic diseases and identifying individuals.
XX
XX
SQ Sequence 18 BP; 3 A; 2 C; 6 G; 7 T; 0 other;
XX
XX
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 1182 TCTATAGGTGAGTGT 1197
DB 1 TCTACGGGTGAGTGT 16
XXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXX
RESULT 650
ABL31090/c
ID ABL31090 standard; DNA; 18 BP.
XX
XX
AC ABL31090;
XX
XX
DT 21-MAR-2002 (first entry)
XX
XX
DE Human HLA genotyping oligonucleotide SEQ ID NO 579.
XX
XX
KW Human; human leukocyte antigen; HLA; genotype; polymorphism;
KW immunogenetic; transplantation; genetic disease; ss.
XX
XX
OS Homo sapiens.
XX
XX
FN WO200192572-A1.
XX
XX
PD 06-DEC-2001.
XX
XX
PF 01-JUN-2001; 2001WO-JP04662.
XX
XX
PR 01-JUN-2000; 2000JP-0164798.
XX
XX
PA (NISR ) NISSHINBO IND INC.
PA (SYST-) SYSTEM RES INC.
XX
XX
PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
XX
XX
WPI; 2002-122074/16.
XX
XX
PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
PT of individuals e.g. by determining immunogenetic differences when
PT transplanting between them -
XX
XX
PS Claim 10; Page 116; 345pp; Japanese.
XX
XX
CC The invention relates to a typing kit for judging human leukocyte antigen
CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
CC genes e.g. belonging to HLA class I antigens on human genome and
CC containing gene polymorphisms as alloantigens have been immobilised as
CC primers for amplification of cleaved nucleic acids relating to gene
CC polymorphisms. The method is useful for judging HLA genotypes of
CC individuals by determining immunogenetic differences before transplanting
CC between them, providing genetic information to decide compatibility of
CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
CC diagnosis of genetic diseases and identifying individuals.
XX
XX
SQ Sequence 18 BP; 4 A; 5 C; 8 G; 1 T; 0 other;
XX
XX
Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
QY 143 CGCTCGGCTCGCTCC 158
DB 18 CGCTCGGCTCGCTCC 3
XXXXXXXXXXXXXXXXXXXX
XXXXXXXXXXXXXXXXXXXX
RESULT 649
ABL30669
ID ABL30669 standard; DNA; 18 BP.
XX
XX
AC ABL30669;
XX
XX
DT 21-MAR-2002 (first entry)
XX
XX
DE Human HLA genotyping oligonucleotide SEQ ID NO 158.
XX
XX
KW Human; human leukocyte antigen; HLA; genotype; polymorphism;
KW immunogenetic; transplantation; genetic disease; ss.
XX
XX

```

PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 PT of individuals e.g. by determining immunogenetic differences when
 PT transplanting between them -
 XX
 XX Claim 10; Page 203; 345pp; Japanese.
 XX
 CC The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals.
 XX
 XX Sequence 18 BP; 4 A; 5 C; 8 G; 1 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 143 CGCTCGGCTCCGCTCC 158
 Db 18 CGCTCGGCTCCGCTCC 3
 RESULT 651
 ABL31108
 ID ABL31108 standard; DNA; 18 BP.
 XX
 AC ABL31108;
 XX
 XX 21-MAR-2002 (first entry)
 DT
 XX Human HLA genotyping oligonucleotide SEQ ID NO 597.
 DE
 XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
 KW immunogenetic; transplantation; genetic disease; ss.
 KW
 XX Homo sapiens.
 OS
 XX WO200192572-A1.
 PN
 XX 06-DEC-2001.
 PD
 XX 01-JUN-2001; 2001WO-JP04662.
 PF
 XX 01-JUN-2000; 2000JP-0164798.
 PR
 XX (NISR) NISSHINBO IND INC.
 PA (SYST-) SYSTEM RES INC.
 XX
 XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 DR
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 PT of individuals e.g. by determining immunogenetic differences when
 PT transplanting between them -
 XX
 XX Claim 10; Page 206; 345pp; Japanese.
 PS
 XX The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of

CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals.
 XX
 XX Sequence 18 BP; 3 A; 3 C; 6 G; 6 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 1182 TCTATAGGTGAGTGTT 1197
 Db 3 TCTACGGGTGAGTGTT 18
 RESULT 652
 ABL31109
 ID ABL31109 standard; DNA; 18 BP.
 XX
 AC ABL31109;
 XX
 XX 21-MAR-2002 (first entry)
 DT
 XX Human HLA genotyping oligonucleotide SEQ ID NO 598.
 DE
 XX Human; human leukocyte antigen; HLA; genotype; polymorphism;
 KW immunogenetic; transplantation; genetic disease; ss.
 KW
 XX Homo sapiens.
 OS
 XX WO200192572-A1.
 PN
 XX 06-DEC-2001.
 PD
 XX 01-JUN-2001; 2001WO-JP04662.
 PF
 XX 01-JUN-2000; 2000JP-0164798.
 PR
 XX (NISR) NISSHINBO IND INC.
 PA (SYST-) SYSTEM RES INC.
 XX
 XX Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 DR
 XX Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 PT of individuals e.g. by determining immunogenetic differences when
 PT transplanting between them -
 XX
 XX Claim 10; Page 206; 345pp; Japanese.
 PS
 XX The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals.
 XX
 XX Sequence 18 BP; 3 A; 2 C; 7 G; 6 T; 0 other;
 SQ
 Query Match 0.9%; Score 12.8; DB 1; Length 18;

Best Local Similarity 87.5%; Pred. No. 2.9e+02; Mismatches 0; Indels 2; Gaps 0; Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1182 TCTATAGGTGAGTGT 1197
 DB 3 TCTAGGGGTGAGTGT 18

RESULT 653
 AAS18869/C
 ID AAS18869 standard; DNA; 18 BP.
 XX AAS18869;
 XX
 XX 12-MAR-2002 (first entry)
 XX
 XX Growth hormone 1 gene (GH1), locus control region (LCR) primer LCR25.
 XX
 XX Growth hormone 1; GH1; osteopathic; gene therapy; protein therapy;
 KW diabetes; obesity; infection; acromegaly; gigantism; sodium retention;
 KW water retention; metabolic syndrome; mood disorder; sleep disorder;
 KW Growth hormone dysfunction; familial growth hormone deficiency;
 KW short stature; pituitary storage defect; human; PCR primer; LCR25;
 KW locus control region; LCR; ss.
 XX
 XX Homo sapiens.
 XX
 XX WO200185993-A2.
 XX
 XX 15-NOV-2001.
 XX
 XX 14-MAY-2001; 2001WO-GB021126.
 XX
 XX 12-MAY-2000; 2000GB-0011459.
 XX
 XX 14-JUL-2000; 2000EP-0306004.
 XX
 XX (UTWA-) UNIV WALES COLLEGE OF MEDICINE.
 XX
 XX Cooper DN, Procter AM, Gregory J, Millar DS;
 XX WPI; 2002-089798/12.
 XX
 XX Detecting growth hormone variants (GH1), useful in screening patients
 PT for growth hormone irregularities, comprises comparing the nucleotide
 PT sequence of a GH1 gene from a test sample with that of a standard
 PT sequence of the human GH1 -
 XX
 XX Claim 11; Page 77; 95pp; English.

The invention described a method of detecting variation in growth hormone
 1 (GH1), and therefore GH dysfunction in an individual. The method
 comprises comparing the nucleotide sequence of GH1 gene obtained from the
 test sample with a standard human GH1 gene sequence, in order to identify
 variation (GH1 variant). The method is useful in screening patients for
 growth hormone irregularities or producing variant proteins for treating
 irregularities, and for the early detection and appropriate clinical
 management of familial GH deficiency. The GH1 variants are useful in
 therapeutic, diagnostic or detection method, particularly for determining
 binding defects and susceptibility to a disease such as diabetes, obesity
 or infection; for treating acromegaly or gigantism conditions associated
 with lactogenic, diabetogenic, lipolytic and protein anabolic effects,
 conditions associated with sodium and water retention, metabolic
 syndromes, mood and sleep disorders; diagnosing GH dysfunction and
 determining pituitary storage defects. The GH1 variants are especially
 useful in gene therapy or protein therapy. The GH1 or GH variant may also
 be used in the preparation of a medicament, diagnostics composition or
 kit, or detection kit. The method has the advantage of: expanding the
 know spectrum of GH1 gene mutations; evaluating the role of GH1 gene
 mutations in the etiology of short stature; identifying of the mode of
 inheritance of novel lesions; evaluation of the effects of GH1 mutations on
 the structure and function of the GH molecule and development of rapid
 diagnostic tests for inherited GH deficiency. This sequence is the GH1
 gene locus control region (LCR) specific primer, LCR25, used to amplify

the LCR during sequence analysis to identify GH1 variants, described in
 the method of the invention.

Sequence 18 BP; 4 A; 7 C; 4 G; 3 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1255 TGAGCCAGGTTGAGG 1270
 DB 16 TGAGGTCAGCTTGAGG 1

RESULT 654
 ABL43144
 ID ABL43144 standard; DNA; 18 BP.
 XX
 XX ABL43144;
 XX
 XX 11-APR-2002 (first entry)
 XX
 XX Human chromosome 1p36-35 PCR primer SEQ ID NO:188.
 XX
 XX Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis;
 KW genome; PCR primer; ss.
 XX
 XX Homo sapiens.
 XX
 XX JP2001321190-A.
 XX
 XX 20-NOV-2001.
 XX
 XX 12-MAR-2001; 2001JP-0068285.
 XX
 XX 10-MAR-2000; 2000JP-0066716.
 XX
 XX (RIKA) RIKAGAKU KENKYUSHO.
 XX
 XX (GENO-) GENOTEX YG.
 XX
 XX WPI; 2002-144136/19.
 XX
 XX Arraying genome clones -
 XX
 XX Claim 4; Page 8; 528pp; Japanese.

The present invention describes a method of arraying genome clones. The
 method comprises: (a) clones of the genomic libraries contained in
 multiwell plates numbered for discrimination are mixed in each of the
 multiwell plates; (b) a primer designed based on the chromosome marker
 sequence is added to the mixture to carry out an amplification reaction;
 (c) a signal corresponding to the marker is detected from the resultant
 amplified product to specify the discrimination Nos. of the multiwell
 plates containing the clones having said marker sequence; (d) the order
 of the markers is changed so that the same discrimination Nos. succeed to
 the maximum in the specified discrimination Nos. to array the multiwell
 plates; (e) the clones in the multiwell plates of the specified
 discrimination Nos. are mixed respectively in each wells of longitudinal
 and lateral directions; (f) the mixed clones are cultured and the
 resultant cultures are amplified by using the above primer; (g) signals
 are detected from the amplified products; (h) the clones in the multiwell
 plates are specified from the detected result; and (i) the clones are
 reconstituted as the positions on the chromosome and arrayed. The
 microarray is useful for gene analysis. ABL42957 to ABL45322 represent
 PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
 represent PCR primers for human chromosome 21q22.1, which are
 specifically claimed for use in the present invention.

Sequence 18 BP; 4 A; 1 C; 11 G; 2 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Thu Jan 8 16:51:54 2004

us09904568-3.rng

QY 936 GGAGAGAGCTGTGAG 951
 Db 2 GGAGCAGGGTGTGAG 17

RESULT 655
 ABL44827
 ID ABL44827 standard; DNA; 18 BP.
 XX AC ABL44827;
 XX AC
 XX DT 11-APR-2002 (first entry)
 XX DE Human chromosome 1p36-35 PCR primer SEQ ID NO:1871.
 XX DE
 XX KW Human; chromosome 1p36-35; chromosome 21q22.1; genetic analysis;
 XX KW genome; PCR primer; ss.
 XX XX
 XX OS Homo sapiens.
 XX XX JP2001321190-A.
 XX XX 20-NOV-2001.
 XX XX 12-MAR-2001; 2001JP-0068285.
 XX XX 10-MAR-2000; 2000JP-0066716.
 XX XX (RIKA) RIKAGAKU KENKYUSHO.
 XX XX (GENO-) GENOTEX YG.
 XX XX WPI; 2002-144136/19.
 XX XX
 XX PT Arraying genome clones
 XX PS Claim 4; Page 41; 528pp; Japanese.
 XX XX
 CC The present invention describes a method of arraying genome clones. The
 CC method comprises: (a) clones of the genomic libraries contained in
 CC multiwell plates numbered for discrimination are mixed in each of the
 CC multiwell plates; (b) a primer designed based on the chromosome marker
 CC sequence is added to the mixture to carry out an amplification reaction;
 CC (c) a signal corresponding to the marker is detected from the resultant
 CC amplified product to specify the discrimination Nos. of the multiwell
 CC plates containing the clones having said marker sequence; (d) the order
 CC of the markers is changed so that the same discrimination Nos. succeed to
 CC the maximum in the specified discrimination Nos. to array the multiwell
 CC plates; (e) the clones in the multiwell plates of the specified
 CC discrimination Nos. are mixed respectively in each well of longitudinal
 CC and lateral directions; (f) the mixed clones are cultured and the
 CC resultant cultures are amplified by using the above primer; (g) signals
 CC are detected from the amplified products; (h) the clones in the multiwell
 CC plates are specified from the detected result; and (i) the clones are
 CC reconstituted as the positions on the chromosome and arrayed. The
 CC microarray is useful for gene analysis. ABL42957 to ABL45322 represent
 CC PCR primers for human chromosome 1p36-35 DNA, and ABL45323 to ABL45634
 CC represent PCR primers for human chromosome 21q22.1, which are
 CC specifically claimed for use in the present invention.
 XX XX
 XX SQ Sequence 18 BP; 6 A; 7 C; 3 G; 2 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 554 CAGGATGCACCACT 569
 Db 2 CAGGATGCACCACT 17

RESULT 656
 ACA60576

ID ACA60576 standard; DNA; 18 BP.
 XX ACA60576;
 XX DT 11-JUN-2003 (first entry)
 XX DE Antisense inhibition of human cyclin D2 related oligonucleotide #13.
 XX DE
 XX KW Human; cyclin D2; diagnostic; therapeutic; prophylaxis;
 XX KW cyclin 2 inhibition; ss.
 XX XX
 XX OS Homo sapiens.
 XX XX US6492173-B1.
 XX XX 10-DEC-2002.
 XX XX 01-AUG-2001; 2001US-0920760.
 XX XX 01-AUG-2001; 2001US-0920760.
 XX XX (ISIS-) ISIS PHARM INC.
 XX XX Cowser LM;
 XX XX WPI; 2003-361492/34.
 XX XX
 CC Novel antisense compound useful for treating diseases associated with
 CC Cyclin D2 expression, comprises an oligonucleotide comprising up to 50
 CC nucleobases in length, which inhibits expression of Cyclin D2 in cells
 CC or tissues in vitro -
 XX XX
 XX PS Example 15; Column 45-46; 40pp; English.
 XX XX
 CC The invention describes a compound (I) of up to 50 nucleobases in
 CC length, which inhibits the expression of Cyclin D2. (I) is useful for
 CC inhibiting the expression of Cyclin D2 in cells or tissues in vitro.
 CC (I) is thus useful for treating disease associated with Cyclin D2
 CC expression. (I) is useful for diagnostics, therapeutics, prophylaxis
 CC and as research reagents and kits. This sequence represents human
 CC cyclin D2 inhibition associated oligonucleotide.
 XX XX
 XX SQ Sequence 18 BP; 2 A; 0 C; 4 G; 12 T; 0 other;
 Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 2.9e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTCTTTTGGAA 1160
 Db 3 TTTTCTTTTGGAA 18

RESULT 657
 ABX75059/c
 ID ABX75059 standard; DNA; 18 BP.
 XX ABX75059;
 XX AC
 XX DT 25-MAR-2003 (first entry)
 XX XX
 XX DE Human gene 216 polymorphism detection PCR primer #116.
 XX XX
 XX KW Human; mouse; ss; primer; gene 216; antiasthmatic; antiinflammatory;
 XX KW anorectic; chromosome 20p13-p12; single nucleotide polymorphism;
 XX KW SNP; gene therapy; respiratory disease; asthma; obesity; PCR;
 XX KW bronchial hyper-responsiveness; chronic obstructive pulmonary disease;
 XX KW adult respiratory distress syndrome; inflammatory bowel syndrome.
 XX OS Homo sapiens.
 XX XX
 XX XX WO2002083077-A2.

```
PD 24-OCT-2002.
XX
XX 15-APR-2002; 2002WO-US12063.
XX
XX 13-APR-2001; 2001US-0834597.
XX
XX 13-APR-2001; 2001WO-US12245.
XX
XX (SCHE ) SCHERING CORP.
XX (GENO-) GENOME THERAPEUTICS CORP.
XX
XX Keith T, Little RD, Van Berdewegh P, Dupuis J, Del Mastro RG;
XX Simon J, Allen K, Pandit S;
XX
XX WPI; 2003-092960/08.
XX
XX New isolated gene 216 nucleic acids, useful for diagnosing, preventing
XX or treating a disorder, such as asthma, bronchial hyper-responsiveness,
XX chronic obstructive pulmonary disease, obesity or inflammatory bowel
XX syndrome -
XX
XX Example 10; Page 156; 650pp; English.
XX
XX This invention relates to a novel isolated nucleic acid, gene 216,
XX identified from human chromosome 20p13-p12. The invention also discloses
XX regions of the 216 gene that contain single nucleotide polymorphisms
XX (SNP's) which may be used as markers for disease susceptibility or
XX severity. The nucleotides of the invention may have anti-infective,
XX anti-inflammatory or anorectic activities and may be used in gene
XX therapy. The nucleic acids, antibodies or its fragments are useful for
XX diagnosing, preventing or treating a disorder, such as respiratory
XX diseases (e.g. asthma, bronchial hyper-responsiveness, chronic
XX obstructive pulmonary disease or adult respiratory distress syndrome),
XX obesity, or inflammatory bowel syndrome. The nucleic acids are also
XX useful for identifying increased susceptibility of a subject to the
XX disorders mentioned. The nucleic acids can also be used as primers and
XX templates for the recombinant production of disorder-associated
XX peptides or polypeptides, for chromosome and gene mapping, or for
XX tissue distribution studies. The present sequence represents a gene
XX 216 specific PCR primer used in the scope of the invention.
XX
XX Sequence 18 BP; 2 A; 7 C; 3 G; 6 T; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 18;
XX Best Local Similarity 87.5%; Pred. No. 2.9e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 725 ACCAGGGGGCCTGGCT 740
XX ||||| ||||| |||||
XX 16 ACCAGAGGGCATGGCT 1
XX
XX RESULT 658
XX AAD50969
XX ID AAD50969 standard; DNA; 18 BP.
XX
XX AC AAD50969;
XX
XX DT 02-APR-2003 (first entry)
XX
XX DE DM20 primer, to detect the presence of pTUBZEO11-2 in Schizochytrium sp.
XX
XX KW Acetolactate synthase; ALS; alpha-tubulin; polyketide synthase; PKS;
XX fatty acid desaturase; primer; ss.
XX
XX OS Schizochytrium sp.
XX
XX PN WO200283869-A2.
XX
XX PD 24-OCT-2002.
XX
XX PF 16-APR-2002; 2002WO-US12040.
XX
XX PR 16-APR-2001; 2001US-284116P.
XX
XX
XX (OMEG-) OMEGATECH INC.
XX
XX Roessler PG, Matthews TD, Ramseier TM, Metz JG;
XX
XX WPI; 2003-075541/07.
XX
XX New nucleic acid molecule, useful for transforming Thraustochytriales -
XX microorganisms or the foreign nucleic acids in a Thraustochytriales -
XX
XX Example 4; Page 106; 112pp; English.
XX
XX The present invention relates to novel nucleic acids and proteins for
XX acetolactate synthase, acetolactate synthase (ALS) regulatory regions,
XX alpha-tubulin promoter, polyketide synthase (PKS) promoter and fatty acid
XX desaturase promoter from Thraustochytriales microorganisms. The nucleic
XX acids of the invention are useful for transforming Thraustochytriales
XX microorganisms or the foreign nucleic acids in a Thraustochytriales.
XX The present sequence is a primer which is used to detect the presence
XX of pTUBZEO11-2 sequences in Schizochytrium species. This sequence is
XX used in the exemplification of the invention.
XX
XX Sequence 18 BP; 2 A; 6 C; 5 G; 5 T; 0 other;
XX
XX Query Match 0.9%; Score 12.8; DB 1; Length 18;
XX Best Local Similarity 87.5%; Pred. No. 2.9e+02;
XX Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
XX
XX QY 978 TTGACCATGCCCATTC 993
XX ||||| ||||| |||||
XX 2 TTGACCATGCCGCTC 17
XX
XX Db
XX
XX RESULT 659
XX ABZ56925/c
XX ID ABZ56925 standard; DNA; 18 BP.
XX
XX AC ABZ56925;
XX
XX DT 04-APR-2003 (first entry)
XX
XX DE Vallinoid receptor (VR1) related PCR primer 1 # SEQ ID 4.
XX
XX KW Dermatological; analgesic; anti-inflammatory; epithelial cell;
XX skin; vallinoid receptor; VR1; PCR; primer; ss.
XX
XX OS Rattus sp.
XX
XX PN WO2002103351-A1.
XX
XX PD 27-DEC-2002.
XX
XX PF 10-JUN-2002; 2002WO-JP05736.
XX
XX PR 14-JUN-2001; 2001JP-0180366.
XX
XX SA (SHIS ) SHISEIDO CO LTD.
XX
XX PI Inoue K, Fujiwara S, Denda M, Denda S;
XX
XX WPI; 2003-140773/13.
XX
XX Receptor-based method for detecting skin stimulation effect useful in
XX screening analgesics, anti-inflammatory agents and inhibitors on
XX epidermal abnormality, comprising measuring changes in calcium ion
XX concentration -
XX
XX Examples; Page 8; 22pp; Japanese.
XX
XX The invention relates to a method for detecting a skin stimulation effect
XX by using a test substance. The method comprises contacting a test
XX substance with epithelial cells, and detecting the increase or decrease
XX of calcium ion concentration in the cells. The method is useful as a
```

CC dermatological agent in the screening of analgesics, antiinflammatory
CC agents and inhibitors on epidermal abnormality. The current sequence
CC represents a rat vallinoid receptor (VR1) related PCR primer sequence
CC used in an example from the invention.
XX
SQ Sequence 18 BP; 5 A; 7 C; 5 G; 1 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 546 CCTGCTGCAGGCGATG 561
Db 18 CCTGCTGGTGGCATG 3

RESULT 560
ABQ83705
ID ABQ83705 standard; DNA; 18 BP.
XX
AC ABQ83705;
DT 28-JAN-2003 (first entry)
DE EPO B-A oligonucleotide.
XX
KW Gene regulation; expression; nucleic acid binding protein; cytostatic;
KW nephrotropic; gene therapy; kidney failure; cancer; ss.
XX
OS Synthetic.
XX
FN WO200274996-A1.
PD 26-SEP-2002.
XX
XX 19-MAR-2002; 2002WO-US08554.
XX
PR 19-MAR-2001; 2001GB-0006786.
XX
FA (SANG-) SANGAMO BIOSCIENCES INC.
XX
PI Girdlestone J, England N, Demaison C;
XX
DR WPI; 2003-058340/05.
XX

Regulating expression of a nucleic acid sequence in a primary cell for
treating or preventing a disease e.g., cancer, comprises contacting the
nucleic acid binding polypeptide with the nucleic acid sequence -
XX
FS Disclosure; Page 3; 81pp; English.
XX
CC The present invention describes a method (M1) for regulating expression
CC of a nucleic acid sequence in a primary cell comprising providing a
CC nucleic acid binding polypeptide capable of binding to the nucleic acid
CC sequence and contacting the nucleic acid binding polypeptide with the
CC nucleic acid sequence in the primary cell. Also described: (1) a nucleic
CC acid binding polypeptide (I) capable of binding to, and regulating the
CC expression of, a nucleic acid sequence in a primary cell; (2) a primary
CC cell (II) comprising an exogenous nucleic acid binding polypeptide;
CC (3) a pharmaceutical composition (III) comprising the polypeptide or the
CC primary cell and a carrier or diluent; (4) treating (M2) or preventing a
CC disease; or (5) expressing (M3) an exogenous nucleic acid binding
CC polypeptide in a primary cell. (I) has cytostatic and nephrotropic
CC activities, and can be used in gene therapy. The method is useful for
CC treating or preventing a disease e.g., kidney failure or cancer. The
CC present sequence represents an oligonucleotide which is used in the
CC exemplification of the present invention.
XX
SQ Sequence 18 BP; 0 A; 2 C; 12 G; 4 T; 0 other;

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 2.9e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 298 TCTGCTCTGGGGGCTG 313
Db 1 TCTGGGGTGGGGGCTG 16

RESULT 661
ABF87744/c
ID ABF87744 standard; DNA; 13 BP.
XX
AC ABF87744;
DT 22-FEB-2002 (first entry)
DE Oligonucleotide SEQ ID NO 187741 for detecting SNP TSC0046249.
XX
KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
OS Homo sapiens.
XX
FN WO200177384-A2.
PD 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
PR 07-APR-2000; 2000DE-1019173.
XX
FA (EPIG-) EPIGENOMICS AG.
XX
PI Olek A, Piepenbrock C, Berlin K;
XX
DR WPI; 2001-657177/75.

Set of oligonucleotides, useful for diagnosis and cell typing, is
designed to detect single nucleotide polymorphisms and cytosine
methylation status -
XX
FS Claim 1; SEQ ID 187741; 29pp + Sequence Listing; German.
XX
CC This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABT00010-ABT99989 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
SQ Sequence 13 BP; 3 A; 0 C; 8 G; 1 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.1e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

Qy 1206 ACACCTCCCTTC 1218
Db 13 RCACCTCCCTTC 1

RESULT 662
ABF87745
ID ABF87745 standard; DNA; 13 BP.
XX
AC ABF87745;
DT 22-FEB-2002 (first entry)

XX
DE Oligonucleotide SEQ ID NO 187742 for detecting SNP TSC0046249.
XX
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
XX Claim 1; SEQ ID 187742; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
XX Sequence 13 BP; 1 A; 8 C; 0 G; 3 T; 1 other;
SQ
Query Match 0.9%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.1e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1206 ACACCTCCCTTC 1218
DB 1 RCACCTCCCTTC 13
RESULT 663
ABF93458
ID ABF93458 standard; DNA; 13 BP.
XX
XX ABF93458;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide SEQ ID NO 193455 for detecting SNP TSC0047595.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
XX Claim 1; SEQ ID 187742; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
XX Sequence 13 BP; 1 A; 8 C; 0 G; 3 T; 1 other;
SQ
Query Match 0.9%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.1e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1206 ACACCTCCCTTC 1218
DB 1 RCACCTCCCTTC 13
RESULT 663
ABF93458
ID ABF93458 standard; DNA; 13 BP.
XX
XX ABF93458;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide SEQ ID NO 193455 for detecting SNP TSC0047595.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX

PF 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX
XX Claim 1; SEQ ID 193455; 29pp + Sequence Listing; German.
XX
XX This invention describes novel oligonucleotide primers or peptide nucleic
CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
CC and cytosine methylation status in chemically pretreated genomic DNA. The
CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
CC range of diseases including immune system, gastrointestinal, respiratory,
CC central nervous system, cardiovascular and metabolic disorders. The
CC oligomers are also used for detecting cell type differentiation.
CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
CC ABI00010-ABI82073 represent the oligomers described in the invention.
CC NOTE: The sequence data for this patent did not form part of the printed
CC specification, but was obtained in electronic format from WIPO at
CC ftp.wipo.int/pub/published_pct_sequences.
XX
XX Sequence 13 BP; 2 A; 0 C; 2 G; 8 T; 1 other;
SQ
Query Match 0.9%; Score 12.6; DB 1; Length 13;
Best Local Similarity 92.3%; Pred. No. 2.1e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 1104 TTATGTAGTTTC 1116
DB 1 TTATGTAGTTTC 13
RESULT 664
ABF93459/c
ID ABF93459 standard; DNA; 13 BP.
XX
XX ABF93459;
AC
XX 22-FEB-2002 (first entry)
DT
XX Oligonucleotide SEQ ID NO 193456 for detecting SNP TSC0047595.
DE
XX SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
XX
XX Homo sapiens.
OS
XX WO200177384-A2.
XX
XX 18-OCT-2001.
XX
XX 06-APR-2001; 2001WO-IB00713.
XX
XX 07-APR-2000; 2000DE-1019173.
XX
XX (EPIG-) EPIGENOMICS AG.
XX
XX Olek A, Piepenbrock C, Berlin K;
XX
XX WPI; 2001-657177/75.
XX
XX Set of oligonucleotides, useful for diagnosis and cell typing, is
PT designed to detect single nucleotide polymorphisms and cytosine
PT methylation status -
XX

PS Claim 1; SEQ ID 193456; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC ABI00010-ABI82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 13 BP; 8 A; 2 C; 0 G; 2 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.1e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1104 TTATGTAGTTTC 1116
 Db 13 TTATGTAGTTT 1

RESULT 665
 ABH10200
 ID ABH10200 standard; DNA; 13 BP.
 XX AC ABH10200;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 210177 for detecting SNP TSC0051320.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB00713.
 XX PR 07-APR-2000; 2000DE-1019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX Claim 1; SEQ ID 210177; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC ABI00010-ABI82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 13 BP; 4 A; 0 C; 3 G; 5 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.1e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1100 GTAATTATGTACT 1112
 Db 1 GTAATTATGTAGY 13

RESULT 666
 ABH10201/C
 ID ABH10201 standard; DNA; 13 BP.
 XX AC ABH10201;
 XX DT 22-FEB-2002 (first entry)
 XX DE Oligonucleotide SEQ ID NO 210178 for detecting SNP TSC0051320.
 XX KW SNP; single nucleotide polymorphism; human; diagnosis; PNA; cancer; CNS;
 KW peptide nucleic acid; cytosine methylation; cardiovascular; primer; ss;
 KW central nervous system; gastrointestinal; respiratory; immune; metabolic.
 XX OS Homo sapiens.
 XX PN WO200177384-A2.
 XX PD 18-OCT-2001.
 XX PF 06-APR-2001; 2001WO-IB00713.
 XX PR 07-APR-2000; 2000DE-1019173.
 XX PA (EPIG-) EPIGENOMICS AG.
 XX PI Olek A, Piepenbrock C, Berlin K;
 XX WPI; 2001-657177/75.
 XX Set of oligonucleotides, useful for diagnosis and cell typing, is
 PT designed to detect single nucleotide polymorphisms and cytosine
 PT methylation status -
 XX Claim 1; SEQ ID 210178; 29pp + Sequence Listing; German.

XX This invention describes novel oligonucleotide primers or peptide nucleic
 CC acid (PNA) oligomers for detecting single nucleotide polymorphisms (SNP)
 CC and cytosine methylation status in chemically pretreated genomic DNA. The
 CC oligonucleotides are used for diagnosis and/or prognosis of cancer and a
 CC range of diseases including immune system, gastrointestinal, respiratory,
 CC central nervous system, cardiovascular and metabolic disorders. The
 CC oligomers are also used for detecting cell type differentiation.
 CC ABC00010-ABC99989, ABF00010-ABF99989, ABH00010-ABH99989 and
 CC ABI00010-ABI82073 represent the oligomers described in the invention.
 CC NOTE: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format from WIPO at
 CC ftp.wipo.int/pub/published_pct_sequences.

XX SQ Sequence 13 BP; 5 A; 3 C; 0 G; 4 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 13;
 Best Local Similarity 92.3%; Pred. No. 2.1e+02;
 Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

QY 1100 GTAATTATGTACT 1112
 Db 13 GTAATTATGTAGY 1

```

RESULT 667
AAL44238
ID AAL44238 standard; DNA; 15 BP.
XX AC
XX AAL44238;
XX AC
XX 08-NOV-2002 (first entry)
XX DT
XX DE Human interleukin 12A (IL-12A) allele specific oligonucleotide primer 6.
XX DE Human; primer; interleukin 12A; IL-12A; drug screening; AIDS; malaria;
XX KW tuberculosis; cancer; haplotyping; genotyping; transgenic animal; ss.
XX KW
XX OS Homo sapiens.
XX XX
XX PN WO200229115-A1.
XX PD
XX PD 11-APR-2002.
XX XX
XX XX 05-OCT-2001; 2001WO-US31656.
XX PF
XX XX 06-OCT-2000; 2000US-238693P.
XX PR
XX XX (GENA-) GENAISSANCE PHARM INC.
XX PA
XX XX Armstrong B, Cappola G, Choi JY, Gilson CR, Kliem SE, Koshy B;
XX PI Parks KE;
XX PI
XX PS WPI; 2002-315865/35.
XX XX
XX XX New interleukin 12A (IL-12A) gene polymorphic variants, for studying
XX PT the expression and function of IL-12A and screening candidate drugs for
XX PT treating AIDS and cancer -
XX PT
XX XX Claim 15; Page 13; 72pp; English.
XX XX
XX CC The invention comprises the amino acid and coding sequence of the human
XX CC interleukin 12A (IL-12A) protein. Specifically the invention relates to
XX CC the identification of polymorphisms within the human (IL-12A) gene
XX CC sequence. The polymorphisms identified in the human IL-12A gene sequence
XX CC are useful in studying the expression and function of IL-12A, and in
XX CC screening drugs for the treatment of disorders such as AIDS, malaria,
XX CC tuberculosis and cancer. The IL-12A polymorphisms may be used to
XX CC haplotype and genotype the IL-12A gene of an individual. The IL-12A DNA
XX CC sequences of the invention can be used to create transgenic animals for
XX CC studying expression of the IL-12A isogenes in vivo. The present DNA
XX CC sequence represents a human interleukin 12A (IL-12A) gene allele specific
XX CC oligonucleotide primer.
XX CC
XX SQ Sequence 15 BP; 3 A; 2 C; 5 G; 4 T; 1 other;
Query Match 0.9%; Score 12.6; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 744 GCATGTTGCTGAC 756
| | | | | | | | | |
Db 2 GCATGTTGCTGAY 14
| | | | | | | | | |
RESULT 668
ABL36325
ID ABL36325 standard; DNA; 15 BP.
XX AC
XX ABL36325;
XX AC
XX 22-APR-2002 (first entry)
XX DT
XX DE Human lysosomal acid phosphatase 2 (ACP2) allele-specific PCR primer 5.
XX DE Human; ss; lysosomal acid phosphatase 2; ACP2; gene; chromosome 11;
XX KW lysosome-specific enzyme; orthophosphoric monoester hydrolysis;
XX KW

```

```

KW Hodgkin's disease; HD; acid phosphatase deficiency;
KW novel polymorphic site; ACP2 haplotype; ACP2 genotype; polymorphism;
KW transgenic animal; primer; probe; primer-extension oligonucleotide;
KW SNP; single nucleotide polymorphism.
XX OS Homo sapiens.
XX XX
XX PN WO200194362-A2.
XX PD
XX PD 13-DEC-2001.
XX XX
XX XX 07-JUN-2001; 2001WO-US18457.
XX PF
XX XX 07-JUN-2000; 2000US-210047P.
XX PR
XX XX (GENA-) GENAISSANCE PHARM INC.
XX PA
XX XX Kliem SE, Messer C, Tanguay DA;
XX PI
XX XX WPI; 2002-154563/20.
XX DR
XX XX Novel genetic variants of acid phosphatase 2, lysosomal polypeptide
XX PT gene useful in studying expression and function of the protein, and for
XX PT screening drugs to treat diseases e.g. Hodgkin's disease -
XX PT
XX XX Claim 17; Page 14; 109pp; English.
XX XX
XX CC The invention comprises the human lysosomal acid phosphatase 2 (ACP2)
XX CC nucleic acid and protein sequences. Specifically, the invention relates
XX CC to the discovery of 22 novel polymorphic sites within the ACP2 gene. The
XX CC invention also comprises methods for haplotyping and genotyping the ACP2
XX CC gene in an individual. The ACP2 gene (located on chromosome 11) encodes a
XX CC lysosomal-specific enzyme that catalyses the hydrolysis of
XX CC orthophosphoric monoesters to alcohol and phosphate. The ACP2 gene and
XX CC protein are pharmaceutically important in the treatment of Hodgkin's
XX CC disease (HD) and acid phosphatase deficiency. The novel ACP2 gene
XX CC polymorphisms of the invention are useful in haplotyping the ACP2 gene.
XX CC ACP2 haplotyping is useful in validating ACP2 as a target (and designing
XX CC drugs) for treating an ACP2-related disease or condition (e.g. Hodgkin's
XX CC disease and acid phosphatase deficiency). The ACP2 gene polymorphisms are
XX CC useful for ACP2 genotyping, which can also be used to develop diagnostic
XX CC tests and therapeutic treatments. The ACP2 protein and nucleic acids of
XX CC the invention are useful in the production of a transgenic animal which
XX CC expresses ACP2 protein. The ACP2 nucleic acids of the invention are
XX CC useful in the production of allele-specific oligonucleotides designed to
XX CC genotype each of the ACP2 polymorphisms. Nucleic acids ABL36299-ABL36320
XX CC represent claimed ACP2 allele-specific probes. Nucleic acids ABL36321-
XX CC ABL36364 represent claimed ACP2 allele-specific PCR primers. Nucleic
XX CC acids ABL36365-ABL36408 represent claimed ACP2 primer-extension
XX CC oligonucleotides.
XX CC
XX SQ Sequence 15 BP; 2 A; 8 C; 3 G; 1 T; 1 other;
Query Match 0.9%; Score 12.6; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 2.6e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;
QY 190 GCGGCCACCCCG 202
| | | | | | | | | |
Db 3 GCGGCCACCCCG 15
| | | | | | | | | |
RESULT 669
AAD44145
ID AAD44145 standard; DNA; 16 BP.
XX AC
XX AAD44145;
XX AC
XX 13-DEC-2002 (first entry)
XX DT
XX DE Oligo-dT PCR primer #5 used to illustrate the method of the invention.
XX DE Sequential consensus region-directed amplification; gene expression;
XX KW

```

KW disease diagnosis; gene analysis; human; matrix metalloproteinase;
XX PCR; primer; ss.

XX Unidentified.

XX US6277571-B1.

XX 21-AUG-2001.

XX 30-SEP-1998; 98US-0163485.

XX 03-OCT-1997; 97US-108152P.

XX (UYVI-) UNIV VIRGINIA COMMONWEALTH INTELLECTUAL.

XX Fillmore H, Broadus W, Gillies G;

XX WPI; 2002-412824/44.

XX Sequential consensus region-directed amplification for sorting mixture
XX of DNAs into 2 or more subsets or distinguishing gene expression
XX patterns in 2 samples, useful for disease diagnosis and gene analysis -

XX Example; Fig 1C; 19pp; English.

XX The invention relates to a method of sequential consensus region-directed
XX amplification for sorting a mixture of DNAs into 2 or more subsets or
XX distinguishing gene expression patterns in 2 samples. The methods, kits
XX and oligonucleotides are useful for sorting a mixture of DNAs into 2 or
XX more subsets or distinguishing gene expression patterns in 2 samples
XX e.g. for disease diagnosis and gene analysis. The present sequence is
XX oligo dT PCR primer used to illustrate the method of the invention.

XX Sequence 16 BP; 0 A; 1 C; 0 G; 14 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.8e+02;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1142 CCTTTTTCCTTTT 1156
DB 1 CTTTTTTTTTTT 15

RESULT 670

AAx87332

ID AAX87332 standard; DNA; 18 BP.

AC AAX87332;

DT 27-SEP-1999 (first entry)

DE Reverse transcription primer P1.

XX SAG gene; sensitive to apoptosis; mouse; cancer; tumour;
KW neurodegenerative disease; muscular dystrophy; wound healing;
KW vulnery; therapy; PCR; primer; ss.

XX Synthetic.

XX WO9932514-A2.

XX 01-JUL-1999.

XX 15-DEC-1998; 98WO-US26705.

XX 11-SEP-1998; 98US-0099840.

XX 19-DEC-1997; 97US-0068179.

XX (WARN) WARNER LAMBERT CO.

XX Sun Y;

XX

DR WPI; 1999-430152/36.

XX SAG: Sensitive to Apoptosis Gene and related proteins, useful for
PT promoting cell growth and protecting cells against apoptosis

XX Example 1; Page 14; 84pp; English.

XX This primer was used for reverse transcription of RNA isolated
CC from mouse tumour lines L-R101 (epidermal tumour cell line) and
CC H-Tx (spontaneously transformed liver line). It was also used as
CC the reverse primer in PCR amplification of the resulting cDNA.
CC Primers P1 and P2 (see AAX87333) reproducibly detected differential
CC expression of a gene between L10-phenanthroline (OP)-treated and
CC OP-nontreated L-R101 and H-Tx cells. An OP-inducible clone was
CC used as a probe to isolate a full-length clone (see AAX87313)
CC corresponding to the mouse sensitive to apoptosis gene (SAG). SAG
CC is a redox-sensitive, haem-binding protein domain that promotes
CC cell growth, protects cells from apoptosis, scavenges oxygen
CC radicals and can be used for the reversion of a tumour phenotype.

XX Sequence 18 BP; 2 A; 1 C; 1 G; 13 T; 1 other;

Query Match 0.9%; Score 12.6; DB 1; Length 18;

Best Local Similarity 86.7%; Pred. No. 3.2e+02;

Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1143 CTTTTTTCCTTTTG 1157

DB 4 CTTTTTTTTTTT 18

RESULT 671

ABT11916/C

ID ABT11916 standard; DNA; 18 BP.

XX ABT11916;

XX 19-DEC-2002 (first entry)

XX Neublabin DNA related PCR primer.

XX Nootropic; neuroprotective; antiparkinsonian; anticonvulsant; analgesic;
KW tranquiliser; antidiabetic; ophthalmological; neurodegenerative disorder;
KW neublabin; ischemic neuronal damage; traumatic brain injury; diabetes;
KW peripheral neuropathy; neuropathic pain; Alzheimer's disease; glaucoma;
KW Huntington's disease; Parkinson's disease; amyotrophic lateral sclerosis;
KW memory impairment; renal disease; PCR; primer; ss.

XX Unidentified.

XX WO200272826-A2.

XX 19-SEP-2002.

XX 12-MAR-2002; 2002WO-EP02691.

XX 12-MAR-2001; 2001US-0804615.

XX (BIOJ) BIOGEN INC.

XX (NSGE-) NS GENE AS.

XX Sah DWY, Johansen TE, Rossomando A;

XX WPI; 2002-713515/77.

XX New truncated neublabin polypeptides lacking one or more
PT amino-terminal amino acids of a mature neublabin polypeptide useful
PT for treating neurodegenerative disorders, e.g. peripheral neuropathy,
PT neuropathic pain, brain injury -

XX Disclosure; Fig 8; 138pp; English.

XX The invention relates to a truncated neublabin polypeptide comprising an

CC amino acid terminus that lacks one or more amino-terminal amino acids of
 CC a mature neublastin polypeptide. The polypeptides and nucleic acids are
 CC useful for treating neurodegenerative disorders such as ischemic neuronal
 CC damage, traumatic brain injury, peripheral neuropathy, neuropathic pain,
 CC Alzheimer's disease, Huntington's disease, Parkinson's disease,
 CC amyotrophic lateral sclerosis, memory impairment, diabetes, renal
 CC diseases, or glaucoma by moderating metabolism, growth, differentiation
 CC or survival of a nerve or neuronal cell. This polynucleotide sequence is
 CC a neublastin PCR primer of the invention.

XX Sequence 18 BP; 1 A; 6 C; 9 G; 2 T; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 18;
 Best Local Similarity 92.9%; Pred. No. 3.5e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 806 CCTGCGAGCGGAGC 819
 18 CCTGCGAGCGGAGC 5

RESULT 672

ABK94277/c
 ID ABK94277 standard; DNA; 21 BP.

AC ABK94277;

XX 27-AUG-2002 (first entry)

DE Endothelin converting enzyme 1 (ECE-1) SNP detection primer #65.

XX Endothelin; EDN; endothelin converting enzyme; ECE; endothelin receptor;
 KW EDNR; signaling system; cardiovascular disease; coronary heart disease;
 KW hypertension; atherosclerosis; angiogenesis; fatty acid metabolism;
 KW diabetes; familial hypercholesterolaemia; forensic marker;
 KW transgenic animal; solid support; cardiovascular regulator; SNP;
 KW single nucleotide polymorphism; PCR; primer; ss.

XX Synthetic.

XX WO200224747-A2.

XX 28-MAR-2002.

XX 31-AUG-2001; 2001WO-EPI0087.

XX 19-SEP-2000; 2000EP-0120123.

PR (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.

XX Brinkmann U, Hoffmeyer S;

XX WPI; 2002-435060/46.

XX Novel polynucleotide of the endothelin/endothelin converting
 PT enzyme/receptors of endothelin and endothelin converting enzyme
 PT signaling system associated with cardiovascular disease, useful for
 PT treating the disease -

PS Claim 1; Page 63; 190pp; English.

XX The invention describes a polynucleotide (I) of the endothelin
 CC (EDN)/endothelin converting enzyme (ECE)/receptors of EDN and ECE (EDNR)
 CC signaling system which is associated with a cardiovascular disease. (I),
 CC the gene encoding EDN, ECE or EDNR (II) or a vector (III) expressing (I),
 CC or (II) is useful for producing cells capable of expressing a molecular
 CC variant polypeptide which is associated with a cardiovascular disease.
 CC (II), (III), the EDN, ECE or EDNR polypeptide, or a cell expressing
 CC a molecular variant gene comprising (I) is useful for identifying and
 CC obtaining a pro-drug or drug capable of modulating the activity of a
 CC molecular variant of a polypeptide of the EDN/EDNR/ECE signaling system
 CC or its gene product, or for identifying and obtaining an inhibitor of
 CC the activity of a molecular variant of a polypeptide of the EDN/EDNR/ECE

CC signaling system or its gene product. The isolated proteins and
 CC polynucleotides encoding them are useful for preparation of a
 CC pharmaceutical composition for treating a cardiovascular disease such as
 CC coronary heart disease, hypertension, atherosclerosis, or related to
 CC abnormal angiogenesis or fatty acid metabolism e.g. diabetes and familial
 CC hypercholesterolaemia. The gene or a polynucleotide fragment of the
 CC EDN/ECE/EDNR signaling system are useful as forensic markers, for
 CC creating a transgenic animal and in creation of a solid support
 CC comprising polynucleotides, genes, vectors, polypeptides, antibodies or
 CC host cells of the invention. This sequence represents a PCR primer used
 CC to identify single nucleotide polymorphisms in DNA encoding
 CC cardiovascular regulator proteins of the EDN/ECE/EDNR signaling pathway.

XX Sequence 21 BP; 6 A; 3 C; 11 G; 1 T; 0 other;

Query Match 0.9%; Score 12.4; DB 1; Length 21;
 Best Local Similarity 92.9%; Pred. No. 4.1e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 802 CGCTCCCTGCAGCC 815
 18 CTCTCCCTGCAGCC 5

RESULT 673

ABK94278
 ID ABK94278 standard; DNA; 21 BP.

AC ABK94278;

XX 27-AUG-2002 (first entry)

DE Endothelin converting enzyme 1 (ECE-1) SNP detection primer #66.

XX Endothelin; EDN; endothelin converting enzyme; ECE; endothelin receptor;
 KW EDNR; signaling system; cardiovascular disease; coronary heart disease;
 KW hypertension; atherosclerosis; angiogenesis; fatty acid metabolism;
 KW diabetes; familial hypercholesterolaemia; forensic marker;
 KW transgenic animal; solid support; cardiovascular regulator; SNP;
 KW single nucleotide polymorphism; PCR; primer; ss.

XX Synthetic.

XX WO200224747-A2.

XX 28-MAR-2002.

XX 31-AUG-2001; 2001WO-EPI0087.

XX 19-SEP-2000; 2000EP-0120123.

PR (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.

XX Brinkmann U, Hoffmeyer S;

XX WPI; 2002-435060/46.

XX Novel polynucleotide of the endothelin/endothelin converting
 PT enzyme/receptors of endothelin and endothelin converting enzyme
 PT signaling system associated with cardiovascular disease, useful for
 PT treating the disease -

PS Claim 1; Page 63; 190pp; English.

XX The invention describes a polynucleotide (I) of the endothelin
 CC (EDN)/endothelin converting enzyme (ECE)/receptors of EDN and ECE (EDNR)
 CC signaling system which is associated with a cardiovascular disease. (I),
 CC the gene encoding EDN, ECE or EDNR (II) or a vector (III) expressing (I),
 CC or (II) is useful for producing cells capable of expressing a molecular
 CC variant polypeptide which is associated with a cardiovascular disease.
 CC (II), (III), the EDN, ECE or EDNR polypeptide, or a cell expressing
 CC a molecular variant gene comprising (I) is useful for identifying and
 CC obtaining a pro-drug or drug capable of modulating the activity of a

CC molecular variant of a polypeptide of the EDN/EDNR/ECE signaling system
 CC or its gene product, or for identifying and obtaining an inhibitor of
 CC the activity of a molecular variant of a polypeptide of the EDN/EDNR/ECE
 CC signaling system or its gene product. The isolated proteins and
 CC polynucleotides encoding them are useful for preparation of a
 CC pharmaceutical composition for treating a cardiovascular disease such as
 CC coronary heart disease, hypertension, atherosclerosis, or related to
 CC abnormal angiogenesis or fatty acid metabolism e.g. diabetes and familial
 CC hypercholesterolaemia. The gene or a polynucleotide fragment of the
 CC EDN/ECE/EDNR signaling system are useful as forensic markers, for
 CC creating a transgenic animal and in creation of a solid support
 CC comprising polynucleotides, genes, vectors, polypeptides, antibodies or
 CC host cells of the invention. This sequence represents a PCR primer used
 CC to identify single nucleotide polymorphisms in DNA encoding
 CC cardiovascular regulator proteins of the EDN/ECE/EDNR signaling pathway.

XX Sequence 21 BP; 1 A; 11 C; 3 G; 6 T; 0 other;
 Query Match 0.9%; Score 12.4; DB 1; Length 21;
 Best Local Similarity 92.9%; Pred. No. 4.1e+02;
 Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 802 CCTCCTCGAGCC 815
 DB 4 CTCCTCGAGCC 17

RESULT 674
 AAX70294/C
 ID AAX70294 standard; RNA; 18 BP.
 XX
 AC AAX70294;
 DT 28-JUL-1999 (first entry)
 XX Homo sapiens.
 DE Human flt1 VEGF receptor hairpin ribozyme substrate #62.
 XX
 KW Vascular endothelial growth factor receptor; VEGF receptor; flt-1;
 KW flk-1; KDR; hammerhead ribozyme; hairpin ribozyme; cleavage;
 KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;
 KW fms-like Tyrosine Kinase 1; Kinase insert domain containing receptor;
 KW foetal liver kinase 1; ss.

XX
 OS Homo sapiens.
 PN WO9715662-A2.
 XX
 PD 01-MAY-1997.
 XX
 PF 25-OCT-1996; 96WO-US17480.
 XX
 PR 11-JAN-1996; 96US-0584040.
 PR 26-OCT-1995; 95US-0005974.
 XX
 PA (CHIR) CHIRON CORP.
 PA (RIBO-) RIBOZYME PHARM INC.

XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;
 DR WPI; 1997-259017/23.
 XX

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or
 PT mRNA stability - useful for treating e.g. tumour angiogenesis,
 PT psoriasis, rheumatoid arthritis, etc., in a human patient

PS Claim 4; Page 94; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate
 CC the synthesis, expression and/or stability of a mRNA encoding 1 or more
 CC receptors of vascular endothelial growth factor (VEGF). A patient
 CC (preferably human) having a condition associated with the level of the
 CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing
 CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour

CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can
 CC be treated by administering the nucleic acid molecule or the expression
 CC vector to the patient. AAX75725 to AAX75752 represent specific examples
 CC of nucleic acid molecules from the present invention.

XX Sequence 18 BP; 2 A; 4 C; 6 G; 6 U; 0 other;

Query Match 0.9%; Score 12.2; DB 1; Length 18;
 Best Local Similarity 82.4%; Pred. No. 3.8e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1027 CAAGTCGAGCTGACTC 1043
 DB 18 CAAAGCAGCTGGCTC 2

RESULT 675
 AAH57086

ID AAH57086 standard; DNA; 20 BP.

XX AAH57086;

DT 10-SEP-2001 (first entry)

XX Human oestrogen receptor alpha probe oligonucleotide 31.

XX Ligand dependent transcriptional factor; oestrogen receptor; ER;
 KW glucocorticoid receptor protein; GR; mineralocorticoid receptor protein;
 KW MR; peroxisome proliferator-activated receptor protein; PPAR;
 KW progesterone receptor protein; PR; pregnane X receptor protein; PXR;
 KW thyroid hormone receptor protein; TR; vitamin D receptor protein; VDR;
 KW transactivation; ERalpha; breast cancer; PCR primer; probe; ss.

XX Homo sapiens.

XX WO200142307-A1.

XX 14-JUN-2001.

XX 01-DEC-2000; 2000WO-JP08553.

XX 07-DEC-1999; 99JP-0348022.

XX 27-DEC-1999; 99JP-0370667.

XX 07-JUL-2000; 2000JP-0207011.

XX 21-JUL-2000; 2000JP-0220508.

XX 02-AUG-2000; 2000JP-0234053.

XX 03-AUG-2000; 2000JP-0235460.

XX 03-AUG-2000; 2000JP-0235461.

XX 03-AUG-2000; 2000JP-0235463.

XX (SUMO) SUMITOMO CHEM CO LTD.

XX Saito K, Ohe N, Satoh H;

XX WPI; 2001-367866/38.

XX Ligand dependent transcriptional factors, nucleic acids encoding them
 PT and cells comprising them and a specified reporter gene, useful for
 PT screening agents for the treatment of breast cancer -
 XX Disclosure; Page 243; 276pp; English.

XX The present invention relates to ligand dependent transcriptional factors
 CC including oestrogen receptor (ER) alpha and beta protein, glucocorticoid
 CC receptor protein (GR), mineralocorticoid receptor protein (MR),
 CC peroxisome proliferator-activated receptor protein (PPAR), progesterone
 CC receptor protein (PR), pregnane X receptor protein (PX), thyroid hormone
 CC receptor protein (TR) and vitamin D receptor protein (VDR), the nucleic
 CC acids encoding them and cells comprising them and a specified reporter
 CC gene for the ligand dependent transcriptional factor. These proteins are
 CC useful in the modulation of ligand dependent transcriptional factor
 CC activity. The cells, mutant ERalpha and the polynucleotide encoding it
 CC may be used in assays for qualitatively analysing an activity for

CC transactivation of a reporter gene by a test ERalpha, for screening
CC mutant ligand dependent transcriptional factors, for evaluating an
CC activity for transactivation of a reporter gene by a test ERalpha and/or
CC for screening a compound useful for treating a disorder of a mutant
CC ERalpha, especially breast cancer.
XX
SQ Sequence 20 BP; 4 A; 7 C; 7 G; 2 T; 0 other;

Query Match 0.9%; Score 12.2; DB 1; Length 20;
Best Local Similarity 82.4%; Pred. No. 4.2e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 960 GCAGGACTGACCTCTCA 976
||||| ||||| ||||| ||||| |||||
Db 3 GCAGGCTGACCTCTGCA 19

RESULT 676
AAA11329/c
ID AAA11329 standard; DNA; 20 BP.
XX
AC AAA11329;
XX
DT 08-NOV-2000 (first entry)
XX
Human TRPC7 gene exon 23/intron 23 junction.
DE
DE Transmembrane protein; TRPC7; brain; transient receptor potential; TRP;
KW calcium channel function; human; Gene therapy; periodic psychosis;
KW mutation; ss.
XX
OS Homo sapiens.

XX Key Location/Qualifiers
FH exon 1..10
FT /tag= a
FT /number= 23
FT intron 11..20
FT /tag= b
FT /number= 23
XX
PN WO200029571-A1.

XX 25-MAY-2000.
XX
XX 11-NOV-1999; 99WO-JP06289.
XX
XX 12-NOV-1998; 98JP-0321200.
XX
XX (EIKE) EIKEN KAGAKU KK.
XX
XX Shimizu N, Nagamine K;
XX WPI; 2000-387784/33.

XX Nucleic acids encoding transmembrane protein TRPC7 expressed in brain
FT and homologous to transient receptor potential protein useful in the
FT treatment of associated diseases such as periodic psychosis
XX
XX Example 7; Page 39; 77pp; Japanese.
XX
XX The invention relates to the isolation of a nucleic acid (AAA11284)
CC coding for a transmembrane protein TRPC7 (AA92944) which is expressed in
CC brain and is homologous to transient receptor potential (TRP) protein.
CC This suggests that the TRPC7 protein may have a calcium channel
CC function. The genomic sequence has been shown to contain 31 introns. This
CC sequence represents an exon/intron junction from the genomic TRPC7
CC sequence. The DNA and protein can be used in the diagnosis and treatment
CC of disorders associated with TRPC7, especially the screening, monitoring
CC and treatment (by gene therapy) of periodic psychosis, which appears to
CC be associated with mutations in the TRPC7 gene.
XX
XX Sequence 20 BP; 4 A; 3 C; 11 G; 2 T; 0 other;

Query Match 0.9%; Score 12; DB 1; Length 20;
Best Local Similarity 75.0%; Pred. No. 4.5e+02;
Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 687 TGGAGCCAGCGCCCTCC 706
||||| ||||| ||||| ||||| |||||
Db 20 TGGAGCCAGCGCTCTCTCC 1

RESULT 677
AAD37217
ID AAD37217 standard; DNA; 20 BP.
XX
AC AAD37217;
XX
DT 21-AUG-2002 (first entry)
XX
Human MEKK4 antisense oligonucleotide, ISIS #123152.

XX Human; MEKK4 modulation; mitogen-activated protein kinase 4; MTK1;
KW MAP3K4; MAP three kinase 1; MAP/ERK kinase 4; MAPKKK4; cytostatic;
KW prophylaxis; immunological; hyperproliferative disorder; cancer; therapy;
KW antisense; inflammatory; phosphorothioate backbone; ss.
XX
OS Homo sapiens.
OS Synthetic.

XX Key Location/Qualifiers
FH modified_base 1..20
FT /tag= a
FT /mod_base= OTHER
FT /note= "Phosphorothioate backbone"
FT modified_base 1..5
FT /tag= b
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
FT modified_base 16..20
FT /tag= c
FT /mod_base= OTHER
FT /note= "2'-methoxyethyl nucleotides"
FT modified_base 5
FT /tag= d
FT /mod_base= m5c
FT modified_base 12
FT /tag= e
FT /mod_base= m5c
FT modified_base 16
FT /tag= f
FT /mod_base= m5c
FT modified_base 20
FT /tag= g
FT /mod_base= m5c
XX

PN WO200227033-A1.

XX 04-APR-2002.
XX
XX 28-SEP-2001; 2001WO-US30549.
XX
XX 29-SEP-2000; 2000US-0676436.
XX

(ISIS-) ISIS PHARM INC.

Ward DT, Gaarde WA, Monia BP, Wyatt JR;

WPI; 2002-416486/44.

XX New antisense compound targeted to nucleic acid encoding
FT mitogen-activated protein kinase 4, useful for treating immunologic
FT disorder, inflammatory disorder or cancer
XX
PS Claim 3; Page 93; 132pp; English.

XX The present invention relates to antisense compounds, compositions and
 CC methods for modulating the expression of MEKK4 (also referred to as mitogen-
 CC activated protein kinase kinase 4; MAP3K4; MAP three kinase 1; MAP/ERK
 CC kinase kinase 4; MAPKKK4; MTK1). The antisense oligos are useful for
 CC inhibiting the expression of MEKK4 in cells or tissues. They are also
 CC useful for treating an animal having a disease or condition associated
 CC with MEKK4 such as immunological, inflammatory, hyperproliferative
 CC disorder or cancer. Sequences of the invention are also useful for
 CC diagnostics, therapeutics, prophylaxis and as research reagents and kits.
 CC They are also useful in antisense therapy. The present sequence is an
 CC antisense oligonucleotide targetted to human MEKK4 DNA. This sequence
 CC is used in the exemplification of the invention.
 XX
 SQ Sequence 20 BP; 2 A; 4 C; 10 G; 4 T; 0 other;
 Query Match 0.9%; Score 12; DB 1; Length 20;
 Best Local Similarity 75.0%; Pred. No. 4.5e+02;
 Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
 QY 659 TGGTGGGACACTGGCCAGC 678
 DB 1 TGGTCGAGGAGCTGGCTGC 20
 RESULT 678
 AAL47730/c
 ID AAL47730 standard; DNA; 21 BP.
 XX
 AC AAL47730;
 XX
 DT 18-SEP-2002 (first entry)
 XX
 DE Ras gene PCR primer SEQ ID NO: 26.
 XX
 KW K-ras; N-ras; H-ras; ras; oncogene; mutation detection; PCR; primer;
 KW probe; restriction mediated selection PCR; cancer; ss.
 XX
 OS Unidentified.
 XX
 PN WO200229005-A2.
 XX
 PD 11-APR-2002.
 XX
 PF 02-OCT-2001; 2001WO-US42422.
 XX
 PR 02-OCT-2000; 2000US-237416P.
 XX
 PA (ORTH) ORTHO CLINICAL DIAGNOSTICS INC.
 XX
 PI Belly RT, Todd AV, Fuery CJ;
 XX
 DR WPI; 2002-479599/51.
 XX
 XX Amplifying and determining mutant sequences in DNA sample using
 PT thermostable restriction enzyme so that during thermocycling mutant
 PT sequences are enriched while wild-type sequences and/or primer induced
 PT sites are cleaved
 XX
 PS Claim 1; Page 74; 116pp; English.
 XX
 CC The present invention relates to a method of amplifying and determining
 CC target mutant Ras sequences in a DNA sample, involving the use of a
 CC thermostable restriction enzyme and primers shown in AAL47705-AAL47771.
 CC The method used is designated restriction mediated selection polymerase
 CC chain reaction (REMS-PCR). The method can be used to detect H-ras, K-ras
 CC and N-ras mutations, which may lead to cancer. The present sequence is a
 CC PCR primer useful in the method of the invention.
 XX
 SQ Sequence 21 BP; 3 A; 9 C; 6 G; 3 T; 0 other;
 Query Match 0.9%; Score 12; DB 1; Length 21;
 Best Local Similarity 75.0%; Pred. No. 4.7e+02;

Matches 15; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
 QY 529 GAGGAGCAGCTGGTGGCCCT 548
 DB 20 GAGGGCGCTGGGTGCACAT 1
 RESULT 679
 ABS52111
 ID ABS52111 standard; DNA; 18 BP.
 XX
 AC ABS52111;
 XX
 DT 05-NOV-2002 (first entry)
 XX
 DE Human adipocyte Clq Tumour Necrosis Factor-like PCR primer 1.
 XX
 KW Human; NOVX; NOVX-associated disorder; cardiomyopathy; atherosclerosis;
 KW cell signal processing; metabolic pathway modulation; metabolic disorder;
 KW obesity; diabetes; infectious disease; neurodegenerative disorder; cancer;
 KW Alzheimer's disease; Parkinson's disease; immune disorder; cancer;
 KW haematopoietic disorder; cirrhosis; pancreatitis; learning defect;
 KW memory defect; infertility; congenital heart defect; hair growth;
 KW pigmentation disorder; endocrine disorder; respiratory disease; health;
 KW gastro-intestinal disease; reproductive; neurological disease;
 KW bone marrow transplantation; endocrine disease; allergy; inflammation;
 KW neurological disorder; urinary system disorder; age-related disorder;
 KW neuropsychiatric disorder; EGF-related protein; SCUBE1; TEN-M4;
 KW adipocyte complement-related Clq tumour necrosis factor; out at first;
 KW beta adrenergic receptor kinase; EphA6/ebk-2; glucose transporter;
 KW type 1a membrane sushi-containing domain; butyrophillin;
 KW type 1a membrane sushi domain containing; PCR; primer; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200257453-A2.
 XX
 PD 25-JUL-2002.
 XX
 PF 19-DEC-2001; 2001WO-US50331.
 XX
 PR 19-DEC-2000; 2000US-265704P.
 PR 20-DEC-2000; 2000US-257314P.
 PR 02-MAY-2001; 2001US-288153P.
 PR 29-MAY-2001; 2001US-294075P.
 PR 24-JUL-2001; 2001US-307506P.
 PR 10-AUG-2001; 2001US-311590P.
 PR 29-AUG-2001; 2001US-315617P.
 PR 14-SEP-2001; 2001US-322358P.
 XX
 PA (CURA-) CURAGEN CORP.
 XX
 PI Gangolli EA, Patturajan M, Vernet CAM, Malyankar UM, Kekuda R;
 PI Stone DJ, Anderson S, Shimkets RA, Burgess CE, Zehusen BD, Liu X;
 PI Spytek KA, Casman SJ, Boldog FL, Smithson G, Li L, Ji W;
 XX
 DR WPI; 2002-590744/63.
 XX
 XX Novel isolated NOVX polypeptide useful for treating cardiomyopathy,
 PT atherosclerosis, metabolic disorders, diabetes, obesity, infectious
 PT disease, anorexia, neurodegenerative disorders, Alzheimer's disease or
 PT cancer
 XX
 PS Example 1; Page 198; 318pp; English.
 XX
 CC The present invention relates to new NOVX polypeptides. The invention is
 CC useful for treating or preventing a NOVX-associated disorder such as
 CC cardiomyopathy or atherosclerosis, where the disorder is related to cell
 CC signal processing and metabolic pathway modulation in a subject,
 CC preferably human. The invention is also useful for treating metabolic
 CC disorders (e.g. obesity), diabetes, infectious disease, neurodegenerative
 CC disorders (e.g. Alzheimer's disease, Parkinson's disease), immune

CC disorders, haematopoietic disorders and various cancers. The molecules of
CC the invention are also useful for treating or preventing cirrhosis,
CC pancreatitis, learning and memory defects, infertility, congenital heart
CC defects, acne, hair growth, pigmentation disorders, endocrine disorders,
CC respiratory disease, gastro-intestinal diseases, reproductive, health,
CC neurological diseases, bone marrow transplantation, endocrine diseases,
CC allergy and inflammation, nephrological disorders, urinary system
CC disorders, neuropsychiatric disorders and age-related disorders.
CC The present nucleic acid sequence represents a PCR primer that was used
CC in the methods of the invention.

SQ Sequence 18 BP; 3 A; 8 C; 5 G; 2 T; 0 other;

Query Match 0.9%; Score 11.8; DB 1; Length 18;
Best Local Similarity 86.7%; Pred. No. 4.4e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1297 CAGCCTGGCCCATG 1311
|||||
Db 2 CAGCAGGCGCATG 16

RESULT 680

ABK85826
ID ABK85826 standard; DNA; 18 BP.

XX
AC ABK85826;

DT 24-SEP-2002 (first entry)

XX Myotonic dystrophy protein kinase (DMPK) isoform, primer 57.

XX Myotonic dystrophy; DM; protein kinase; DMPK; myocardial infarction;
KW muscle damage; dysfunction; reverse transcriptase PCR; RT-PCR;
KW primer; ss.

XX Homo sapiens.

XX US2002061571-A1.

XX 23-MAY-2002.

XX 20-MAR-2001; 2001US-0813289.

XX 20-MAR-2000; 2000US-190590P.

XX (MAHA/) MAHADEVAN M S.

XX (TISC/) TISCORNIA G.

XX Mahadevan MS, Tiscornia G;

XX WPI; 2002-507644/54.

XX A new isoform of myotonic dystrophy protein kinase includes a sequence
PT encoded by exon 16 of the gene and is useful to detect presence or risk
PT of myotonic dystrophy, myocardial infarction or a condition associated
PT with muscle damage

PS Example; Page 7; 26pp; English.

XX The invention describes an isolated and purified polypeptide, comprising
CC an amino acid sequence encoded by exon 16 of the myotonic dystrophy
CC protein kinase (DMPK) gene. The invention is used to detect presence or
CC risk of myotonic dystrophy, myocardial infarction or a condition
CC associated with muscle damage or dysfunction. This sequence represents a
CC reverse transcriptase PCR primer used to isolate cDNA encoding exon 16 of
CC the novel Myotonic dystrophy protein kinase DMPK isoform studied in the
CC invention.

SQ Sequence 18 BP; 3 A; 3 C; 9 G; 3 T; 0 other;

Query Match 0.9%; Score 11.6; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 4.8e+02;

Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1258 GGCCAGGTGAGGCCCTT 1275
|||||
Db 1 GGGCAGATGGAGGCCCTT 18

RESULT 681

AAT87896
ID AAT87896 standard; DNA; 18 BP.

XX
AC AAT87896;

DT 12-JAN-1998 (first entry)

XX Lower primer for exon 1 of human interleukin 9 gene.

XX Human; interleukin 9; asthma associated factor 1; IL-9; primer;
KW atopic allergy; asthma; bronchial hyperresponsiveness; BHR; eczema;
KW rhinitis; urticaria; allergic inflammation; bowel; amplification;
KW polymorphism; polymerase chain reaction; PCR; exon 1; ss.

XX Synthetic.

XX WO9708321-A1.

XX 06-MAR-1997.

XX 23-AUG-1996; 96WO-US12757.

XX 06-AUG-1996; 96US-0023800.

XX 24-AUG-1995; 95US-0002765.

XX (MAGA-) MAGAININ PHARM INC.

XX Lee MW, Levitt RC, Nicholas N, Prasad KU;

XX WPI; 1997-179278/16.

XX Human interleukin-9 variant with Met at position 117 - useful for
PT treating atopic allergy, esp. asthma

XX Disclosure; Page 42; 142pp; English.

XX The present sequence is a primer for the PCR amplification of
CC exon 1 from the human interleukin 9 (hIL-9), also known as asthma
CC associated factor 1, gene. hIL-9 plays a role in atopic allergy,
CC asthma and related disorders, e.g. bronchial hyperresponsiveness,
CC (BHR), rhinitis, urticaria, allergic inflammatory disorders of the
CC bowel and various forms of eczema. A naturally occurring
CC polymorphism has been identified at position 117 of hIL-9,
CC individuals homozygous for Met at position 117 demonstrate, e.g. a
CC lack of asthma and low serum immunoglobulin E (IgE) levels, while
CC Thr/Thr homozygotes and Thr/Met heterozygotes are susceptible to
CC asthma.

SQ Sequence 18 BP; 2 A; 11 C; 2 G; 3 T; 0 other;

Query Match 0.9%; Score 11.6; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 4.8e+02;

Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 802 CGCTCCCTGCAGCCGAGC 819
|||||
Db 1 CTCCCTGCAGCCCTACC 18

RESULT 682

AAV41332
ID AAV41332 standard; DNA; 18 BP.

XX
AC AAV41332;

XX

DT 06-OCT-1998 (first entry)

XX Interleukin-9 (IL-9) gene exon 1 specific lower primer.

DE Interleukin; IL-9; AAF1; asthma associated factor; human; IBD;

XX inflammatory bowel disease; Th2 mediated immune response; lupus;

KW Crohn's disease; chronic non-specific ulcerative colitis; diabetes;

KW multiple sclerosis; arthritis; autoimmune disease; PCR primer; ss.

XX Synthetic.

OS Homo sapiens.

XX WO9827997-A1.

XX 02-JUL-1998.

XX 22-DEC-1997; 97WO-US2527.

XX 19-DEC-1997; 97US-0994986.

PR 20-DEC-1996; 96US-0034331.

XX (MAGA-) MAGAININ PHARM INC.

PA Levitt RC, Nicolaides NC;

XX WPI; 1998-377404/32.

XX Treating inflammatory bowel diseases, e.g. Crohn's disease - and

PT chronic non-specific ulcerative colitis by administering compounds

PT up-regulating function of interleukin-9 or its receptor

XX Disclosure; Page 23; 61pp; English.

XX Sequences shown in AAV41331 to AAV41340 represent exon specific primers

CC of human interleukin (IL-9) gene. The invention provides a method

CC for the treatment of inflammatory bowel disease (IBD) or related

CC disorders that comprises administering a compound that up-regulates the

CC function of IL-9 or the IL-9 receptor. A method for monitoring humans

CC undergoing IBD treatment with polypeptides with human IL-9 sequence

CC (or fragments), by evaluating IL-9 levels in samples taken at different

CC times, and a method for screening for cells expressing the IL-9 receptor

CC by detecting binding of a specific ligand are also provided. Compounds

CC up-regulating the function of IL-9 or the IL-9 receptor can be used

CC therapeutically (in pharmaceutical compositions, optionally with

CC acceptable carriers) to treat IBD and other related inflammatory

CC disorders. IBDs (which include Crohn's diseases and chronic non-specific

CC ulcerative colitis) are diseases characterised by an inappropriate

CC inflammatory response to environmental stimuli. Immune responses to

CC antigens are classified as Th1 or Th2 responses, and evidence suggests

CC that IBDs are dominated by a Th1 mediated, antigen induced, inflammatory

CC response. Other related Th1 mediated diseases include multiple

CC sclerosis, diabetes, arthritis, lupus and autoimmune diseases. The method

CC is based on the observation that the Th2 response is up-regulated by

IL-9.

XX

SQ Sequence 18 BP; 2 A; 11 C; 2 G; 3 T; 0 other;

Query Match 0.9%; Score 11.6; DB 1; Length 18;

Best Local Similarity 77.8%; Pred. No. 4.8e+02;

Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 802 CGCTCCCTGCGAGCGGAC 819

DB 1 CTCCCCCTGAGCTTACC 18

RESULT 683

AAAX75628/c

ID AAX75628 standard; RNA; 18 BP.

XX

AC AAX75628;

XX 28-JUL-1999 (first entry)

DT

XX Mouse flt-1 VEGF receptor hairpin ribozyme substrate #87.

DE

XX Vascular endothelial growth factor receptor; VEGF receptor; flt-1;

KW flk-1; KDR; hamsterhead ribozyme; hairpin ribozyme; cleavage;

KW tumour angiogenesis; psoriasis; rheumatoid arthritis; ocular disease;

KW fms-like tyrosine kinase 1; kinase insert domain containing receptor;

KW foetal liver kinase 1; ss.

XX

OS Mus sp.

XX WO9715662-A2.

XX 01-MAY-1997.

XX 25-OCT-1996; 96WO-US17480.

XX 11-JAN-1996; 96US-0584040.

PR 26-OCT-1995; 95US-0005974.

XX (CHIR) CHIRON CORP.

PA (RIBO-) RIBOZYME PHARM INC.

XX Escobedo J, McSwiggen J, Pavco P, Stinchcomb D;

XX WPI; 1997-259017/23.

XX Nucleic acid molecule modulating VEGF receptor(s) gene expression or

PT mRNA stability - useful for treating e.g. tumour angiogenesis,

PT psoriasis, rheumatoid arthritis, etc., in a human patient

XX Claim 4; Page 188; 218pp; English.

XX The present invention describes nucleic acid molecules which modulate

CC the synthesis, expression and/or stability of a mRNA encoding 1 or more

CC receptors of vascular endothelial growth factor (VEGF). A patient

CC (preferably human) having a condition associated with the level of the

CC fms-like tyrosine kinase 1 (flt-1), kinase insert domain containing

CC receptor (KDR) and/or foetal liver kinase 1 (flk-1) (e.g. tumour

CC angiogenesis, ocular diseases, psoriasis and rheumatoid arthritis) can

CC be treated by administering the nucleic acid molecule or the expression

CC vector to the patient. AAX67275 to AAX75752 represent specific examples

CC of nucleic acid molecules from the present invention.

XX Sequence 18 BP; 2 A; 5 C; 6 G; 5 U; 0 other;

SQ

Query Match 0.9%; Score 11.6; DB 1; Length 18;

Best Local Similarity 77.8%; Pred. No. 4.8e+02;

Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 210 CGAAGCCGAGCGGCTCC 227

DB 18 CGAAGCCGAGCGGCTCC 1

RESULT 684

AAAX32336

ID AAX32336 standard; DNA; 19 BP.

XX

AC AAX32336;

XX 25-JUN-1999 (first entry)

DT

XX Wheat viviparous 1 (taVPI) primer #3.

DE

XX Wheat; oat; viviparous 1; VPI; afVPI; taVPI; maize; detection; PHS;

KW pre-harvest sprouting; dormant; germination; crop plant; primer; ss.

XX Synthetic.

OS Triticum aestivum.

XX WO9915667-A1.

XX

PD 01-APR-1999.
XX
XX
PF 18-SEP-1998; 98WO-GB02835.
XX
XX
PR 19-SEP-1997; 97GB-0020060.
XX
XX (PLAN-) PLANT BIOSCIENCE LTD.
PA
XX Plintham JE, Gale MD, Holdsworth MJ;
PI
XX WPI; 1999-244424/20.
DR
XX
XX New isolated oat and wheat Vp1 genes, used, e.g. to impose
PT sufficient dormancy to avoid pre-harvest sprouting
PT
XX
XX Claim 56; Page 89; 120pp; English.
XX
XX The present sequence represents a primer for the wheat viviparous 1 (Vp1)
CC gene, which keeps mature seeds dormant and inhibits germination. The
CC present invention describes genes which are homologues of the maize
CC Viviparous 1 gene, obtained from oat Avena fatua and wheat which encode
CC polypeptides designated afv1 and tav1 respectively. The Vp1 activity
CC keeps mature seeds dormant and inhibits germination and can be used to
CC maintain or impose sufficient intensity and duration of dormancy to
CC avoid pre-harvest sprouting (PHS) before harvest. The products can be
CC used in the production of transformed crop plants having desirable
CC primary or secondary dormancy, or after-ripening properties, and in
CC particular may be resistant to PHS.
XX
XX Sequence 19 BP; 3 A; 4 C; 11 G; 1 T; 0 other;
SQ
Query Match 0.8%; Score 11.6; DB 1; Length 19;
Best Local Similarity 77.8%; Pred. No. 5e+02; Indels 0; Gaps 0;
Matches 14; Conservative 0; Mismatches 4;
QY 721 CAGCAGCAGGGGGCTGG 738
Db 2 CGCAGCAGGGTGCAGG 19
RESULT 685
ABV89507/C
ID ABV89507 standard; DNA; 17 BP.
XX
XX
AC ABV89507;
XX
XX 23-DEC-2002 (first entry)
XX
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 220.
DE
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
XX Homo sapiens.
XX
XX EPI239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-0001165.
XX
XX 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 23-MAY-2001; 2001US-0864761.
PR 10-OCT-2001; 2001US-0328205.
XX

PA (AEOM-) AEOMICA INC.
XX
XX Shannon M;
XX
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
PT POSHL-1, useful for treating disorders associated with decreased
PT expression or activity of human POSHL1 -
XX
XX Example 2; SEQ ID NO 220; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
CC protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
CC acids (SI, AB883999), a sequence having 65% sequence identity to (SI),
CC (SI) having 95% deviations, especially conservative substitutions or a
CC fragment of the sequences comprising at least 8 contiguous amino acids.
CC Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
CC adaptor protein that interacts with Rho family small GTPases as well as
CC downstream components of the signal transduction pathway. (I) is useful
CC for identifying a specific binding partner. (I) and nucleic acids (II)
CC encoding (I) are useful for diagnosing, monitoring disease and treating
CC caused by altered expression of human POSHL1 including diagnosing and
CC treating cancer, they are useful in the development of vaccines and (II) is
CC useful in gene therapy. (II) is useful for constructing microarrays which
CC are useful for measuring and for surveying gene expression and creating
CC transgenic non-human animals capable of producing the proteins. The
CC present sequence is that of a scanning oligonucleotide useful in examples
CC of the invention.
CC Note: The present sequence did not form part of the printed
CC specification, but is based on sequence information supplied to Derwent
CC by the European Patent Office.
XX
XX Sequence 17 BP; 2 A; 7 C; 4 G; 4 T; 0 other;
SQ
Query Match 0.8%; Score 11.4; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 4.9e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 526 CCGAGGAGGAGC 538
Db 15 CTGGAGGAGGAGC 3
RESULT 686
ABV89508/C
ID ABV89508 standard; DNA; 17 BP.
XX
XX
AC ABV89508;
XX
XX 23-DEC-2002 (first entry)
XX
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 221.
DE
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
KW Rho GTPase; signal transduction; gene expression; cancer; vaccine;
KW gene therapy; transgenic; ss.
XX
XX Homo sapiens.
XX
XX EPI239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-0001165.
XX
XX 30-JAN-2001; 2001WO-US00663.
PR 30-JAN-2001; 2001WO-US00664.
PR 30-JAN-2001; 2001WO-US00665.
PR 30-JAN-2001; 2001WO-US00666.
PR 30-JAN-2001; 2001WO-US00667.
PR 30-JAN-2001; 2001WO-US00668.
PR 30-JAN-2001; 2001WO-US00669.
PR 30-JAN-2001; 2001WO-US00670.
PR 23-MAY-2001; 2001US-0864761.
PR 10-OCT-2001; 2001US-0328205.
XX

PR 30-JAN-2001; 2001WO-US00670.
PR 23-MAY-2001; 2001US-0864761.
PR 10-OCT-2001; 2001US-0328205.
XX
XX (AEOM-) AEOMICA INC.
XX Shannon M;
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
XX POSHL-1, useful for treating disorders associated with decreased
XX expression or activity of human POSHL1 -
XX
XX Example 2; SEQ ID NO 221; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
XX protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
XX acids (S1, ABB83999), a sequence having 65% sequence identity to (S1),
XX (S1) having 95% deviations, especially conservative substitutions or a
XX fragment of the sequences comprising at least 8 contiguous amino acids.
XX Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
XX adaptor protein that interacts with Rho family small GTPases as well as
XX downstream components of the signal transduction pathway. (I) is useful
XX for identifying a specific binding partner. (II) and nucleic acids (II)
XX encoding (I) are useful for diagnosing, monitoring disease and treating
XX caused by altered expression of human POSHL1 including diagnosing and
XX treating cancer, they useful in the development of vaccines and (II) is
XX useful in gene therapy. (II) is useful for constructing microarrays which
XX are useful for measuring and for surveying gene expression and creating
XX transgenic non-human animals capable of producing the proteins. The
XX present sequence is that of a scanning oligonucleotide useful in examples
XX of the invention.
XX Note: The present sequence did not form part of the printed
XX specification, but is based on sequence information supplied to Derwent
XX by the European Patent Office.
XX
XX Sequence 17 BP; 1 A; 7 C; 5 G; 4 T; 0 other;
XX
XX Query Match 0.8%; Score 11.4; DB 1; Length 17;
XX Best Local Similarity 92.3%; Pred. No. 4.9e+02;
XX Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 526 CCGGAGGAGCAGC 538
XX 14 CTGGAGGAGCAGC 2
XX
XX RESULT 687
XX AAT80260
XX ID AAT80260 standard; DNA; 18 BP.
XX AC AAT80260;
XX
XX DT 15-OCT-1997 (first entry)
XX
XX DE Oligo HCV91, targetted to HCV region -1 to -6.
XX
XX KW Complementary; 5' untranslated region; UTR; hepatitis C virus; HCV;
XX inhibition; replication; expression; detection; chronic hepatitis;
XX acute hepatitis; hepatocarcinoma; ss.
XX
XX OS Synthetic.
XX
XX PH Key Location/Qualifiers
XX modified_base 7..18
XX FT /tag= a
XX FT /note= "2' Ome modified"
XX modified_base 1..6
XX FT /tag= b
XX FT /note= "Phosphorothioate linkages"
XX
XX WO9639500-A2.

XX 12-DEC-1996.
XX 04-JUN-1996; 96WO-EP02427.
XX 06-JUN-1995; 95US-0471968.
XX (HOFF) HOFFMANN LA ROCHE & CO AG F.
XX (HYER-) HYERIDON INC.
XX Frank BL, Goodchild J, Hamlin HA, Kilkuskie RE;
XX Roberts NA, Roberts PC, Walther DM, Wolfe JL;
XX WPI; 1997-043122/04.
XX
XX Oligonucleotide(s) complementary to HCV 5' untranslated region -
XX used in the treatment and detection of HCV infection, esp. hepatitis
XX and hepato-carcinoma
XX Claim 19; Page 31; 100pp; English.
XX
XX The sequences given in AAT80211-382 represent synthetic oligonucleotides
XX which are complementary to a portion of the 5' untranslated region (UTR)
XX of hepatitis C virus (HCV). These sequences may be used in a
XX pharmaceutical composition for the control or prevention of HCV
XX infection. They may be used to inhibit replication or expression of
XX HCV or for detecting the presence of HCV in a sample. They may be used
XX to inhibit HCV replication in a cell and are therefore useful in the
XX treatment of HCV infections such as chronic and acute hepatitis and
XX hepatocarcinoma. This oligo was used in a luciferase assay to determine
XX whether it binds successfully to its target.
XX
XX Sequence 18 BP; 2 A; 3 C; 10 G; 1 T; 2 U; 0 Other;
XX
XX Query Match 0.8%; Score 11.4; DB 1; Length 18;
XX Best Local Similarity 84.6%; Pred. No. 5.1e+02;
XX Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
XX
XX QY 726 GCAGGGGGCCTGG 738
XX 4 GCAGGGGGCCTGG 16
XX
XX RESULT 688
XX ABS65844
XX ID ABS65844 standard; DNA; 18 BP.
XX AC ABS65844;
XX
XX DT 15-NOV-2002 (first entry)
XX
XX DE Inhibitory oligonucleotide specific for hepatitis C virus #50.
XX
XX KW Hepatitis C virus; HCV; hepatocyte infection; non-A hepatitis;
XX non-B hepatitis; acute hepatitis; chronic hepatitis;
XX hepatocellular carcinoma; virucide; cytostatic; antisense therapy;
XX gene therapy; ss; DNA-RNA hybrid.
XX
XX OS Synthetic.
XX
XX PN US2002081577-A1.
XX
XX PD 27-JUN-2002.
XX
XX PF 02-JUL-1997; 97US-0887505.
XX
XX PR 02-JUL-1996; 96US-021104P.
XX 06-JUN-1995; 95US-0471968.
XX
XX (KILK/) KILKUSKIE R L.
XX (FRAN/) FRANK B L.
XX (GOOD/) GOODCHILD J.
XX (WOLF/) WOLFE J L.

PA (ROBE/) ROBERTS P C.
 PA (HAML/) HAMLIN H A.
 PA (ROBE/) ROBERTS N A.
 PA (WALT/) WALTHER D M.
 XX
 XX Kilkuskie RL, Frank BL, Goodchild J, Wolfe JL, Roberts PC;
 PI Hamlin HA, Roberts NA, Walther DM;
 XX
 XX WPI; 2002-537132/57.
 DR
 XX
 XX Synthetic oligonucleotides complementary to a portion of the 5'
 PT untranslated region of hepatitis C virus (HCV), useful for diagnosing
 PT and treating HCV infections and hepatocellular carcinoma -
 XX
 XX Claim 22; Page 11; 74pp; English.
 XX
 XX The invention describes synthetic oligonucleotides complementary to a
 CC portion of the 5' untranslated region of hepatitis C virus. The
 CC oligonucleotides may be used in methods for controlling, preventing, and
 CC treating hepatitis C virus infection, in antisense technology and gene
 CC therapy, and of detecting the presence of hepatitis C virus in a sample.
 CC Hepatitis C virus (HCV) is an enveloped, positive sense, single-stranded
 CC RNA virus which infects hepatocytes. HCV is the major cause of non-A,
 CC non-B, acute and chronic hepatitis, and has been associated with
 CC hepatocellular carcinoma. The invention describes methods and kits for
 CC inhibiting replication of HCV, inhibiting the expression of HCV nucleic
 CC acid and protein, and for treating HCV infections. This sequence
 CC represents a synthetic DNA-RNA hybrid oligonucleotide used for inhibiting
 CC HCV replication and expression of HCV.
 XX
 SQ Sequence 18 BP; 2 A; 3 C; 10 G; 1 T; 2 U; 0 other;
 Query Match 0.8%; Score 11.4; DB 1; Length 18;
 Best Local Similarity 84.8%; Pred. No. 5.1e+02;
 Matches 11; Conservative 1; Mismatches 1; Indels 0; Gaps 0;
 QY 726 GCAGGGGGCTGG 738
 DB 4 GCAGGGGGCTGG 16
 RESULT 689
 AAH89204/c
 ID AAH89204 standard; DNA; 20 BP.
 AC
 AC AAH89204;
 XX
 XX 27-FEB-2002 (first entry)
 DT
 XX
 XX Human polymorphic oligonucleotide U85199 fragment #2.
 DE
 XX
 XX Human; single nucleotide polymorphic; SNP; forensic science;
 KW paternity testing; phenotypic trait; genetic mapping; animal breeding;
 KW plant breeding; ds.
 XX
 XX Homo sapiens.
 OS
 XX
 XX Key Location/Qualifiers
 FH Variation replace(10,c)
 FT /*tag= a
 FT /standard_name= "single nucleotide polymorphism"
 FT
 XX WO200134840-A2.
 PN
 XX
 XX 17-MAY-2001.
 PD
 XX
 XX 10-NOV-2000; 2000WO-US30766.
 PF
 XX
 XX 10-NOV-1999; 99US-0164596.
 PR
 XX
 XX (GLAX) GLAXO GROUP LTD.
 PA (AFFY-) AFFYMETRIX INC.
 PA
 XX

PI Au K, Chen J, Patil N, Thomas D;
 XX
 XX WPI; 2001-335945/35.
 DR
 XX
 XX New polymorphic sites derived from the human genome are useful to
 PT determine sites correlating with phenotypic traits, particularly
 PT disease, and also in forensics and paternity testing -
 XX
 XX Claim 95; Page 16; 43pp; English.
 PS
 XX
 XX The present invention relates to human oligonucleotides comprising a
 CC single nucleotide polymorphic site (SNP: AAH89219). The present
 CC sequence is one such oligonucleotide. The oligonucleotides can be used in
 CC forensics, paternity testing, correlation of polymorphisms with
 CC phenotypic traits, genetic mapping of phenotypic traits and marker
 CC assisted breeding of animals and crop plants.
 XX
 SQ Sequence 20 BP; 3 A; 7 C; 6 G; 4 T; 0 other;
 Query Match 0.8%; Score 11.4; DB 1; Length 20;
 Best Local Similarity 92.3%; Pred. No. 5.6e+02;
 Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 226 CCTCAGCCTCAGG 238
 DB 20 CCTCAGCCTCAGG 8
 RESULT 690
 ABK94275/c
 ID ABK94275 standard; DNA; 21 BP.
 XX
 AC ABK94275;
 AC
 XX 27-AUG-2002 (first entry)
 DT
 XX
 XX Endothelin converting enzyme 1 (ECE-1) SNP detection primer #63.
 DE
 XX
 XX Endothelin; EDN; endothelin converting enzyme; ECE; endothelin receptor;
 KW EDNR; signaling system; cardiovascular disease; coronary heart disease;
 KW hypertension; atherosclerosis; angiogenesis; fatty acid metabolism;
 KW diabetes; familial hypercholesterolemia; forensic marker;
 KW transgenic animal; solid support; cardiovascular regulator; SNP;
 KW single nucleotide polymorphism; PCR; primer; ss.
 XX
 OS Synthetic.
 XX
 XX WO200224747-A2.
 PN
 XX
 XX 28-MAR-2002.
 PD
 XX
 XX 31-AUG-2001; 2001WO-BP10087.
 PF
 XX
 XX 19-SEP-2000; 2000EP-0120123.
 PR
 XX
 XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
 PA
 XX
 XX Brinkmann U, Hoffmeyer S;
 PI
 XX
 XX WPI; 2002-435060/46.
 DR
 XX
 XX Novel polymorphic site of the endothelin/endothelin converting
 PT enzyme/receptors of endothelin and endothelin converting enzyme
 PT signaling system associated with cardiovascular disease, useful for
 PT treating the disease -
 XX
 XX Example 6; Page 63; 190pp; English.
 PS
 XX
 XX The invention describes a polymorphic site (I) of the endothelin
 CC (EDN)/endothelin converting enzyme (ECE)/receptors of EDN and ECE (EDNR)
 CC signaling system which is associated with a cardiovascular disease. (I),
 CC the gene encoding EDN, ECE or EDNR (II) or a vector (III) expressing (I)
 CC or (II) is useful for producing cells capable of expressing a molecular

variant polypeptide which is associated with a cardiovascular disease. (I), (II), (III), the EDN, ECE or EDNR polypeptide, or a cell expressing a molecular variant gene comprising (I) is useful for identifying and obtaining a pro-drug or drug capable of modulating the activity of a molecular variant of a polypeptide of the EDN/EDNR/ECE signaling system or its gene product, or for identifying and obtaining an inhibitor of the activity of a molecular variant of a polypeptide of the EDN/EDNR/ECE signaling system or its gene product. The isolated proteins and polynucleotides encoding them are useful for preparation of a pharmaceutical composition for treating a cardiovascular disease such as coronary heart disease, hypertension, atherosclerosis, or related to abnormal angiogenesis or fatty acid metabolism e.g. diabetes and familial hypercholesterolaemia. The gene or a polynucleotide fragment of the EDN/ECE/EDNR signaling system are useful as forensic markers, for creating a transgenic animal and in creation of a solid support comprising polynucleotides, genes, vectors, polypeptides, antibodies or host cells of the invention. This sequence represents a PCR primer used to identify single nucleotide polymorphisms in DNA encoding cardiovascular regulator proteins of the EDN/ECE/EDNR signaling pathway.

Sequence 21 BP; 5 A; 3 C; 11 G; 1 T; 1 other;

Query Match 0.8%; Score 11.4; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 5.8e+02;
Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 802 CGCTCCCTGCAGCC 815
Db 18 CTCCTCCNGCAGCC 5

RESULT 691
ABK94276

ID ABK94276 standard; DNA; 21 BP.

AC ABK94276;

DT 27-AUG-2002 (first entry)

DE Endothelin converting enzyme 1 (ECE-1) SNP detection primer #64.

KW Endothelin; EDN; endothelin converting enzyme; ECE; endothelin receptor; EDNR; signaling system; cardiovascular disease; coronary heart disease; hypertension; atherosclerosis; angiogenesis; fatty acid metabolism; diabetes; familial hypercholesterolaemia; forensic marker;
KW transgenic animal; solid support; cardiovascular regulator; SNP;
KW single nucleotide polymorphism; PCR; primer; ss.

OS Synthetic.

PN WO200224747-A2.

PD 28-MAR-2002.

PF 31-AUG-2001; 2001WO-BP10087.

PR 19-SEP-2000; 2000EP-0120123.

PA (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.

PI Brinkmann U, Hoffmeyer S;

XX WPI; 2002-435060/46.

PT Novel polynucleotide of the endothelin/endothelin converting enzyme/receptors of endothelin and endothelin converting enzyme signaling system associated with cardiovascular disease, useful for treating the disease

PS Example 6; Page 63; 190pp; English.

CC The invention describes a polynucleotide (I) of the endothelin (EDN)/endothelin converting enzyme (ECE)/receptors of EDN and ECE (EDNR)

CC signaling system which is associated with a cardiovascular disease. (I), the gene encoding EDN, ECE or EDNR (II) or a vector (III) expressing (I) or (II) is useful for producing cells capable of expressing a molecular variant polypeptide which is associated with a cardiovascular disease. (II), (III), the EDN, ECE or EDNR polypeptide, or a cell expressing a molecular variant gene comprising (I) is useful for identifying and obtaining a pro-drug or drug capable of modulating the activity of a molecular variant of a polypeptide of the EDN/EDNR/ECE signaling system or its gene product, or for identifying and obtaining an inhibitor of the activity of a molecular variant of a polypeptide of the EDN/EDNR/ECE signaling system or its gene product. The isolated proteins and polynucleotides encoding them are useful for preparation of a pharmaceutical composition for treating a cardiovascular disease such as coronary heart disease, hypertension, atherosclerosis, or related to abnormal angiogenesis or fatty acid metabolism e.g. diabetes and familial hypercholesterolaemia. The gene or a polynucleotide fragment of the EDN/ECE/EDNR signaling system are useful as forensic markers, for creating a transgenic animal and in creation of a solid support comprising polynucleotides, genes, vectors, polypeptides, antibodies or host cells of the invention. This sequence represents a PCR primer used to identify single nucleotide polymorphisms in DNA encoding cardiovascular regulator proteins of the EDN/ECE/EDNR signaling pathway.

Sequence 21 BP; 1 A; 11 C; 3 G; 5 T; 1 other;

Query Match 0.8%; Score 11.4; DB 1; Length 21;

Best Local Similarity 85.7%; Pred. No. 5.8e+02;

Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 802 CGCTCCCTGCAGCC 815

Db 4 CTCCTCCNGCAGCC 17

RESULT 692

ID AAF96193/c

XX AAF96193 standard; DNA; 21 BP.

AC AAF96193;

XX 06-JUN-2001 (first entry)

DT Human gene single nucleotide polymorphism #954.

DE Human; variant thrombospondin 1; variant thrombospondin 4; SNP;
KW polymorphism; vascular disease; coronary artery disease; forensics;
KW myocardial infarction; atherosclerosis; stroke; venous thromboembolism;
KW pulmonary embolism; paternity test; ds.

OS Homo sapiens.

XX Key Location/Qualifiers

FT Variation replace(11,T)

FT /*tag= a

FT /standard_name= "single nucleotide polymorphism"

XX WO200118250-A2.

XX 15-MAR-2001.

XX 07-SEP-2000; 2000WO-US24503.

XX 10-SEP-1999; 99US-0153357.

XX 26-JUL-2000; 2000US-0220947.

XX 16-AUG-2000; 2000US-0225724.

XX (WHEE) WHITEHEAD INST BIOMEDICAL RES.

XX (MILL-) MILLENNIUM PHARM INC.

XX Lander ES, Gargill M, Ireland JS, Bolk S, Daley GO, McCarthy JT;

XX WPI; 2001-226749/23.

XX

PT Nucleic acids comprising single nucleotide polymorphisms, useful in
PT applications such as forensics, paternity testing, medicine, genetic
PT analysis and phenotype correlations to diseases such as diabetes and
PT atherosclerosis -
XX PS Examples; Page 116; 242pp; English.
XX CC The present invention provides a method of diagnosing a vascular disease
CC in an individual, involving determining the sequence at various
CC polymorphic sites within the human thrombospondin 1 and thrombospondin 4
CC genes. The sequences at a number of polymorphic sites are also provided
CC in the specification. In particular, the method can be used in the
CC diagnosis of atherosclerosis, myocardial infarction, coronary heart
CC disease, stroke, peripheral vascular diseases, venous thromboembolism
CC and pulmonary embolism. Single nucleotide polymorphisms (SNPs) are also
CC useful in forensics, paternity testing, genetic analysis and phenotype
CC correlations to diseases. The present sequence is an example of one of
CC the human gene SNPs shown in the specification.
XX SQ Sequence 21 BP; 5 A; 8 C; 7 G; 1 T; 0 other;
Query Match 0.8%; Score 11.4; DB 1; Length 21;
Best Local Similarity 71.4%; Pred. No. 5.8e+02;
Matches 15; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
QY 892 CTGCGGTACAGCGGCGCTG 912
||||| ||||| ||||| |||||
Db 21 CTGCCCTGCAGGTGGCGCTG 1
RESULT 693
ACA06326/c
ID ACA06326 standard; RNA; 17 BP.
XX AC ACA06326;
XX DT 03-JUN-2003 (first entry)
XX DE NFKB sub-unit modulating inozyme substrate #145.
XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
KW G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;
KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
KW gencitabine; radiation therapy; inflammatory disease; asthma; diabetes;
KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
KW allergic airway inflammation; inflammatory bowel disease; infection;
ss.
XX OS Homo sapiens.
XX US2002177568-A1.
XX 28-NOV-2002.
XX 23-MAY-2001; 2001US-0864785.
XX 15-AUG-1994; 94US-0291932.
XX 07-DEC-1992; 92US-0987132.
XX 18-MAY-1994; 94US-0245466.
XX 23-DEC-1996; 96US-0777916.
XX (STIN/) STINCHOMB D T.
XX PA (MCSW/) MCSWIGGEN J.
XX PA (DRAP/) DRAPER K G.
XX Stinchcomb DT, Mcswiggen J, Draper KG;

XX WPI; 2003-340953/32.
XX Novel enzymatic nucleic acid molecules which down regulates expression
PT of a sequence encoding a subunit of nuclear factor kappa B useful for
PT treating cancer, inflammatory disorders and autoimmune diseases -
XX Claim 3; Page 29; 72pp; English.
XX The invention describes an enzymatic nucleic acid molecule (I) which down
CC regulates expression of a sequence encoding a subunit of nuclear factor
CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberyne
CC configuration. The enzymatic nucleic acid molecule is adapted to treat
CC cancer and is useful for down-regulating REL-A activity in a cell, for
CC treating a patient having a condition associated with the level of REL-A.
CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
CC antisenase nucleic acid molecules are useful for treating breast, lung,
CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
CC multidrug resistant cancer. The method involves use of other drug
CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
CC gencitabine or radiation therapy. The enzymatic and antisenase nucleic
CC acid molecules are also useful for treating inflammatory disease such as
CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
CC rejection, gene therapy applications, ischaemia/reperfusion injury
CC (central nervous system (CNS) and myocardial), glomerulonephritis,
CC sepsis, allergic airway inflammation, inflammatory bowel disease or
CC infection. This sequence represents the substrate of a novel
CC enzymatic nucleic acid molecule.
XX SQ Sequence 17 BP; 0 A; 11 C; 3 G; 3 U; 0 other;
Query Match 0.8%; Score 11.2; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 5.3e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 466 AGCCTGCAGCGGGGAGG 481
||||| ||||| |||||
Db 17 AGCGCGCAGCGGGAGG 2
RESULT 694
AAQ26549
ID AAQ26549 standard; DNA; 18 BP.
XX AC AAQ26549;
XX 08-JAN-1993 (first entry)
XX Control probe #4 for caucosoid RING11 gene.
XX immunosuppressants; immunoenhancers; treatment; diagnosis; screening;
KW immune disorders; transporter peptides; proteasome complex;
KW MHC class I molecules; HLA; antigen processing;
KW antigen presentation; autoimmune disease; ankylosing spondylitis;
KW prenatal diagnosis; polymerase chain reaction; ss.
XX OS Synthetic.
XX WO9211289-A.
XX 09-JUL-1992.
XX 19-DEC-1991; 91WO-GB02278.
XX 19-DEC-1990; 90GB-0027520.
XX 16-SEP-1991; 91GB-0019711.
XX (IMCR) IMPERIAL CANCER RES TECHNOLOGY.

XX Glynn R, Kelly AP, Powis SH, Trowsdale J;
 PI WPI; 1992-250030/30.
 XX
 XX DNA encoding RING4, RING10, RING11 AND RING12 proteins - for
 PT treatment and diagnosis of immune disorders and screening of new
 PT immunosuppressants and immuno-enhancers
 XX
 PS Example 2; Page 40; 101pp; English.
 XX
 XX This probe was used together with AAQ26546-51 to analyse caucosoid
 CC controls by oligonucleotide typing, whilst investigating RING 11
 CC polymorphisms - see AAQ26544,5.
 XX
 SQ Sequence 18 BP; 3 A; 6 C; 6 G; 3 T; 0 other;
 Query Match 0.8%; Score 11.2; DB 1; Length 18;
 Best Local Similarity 81.2%; Pred. No. 5.5e+02;
 Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 631 CTCGAGGAGCTCTGCA 646
 Db |||||:|||||
 2 CTCCTGGAGCTGGCA 17
 RESULT 695
 ABZ61566
 ID ABZ61566 standard; RNA; 17 BP.
 XX
 AC ABZ61566;
 XX
 XX 21-MAR-2003 (first entry)
 XX
 DE Human H-Ras DNazyme target #357.
 XX
 KW Human; ribozyme; short interfering RNA; siRNA; HER2; K-Ras;
 KW enzymatic nucleic acid; H-Ras; N-Ras; HIV; cytotostatic; anti-HIV;
 KW anti-rheumatic; cancer; AIDS; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200297114-A2.
 XX
 PD 05-DEC-2002.
 XX
 PF 29-MAY-2002; 2002WO-US16840.
 XX
 PR 29-MAY-2001; 2001US-294140P.
 PR 06-JUN-2001; 2001US-296249P.
 PR 10-SEP-2001; 2001US-318471P.
 XX
 XX (RIBO-) RIBOZYME PHARM INC.
 XX
 XX Mcswiggen J;
 PI
 XX WPI; 2003-140484/13.
 DR
 XX Novel short interfering RNA and enzymatic nucleic acid useful for
 PT treating cancer, modulates the expression of a nucleic acid encoding
 PT HER2, K-Ras, H-Ras, N-Ras, and human deficiency virus sequences -
 XX
 PS Claim 58; Page 117; 185pp; English.
 XX
 CC The invention relates to a novel short interfering RNA (siRNA) nucleic
 CC acid molecule or an enzymatic nucleic acid molecule, that modulates
 CC expression of a nucleic acid molecule encoding HER2, K-Ras, H-Ras, N-Ras,
 CC human immunodeficiency virus (HIV) or a component of HIV. The nucleic
 CC acid molecule of the invention has cytotostatic, anti-HIV, and
 CC anti-rheumatic activity. The nucleic acid molecules are useful for
 CC reducing HER2, K-Ras, H-Ras, and HIV activity in a cell. The nucleic
 CC acids are also useful for treating breast, ovarian, colorectal, lung,
 CC prostate, bladder, or pancreatic cancer, and HIV infection, and AIDS.

CC The sequences shown in ABZ59889 - ABZ62216, ABZ64544 - ABZ65531,
 CC ABZ6520 - ABZ66524, ABZ66530 - ABZ66585 represent substrate/target
 CC sequences for the human ribozymes of the invention.
 XX
 SQ Sequence 17 BP; 2 A; 4 C; 8 G; 3 U; 0 other;
 Query Match 0.8%; Score 11; DB 1; Length 17;
 Best Local Similarity 81.8%; Pred. No. 5.7e+02;
 Matches 9; Conservative 2; Mismatches 0; Indels 0; Gaps 0;
 QY 731 GGGCCCTGGCTG 741
 Db |||||:|||||
 2 GGGCCUGGCG 12
 RESULT 696
 AAX33259/C
 ID AAX33259 standard; DNA; 20 BP.
 XX
 AC AAX33259;
 XX
 XX 30-JUN-1999 (first entry)
 DT
 DE PEBP2 alpha A gene expression regulating DNA PCR primer SEQ ID NO:16.
 XX
 DE PEBP2 alpha A gene; expression; regulation; bone disease;
 KW osteoporosis; PCR primer; ss.
 XX
 OS Synthetic.
 XX
 XX WO9911787-A1.
 PN
 XX 11-MAR-1999.
 PD
 XX 02-SEP-1998; 98WO-JF03920.
 PF
 XX 08-APR-1998; 98JP-0114135.
 PR
 XX 02-SEP-1997; 97JP-0254250.
 PR
 XX 15-OCT-1997; 97JP-0299407.
 PR
 XX (SUMU) SUMITOMO PHARM CO LTD.
 PA
 XX Fujiwara M, Harada H, Katsumata T, Nakatsuka M;
 PI Ogawa S, Tagashira S;
 XX WPI; 1999-243621/20.
 DR
 XX DNA regulating expression of PEBP2 alphaA gene to produce regulator
 PT protein, useful as promoter for prevention or/and treatment of bone
 PT diseases e.g. osteoporosis
 XX
 PS Example 2; Page 29; 118pp; Japanese.
 XX
 CC The present invention describes DNA which participates in the regulation
 CC of expression of PEBP2 alpha A gene. The DNA produces a regulator
 CC protein with the activity of promoting bone formation and can serve as a
 CC promoter for prevention and treatment of bone diseases including
 CC osteoporosis. The present sequence represents a PCR primer used in an
 CC example from the present invention.
 XX
 SQ Sequence 20 BP; 3 A; 11 C; 4 G; 2 T; 0 other;
 Query Match 0.8%; Score 11; DB 1; Length 20;
 Best Local Similarity 73.7%; Pred. No. 6.4e+02;
 Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
 QY 460 GTCAGCAGCTGCAGGGG 478
 Db |||||:|||||
 20 GCTGCAGGCTGCTGGAGG 2
 RESULT 697
 ABS74296/C

ID ABS74296 standard; DNA; 20 BP.
 AC ABS74296;
 XX
 XX
 DT 09-DEC-2002 (first entry)
 DE Human calcium channel alpha2delta SSCP PCR primer #20.
 DE
 XX Human; ss; primer; calcium channel alpha2delta; splice isoform; CACNA2D2;
 KW gene therapy; Lambert-Eaton myasthenic syndrome; LEMS; PCR;
 KW autoimmune disease; epilepsy; migraine; episodic ataxia; cancer; stroke;
 KW brain trauma; Alzheimer's disease; multiinfarct dementia; convulsion;
 KW Korsakoff's disease; amytrophic lateral sclerosis; seizure;
 KW Huntington's disease; amnesia; cardiac arrhythmia; angina pectoris;
 KW hypoxia; ischaemia; myocardi infarction; congestive heart failure;
 KW muscular dystrophy; hypertension; chromosome 3p21.3; lung cancer;
 KW breast cancer; preneoplastic lesion; hyperplasia; dysplasia; carcinoma;
 KW SSCP; single strand change polymorphism.
 XX
 OS Homo sapiens.
 XX
 XX US6441156-B1.
 XX
 PD 27-AUG-2002.
 XX
 XX 22-DEC-1999; 99US-0470443.
 XX
 XX 30-DEC-1998; 98US-114359P.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 XX Lerman MI, Latif F, Wei M, Duh F, Minna JD, Sekido Y, Gao B;
 XX WPI; 2002-730574/79.
 DR
 XX Novel purified nucleic acid sequence encoding human calcium channel
 PT alpha2delta subunit protein, useful for detecting, preventing and
 PT treating cancer, stroke, brain trauma, Huntington's disease, myocardial
 PT infarction -
 XX
 XX Example 7; Column 46; 77pp; English.
 XX
 CC The invention relates to a purified nucleic acid sequence (referred as
 CC CACNA2D2 gene which encodes human calcium channel alpha2delta-2 subunit
 CC protein) comprising a fully defined alpha2delta splice isoform 1, 2 or 3
 CC nucleic acid sequence, or its complement and the encoded proteins.
 CC Also include are: (1) a method of producing a calcium channel protein
 CC which involves introducing a recombinant expression vector comprising the
 CC CACNA2D2 nucleic acids and encoding the calcium channel protein, into
 CC a cultured host cell under conditions such that the host cell expresses
 CC the amino acid sequences; and (2) a method for co-expressing calcium
 CC channel proteins, comprising carrying out the method of (1), but with one
 CC or more than one expression vector comprising one or more nucleic acid
 CC sequences encoding the splice variants. CACNA2D2 nucleic acid is useful
 CC for producing a calcium channel protein. The recombinantly expressed
 CC polypeptide is useful for treating patients with Lambert-Eaton myasthenic
 CC syndrome (LEMS) (an autoimmune disease) and for identifying compounds
 CC useful for treating other diseases associated with abnormal calcium
 CC channel protein activity (e.g. epilepsy, migraine, episodic ataxia,
 CC cancer, stroke, brain trauma, Alzheimer's disease, multiinfarct dementia,
 CC Korsakoff's disease, amytrophic lateral sclerosis, convulsions,
 CC seizures, Huntington's disease, amnesia, cardiac arrhythmia, angina
 CC pectoris, hypoxic damage to the cardiovascular system, ischaemic damage
 CC to the cardiovascular system, myocardial infarction, congestive heart
 CC failure, muscular dystrophy and hypertension) CACNA2D2 nucleic acid is
 CC useful as primers and probes for detecting presence of nucleic acid
 CC sequence encoding at least a portion of calcium channel protein, in
 CC detection, identification and isolation of alpha2delta sequences
 CC diagnosing and typing of preneoplasias and cancers, since genetic
 CC disruption of 3p21.3 region (in which the alpha 2delta gene is located)
 CC is common in cancer (e.g. lung cancer and breast cancer) and
 CC preneoplastic lesion (e.g. hyperplasia, dysplasia, carcinoma in situ).
 CC The present is an SSCP (single strand change polymorphism) PCR primer

CC used to detect polymorphisms in sequences encoding a human calcium
 CC channel alpha2delta splice isoform protein.
 XX
 XX Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 other;
 DE
 DE Query Match 0.8%; Score 11; DB 1; Length 20;
 DE Best Local Similarity 73.7%; Pred. No. 6.4e+02;
 DE Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;
 QY 618 CTTGAGGAGGACCTCCAG 636
 DB 19 CTCCTGTGACCATCACCAG 1
 RESULT 698
 ABS74306/C
 ID ABS74306 standard; DNA; 20 BP.
 XX
 XX ABS74306;
 XX
 XX 09-DEC-2002 (first entry)
 DE Human calcium channel alpha2delta SSCP PCR primer #30.
 DE
 XX Human; ss; primer; calcium channel alpha2delta; splice isoform; CACNA2D2;
 KW gene therapy; Lambert-Eaton myasthenic syndrome; LEMS; PCR;
 KW autoimmune disease; epilepsy; migraine; episodic ataxia; cancer; stroke;
 KW brain trauma; Alzheimer's disease; multiinfarct dementia; convulsion;
 KW Korsakoff's disease; amytrophic lateral sclerosis; seizure;
 KW Huntington's disease; amnesia; cardiac arrhythmia; angina pectoris;
 KW hypoxia; ischaemia; myocardi infarction; congestive heart failure;
 KW muscular dystrophy; hypertension; chromosome 3p21.3; lung cancer;
 KW breast cancer; preneoplastic lesion; hyperplasia; dysplasia; carcinoma;
 KW SSCP; single strand change polymorphism.
 XX
 OS Homo sapiens.
 XX
 XX US6441156-B1.
 XX
 PD 27-AUG-2002.
 XX
 XX 22-DEC-1999; 99US-0470443.
 XX
 XX 30-DEC-1998; 98US-114359P.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 XX Lerman MI, Latif F, Wei M, Duh F, Minna JD, Sekido Y, Gao B;
 XX WPI; 2002-730574/79.
 DR
 XX Novel purified nucleic acid sequence encoding human calcium channel
 PT alpha2delta subunit protein, useful for detecting, preventing and
 PT treating cancer, stroke, brain trauma, Huntington's disease, myocardial
 PT infarction -
 XX
 XX Example 7; Column 46; 77pp; English.
 XX
 CC The invention relates to a purified nucleic acid sequence (referred as
 CC CACNA2D2 gene which encodes human calcium channel alpha2delta-2 subunit
 CC protein) comprising a fully defined alpha2delta splice isoform 1, 2 or 3
 CC nucleic acid sequence, or its complement and the encoded proteins.
 CC Also include are: (1) a method of producing a calcium channel protein
 CC which involves introducing a recombinant expression vector comprising the
 CC CACNA2D2 nucleic acids and encoding the calcium channel protein, into
 CC a cultured host cell under conditions such that the host cell expresses
 CC the amino acid sequences; and (2) a method for co-expressing calcium
 CC channel proteins, comprising carrying out the method of (1), but with one
 CC or more than one expression vector comprising one or more nucleic acid
 CC sequences encoding the splice variants. CACNA2D2 nucleic acid is useful
 CC for producing a calcium channel protein. The recombinantly expressed
 CC polypeptide is useful for treating patients with Lambert-Eaton myasthenic
 CC syndrome (LEMS) (an autoimmune disease) and for identifying compounds
 CC useful for treating other diseases associated with abnormal calcium
 CC channel protein activity (e.g. epilepsy, migraine, episodic ataxia,
 CC cancer, stroke, brain trauma, Alzheimer's disease, multiinfarct dementia,
 CC Korsakoff's disease, amytrophic lateral sclerosis, convulsions,
 CC seizures, Huntington's disease, amnesia, cardiac arrhythmia, angina
 CC pectoris, hypoxic damage to the cardiovascular system, ischaemic damage
 CC to the cardiovascular system, myocardial infarction, congestive heart
 CC failure, muscular dystrophy and hypertension) CACNA2D2 nucleic acid is
 CC useful as primers and probes for detecting presence of nucleic acid
 CC sequence encoding at least a portion of calcium channel protein, in
 CC detection, identification and isolation of alpha2delta sequences
 CC diagnosing and typing of preneoplasias and cancers, since genetic
 CC disruption of 3p21.3 region (in which the alpha 2delta gene is located)
 CC is common in cancer (e.g. lung cancer and breast cancer) and
 CC preneoplastic lesion (e.g. hyperplasia, dysplasia, carcinoma in situ).
 CC The present is an SSCP (single strand change polymorphism) PCR primer

useful for treating other diseases associated with abnormal calcium channel protein activity (e.g. epilepsy, migraine, episodic ataxia, cancer, stroke, brain trauma, Alzheimer's disease, multiinfarct dementia, Korsakoff's disease, amyotrophic lateral sclerosis, convulsions, seizures, Huntington's disease, amnesia, cardiac arrhythmia, angina pectoris, hypoxic damage to the cardiovascular system, ischaemic damage to the cardiovascular system, myocardial infarction, congestive heart failure, muscular dystrophy and hypertension) CACNA2D2 nucleic acid is useful as primers and probes for detecting presence of nucleic acid sequence encoding at least a portion of calcium channel protein, in detection, identification and isolation of alpha2delta sequences diagnosing and typing of preneoplasias and cancers, since genetic disruption of 3p21.3 region (in which the alpha2delta gene is located) is common in cancer (e.g. lung cancer and breast cancer) and preneoplastic lesion (e.g. hyperplasia, dysplasia, carcinoma in situ). The present is an SSCP (single strand change polymorphism) PCR primer used to detect polymorphisms in sequences encoding a human calcium channel alpha2delta splice isoform protein.

XX Sequence 20 BP; 4 A; 4 C; 8 G; 4 T; 0 other;
SQ
Query Match 0.8%; Score 11; DB 1; Length 20;
Best Local Similarity 73.7%; Pred. NO. 6.4e+02;
Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 618 CTTGAGGACCACTCCAG 636
19 CTCCTGTGACCATCACAG 1

RESULT 699
AAI66616
ID AAI66616 standard; DNA; 20 BP.

XX AAI66616;

AC AAI66616;

XX 07-JAN-2002 (first entry)

DE Rat leukotriene B4 receptor JULF2 DNA amplifying PCR primer.
XX
XX Leukotriene receptor; leukotriene B4; inflammatory disease; rat;
KW JULF2; bronchitis; dermatitis; psoriasis; ulcerative colitis;
KW rheumatoid arthritis; edema; PCR primer; ss.

XX Rattus norvegicus.

XX WO200170815-A1.

XX 27-SEP-2001.

XX 15-MAR-2001; 2001WO-JP02060.

XX 21-MAR-2000; 2000JP-0078992.

XX 22-JUN-2000; 2000JP-0187978.

XX (YAMA) YAMANOUCHI PHARM CO LTD.

XX Kamohara M, Matsumoto M, Takasaki J, Saito T, Ohishi T;

XX WPI; 2001-611487/70.

XX New polypeptide for screening for compounds which treat inflammatory diseases such as bronchitis, dermatitis, psoriasis, ulcerative colitis, rheumatoid arthritis, and edema comprises the leukotriene B4 receptor - Example 10; Page 47; 55pp; Japanese.

XX The invention provides a leukotriene receptor, which binds leukotriene B4 and polynucleotides encoding the leukotriene B4 receptor. The receptor can be expressed by standard recombinant methodology. Pharmaceutical compositions containing materials which modify the receptor activity, other than 4-octyloxybenzene carboximidoamide are used for treating and preventing inflammatory disease. The materials detected by screening the

CC receptor (JULF2) are useful for treating diseases such as bronchitis, CC dermatitis, psoriasis, ulcerative colitis, rheumatoid arthritis, and CC edema. Sequences AAI66614-19 represent PCR primers for amplifying a CC rat leukotriene B4 receptor JULF2 DNA.

XX Sequence 20 BP; 5 A; 11 C; 4 G; 0 U; 0 other;

XX Query Match 0.8%; Score 11; DB 1; Length 20;
Best Local Similarity 73.7%; Pred. NO. 6.4e+02;
Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 585 CCGTCGCGCCGCCACGAGC 603

DB 2 CAGCCAGACCCGAGCAGC 20

RESULT 700

ABK15887/C

ID ABK15887 standard; DNA; 20 BP.

XX ABK15887;

XX 21-MAY-2002 (first entry)

XX HES-1 (hairy-enhancer of split-1) forward PCR primer DNA sequence.

XX Hairy-enhancer of split-1; HES-1; real-time PCR; primer; ss;
KW multiple sclerosis; rheumatoid arthritis; diabetes; organ transplant;
KW asthma; allergy; autoimmunity; graft rejection; tumour; cytostatic;
KW Notch signal modulator; T-cell mediated disease; infectious disease;
KW human immunodeficiency virus; HIV; virucide; hepatotropic; protozoacide;
KW neuroprotective; cancer.

XX Unidentified.

XX WO200212890-A2.

XX 14-FEB-2002.

XX 03-AUG-2001; 2001WO-GB03503.

XX 04-AUG-2000; 2000GB-0019242.

XX (LORA-) LORANTIS LTD.

XX Lamb JR, Hoyle GF, Dallman MJ, Champion BR;

XX WPI; 2002-217232/27.

XX Monitoring the immune system for prevention and/or treatment of T-cell mediated diseases e.g. allergy, autoimmunity or cancer, involves detecting modulation of Notch signalling

XX Disclosure; Fig 13; 75pp; English.

XX The present invention relates to a new method for monitoring the immune system that involves detecting modulation of Notch signalling. The method of the invention can be used for monitoring the immune system such as detecting or monitoring T-cell activation or inactivation, immunological tolerance or activity, monitoring the efficacy of immunotherapy and for detecting or monitoring the reactivity of a T-cell to an antigen e.g. for detecting increased or decreased reactivity of a T-cell to an antigen and detecting toleration of a T-cell to an antigen, and for detecting whether the antigen is self or foreign antigen. The method is used in the prevention and/or treatment of T-cell mediated diseases such as asthma, allergy, autoimmunity, graft rejection, tumour induced aberrations to the T-cell system, and infectious diseases caused by e.g. Cytomegalovirus, Pseudomonas, Toxoplasma, Microfilariae, Helminths, Mycobacteria, human immunodeficiency virus (HIV), plasmodium species, Echinosoccus, Haemophilus influenza type B, measles, Hepatitis C or Toxocara. The method is also used for the treatment of multiple sclerosis, rheumatoid arthritis, diabetes and for organ transplantation. The present assay method provides a much more objective measure of the effectiveness of

CC therapy than the rather subjective symptoms-based measures which are
 CC often used at present. The ability to detect an immune response could be
 CC used in identifying the cause of an allergic reaction by monitoring the
 CC activity of the immune system in the presence of different potential
 CC allergens. The assay could be used to check for successful immunisation
 CC against a given disease antigen. The present nucleic acid sequence
 CC represents the human HES-1 (hairy-enhancer of split-1) forward PCR primer
 CC that was used in the invention with the HES-1 reverse PCR primer
 CC (ABK15888) and the HES-1 probe (ABK09925) for real-time PCR of the
 CC HES-1 gene.

XX SQ Sequence 20 BP; 5 A; 5 C; 6 G; 4 T; 0 other;

Query Match 0.8%; Score 11; DB 1; Length 20;
 Best Local Similarity 73.7%; Pred. No. 6.6e+02;
 Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 435 GTTCAGAAAGTTGCTGAAG 453
 Db 20 GTTCATGCACTCGCTGAAG 2

RESULT 701

AAV47652/c
 ID AAV47652 standard; DNA; 21 BP.

XX AC AAV47652;

XX AC AAV47652;

XX 07-DEC-1998 (first entry)

XX Mouse focal adhesion kinase cDNA 3' PCR primer.

XX Protein tyrosine kinase 2; PYK2; mouse; cell adhesion kinase-beta;

XX related adhesion focal tyrosine kinase; focal adhesion kinase;

XX platelet; PCR; primer; ss.

XX Synthetic.

XX Mus sp.

XX WO9835016-A1.

XX 13-AUG-1998.

XX 09-FEB-1998; 98WO-US02494.

XX 11-FEB-1997; 97US-0037561.

XX (MERI) MERCK & CO INC.

XX Duong LT, Rodan GA;

XX WPI; 1998-447214/38.

XX New nucleic acid encoding murine protein tyrosine kinase 2 and cells
 XX expressing the recombinant kinase - used to identify specific
 XX modulators, potentially useful for controlling the level of
 XX platelets

XX Example 2; Page 6; 25pp; English.

XX This 3' primer and a 5' primer (see AAV47651) are based on an area
 CC of non-homology between murine protein tyrosine kinase 2 (PYK2)
 CC and focal adhesion kinase (FAK) that is adjacent to the C-terminus
 CC of the kinase domain. They were used in a PCR amplification of
 CC cDNAs of mouse osteoblastic MB1.8. The PCR product (700 bp) was
 CC used as a FAK-specific probe to isolate mouse FAK cDNA. The
 CC invention relates to new nucleic acid (see AAV47653) encoding mouse
 CC PYK2 (see AAW61196), a member of the FAK family. PYK2 can be used in
 CC a claimed method for identifying specific modulators of PYK2
 CC activity.

XX SQ Sequence 21 BP; 5 A; 7 C; 4 G; 5 T; 0 other;

Query Match 0.8%; Score 11; DB 1; Length 21;
 Best Local Similarity 73.7%; Pred. No. 6.6e+02;
 Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1019 GATGGTGCCAAAGTGCAGC 1037

Db 19 GAGGGTGTCAGGCTTCAGC 1

RESULT 702

AAV49607/c

ID AAV49607 standard; DNA; 21 BP.

XX AC AAV49607;

XX 24-NOV-1998 (first entry)

XX Focal adhesion kinase 3' PCR primer.

XX Focal adhesion kinase; protein tyrosine kinase 2; PYK2 gene; mouse;

XX podosome; related adhesion focal tyrosine kinase;

XX cell adhesion kinase; ligand; monocyte; osteoporosis;

XX inflammation; therapy; PCR; primer; ss.

XX Synthetic.

XX Mus sp.

XX WO9835056-A1.

XX 13-AUG-1998.

XX 09-FEB-1998; 98WO-US02797.

XX 11-FEB-1997; 97US-0037560.

XX (MERI) MERCK & CO INC.

XX Duong Le T, Rodan GA;

XX WPI; 1998-447250/38.

XX Identifying agents that bind and modulate protein tyrosine kinase 2
 PT - useful for inhibiting migration, adhesion or activity of monocytic
 PT cells, particularly for treatment and prevention of osteoporosis and
 PT inflammation

XX Example 3; Page 20; 56pp; English.

XX This oligonucleotide is based on a non-homologous region, found
 CC adjacent to the C-terminal of the kinase domain, of murine
 CC protein tyrosine kinase 2 (PYK2) and focal adhesion kinase (FAK)
 CC sequences. It was used as a 3' primer, together with a 5' primer
 CC (see AAV49606), in the PCR amplification of mouse osteoblastic MB1.8
 CC cell cDNA. The PCR product was used as a FAK-specific probe to
 CC isolate full-length FAK cDNA. FAK shows homology to murine PYK2
 CC (see AAW64568), another cell adhesion-dependent kinase. Agents that
 CC bind to and modulate PYK2 are isolated using methods of the
 CC invention, and are useful in treating osteoporosis and/or
 CC inflammation.

XX SQ Sequence 21 BP; 5 A; 7 C; 4 G; 5 T; 0 other;

Query Match 0.8%; Score 11; DB 1; Length 21;
 Best Local Similarity 73.7%; Pred. No. 6.6e+02;
 Matches 14; Conservative 0; Mismatches 5; Indels 0; Gaps 0;

QY 1019 GATGGTGCCAAAGTGCAGC 1037

Db 19 GAGGGTGTCAGGCTTCAGC 1

RESULT 703

ABL31720/c

ID ABL31720 standard; DNA; 17 BP.
 AC ABL31720;
 XX
 DT 21-MAR-2002 (first entry)
 XX
 DE Human HLA genotyping oligonucleotide SEQ ID NO 1209.
 XX
 KW Human; human leukocyte antigen; HLA; genotype; polymorphism;
 KW immunogenetic; transplantation; genetic disease; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200192572-A1.
 XX
 PD 06-DEC-2001.
 XX
 PF 01-JUN-2001; 2001WO-JP04662.
 XX
 PR 01-JUN-2000; 2000JP-0164798.
 XX
 PA (NIN) NISSHINBO IND INC.
 PA (SYST-) SYSTEM RES INC.
 XX
 PI Inoko H, Kagiya T, Ichihara T, Matsumura Y, Moriya S, Nishida M;
 XX WPI; 2002-122074/16.
 DR
 XX
 PT Human leukocyte antigen (HLA) typing, useful for judging HLA genotypes
 PT of individuals e.g. by determining immunogenetic differences when
 PT transplanting between them -
 XX
 PS Claim 10; Page 322; 345pp; Japanese.
 XX
 CC The invention relates to a typing kit for judging human leukocyte antigen
 CC (HLA) genotype of a sample by hybridising a substrate on which 10-24 base
 CC oligonucleotides (ABL30512-ABL31809) originating in the sequences of
 CC genes e.g. belonging to HLA class I antigens on human genome and
 CC containing gene polymorphisms as alloantigens have been immobilised as
 CC primers for amplification of cleaved nucleic acids relating to gene
 CC polymorphisms. The method is useful for judging HLA genotypes of
 CC individuals by determining immunogenetic differences before transplanting
 CC between them, providing genetic information to decide compatibility of
 CC organ and tissue for transplantation e.g. of bone marrow, kidney, liver,
 CC pancreas, Langerhans islet in pancreas and cornea, susceptibility
 CC diagnosis of genetic diseases and identifying individuals.
 XX
 SQ Sequence 17 BP; 5 A; 4 C; 6 G; 2 T; 0 other;
 Query Match 0.8%; Score 10.8; DB 1; Length 17;
 Best Local Similarity 85.7%; Pred. No. 6.1e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 974 TCACCTTGACAGTC 987
 DB 17 TCACCTGCGCAGTC 4
 RESULT 704
 ACA07770
 ID ACA07770 standard; RNA; 17 BP.
 AC ACA07770;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFKB sub-unit modulating zinzyme substrate #169.
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;

KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel, docetaxel, cisplatin; methotrexate;
 KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 XX ss.
 XX
 OS Homo sapiens.
 XX
 PN US2002177568-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 23-MAY-2001; 2001US-0864785.
 XX
 PR 15-AUG-1994; 94US-0291932.
 PR 07-DEC-1992; 92US-0987132.
 PR 18-MAY-1994; 94US-0245466.
 PR 23-DEC-1996; 96US-0777916.
 XX
 PI (STIN/) STINCHCOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 PI Stinchcomb DT, Mcswiggen J, Draper KG;
 XX WPI; 2003-340953/32.
 DR
 XX Novel enzymatic nucleic acid molecules which down regulates expression
 PT of a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases -
 XX
 PS Claim 3; Page 40; 72pp; English.
 XX
 CC The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel
 CC enzymatic nucleic acid molecule.
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 6 G; 3 U; 0 other;

Query Match 0.8%; Score 10.8; DB 1; Length 17;
 Best Local Similarity 64.3%; Pred. No. 6.1e+02;
 Matches 9; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
 QY 820 GTCCTGATCAGCT 833
 DB 4 GCCCUGCUGCAGCU 17

RESULT 705
 AAX26904/c
 ID AAX26904 standard; DNA; 20 BP.
 XX AC AAX26904;
 XX DT 23-JUN-1999 (first entry)
 XX XX
 XX DE Primer used for STS-PCR mapping of RIGUI nucleic acids.
 XX RIGUI, Drosophila circadian rhythm period gene; circadian clock gene;
 XX Drosophila timeless ortholog; PCR primer; ss.
 XX OS Synthetic.
 XX XX WO9912952-A1.
 XX PN 18-MAR-1999.
 XX PD
 XX PF 09-SEP-1998; 98WO-US18755.
 XX PR 04-NOV-1997; 97US-0065957.
 XX PR 09-SEP-1997; 97US-0058256.
 XX PA (RERE-) RES DEV FOUND.
 XX XX
 XX PI Albrecht U, Eichele G, Lee C, Sun ZS;
 XX XX WPI; 1999-229221/19.
 XX DT
 XX XX New isolated mammalian circadian rhythm genes
 XX PS Example 1; Page 30; 73pp; English.
 XX CC Primers AAX26903-04 were used for STS-PCR mapping of RIGUI nucleic
 CC acids. RIGUI is a gene corresponding to the Drosophila circadian
 CC rhythm period gene. The specification describes both mouse and
 CC human genes. The RIGUI polypeptides act as regulators of circadian
 CC rhythms. The identification of RIGUI as a putative circadian clock
 CC gene provides a useful tool to explore the molecular mechanism of
 CC the mammalian circadian machinery. Using interaction screening
 CC approaches, it should be possible to find interacting proteins,
 CC perhaps in the form of a Drosophila Timeless ortholog. Furthermore,
 CC promoter analyses of the RIGUI gene should uncover how light cues
 CC and possibly other environmental stimuli, regulate the expression of
 CC this gene. Targeted disruption of the m-rigui gene using stem cell
 CC technology, may provide a valuable model system to study the various
 CC physiological and pathological aspects of disrupting circadian
 CC rhythms.
 XX SQ Sequence 20 BP; 5 A; 7 C; 5 G; 3 T; 0 other;
 Query Match 0.8%; Score 10.8; DB 1; Length 20;
 Best Local Similarity 85.7%; Pred. No. 6.8e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 333 TCCTGGTGAATGTC 346
 ||||| |||||
 Db 15 TCCTGGAGATGGTC 2
 RESULT 706
 ABK94273/c
 ID ABK94273 standard; DNA; 21 BP.
 XX AC ABK94273;
 XX XX
 XX DT 27-AUG-2002 (first entry)
 XX XX Endothelin converting enzyme 1 (ECE-1) SNP detection primer #61.
 XX DE Endothelin; EDN; endothelin converting enzyme; ECE; endothelin receptor;
 XX EDNR; signaling system; cardiovascular disease; coronary heart disease;

KW hypertension; atherosclerosis; angiogenesis; fatty acid metabolism;
 KW diabetes; familial hypercholesterolemia; forensic marker;
 KW transgenic animal; solid support; cardiovascular regulator; SNP;
 KW single nucleotide polymorphism; PCR; primer; ss.
 XX OS Synthetic.
 XX XX WO200224747-A2.
 XX PN 28-MAR-2002.
 XX PD
 XX PF 31-AUG-2001; 2001WO-EP10087.
 XX PR 19-SEP-2000; 2000EP-0120123.
 XX XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
 XX PA Brinkmann U, Hoffmeyer S;
 XX PI WPI; 2002-435060/46.
 XX DR
 XX XX Novel polynucleotide of the endothelin/endothelin converting
 PT enzyme/receptors of endothelin and endothelin converting enzyme
 PT signaling system associated with cardiovascular disease, useful for
 PT treating the disease
 XX XX Example 6; Page 63; 190pp; English.
 XX CC The invention describes a polynucleotide (I) of the endothelin
 CC (EDN)/endothelin converting enzyme (ECE)/receptors of EDN and ECE (EDNR)
 CC signaling system which is associated with a cardiovascular disease. (I),
 CC the gene encoding EDN, ECE or EDNR (II) or a vector (III) expressing (I),
 CC or (II) is useful for producing cells capable of expressing a molecular
 CC variant polypeptide which is associated with a cardiovascular disease.
 CC (II), (III), the EDN, ECE or EDNR polypeptide, or a cell expressing
 CC a molecular variant gene comprising (I) is useful for identifying and
 CC obtaining a pro-drug or drug capable of modulating the activity of a
 CC molecular variant of a polypeptide of the EDN/EDNR/ECE signaling system
 CC or its gene product, or for identifying and obtaining an inhibitor of
 CC the activity of a molecular variant of a polypeptide of the EDN/EDNR/ECE
 CC signaling system or its gene product. The isolated proteins and
 CC polynucleotides encoding them are useful for preparation of a
 CC pharmaceutical composition for treating a cardiovascular disease such as
 CC coronary heart disease, hypertension, atherosclerosis, or related to
 CC EDN/ECE/EDNR signaling system are useful as forensic markers, for
 CC hypercholesterolemia. The gene or a polynucleotide fragment of the
 CC EDN/ECE/EDNR signaling system and in creation of a solid support
 CC comprising polynucleotides, genes, vectors, polypeptides, antibodies or
 CC host cells of the invention. This sequence represents a PCR primer used
 CC to identify single nucleotide polymorphisms in DNA encoding
 CC cardiovascular regulator proteins of the EDN/ECE/EDNR signaling pathway.
 XX SQ Sequence 21 BP; 5 A; 3 C; 12 G; 1 T; 0 other;
 Query Match 0.8%; Score 10.8; DB 1; Length 21;
 Best Local Similarity 85.7%; Pred. No. 7e+02;
 Matches 12; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
 QY 802 CGCTCCCTGCAGCC 815
 ||||| |||||
 Db 18 CTCTCCCGCAGCC 5
 RESULT 707
 ABK94274
 ID ABK94274 standard; DNA; 21 BP.
 XX AC ABK94274;
 XX XX
 XX DT 27-AUG-2002 (first entry)
 XX XX Endothelin converting enzyme 1 (ECE-1) SNP detection primer #62.
 XX DE Endothelin converting enzyme 1 (ECE-1) SNP detection primer #62.

XX Endothelin; EDN; endothelin converting enzyme; ECE; endothelin receptor;
KW EDNR; signaling system; cardiovascular disease; ECE; coronary heart disease;
KW hypertension; atherosclerosis; angiogenesis; fatty acid metabolism;
KW diabetes; familial hypercholesterolaemia; forensic marker;
KW transgenic animal; solid support; cardiovascular regulator; SNP;
KW single nucleotide polymorphism; PCR; primer; ss.
XX Synthetic.
XX WO200224747-A2.
XX 28-MAR-2002.
XX 31-AUG-2001; 2001WO-EF10087.
XX 19-SEP-2000; 2000EP-0120123.
XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
XX Brinkmann U, Hoffmeyer S;
XX WPI; 2002-435060/46.
XX Novel polynucleotide of the endothelin/endothelin converting
PT enzyme/receptors of endothelin and endothelin converting enzyme
PT signaling system associated with cardiovascular disease, useful for
PT treating the disease
XX Example 6; Page 63; 190pp; English.
XX The invention describes a polynucleotide (I) of the endothelin
CC (EDN)/endothelin converting enzyme (ECE)/receptors of EDN and ECE (EDNR)
CC signaling system which is associated with a cardiovascular disease. (I),
CC the gene encoding EDN, ECE or EDNR (II) or a vector (III) expressing (I),
CC or (II) is useful for producing cells capable of expressing a molecular
CC variant polypeptide which is associated with a cardiovascular disease.
CC (II), (III), the EDN, ECE or EDNR polypeptide, or a cell expressing
CC a molecular variant gene comprising (I) is useful for identifying and
CC obtaining a pro-drug or drug capable of modulating the activity of a
CC molecular variant of a polypeptide of the EDN/EDNR/ECE signaling system
CC or its gene product, or for identifying and obtaining an inhibitor of
CC the activity of a molecular variant of a polypeptide of the EDN/EDNR/ECE
CC signaling system or its gene product. The isolated proteins and
CC polynucleotides encoding them are useful for preparation of a
CC pharmaceutical composition for treating a cardiovascular disease such as
CC coronary heart disease, hypertension, atherosclerosis, or related to
CC abnormal angiogenesis or fatty acid metabolism e.g. diabetes and familial
CC hypercholesterolaemia. The gene or a polynucleotide fragment of the
CC EDN/ECE/EDNR signaling system are useful as forensic markers, for
CC creating a transgenic animal and in creation of a solid support
CC comprising polynucleotides, genes, vectors, polypeptides, antibodies or
CC host cells of the invention. This sequence represents a PCR primer used
CC to identify single nucleotide polymorphisms in DNA encoding
CC cardiovascular regulator proteins of the EDN/ECE/EDNR signaling pathway.
XX Sequence 21 BP; 1 A; 12 C; 3 G; 5 T; 0 other;
SQ
Query Match 0.8%; Score 10.8; DB 1; Length 21;
Best Local Similarity 85.7%; Pred. No. 7e+02; Indels 0; Gaps 0;
Matches 12; Conservative 0; Mismatches 2;
QY 802 CGCTCCCTGCAGCC 815
DB 4 CTCTCCCGCAGCC 17
RESULT 708
ABQ63635
ID ABQ63635 standard; DNA; 17 BP.
XX AC ABQ63635;
XX

DT 20-AUG-2002 (first entry)
XX Human KTOM1a portion (ABQ63232) probe # 348.
DE Human; KTOM1a; KTOM1; kidney tumor overexpressed membrane; cytostatic;
XX gene therapy; cancer; kidney; liver; bone marrow; brain; heart; lung;
KW kidney; colon; skeletal muscle; testis; uterus; placenta; probe; ss.
XX Homo sapiens.
XX WO200224750-A2.
XX 28-MAR-2002.
XX 21-SEP-2001; 2001WO-US29656.
XX 21-SEP-2000; 2000US-234687P.
XX 27-SEP-2000; 2000US-236359P.
XX 04-OCT-2000; 2000GB-0024263.
XX 30-JAN-2001; 2001WO-US00661.
XX 30-JAN-2001; 2001WO-US00662.
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00666.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 30-JAN-2001; 2001WO-US00670.
XX 23-MAY-2001; 2001US-0864761.
XX 28-AUG-2001; 2001US-315676P.
XX (AEOM-) AEOMICA INC.
XX Zhang J;
XX WPI; 2002-479509/51.
XX New human kidney tumor overexpressed membrane (KTOM1) protein and
PT nucleic acids encoding the protein, useful for treating subjects having
PT defects in KTOM1 which can manifest as cancer of the kidney, or as a
PT disorder of e.g., liver or bone
XX Example 2; Page 203; 418pp; English.
XX The invention relates to a novel isolated nucleic acid encoding human
CC KTOM1 (kidney tumor overexpressed membrane) protein. The protein of the
CC invention has cytostatic activity. The nucleotide may have a use in gene
CC therapy. The KTOM1 nucleic acids may be used to diagnose, treat or
CC monitor a disease caused by altered expression of human KTOM1.
CC Compositions comprising the nucleic acids, proteins or antibodies may be
CC used to treat subjects having defects in KTOM1 which can manifest as
CC cancer of the kidney, as well as a disorder of liver, bone marrow, brain,
CC heart, lung, kidney, colon, skeletal muscle, testis, uterus and placenta
CC function. The sequence represents a probe used in the invention to
CC scan the nt 1-1001 portion of human KTOM1a (ABQ63232).
XX Sequence 17 BP; 2 A; 9 C; 5 G; 1 T; 0 other;
SQ
Query Match 0.8%; Score 10.6; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 6.5e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 1300 CCTGGCCCCATGTAGCC 1316
DB 1 CCTGGCCCCACAGGCC 17
RESULT 709
ABV89781
ID ABV89781 standard; DNA; 17 BP.
XX AC ABV89781;
XX

```
XX 23-DEC-2002 (first entry)
XX Human POSHL1 scanning oligonucleotide SEQ ID NO 494.
DE
XX Human; POSHL 1; SH3 domain; POSH-like signalling protein 1; oncogene;
XX Rho GTPase; signal transduction; gene expression; cancer; vaccine;
XX gene therapy; transgenic; ss.
XX Homo sapiens.
XX EP1239051-A2.
XX
XX 11-SEP-2002.
XX
XX 28-JAN-2002; 2002EP-0001165.
XX
XX 30-JAN-2001; 2001WO-US00663.
XX 30-JAN-2001; 2001WO-US00664.
XX 30-JAN-2001; 2001WO-US00665.
XX 30-JAN-2001; 2001WO-US00666.
XX 30-JAN-2001; 2001WO-US00667.
XX 30-JAN-2001; 2001WO-US00668.
XX 30-JAN-2001; 2001WO-US00669.
XX 30-JAN-2001; 2001WO-US00670.
XX 23-MAY-2001; 2001US-0864761.
XX 10-OCT-2001; 2001US-0328205.
XX
XX (AEOM-) AEOMICA INC.
XX
XX Shannon M;
XX
XX WPI; 2002-684061/74.
XX
XX Novel human SH3 domain (POSH)-like signalling protein 1 polypeptide,
XX POSHL-1, useful for treating disorders associated with decreased
XX expression or activity of human POSHL1 -
XX
XX Example 2; SEQ ID NO 494; 60pp + Sequence Listing; English.
XX
XX The invention relates to an isolated SH3 domain (POSH)-like signalling
XX protein 1 (POSHL 1) polypeptide (I), comprising a sequence of 730 amino
XX acids (SI, AB83999), a sequence having 65% sequence identity to (SI),
XX (SI) having 95% deviations, especially conservative substitutions or a
XX fragment of the sequences comprising at least 8 contiguous amino acids.
XX Human POSHL 1 is a proto-oncogene/oncogene product that functions as an
XX adaptor protein that interacts with Rho family small GTPases as well as
XX downstream components of the signal transduction pathway. (I) is useful
XX for identifying a specific binding partner. (I) and nucleic acids (II)
XX encoding (I) are useful for diagnosing, monitoring disease and treating
XX caused by altered expression of human POSHL1 including diagnosing and
XX treating cancer, they are useful in the development of vaccines and (II) is
XX useful in gene therapy. (II) is useful for constructing microarrays which
XX are useful for measuring and for surveying gene expression and creating
XX transgenic non-human animals capable of producing the proteins. The
XX present sequence is that of a scanning oligonucleotide useful in examples
XX of the invention.
XX Note: The present sequence did not form part of the printed
XX specification, but is based on sequence information supplied to Derwent
XX by the European Patent Office.
XX
XX Sequence 17 BP; 3 A; 4 C; 9 G; 1 T; 0 other;
XX
XX Query Match 0.8%; Score 10.6; DB 1; Length 17;
XX Best Local Similarity 76.5%; Pred. No. 6.5e+02;
XX Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
XX
XX 623 GGGACACGAGTCCAGGAG 629
XX |||||
XX 1 GGGCAGAGCTCCGGGAG 17
XX
XX RESULT 710
XX
XX Query Match 0.8%; Score 10.6; DB 1; Length 17;
XX Best Local Similarity 76.5%; Pred. No. 6.5e+02;
XX Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
XX
XX Sequence 17 BP; 3 A; 4 C; 9 G; 1 T; 0 other;
XX
XX Query Match 0.8%; Score 10.6; DB 1; Length 18;
XX Best Local Similarity 76.5%; Pred. No. 6.8e+02;
XX Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
XX
XX 1077 GGCTCTTCAGTGAGTGT 1093
XX |||||
XX 1 GGCACCTTCAGTAACTTT 17
XX
XX RESULT 711
XX AAH55881/C
XX ID AAH55881 standard; DNA; 18 BP.
XX
XX AAH55881;
XX AC
XX
XX 04-SEP-2001 (first entry)
XX
XX Human SCN1A PCR-SSCP PCR primer SEQ ID NO:125.
XX
XX Human; epilepsy; chromosome 2; SCN1A; SCN2A; SCN3A; identification;
XX diagnosis; mutation; chromosome 2q23-q31; neurological disorder;
```

```
AAZ35905
ID AAZ35905 standard; DNA; 18 BP.
XX
XX AC AAZ35905;
XX
XX 03-FEB-2000 (first entry)
XX
XX Human sentrin phosphorothioate antisense oligonucleotide SEQ ID NO:47.
XX
XX Human; sentrin; antisense oligonucleotide; phosphorothioate;
XX inhibition; modulation; expression; diagnosis; ss.
XX
XX Synthetic.
XX Homo sapiens.
XX
XX Key Location/Qualifiers
XX modified_base 1..18
XX FT /tag= a
XX FT /note= "phosphorothioate linkages"
XX
XX US5985664-A.
XX
XX 16-NOV-1999.
XX
XX 17-DEC-1998; 98US-0213768.
XX
XX 17-DEC-1998; 98US-0213768.
XX
XX (ISIS-) ISIS PHARM INC.
XX
XX Baker BE, Cowser LM;
XX
XX WPI; 2000-022284/02.
XX
XX Antisense compound which modulates human sentrin expression, useful for
XX treating diseases associated with sentrin expression -
XX
XX Example 15; Column 38; 29pp; English.
XX
XX The present invention describes an antisense compound (I) 8-30
XX nucleotides long targeted to a nucleic acid molecule encoding human
XX sentrin. The antisense compound comprises a phosphorothioate antisense
XX oligonucleotide which inhibits expression of human sentrin. (I) is
XX useful for inhibiting expression of sentrin in human cells or tissues
XX in vitro, for treating humans or other animals suspected of having or
XX being prone to a disease associated with sentrin expression. (I) can
XX also be used for research or diagnostic purposes. The present
XX sequence represents a human sentrin phosphorothioate antisense
XX oligonucleotide from the present invention.
XX
XX Sequence 18 BP; 4 A; 5 C; 3 G; 6 T; 0 other;
XX
XX Query Match 0.8%; Score 10.6; DB 1; Length 18;
XX Best Local Similarity 76.5%; Pred. No. 6.8e+02;
XX Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
XX
XX 1077 GGCTCTTCAGTGAGTGT 1093
XX |||||
XX 1 GGCACCTTCAGTAACTTT 17
XX
XX RESULT 711
XX AAH55881/C
XX ID AAH55881 standard; DNA; 18 BP.
XX
XX AAH55881;
XX AC
XX
XX 04-SEP-2001 (first entry)
XX
XX Human SCN1A PCR-SSCP PCR primer SEQ ID NO:125.
XX
XX Human; epilepsy; chromosome 2; SCN1A; SCN2A; SCN3A; identification;
XX diagnosis; mutation; chromosome 2q23-q31; neurological disorder;
```

anticonvulsant; neuroprotective; PCR primer; ss.

Homo sapiens.
Synthetic.

WO200138564-A2.

31-MAY-2001.

24-NOV-2000; 2000WO-CA01404.

26-NOV-1999; 99US-0167623.

(UNMC-) UNIV MCGILL.

Rouleau GA, LaFreniere RG, Rochefort D, Cossette P, Ragsdale D;

WPI; 2001-355945/37.

Determining a predisposition to epilepsy and/or development of epilepsy comprises determining the genotype of SCN1A, SCN2A and/or SCN3A, or a DNA variant, equivalent, or mutation which shows a linkage disequilibrium -

Example 3; Fig 2; 268pp; English.

The present invention describes a method (M1) of determining an individual's predisposition to epilepsy and/or development of epilepsy, as well as predicting the individual's response to medication. The method comprises determining the genotype of at least one gene selected from SCN1A, SCN2A or SCN3A, or a DNA variant, equivalent, or mutation which shows a linkage disequilibrium. SCN1A, SCN2A and SCN3A are all sodium channel genes located on chromosome 2. The idiopathic generalised epilepsy (IGE) gene is more specifically localised on chromosome 2 of SCN1A, SCN2A or SCN3A proteins or genes, are useful for treating epilepsy or other neurological disorders. They have anticonvulsant and neuroprotective activities. AAH55763 to AAH56164 and AAH9674 to AAH99679 represent SCN1A, SCN2A, and SCN3A cDNAs, gene fragments, PCR primers, oligonucleotides and proteins given in the exemplification of the present invention.

Sequence 18 BP; 4 A; 6 C; 6 G; 2 T; 0 other;

Query Match 0.8%; Score 10.6; DB 1; Length 18;

Best Local Similarity 76.5%; Pred. No. 6.8e+02;

Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 729 GGCGGCTGCTGCCGC 745

Db 17 GAGAGCCTGCTCTGTC 1

RESULT 712

AAV95056/c

ID AAV95056 standard; RNA; 18 BP.

AC AAV95056;

24-FEB-1999 (first entry)

Mouse IL-2 receptor g-chain substrate position 399.

Human, IL-2 receptor g-chain; interleukin 2 receptor gamma chain;

hammerhead ribozyme; hairpin ribozyme; substrate; expression; cancer;

autoimmune disease; psoriasis; allergy; inflammatory disease;

graft rejection; ss.

Mus sp.

WO9824913-A2.

11-JUN-1998.

XX

PF

XX

PR

XX

XX

PA

XX

XX

PI

XX

XX

DR

XX

XX

XX

PT

XX

XX

XX

PS

XX

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

CC

02-DEC-1997; 97WO-US21748.

03-DEC-1996; 96US-0758306.

(RIBO-) RIBOZYME PHARM INC.

McSwiggen JA, Stinchcomb DT;

WPI; 1998-333332/29.

Ribozymes targeted to interleukin 2 - useful for treating e.g.

cancer, autoimmune disease and allergies

Claim 4; Page 44; 61pp; English.

The present sequence invention describes ribozymes targeted to modulate the synthesis and/or expression of interleukin (IL)-2R gamma encoded RNA. AAV93899 to AAV94574 represent specifically claimed ribozymes, and AAV94575 to AAV95260 represent specifically claimed substrate sequences from the present invention. The ribozymes can be used for the treatment of, e.g. graft rejection, autoimmune disease, cancer, psoriasis, allergy and other inflammatory conditions. The ribozymes are also used to induce tolerance in a recipient to alloantigen from a donor.

Sequence 18 BP; 3 A; 7 C; 4 G; 4 U; 0 other;

Query Match 0.8%; Score 10.6; DB 1; Length 18;

Best Local Similarity 76.5%; Pred. No. 6.8e+02;

Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 1236 GGTCGCTGCGCTGCCCA 1252

Db 18 GGTCCTGGAGCTGGACA 2

RESULT 713

AAF91219

ID AAF91219 standard; DNA; 19 BP.

AC AAF91219;

04-MAY-2001 (first entry)

Human multi drug resistance-1 gene related sequence SEQ ID NO: 306.

Human; MDR-1; multi drug resistance-1; drug uptake; disease; cancer;

inflammatory disease; neuronal disease; CNS disease;

cardiovascular disease; PCR primer; ss.

Homo sapiens.

WO200109183-A2.

08-FEB-2001.

28-JUL-2000; 2000WO-EP07314.

30-JUL-1999; 99EP-0114938.

22-FEB-2000; 2000EP-0103361.

(EPID-) EPIDAUROS BIOTECHNOLOGIE AG.

Brinkmann U, Hoffmeyer S, Eichelbaum M, Roots I;

WPI; 2001-159855/16.

New polynucleotide encoding a molecular variant Multi Drug Resistance (MDR)-1 polypeptide is useful for diagnosing and treating diseases associated with abnormal MDR-1 expression or function, e.g. cancer -

Disclosure; Page 140; 154pp; English.

PD 08-FEB-2001.
 XX 28-JUL-2000; 2000WO-EP07314.
 XX 30-JUL-1999; 39EP-0114938.
 PR 22-FEB-2000; 2000EP-0103361.
 XX (EPID-) EPIDAUROS BIOTECHNOLOGIE AG.
 XX Brinkmann U, Hoffmeyer S, Eichelbaum M, Roots I;
 XX WPI; 2001-159855/16.
 XX New polynucleotide encoding a molecular variant Multi Drug Resistance
 PT (MDR)-1 polypeptide is useful for diagnosing and treating diseases
 PT associated with abnormal MDR-1 expression or function, e.g. cancer -
 XX Disclosure; Page 140; 154pp; English.
 XX The present invention provides nucleotides encoding molecular variants of
 CC the human multi drug resistance-1 (MDR-1) protein. These can be used to
 CC identify compounds capable of treating multidrug resistance and
 CC sensitivity interfering resulting from polymorphisms in MDR-1, which can
 CC lead to difficulties in treating cancer, cardiovascular, neuronal,
 CC inflammatory and CNS diseases.
 XX Sequence 19 BP; 3 A; 8 C; 5 G; 2 T; 1 other;
 SQ Query Match 0.8%; Score 10.6; DB 1; Length 19;
 Best Local Similarity 76.5%; Pred. No. 7.1e+02;
 Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 896 GGTCAGCGTGGCCCTG 912
 DB 17 GGCAGACRGTGGCCCTG 1
 RESULT 717
 AAD04572/c
 ID AAD04572 standard; DNA; 19 BP.
 XX AAD04572;
 XX 04-JUL-2001 (first entry)
 XX Human insulinoma-associated antigen, IA-1 cDNA sequencing primer #5.
 XX Human; insulinoma-associated antigen; IA-1; regulatory factor;
 KW tumour marker; therapy; neuroendocrine tumour; cancer; primer; ss.
 KW Homo sapiens.
 OS US6225049-B1.
 XX 01-MAY-2001.
 XX 19-MAY-1994; 94US-0246489.
 XX 17-JUN-1992; 92US-0901715.
 XX (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX Lan MS, Notkins AL;
 XX WPI; 2001-299371/31.
 XX Novel insulinoma-associated neuroendocrine tumor-associated cDNA,
 PT useful for diagnosing and identifying insulinoma, neuroendocrine tumors
 PT and cancers -
 XX Example 5; Column 25; 26pp; English.
 XX The present sequence is a sequencing primer which is used for

CC sequencing the human insulinoma-associated antigen, IA-1 cDNA clone.
 CC The IA-1 function as a regulatory factor in islet cell transformation.
 CC The IA-1 is used as a tumour marker for diagnosis and identification
 CC of insulinoma and neuroendocrine tumours. It is also used for
 CC identifying cancers. Correct identification of insulinomas and cancers
 CC is possible. The IA-1 fragments may be used to immunise animals for the
 CC generation of polyclonal and monoclonal antibodies.
 XX Sequence 19 BP; 5 A; 6 C; 5 G; 3 T; 0 other;
 SQ Query Match 0.8%; Score 10.6; DB 1; Length 19;
 Best Local Similarity 76.5%; Pred. No. 7.1e+02;
 Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 459 GGTGATCTCTCTGCAGG 475
 DB 18 GGTGATCTCTCTGCAGG 2
 RESULT 718
 AAZ94157
 ID AAZ94157 standard; DNA; 19 BP.
 XX AAZ94157;
 XX 19-JUN-2000 (first entry)
 XX Human PENT2 PCR primer.
 XX Phosphatidylethanolamine N-methyltransferase-2; PENT2; human;
 KW liver cancer; hepatoma; antitumour; antiproliferative;
 KW therapy; diagnosis; PCR primer; ss.
 XX Homo sapiens.
 OS WO200014198-A2.
 XX 16-MAR-2000.
 XX 13-AUG-1999; 99WO-US18463.
 XX 02-SEP-1998; 98US-0146218.
 XX (RESE) RESEARCH CORP TECHNOLOGIES INC.
 XX Vance DE, Walkey CJ, Cui Z;
 XX WPI; 2000-256956/22.
 XX Isolated nucleic acid molecule encoding phosphatidylethanolamine
 PT N-methyltransferase protein used to treat phosphatidylethanolamine
 PT N-methyltransferase-associated disorders such as liver cancer -
 XX Example 8; Page 57; 111pp; English.
 XX The present sequence is that of a primer used in the PCR
 CC amplification of the open reading frame of a cDNA clone (see
 CC AAZ94150) encoding human phosphatidylethanolamine N-methyltransferase-2
 CC (PENT-2, see AAY79199). The PCR product was subcloned into
 CC mammalian expression vector pCI, and PENT-2 was expressed in
 CC rat hepatoma McArdle-RH7777 cells. The invention relates to
 CC novel human PENT2 polynucleotides and protein (see AAY79199), and
 CC to methods of using them in the treatment and diagnosis of liver
 CC disorders, such as liver cancer.
 XX Sequence 19 BP; 2 A; 7 C; 7 G; 3 T; 0 other;
 SQ Query Match 0.8%; Score 10.6; DB 1; Length 19;
 Best Local Similarity 76.5%; Pred. No. 7.1e+02;
 Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
 QY 404 CCGGCTACTAGGGGAC 420
 ||||| |||||

```

Db      2 CCCGGCTGCTGGCTAC 18

RESULT 719
AAS08740
ID      AAS08740 standard; DNA; 20 BP.
XX
AC      AAS08740;
XX
DT      26-SEP-2001 (first entry)
XX
DE      Human PD-ABC form 1 DNA exon 11 3' splice site.
XX
KW      PD-ATP-binding cassette; PD-ABC; chromosome 19p13.3; spleen; thymus; ds;
KW      peripheral blood leukocyte; bone marrow; lymph node; dyslipidaemia;
KW      cardiovascular disorder; inflammatory disorder; abnormal calcium flux;
KW      epilepsy; coronary artery disease; Tangier's disease; atherosclerosis;
KW      familial high-density lipoprotein deficiency; fatty liver disease;
KW      atherosclerosis; diabetes; insulin resistance; obesity; drug screening;
KW      alcoholism; retinal degeneration; hypertension; vascular disease.
XX
OS      Homo sapiens.
XX
FN      WO200153490-A1.
XX
PD      26-JUL-2001.
XX
PF      23-JAN-2001; 2001WO-US02191.
XX
PR      24-JAN-2000; 2000US-0177889.
XX
PR      30-JUN-2000; 2000US-0215405.
XX
PA      (WARN ) WARNER LAMBERT CO.
XX
PI      Johns MA, Tafuri SR, Wang M;
XX
WPI; 2001-442259/47.
XX
DR      New Human PD-ABC DNA molecules and proteins for diagnosis and treatment
XX      of dyslipidaemia, epilepsy and diseases related to abnormal calcium flux
XX
-
XX
PS      Disclosure; Page 37; 77pp; English.
XX
CC      The sequence represents a splice site within a DNA molecule encoding
CC      human PD-ATP-binding cassette (PD-ABC) protein. PD-ABC maps to chromosome
CC      19p13.3 and is expressed in various tissues including spleen, thymus,
CC      peripheral blood leukocytes, bone marrow and lymph nodes. The PD-ABC DNA
CC      molecules and proteins are used to diagnose and treat cardiovascular
CC      disorders, inflammatory disorders, dyslipidaemia, epilepsy, diseases
CC      related to abnormal calcium flux, coronary artery disease, Tangier's
CC      disease, familial high-density lipoprotein deficiency, atherosclerosis,
CC      diabetes, fatty liver disease, insulin resistance, obesity, alcoholism,
CC      retinal degeneration, hypertension and vascular disease. The sequences
CC      are also used in drug screening assays.
XX
SQ      Sequence 20 BP; 5 A; 3 C; 11 G; 1 T; 0 other;
XX
Query Match      0.8%; Score 10.6; DB 1; Length 20;
Best Local Similarity 76.5%; Pred. No. 7.3e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY      1248 GCCCATGTGAGGCCAGG 1264
        ||| ||| ||| ||| ||| ||| |||
Db      3 GGACAGGTCAGCGCAGG 19

RESULT 720
AAS08831
ID      AAS08831 standard; DNA; 20 BP.
XX
AC      AAS08831;
XX
DT      05-APR-2001 (first entry)
XX
DE      PCR primer for Human secreted protein PRO6496 coding sequence.
XX
KW      Secreted protein; human; PRO protein; neoplastic cell growth; tumour;
KW      proliferation; leukaemia; lymphoid malignancy; inflammatory disorder;
KW      angiogenic disorder; immunologic disorder; PRO6496; PCR primer; ss.
XX
OS      Homo sapiens.

```

XX PN WO200075317-A2.
XX PD 14-DEC-2000.
XX PF 15-MAY-2000; 2000WO-US13358.
XX PR 09-JUN-1999; 99US-0138385.
XX PR 20-JUL-1999; 99US-0144790.
XX PR 03-AUG-1999; 99US-0146843.
XX PR 10-AUG-1999; 99US-0148188.
XX PR 17-AUG-1999; 99US-0149320.
XX PR 17-AUG-1999; 99US-0149327.
XX PR 17-AUG-1999; 99US-0149396.
XX PR 20-AUG-1999; 99US-0150114.
XX PR 31-AUG-1999; 99US-0151700.
XX PR 31-AUG-1999; 99US-0151734.
XX PA (GETH) GENENTECH INC.
XX PI Botstein DA, Goddard A, Gurney AL, Smith V, Watanabe CK, Wood WT;
XX PT WPI; 2001-071075/08.
XX DR
XX PS Antibodies against PRO polypeptides, useful for diagnosing and treating
XX PT tumours are associated with gene amplification, neoplastic cell growth
XX PT and proliferation in mammals -
XX PS Example 11; Page 95; 143pp; English.
XX CC This sequence represents a PCR primer used to isolate DNA encoding
XX CC human PRO580 protein of the invention. The PRO proteins are secreted
XX CC proteins. Antagonists or antibodies of PRO polypeptides are useful for
XX CC diagnosing and treating tumours are associated with gene amplification,
XX CC neoplastic cell growth and proliferation in mammals, and those conditions
XX CC characterised by overexpression and/or activation of the amplified genes.
XX CC Such conditions include benign or malignant tumours (e.g. renal, liver,
XX CC kidney, bladder, breast, gastric, thyroid, ovarian, colorectal, prostate,
XX CC pancreatic, lung, vulval, testicular, hepatic carcinomas, sarcomas,
XX CC glioblastomas and various head and neck tumours); leukaemias and lymphoid
XX CC malignancies; neuronal, glial, astrocytic, hypothalamic, and other
XX CC glandular, macrophageal, epithelial, stromal and blastocoele disorders;
XX CC and inflammatory, angiogenic and immunologic disorders. These may further
XX CC be used to qualitatively or quantitatively detect the expression of
XX CC proteins encoded by the amplified genes, and in tumour diagnostics or
XX CC prognostics. The PRO polypeptide or its antagonist may be used for the
XX CC preparation of a medicament in the treatment of a condition, which is
XX CC responsive to the PRO polypeptide, its antagonist or anti-PRO antibody.
XX CC
XX CC Sequence 20 BP; 5 A; 6 C; 4 G; 5 T; 0 other;
Query Match 0.8%; Score 10.6; DB 1; Length 20;
Best Local Similarity 76.3%; Pred. No. 7.3e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 828 GCAGCTGAAGCTTTCAG 844
Dd 18 GAACCTGAAGCTTTCAG 2
RESULT 722
AAA59547
ID AAA59547 standard; DNA; 21 BP.
AC AAA59547;
XX 14-NOV-2000 (first entry)
XX PCR primer used to amplify DNA encoding beta-secretase enzyme.
XX DE
XX DE Beta-secretase; beta-amyloid precursor protein; beta-amyloid peptide;
XX KW amyloid plaque component; Alzheimer's disease; amyloidogenic disease;
XX KW inhibitor; PCR primer; ss.

XX OS Homo sapiens.
XX PN WO200047618-A2.
XX PD 17-AUG-2000.
XX PF 10-FEB-2000; 2000WO-US03819.
XX PR 10-FEB-1999; 99US-0119571.
XX PR 15-JUN-1999; 99US-0139172.
XX PA (ELAN-) ELAN PHARM INC.
XX PI Anderson JP, Basi G, Doane MT, Frigon N, John V, Power M;
XX PI Sinha S, Tatsuno G, Tung J, Wang S, McConlogue L;
XX DR WPI; 2000-533011/48.
XX PT Purified beta-secretase protein used in assays to discover inhibitors
XX PT which can be used for the treatment of amyloidogenic diseases e.g.
XX PT Alzheimer's disease -
XX PS Example 3; Page 66; 121pp; English.
XX CC The specification describes a beta-secretase enzyme. The enzyme cleaves
XX CC beta-amyloid precursor protein to produce beta-amyloid peptide. This
XX CC enzyme is therefore implicated in the production of amyloid plaque
XX CC components which accumulate in the brains of individuals afflicted with
XX CC Alzheimer's disease. Inhibitors of beta-secretase are administered to
XX CC a mammalian subject e.g. with Alzheimer's disease or Alzheimer's
XX CC disease-like pathology to test if they maintain or improve cognitive
XX CC ability or reduce the plaque burden. The compounds are used for the
XX CC treatment of amyloidogenic diseases e.g. Alzheimer's disease. PCR
XX CC primers AAA59530-49 were used to amplify DNA encoding beta-secretase
XX CC enzyme.
XX CC Sequence 21 BP; 3 A; 9 C; 7 G; 2 T; 0 other;
Query Match 0.8%; Score 10.6; DB 1; Length 21;
Best Local Similarity 76.5%; Pred. No. 7.4e+02;
Matches 13; Conservative 0; Mismatches 4; Indels 0; Gaps 0;
QY 575 AGCAGGCGCTCCGTCG 591
Dd 3 AGCTGCCCTCCGCGCG 19
RESULT 723
AAQ68252
ID AAQ68252 standard; DNA; 16 BP.
XX AC AAQ68252;
XX 25-MAR-2003 (updated)
XX DT 16-FEB-1995 (first entry)
XX DE Triple helix forming methylphosphonate oligomer 2104.
XX KW Methylphosphonate; MP; triple helix; translation;
XX KW oligonucleoside; ss.
XX OS Synthetic.
XX XX WO9413326-A1.
XX PD 23-JUN-1994.
XX PF 08-DEC-1993; 93WO-US11986.
XX PR 08-DEC-1992; 92US-0987746.
XX PA (GENT-) GENTA INC.

AC ACA07666;
 XX
 XX
 XX 03-JUN-2003 (first entry)
 XX
 XX NFKB sub-unit modulating zinyzyme substrate #85.
 XX
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinyzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 XX ss.
 XX
 XX Homo sapiens.
 XX
 XX OS
 XX US2002177568-A1.
 XX
 XX 28-NOV-2002.
 XX
 XX 23-MAY-2001; 2001US-0864785.
 XX
 XX 15-AUG-1994; 94US-0291932.
 PR 07-DEC-1992; 92US-0987132.
 PR 18-MAY-1994; 94US-0245466.
 PR 23-DEC-1996; 96US-0777916.
 XX
 XX (STIN/) STINCHCOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 XX WPI; 2003-340953/32.
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression
 PT of a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases -
 XX
 XX Claim 3; Page 38; 72pp; English.
 XX
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (I) is an inozyme, zinyzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel
 CC enzymatic nucleic acid molecule.

SQ Sequence 17 BP; 3 A; 9 C; 4 G; 1 U; 0 other;
 Query Match 0.8%; Score 10.4; DB 1; Length 17;
 Best Local Similarity 91.7%; Pred. No. 7e-02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 730 GGGGCTGGCTG 741
 Db 17 GGGGCTGGCTG 6
 RESULT 727
 ACA06320/c
 ID ACA06320 standard; RNA; 17 BP.
 XX
 XX ACA06320;
 XX
 XX 03-JUN-2003 (first entry)
 XX
 XX NFKB sub-unit modulating inozyme substrate #139.
 XX
 XX Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinyzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 XX ss.
 XX
 XX Homo sapiens.
 XX
 XX OS
 XX US2002177568-A1.
 XX
 XX 28-NOV-2002.
 XX
 XX 23-MAY-2001; 2001US-0864785.
 XX
 XX 15-AUG-1994; 94US-0291932.
 PR 07-DEC-1992; 92US-0987132.
 PR 18-MAY-1994; 94US-0245466.
 PR 23-DEC-1996; 96US-0777916.
 XX
 XX (STIN/) STINCHCOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 XX WPI; 2003-340953/32.
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression
 PT of a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases -
 XX
 XX Claim 3; Page 38; 72pp; English.
 XX
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (I) is an inozyme, zinyzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel
 CC enzymatic nucleic acid molecule.

CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC enzymatic nucleic acid molecule.
 XX
 SQ Sequence 17 BP; 3 A; 8 C; 4 G; 2 U; 0 other;
 Query Match 0.8%; Score 10.4; DB 1; Length 17;
 Best Local Similarity 91.7%; Pred. No. 7e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 730 GGGGCTGGCTG 741
 |||||
 Db 15 GGGGCTGGCTG 4
 RESULT 728
 ACA06587/c
 ID ACA06587 standard; RNA; 17 BP.
 AC
 AC ACA06587;
 XX
 DT 03-JUN-2003 (first entry)
 DE NFKB sub-unit modulating inozyme substrate #406.
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; diabetes;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 ss.
 XX
 OS Homo sapiens.
 XX
 US2002177568-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 23-MAY-2001; 2001US-0864785.
 XX
 15-AUG-1994; 94US-0291932.
 PR 07-DEC-1992; 92US-0987132.
 PR 18-MAY-1994; 94US-0245466.
 PR 23-DEC-1996; 96US-0777916.
 XX
 (STIN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 XX
 Stinchcomb DT, Mcswiggen J, Draper KG;
 PI
 XX
 DR WPI; 2003-340953/32.
 XX
 PT Novel enzymatic nucleic acid molecules which down regulates expression

PT of a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases -
 XX
 PS Claim 3; Page 33; 72pp; English.
 XX
 CC The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFKB), where (I) is an inozyme, zinzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel
 CC enzymatic nucleic acid molecule.
 XX
 SQ Sequence 17 BP; 2 A; 6 C; 5 G; 4 U; 0 other;

Query Match 0.8%; Score 10.4; DB 1; Length 17;
 Best Local Similarity 91.7%; Pred. No. 7e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 Qy 827 TGCAGCTGAGC 838
 |||||
 Db 15 TGCAGCTGAGC 4
 RESULT 729
 ACA08920/c
 ID ACA08920 standard; RNA; 17 BP.
 AC
 AC ACA08920;
 XX
 DT 03-JUN-2003 (first entry)
 XX
 DE NFKB sub-unit modulating amberzyme substrate #83.
 XX
 KW Enzymatic nucleic acid; nuclear factor kappa B; NFKB; inozyme; zinzyme;
 KW G-cleaver; amberzyme; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel; docetaxel; cisplatin; methotrexate;
 KW cyclophosphamide; doxorubicin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 ss.
 XX
 OS Homo sapiens.
 XX
 US2002177568-A1.
 XX
 PD 28-NOV-2002.
 XX
 PF 23-MAY-2001; 2001US-0864785.

XX PR 15-AUG-1994; 94US-0291932.
 XX PR 07-DEC-1992; 92US-0987132.
 XX PR 18-MAY-1994; 94US-0245466.
 XX PR 23-DEC-1996; 96US-0777916.
 XX (STIN/) STINCHOMB D T.
 XX PA (MCSW/) MCSWIGGEN J.
 XX PA (DRAP/) DRAPER K G.
 XX PI Stinchcomb DT, Mcswiggen J, Draper KG;
 XX DR WPI; 2003-340953/32.
 XX Novel enzymatic nucleic acid molecules which down regulates expression
 PT of a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases -
 XX Claim 3; Page 51; 72pp; English.
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zynzyme, G-cleaver or amberzyme
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapies including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubicin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel
 CC enzymatic nucleic acid molecule.
 XX SQ Sequence 17 BP; 3 A; 8 C; 4 G; 2 U; 0 other;
 Query Match 0.8%; Score 10.4; DB 1; Length 17;
 Best Local Similarity 91.7%; Pred. No. 7e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 730 GGGGCTGGCTG 741
 |||||
 Db 14 GGGGCTGGCTG 3
 RESULT 730
 AAS45551
 ID AAS45551 standard; DNA; 20 BP.
 XX AC AAS45551;
 XX 18-DEC-2001 (first entry)
 XX Tumour-specific IgV region H chain, PCR primer gamma.
 XX Human; B cell lymphoma; cytostatic; immunostimulator; self-antigen;
 XX tumour-specific vaccine; tumour; polyclonal immune response;
 XX idiotype-specific anti-lymphoma immune response; PCR primer; ss.
 XX Homo sapiens.
 XX WO200168682-A1.

XX 20-SEP-2001.
 XX 13-OCT-2000; 2000WO-US28362.
 XX 10-MAR-2000; 2000US-0522900.
 XX (LARG-) LARGE SCALE BIOLOGY CORP.
 XX (MCCO/) MCCORMICK A A.
 XX (TUSE/) TUSE D.
 XX Reini SJ, Turpen TH;
 XX WPI; 2001-596903/67.
 XX Novel polypeptide vaccine produced in plants, useful for inducing an
 PT immune response to a self-antigen on the surface of certain tumour cells
 PT -
 XX Disclosure; Page 30; 89pp; English.
 XX The invention relates to a novel polypeptide self-antigen (I) useful as a
 CC tumour-specific vaccine in a subject with a tumour or at risk of
 CC developing a tumour. (I) includes an epitope or epitopes unique to,
 CC or over expressed by, cells of the tumour, thereby distinguishing the
 CC tumour from all other tumours of the same or different histological type,
 CC or in the subject or in another member of the subject's species. (I) is
 CC epitopes in their native form. (I) is capable of inducing an immune
 CC response in a mammal, when used as an individual-specific immunogenic
 CC product comprising (I); and as a vaccine composition useful for inducing
 CC a tumour-specific immune response, idiotype-specific anti-lymphoma immune
 CC response, a polyclonal immune response to at least one idiotype of a
 CC surface immunoglobulin or a polyclonal immune response to an idiotype.
 CC The vaccine composition is useful for inducing a tumour-specific immune
 CC antibody response in a tumour-bearing subject or a subject who had a
 CC tumour e.g. B-cell lymphoma, and was treated so that no tumour is
 CC clinically or radiographically evident. (I) is useful for inducing a
 CC protective antitumour immune response. (I) can be produced at high
 CC levels, is easy to purify and can be appropriately folded to mimic the
 CC conformation of the native epitopes displayed at the tumour cell surface.
 CC AAS45529-AAS45579 represent B cell lymphoma self antigen vaccine
 CC linker sequences and PCR primers of the invention.
 XX SQ Sequence 20 BP; 4 A; 8 C; 6 G; 2 T; 0 other;
 Query Match 0.8%; Score 10.4; DB 1; Length 20;
 Best Local Similarity 70.0%; Pred. No. 7.7e+02;
 Matches 14; Conservative 0; Mismatches 6; Indels 0; Gaps 0;
 QY 1043 CTTCCACGACAGCCCTGCG 1062
 |||||
 Db 1 CTTGACCGAGGCCGAGGC 20
 RESULT 731
 ABZ76936
 ID ABZ76936 standard; DNA; 20 BP.
 XX AC ABZ76936;
 XX 07-MAY-2003 (first entry)
 XX Bovine DGAT BAC-DNA sequencing primer #9.
 XX Acyl CoA:diacylglycerol transferase; DGAT; enzyme; chromosome 14;
 XX bovine; milk; meat marbling; low fat; polymorphic; SNP;
 XX single nucleotide polymorphism; PCR primer; ss.
 XX Bos taurus.
 XX Synthetic.
 XX WO2003004630-A2.

PD 16-JAN-2003.
 XX 05-JUL-2002; 2002WO-EP07520.
 XX 06-JUL-2001; 2001EP-0116412.
 PR 13-MAY-2002; 2002US-379412P.
 XX (ARBE-) ARBEITSGEMEINSCHAFT DEUT RINDERZUECHTER.
 XX Fries H, Winter A;
 PI WPI; 2003-239205/23.
 DR New nucleic acid molecule comprising a sequence of an allele of a
 PT polymorphic bovine acyl CoA-diacylglycerol transferase gene useful for
 PT testing a mammal for its predisposition for fat content of milk and for
 PT meat marbling -
 XX Example 1; Page 35; 91pp; English.
 XX The present invention describes a nucleic acid molecule (NA) (I) encoding
 CC a bovine acyl CoA-diacylglycerol transferase (DGAT) contributing to or
 CC indicative for low fat content of milk and to low meat marbling
 CC (intramuscular fat content). Human DGAT is located to chromosome 8, and
 CC bovine DGAT is located to chromosome 14. (I) is useful for testing a
 CC mammal for its predisposition for fat content of milk and/or its
 CC predisposition for meat marbling. The method comprises analysing the
 CC gene encoding DGAT for nucleotide polymorphisms (e.g. single nucleotide
 CC polymorphisms (SNPs)) which are connected with the predisposition. The
 CC nucleotide polymorphisms are located in the coding region of the DGAT
 CC gene and result in substitution, deletion and/or addition of an amino
 CC acid sequence of the polypeptide which is encoded by the gene. The
 CC nucleic acid molecule has at the position 10433 and 10434 of the DGAT
 CC gene a guanine and a cytosine residue, at position 3343 a cytosine or
 CC thymine, which correlate with a predisposition for low fat content of
 CC milk and low meat marbling. The nucleic acid molecule has at the position
 CC corresponding to position 10433 and 10434 of the DGAT gene two adenine
 CC residues which correlate with a predisposition for high content of milk
 CC and high meat marbling. The nucleotide polymorphisms are located in a
 CC region which is responsible for the regulation of the expression of the
 CC product of the gene encoding DGAT. ABZ76924 to ABZ77045 and ABP96035 to
 CC ABP96046 represent sequences used in the exemplification of the present
 CC invention.
 XX Sequence 20 BP; 7 A; 7 C; 5 G; 1 T; 0 other;
 SQ Query Match 0.8%; Score 10.4; DB 1; Length 20;
 Best Local Similarity 91.7%; Pred. No. 7.7e+02;
 Matches 1; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 866 AGGTCCCCACAG 877
 ||| |||||
 Db 1 AGGCCCCACAG 12
 RESULT 732
 ABZ77002
 ID ABZ77002 standard; DNA; 20 BP.
 XX AC ABZ77002;
 XX 07-MAY-2003 (first entry)
 XX Bovine DGAT PCR primer #38.
 DE Acyl CoA-diacylglycerol transferase; DGAT; enzyme; chromosome 14;
 KW bovine; milk; meat marbling; low fat; polymorphic; SNP;
 KW single nucleotide polymorphism; PCR primer; ss.
 XX Bos taurus.
 OS Synthetic.
 XX

PN W02003004630-A2.
 XX 16-JAN-2003.
 XX 05-JUL-2002; 2002WO-EP07520.
 XX 06-JUL-2001; 2001EP-0116412.
 PR 13-MAY-2002; 2002US-379412P.
 XX (ARBE-) ARBEITSGEMEINSCHAFT DEUT RINDERZUECHTER.
 XX Fries H, Winter A;
 PI WPI; 2003-239205/23.
 DR New nucleic acid molecule comprising a sequence of an allele of a
 PT polymorphic bovine acyl CoA-diacylglycerol transferase gene useful for
 PT testing a mammal for its predisposition for fat content of milk and for
 PT meat marbling -
 XX Example 1; Page 36; 91pp; English.
 XX The present invention describes a nucleic acid molecule (NA) (I) encoding
 CC a bovine acyl CoA-diacylglycerol transferase (DGAT) contributing to or
 CC indicative for low fat content of milk and to low meat marbling
 CC (intramuscular fat content). Human DGAT is located to chromosome 8, and
 CC bovine DGAT is located to chromosome 14. (I) is useful for testing a
 CC mammal for its predisposition for fat content of milk and/or its
 CC predisposition for meat marbling. The method comprises analysing the
 CC gene encoding DGAT for nucleotide polymorphisms (e.g. single nucleotide
 CC polymorphisms (SNPs)) which are connected with the predisposition. The
 CC nucleotide polymorphisms are located in the coding region of the DGAT
 CC gene and result in substitution, deletion and/or addition of an amino
 CC acid sequence of the polypeptide which is encoded by the gene. The
 CC nucleic acid molecule has at the position 10433 and 10434 of the DGAT
 CC gene a guanine and a cytosine residue, at position 3343 a cytosine or
 CC thymine, which correlate with a predisposition for low fat content of
 CC milk and low meat marbling. The nucleic acid molecule has at the position
 CC corresponding to position 10433 and 10434 of the DGAT gene two adenine
 CC residues which correlate with a predisposition for high content of milk
 CC and high meat marbling. The nucleotide polymorphisms are located in a
 CC region which is responsible for the regulation of the expression of the
 CC product of the gene encoding DGAT. ABZ76924 to ABZ77045 and ABP96035 to
 CC ABP96046 represent sequences used in the exemplification of the present
 CC invention.
 XX Sequence 20 BP; 7 A; 7 C; 5 G; 1 T; 0 other;
 SQ Query Match 0.8%; Score 10.4; DB 1; Length 20;
 Best Local Similarity 91.7%; Pred. No. 7.7e+02;
 Matches 1; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 866 AGGTCCCCACAG 877
 ||| |||||
 Db 1 AGGCCCCACAG 12
 RESULT 733
 AAZ71860
 ID AAZ71860 standard; DNA; 20 BP.
 XX AC AAZ71860;
 XX 10-SEP-2001 (first entry)
 XX Human biallelic marker upstream amplification primer SEQ ID NO:6216.
 DE Human genome; biallelic marker; high density disequilibrium map;
 KW genomic map; haplotype; phenotype; polymorphic base; genotyping;
 KW haplotyping; hybridisation; identification; characterisation;
 KW amplification; single nucleotide polymorphism; SNP; PCR primer;
 KW diagnosis; ss.

```

XX OS Homo sapiens.
XX XX
XX EN WO9954500-A2.
XX XX
XX FD 28-OCT-1999.
XX XX
XX PF 21-APR-1999; 99WO-1B00822.
XX XX
XX PR 21-APR-1998; 98US-0082614.
XX PR 23-NOV-1998; 98US-0109732.
XX XX
XX PA (GEST ) GENSET.
XX XX
XX PI Cohen D, Blumenfeld M, Chumakov I;
XX XX
XX DR WPI; 2000-013267/01.
XX XX
XX PT Novel biallelic markers used to construct a high density disequilibrium
XX PT map of the human genome -
XX PS Claim 9; Page 1556; 2745pp; English.
XX XX
XX CC AAZ55654 to AAZ69578 represent human biallelic markers from the present
XX CC invention, which contain a polymorphic base at position 24 of their
XX CC nucleotide sequences. AAZ69579 to AAZ77440 represent amplification
XX CC primers for the biallelic markers. The biallelic markers of the
XX CC invention have a variety of uses: they can be used for high density
XX CC mapping of the human genome, and in complex association studies and
XX CC haplotyping studies which are useful in determining the genetic basis
XX CC for disease states. Compositions and methods of the invention can also
XX CC be useful for the identification of the targets for the development of
XX CC pharmaceutical agents and diagnostic methods, as well as the
XX CC characterisation of the differential efficacious responses to and side
XX CC effects from pharmaceutical agents acting on a disease as well as other
XX CC treatment.
XX CC N.B. The SEQ ID NOs 2852, 2913, 2974, 3035, 3096, 3157, 3227, 3297
XX CC and 3367, are not actually given a sequence in the Sequence Listing
XX CC from the present invention.
XX SQ Sequence 20 BP; 5 A; 2 C; 9 G; 4 T; 0 other;

Query Match 0.8%; Score 10.4; DB 1; Length 20;
Best Local Similarity 91.7%; Pred. No. 7.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 6 GGCAGTTGAGGT 17
DB 5 GGAAGTTGAGGT 16

RESULT 734
AAAC93165
ID AAC93165 standard; DNA; 20 BP.
XX AC AAC93165;
XX XX
XX DT 15-FEB-2001 (first entry)
XX XX
XX DE Human STAT3 phosphorothioate antisense oligonucleotide SEQ ID NO:16.
XX XX
XX KW Human; mouse; STAT3; phosphorothioate; antisense oligonucleotide;
XX KW modulation; signal transducer and activator of transcription;
XX KW DNA-binding protein; signal transduction; inhibition; apoptosis;
XX KW inflammatory disease; cancer; antinflammatory; antirheumatic;
XX KW cytostatic; immunostimulatory; rheumatoid arthritis; leukaemia;
XX KW myeloma; melanoma; lymphoma; diagnosis; ss.
XX XX
XX OS Homo sapiens.
XX XX
XX PN WO2000061602-A1.
XX XX
XX FD 19-OCT-2000.

```

```

XX XX
XX PF 06-APR-2000; 2000WO-US09054.
XX XX
XX PR 08-APR-1999; 99US-0288461.
XX XX
XX PA (ISIS-) ISIS PHARM INC.
XX XX
XX PI Karras JG;
XX XX
XX DR WPI; 2000-619223/59.
XX XX
XX PT New antisense compound for inhibiting the expression of signal
XX PT transducer and activator of transcription 3 (STAT3) in cells or tissues
XX PT and treating diseases or condition associated with STAT3, such as
XX PT rheumatoid arthritis and cancer -
XX XX
XX XX Example 2; Page 46; 104pp; English.
XX XX
XX CC The present invention describes an antisense compound (I), 8 to 30
XX CC nucleobases in length, that is targeted to a nucleic acid molecule
XX CC encoding STAT3 (Signal Transducer and Activator of Transcription) and
XX CC which inhibits the expression of it. (I) has antiinflammatory,
XX CC antirheumatic, cytostatic and immunostimulatory activities. (I) is used
XX CC for inhibiting the expression of STAT3 in cells or tissues, treating
XX CC an animal having a disease or condition associated with STAT3 or a
XX CC human having a disease or condition characterised by a reduction in
XX CC apoptosis, and inducing apoptosis in a cell. Diseases or conditions
XX CC that are treated are rheumatoid arthritis, cancer of the breast,
XX CC prostate, brain, head and/or neck, leukaemia, myeloma, melanoma or
XX CC lymphoma. (I) can also be used for diagnostic methods in detecting and
XX CC determining the role of STAT3 in various cell functions, physiological
XX CC processes and conditions and for diagnosing the conditions associated
XX CC with expression of STAT3. (I) can be used alone or with other drugs as
XX CC an immunostimulator. (I) is used in sandwich and colourimetric assays,
XX CC involving enzyme conjugation and radiolabeling and is used in
XX CC diagnostic kits. AAC93150 encodes human STAT3 and AAC93231 encodes mouse
XX CC STAT3 as given in the exemplification of the present invention. AAC93151
XX CC to AAC93230 and AAC93232 to AAC93299 represent STAT3 phosphorothioate
XX CC antisense oligonucleotides, and AAC93300 represents a mismatch control
XX CC oligonucleotide which are used in example from the present invention.
XX XX
XX SQ Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 other;

Query Match 0.8%; Score 10.4; DB 1; Length 20;
Best Local Similarity 91.7%; Pred. No. 7.7e+02;
Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 823 CTGATGCAGCTG 834
DB 9 CTGATGCAGCTG 20

RESULT 735
AAS96782
ID AAS96782 standard; DNA; 20 BP.
XX AC AAS96782;
XX XX
XX DT 26-FEB-2002 (first entry)
XX XX
XX DE Human STAT3 antisense phosphorothioate oligodeoxynucleotide #15.
XX XX
XX KW STAT3; human; signal transducer and activator of transcription; ss; STAT;
XX KW antisense gene therapy; Fas-mediated apoptosis; inflammatory disease;
XX KW autoimmune disease; rheumatoid arthritis; cancer; breast; prostate; head;
XX KW neck; brain; leukaemia; myeloma; melanoma; lymphoma; apoptosis;
XX KW antinflammatory; immunosuppressive; antirheumatic; antiarthritic;
XX KW cytostatic.
XX XX
XX OS Homo sapiens.
XX OS Synthetic.
XX XX
XX PN US2001029250-A1.

```

XX PD 11-OCT-2001.
 XX PF 11-JAN-2001; 2001US-0758881.
 XX PR 08-APR-1999; 99US-0288461.
 XX PR 06-APR-2000; 2000WO-US09054.
 XX PA (KARR/) KARRAS J G.
 XX PI Karas JG;
 XX DR WPI; 2002-009991/01.
 XX CC Novel antisense compound useful for treating and diagnosing
 PT inflammatory diseases and cancers, is targeted to a nucleic acid
 PT molecule encoding signal transducer and activator of transcription
 PT proteins -
 XX Example 2; Page 13; 21pp; English.
 XX PS The invention relates to antisense compounds targeted to a nucleic acid
 CC molecule encoding a signal transducer and activator of transcription
 CC (STAT) protein, specifically STAT3, where the antisense compounds inhibit
 CC the expression of STAT3. The antisense sequences are useful for
 CC inhibiting the expression of STAT3 in cells or tissues, inducing
 CC Fas-mediated apoptosis in cells, and sensitizing cells to apoptosis. They
 CC are also useful for treating an animal having a disease or condition
 CC associated with STAT3. These disorders include inflammatory or autoimmune
 CC disease, particularly rheumatoid arthritis, cancers, such as those of the
 CC breast, prostate, brain and head and neck and leukaemias, myelomas,
 CC melanomas and lymphomas. Also treatable are human diseases or conditions
 CC characterised by a reduction in apoptosis or an insensitivity to
 CC apoptotic signals. The sequences of the invention can be used in clinical
 CC research, for detecting and determining the role of STAT3 in various cell
 CC functions and physiological processes and for diagnosing conditions
 CC associated with the expression of STAT3. The sequences represent cDNA
 CC encoding human STAT3 and human STAT3 oligonucleotides.
 XX Sequence 20 BP; 4 A; 3 C; 8 G; 5 T; 0 other;
 Query Match 0.8%; Score 10.4; DB 1; Length 20;
 Best Local Similarity 91.7%; Pred. No. 7.7e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 823 CTGATGCAGCTG 834
 DB ||||| |||||
 9 CTGATGCAGCTG 20
 RESULT 736
 AAT84695
 ID AAT84695 standard; DNA; 21 BP.
 XX AC AAT84695;
 XX 02-JAN-1998 (first entry)
 DE KSHV DNA polymerase antisense oligonucleotide HVLOB.
 KW KSHV; gamma herpes virus; glycoprotein B; vaccine; infection;
 KW human Kaposi's sarcoma-associated herpes virus; probe; primer;
 XX DNA polymerase; ss.
 OS Synthetic.
 XX WO9712042-A2.
 XX 03-APR-1997.
 XX 26-SEP-1996; 96WO-US15702.
 XX 26-SEP-1995; 95US-0004297.

XX PA (UNIW) UNIV WASHINGTON.
 XX Bosch ML, Rose TM, Strand K;
 XX WPI; 1997-212901/19.
 XX DNA encoding glycoprotein B of retroperitoneal fibromatosis and
 PT Kaposi's sarcoma associated herpes viruses - useful in vaccines for
 PT treatment of herpes infection or for detection of viral DNA
 XX Claim 37; Page 76; 138pp; English.
 XX CC Claimed type 3 oligonucleotides (AAT84694-96) are specific
 CC non-degenerate oligonucleotides for the human Kaposi's sarcoma-
 CC associated herpes virus (KSHV) DNA polymerase (GB). They can
 CC be used for detecting, amplifying or characterising KSHV
 CC polynucleotides encoding DNA polymerase (see AAT84697).
 XX Sequence 21 BP; 3 A; 4 C; 11 G; 3 T; 0 other;
 Query Match 0.8%; Score 10.4; DB 1; Length 21;
 Best Local Similarity 91.7%; Pred. No. 7.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
 QY 522 CCTGCGCGAGGA 533
 DB ||||| |||||
 6 CCTGCTGGAGGA 17
 RESULT 737
 AAT51587
 ID AAT51587 standard; DNA; 21 BP.
 XX AC AAT51587;
 XX 06-NOV-1997 (first entry)
 DE KSHV DNA polymerase specific oligonucleotide HVLOB.
 KW Retroperitoneal fibromatosis herpes virus; detection; infection;
 KW Kaposi's sarcoma herpes virus; viral DNA; viral RNA; vaccine;
 XX antigen; antibody; ss.
 OS Synthetic.
 XX WO9704105-A1.
 XX 06-FEB-1997.
 XX 12-JUL-1996; 96WO-US11688.
 XX 11-JUL-1996; 96US-0001148.
 XX 14-JUL-1995; 95US-0001148.
 XX (UNIW) UNIV WASHINGTON.
 XX Bosch ML, Rose TM, Strand K, Todaro GJ;
 XX WPI; 1997-132644/12.
 XX Herpes virus DNA polymerase and corresponding nucleotide sequence -
 PT used in the detection and treatment of herpes virus infection
 XX Claim 26; Page 92; 132pp; English.
 XX The present sequence represents oligonucleotide HVLOB which is
 CC specific for polynucleotides encoding DNA polymerases from Kaposi's
 CC sarcoma herpes virus (KSHV). The oligonucleotide may be used for
 CC detecting viral DNA or RNA in a sample of primate origin, especially
 CC in the diagnosis of herpes viral infection. Herpes virus DNA
 CC polymerases of this invention, may be used in vaccines for the
 CC protection against infection by a herpes virus of the RFHV/KSHV

CC family. They may also be used in the design and screening of
 CC anti-viral drugs. Antibodies raised against the polymerase or
 CC fragments of it, may be used in the detection of herpes virus
 CC infection and for drug targeting for the therapy of herpes virus
 CC infection.

XX Sequence 21 BP; 3 A; 4 C; 11 G; 3 T; 0 other;

Query Match 0.8%; Score 10.4; DB 1; Length 21;
 Best Local Similarity 91.7%; Pred. No. 7.8e+02;
 Matches 11; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 522 CCTGCGGAGGA 533
 ||||| |||||
 Db 6 CTTGCTGGAGGA 17

RESULT 738

AAQ64857
 ID AAQ64857 standard; DNA; 23 BP.

XX AC AAQ64857;

XX DT 25-MAR-2003 (updated)
 DT 18-OCT-1994 (first entry)

XX DE Ig gamma chain probe gamma-CH1.

XX KW SpA domain D; Ig binding region; gamma chain; B-cell superantigen; sAg;
 KW superantigen; heavy chain variable region; VH3 restricted antibody;
 KW VH; protein-A; Vh26C; combinatorial library; B-lymphocyte;
 KW vaccine; DNA probe; hybridization; ss.

XX OS Synthetic.

XX PN W09409818-Al.

XX PD 11-MAY-1994.

XX PF 29-OCT-1993; 93WO-US10555.

XX PR 30-OCT-1992; 92US-0969936.

XX PA (REGC) UNIV CALIFORNIA.

XX PI Silverman GJ;

XX DR WPI; 1994-167127/20.

XX PT Stimulating prodn. of variable region gene family restricted
 PT antibodies - through B-cell super-antigen vaccination

XX PS Disclosure; Page 24; 130pp; English.

XX CC A B-cell superantigen (sAg) is a fragment of SpA D domain that
 CC specifically binds the Fab portion of variable region restricted
 CC antibodies. The sAg is used to enhance production of VH, especially
 CC VH3, restricted Abs. To detect Ig gamma chain expression, the
 CC antisense sequence given in AAQ64857 was used as probe. Detection of
 CC VH families used the sense oligonucleotides given in AAQ64859-60.
 CC (Updated on 25-MAR-2003 to correct PN field.)

SQ Sequence 23 BP; 4 A; 8 C; 8 G; 3 T; 0 other;

Query Match 0.8%; Score 10.4; DB 1; Length 23;
 Best Local Similarity 70.0%; Pred. No. 8e+02;
 Matches 14; Conservative 0; Mismatches 6; Indels 0; Gaps 0;

QY 704 TCCTTGATTCGTGCCAG 723
 ||||| |||||
 Db 2 TCCTTGACCGCAGCCAG 21

RESULT 739

AAF45161/c
 ID AAF45161 standard; RNA; 15 BP.

XX AC AAF45161;

XX DT 30-MAR-2001 (first entry)

XX DE Antisense oligonucleotide #10.

XX KW Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; Insulin-like Growth Factor 1 receptor; IGF-1; pityriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.

XX OS Homo sapiens.

XX PN W0200078341-Al.

XX PD 28-DEC-2000.

XX PF 21-JUN-2000; 2000WO-AU00693.

XX PR 21-JUN-1999; 98US-0140345.

XX PA (MURD-) MURDOCH CHILDRENS RES INST.

XX PI Wright CJ, Werther GA, Edmondson SR;

XX DR WPI; 2001-041421/05.

XX PT Ameliorating the effects of a disorder, e.g. psoriasis, by
 PT administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -

XX PS Claim 15; Page 115; 201pp; English.

XX CC The present invention relates to a method for ameliorating the effects of
 CC skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for insulin-like Growth factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is one such
 CC antisense oligonucleotide. The method is useful for ameliorating the
 CC effects of psoriasis, ichthyosis, pityriasis, ruba, pilaris, serborrhea,
 CC keloids, keratosis, neoplasias, scleroderma, warts, benign growths,
 CC cancers of the skin, a hyperneovascular condition such as a neovascular
 CC condition of the retina, brain or skin, growth factor-mediated
 CC malignancies, other sclerotic disease, kidney disease, hyperproliferation
 CC of the inside of blood vessels or any other hyperplasia.

SQ Sequence 15 BP; 4 A; 5 C; 6 G; 0 U; 0 other;

Query Match 0.8%; Score 10.2; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 6.8e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 729 GGGGGCTGGCTGCC 743
 ||||| |||||
 Db 15 GTGTGCTGCTGCC 1

RESULT 740

AAF49864
 ID AAF49864 standard; DNA; 15 BP.

XX AC AAF49864;

XX XX

DT 30-MAR-2001 (first entry)
 XX IGF-I oligonucleotide #824.
 XX Antisense therapy; antiproliferative; antiinflammatory; antipsoriatic;
 KW cytostatic; dermatological; cardiant; virucide; ophthalmological; keloid;
 KW skin disorder; insulin-like Growth Factor 1 receptor; IGF-1; ptyriasis;
 KW IGF binding protein; IGFBP-2; IGFBP3; inflammation; psoriasis; pilaris;
 KW growth factor mediated cell proliferation; ichthyosis; serborrhea; ruba;
 KW keratosis; neoplasia; scleroderma; wart; skin cancer; sclerotic disease;
 KW hyperneovascular condition; hyperplasia; kidney disease;
 KW neovascular condition of the retina; ss.
 XX Homo sapiens.
 OS
 XX WO200078341-A1.
 XX
 XX 28-DEC-2000.
 XX
 XX 21-JUN-2000; 2000WO-AU00693.
 XX
 XX 21-JUN-1999; 99US-0140345.
 XX (MURD-) MURDOCH CHILDRENS RES INST.
 PA
 XX Wright CJ, Werther GA, Edmondson SR;
 PI
 XX WPI; 2001-041421/05.
 DR
 XX
 XX Ameliorating the effects of a disorder, e.g. psoriasis, by
 PT administering UV (ultra-violet) treatment (optional) and an antisense
 PT nucleic acid that inhibits or reduces growth factor mediated cell
 PT proliferation and/or inflammation -
 XX
 XX Example 8; Page 66; 201pp; English.
 XX
 XX The present invention relates to a method for ameliorating the effects
 CC of skin disorders. The method comprises contacting the skin with an
 CC antisense oligonucleotide, (for Insulin-like Growth Factor [IGF]-1
 CC receptor, IGF binding protein [IGFBP]-2 or IGFBP3), which is capable of
 CC inhibiting or reducing growth factor mediated cell proliferation,
 CC inflammation and/or other disorders. The present sequence is an
 CC oligonucleotide which can be used to design the antisense
 CC oligonucleotides of the present invention (see AAF45151 and
 CC AAF45153-F45161). The method is useful for ameliorating the effects of
 CC psoriasis, ichthyosis, ptyriasis, ruba, pilaris, serborrhea, keloids,
 CC keratosis, neoplasias, scleroderma, warts, benign growths, cancers of the
 CC skin, a hyperneovascular condition such as a neovascular condition of the
 CC retina, brain or skin, growth factor-mediated malignancies, other
 CC sclerotic disease, kidney disease, hyperproliferation of the inside of
 CC blood vessels or any other hyperplasia.
 XX
 XX Sequence 15 BP; 0 A; 6 C; 5 G; 4 T; 0 other;
 SQ
 Query Match 0.8%; Score 10.2; DB 1; Length 15;
 Best Local Similarity 80.0%; Pred. No. 6.8e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 Qy 729 GGGGGCTGGTGGC 743
 Db 1 GTGTGCTGGTGGC 15
 RESULT 741
 ACA06585
 ID ACA06585 standard; RNA; 17 BP.
 XX
 XX ACA06585;
 AC
 XX
 XX 03-JUN-2003 (first entry)
 DT
 XX NFKB sub-unit modulating inozyme substrate #404.
 DE
 XX

KW Enzymatic nucleic acid; nuclear factor kappa B; NFkB; inozyme; zinzyme;
 KW G-cleaver; amberyne; cancer; REL-A activity; breast cancer; human;
 KW lung cancer; prostate cancer; colorectal cancer; brain cancer;
 KW oesophageal cancer; stomach cancer; bladder cancer; pancreatic cancer;
 KW cervical cancer; head and neck cancer; ovarian cancer; melanoma;
 KW lymphoma; glioma; multidrug resistant cancer; REL-A-specific inhibitor;
 KW chemotherapy; paclitaxel, docetaxel, cisplatin, methotrexate;
 KW cyclophosphamide; doxorubin; fluorouracil carboplatin; edatrexate;
 KW gemcitabine; radiation therapy; inflammatory disease; asthma; diabetes;
 KW rheumatoid arthritis; restenosis; Crohn's disease; obesity; ischaemia;
 KW gene therapy; autoimmune disease; lupus; multiple sclerosis; sepsis;
 KW transplant/graft rejection; reperfusion injury; glomerulonephritis;
 KW allergic airway inflammation; inflammatory bowel disease; infection;
 KW ss.
 XX
 XX Homo sapiens.
 OS
 XX US2002177568-A1.
 XX
 XX 28-NOV-2002.
 PD
 XX
 XX 23-MAY-2001; 2001US-0864785.
 XX
 XX 15-AUG-1994; 94US-0291932.
 PR
 XX 07-DEC-1992; 92US-0987132.
 PR
 XX 18-MAY-1994; 94US-0245466.
 PR
 XX 23-DEC-1996; 96US-0777916.
 PR
 XX (STIN/) STINCHOMB D T.
 PA (MCSW/) MCSWIGGEN J.
 PA (DRAP/) DRAPER K G.
 PA
 XX Stinchcomb DT, Mcswiggen J, Draper KG;
 PI
 XX WPI; 2003-340953/32.
 DR
 XX
 XX Novel enzymatic nucleic acid molecules which down regulates expression
 PT of a sequence encoding a subunit of nuclear factor kappa B useful for
 PT treating cancer, inflammatory disorders and autoimmune diseases -
 XX
 XX Claim 3; Page 33; 72pp; English.
 XX
 XX The invention describes an enzymatic nucleic acid molecule (I) which down
 CC regulates expression of a sequence encoding a subunit of nuclear factor
 CC kappa B (NFkB), where (I) is an inozyme, zinzyme, G-cleaver or amberyne
 CC configuration. The enzymatic nucleic acid molecule is adapted to treat
 CC cancer and is useful for down-regulating REL-A activity in a cell, for
 CC treating a patient having a condition associated with the level of REL-A.
 CC (I) is useful for cleaving RNA comprising a sequence of REL-A gene, in
 CC the presence of a divalent cation, especially Mg²⁺. The enzymatic and
 CC antisense nucleic acid molecules are useful for treating breast, lung,
 CC prostate, colorectal, brain, oesophageal, stomach, bladder, pancreatic,
 CC cervical, head and neck, ovarian cancer, melanoma, lymphoma, glioma or
 CC multidrug resistant cancer. The method involves use of other drug
 CC therapies such as monoclonal antibodies, REL-A-specific inhibitors or
 CC chemotherapy including paclitaxel, docetaxel, cisplatin, methotrexate,
 CC cyclophosphamide, doxorubin, fluorouracil carboplatin, edatrexate,
 CC gemcitabine or radiation therapy. The enzymatic and antisense nucleic
 CC acid molecules are also useful for treating inflammatory disease such as
 CC rheumatoid arthritis, restenosis, asthma, Crohn's disease, diabetes,
 CC obesity, autoimmune disease, lupus, multiple sclerosis, transplant/graft
 CC rejection, gene therapy applications, ischaemia/reperfusion injury
 CC (central nervous system (CNS) and myocardial), glomerulonephritis,
 CC sepsis, allergic airway inflammation, inflammatory bowel disease or
 CC infection. This sequence represents the substrate of a novel
 CC enzymatic nucleic acid molecule.
 XX
 XX Sequence 17 BP; 3 A; 6 C; 6 G; 2 U; 0 other;
 SQ
 Query Match 0.8%; Score 10.2; DB 1; Length 17;
 Best Local Similarity 80.0%; Pred. No. 7.5e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 715 GTGGCCAGCAGCAG 729
 DB 2 GAGGCCCGCAGCAG 16

RESULT 742
 AAX67028
 ID AAX67028 standard; RNA; 18 BP.
 XX
 AC AAX67028;
 XX
 DT 20-JUL-1999 (first entry)
 XX
 DE Mouse B7 hairpin ribozyme target SEQ ID NO:3660.
 XX
 KW Arthritic condition; graft tolerance; immune response; target; cleavage;
 KW hammerhead ribozyme; hairpin ribozyme; human; rabbit; mouse; collagenase;
 KW stromelysin; synovial membrane; joint; arthritis; osteoarthritis;
 KW rheumatoid arthritis; autoimmune disease; allergy; inflammation;
 KW diagnosis; ss.
 XX
 OS Mus sp.
 XX
 PN WO9618736-A2.
 XX
 PD 20-JUN-1996.
 XX
 PF 22-NOV-1995; 95WO-US15516.
 XX
 PR 05-OCT-1995; 95US-0541365.
 PR 13-DEC-1994; 94US-0354920.
 PR 23-DEC-1994; 94US-0363253.
 PR 23-DEC-1994; 94US-0363254.
 PR 17-FEB-1995; 95US-0390850.
 PR 20-APR-1995; 95US-0426124.
 PR 02-MAY-1995; 95US-0432874.
 PR 04-MAY-1995; 95US-0434509.
 PR 07-JUL-1995; 95US-0000951.
 PR 07-JUL-1995; 95US-0000974.
 PR 07-AUG-1995; 95US-0512861.
 XX
 PA (RIBO-) RIBOZYME PHARM INC.
 XX
 PI Draper K, Gustofson J, McSwiggen J, Pavco P, Stinchcomb DT;
 PI Beigelman L, Karpeisky A, Modak A, Usman N, Burgin A;
 PI Matulich-Adamic J, Jarvis T, Thompson JD, Wincott F;
 XX
 DR WPI; 1996-300653/30.
 XX
 PT Enzymatic nucleic acid molecules having a hammer-head motif - used
 PT for the treatment of arthritis, induction of graft tolerance or
 PT treatment of auto-immune diseases
 XX
 PS Claim 10; Page 215; 307pp; English.
 XX
 CC The present invention describes a novel enzymatic nucleic acid (ENA)
 CC having a hammerhead motif (HM) comprising: (i) at least 5 ribose
 CC residues; (ii) a 2'-C-allyl modification at position 4 of the ENA; (iii)
 CC at least ten 2'-O-methyl modifications; and (iv) a 3'-end modification.
 CC The ENA's can inhibit collagenase and stromelysin production in the
 CC synovial membrane of joints for the treatment or prevention of arthritis,
 CC particularly osteoarthritis or rheumatoid arthritis. The ENA's can also
 CC be used to treat antigen presenting cells of a donor to induce tolerance
 CC in a recipient to an alloantigen of a donor. They can also be used for
 CC enhancing graft tolerance or for treating autoimmune disease, and for
 CC treating allergies and other inflammatory conditions. The ENA's can also
 CC be used in diagnosis. Ribozyme therapy impacts on the expression of
 CC stromelysin without introducing the non-specific effects upon gene
 CC expression which accompany treatment with retinoids and dexamethasone.
 CC The concentration of ribozyme required to affect a therapeutic treatment
 CC is lower than that required of antisense molecules, and is highly
 CC specific. The present sequence is used in the exemplification of the
 CC present invention.

XX Sequence 18 BP; 1 A; 4 C; 4 G; 9 U; 0 other;
 SQ Query Match 0.8%; Score 10.2; DB 1; Length 18;
 Best Local Similarity 53.3%; Pred. No. 7.7e+02;
 Matches 8; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1032 TGCAGCTGACTCTTC 1046
 DB 1 UGCUCGUGAUGGUC 15

RESULT 743
 AAV57794/c
 ID AAV57794 standard; DNA; 18 BP.
 XX
 AC AAV57794;
 XX
 DT 18-NOV-1998 (first entry)
 XX
 DE Human chromosome 18 PCR mapping primer clone 47r.
 XX
 KW Manic-depressive illness; susceptibility; genotype; diagnosis;
 KW chromosomal marker; polymorphic marker; chromosome 18; human;
 KW myo-inositol monophosphatase protein; IMP-18p; PCR primer; ss.
 XX
 OS Synthetic.
 OS Homo sapiens.
 XX
 PN WO9818963-A1.
 XX
 PD 07-MAY-1998.
 XX
 PF 28-OCT-1997; 97WO-US19381.
 XX
 PR 28-OCT-1996; 96US-0029278.
 XX
 PA (USSH) US DEPT HEALTH & HUMAN SERVICES.
 XX
 PI Badner JA, Barrettini WH, Detera-Wadleigh SD, Esterling LE;
 PI Gershon ES, Goldin LR, Sanders AR, Yoshikawa T;
 XX
 DR WPI; 1998-272247/24.
 XX
 PT New isolated IMP.18p myo-inositol monophosphatase - used to develop
 PT products for determining susceptibility to manic depressive illness
 PT and as targets for preventive and therapeutic treatments
 XX
 PS Example 5; Page 71; 118pp; English.
 XX
 CC A method has been developed for determining a genotype associated with
 CC increased susceptibility to manic-depressive (MD) illness. The method
 CC comprises determining the genotype of an affected individual with at
 CC least one polymorphic marker localised within the chromosomal region
 CC defined by and including markers D18S843 and D18S869 and determining the
 CC genotype associated with increased susceptibility to MD disorder. The
 CC method can be used for determining susceptibility to MD illness
 CC including bipolar disorder, genetic counselling of individuals from
 CC families affected with MD illness, and aid in the differential diagnosis
 CC of MD illness from other psychiatric pathologies. Products from the
 CC present invention can also be used to obtain modulators of IMP.18p myo-
 CC inositol monophosphatase protein activity and as targets for preventive
 CC and therapeutic treatments. The present sequence represents a PCR primer
 CC used in the mapping of human chromosome 18 for determining the genotype
 CC of MD illness susceptibility, used in an example from the present
 CC invention.
 XX
 SQ Sequence 18 BP; 2 A; 4 C; 4 G; 8 T; 0 other;
 Query Match 0.8%; Score 10.2; DB 1; Length 18;
 Best Local Similarity 80.0%; Pred. No. 7.7e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

PN W09852976-A1.
 XX
 PD 26-NOV-1998.
 XX
 XX
 PF 21-MAY-1998; 98WO-GB01473.
 XX
 XX 14-APR-1998; 98GB-0007751.
 PR 21-MAY-1997; 97GB-0010480.
 PR 31-JUL-1997; 97GB-0016197.
 PR 28-NOV-1997; 97GB-0025270.
 PR 02-DEC-1997; 97US-0067235.
 XX
 PA (BIOV-) BIOVATION LTD.
 XX
 XX Carr RJ;
 PI
 DR WP1; 1999-045301/04.
 XX
 XX Reducing immunogenicity of proteins - by modifying the amino acid
 PT sequence of the protein to eliminate potential epitopes for T-cells
 PT of a given species
 XX
 PS Example 3; Fig 16; 77pp; English.
 XX
 CC The invention relates to a method for the production of non-immunogenic
 CC proteins. The method comprises determining at least part of the amino
 CC acid sequence of the protein; (b) identifying in the amino acid sequence
 CC one or more potential epitopes for T-cells (T-cell epitopes) of the
 CC given species; and (c) modifying the amino acid sequence to eliminate at
 CC least one of the T-cell epitopes identified in step (b) thereby to
 CC eliminate or reduce the immunogenicity of the protein when exposed to the
 CC immune system of the given species. A method of analysing a pre-existing
 CC protein to predict the basis for immunogenic responses is also provided.
 CC The methods can be used particularly for reducing the immunogenicity of
 CC immunoglobulins or therapeutic proteins, e.g. Streptokinase (SK). The
 CC products can be used for diagnosis and therapy. Sequences AAV81047-68
 CC represent oligonucleotides used for the construction of de-immunised 708
 CC Vh and Vk.
 XX
 SQ Sequence 18 BP; 2 A; 5 C; 4 G; 7 T; 0 other;
 Query Match 0.8%; Score 10.2; DB 1; Length 18;
 Best Local Similarity 80.0%; Pred. No. 7.7e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 1026 CCAGAGTCAGCTGA 1040
 ||||| |||||
 DB 17 CCAGCTGGAGCTGA 3
 RESULT 747
 AAV51978/c
 ID AAV51978 standard; DNA; 19 BP.
 XX
 AC AAV51978;
 XX
 DT 02-FEB-1999 (first entry)
 XX
 DE Zea mays genome reverse PCR primer #274.
 XX
 KW Polymorphic marker; allele-specific; probe; amplification; PCR primer;
 KW hybridisation; plant; hybrid certification; genetic contribution;
 KW progeny; back-cross; hybrid; ancestry; corn; ss.
 XX
 OS Synthetic.
 OS Zea mays.
 XX
 PN W09824796-A1.
 XX
 PD 11-JUN-1998.
 XX
 PF 02-FEB-1999 (first entry)
 XX
 DE Zea mays genome reverse PCR primer #274.
 XX
 KW Polymorphic marker; allele-specific; probe; amplification; PCR primer;
 KW hybridisation; plant; hybrid certification; genetic contribution;
 KW progeny; back-cross; hybrid; ancestry; corn; ss.
 XX
 OS Synthetic.
 OS Zea mays.
 XX
 PN W09824796-A1.
 XX
 PD 11-JUN-1998.
 XX
 PF 01-DEC-1997; 97WO-US21782.
 XX
 XX

PR 07-MAR-1997; 97US-0813507.
 PR 02-DEC-1996; 96US-0032069.
 XX
 PA (AFFY-) AFFYMETRIX INC.
 XX
 PI Landry BS, Lemieux B, Murigneux A, Sapolsky RJ;
 XX
 XX WPI; 1998-333252/29.
 DR
 XX Brassica species allele-specific oligonucleotide probes and primers
 PT - useful for plant breeding
 PT
 XX Example 1; Page Page 54; 65pp; English.
 PS
 XX AAV51705-V52008 are reverse PCR primers used to amplify fragments of the
 CC Zea mays genome in order to detect polymorphic markers. Such markers can
 CC be used in the construction of allele-specific primers and probes for
 CC amplification or hybridisation, e.g. to determine common or disparate
 CC ancestry between 2 or more plants, to monitor the genetic contribution
 CC of an ancestral plant, to trace the progeny of proprietary plants, in
 CC certification of a hybrid plant or to identify the progeny of a
 CC back-crossed plant with an ancestral plant.
 XX
 SQ Sequence 19 BP; 5 A; 6 C; 7 G; 1 T; 0 other;
 Query Match 0.8%; Score 10.2; DB 1; Length 19;
 Best Local Similarity 80.0%; Pred. No. 8e+02; 3; Indels 0; Gaps 0;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
 QY 729 GCGGCGCTGGCTGCC 743
 ||||| |||||
 DB 15 GCGTGGCTGGCTGCC 1
 RESULT 748
 AAV51979/c
 ID AAV51979 standard; DNA; 19 BP.
 XX
 AC AAV51979;
 XX
 DT 02-FEB-1999 (first entry)
 XX
 DE Zea mays genome reverse PCR primer #275.
 XX
 KW Polymorphic marker; allele-specific; probe; amplification; PCR primer;
 KW hybridisation; plant; hybrid certification; genetic contribution;
 KW progeny; back-cross; hybrid; ancestry; corn; ss.
 XX
 OS Synthetic.
 OS Zea mays.
 XX
 PN W09824796-A1.
 XX
 PD 11-JUN-1998.
 XX
 PF 01-DEC-1997; 97WO-US21782.
 XX
 PR 07-MAR-1997; 97US-0813507.
 PR 02-DEC-1996; 96US-0032069.
 XX
 PA (AFFY-) AFFYMETRIX INC.
 XX
 PI Landry BS, Lemieux B, Murigneux A, Sapolsky RJ;
 XX
 XX WPI; 1998-333252/29.
 DR
 XX Brassica species allele-specific oligonucleotide probes and primers
 PT - useful for plant breeding
 PT
 XX Example 1; Page Page 54; 65pp; English.
 PS
 XX AAV51705-V52008 are reverse PCR primers used to amplify fragments of the
 CC Zea mays genome in order to detect polymorphic markers. Such markers can

CC be used in the construction of allele-specific primers and probes for
 CC amplification or hybridisation, e.g. to determine common or disparate
 CC ancestry between 2 or more plants, to monitor the genetic contribution
 CC of an ancestral plant, to trace the progeny of proprietary plants, in
 CC certification of a hybrid plant or to identify the progeny of a
 CC back-crossed plant with an ancestral plant.
 XX
 SQ Sequence 19 BP; 5 A; 6 C; 7 G; 1 T; 0 other;

Query Match 0.8%; Score 10.2; DB 1; Length 19;
 Best Local Similarity 80.0%; Pred. No. 8e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 729 GGGGCGCTGGTGGC 743
 Db 15 GCGTGCCTGCGCTGCC 1

RESULT 749

AAT39478
 ID AAT39478 standard; DNA; 20 BP.

XX AAT39478;

XX 21-MAY-1997 (first entry)

XX Steroidogenesis acute regulatory protein antisense PCR primer 2.

XX Human; steroidogenesis; acute regulatory protein; hSTAR; analysis;
 KW mutation; detection; prenatal; genetic defect; congenital; protein;
 KW lipid adrenal hyperplasia; treatment; prevention; gene;
 KW replacement therapy; hypercholesterolaemia; primer; PCR;
 KW polymerase chain reaction; ss.

XX Synthetic.

XX WO9629338-A1.

XX 26-SEP-1996.

XX 22-MAR-1996; 96WO-US03896.

XX 23-MAR-1995; 95US-0410540.

XX (REGC) UNIV CALIFORNIA.

XX (UTPE-) UNIV PENNSYLVANIA.

XX Lin D, Miller WL, Strauss JF;

XX WPI; 1996-443130/44.

XX Isolated human steroidogenesis acute regulatory protein gene - used
 PT for detection of mutation(s) of this gene that cause congenital
 PT lipid adrenal hyperplasia

XX Example 7; Page 4; 89pp; English.

XX The present sequence is a PCR primer (nt 717-738) for the human
 CC steroidogenesis acute regulatory protein (hSTAR) cDNA. The hSTAR
 CC gene can be analysed for mutations to detect (e.g. prenatally)
 CC genetic defects associated with congenital lipid adrenal
 CC hyperplasia (CAH), or its transmission to children. CAH can be
 CC treated by protein or gene replacement therapy, which can also be
 CC used to prevent or treat hypercholesterolaemia.
 CC A human adrenal cortex cDNA library was screened with a mouse STAR
 CC probe to isolate a 1.6 kb insert, including an ORF for a 285
 CC residue protein. When it was cloned into pSPORT and expressed in
 CC COS-1 cells cotransfected with pp450scd and pADX, it increased the
 CC level of pregnenolone synthesis from cholesterol or
 CC 20-alpha-hydroxycholesterol.

XX Sequence 20 BP; 4 A; 7 C; 6 G; 3 T; 0 other;

Query Match 0.8%; Score 10.2; DB 1; Length 20;
 Best Local Similarity 80.0%; Pred. No. 8.1e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1246 GTGCCCATTGTGAGGC 1260
 Db 2 GTGCCCATTGCCAGCC 16

RESULT 750

AAT99084
 ID AAT99084 standard; DNA; 20 BP.

XX AAT99084;

XX 24-MAR-1998 (first entry)

XX Primer alphaEN-S2 for alphaENAC coding sequence.

XX Alpha epithelial sodium channel; alphaENACa; alphaENACb; binding assay;
 KW amiloride-sensitive salt channel alpha subunit; membrane-transport;
 KW salt substitute; salty taste blocker; PCR primer; amplify; ss.

XX Synthetic.

XX Rattus rattus.

XX US5693756-A.

XX 02-DEC-1997.

XX 23-JAN-1995; 95US-0376362.

XX 23-JAN-1995; 95US-0376362.

XX 28-FEB-1994; 94US-0202654.

XX (UVJO) UNIV JOHNS HOPKINS.

XX Blackshaw S, Li X, Snyder SH;

XX WPI; 1998-031814/03.

XX Alternatively spliced epithelial sodium channel alpha subunit
 PT proteins - useful in screening assays for salty taste enhancers or
 PT blockers

XX Disclosure; Column 9; 33pp; English.

XX This sequence represents a primer for the coding sequence for the alpha
 CC epithelial sodium channel a (alphaENACa). AlphaENACa (see AAM34529) and
 CC alphaENACb (see AAM34530) represent the sequences of the invention. The
 CC two sodium channels are alternatively spliced forms of the
 CC amiloride-sensitive salt channel alpha subunit and can be used in
 CC membrane-transport or binding assays to identify substances that enhance
 CC or block perception of a salty taste. Enhancers could be used as salt
 CC substitutes and blockers could be used to mask salty tastes in foods and
 CC pharmaceuticals.

XX Sequence 20 BP; 3 A; 5 C; 7 G; 5 T; 0 other;

Query Match 0.8%; Score 10.2; DB 1; Length 20;
 Best Local Similarity 80.0%; Pred. No. 8.1e+02;
 Matches 12; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 629 AGCTCCAGGAGCTCT 643
 Db 4 AGCTCCTGGGCTAT 18

Search completed: January 8, 2004, 16:40:18
 Job time : 26 secs

GenCore version 5.1.6
Copyright (c) 1993 - 2004 Compugen Ltd.

OM nucleic - nucleic search, using sw model

Run on: January 8, 2004, 16:43:28 ; Search time 13 Seconds
(without alignments)
1.953 Million cell updates/sec

Title: us-09-904-568-3
Perfect score: 1355
Sequence: 1 gggcaggcagttgaggtgga.....gtgttcaggcaggccggcgg 1355

Scoring table: IDENTITY NUC
Gapop 10.0 , Gapext 0.5

Searched: 541 seqs, 9368 residues

Total number of hits satisfying chosen parameters: 1082

Minimum DB seq length: 12
Maximum DB seq length: 50

Post-processing: Minimum Match 0%
Maximum Match 100%
Listing first 550 summaries

Database : rni3.seq.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

Result No.	Score	Query Match %	Length	ID	Description
1	22	1.6	22	1	US-09-302-681-65
2	17.8	1.3	21	1	US-09-667-135-7
3	17.6	1.3	24	1	US-08-249-037C-16
4	17.6	1.3	24	1	US-08-788-622B-16
5	17.6	1.3	24	1	US-08-788-621B-16
6	16.8	1.2	21	1	US-08-052-997-22
7	16.8	1.2	21	1	US-08-684-672-22
8	16.4	1.2	18	1	US-09-244-794A-29
9	16.4	1.2	18	1	US-09-007-005-29
10	16.4	1.2	18	1	US-09-247-190-29
11	16.4	1.2	18	1	US-09-244-796-29
12	16.4	1.2	18	1	US-09-238-710-29
13	16.2	1.2	21	1	US-09-302-681-76
14	16.2	1.2	23	1	US-08-709-731A-5
15	15.8	1.2	20	1	US-09-136-959A-6
16	15.8	1.2	20	1	US-09-556-031-2
17	15.8	1.2	20	1	US-09-702-246-25
18	15.8	1.2	20	1	US-09-322-624-19
19	15.8	1.2	21	1	US-09-422-978-10530
20	15.4	1.1	21	1	US-09-422-978-11451
21	15.4	1.1	21	1	US-08-680-326-140
22	15.4	1.1	21	1	US-08-804-439A-89
23	15.4	1.1	21	1	US-08-720-229-89
24	15.2	1.1	20	1	US-07-977-284A-89
25	15.2	1.1	20	1	US-08-410-540-8
26	15.2	1.1	20	1	US-08-256-426B-89
27	15.2	1.1	20	1	US-09-661-753-55
28	15.2	1.1	20	1	US-09-470-443-33
29	15.2	1.1	20	1	US-09-470-443-43
30	15.2	1.1	20	1	US-09-659-845A-168
31	15.2	1.1	20	1	US-09-198-452A-1582
32	15.2	1.1	20	1	US-09-198-452A-3952
33	15.2	1.1	21	1	US-08-276-852-49
34	15.2	1.1	21	1	US-08-162-102C-30
35	15.2	1.1	21	1	US-08-899-575-49
36	15.2	1.1	21	1	US-08-899-575-49
37	15.2	1.1	21	1	US-07-974-409C-137
38	15.2	1.1	21	1	US-08-635-109-21
39	15.2	1.1	21	1	PCT-US93-00977-137
40	15.2	1.1	21	1	PCT-US95-00743-49
41	15	1.1	15	1	US-09-081-646-727
42	14.8	1.1	18	1	US-08-585-684B-2539
43	14.8	1.1	18	1	US-09-038-073-2539
44	14.8	1.1	19	1	US-08-630-592-14
45	14.8	1.1	19	1	US-08-714-991-14
46	14.8	1.1	19	1	US-09-032-365A-26
47	14.8	1.1	20	1	US-08-623-891-3
48	14.8	1.1	20	1	US-09-286-904-42
49	14.8	1.1	20	1	US-09-742-703-11
50	14.8	1.1	20	1	US-09-340-861-3
51	14.8	1.1	20	1	US-09-634-262-3
52	14.8	1.1	20	1	US-09-640-101-42
53	14.8	1.1	21	1	US-09-099-053-19
54	14.4	1.1	17	1	US-09-359-921-27
55	14.4	1.1	18	1	US-09-178-115-113
56	14.4	1.1	18	1	US-09-177-776-113
57	14.4	1.1	20	1	US-08-376-362A-8
58	14.4	1.1	20	1	US-08-634-331-3
59	14.4	1.1	20	1	US-08-450-905B-134
60	14.4	1.1	20	1	US-07-982-759F-134
61	14.4	1.1	20	1	US-09-280-805-48
62	14.4	1.1	20	1	US-09-150-460B-2
63	14.4	1.1	20	1	US-09-228-942-7
64	14.4	1.1	20	1	US-09-517-467B-240
65	14.2	1.0	19	1	US-08-246-489-7
66	14.2	1.0	20	1	US-08-033-081B-18
67	14.2	1.0	20	1	US-08-117-952-417
68	14.2	1.0	20	1	US-09-048-880-11
69	14.2	1.0	20	1	US-08-991-300-4
70	14.2	1.0	20	1	US-08-715-461-4
71	14.2	1.0	20	1	US-08-755-587-59
72	14.2	1.0	20	1	US-09-287-796-123
73	14.2	1.0	20	1	US-09-288-461-16
74	14.2	1.0	20	1	US-09-488-671-52
75	14.2	1.0	20	1	US-09-288-461-68
76	14.2	1.0	20	1	US-09-130-616-23
77	14.2	1.0	20	1	US-09-270-542-155
78	14.2	1.0	20	1	US-09-851-062-47
79	14.2	1.0	20	1	US-09-920-672-52
80	14.2	1.0	20	1	US-09-527-073-4
81	14.2	1.0	20	1	US-09-422-978-6216
82	14.2	1.0	20	1	US-03-422-978-11618
83	14.2	1.0	20	1	US-09-230-652-103
84	14.2	1.0	20	1	US-08-843-376-62
85	14	1.0	19	1	US-08-679-529-6
86	14	1.0	19	1	PCT-US91-03680-3
87	14	1.0	20	1	US-08-921-426-14
88	14	1.0	20	1	US-08-816-915-14
89	14	1.0	20	1	US-08-816-239-2
90	14	1.0	20	1	US-09-405-564-2
91	14	1.0	20	1	US-09-309-317-7
92	14	1.0	20	1	US-09-422-978-7294
93	14	1.0	20	1	US-03-705-390-2
94	14	1.0	20	1	PCT-US95-07743-14
95	13.8	1.0	17	1	US-08-531-747-4
96	13.8	1.0	17	1	US-08-373-124A-2029
97	13.8	1.0	17	1	US-08-531-749-4
98	13.8	1.0	17	1	US-08-781-432-4
99	13.8	1.0	17	1	US-08-435-628-2029
100	13.8	1.0	17	1	US-08-985-162-17
101	13.8	1.0	17	1	US-08-985-162-645
102	13.8	1.0	17	1	US-08-964-020-2
103	13.8	1.0	17	1	US-09-474-432B-684
104	13.8	1.0	17	1	US-08-585-684B-2548
105	13.8	1.0	18	1	US-08-702-105A-33
106	13.8	1.0	18	1	US-08-702-110A-33

Sequence 30, Appl
Sequence 49, Appl
Sequence 49, Appl
Sequence 137, Appl
Sequence 21, Appl
Sequence 137, Appl
Sequence 49, Appl
Sequence 2539, Ap
Sequence 2539, Ap
Sequence 14, Appl
Sequence 14, Appl
Sequence 26, Appl
Sequence 3, Appl
Sequence 42, Appl
Sequence 19, Appl
Sequence 27, Appl
Sequence 113, Appl
Sequence 113, Appl
Sequence 8, Appl
Sequence 3, Appl
Sequence 134, App
Sequence 134, App
Sequence 48, Appl
Sequence 2, Appl
Sequence 7, Appl
Sequence 7, Appl
Sequence 16, Appl
Sequence 68, Appl
Sequence 52, Appl
Sequence 123, App
Sequence 155, App
Sequence 47, Appl
Sequence 52, Appl
Sequence 4, Appl
Sequence 6216, Ap
Sequence 11618, A
Sequence 103, App
Sequence 62, Appl
Sequence 6, Appl
Sequence 3, Appl
Sequence 14, Appl
Sequence 14, Appl
Sequence 2, Appl
Sequence 2, Appl
Sequence 7294, Ap
Sequence 2, Appl
Sequence 14, Appl
Sequence 4, Appl
Sequence 2029, Ap
Sequence 4, Appl
Sequence 645, App
Sequence 2, Appl
Sequence 684, App
Sequence 2548, Ap
Sequence 33, Appl
Sequence 33, Appl

C 107	13.8	1.0	18	1	US-09-038-073-2548	Sequence 2548, Ap	C 180	13.2	1.0	20	1	US-07-982-759F-134	Sequence 134, App
C 108	13.8	1.0	18	1	US-09-325-571-33	Sequence 33, Appl	181	13	1.0	15	1	US-08-291-932A-311	Sequence 311, App
C 109	13.8	1.0	18	1	US-09-630-706-86	Sequence 86, Appl	182	13	1.0	17	1	US-08-152-313-111	Sequence 111, App
C 110	13.8	1.0	18	1	US-08-679-645-583	Sequence 583, Appl	183	13	1.0	17	1	US-08-250-740-23	Sequence 23, Appl
C 111	13.8	1.0	18	1	US-08-535-249-98	Sequence 98, Appl	184	13	1.0	17	1	US-08-579-223-111	Sequence 111, App
C 112	13.8	1.0	18	1	US-09-091-952A-193	Sequence 193, Appl	185	13	1.0	17	1	US-07-695-472B-29	Sequence 29, Appl
C 113	13.8	1.0	18	1	US-09-422-978-4727	Sequence 4727, Ap	C 186	13	1.0	17	1	US-08-985-162-4	Sequence 4, Appl
C 114	13.8	1.0	19	1	US-07-741-940-49	Sequence 49, Appl	187	13	1.0	17	1	US-09-106-375-29	Sequence 29, Appl
C 115	13.8	1.0	19	1	US-08-289-548A-49	Sequence 49, Appl	188	13	1.0	17	1	PCT-US94-12947A-111	Sequence 111, App
C 116	13.8	1.0	19	1	US-08-452-654-49	Sequence 49, Appl	C 189	13	1.0	18	1	US-08-469-802B-13	Sequence 13, Appl
C 117	13.8	1.0	19	1	US-08-452-655B-49	Sequence 49, Appl	190	13	1.0	18	1	US-08-267-803B-31	Sequence 31, Appl
C 118	13.8	1.0	19	1	US-08-468-037A-33	Sequence 33, Appl	C 191	13	1.0	18	1	US-08-405-905B-135	Sequence 135, App
C 119	13.8	1.0	19	1	US-08-471-973A-33	Sequence 33, Appl	192	13	1.0	18	1	US-09-205-860-29	Sequence 29, Appl
C 120	13.8	1.0	19	1	US-08-465-880-28	Sequence 28, Appl	C 193	13	1.0	18	1	US-07-982-759F-135	Sequence 135, App
C 121	13.8	1.0	19	1	US-09-035-357-33	Sequence 33, Appl	C 194	13	1.0	18	1	PCT-US91-03680-4	Sequence 4, Appl
C 122	13.8	1.0	19	1	US-08-450-582-49	Sequence 49, Appl	195	13	1.0	18	1	PCT-US91-03680-5	Sequence 5, Appl
C 123	13.8	1.0	19	1	US-09-016-520-4	Sequence 4, Appl	C 196	13	1.0	18	1	PCT-US95-04094-19	Sequence 19, Appl
C 124	13.8	1.0	19	1	US-09-144-611-12	Sequence 12, Appl	C 197	13	1.0	16	1	US-09-364-539-10	Sequence 10, Appl
C 125	13.8	1.0	19	1	US-09-130-973-4	Sequence 4, Appl	198	12.8	0.9	16	1	US-09-371-772B-5925	Sequence 5925, Ap
C 126	13.8	1.0	19	1	US-09-477-902-4	Sequence 12, Appl	199	12.8	0.9	16	1	US-08-373-124A-420	Sequence 420, App
C 127	13.8	1.0	19	1	US-09-315-886C-32	Sequence 32, Appl	200	12.8	0.9	17	1	US-08-373-124A-2031	Sequence 2031, Ap
C 128	13.8	1.0	19	1	US-09-453-514B-12	Sequence 12, Appl	201	12.8	0.9	17	1	US-08-758-306-655	Sequence 655, App
C 129	13.8	1.0	19	1	US-09-335-202-33	Sequence 33, Appl	202	12.8	0.9	17	1	US-08-758-306-721	Sequence 721, App
C 130	13.8	1.0	19	1	US-08-449-731-49	Sequence 49, Appl	203	12.8	0.9	17	1	US-08-435-628-420	Sequence 420, App
C 131	13.8	1.0	19	1	US-08-802-331-29	Sequence 29, Appl	204	12.8	0.9	17	1	US-08-435-628-2031	Sequence 2031, Ap
C 132	13.8	1.0	19	1	US-09-375-318-29	Sequence 29, Appl	205	12.8	0.9	17	1	US-08-292-620A-1727	Sequence 1727, Ap
C 133	13.8	1.0	19	1	US-09-375-318-43	Sequence 43, Appl	C 206	12.8	0.9	17	1	US-08-292-620A-1937	Sequence 1937, Ap
C 134	13.8	1.0	19	1	US-09-389-283-33	Sequence 33, Appl	C 207	12.8	0.9	17	1	US-08-765-783A-79	Sequence 79, Appl
C 135	13.6	1.0	21	1	US-09-302-681-76	Sequence 76, Appl	208	12.8	0.9	17	1	US-08-985-163-452	Sequence 452, App
C 136	13.4	1.0	15	1	US-08-322-021-49	Sequence 49, Appl	209	12.8	0.9	17	1	US-09-071-845-1727	Sequence 1727, Ap
C 137	13.4	1.0	17	1	US-08-445-515-37	Sequence 37, Appl	C 210	12.8	0.9	17	1	US-09-071-845-1937	Sequence 1937, Ap
C 138	13.4	1.0	17	1	US-09-296-243-493	Sequence 493, App	C 211	12.8	0.9	17	1	US-09-416-557-79	Sequence 79, Appl
C 139	13.4	1.0	17	1	US-09-371-772B-5187	Sequence 5187, Ap	C 212	12.8	0.9	17	1	US-08-584-040-4374	Sequence 4374, Ap
C 140	13.4	1.0	18	1	US-08-585-684B-2595	Sequence 2595, Ap	C 213	12.8	0.9	17	1	US-08-679-645-886	Sequence 886, App
C 141	13.4	1.0	18	1	US-09-213-768-47	Sequence 47, Appl	214	12.8	0.9	17	1	US-09-474-432B-388	Sequence 388, App
C 142	13.4	1.0	18	1	US-09-205-921-18	Sequence 18, Appl	215	12.8	0.9	17	1	US-09-371-772B-3707	Sequence 3707, Ap
C 143	13.4	1.0	18	1	US-09-205-921-11	Sequence 11, Appl	216	12.8	0.9	17	1	US-09-371-772B-4175	Sequence 4175, Ap
C 144	13.4	1.0	18	1	US-09-038-073-2595	Sequence 2595, Ap	C 217	12.8	0.9	17	1	US-08-219-843-85	Sequence 85, Appl
C 145	13.4	1.0	18	1	US-09-632-580A-34	Sequence 34, Appl	C 218	12.8	0.9	17	1	US-08-363-240A-1187	Sequence 1187, Ap
C 146	13.4	1.0	19	1	US-07-834-539A-8	Sequence 8, Appl	219	12.8	0.9	18	1	US-08-451-096-52	Sequence 52, Appl
C 147	13.4	1.0	19	1	US-08-053-131-16	Sequence 16, Appl	220	12.8	0.9	18	1	US-08-800-751-39	Sequence 39, Appl
C 148	13.4	1.0	19	1	US-08-845-641-16	Sequence 16, Appl	221	12.8	0.9	18	1	US-08-800-751-40	Sequence 40, Appl
C 149	13.4	1.0	19	1	US-07-853-408B-16	Sequence 16, Appl	222	12.8	0.9	18	1	US-08-758-306-971	Sequence 971, App
C 150	13.4	1.0	19	1	US-08-096-762-16	Sequence 16, Appl	223	12.8	0.9	18	1	US-08-990-818-39	Sequence 39, Appl
C 151	13.4	1.0	19	1	US-08-308-865-16	Sequence 16, Appl	224	12.8	0.9	18	1	US-09-205-144-34	Sequence 34, Appl
C 152	13.4	1.0	19	1	US-08-308-865-16	Sequence 16, Appl	C 225	12.8	0.9	18	1	US-09-189-583-18	Sequence 18, Appl
C 153	13.4	1.0	19	1	US-09-042-353-184	Sequence 184, App	C 226	12.8	0.9	18	1	US-08-413-740A-85	Sequence 85, Appl
C 154	13.4	1.0	19	1	US-08-758-417A-32	Sequence 32, Appl	227	12.8	0.9	18	1	US-08-411-098-35	Sequence 35, Appl
C 155	13.4	1.0	19	1	PCT-US92-06185-8	Sequence 9, Appl	228	12.8	0.9	18	1	US-08-990-818-40	Sequence 40, Appl
C 156	13.4	1.0	19	1	US-07-517-467B-9	Sequence 9, Appl	229	12.8	0.9	18	1	US-09-205-144-34	Sequence 34, Appl
C 157	13.4	1.0	19	1	PCT-US92-10983-16	Sequence 16, Appl	230	12.8	0.9	18	1	US-08-413-740A-28	Sequence 28, Appl
C 158	13.2	1.0	18	1	US-07-759-841C-2	Sequence 2, Appl	231	12.8	0.9	18	1	US-08-880-557-18	Sequence 18, Appl
C 159	13.2	1.0	18	1	US-07-759-841C-3	Sequence 3, Appl	232	12.8	0.9	18	1	US-08-990-818-39	Sequence 39, Appl
C 160	13.2	1.0	18	1	US-09-339-964-33	Sequence 33, Appl	233	12.8	0.9	18	1	US-08-990-818-40	Sequence 40, Appl
C 161	13.2	1.0	18	1	US-09-339-993-23	Sequence 23, Appl	234	12.8	0.9	18	1	US-09-205-144-34	Sequence 34, Appl
C 162	13.2	1.0	18	1	US-09-073-465-7	Sequence 7, Appl	235	12.8	0.9	18	1	US-09-189-583-18	Sequence 18, Appl
C 163	13.2	1.0	18	1	US-09-339-775-31	Sequence 31, Appl	236	12.8	0.9	18	1	US-08-413-740A-85	Sequence 85, Appl
C 164	13.2	1.0	18	1	US-09-199-859-14	Sequence 14, Appl	237	12.8	0.9	18	1	US-08-584-040-3044	Sequence 3044, Ap
C 165	13.2	1.0	18	1	US-08-795-430-31	Sequence 31, Appl	238	12.8	0.9	18	1	US-08-584-040-8378	Sequence 8378, Ap
C 166	13.2	1.0	18	1	US-09-487-444-10	Sequence 10, Appl	239	12.8	0.9	18	1	US-08-679-645-609	Sequence 609, App
C 167	13.2	1.0	18	1	US-09-338-907-354	Sequence 354, App	C 240	12.8	0.9	18	1	US-08-679-645-629	Sequence 629, App
C 168	13.2	1.0	18	1	US-09-218-207-354	Sequence 218, App	241	12.8	0.9	18	1	US-08-614-151-51	Sequence 51, Appl
C 169	13.2	1.0	18	1	US-08-584-040-2983	Sequence 2983, Ap	242	12.8	0.9	18	1	US-09-920-760-14	Sequence 14, Appl
C 170	13.2	1.0	18	1	US-08-584-040-4454	Sequence 4454, Ap	243	12.8	0.9	18	1	US-09-077-619-17	Sequence 17, Appl
C 171	13.2	1.0	18	1	US-08-584-040-8393	Sequence 8393, Ap	244	12.8	0.9	18	1	US-09-422-978-7504	Sequence 7504, Ap
C 172	13.2	1.0	18	1	US-09-355-700-31	Sequence 31, Appl	245	12.8	0.9	18	1	US-09-422-978-11175	Sequence 11175, A
C 173	13.2	1.0	18	1	US-08-167-109-8	Sequence 8, Appl	246	12.8	0.9	18	1	US-09-742-373-6	Sequence 6, Appl
C 174	13.2	1.0	18	1	US-08-275-951-33	Sequence 33, Appl	247	12.8	0.9	18	1	US-09-371-772B-1472	Sequence 1472, Ap
C 175	13.2	1.0	18	1	US-09-422-978-6039	Sequence 6039, Ap	248	12.8	0.9	18	1	US-09-371-772B-4034	Sequence 4034, Ap
C 176	13.2	1.0	18	1	US-09-371-772B-1411	Sequence 1411, Ap	249	12.8	0.9	18	1	PCT-US93-12600-16	Sequence 16, Appl
C 177	13.2	1.0	18	1	US-09-371-772B-2167	Sequence 2167, Ap	250	12.8	0.9	18	1	PCT-US95-04063-28	Sequence 28, Appl
C 178	13.2	1.0	18	1	US-09-371-772B-4049	Sequence 4049, Ap	251	12.8	0.9	18	1	5182195-70	Patent No. 5182195
C 179	13.2	1.0	20	1	US-08-450-905B-134	Sequence 134, App	C 252	12.8	0.9	18	1		

C 253	12.6	0.9	15	1	US-08-882-649A-7	Sequence 7, Appl	Sequence 7, Appl	326	12.2	0.9	17	1	US-08-444-733-104	Sequence 104, App
C 254	12.6	0.9	14	1	US-09-661-753-55	Sequence 55, Appl	Sequence 55, Appl	C 327	12.2	0.9	17	1	US-08-710-134-49	Sequence 49, Appl
C 255	12.4	0.9	20	1	US-08-832-021-15	Sequence 15, Appl	Sequence 15, Appl	C 328	12.2	0.9	17	1	US-08-292-620A-1644	Sequence 1644, Ap
C 256	12.4	0.9	14	1	US-08-985-162-1842	Sequence 1842, Ap	Sequence 1842, Ap	C 329	12.2	0.9	17	1	US-08-292-620A-1697	Sequence 1697, Ap
C 257	12.4	0.9	14	1	US-08-724-466B-12	Sequence 12, Appl	Sequence 12, Appl	C 330	12.2	0.9	17	1	US-08-292-620A-1700	Sequence 1700, Ap
C 258	12.4	0.9	14	1	US-08-882-164D-12	Sequence 12, Appl	Sequence 12, Appl	C 331	12.2	0.9	17	1	US-08-292-620A-1707	Sequence 1707, Ap
C 259	12.4	0.9	14	1	US-08-319-492B-23	Sequence 23, Appl	Sequence 23, Appl	C 332	12.2	0.9	17	1	US-08-292-620A-1743	Sequence 1743, Ap
C 260	12.4	0.9	15	1	US-08-863-639A-7	Sequence 7, Appl	Sequence 7, Appl	C 333	12.2	0.9	17	1	US-08-292-620A-1796	Sequence 1796, Ap
C 261	12.4	0.9	15	1	US-08-832-021-50	Sequence 50, Appl	Sequence 50, Appl	C 334	12.2	0.9	17	1	US-08-292-620A-1873	Sequence 1873, Ap
C 262	12.4	0.9	15	1	US-08-832-021-51	Sequence 51, Appl	Sequence 51, Appl	C 335	12.2	0.9	17	1	US-08-292-620A-1873	Sequence 1873, Ap
C 263	12.4	0.9	15	1	US-08-832-021-52	Sequence 52, Appl	Sequence 52, Appl	C 336	12.2	0.9	17	1	US-08-485-885-49	Sequence 49, Appl
C 264	12.4	0.9	15	1	US-08-275-951-31	Sequence 31, Appl	Sequence 31, Appl	C 337	12.2	0.9	17	1	US-08-464-134-104	Sequence 104, App
C 265	12.4	0.9	16	1	US-08-087-387-6	Sequence 6, Appl	Sequence 6, Appl	C 338	12.2	0.9	17	1	US-08-461-361-104	Sequence 104, App
C 266	12.4	0.9	16	1	US-08-061-697-23	Sequence 23, Appl	Sequence 23, Appl	C 339	12.2	0.9	17	1	US-08-485-910-104	Sequence 104, App
C 267	12.4	0.9	16	1	US-08-131-365B-23	Sequence 23, Appl	Sequence 23, Appl	C 340	12.2	0.9	17	1	US-08-474-450A-62	Sequence 62, Appl
C 268	12.4	0.9	16	1	US-08-455-627-6	Sequence 6, Appl	Sequence 6, Appl	C 341	12.2	0.9	17	1	US-08-798-738-10	Sequence 10, Appl
C 269	12.4	0.9	16	1	US-08-284-484A-4	Sequence 4, Appl	Sequence 4, Appl	C 342	12.2	0.9	17	1	US-08-484-661A-17	Sequence 17, Appl
C 270	12.4	0.9	16	1	US-08-461-271-6	Sequence 6, Appl	Sequence 6, Appl	C 343	12.2	0.9	17	1	US-08-181-664-64	Sequence 64, Appl
C 271	12.4	0.9	16	1	US-08-713-685A-6	Sequence 6, Appl	Sequence 6, Appl	C 344	12.2	0.9	17	1	US-08-985-162-85	Sequence 85, Appl
C 272	12.4	0.9	16	1	US-08-689-856-6	Sequence 6, Appl	Sequence 6, Appl	C 345	12.2	0.9	17	1	US-08-985-162-104	Sequence 104, App
C 273	12.4	0.9	16	1	US-08-668-123-23	Sequence 23, Appl	Sequence 23, Appl	C 346	12.2	0.9	17	1	US-08-985-162-237	Sequence 237, App
C 274	12.4	0.9	16	1	US-09-070-477-6	Sequence 6, Appl	Sequence 6, Appl	C 347	12.2	0.9	17	1	US-08-985-162-293	Sequence 293, App
C 275	12.4	0.9	16	1	5256545-4	Patent No. 5256545	Patent No. 5256545	C 348	12.2	0.9	17	1	US-08-985-162-293	Sequence 293, App
C 276	12.4	0.9	16	1	5256545-33	Patent No. 5256545	Patent No. 5256545	C 349	12.2	0.9	17	1	US-08-985-162-293	Sequence 293, App
C 277	12.4	0.9	17	1	US-08-373-124A-338	Sequence 338, App	Sequence 338, App	C 350	12.2	0.9	17	1	US-09-071-845-1544	Sequence 1544, Ap
C 278	12.4	0.9	17	1	US-08-373-124A-2047	Sequence 2047, Ap	Sequence 2047, Ap	C 351	12.2	0.9	17	1	US-09-071-845-1597	Sequence 1597, Ap
C 279	12.4	0.9	17	1	US-08-373-124A-2049	Sequence 2049, Ap	Sequence 2049, Ap	C 352	12.2	0.9	17	1	US-09-071-845-1700	Sequence 1700, Ap
C 280	12.4	0.9	17	1	US-08-261-822A-30	Sequence 30, Appl	Sequence 30, Appl	C 353	12.2	0.9	17	1	US-09-071-845-1707	Sequence 1707, Ap
C 281	12.4	0.9	17	1	US-08-435-628-338	Sequence 338, App	Sequence 338, App	C 354	12.2	0.9	17	1	US-09-071-845-1743	Sequence 1743, Ap
C 282	12.4	0.9	17	1	US-08-435-628-2047	Sequence 2047, Ap	Sequence 2047, Ap	C 355	12.2	0.9	17	1	US-09-071-845-1796	Sequence 1796, Ap
C 283	12.4	0.9	17	1	US-08-435-628-2049	Sequence 2049, Ap	Sequence 2049, Ap	C 356	12.2	0.9	17	1	US-09-071-845-1873	Sequence 1873, Ap
C 284	12.4	0.9	17	1	US-08-485-611A-9	Sequence 9, Appl	Sequence 9, Appl	C 357	12.2	0.9	17	1	US-09-071-845-1934	Sequence 1934, Ap
C 285	12.4	0.9	17	1	US-08-985-162-118	Sequence 118, App	Sequence 118, App	C 358	12.2	0.9	17	1	US-08-961-810-104	Sequence 104, App
C 286	12.4	0.9	17	1	US-08-985-162-119	Sequence 119, App	Sequence 119, App	C 359	12.2	0.9	17	1	US-08-352-902D-104	Sequence 104, App
C 287	12.4	0.9	17	1	US-08-998-099-95	Sequence 95, Appl	Sequence 95, Appl	C 360	12.2	0.9	17	1	US-08-983-466-93	Sequence 93, Appl
C 288	12.4	0.9	17	1	US-09-017-974-79	Sequence 79, Appl	Sequence 79, Appl	C 361	12.2	0.9	17	1	US-09-021-701-53	Sequence 53, Appl
C 289	12.4	0.9	17	1	US-08-682-255A-79	Sequence 79, Appl	Sequence 79, Appl	C 362	12.2	0.9	17	1	US-09-021-701-111	Sequence 111, App
C 290	12.4	0.9	17	1	US-08-584-040-2256	Sequence 2256, Ap	Sequence 2256, Ap	C 363	12.2	0.9	17	1	US-09-338-907-84	Sequence 84, Appl
C 291	12.4	0.9	17	1	US-08-584-040-2257	Sequence 2257, Ap	Sequence 2257, Ap	C 364	12.2	0.9	17	1	US-08-584-040-1909	Sequence 1909, Ap
C 292	12.4	0.9	17	1	US-08-584-040-2258	Sequence 2258, Ap	Sequence 2258, Ap	C 365	12.2	0.9	17	1	US-08-584-040-1922	Sequence 1922, Ap
C 293	12.4	0.9	17	1	US-08-584-040-2259	Sequence 2259, Ap	Sequence 2259, Ap	C 366	12.2	0.9	17	1	US-08-584-040-2028	Sequence 2028, Ap
C 294	12.4	0.9	17	1	US-08-584-040-2260	Sequence 2260, Ap	Sequence 2260, Ap	C 367	12.2	0.9	17	1	US-08-584-040-2224	Sequence 2224, Ap
C 295	12.4	0.9	17	1	US-08-584-040-2261	Sequence 2261, Ap	Sequence 2261, Ap	C 368	12.2	0.9	17	1	US-08-584-040-2254	Sequence 2254, Ap
C 296	12.4	0.9	17	1	US-08-584-040-6008	Sequence 6008, Ap	Sequence 6008, Ap	C 369	12.2	0.9	17	1	US-08-584-040-3739	Sequence 3739, Ap
C 297	12.4	0.9	17	1	US-08-584-040-6009	Sequence 6009, Ap	Sequence 6009, Ap	C 370	12.2	0.9	17	1	US-08-584-040-3840	Sequence 3840, Ap
C 298	12.4	0.9	17	1	US-08-679-645-139	Sequence 139, App	Sequence 139, App	C 371	12.2	0.9	17	1	US-08-584-040-3911	Sequence 3911, Ap
C 299	12.4	0.9	17	1	US-09-429-130-79	Sequence 79, Appl	Sequence 79, Appl	C 372	12.2	0.9	17	1	US-08-584-040-3912	Sequence 3912, Ap
C 300	12.4	0.9	17	1	US-09-788-338-3	Sequence 3, Appl	Sequence 3, Appl	C 373	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 301	12.4	0.9	17	1	US-09-300-958A-64	Sequence 64, Appl	Sequence 64, Appl	C 374	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 302	12.4	0.9	17	1	US-09-474-432B-409	Sequence 409, App	Sequence 409, App	C 375	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 303	12.4	0.9	17	1	US-09-474-432B-421	Sequence 421, App	Sequence 421, App	C 376	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 304	12.4	0.9	17	1	US-09-474-432B-557	Sequence 557, App	Sequence 557, App	C 377	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 305	12.4	0.9	17	1	US-09-474-432B-815	Sequence 815, App	Sequence 815, App	C 378	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 306	12.4	0.9	17	1	US-09-371-772B-801	Sequence 801, App	Sequence 801, App	C 379	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 307	12.4	0.9	17	1	US-09-371-772B-1071	Sequence 1071, App	Sequence 1071, App	C 380	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 308	12.4	0.9	17	1	US-09-371-772B-1072	Sequence 1072, App	Sequence 1072, App	C 381	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 309	12.4	0.9	17	1	US-09-371-772B-1073	Sequence 1073, App	Sequence 1073, App	C 382	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 310	12.4	0.9	17	1	US-09-371-772B-1074	Sequence 1074, App	Sequence 1074, App	C 383	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 311	12.4	0.9	17	1	US-09-371-772B-2845	Sequence 2845, App	Sequence 2845, App	C 384	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 312	12.4	0.9	17	1	US-09-371-772B-2846	Sequence 2846, App	Sequence 2846, App	C 385	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 313	12.4	0.9	17	1	US-09-371-772B-5053	Sequence 5053, App	Sequence 5053, App	C 386	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 314	12.4	0.9	17	1	US-09-371-772B-5054	Sequence 5054, App	Sequence 5054, App	C 387	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 315	12.4	0.9	17	1	US-09-371-772B-5055	Sequence 5055, App	Sequence 5055, App	C 388	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 316	12.4	0.9	17	1	US-09-371-772B-6554	Sequence 6554, App	Sequence 6554, App	C 389	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 317	12.4	0.9	17	1	PCT-US95-07744A-30	Sequence 30, Appl	Sequence 30, Appl	C 390	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 318	12.4	0.9	17	1	US-09-371-772B-5055	Sequence 5055, App	Sequence 5055, App	C 391	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 319	12.4	0.9	17	1	US-08-281-940-49	Sequence 49, Appl	Sequence 49, Appl	C 392	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 320	12.4	0.9	17	1	US-08-390-850-589	Sequence 589, App	Sequence 589, App	C 393	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 321	12.4	0.9	17	1	US-08-390-850-590	Sequence 590, App	Sequence 590, App	C 394	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 322	12.4	0.9	17	1	US-08-390-850-592	Sequence 592, App	Sequence 592, App	C 395	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 323	12.4	0.9	17	1	US-08-435-634-589	Sequence 589, App	Sequence 589, App	C 396	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 324	12.4	0.9	17	1	US-08-435-634-590	Sequence 590, App	Sequence 590, App	C 397	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap
C 325	12.4	0.9	17	1	US-08-466-033-104	Sequence 104, App	Sequence 104, App	C 398	12.2	0.9	17	1	US-08-584-040-5441	Sequence 5441, Ap

399	12.2	0.9	17	1	US-09-371-772B-1607	Sequence 1607, Ap	C 472	11.8	0.9	15	1	US-08-471-033-34	Sequence 34, Appl
400	12.2	0.9	17	1	US-09-371-772B-1678	Sequence 1678, Ap	C 473	11.8	0.9	15	1	US-08-292-620A-74	Sequence 74, Appl
401	12.2	0.9	17	1	US-09-371-772B-1679	Sequence 1679, Ap	C 474	11.8	0.9	15	1	US-08-292-620A-105	Sequence 105, App
C 402	12.2	0.9	17	1	US-09-371-772B-2697	Sequence 2697, Ap	C 475	11.8	0.9	15	1	US-08-292-620A-393	Sequence 393, App
C 403	12.2	0.9	17	1	US-09-371-772B-2764	Sequence 2764, Ap	C 476	11.8	0.9	15	1	US-08-292-620A-656	Sequence 656, App
C 404	12.2	0.9	17	1	US-09-371-772B-3069	Sequence 3069, Ap	C 477	11.8	0.9	15	1	US-08-471-044-34	Sequence 34, Appl
C 405	12.2	0.9	17	1	US-09-371-772B-3313	Sequence 3313, Ap	C 478	11.8	0.9	15	1	US-08-463-483A-34	Sequence 34, Appl
C 406	12.2	0.9	17	1	US-09-371-772B-3387	Sequence 3387, Ap	C 479	11.8	0.9	15	1	US-08-173-489C-61	Sequence 61, Appl
C 407	12.2	0.9	17	1	US-09-371-772B-3660	Sequence 3660, Ap	C 480	11.8	0.9	15	1	US-08-173-489C-87	Sequence 87, Appl
C 408	12.2	0.9	17	1	US-09-371-772B-4161	Sequence 4161, Ap	C 481	11.8	0.9	15	1	US-08-471-046A-34	Sequence 34, Appl
C 409	12.2	0.9	17	1	US-09-371-772B-4457	Sequence 4457, Ap	C 482	11.8	0.9	15	1	US-08-774-306A-201	Sequence 201, App
C 410	12.2	0.9	17	1	US-09-371-772B-4643	Sequence 4643, Ap	C 483	11.8	0.9	15	1	US-08-470-568B-34	Sequence 34, Appl
C 411	12.2	0.9	17	1	US-09-371-772B-4722	Sequence 4722, Ap	C 484	11.8	0.9	15	1	US-08-585-684B-776	Sequence 776, App
C 412	12.2	0.9	17	1	US-09-371-772B-5116	Sequence 5116, Ap	C 485	11.8	0.9	15	1	US-08-585-684B-775	Sequence 775, App
C 413	12.2	0.9	17	1	US-09-371-772B-5579	Sequence 5579, Ap	C 486	11.8	0.9	15	1	US-08-585-684B-1365	Sequence 1365, Ap
C 414	12.2	0.9	17	1	US-09-371-772B-6296	Sequence 6296, Ap	C 487	11.8	0.9	15	1	US-08-585-684B-1376	Sequence 1376, Ap
C 415	12.2	0.9	17	1	US-09-371-772B-6439	Sequence 6439, Ap	C 488	11.8	0.9	15	1	US-08-585-684B-2270	Sequence 2270, Ap
C 416	12.2	0.9	17	1	US-09-371-772B-6624	Sequence 6624, Ap	C 489	11.8	0.9	15	1	US-08-854-041-4	Sequence 4, Appl
C 417	12.2	0.9	17	1	US-09-371-772B-6701	Sequence 6701, Ap	C 490	11.8	0.9	15	1	US-08-485-133-7	Sequence 7, Appl
C 418	12.2	0.9	17	1	PCT-US95-06266-87	Sequence 87, Appl	C 491	11.8	0.9	15	1	US-08-469-334-34	Sequence 34, Appl
C 419	12.2	0.9	17	1	PCT-US96-09641-17	Sequence 17, Appl	C 492	11.8	0.9	15	1	US-08-343-998-24	Sequence 24, Appl
C 420	12.2	0.9	18	1	US-08-584-040-3044	Sequence 3044, Ap	C 493	11.8	0.9	15	1	US-08-832-021-25	Sequence 25, Appl
C 421	12.2	0.9	18	1	US-09-371-772B-1472	Sequence 1472, Ap	C 494	11.8	0.9	15	1	US-08-832-021-37	Sequence 37, Appl
C 422	12.2	0.9	18	1	US-08-214-603-11	Sequence 11, Appl	C 495	11.8	0.9	15	1	US-08-832-021-41	Sequence 41, Appl
C 423	12.2	0.9	13	1	US-08-242-664-14	Sequence 14, Appl	C 496	11.8	0.9	15	1	US-08-832-021-43	Sequence 43, Appl
C 424	12.2	0.9	13	1	US-08-484-138-14	Sequence 14, Appl	C 497	11.8	0.9	15	1	US-08-832-021-45	Sequence 45, Appl
C 425	12.2	0.9	13	1	PCT-US95-06379-14	Sequence 14, Appl	C 498	11.8	0.9	15	1	US-08-832-021-47	Sequence 47, Appl
C 426	12.2	0.9	14	1	US-08-146-010A-8	Sequence 8, Appl	C 499	11.8	0.9	15	1	US-08-832-021-61	Sequence 61, Appl
C 427	12.2	0.9	14	1	US-08-683-839B-15	Sequence 15, Appl	C 500	11.8	0.9	15	1	US-09-300-529-34	Sequence 34, Appl
C 428	12.2	0.9	14	1	US-08-674-168-10	Sequence 10, Appl	C 501	11.8	0.9	15	1	US-09-064-156A-201	Sequence 201, App
C 429	12.2	0.9	14	1	US-08-846-021A-14	Sequence 14, Appl	C 502	11.8	0.9	15	1	US-09-071-845-74	Sequence 74, Appl
C 430	12.2	0.9	15	1	US-08-365-189-10	Sequence 10, Appl	C 503	11.8	0.9	15	1	US-09-071-845-105	Sequence 105, App
C 431	12.2	0.9	15	1	US-08-208-886C-29	Sequence 29, Appl	C 504	11.8	0.9	15	1	US-09-071-845-393	Sequence 393, App
C 432	12.2	0.9	15	1	US-08-704-744-29	Sequence 29, Appl	C 505	11.8	0.9	15	1	US-09-071-845-656	Sequence 656, App
C 433	12.2	0.9	15	1	US-08-469-557-29	Sequence 29, Appl	C 506	11.8	0.9	15	1	US-09-038-073-775	Sequence 775, App
C 434	12.2	0.9	15	1	US-08-290-793B-29	Sequence 29, Appl	C 507	11.8	0.9	15	1	US-09-038-073-776	Sequence 776, App
C 435	12.2	0.9	15	1	US-08-606-505B-62	Sequence 62, Appl	C 508	11.8	0.9	15	1	US-09-038-073-1365	Sequence 1365, Ap
C 436	12.2	0.9	15	1	US-09-115-446-3	Sequence 3, Appl	C 509	11.8	0.9	15	1	US-09-038-073-1376	Sequence 1376, Ap
C 437	12.2	0.9	15	1	US-09-177-359-26	Sequence 26, Appl	C 510	11.8	0.9	15	1	US-09-038-073-2270	Sequence 2270, Ap
C 438	12.2	0.9	15	1	US-09-616-990-62	Sequence 62, Appl	C 511	11.8	0.9	15	1	US-09-275-850-19	Sequence 19, Appl
C 439	12.2	0.9	15	1	US-08-812-951B-1	Sequence 1, Appl	C 512	11.8	0.9	15	1	US-09-344-888A-9	Sequence 9, Appl
C 440	12.2	0.9	15	1	US-08-812-951B-2	Sequence 2, Appl	C 513	11.8	0.9	15	1	US-09-081-646-513	Sequence 513, App
C 441	12.2	0.9	15	1	US-08-784-747-2	Sequence 2, Appl	C 514	11.8	0.9	15	1	US-09-081-646-616	Sequence 616, App
C 442	12.2	0.9	15	1	US-08-784-747-3	Sequence 3, Appl	C 515	11.8	0.9	15	1	US-09-011-336-23	Sequence 23, Appl
C 443	12.2	0.9	15	1	US-09-409-778-9	Sequence 9, Appl	C 516	11.8	0.9	15	1	PCR-US94-06331A-9	Sequence 9, Appl
C 444	12.2	0.9	15	1	US-09-409-778-10	Sequence 10, Appl	C 517	11.8	0.9	15	1	5182195-24	Patent No. 5182195
C 445	12.2	0.9	16	1	US-08-232-087A-5	Sequence 5, Appl	C 518	11.8	0.9	16	1	US-07-988-194A-16	Sequence 16, Appl
C 446	12.2	0.9	16	1	US-08-882-649A-8	Sequence 8, Appl	C 519	11.8	0.9	16	1	US-08-233-030-52	Sequence 52, Appl
C 447	12.2	0.9	17	1	US-09-328-501-14	Sequence 14, Appl	C 520	11.8	0.9	16	1	US-08-291-932A-780	Sequence 780, App
C 448	12.2	0.9	17	1	US-08-984-709A-45	Sequence 45, Appl	C 521	11.8	0.9	16	1	US-08-291-932A-814	Sequence 814, App
C 449	12.2	0.9	17	1	US-08-584-040-1844	Sequence 1844, Ap	C 522	11.8	0.9	16	1	US-08-258-152-18	Sequence 18, Appl
C 450	12.2	0.9	17	1	US-08-584-040-7538	Sequence 7538, Ap	C 523	11.8	0.9	16	1	US-08-241-465B-17	Sequence 17, Appl
C 451	12.2	0.9	17	1	US-09-537-720B-15	Sequence 15, Appl	C 524	11.8	0.9	16	1	US-08-465-485A-16	Sequence 16, Appl
C 452	12.2	0.9	17	1	US-08-937-067-17	Sequence 17, Appl	C 525	11.8	0.9	16	1	US-08-076-299A-18	Sequence 18, Appl
C 453	12.2	0.9	17	1	US-09-777-710A-14	Sequence 14, Appl	C 526	11.8	0.9	16	1	US-08-527-060-2	Sequence 2, Appl
C 454	12.2	0.9	17	1	US-09-371-772B-389	Sequence 389, App	C 527	11.8	0.9	16	1	US-08-527-060-12	Sequence 12, Appl
C 455	12.2	0.9	17	1	US-09-371-772B-4638	Sequence 4638, Ap	C 528	11.8	0.9	16	1	US-08-292-620A-1628	Sequence 1628, Ap
C 456	12.2	0.9	17	1	PCT-US91-03680-7	Sequence 7, Appl	C 529	11.8	0.9	16	1	US-08-438-582-18	Sequence 18, Appl
C 457	12.2	0.9	17	1	US-08-041-599-2	Sequence 2, Appl	C 530	11.8	0.9	16	1	US-08-282-197C-20	Sequence 20, Appl
C 458	11.8	0.9	15	1	US-08-127-954-50	Sequence 50, Appl	C 531	11.8	0.9	16	1	US-08-137-024-2	Sequence 2, Appl
C 459	11.8	0.9	15	1	US-08-337-025-2	Sequence 2, Appl	C 532	11.8	0.9	16	1	US-08-817-145-8	Sequence 8, Appl
C 460	11.8	0.9	15	1	US-08-276-099A-8	Sequence 8, Appl	C 533	11.8	0.9	16	1	US-09-080-285-16	Sequence 16, Appl
C 461	11.8	0.9	15	1	US-08-182-968A-201	Sequence 201, App	C 534	11.8	0.9	16	1	US-09-071-845-1628	Sequence 1628, Ap
C 462	11.8	0.9	15	1	US-08-291-932A-33	Sequence 33, Appl	C 535	11.8	0.9	16	1	US-09-266-596-18	Sequence 18, Appl
C 463	11.8	0.9	15	1	US-08-291-932A-378	Sequence 378, App	C 536	11.8	0.9	16	1	US-08-479-737-16	Sequence 16, Appl
C 464	11.8	0.9	15	1	US-08-334-847-606	Sequence 606, App	C 537	11.8	0.9	16	1	US-08-679-645-523	Sequence 523, App
C 465	11.8	0.9	15	1	US-08-334-847-631	Sequence 631, App	C 538	11.8	0.9	16	1	US-08-475-442A-16	Sequence 16, Appl
C 466	11.8	0.9	15	1	US-08-334-847-631	Sequence 631, App	C 539	11.8	0.9	16	1	US-09-724-426-16	Sequence 16, Appl
C 467	11.8	0.9	15	1	US-08-363-240A-142	Sequence 142, App	C 540	11.8	0.9	16	1	US-08-535-249-97	Sequence 97, Appl
C 468	11.8	0.9	15	1	US-08-363-240A-541	Sequence 541, App	C 541	11.8	0.9	16	1	US-09-916-228-14	Sequence 14, Appl
C 469	11.8	0.9	15	1	US-08-363-240A-541	Sequence 541, App	C 542	11.8	0.9	16	1	US-09-944-411-18	Sequence 18, Appl
C 470	11.8	0.9	15	1	US-08-363-240A-558	Sequence 558, App	C 543	11.8	0.9	16	1	US-08-754-477A-38	Sequence 38, Appl
C 471	11.8	0.9	15	1	US-08-781-890-8	Sequence 8, Appl	C 544	11.8	0.9	16	1	US-09-060-299-420	Sequence 420, App

545 11.8 0.9 16 1 US-09-402-923A-420 Sequence 420, App
546 11.8 0.9 16 1 US-09-371-772B-5660 Sequence 5660, Ap
547 11.8 0.9 16 1 US-09-371-772B-5661 Sequence 5661, Ap
c 548 11.8 0.9 16 1 PCT-US96-00331-19 Sequence 19, Appl
549 11.6 0.9 18 1 US-08-702-105A-33 Sequence 33, Appl
550 11.6 0.9 18 1 US-08-702-110A-33 Sequence 33, Appl

ALIGNMENTS

RESULT 1

US-09-302-681-65
; Sequence 65, Application US/09302681
; Patent No. 6441149
; GENERAL INFORMATION:
; APPLICANT: Herrnstadt, Corrina
; APPLICANT: Ghosh, Soumitra S.
; APPLICANT: Clevenger, William
; APPLICANT: Fahy, Eoin F.
; APPLICANT: Davis, Robert E.
; TITLE OF INVENTION: DIAGNOSTIC METHOD BASED ON
; FILE OF INVENTION: QUANTIFICATION OF EXTRAMITOCHONDRIAL DNA
; FILE REFERENCE: 660088.416C1
; CURRENT APPLICATION NUMBER: US/09/302,681
; CURRENT FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 65
; LENGTH: 22
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer corresponding to NDH
; OTHER INFORMATION: dehydrogenase encoding mitochondrial DNA
US-09-302-681-65

Query Match 1.6%; Score 22; DB 1; Length 22;
Best Local Similarity 100.0%; Pred. No. 2.5;
Matches 22; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 34 AGCTACGCAAAATCTTAGCATA 55
|||||
Db 1 AGCTACGCAAAATCTTAGCATA 22

RESULT 2

US-09-667-135-7/c
; Sequence 7, Application US/09667135
; Patent No. 6521749
; GENERAL INFORMATION:
; APPLICANT: Vincent Ling
; APPLICANT: Kyriaki Dunussi-Joannopoulos
; TITLE OF INVENTION: NOVEL GL50 MOLECULES AND USES THEREFOR
; FILE REFERENCE: GNN-007
; CURRENT APPLICATION NUMBER: US/09/667,135
; CURRENT FILING DATE: 2000-09-21
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 7
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: primer
US-09-667-135-7

Query Match 1.3%; Score 17.8; DB 1; Length 21;
Best Local Similarity 90.5%; Pred. No. 21;
Matches 19; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 944 GGTGTGAGCGCAGACTGCAGG 964
|||||

Db 21 GGTGCGAGCGCAGACTGCGGG 1

RESULT 3

US-08-249-037C-16/c
; Sequence 16, Application US/08249037C
; Patent No. 5929317
; GENERAL INFORMATION:
; APPLICANT: Kilburn, Douglas G.
; APPLICANT: Miller, Robert C.
; APPLICANT: Warren, Richard A.J.
; APPLICANT: Gilkes, Neil R.
; TITLE OF INVENTION: Polysaccharide binding fusion proteins
; TITLE OF INVENTION: and conjugates
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Rae-Venter Law Group, P.C.
; STREET: P.O.Box 60039
; CITY: Palo Alto
; STATE: CA
; COUNTRY: U.S.
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/249,037C
; FILING DATE: 24-MAY-1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/865,095
; FILING DATE: 08-APR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/603,987
; FILING DATE: 25-OCT-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/216,794
; FILING DATE: 08-JUL-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Kung, Viola T.
; REGISTRATION NUMBER: 41,131
; REFERENCE/DOCKET NUMBER: CBDT.002.04US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650)328-4400
; TELEFAX: (650)328-4477
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 24 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-249-037C-16

Query Match 1.3%; Score 17.6; DB 1; Length 24;
Best Local Similarity 83.3%; Pred. No. 32;
Matches 20; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 188 CCGCGCGCCCGCAGCGCGCAGC 211
|||||

Db 24 CCGACCCCGCCCGCAGCGCGCAGC 1
|||||

RESULT 4

US-08-788-622B-16/c
; Sequence 16, Application US/08788622B
; Patent No. 5962289
; GENERAL INFORMATION:
; APPLICANT: Kilburn, Douglas G.
; APPLICANT: Miller, Robert C.
; APPLICANT: Warren, Richard A.J.


```

1 COUNTRY: U.S.
2 ZIP: 94306
3 COMPUTER READABLE FORM:
4 MEDIUM TYPE: Floppy disk
5 COMPUTER: IBM PC compatible
6 OPERATING SYSTEM: PC-DOS/MS-DOS
7 SOFTWARE: Patentin Release #1.0, Version #1.30
8 CURRENT APPLICATION DATA:
9 APPLICATION NUMBER: US/08/788,621B
10 FILING DATE: January 23, 1997
11 PRIOR APPLICATION DATA:
12 APPLICATION NUMBER: US 08/249,037
13 FILING DATE: 24-MAY-1994
14 PRIOR APPLICATION DATA:
15 APPLICATION NUMBER: US 07/865,095
16 FILING DATE: 08-APR-1992
17 PRIOR APPLICATION DATA:
18 APPLICATION NUMBER: US 07/603,987
19 FILING DATE: 25-OCT-1990
20 PRIOR APPLICATION DATA:
21 APPLICATION NUMBER: US 07/216,794
22 FILING DATE: 08-JUL-1988
23 ATTORNEY/AGENT INFORMATION:
24 NAME: Kung, Viola T.
25 REGISTRATION NUMBER: 41,131
26 REFERENCE/DOCKET NUMBER: CBOT.002.05US
27 TELECOMMUNICATION INFORMATION:
28 TELEPHONE: (650)328-4400
29 TELEFAX: (650)328-4477
30 INFORMATION FOR SEQ ID NO: 16:
31 SEQUENCE CHARACTERISTICS:
32 LENGTH: 24 base pairs
33 TYPE: nucleic acid
34 STRANDEDNESS: single
35 TOPOLOGY: linear
36 MOLECULE TYPE: DNA (genomic)
37 US-08-788-621B-16
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
340
341
342
343
344
345
346
347
348
349
350
351
352
353
354
355
356
357
358
359
360
361
362
363
364
365
366
367
368
369
370
371
372
373
374
375
376
377
378
379
380
381
382
383
384
385
386
387
388
389
390
391
392
393
394
395
396
397
398
399
400
401
402
403
404
405
406
407
408
409
410
411
412
413
414
415
416
417
418
419
420
421
422
423
424
425
426
427
428
429
430
431
432
433
434
435
436
437
438
439
440
441
442
443
444
445
446
447
448
449
450
451
452
453
454
455
456
457
458
459
460
461
462
463
464
465
466
467
468
469
470
471
472
473
474
475
476
477
478
479
480
481
482
483
484
485
486
487
488
489
490
491
492
493
494
495
496
497
498
499
500
501
502
503
504
505
506
507
508
509
510
511
512
513
514
515
516
517
518
519
520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536
537
538
539
540
541
542
543
544
545
546
547
548
549
550
551
552
553
554
555
556
557
558
559
560
561
562
563
564
565
566
567
568
569
570
571
572
573
574
575
576
577
578
579
580
581
582
583
584
585
586
587
588
589
590
591
592
593
594
595
596
597
598
599
600
601
602
603
604
605
606
607
608
609
610
611
612
613
614
615
616
617
618
619
620
621
622
623
624
625
626
627
628
629
630
631
632
633
634
635
636
637
638
639
640
641
642
643
644
645
646
647
648
649
650
651
652
653
654
655
656
657
658
659
660
661
662
663
664
665
666
667
668
669
670
671
672
673
674
675
676
677
678
679
680
681
682
683
684
685
686
687
688
689
690
691
692
693
694
695
696
697
698
699
700
701
702
703
704
705
706
707
708
709
710
711
712
713
714
715
716
717
718
719
720
721
722
723
724
725
726
727
728
729
730
731
732
733
734
735
736
737
738
739
740
741
742
743
744
745
746
747
748
749
750
751
752
753
754
755
756
757
758
759
760
761
762
763
764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805
806
807
808
809
810
811
812
813
814
815
816
817
818
819
820
821
822
823
824
825
826
827
828
829
830
831
832
833
834
835
836
837
838
839
840
841
842
843
844
845
846
847
848
849
850
851
852
853
854
855
856
857
858
859
860
861
862
863
864
865
866
867
868
869
870
871
872
873
874
875
876
877
878
879
880
881
882
883
884
885
886
887
888
889
890
891
892
893
894
895
896
897
898
899
900
901
902
903
904
905
906
907
908
909
910
911
912
913
914
915
916
917
918
919
920
921
922
923
924
925
926
927
928
929
930
931
932
933
934
935
936
937
938
939
940
941
942
943
944
945
946
947
948
949
950
951
952
953
954
955
956
957
```

ATTORNEY/AGENT INFORMATION:
NAME: O'Shaughnessy, Brian P.
REGISTRATION NUMBER: 32,747
REFERENCE/DOCKET NUMBER: 9594/81-2189
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 289-1200
TELEFAX: (202) 289-6674
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
IMMEDIATE SOURCE:
CLONE: Yeast artificial chromosome
US-08-052-997-22

Query Match 1.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 35;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 78 TGAATAATAGCAGTTCTACC 97
|||||
DB 2 TGAATAATAGCAGTTCTGCC 21

RESULT 7

US-08-684-672-22
Sequence 22, Application US/08684672
Patent No. 5700926
GENERAL INFORMATION:

APPLICANT: KERE Juha
APPLICANT: SCHLESSINGER, David
APPLICANT: de la CHAPELLE, Albert
APPLICANT: SRIVASTAVA, Anand Kumar
TITLE OF INVENTION: MOLECULAR CLONING OF THE ANHIDROTIC
TITLE OF INVENTION: ECTODERMAL DYSPLASIA GENE
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: BURNS, DOANE, SWECKER & MATHIS, L.L.P.
STREET: P.O. Box 1404
CITY: Alexandria
STATE: Virginia
COUNTRY: United States
ZIP: 22313-1404

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/684,672
FILING DATE: 22-JUL-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/052,997
FILING DATE: 27-APR-1993

ATTORNEY/AGENT INFORMATION:
NAME: O'Shaughnessy, Brian P.
REGISTRATION NUMBER: 32,747
REFERENCE/DOCKET NUMBER: 030956-002
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-2021
INFORMATION FOR SEQ ID NO: 22:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-684-672-22

Query Match 1.2%; Score 16.8; DB 1; Length 21;
Best Local Similarity 90.0%; Pred. No. 35;
Matches 18; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 78 TGAATAATAGCAGTTCTACC 97
|||||
DB 2 TGAATAATAGCAGTTCTGCC 21

RESULT 8

US-09-244-794A-29
Sequence 29, Application US/09244794A
Patent No. 6214553
GENERAL INFORMATION:

APPLICANT: Szostak, Jack W.
APPLICANT: Roberts, Richard W.
APPLICANT: Liu, Rihe
TITLE OF INVENTION: SELECTION OF PROTEINS USING RNA-PROTEIN
TITLE OF INVENTION: FUSIONS
FILE REFERENCE: 00786/350006
CURRENT APPLICATION NUMBER: US/09/244,794A
CURRENT FILING DATE: 1999-02-05
PRIOR APPLICATION NUMBER: 60/035,963
PRIOR FILING DATE: 1997-01-27
PRIOR APPLICATION NUMBER: 60/064,491
PRIOR FILING DATE: 1997-11-06
PRIOR APPLICATION NUMBER: 09/007,005
PRIOR FILING DATE: 1998-01-14
NUMBER OF SEQ ID NOS: 33
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 29
LENGTH: 18
TYPE: DNA
ORGANISM: Homo sapiens
US-09-244-794A-29

Query Match 1.2%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 29;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 679 GTGGTATTGGAGCCAG 696
|||||
DB 1 GTGGTATTGGAGCCAG 18

RESULT 9

US-09-007-005-29
Sequence 29, Application US/09007005B
Patent No. 6258558
GENERAL INFORMATION:

APPLICANT: Szostak, Jack W.
APPLICANT: Roberts, Richard W.
APPLICANT: Liu, Rihe
TITLE OF INVENTION: SELECTION OF PROTEINS USING RNA-PROTEIN
TITLE OF INVENTION: FUSIONS
FILE REFERENCE: 00786/350003
CURRENT APPLICATION NUMBER: US/09/007,005B
CURRENT FILING DATE: 1998-01-14
EARLIER APPLICATION NUMBER: 60/035,963
EARLIER FILING DATE: 1997-01-27
EARLIER APPLICATION NUMBER: 60/064,491
EARLIER FILING DATE: 1997-11-06
NUMBER OF SEQ ID NOS: 33
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 29
LENGTH: 18
TYPE: DNA
ORGANISM: Homo sapiens

US-09-007-005-29

Query Match 1.2%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 29;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 679 GTGGTATTGGAGCCAG 696
|||||
Db 1 GTGGTATTGGAGCCAG 18

RESULT 10

US-09-247-190-29
; Sequence 29, Application US/09247190
; Patent No. 6261804
; GENERAL INFORMATION:
; APPLICANT: Szostak, Jack W.
; APPLICANT: Roberts, Richard W.
; APPLICANT: Liu, Rihe
; TITLE OF INVENTION: SELECTION OF PROTEINS USING RNA-PROTEIN
; TITLE OF INVENTION: FUSIONS
; FILE REFERENCE: 00786/350005
; CURRENT APPLICATION NUMBER: US/09/247,190
; CURRENT FILING DATE: 1999-02-09
; EARLIER APPLICATION NUMBER: 60/035,963
; EARLIER FILING DATE: 1997-01-21
; EARLIER APPLICATION NUMBER: 60/064,491
; EARLIER FILING DATE: 1997-11-06
; EARLIER APPLICATION NUMBER: 09/007,005
; EARLIER FILING DATE: 1998-01-14
; NUMBER OF SEQ ID NOS: 38
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-247-190-29

Query Match 1.2%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 29;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 679 GTGGTATTGGAGCCAG 696
|||||
Db 1 GTGGTATTGGAGCCAG 18

RESULT 11

US-09-244-796-29
; Sequence 29, Application US/09244796
; Patent No. 6281344
; GENERAL INFORMATION:
; APPLICANT: Szostak, Jack W.
; APPLICANT: Roberts, Richard W.
; APPLICANT: Liu, Rihe
; TITLE OF INVENTION: SELECTION OF PROTEINS USING RNA-PROTEIN
; TITLE OF INVENTION: FUSIONS
; FILE REFERENCE: 00786/350007
; CURRENT APPLICATION NUMBER: US/09/244,796
; CURRENT FILING DATE: 1999-02-05
; EARLIER APPLICATION NUMBER: 60/035,963
; EARLIER FILING DATE: 1997-01-27
; EARLIER APPLICATION NUMBER: 60/064,491
; EARLIER FILING DATE: 1997-11-06
; EARLIER APPLICATION NUMBER: 09/007,005
; EARLIER FILING DATE: 1998-01-14
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-244-796-29

Query Match 1.2%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 29;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 679 GTGGTATTGGAGCCAG 696
|||||
Db 1 GTGGTATTGGAGCCAG 18

RESULT 12

US-09-238-710-29
; Sequence 29, Application US/09238710A
; Patent No. 6518018
; GENERAL INFORMATION:
; APPLICANT: Szostak, Jack W.
; APPLICANT: Roberts, Richard W.
; APPLICANT: Liu, Rihe
; TITLE OF INVENTION: SELECTION OF PROTEINS USING RNA-PROTEIN
; TITLE OF INVENTION: FUSIONS
; FILE REFERENCE: 00786/350004
; CURRENT APPLICATION NUMBER: US/09/238,710A
; CURRENT FILING DATE: 1999-01-28
; EARLIER APPLICATION NUMBER: 60/035,963
; EARLIER FILING DATE: 1997-01-27
; EARLIER APPLICATION NUMBER: 60/064,491
; EARLIER FILING DATE: 1997-11-06
; EARLIER APPLICATION NUMBER: 09/007,005
; EARLIER FILING DATE: 1998-01-14
; NUMBER OF SEQ ID NOS: 33
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 29
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-238-710-29

Query Match 1.2%; Score 16.4; DB 1; Length 18;
Best Local Similarity 94.4%; Pred. No. 29;
Matches 17; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 679 GTGGTATTGGAGCCAG 696
|||||
Db 1 GTGGTATTGGAGCCAG 18

RESULT 13

US-09-302-681-76/c
; Sequence 76, Application US/09302681
; Patent No. 6441149
; GENERAL INFORMATION:
; APPLICANT: HerinStadt, Corrina
; APPLICANT: Ghosh, Soumitra S.
; APPLICANT: Clevenger, William
; APPLICANT: Fahy, Eoin P.
; APPLICANT: Davis, Robert B.
; TITLE OF INVENTION: DIAGNOSTIC METHOD BASED ON
; TITLE OF INVENTION: QUANTIFICATION OF EXTRAMITOCHONDRIAL DNA
; FILE REFERENCE: 660088.416C1
; CURRENT APPLICATION NUMBER: US/09/302,681
; CURRENT FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 76
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer corresponding to NADH
; OTHER INFORMATION: dehydrogenase encoding mitochondrial DNA
US-09-302-681-76

Query Match 1.2%; Score 16.2; DB 1; Length 21;

```
Best Local Similarity 85.7%; Pred. No. 48;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 51 GCATCTCTCAATACCCAC 71
    ||||| ||||| |||||
Db 21 GCATCTCTCAATACCCAC 1

RESULT 14
US-08-709-731A-5/c
; Sequence 5, Application US/08709731A
; Patent No. 6322780
; GENERAL INFORMATION:
; APPLICANT: Lee, Lucy F
; APPLICANT: Nazerian, Keyvan
; APPLICANT: Witter, Richard L
; APPLICANT: Wu, Ping
; APPLICANT: Yanagida, No. 6322780oru
; TITLE OF INVENTION: Marek's Disease Virus Genes and Their
; TITLE OF INVENTION: Use in Vaccines for Protection Against Marek's Disease
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Birch, Stewart, Kolasch and Birch, LLP
; STREET: P.O. Box 747
; CITY: Falls Church
; STATE: VA
; COUNTRY: US
; ZIP: 22040-0747
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/709,731A
; FILING DATE: 05-JUL-1996
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: U.S. 08/499,474
; FILING DATE: 07-JUL-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Murphy Jr., Gerald M
; REGISTRATION NUMBER: 28,977
; REFERENCE/DOCKET NUMBER: 1644-110PPC
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)-205-8000
; TELEFAX: (703) 205-8050
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 23 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-709-731A-5

Query Match 1.2%; Score 16.2; DB 1; Length 23;
Best Local Similarity 85.7%; Pred. No. 60;
Matches 18; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 519 CAACCTGCCGAGGAGCAGCT 539
    ||||| ||||| |||||
Db 21 CAACTTGCCGGGGGCGAGCT 1

RESULT 15
US-09-136-959A-6
; Sequence 6, Application US/09136959A
; Patent No. 6248522
; GENERAL INFORMATION:
; APPLICANT: HABERHAUSEN, Gerd
```

```
; APPLICANT: JOGER, Stephan
; APPLICANT: SOBEK, Harald
; TITLE OF INVENTION: REDUCTION OF CROSS-CONTAMINATIONS IN NUCLEIC ACID
; TITLE OF INVENTION: AMPLIFICATIONS
; FILE REFERENCE: 1614-8065
; CURRENT APPLICATION NUMBER: US/09/136,959A
; CURRENT FILING DATE: 1998-08-20
; PRIOR APPLICATION NUMBER: DE 197 36 062.9
; PRIOR FILING DATE: 1997-08-20
; NUMBER OF SEQ ID NOS: 6
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 6
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:Primer
US-09-136-959A-6

Query Match 1.2%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 52;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 274 ATCAAGAGGAAGCAGCAG 292
    ||||| ||||| |||||
Db 1 ATCAATGAGGAGCTGCAG 19

RESULT 16
US-09-556-031-2/c
; Sequence 2, Application US/09556031
; Patent No. 6350868
; GENERAL INFORMATION:
; APPLICANT: Weston, Brent W.
; APPLICANT: Hiller, Kara B.
; TITLE OF INVENTION: Antisense Fucosyltransferase Sequences and Methods of
; TITLE OF INVENTION: Use Thereof
; FILE REFERENCE: Weston and Hiller
; CURRENT APPLICATION NUMBER: US/09/556,031
; CURRENT FILING DATE: 2000-04-20
; PRIOR APPLICATION NUMBER: 60/131,068
; PRIOR FILING DATE: 1999-04-26
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:antisense
; OTHER INFORMATION: oligonucleotide
US-09-556-031-2

Query Match 1.2%; Score 15.8; DB 1; Length 20;
Best Local Similarity 89.5%; Pred. No. 52;
Matches 17; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1322 CTTTGTAGATCTTGCTT 1340
    ||||| ||||| |||||
Db 19 CTTTGTAGATCTTCAGTT 1

RESULT 17
US-09-702-246-25/c
; Sequence 25, Application US/09702246
; Patent No. 6383809
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF CYTOKINESIN-1 EXPRESSION
; FILE REFERENCE: RTS-0195
; CURRENT APPLICATION NUMBER: US/09/702,246
; CURRENT FILING DATE: 2000-10-30
```


COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICANT: PatentIn Release #1.0, Version #1.30
FILING DATE: US/08/680,326
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: Schiff, J. Michael
REGISTRATION NUMBER: 40,253
REFERENCE/DOCKET NUMBER: 29938-20001.00
TELEPHONE: (415) 813-5600
TELEFAX: (415) 494-0792
TELEX: 706141
INFORMATION FOR SEQ ID NO: 140:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-680-326-140

Query Match 1.1%; Score 15.4; DB 1; Length 21;
Best Local Similarity 94.1%; Pred. No. 72;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TGCTCCAGCAGGCCCTC 585
DB 17 TCCTCCAGCAGGCCCTC 1

RESULT 22
US-08-804-439A-89/c
Sequence 89, Application US/08804439A
Patent No. 6015565
GENERAL INFORMATION:
APPLICANT: Rose, Timothy M.
APPLICANT: Bosch, Marnix L.
APPLICANT: Strand, Kurt
TITLE OF INVENTION: GLYCOPROTEIN B OF THE RFHV/KSHV
TITLE OF INVENTION: SUBFAMILY OF HERPES VIRUSES
NUMBER OF SEQUENCES: 113
CORRESPONDENCE ADDRESS:
ADDRESSEE: Fish & Richardson P.C.
STREET: 4225 Executive Square, Ste 1400
CITY: La Jolla
STATE: CA
COUNTRY: USA
ZIP: 92037
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/804.439A
FILING DATE: February 21, 1997
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Haile, Lisa A.
REGISTRATION NUMBER: 38,347
REFERENCE/DOCKET NUMBER: 09176/004001
TELEPHONE: (619) 678-5070
TELEFAX: (619) 678-5099
TELEX:
INFORMATION FOR SEQ ID NO: 89:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-804-439A-89

Query Match 1.1%; Score 15.4; DB 1; Length 21;
Best Local Similarity 94.1%; Pred. No. 72;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TGCTCCAGCAGGCCCTC 585
DB 17 TCCTCCAGCAGGCCCTC 1

RESULT 23
US-08-720-229-89/c
Sequence 89, Application US/08720229
Patent No. 6022542
GENERAL INFORMATION:
APPLICANT: Rose, Timothy M.
APPLICANT: Bosch, Marnix L.
APPLICANT: Strand, Kurt
TITLE OF INVENTION: GLYCOPROTEIN B OF THE RFHV/KSHV
TITLE OF INVENTION: SUBFAMILY OF HERPES VIRUSES
NUMBER OF SEQUENCES: 100
CORRESPONDENCE ADDRESS:
ADDRESSEE: Morrison & Foerster
STREET: 755 Page Mill Road
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94304-1018
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/720,229
FILING DATE: 26-SEP-1996
CLASSIFICATION: 424
ATTORNEY/AGENT INFORMATION:
NAME: Schiff, J. Michael
REGISTRATION NUMBER: 40,253
REFERENCE/DOCKET NUMBER: 29938-20002.00
TELEPHONE: (415) 813-5600
TELEFAX: (415) 494-0792
TELEX: 706141
INFORMATION FOR SEQ ID NO: 89:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-720-229-89

Query Match 1.1%; Score 15.4; DB 1; Length 21;
Best Local Similarity 94.1%; Pred. No. 72;
Matches 16; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 569 TGCTCCAGCAGGCCCTC 585
DB 17 TCCTCCAGCAGGCCCTC 1

RESULT 24
US-07-977-284A-89/c
Sequence 89, Application US/07977284A
Patent No. 5558988
GENERAL INFORMATION:
APPLICANT: Prockop, Darwin J.
APPLICANT: Ala-Kokko, Leena
APPLICANT: Williams, Charlene J.
APPLICANT: Ritvaniemi, Pertti
APPLICANT: Baldwin, Clinton

```

; APPLICANT: Hopkinson, Ian
; APPLICANT: Ahmad, Nilofer Nina
; TITLE OF INVENTION: METHODS OF DETECTING A GENETIC
; TITLE OF INVENTION: PREDISPOSITION FOR OSTEOARTHRITIS
; NUMBER OF SEQUENCES: 261
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & No. 5558988ris
; STREET: One Liberty Place, 46th floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/977,284A
; FILING DATE: 13-NOV-1992
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Deluca, Mark
; REGISTRATION NUMBER: 33,229
; REFERENCE/DOCKET NUMBER: TJU-0697
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 89:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: NUCLEIC ACID
; STRANDEDNESS: SINGLE
; TOPOLOGY: LINEAR
; ANTI-SENSE: NO
; US-07-977-284A-89

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 282 GGAAGCAGCAGCAATGCTG 301
Db 20 GGAAGCAGCAGCAGTGACAG 1

RESULT 25
US-08-410-540-8/c
; Sequence 8, Application US/08410540
; Patent No. 5807678
; GENERAL INFORMATION:
; APPLICANT: Miller, Walter L.
; APPLICANT: Lin, Dong
; APPLICANT: Strauss III, Jerome F.
; TITLE OF INVENTION: IDENTIFICATION OF GENE MUTATIONS
; TITLE OF INVENTION: ASSOCIATED WITH CONGENITAL LIPOID ADRENAL HYPERPLASIA
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooley Godward Castro Huddleson & Tatum
; STREET: 5 Palo Alto Square
; CITY: Palo Alto
; STATE: CA
; COUNTRY: US
; ZIP: 94306-2155
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Mark Deluca
; REGISTRATION NUMBER: 33,229
; REFERENCE/DOCKET NUMBER: TJU-1082
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100

```

```

; APPLICATION NUMBER: US/08/410,540
; FILING DATE: 23-MAR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Neeley, Richard L.
; REGISTRATION NUMBER: 30,092
; REFERENCE/DOCKET NUMBER: UCAL-238/00US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415 853 5070
; TELEFAX: 415 857 0663
; TELEX: 380816COOLEYPA
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (synthetic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; US-08-410-540-8

Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 548 TGCTGGCAGGCATGCACACA 567
Db 20 TGCTGGCAGGCATGCACACA 1

RESULT 26
US-08-256-426B-89/c
; Sequence 89, Application US/08256426B
; Patent No. 5948611
; GENERAL INFORMATION:
; APPLICANT: Prockop, Darwin J.
; APPLICANT: Ala-Kokko, Leena
; APPLICANT: Williams, Charlene J.
; APPLICANT: Ritvaniemi, Pertti
; APPLICANT: Baldwin, Clinton
; APPLICANT: Hopkinson, Ian
; APPLICANT: Ahmad, Nilofer Nina
; TITLE OF INVENTION: Methods of Detecting A Genetic
; NUMBER OF SEQUENCES: 293
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5948611ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: Windows 3.1
; SOFTWARE: WORDPERFECT 6.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/256,426B
; FILING DATE: 03-FEB-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US93/10964
; FILING DATE: 12-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/977,284
; FILING DATE: 13-NOV-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Mark Deluca
; REGISTRATION NUMBER: 33,229
; REFERENCE/DOCKET NUMBER: TJU-1082
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100

```

```
;
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 89:
; SEQUENCE CHARACTERISTICS:
;   LENGTH: 20
;   TYPE: NUCLEIC ACID
;   STRANDEDNESS: SINGLE
;   TOPOLOGY: LINEAR
;   ANTI-SENSE: NO
; US-08-256-426B-89

Query Match      1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      282 GGAAGCAGCAGCATGCTG 301
Db      20 GGAAGCAGCAGCATGAGAG 1

RESULT 27
US-09-661-753-55
; Sequence 55, Application US/09661753
; Patent No. 6436909
; GENERAL INFORMATION:
; APPLICANT: Nicholas M. Dean
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA
; FILE REFERENCE: ISH-0498
; CURRENT APPLICATION NUMBER: US/09/661,753
; CURRENT FILING DATE: 2000-09-14
; EARLIER APPLICATION NUMBER: 60/154,546
; EARLIER FILING DATE: 1999-09-17
; NUMBER OF SEQ ID NOS: 68
; SEQ ID NO 55
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-661-753-55

Query Match      1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      621 CAGGACAGCTCCAGGAGC 640
Db      1 CCGGACAGCATGAGGAGC 20

RESULT 28
US-09-470-443-33
; Sequence 33, Application US/09470443
; Patent No. 6441156
; GENERAL INFORMATION:
; APPLICANT: Lerman, Michael I.
; APPLICANT: Minna, John D.
; APPLICANT: Latif, Farida
; APPLICANT: Wei, Ming-Hui
; APPLICANT: Sekido, Yoshitaka
; APPLICANT: Gao, Boning
; APPLICANT: Duh, Fuh-Mei
; TITLE OF INVENTION: Calcium Channel Compositions and Methods of Use Thereof
; FILE REFERENCE: NIH-05043
; CURRENT APPLICATION NUMBER: US/09/470,443
; CURRENT FILING DATE: 1999-12-22
; EARLIER APPLICATION NUMBER: 60/114,359
; EARLIER FILING DATE: 1998-12-30
; NUMBER OF SEQ ID NOS: 114
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 33
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-470-443-33

Query Match      1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      335 CTGGTGATGTCACAGTGGC 354
Db      1 CTGGTGATGTCACAGGAGC 20

RESULT 29
US-09-470-443-43
; Sequence 43, Application US/09470443
; Patent No. 6441156
; GENERAL INFORMATION:
; APPLICANT: Lerman, Michael I.
; APPLICANT: Minna, John D.
; APPLICANT: Latif, Farida
; APPLICANT: Wei, Ming-Hui
; APPLICANT: Sekido, Yoshitaka
; APPLICANT: Gao, Boning
; APPLICANT: Duh, Fuh-Mei
; TITLE OF INVENTION: Calcium Channel Compositions and Methods of Use Thereof
; FILE REFERENCE: NIH-05043
; CURRENT APPLICATION NUMBER: US/09/470,443
; CURRENT FILING DATE: 1999-12-22
; EARLIER APPLICATION NUMBER: 60/114,359
; EARLIER FILING DATE: 1998-12-30
; NUMBER OF SEQ ID NOS: 114
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 43
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-470-443-43

Query Match      1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      335 CTGGTGATGTCACAGTGGC 354
Db      1 CTGGTGATGTCACAGGAGC 20

RESULT 30
US-09-659-845A-168
; Sequence 168, Application US/09659845A
; Patent No. 6492170
; GENERAL INFORMATION:
; APPLICANT: Hong Zhang
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF CASPASE 9 EXPRESSION
; FILE REFERENCE: RTS-0183
; CURRENT APPLICATION NUMBER: US/09/659,845A
; CURRENT FILING DATE: 2001-07-23
; NUMBER OF SEQ ID NOS: 174
; SEQ ID NO 168
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-659-845A-168

Query Match      1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
```



```
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 567 ACTGCTCCAGCAGGCGCTCC 586
Db 1 ACTGCTCCAGATGCCATCC 20
RESULT 31
US-09-198-452A-1582/c
; Sequence 1582, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Grifflais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; FILE REFERENCE: 9710-003-999
; CURRENT FILING DATE: 1998-11-24
; CURRENT APPLICATION NUMBER: US/09/198,452A
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 1582
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-1582
Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 274 ATCAAGAGGAGGAGCAGC 293
Db 20 ATCAATGCGAAGCAGC 1
RESULT 32
US-09-198-452A-3952/c
; Sequence 3952, Application US/09198452A
; Patent No. 6559294
; GENERAL INFORMATION:
; APPLICANT: Grifflais, R.
; TITLE OF INVENTION: Chlamydia pneumoniae genomic sequence and polypeptides, fragments
; FILE REFERENCE: 9710-003-999
; CURRENT FILING DATE: 1998-11-24
; CURRENT APPLICATION NUMBER: US/09/198,452A
; NUMBER OF SEQ ID NOS: 6849
; SEQ ID NO 3952
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Chlamydia pneumoniae
US-09-198-452A-3952
Query Match 1.1%; Score 15.2; DB 1; Length 20;
Best Local Similarity 85.0%; Pred. No. 71;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 17 TGGATTAAACCAACCCAGC 36
Db 20 TGGATTATACCAACCCAGC 1
RESULT 33
US-08-276-852-49/c
; Sequence 49, Application US/08276852
; Patent No. 5652138
; GENERAL INFORMATION:
; APPLICANT: Burton, Dennis R
; APPLICANT: Barbas, Carlos F
; APPLICANT: Lerner, Richard A
; TITLE OF INVENTION: HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES
; TITLE OF INVENTION: TO HUMAN IMMUNODEFICIENCY VIRUS
```

```
; NUMBER OF SEQUENCES: 170
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: The Scripps Research Institute, Office of
; ADDRESSEE: Patent Counsel
; STREET: 10666 No. 5652138th Torrey Pines Road, Suite 220,
; STREET: Mail Drop TPC8
; CITY: La Jolla
; STATE: CA
; COUNTRY: USA
; ZIP: 92037
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC Compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/276,852
; FILING DATE: 18-JUL-1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/178,302
; FILING DATE: 30-SEP-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/954,148
; FILING DATE: 30-SEP-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Fitting, Thomas
; REGISTRATION NUMBER: 34,163
; REFERENCE/DOCKET NUMBER: SCR1452P
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 619-554-2937
; TELEFAX: 619-554-6312
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 21 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLSCULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-276-852-49
Query Match 1.1%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 262 CTGGGCTGGCTGATCAAGA 281
Db 21 CTGGGCTGGCTGATCAAGA 2
RESULT 34
US-08-162-102C-30/c
; Sequence 30, Application US/08162102C
; Patent No. 5762905
; GENERAL INFORMATION:
; APPLICANT: Burton, Dennis R.
; APPLICANT: Barbas, III, Carlos F.
; APPLICANT: Chanock, Robert M.
; APPLICANT: Murphy, Brian R.
; APPLICANT: Crowe, Jr., James E.
; TITLE OF INVENTION: HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES
; TITLE OF INVENTION: TO RESPIRATORY SYNCYTIAL VIRUS
; NUMBER OF SEQUENCES: 49
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson P.C.
; STREET: 4225 Executive Square, Suite 1400
; CITY: La Jolla
; STATE: California
; COUNTRY: USA
; ZIP: 92037
; COMPUTER READABLE FORM:
```

;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/162,102C
;; FILING DATE: 10-DEC-1993
;; CLASSIFICATION: 424
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Haile, Ph.D., Lisa A.
;; REGISTRATION NUMBER: 36,347
;; REFERENCE/DOCKET NUMBER: 07300/007001
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (619) 678-5070
;; TELEFAX: (619) 678-5099
;; INFORMATION FOR SEQ ID NO: 30:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 21 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; IMMEDIATE SOURCE:
;; CLONE: Gb
;; FEATURES:
;; NAME/KEY: CDS
;; LOCATION: 1..21
US-08-162-102C-30

Query Match 1.1%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 262 CTGGGCTGGCTGATCAAGA 281
Db 21 CTGGGCTGGCTGATCAAGA 2

RESULT 35
US-08-899-575-49/c
Sequence 49, Application US/08899575
Patent No. 5770440
GENERAL INFORMATION:
APPLICANT: Burton, Dennis R
APPLICANT: Barbas, Carlos F
APPLICANT: Lerner, Richard A
TITLE OF INVENTION: HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES
TITLE OF INVENTION: TO HUMAN IMMUNODEFICIENCY VIRUS
NUMBER OF SEQUENCES: 170
CORRESPONDENCE ADDRESS:
ADDRESSEE: The Scripps Research Institute, Office of
ADDRESSEE: Patent Counsel
STREET: 10666 No. 5770440th Torrey Pines Road, Suite 220,
STREET: Mail Drop TPC8
CITY: La Jolla
STATE: CA
COUNTRY: USA
ZIP: 92037
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/899,575
FILING DATE: 24-JUL-1997
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/276,852
FILING DATE: 18-JUL-1994
APPLICATION NUMBER: US 08/178,302
FILING DATE: 30-SEP-1993
PRIOR APPLICATION DATA:

;; APPLICATION NUMBER: US 07/954,148
;; FILING DATE: 30-SEP-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Fitting, Thomas
;; REGISTRATION NUMBER: 34,163
;; REFERENCE/DOCKET NUMBER: SCRI452P
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 619-554-2937
;; TELEFAX: 619-554-6312
;; INFORMATION FOR SEQ ID NO: 49:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 21 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;; HYPOTHETICAL: NO
;; ANTI-SENSE: NO
US-08-899-575-49
Query Match 1.1%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
QY 262 CTGGGCTGGCTGATCAAGA 281
Db 21 CTGGGCTGGCTGATCAAGA 2

RESULT 36
US-08-899-575-49/c
Sequence 49, Application US/08899575
Patent No. 5804440
GENERAL INFORMATION:
APPLICANT: Burton, Dennis R
APPLICANT: Barbas, Carlos F
APPLICANT: Lerner, Richard A
TITLE OF INVENTION: HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES
TITLE OF INVENTION: TO HUMAN IMMUNODEFICIENCY VIRUS
NUMBER OF SEQUENCES: 170
CORRESPONDENCE ADDRESS:
ADDRESSEE: The Scripps Research Institute, Office of
ADDRESSEE: Patent Counsel
STREET: 10666 No. 5804440th Torrey Pines Road, Suite 220,
STREET: Mail Drop TPC8
CITY: La Jolla
STATE: CA
COUNTRY: USA
ZIP: 92037
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/899,575
FILING DATE: 24-JUL-1997
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/276,852
FILING DATE: 18-JUL-1994
APPLICATION NUMBER: US 08/178,302
FILING DATE: 30-SEP-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/954,148
FILING DATE: 30-SEP-1992
ATTORNEY/AGENT INFORMATION:
NAME: Fitting, Thomas
REGISTRATION NUMBER: 34,163
REFERENCE/DOCKET NUMBER: SCRI452P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 619-554-2937
TELEFAX: 619-554-6312

INFORMATION FOR SEQ ID NO: 49:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-08-899-575-49

Query Match 1.1%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 262 CTGGGCTGGCTGATCAAGA 281
|||||
Db 21 CTGGGCTGCTGCTCAACGA 2

RESULT 37

US-07-974-409C-137/c
Sequence 137, Application US/07974409C
Patent No. 6300058
GENERAL INFORMATION:
APPLICANT: Akitaya, Tatsuo
APPLICANT: Mitsuhashi, Masato
TITLE OF INVENTION: METHOD AND REAGENT
FOR MEASURING MESSENGER RNA
NUMBER OF SEQUENCES: 457
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knobbe, Martens, Olson, and Bear
STREET: 620 Newport Center Dr. Sixteenth Floor
CITY: Newport Beach
STATE: CA
COUNTRY: USA
ZIP: 92660

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/974,409C
FILING DATE: 12-NOV-1992
CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:
NAME: Altman, Daniel E.
REGISTRATION NUMBER: 34,115
REFERENCE/DOCKET NUMBER: HITACHI.006CP2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 714-760-0404
TELEFAX: 714-760-9502
INFORMATION FOR SEQ ID NO: 137:

SEQUENCE CHARACTERISTICS:
LENGTH: 21
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA to mRNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
US-07-974-409C-137

Query Match 1.1%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 492 CGGTGTCAGCGCTCTTGGG 511
|||||
Db 21 CGGTGTCAGCTTCTGAGG 2

RESULT 38

US-08-635-109-21/c
Sequence 21, Application US/08635109
Patent No. 6538114
GENERAL INFORMATION:
APPLICANT: Persson, Mats A. A.
APPLICANT: Allander, Tobias E.
TITLE OF INVENTION: HUMAN MONOCLONAL ANTIBODIES SPECIFIC FOR
HEPATITIS C VIRUS (HCV) E2 ANTIGEN
NUMBER OF SEQUENCES: 23
CORRESPONDENCE ADDRESS:
ADDRESSEE: REED & ROBINS
STREET: 285 Hamilton Avenue, Suite 200
CITY: Palo Alto
STATE: California
COUNTRY: USA
ZIP: 94301

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/635,109
FILING DATE: 19-APR-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: McCracken, Thomas P
REGISTRATION NUMBER: 38,548
REFERENCE/DOCKET NUMBER: 2300-6146
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 327-3400
TELEFAX: (415) 327-3231
INFORMATION FOR SEQ ID NO: 21:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-635-109-21

Query Match 1.1%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 262 CTGGGCTGGCTGATCAAGA 281
|||||
Db 21 CTGGGCTGCTGCTCAACGA 2

RESULT 39

PCT-US93-00977-137/c
Sequence 137, Application PC/TUS9300977
GENERAL INFORMATION:
TITLE OF INVENTION: METHOD AND REAGENT FOR MEASURING MESSENGER RNA
NUMBER OF SEQUENCES: 711
CORRESPONDENCE ADDRESS:
ADDRESSEE: Knobbe, Martens, Olson, and Bear
STREET: 620 Newport Center Dr. Sixteenth Floor
CITY: Newport Beach
STATE: CA
COUNTRY: USA
ZIP: 92660
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/00977
FILING DATE: 19930129

CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Altman, Daniel E.
REGISTRATION NUMBER: 34,115
REFERENCE/DOCKET NUMBER: HITACHI.006H
TELEPHONE: 714-760-0404
TELEFAX: 714-760-9502
INFORMATION FOR SEQ ID NO: 137:
SEQUENCE CHARACTERISTICS:
LENGTH: 21
TYPE: NUCLEIC ACID
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: cDNA to mRNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
PCT-US93-00977-137

Query Match 1.1%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 492 CGGTGTGACGCTCTTGGGG 511
||||| ||||| ||||| |||||
Db 21 CGGTGTGACGCTCTTGGGG 2

RESULT 40
PCT-US95-08743-49/c
Sequence 49, Application PC/TUS9508743
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: HUMAN NEUTRALIZING MONOCLONAL ANTIBODIES
TITLE OF INVENTION: TO HUMAN IMMUNODEFICIENCY VIRUS
NUMBER OF SEQUENCES: 170
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25 (EPO)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/08743
FILING DATE: 11-JUL-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/276,852
FILING DATE: 18-JUL-1994
INFORMATION FOR SEQ ID NO: 49:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
PCT-US95-08743-49

Query Match 1.1%; Score 15.2; DB 1; Length 21;
Best Local Similarity 85.0%; Pred. No. 80;
Matches 17; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 262 CTGGGCTGGCTGATCAAGA 281
||||| ||||| ||||| |||||
Db 21 CTGGGCTGGCTGATCAAGA 2

RESULT 41
US-09-081-646-727
Sequence 727, Application US/09081646
Patent No. 6333152
GENERAL INFORMATION:
APPLICANT: Kinzler, Kenneth

APPLICANT: Vogelstein, Bert
APPLICANT: Zhang, Lin
APPLICANT: Zhou, Wei
TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
REFERENCE/DOCKET NUMBER: HITACHI.006H
TELEPHONE: 01107.74664
CURRENT APPLICATION NUMBER: US/09/081,646
CURRENT FILING DATE: 1998-05-20
EARLIER APPLICATION NUMBER: 60/047,352
EARLIER FILING DATE: 1997-05-21
NUMBER OF SEQ ID NOS: 871
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 727
LENGTH: 15
TYPE: DNA
ORGANISM: Homo sapiens
US-09-081-646-727

Query Match 1.1%; Score 15; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 38;
Matches 15; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 745 CATGTTGCTGACTTT 759
||||| ||||| ||||| |||||
Db 1 CATGTTGCTGACTTT 15

RESULT 42
US-08-585-684B-2539/c
Sequence 2539, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2539:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-585-684B-2539

Query Match 1.1%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 67;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 277 AAAGAGGAAGCAGCAGCA 294
Db 18 AAAGAGGAATCAGCAGCA 1

RESULT 43

US-09-038-073-2539/c
; Sequence 2539, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 2539:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-038-073-2539

Query Match 1.1%; Score 14.8; DB 1; Length 18;
Best Local Similarity 88.9%; Pred. No. 67;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 277 AAAGAGGAAGCAGCAGCA 294
Db 18 AAAGAGGAATCAGCAGCA 1

RESULT 44

US-08-630-592-14
; Sequence 14, Application US/08630592
; Patent No. 5770432
; GENERAL INFORMATION:

; APPLICANT: Nishina, Patsy
; APPLICANT: No. 5770432enTrauth, Konrad
; APPLICANT: Naggert, Juergen
; APPLICANT: No. 5770432th, Michael
; TITLE OF INVENTION: Obesity Associated Genes
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FLEHR, HOHBACH, TEST, ALBRITTON & HERBERT
; STREET: 3400 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-4187

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PCDOS/MSDOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/630,592
; FILING DATE:
; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:
; NAME: Sherwood, Pamela J.
; REGISTRATION NUMBER: 36,677
; REFERENCE/DOCKET NUMBER: A59504/BJR/PJS
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 7811989
; TELEFAX: (415) 3983249
; TELEX: 910 277299
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "primer"
US-08-630-592-14

Query Match 1.1%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 76;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 822 CCTGATCAGCTGAAGCT 839
Db 2 CCTGAGGCAGCAGCAAGCT 19

RESULT 45

US-08-714-991-14
; Sequence 14, Application US/08714991
; Patent No. 5776762
; GENERAL INFORMATION:
; APPLICANT: NISHINA, Patsy
; APPLICANT: NORTH, Michael
; APPLICANT: No. 5776762en-Trauth, Konrad
; APPLICANT: NAGGERT, Juergen
; TITLE OF INVENTION: OBESITY ASSOCIATED GENES
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FLEHR, HOHBACH, TEST, ALBRITTON & HERBERT
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-4187

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:

```

; APPLICATION NUMBER: US/08/714,991
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: SHERWOOD, Pamela J.
; REGISTRATION NUMBER: 36,677
; REFERENCE/DOCKET NUMBER: A-59504-1/PJS
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-494-8700
; TELEFAX: 415-494-8771
; TELEX: 910 277299
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "primer"
US-08-714-991-14

Query Match 1.1%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 76;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 822 CCTGATGCAGCTGAAGCT 839
Db 2 CCTGAGGCAGCAGAGCT 19

RESULT 46
US-09-032-365A-26
; Sequence 26, Application US/09032365A
; Patent No. 6114502
; GENERAL INFORMATION:
; APPLICANT: No. 6114502th, Michael
; APPLICANT: Nishina, Patsy
; APPLICANT: Naggart, Juergen
; APPLICANT: No. 6114502en-Trauth, Konrad
; TITLE OF INVENTION: GENE FAMILY ASSOCIATED WITH
; TITLE OF INVENTION: NEUROSENSORY DEFECTS
; NUMBER OF SEQUENCES: 67
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Bozicevic & Reed, LLP
; STREET: 285 Hamilton Avenue, Suite 200
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94301
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/032,365A
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Sherwood, Pamela J
; REGISTRATION NUMBER: 36,677
; REFERENCE/DOCKET NUMBER: SEQ-2CIP2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-327-3400
; TELEFAX: 650 327-3231
; TELEX:
; INFORMATION FOR SEQ ID NO: 26:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
```

```

; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-09-032-365A-26

Query Match 1.1%; Score 14.8; DB 1; Length 19;
Best Local Similarity 88.9%; Pred. No. 76;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 822 CCTGATGCAGCTGAAGCT 839
Db 2 CCTGAGGCAGCAGAGCT 19

RESULT 47
US-08-623-891-3/c
; Sequence 3, Application US/08623891
; Patent No. 5795778
; GENERAL INFORMATION:
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HERPES SIMPLEX
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 115
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/623,891
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/238,200
; FILING DATE:
; APPLICATION NUMBER: US/07/987,133
; FILING DATE:
; APPLICATION NUMBER: 07/882,921
; FILING DATE: May 14, 1992
; APPLICATION NUMBER: 07/948,359
; FILING DATE: September 18, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 200/209
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-623-891-3

Query Match 1.1%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 130 GGACAGGGAGCGCCGCTC 147
Db 19 GGACAGGGAGCGCCGATC 2
```

```
RESULT 48
US-09-286-904-42/c
; Sequence 42, Application US/09286904A
; Patent No. 6140124
; GENERAL INFORMATION:
; APPLICANT: Monia, Brett P.
; APPLICANT: Gaarde, William A.
; APPLICANT: Nero, Pamela S.
; APPLICANT: McKay, Robert
; TITLE OF INVENTION: Antisense oligonucleotide Modulation of p38 Mitogen
; FILE REFERENCE: ISPH-0347
; CURRENT APPLICATION NUMBER: US/09/286,904A
; CURRENT FILING DATE: 1999-04-06
; NUMBER OF SEQ ID NOS: 95
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 42
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-09-286-904-42

Query Match 1.1%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1287 TACAGTGTCTCAGCCTGG 1304
Db 19 TAGAGCTGCTCAGCCTGG 2

RESULT 49
US-09-742-703-11
; Sequence 11, Application US/09742703
; Patent No. 6423543
; GENERAL INFORMATION:
; APPLICANT: Patrick Allen Marcotte
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF HEPSEN EXPRESSION
; FILE REFERENCE: R1S-0090
; CURRENT APPLICATION NUMBER: US/09/742,703
; CURRENT FILING DATE: 2000-12-20
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 11
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense oligonucleotide
US-09-742-703-11

Query Match 1.1%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 721 CAGCAGCGGGCGGCTGG 738
Db 2 CAGCAGCGGGCGGCTGG 19

RESULT 50
US-09-340-861-3/c
; Sequence 3, Application US/09340861
; Patent No. 6432704
; GENERAL INFORMATION:
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HERPES SIMPLEX
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 115
```

```
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/340,861
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/987,133
; FILING DATE:
; APPLICATION NUMBER: 07/882,921
; FILING DATE: May 14, 1992
; APPLICATION NUMBER: 07/948,359
; FILING DATE: September 18, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 200/209
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-340-861-3

Query Match 1.1%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 130 GGACAGGCGGCGGCTC 147
Db 19 GGACAGGCGGCGGCTC 2

RESULT 51
US-09-634-262-3/c
; Sequence 3, Application US/09634262
; Patent No. 6440719
; GENERAL INFORMATION:
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HERPES SIMPLEX
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 115
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 611 West Sixth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/634,262
; FILING DATE:
```

CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/07/987,133
FILING DATE:
APPLICATION NUMBER: 07/882,921
FILING DATE: May 14, 1992
APPLICATION NUMBER: 07/948,359
FILING DATE: September 18, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 200/209
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 20
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-09-634-262-3

Query Match 1.1%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 130 GGACGGGACGCCGCTC 147
Db 19 GGACGGGACGCCGATC 2

RESULT 52

US-09-640-101-42/c
Sequence 42, Application US/09640101
Patent No. 6448079
GENERAL INFORMATION:
APPLICANT: Monia, Brett P.
APPLICANT: Gaarde, William A.
APPLICANT: Nero, Pamela S.
APPLICANT: McKay, Robert
TITLE OF INVENTION: Antisense Modulation of p38 Mitogen
FILE REFERENCE: ISPH-0488
CURRENT APPLICATION NUMBER: US/09/640,101
CURRENT FILING DATE: 2000-08-15
PRIOR APPLICATION NUMBER: 09/286,904
PRIOR FILING DATE: 1999-04-06
NUMBER OF SEQ ID NOS: 107
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 42
LENGTH: 20
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: antisense sequence
US-09-640-101-42

Query Match 1.1%; Score 14.8; DB 1; Length 20;
Best Local Similarity 88.9%; Pred. No. 87;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1287 TAGAGTGTCTCAGCTGG 1304
Db 19 TAGAGTGTCTCAGCTGG 2

RESULT 53

US-09-099-053-19
Sequence 19, Application US/09099053
Patent No. 6388063
GENERAL INFORMATION:

APPLICANT: Greg Plowman
APPLICANT: Susan Onrust
APPLICANT: David Markby
APPLICANT: Sara Courtneise
TITLE OF INVENTION: DIAGNOSIS AND TREATMENT OF
NUMBER OF SEQUENCES: 28
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/099,053
FILING DATE: Herewith
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/049,914
FILING DATE: June 18, 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 235/121
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 21 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-099-053-19

Query Match 1.1%; Score 14.8; DB 1; Length 21;
Best Local Similarity 88.9%; Pred. No. 98;
Matches 16; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 374 CCCAGCTTCTCCAGAGG 391
Db 4 CCCAGCTTCTCCAGG 21

RESULT 54

US-09-359-921-27/c
Sequence 27, Application US/09359921
Patent No. 6545162
GENERAL INFORMATION:
APPLICANT: DERVAN, PETER B.
APPLICANT: BAIRD, ELDON E.
TITLE OF INVENTION: METHOD FOR THE SYNTHESIS OF PYRROLE AND IMIDAZOLE
FILE REFERENCE: 025098-1602
CURRENT APPLICATION NUMBER: US/09/359,921
CURRENT FILING DATE: 1999-07-22
NUMBER OF SEQ ID NOS: 31
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 27
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic

; OTHER INFORMATION: oligonucleotide
US-09-359-921-27

Query Match 1.1%; Score 14.4; DB 1; Length 17;
Best Local Similarity 93.8%; Pred. No. 71;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1142 CCTTTTCTTTTGG 1157
17 CCTTTTGTCTTTG 2

RESULT 55

US-09-178-115-113/c
; Sequence 113, Application US/09178115
; Patent No. 6297041
; GENERAL INFORMATION:
; APPLICANT: Zavada, Jan
; APPLICANT: Pastorekova, Silvia
; TITLE OF INVENTION: MN Gene and Protein
; FILE REFERENCE: D-0021.5A
; CURRENT APPLICATION NUMBER: US/09/178,115
; CURRENT FILING DATE: 1998-10-23
; EARLIER APPLICATION NUMBER: 09/177,776
; EARLIER FILING DATE: 1998-10-23
; EARLIER APPLICATION NUMBER: 08/787,739
; EARLIER FILING DATE: 1997-01-24
; EARLIER APPLICATION NUMBER: 08/485,049
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/486,756
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/477,504
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/481,658
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/485,862
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/485,863
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/487,077
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/260,190
; EARLIER FILING DATE: 1994-06-15
; EARLIER APPLICATION NUMBER: 08/177,093
; EARLIER FILING DATE: 1993-12-30
; EARLIER APPLICATION NUMBER: 07/964,589
; EARLIER FILING DATE: 1992-10-21
; EARLIER APPLICATION NUMBER: PV-709-92
; EARLIER FILING DATE: 1992-03-11
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 113
; LENGTH: 18
; TYPE: DNA
; ORGANISM: HUMAN
US-09-178-115-113

Query Match 1.1%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 82;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1017 GAGATGGTGCCAAAGT 1032
18 GAGATGGAGCCAAAGT 3

RESULT 56

US-09-177-776-113/c
; Sequence 113, Application US/0917776A
; Patent No. 6297051
; GENERAL INFORMATION:
; APPLICANT: Zavada, Jan

; APPLICANT: Pastorekova, Silvia
; APPLICANT: Pastorek, Jaromir
; TITLE OF INVENTION: MN Gene and Protein
; FILE REFERENCE: D-0021.5A
; CURRENT APPLICATION NUMBER: US/09/177,776A
; CURRENT FILING DATE: 1998-10-23
; EARLIER APPLICATION NUMBER: 08/787,739
; EARLIER FILING DATE: 1997-01-24
; EARLIER APPLICATION NUMBER: 08/485,049
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/486,756
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/477,504
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/481,658
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/485,862
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/485,863
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/487,077
; EARLIER FILING DATE: 1995-06-07
; EARLIER APPLICATION NUMBER: 08/260,190
; EARLIER FILING DATE: 1994-06-15
; EARLIER APPLICATION NUMBER: 08/177,093
; EARLIER FILING DATE: 1993-12-30
; EARLIER APPLICATION NUMBER: 07/964,589
; EARLIER FILING DATE: 1992-10-21
; EARLIER APPLICATION NUMBER: PV-709-92
; EARLIER FILING DATE: 1992-03-11
; NUMBER OF SEQ ID NOS: 116
; SOFTWARE: Patentin Ver. 2.0
; SEQ ID NO 113
; LENGTH: 18
; TYPE: DNA
; ORGANISM: HUMAN
US-09-177-776-113

Query Match 1.1%; Score 14.4; DB 1; Length 18;
Best Local Similarity 93.8%; Pred. No. 82;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1017 GAGATGGTGCCAAAGT 1032
18 GAGATGGAGCCAAAGT 3

RESULT 57

US-08-376-362A-8/c
; Sequence 8, Application US/08376362A
; Patent No. 5693756
; GENERAL INFORMATION:
; APPLICANT: Li, Xiao-Jiang
; APPLICANT: Blackshaw, Seth
; APPLICANT: Snyder, Solomon H.
; TITLE OF INVENTION: AMILORIDE-SENSITIVE SODIUM CHANNEL AND
; TITLE OF INVENTION: METHOD OF IDENTIFYING SUBSTANCES WHICH STIMULATE OR BLOCK
; TITLE OF INVENTION: SALT TASTE PERCEPTION
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Allegretti, LTD
; STREET: 1001 G Street, N.W., Eleventh Floor
; CITY: Washington
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20001-4597
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/376,362A

```
; FILING DATE: 23-JAN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Kagan A., Sarah
; REGISTRATION NUMBER: 32,141
; REFERENCE/DOCKET NUMBER: 01107.48125
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202 508-9100
; TELEFAX: 202-508-9299
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
US-08-376-362A-8

Query Match 1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 629 AGCTCCAGGAGCTCTG 644
Db 16 AGCCCCAGGAGCTCTG 1

RESULT 59
US-08-634-331-3
; Sequence 3, Application US/08634331
; Patent No. 5707809
; GENERAL INFORMATION:
; APPLICANT: HALVERSON, Joy L.
; TITLE OF INVENTION: AVIAN SEX IDENTIFICATION PROBES
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FLEHR, HOBRACH, TEST, ALBRITTON & HERBERT
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-4187
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/634,331
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: SHERWOOD, Pamela J.
; REGISTRATION NUMBER: 36,677
; REFERENCE/DOCKET NUMBER: A-55362-3/BIR/PJS
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 494-8700
; TELEFAX: (415) 494-8771
; TELEX: 910 2777299FHT UR
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Primer"
US-08-634-331-3

Query Match 1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
```

```
QY 670 TTGGCCAGCGTGGTAT 685
Db 3 TAGGCCAGCGTGGTAT 18

RESULT 59
US-08-450-905B-134
; Sequence 134, Application US/08450905B
; Patent No. 5856301
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Stem Cell Inhibiting Proteins
; NUMBER OF SEQUENCES: 178
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE and DORR
; STREET: 60 State Street
; CITY: Boston
; STATE: MA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/450,905B
; FILING DATE: 26-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/982,759
; FILING DATE: 08-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9127319.3
; FILING DATE: 23-DEC-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9221587.0
; FILING DATE: 14-OCT-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: BAKER, HOLLIE L.
; REGISTRATION NUMBER: 31,321
; REFERENCE/DOCKET NUMBER: 102.378.120DV-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-526-6110
; TELEFAX: 617-526-5000
; INFORMATION FOR SEQ ID NO: 134:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..20
; OTHER INFORMATION: /product= "BB9513 oligomer"
US-08-450-905B-134

Query Match 1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 840 TTCAGATGGGTGACGA 855
Db 4 TTCAGATGGGTGACGA 19

RESULT 60
US-07-982-759F-134
; Sequence 134, Application US/07982759F
; Patent No. 6057123
; GENERAL INFORMATION:
; APPLICANT: CRAIG, Stewart
; APPLICANT: GEORGE, Michael
```

```
;; APPLICANT: EDWARDS, Richard Mark
;; APPLICANT: CZAPLEWSKI, Lloyd George
;; APPLICANT: GILBERT, Richard
;; TITLE OF INVENTION: Stem Cell Inhibiting Proteins
;; NUMBER OF SEQUENCES: 178
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: HALE and DORR LLP
;; STREET: 60 State Street
;; CITY: Boston
;; STATE: MA
;; ZIP: 02109
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/07/982,759F
;; FILING DATE: 08-MAR-1993
;; PRIOR APPLICATION DATA: GB 9127319.3
;; FILING DATE: 23-DEC-1991
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: GB 9221587.0
;; FILING DATE: 14-OCT-1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: BAKER, HOLLIE L.
;; REGISTRATION NUMBER: 31,321
;; REFERENCE/DOCKET NUMBER: 102378.120
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 617-526-6000
;; TELEFAX: 617-526-5000
;; INFORMATION FOR SEQ ID NO: 134:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA
;; FEATURE:
;; NAME/KEY: misc_feature
;; LOCATION: 1..20
;; OTHER INFORMATION: /product= "BB9513 oligomer"
US-07-982-759F-134

Query Match 1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 840 TTCAGATGGGTGACGA 855
Db 4 TTCAGATGGGTGACGA 19

RESULT 61
US-09-280-805-48/c
; Sequence 48, Application US/09280805
; Patent No. 6184212
; GENERAL INFORMATION:
; APPLICANT: Loren J. Miraglia, Pamela Nero, Mark J.
; APPLICANT: Graham, Brett P. Monia
; TITLE OF INVENTION: ANTISENSE MODULATION OF HUMAN MDM2
; TITLE OF INVENTION: EXPRESSION
; NUMBER OF SEQUENCES: 271
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Law Offices of Jane Massey Licata
; STREET: 66 East Main Street
; CITY: Marlton
; STATE: NJ
; COUNTRY: U.S.A.
; ZIP: 08053
; COMPUTER READABLE FORM:
; MEDIUM TYPE: DISKETTE, 3.5 INCH, 1.44 MB STORAGE

;; COMPUTER: IBM PC
;; OPERATING SYSTEM: WINDOWS 95
;; SOFTWARE: WORDPERFECT 6.0
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/280,805
;; FILING DATE: herewith
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 09/048,810
;; FILING DATE: March 26, 1998
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Licata, Jane Massey
;; REGISTRATION NUMBER: 32,257
;; REFERENCE/DOCKET NUMBER: ISPH-0346
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 609-810-1515
;; TELEFAX: 609-810-1454
;; INFORMATION FOR SEQ ID NO: 48:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 20 base pairs
;; TYPE: Nucleic Acid
;; STRANDEDNESS: Single
;; TOPOLOGY: Linear
;; ANTI-SENSE: Yes
US-09-280-805-48

Query Match 1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 788 CCAGTGCCTGGCTCG 803
Db 20 CCAGTGCCTGGCCCG 5

RESULT 62
US-09-150-460B-2
; Sequence 2, Application US/09150460B
; Patent No. 6190882
; GENERAL INFORMATION:
; APPLICANT: Lee, Cheng-Chi
; APPLICANT: Albrecht, Urs
; APPLICANT: Bichele, Gregor
; APPLICANT: Sun, Zhong Sheng
; TITLE OF INVENTION: Mammalian Circadian Rhythm-Like Gene
; FILE REFERENCE: D6039
; CURRENT APPLICATION NUMBER: US/09/150,460B
; CURRENT FILING DATE: 1998-09-09
; PRIOR APPLICATION NUMBER: US 60/058,256
; PRIOR FILING DATE: 1997-09-09
; NUMBER OF SEQ ID NOS: 21
; SEQ ID NO 2
; LENGTH: 20
; TYPE: DNA
; ORGANISM: artificial sequence
; FEATURE:
; OTHER INFORMATION: Primer used for the STS-PCR mapping of RIGUI
US-09-150-460B-2

Query Match 1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 624 GGACCAGCTCCAGGAG 639
Db 1 GGACCATCTCCAGGAG 16

RESULT 63
US-09-228-942-7/c
; Sequence 7, Application US/09228942
; Patent No. 6203988
; GENERAL INFORMATION:
```

```
; APPLICANT: Kambara, Hideki
; APPLICANT: Uematsu, Chihiro
; TITLE OF INVENTION: DNA FRAGMENT ANALYSIS METHOD AND REAGENT KIT
; FILE REFERENCE: ASA-757
; CURRENT APPLICATION NUMBER: US/09/228,942
; CURRENT FILING DATE: 1999-01-12
; NUMBER OF SEQ ID NOS: 8
; SOFTWARE: Patent In Ver. 2.0
; SEQ ID NO 7
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence:
; OTHER INFORMATION: oligonucleotide ligated to 3' end of DNA fragment
US-09-228-942-7

Query Match          1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1144 TTTTTCCTTTTGA 1159
Db      18 TTTTTCCTTTTGA 3

RESULT 64
US-09-517-467B-240
; Sequence 240, Application US/09517467B
; Patent No. 6451602
; GENERAL INFORMATION:
; APPLICANT: Ian Popoff
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF PAMP EXPRESSION
; FILE REFERENCE: RTS-0150
; CURRENT APPLICATION NUMBER: US/09/517,467B
; CURRENT FILING DATE: 2001-03-02
; PRIOR APPLICATION NUMBER: 09/517,467
; PRIOR FILING DATE: 2000-03-02
; NUMBER OF SEQ ID NOS: 345
; SEQ ID NO 240
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-517-467B-240

Query Match          1.1%; Score 14.4; DB 1; Length 20;
Best Local Similarity 93.8%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      1289 CAGTTCCTCAGCTGG 1304
Db      2 CAGTTCCTCAGCTGG 17

RESULT 65
US-08-246-489-7
; Sequence 7, Application US/08246489
; Patent No. 6225049
; GENERAL INFORMATION:
; APPLICANT: Ian, Michael S.
; APPLICANT: No. 6225049Kins, Abner L.
; TITLE OF INVENTION: NOVEL HUMAN INSULINOMA-ASSOCIATED CDNA
; NUMBER OF SEQUENCES: 27
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Knobbe, Martens, Olson & Bear
; STREET: 620 Newport Center Drive
; CITY: Newport Beach
; STATE: California
; COUNTRY: USA
; ZIP: 92660
```

```
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/246,489
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/901,715
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Israelsen, Ned A.
; REGISTRATION/DOCKET NUMBER: 29,655
; REFERENCE/DOCKET NUMBER: NIH012.012A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 235-8550
; TELEFAX: (619) 235-0176
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-246-489-7

Query Match          1.0%; Score 14.2; DB 1; Length 19;
Best Local Similarity 84.2%; Pred. No. 1e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      521 ACCTGCCGAGGAGCAGCT 539
Db      1 ACCTGCAGGAGGATCACCT 19

RESULT 66
US-08-033-081B-18
; Sequence 18, Application US/08033081B
; Patent No. 5498521
; GENERAL INFORMATION:
; APPLICANT: Dryja, Thaddeus P.
; APPLICANT: Berson, Elliot L.
; TITLE OF INVENTION: DIAGNOSIS OF HEREDITARY RETINAL
; TITLE OF INVENTION: DEGENERATIVE DISEASES
; NUMBER OF SEQUENCES: 25
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Fish & Richardson
; STREET: 225 Franklin Street
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: U.S.A.
; ZIP: 02110-2804
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM PS/2 Model 502 or 55SX
; OPERATING SYSTEM: MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/033,081B
; FILING DATE: March 11, 1993
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/825,296
; FILING DATE: January 23, 1992
; APPLICATION NUMBER: 07/469,215
; FILING DATE: January 24, 1990
; ATTORNEY/AGENT INFORMATION:
; NAME: Clark, Paul T.
; REGISTRATION NUMBER: 30,162
```

REFERENCE/DOCKET NUMBER: 00246/069005
TELECOMMUNICATION INFORMATION:

TELEPHONE: (617) 542-5070
TELEFAX: (617) 542-8906
TELEX: 200154

INFORMATION FOR SEQ ID NO: 18:

SEQUENCE CHARACTERISTICS:

LENGTH: 20

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-033-081B-18

Query Match 1.0%; Score 14.2; DB 1; Length 20;

Best Local Similarity 84.2%; Pred. No. 1.2e+02;

Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 324 CCTGCATCATCCTGGTGAT 342

Db 2 CCTGCACACCTGGTGAT 20

RESULT 67

US-08-117-952-417

Sequence 417, Application US/08117952

Patent No. 5851760

GENERAL INFORMATION:

APPLICANT: Evans, Glen A.

APPLICANT: Smith, Michael W.

TITLE OF INVENTION: METHOD FOR GENERATION OF SEQUENCE

TITLE OF INVENTION: SAMPLED MAPS OF COMPLEX GENOMES

NUMBER OF SEQUENCES: 797

CORRESPONDENCE ADDRESS:

ADDRESSEE: Pretty, Schroeder, Brueggemann & Clark

STREET: 444 South Flower Street, Suite 2000

CITY: Los Angeles

STATE: CA

COUNTRY: USA

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, Version #1.25

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/117,952

FILING DATE: 07-SEP-1993

CLASSIFICATION: 435

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 08/078,471

FILING DATE: 15-JUN-1993

ATTORNEY/AGENT INFORMATION:

NAME: Reiter, Stephen E.

REGISTRATION NUMBER: 31,192

REFERENCE/DOCKET NUMBER: P41 9423

TELEPHONE: 619-546-4737

TELEFAX: 619-546-9392

INFORMATION FOR SEQ ID NO: 417:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: Oligonucleotide

HYPOTHETICAL: NO

ANTI-SENSE: NO

US-08-117-952-417

Query Match

Best Local Similarity 1.0%; Score 14.2; DB 1; Length 20;

Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1159 AGTAAAGCAGCTAAACA 1177

Db 1 AAGTAAAGCGCAAAAGCA 19

RESULT 68

US-09-048-880-11/c

Sequence 11, Application US/09048880

Patent No. 5952202

GENERAL INFORMATION:

APPLICANT: Aoyagi et al.

TITLE OF INVENTION: METHODS FOR EXOGENOUS, INTERNAL CONTROLS

TITLE OF INVENTION: DURING NUCLEIC ACID AMPLIFICATION

NUMBER OF SEQUENCES: 16

CORRESPONDENCE ADDRESS:

ADDRESSEE: The Perkin-Elmer Corporation

STREET: 850 Lincoln Centre Drive

CITY: Foster City,

STATE: California

COUNTRY: USA

ZIP: 94044

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: FastSeq for Windows Version 2.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/048,880

FILING DATE: 26-MAR-1998

PRIOR APPLICATION DATA:

APPLICATION NUMBER: To Be Assigned

FILING DATE: March 26, 1998

ATTORNEY/AGENT INFORMATION:

NAME: Scott R. Bortner

REGISTRATION NUMBER: 34,298

REFERENCE/DOCKET NUMBER: 4382

TELECOMMUNICATION INFORMATION:

TELEPHONE: (650) 638-6245

TELEFAX: (650) 638-6071

INFORMATION FOR SEQ ID NO: 11:

SEQUENCE CHARACTERISTICS:

LENGTH: 20 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-09-048-880-11

Query Match

Best Local Similarity 1.0%; Score 14.2; DB 1; Length 20;

Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 620 TCAGGGACGAGCTCCAGGA 638

Db 20 TCAGGAACCTGGTCCAGGA 2

RESULT 69

US-08-991-300-4/c

Sequence 4, Application US/08991300

Patent No. 5973225

GENERAL INFORMATION:

APPLICANT: D'OVIDIO, RENATO

APPLICANT: PORCEDDU, ENRICO

APPLICANT: MERCHITELLI, CINZIA

APPLICANT: CARDELLI, LUISA ERCOLI

TITLE OF INVENTION: ISOLATION AND CHARACTERIZATION OF A GENE

TITLE OF INVENTION: ENCODING A LOW MOLECULAR WEIGHT GLUTENIN

NUMBER OF SEQUENCES: 6

CORRESPONDENCE ADDRESS:

ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,

ADDRESSEE: P.C.

STREET: 1755 S. JEFFERSON DAVIS HIGHWAY

CITY: ARLINGTON

```
/ STATE: VA
/ COUNTRY: USA
/ ZIP: 22202
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/991,300
/ FILING DATE: 16-DEC-1997
/ CLASSIFICATION: 800
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: IT MI 96/A 002663
/ FILING DATE: 19-DEC-1996
/ ATTORNEY/AGENT INFORMATION:
/ NAME: OBLON, NORMAN F.
/ REGISTRATION NUMBER: 24,618
/ REFERENCE/DOCKET NUMBER: 2264-0201-0X
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 703-413-3000
/ TELEFAX: 703-413-2220
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: other nucleic acid
/ DESCRIPTION: /desc = "PRIMER"
US-08-991-300-4

Query Match
Best Local Similarity 1.0%; Score 14.2; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1011 GCACCTGAGAGTGTGCCAA 1029
DB 20 GCACCGGAGTGTGTCCTA 2

RESULT 70
US-08-715-461-4
/ Sequence 4, Application US/08715461
/ Patent No. 5985556
/ GENERAL INFORMATION:
/ APPLICANT: KAMBARA, Hideki
/ APPLICANT: OKANO, Kazumori
/ TITLE OF INVENTION: DNA SEQUENCING METHOD AND DNA SAMPLE
/ TITLE OF INVENTION: PREPARATION METHOD
/ NUMBER OF SEQUENCES: 9
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: ANTONELLI, TERRY STOUT & KRAUS
/ STREET: 1300 No. 598556th Seventeenth Street, Suite 1800
/ CITY: Arlington
/ STATE: VA
/ COUNTRY: USA
/ ZIP: 22209
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/715,461
/ FILING DATE: 18-SEP-1996
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: TERRY, David T.
/ REGISTRATION NUMBER: 20,178
/ REFERENCE/DOCKET NUMBER: 500.34872X00
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 703-312-6600
```

```
/ TELEFAX: 703-312-6666
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: other nucleic acid
/ HYPOTHETICAL: NO
/ ANTI-SENSE: NO
US-08-715-461-4

Query Match
Best Local Similarity 1.0%; Score 14.2; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1144 TTTTCTCTTTTGAAGT 1162
DB 2 TTTTCTCTTTTGAAGT 20

RESULT 71
US-08-755-587-59/c
/ Sequence 59, Application US/08755587
/ Patent No. 6045997
/ GENERAL INFORMATION:
/ APPLICANT: Futreal, Phillip A
/ APPLICANT: Wooster, Richard F
/ APPLICANT: Ashworth, Alan
/ APPLICANT: Stratton, Michael R
/ TITLE OF INVENTION: Materials and methods relating to the
/ TITLE OF INVENTION: identification and sequencing of the BRCA2 cancer
/ NUMBER OF SEQUENCES: 222
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Bell Seltzer Park & Gibson
/ STREET: 310 UCB Plaza, 3605 Glenwood Avenue, PO Drawer 31107
/ CITY: Raleigh
/ STATE: NC
/ COUNTRY: USA
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25 (EPO)
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/755,587
/ FILING DATE: 25-NOV-1996
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: GB 9523959.6
/ FILING DATE: 23-NOV-1995
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: GB 9525555.0
/ FILING DATE: 14-DEC-1995
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: GB 9617961.9
/ FILING DATE: 28-AUG-1996
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Kenneth D Sibley
/ REGISTRATION NUMBER: 31,665
/ REFERENCE/DOCKET NUMBER: 5405-135
/ INFORMATION FOR SEQ ID NO: 59:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-755-587-59

Query Match
Best Local Similarity 1.0%; Score 14.2; DB 1; Length 20;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```



```

; CURRENT APPLICATION NUMBER: US/09/130,616C
; CURRENT FILING DATE: 1998-08-07
; EARLIER APPLICATION NUMBER: 08/910,629
; EARLIER FILING DATE: 1997-08-03
; NUMBER OF SEQ ID NOS: 178
; SEQ ID NO 123
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Synthetic sequence
US-09-130-616-123

```

Query Match	1.0%	Score 14.2	DB 1	Length 20
Best Local Similarity	84.2%	Pred. No. 1.2e+02		
Matches 16	Conservative	0	Mismatches 3	Indels 0
				Gaps 0

Qy 910 CTGGTCCTAAAGGAGATGG 928
Db 2. CTGCACCTAAAGGAGACGG 20

RESULT 77
US-09-270-542-155/c
; Sequence 155, Application US/09270542
; Patent No. 6322976
; GENERAL INFORMATION:
; APPLICANT: Altman, Timothy
; APPLICANT: Scott, James
; APPLICANT: Stanton, Lawrence
; TITLE OF INVENTION: Compositions and Methods of Disease Diagnosis and
; TITLE OF INVENTION: Therapy
; FILE REFERENCE: 4198/78179
; CURRENT APPLICATION NUMBER: US/09/270,542
; CURRENT FILING DATE: 1999-03-17
; EARLIER APPLICATION NUMBER: 09/221,222
; EARLIER FILING DATE: 1999-12-23
; NUMBER OF SEQ ID NOS: 207
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 155
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Rattus norvegicus
US-09-270-542-155

Query Match	1.0%;	Score 14.2;	DB 1;	Length 20;
Best Local Similarity	84.2%;	Pred. No. 1.2e+02;		
Matches 16;	Conservative	0;	Mismatches 3;	Indels 0;
				Gaps 0;

Qy 622 AGGACCAAGTCCAGGAGC 640
Dy 19 AGGACCAAGTCCAGGGGC 1

```

RESULT 78
US-09-851-062-47/c
; Sequence 47, Application US/09851062
; Patent No. 6448081
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF INTERLEUKIN 12 P40 SUBUNIT EXPRESSION
; FILE REFERENCE: RTS-0347
; CURRENT APPLICATION NUMBER: US/09/851,062
; CURRENT FILING DATE: 2001-05-07
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 47
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-851-062-47

```

```

Query Match      1.0%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.2e+00;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy      227 CTCAGCCTCAGGCATCTGC 245
      ||||| | | | | | | | |
Db      20 CTCAGCCACGGTCATCTGC 2

```

RESULT 79
US-09-920-672-52/c
; Sequence 52, Application US/09920672
; Patent No. 6455308
; GENERAL INFORMATION:
; APPLICANT: Mark J. Graham
; APPLICANT: Susan M. Freier
; TITLE OF INVENTION: ANTISENSE MODULATION OF SERUM AMYLOID A4 EXPRESSION
; FILE REFERENCE: RTS-0251
; CURRENT APPLICATION NUMBER: US/09/920,672
; CURRENT FILING DATE: 2001-08-01
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 52
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-920-672-52

Query Match	1.0%	Score 14.2	DB 1	Length 20
Best Local Similarity	84.2%	Pred. No. 1.2e+02		
Matches 16	Conservative	0	Mismatches 3	Indels 0
				Gaps 0

QY 282 GGAAGCAGCAGCAATGTCT 300
|||
Db 20 GGAACAGCAGCACTGTAT 2

```

RESULT 80
US-09-527-073-4/c
; Sequence 4, Application US/09527073
; Patent No. 6534313
; GENERAL INFORMATION:
; APPLICANT: Michael M. Neff
; APPLICANT: Joanne Chory
; TITLE OF INVENTION: GENETICALLY MODIFIED PLANTS HAVING
; TITLE OF INVENTION: MODULATED BRASSINOSTEROID SIGNALING
; FILE REFERENCE: SALKINS 024A
; CURRENT APPLICATION NUMBER: US/09/527,073
; CURRENT FILING DATE: 2000-03-16
; PRIOR APPLICATION NUMBER: US 60/124570
; PRIOR FILING DATE: 1999-03-16
; PRIOR APPLICATION NUMBER: US 60/170,931
; PRIOR FILING DATE: 1999-12-14
; PRIOR APPLICATION NUMBER: US 60/172,832
; PRIOR FILING DATE: 1999-12-20
; NUMBER OF SEQ ID NOS: 16
; SOFTWARE: FastSeq for Windows Version 4.0
; SEQ ID NO 4
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer
US-09-527-073-4

```

Query Match	1.0%	Score 14.2;	DB 1;	Length 20;
Best Local Similarity	84.2%;	Pred. No. 1.2e+02;		
Matches 16;	Conservative 0;	Mismatches 3;	Indels 0;	Gaps 0;
QY	1037	CTGACTCTTCCACGACAG	1055	

Db 19 CTCACACTTCCACGACAG 1

RESULT 81
US-09-422-978-6216/c
; Sequence 6216, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET 020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6216
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: upstream amplification primer 99-10151 for SEQ 2282,
US-09-422-978-6216

Query Match 1.0%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1205 CACACCTCCCTCCCTGT 1223
Db 19 CAGACCTCACTCCCTGT 1

RESULT 82
US-09-422-978-11618/c
; Sequence 11618, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET 020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11618
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..20
; OTHER INFORMATION: downstream amplification primer 99-11303 for SEQ 3753, in complete
US-09-422-978-11618

Query Match 1.0%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1232 CTTGGTGTGACGTGGC 1250
Db 20 CTTGGTGTGGAAGGGC 2

RESULT 83
US-09-230-652-103/c
; Sequence 103, Application US/09230652A
; Patent No. 6537775
; GENERAL INFORMATION:
; APPLICANT: Tournier-Lasserre, Elisabeth
; APPLICANT: Joutel, Anne
; APPLICANT: Bousser, Marie-Germaine
; APPLICANT: Bach, Jean-Francois
; TITLE OF INVENTION: GENE INVOLVED IN CADASIL, METHOD OF DIAGNOSIS AND
; FILE REFERENCE: 03715.0048-00000
; CURRENT APPLICATION NUMBER: US/09/230,652A
; CURRENT FILING DATE: 1999-05-17
; EARLIER APPLICATION NUMBER: FR 96 09733
; EARLIER FILING DATE: 1996-08-01
; EARLIER APPLICATION NUMBER: FR 97 04680
; EARLIER FILING DATE: 1997-04-16
; EARLIER APPLICATION NUMBER: PCT/FR97/01433
; EARLIER FILING DATE: 1997-07-31
; NUMBER OF SEQ ID NOS: 163
; SOFTWARE: Patentin Ver. 2.1
; SEQ ID NO 103
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-230-652-103

Query Match 1.0%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1208 ACCTCCCTTCCCTGTACA 1226
Db 20 ACCTCACCCTCCCTGTGCA 2

RESULT 84
US-09-843-376-62
; Sequence 62, Application US/09843376
; Patent No. 6566132
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Andrew T. Watt
; TITLE OF INVENTION: ANTISENSE MODULATION OF INTERFERON GAMMA RECEPTOR 1 EXPRESSION
; FILE REFERENCE: RTS-0234
; CURRENT APPLICATION NUMBER: US/09/843,376
; CURRENT FILING DATE: 2001-04-26
; NUMBER OF SEQ ID NOS: 88
; SEQ ID NO 62
; LENGTH: 20
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-843-376-62

Query Match 1.0%; Score 14.2; DB 1; Length 20;
Best Local Similarity 84.2%; Pred. No. 1.2e+02;
Matches 16; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1158 GAGTAAAGCAGCTAAAC 1176
Db 1 GTAGTAAAGCAGCAAC 19

RESULT 85
US-08-679-529-6
; Sequence 6, Application US/08679529
; Patent No. 6171779
; GENERAL INFORMATION:
; APPLICANT: Chada, Kirin K.
; APPLICANT: Ashar, Hena
; APPLICANT: Tkachenko, Alex
; APPLICANT: Zhou, Xianjin
; TITLE OF INVENTION: HMGI Proteins in Cancer and Obesity
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richard R. Muccino
; STREET: 758 Springfield Avenue
; CITY: Summit
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07901
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,529
; FILING DATE: 12-JUL-1996
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Muccino, Richard R.
; REGISTRATION NUMBER: 32,538
; REFERENCE/DOCKET NUMBER: UMD1-037
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (908) 273-4988
; TELEFAX: (908) 273-4679
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: unknown
; TOPOLOGY: unknown
; MOLECULE TYPE: DNA (genomic)
; HYPOTHETICAL: NO
US-08-679-529-6
Query Match 1.0%; Score 14; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 282 GGAAGCAGCAGCAA 295
Db 1 GGAAGCAGCAGCAA 14
RESULT 86
PCT-US91-03680-3
; Sequence 3, Application PC/TUS9103680
; GENERAL INFORMATION:
; APPLICANT: Matteucci, Mark D.
; APPLICANT: Krawczyk, Steven
; TITLE OF INVENTION: SEQUENCE-SPECIFIC NONPHOTOACTIVATED
; CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
; TITLE OF INVENTION: DUPLUX DNA
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM: disk
; MEDIUM TYPE: Floppy

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US91/03680
FILING DATE: 19910524
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Murashige, Kate H.
REGISTRATION NUMBER: 29,959
REFERENCE/DOCKET NUMBER: 4610-0011.40
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-327-7250
TELEFAX: 415-327-2951
TELEX: 706141
INFORMATION FOR SEQ ID NO: 3:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: linear
FEATURE:
NAME/KEY: modified_base
LOCATION: 1
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "5-methylcytosine"
FEATURE:
NAME/KEY: modified_base
LOCATION: 9
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "5-methylcytosine"
FEATURE:
NAME/KEY: modified_base
LOCATION: 15
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "5-methylcytosine"
FEATURE:
NAME/KEY: modified_base
LOCATION: 18
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "5-methylcytosine"
FEATURE:
NAME/KEY: modified_base
LOCATION: 19
OTHER INFORMATION: /mod_base= OTHER
OTHER INFORMATION: /note= "1,3-propanediol"
PCT-US91-03680-3
Query Match 1.0%; Score 14; DB 1; Length 19;
Best Local Similarity 100.0%; Pred. No. 1.1e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 1143 CTTTCTTCTTTT 1156
Db 1 CTTTCTTCTTTT 14
RESULT 87
US-08-921-426-14
; Sequence 14, Application US/08921426
; Patent No. 5837847
; GENERAL INFORMATION:
; APPLICANT: Royer, John C
; APPLICANT: Moyer, Donna L
; APPLICANT: Yoder, Wendy T
; APPLICANT: Shuster, Jeffrey R
; TITLE OF INVENTION: NON-TOXIC, NON-PATHOGENIC
; TITLE OF INVENTION: FUSARIUM EXPRESSION SYSTEM
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: No. 5837847o No. 5837847disk of No. 5837847th America, Inc.
; STREET: 405 Lexington Avenue, 64th Floor
; CITY: New York

```
/ STATE: New York
/ COUNTRY: USA
/ ZIP: 10174-6401
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ FILING DATE: 29-AUG-1997
/ APPLICATION NUMBER: US/08/921,426
/ CLASSIFICATION: 435
/ PRIORITY INFORMATION:
/ APPLICATION NUMBER: US 08/456,433
/ FILING DATE: 01-JUN-1995
/ APPLICATION NUMBER: US 08/404,678
/ FILING DATE: 15-MAR-1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Agris Dr., Cheryl H.
/ REGISTRATION NUMBER: 34,086
/ REFERENCE/DOCKET NUMBER: 4216.010-US
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 212-867-0123
/ TELEFAX: 212-878-9655
/ INFORMATION FOR SEQ ID NO: 14:
/ LENGTH: 20 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-921-426-14

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 387 AGAGGTGGCAGCAA 400
Db 5 AGAGGTGGCAGCAA 18

RESULT 88
US-08-816-915-14
; Sequence 14, Application US/08816915
; Patent No. 6060305
; GENERAL INFORMATION:
; APPLICANT: Royer, John C.
; APPLICANT: Moyer, Donna L.
; APPLICANT: Yoder, Wendy T.
; APPLICANT: Shuster, Jeffrey R.
; TITLE OF INVENTION: NON-TOXIC, NON-TOXIGENIC, NON-PATHOGENIC
; TITLE OF INVENTION: FUSARIUM EXPRESSION SYSTEM
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESS: No. 6060305 No. 6060305disk of No. 6060305th America, Inc.
; STREET: 405 Lexington Avenue, 64th Floor
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10174-6401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/816,915
; FILING DATE: 13-MAR-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Agris Dr., Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 4216.240-US
; US-08-816-915-14

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 387 AGAGGTGGCAGCAA 400
Db 5 AGAGGTGGCAGCAA 18

RESULT 88
US-08-816-915-14
; Sequence 14, Application US/08816915
; Patent No. 6060305
; GENERAL INFORMATION:
; APPLICANT: Royer, John C.
; APPLICANT: Moyer, Donna L.
; APPLICANT: Yoder, Wendy T.
; APPLICANT: Shuster, Jeffrey R.
; TITLE OF INVENTION: NON-TOXIC, NON-TOXIGENIC, NON-PATHOGENIC
; TITLE OF INVENTION: FUSARIUM EXPRESSION SYSTEM
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESS: No. 6060305 No. 6060305disk of No. 6060305th America, Inc.
; STREET: 405 Lexington Avenue, 64th Floor
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10174-6401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/816,915
; FILING DATE: 13-MAR-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Agris Dr., Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 4216.240-US
; US-08-816-915-14
```

```
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 212-867-0123
/ TELEFAX: 212-878-9655
/ INFORMATION FOR SEQ ID NO: 14:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 20 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-816-915-14

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 387 AGAGGTGGCAGCAA 400
Db 5 AGAGGTGGCAGCAA 18

RESULT 89
US-08-816-239-2
; Sequence 2, Application US/08816239
; Patent No. 6066493
; GENERAL INFORMATION:
; APPLICANT: Shuster, Jeffrey R.
; APPLICANT: Royer, John C.
; TITLE OF INVENTION: Morphological Mutants of Filamentous
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESS: No. 6066493 No. 6066493disk of No. 6066493th America, Inc.
; STREET: 405 Lexington Avenue
; CITY: New York
; STATE: NY
; COUNTRY: USA
; ZIP: 10174
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/816,239
; FILING DATE: 13-MAR-1997
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Starnes, Robert L.
; REGISTRATION NUMBER: 41,324
; REFERENCE/DOCKET NUMBER: 4592.210-US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212-867-0123
; TELEFAX: 212-878-9655
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-816-239-2

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 387 AGAGGTGGCAGCAA 400
Db 5 AGAGGTGGCAGCAA 18

RESULT 90
US-09-405-564-2
; Sequence 2, Application US/09405564
```

Patent No. 6184026
GENERAL INFORMATION:
APPLICANT: Shuster, Jeffrey R.
APPLICANT: Royer, John C.
TITLE OF INVENTION: Morphological Mutants of Filamentous
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 6184026 of No. 6184026disk of No. 6184026th America, Inc.
STREET: 405 Lexington Avenue
CITY: New York
STATE: NY
COUNTRY: USA
ZIP: 10174
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette
COMPUTER: IBM Compatible
OPERATING SYSTEM: DOS
SOFTWARE: FastSeq for Windows Version 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/405,564
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/816,239
Filing Date: 13-MAR-1997
ATTORNEY/AGENT INFORMATION:
NAME: Starnes, Robert L.
REGISTRATION NUMBER: 41,324
REFERENCE/DOCKET NUMBER: 4592.210-US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-867-0123
TELEFAX: 212-878-9655
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 20 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-09-405-564-2

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0;
Gaps 0;

QY 387 AGAGGTGGCAGCAA 400
|||||
Db 5 AGAGGTGGCAGCAA 18

RESULT 91
US-09-309-317-7/c
Sequence 7, Application US/09309317
Patent No. 6277970
GENERAL INFORMATION:
APPLICANT: Prusiner, Stanley
APPLICANT: Tremblay, Patrick
APPLICANT: Moore, Richard
APPLICANT: Westaway, David
APPLICANT: Hood, Leroy E.
APPLICANT: Lee, Inyoul
TITLE OF INVENTION: PrP-like Gene
FILE REFERENCE: 6510-130US1
CURRENT APPLICATION NUMBER: US/09/309,317
CURRENT FILING DATE: 1999-05-11
NUMBER OF SEQ ID NOS: 21
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 7
LENGTH: 20
TYPE: DNA
ORGANISM: homosapien
US-09-309-317-7

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0;
Gaps 0;

QY 971 CCTCAGCTTGACCA 984
|||||
Db 14 CCTCAGCTTGACCA 1

RESULT 93
US-09-705-390-2
Sequence 2, Application US/09705390
Patent No. 6544774
GENERAL INFORMATION:
APPLICANT: Shuster, Jeffrey R.
APPLICANT: Royer, John C.
TITLE OF INVENTION: Morphological Mutants of Filamentous
FILE REFERENCE: 4592.230-US
CURRENT APPLICATION NUMBER: US/09/705,390
CURRENT FILING DATE: 2000-11-02
PRIOR APPLICATION NUMBER: 60/010238
PRIOR FILING DATE: 1996-01-19
PRIOR APPLICATION NUMBER: 08/726114
PRIOR FILING DATE: 1996-10-04
PRIOR APPLICATION NUMBER: 08/816239
PRIOR FILING DATE: 1997-03-13
NUMBER OF SEQ ID NOS: 2
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 20
TYPE: DNA
ORGANISM: Fusarium oxysporum
US-09-705-390-2

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0;
Gaps 0;

QY 971 CCTCAGCTTGACCA 984
|||||
Db 14 CCTCAGCTTGACCA 1

RESULT 92
US-09-422-978-7294/c
Sequence 7294, Application US/09422978
Patent No. 6537751
GENERAL INFORMATION:
APPLICANT: Cohen, Daniel
APPLICANT: Blumenfeld, Marta
APPLICANT: Chumakov, Ilya
TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
FILE REFERENCE: GENSET.020CPI
CURRENT APPLICATION NUMBER: US/09/422,978
CURRENT FILING DATE: 1999-10-20
EARLIER APPLICATION NUMBER: US 09/298,850
EARLIER FILING DATE: 1999-04-21
EARLIER APPLICATION NUMBER: US 60/109,732
EARLIER FILING DATE: 1998-11-23
EARLIER APPLICATION NUMBER: US 60/082,614
EARLIER FILING DATE: 1998-04-21
NUMBER OF SEQ ID NOS: 11796
SEQ ID NO 7294
LENGTH: 20
TYPE: DNA
ORGANISM: Homo Sapiens
FEATURE:
NAME/KEY: primer_bind
LOCATION: 1..20
OTHER INFORMATION: upstream amplification primer 99-3483 for SEQ 3360,
US-09-422-978-7294

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0;
Gaps 0;

QY 971 CCTCAGCTTGACCA 984
|||||
Db 14 CCTCAGCTTGACCA 1

RESULT 93
US-09-705-390-2
Sequence 2, Application US/09705390
Patent No. 6544774
GENERAL INFORMATION:
APPLICANT: Shuster, Jeffrey R.
APPLICANT: Royer, John C.
TITLE OF INVENTION: Morphological Mutants of Filamentous
FILE REFERENCE: 4592.230-US
CURRENT APPLICATION NUMBER: US/09/705,390
CURRENT FILING DATE: 2000-11-02
PRIOR APPLICATION NUMBER: 60/010238
PRIOR FILING DATE: 1996-01-19
PRIOR APPLICATION NUMBER: 08/726114
PRIOR FILING DATE: 1996-10-04
PRIOR APPLICATION NUMBER: 08/816239
PRIOR FILING DATE: 1997-03-13
NUMBER OF SEQ ID NOS: 2
SOFTWARE: FastSeq for Windows Version 4.0
SEQ ID NO 2
LENGTH: 20
TYPE: DNA
ORGANISM: Fusarium oxysporum
US-09-705-390-2

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 387 AGAGGTGGCAGCA 400
|||||
DB 5 AGAGGTGGCAGCA 18

RESULT 94

PCT-US95-07743-14
; Sequence 14, Application PC/TUS9507743
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: NON-TOXIC, NON-TOXIGENIC, NON-PATHOGENIC
; FUSARIUM EXPRESSION SYSTEM AND PROMOTERS FOR U
; NUMBER OF SEQUENCES: 16
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Novo Nordisk of North America, Inc.
; STREET: 405 Lexington Avenue, 64th Floor
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10174-6401
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/07743
; FILING DATE: 15-June-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/269,449
; FILING DATE: 30-June-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/404,678
; FILING DATE: 15-March-1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Agis Dr., Cheryl H.
; REGISTRATION NUMBER: 34,086
; REFERENCE/DOCKET NUMBER: 4216.204-WO
; TELEPHONE: 212-867-0123
; TELEFAX: 212-878-9655
; INFORMATION FOR SEQ ID NO: 14:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
PCT-US95-07743-14

Query Match 1.0%; Score 14; DB 1; Length 20;
Best Local Similarity 100.0%; Pred. No. 1.3e+02;
Matches 14; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 387 AGAGGTGGCAGCA 400
|||||
DB 5 AGAGGTGGCAGCA 18

RESULT 95

US-08-531-747-4/c
; Sequence 4, Application US/08531747
; Patent No. 5631147
; GENERAL INFORMATION:
; APPLICANT: Lohman, Kenton L.
; APPLICANT: Ostrova, Natalie V.
; APPLICANT: Van Cleve, Mark
; APPLICANT: Reid, Robert A.
; TITLE OF INVENTION: DETECTION OF NUCLEIC ACIDS IN CELLS BY

; TITLE OF INVENTION: THERMOPHILIC STRAND DISPLACEMENT AMPLIFICATION
; NUMBER OF SEQUENCES: 14
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Richard J. Rodrick, Becton Dickinson and
; ADDRESSEE: Company
; STREET: 1 Becton Drive
; CITY: Franklin Lakes
; STATE: NJ
; COUNTRY: US
; ZIP: 07417
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/531,747
; FILING DATE:

; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Fugit, Donna R.
; REGISTRATION NUMBER: 32,135
; REFERENCE/DOCKET NUMBER: P-3462
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-531-747-4

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 274 ATCAAAGAGGAGCAGC 290
|||||
DB 17 ATCAATGAGGAGCTGC 1

RESULT 96

US-08-373-124A-2029
; Sequence 2029, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TREATMENT OF RESTENOSIS AND
; CANCELS USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466

```
/
/ FILING DATE: May 18, 1994
/ APPLICATION NUMBER: 08/192,943
/ FILING DATE: February 7, 1994
/ APPLICATION NUMBER: 07/987,132
/ FILING DATE: December 7, 1992
/ APPLICATION NUMBER: 07/936,422
/ FILING DATE: August 26, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 209/035
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 2029:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
US-08-373-124A-2029
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 97;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1094 TTGACGCTAATTATGTA 1110
Db 1 UUGAAAGUUAUUGUA 17

RESULT 97
US-08-531-749-4/c
/ Sequence 4, Application US/08531749
/ Patent No. 5733752
/ GENERAL INFORMATION:
/ APPLICANT: Lohman, Kenton L.
/ APPLICANT: Ostrova, Natalie V.
/ APPLICANT: Van Cleve, Mark
/ APPLICANT: Reid, Robert A.
/ TITLE OF INVENTION: DETECTION OF NUCLEIC ACIDS IN CELLS BY
/ NUMBER OF SEQUENCES: 14
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Richard J. Rodrick, Becton Dickinson and
/ COMPANY:
/ STREET: 1 Becton Drive
/ CITY: Franklin Lakes
/ STATE: NJ
/ COUNTRY: US
/ ZIP: 07417
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/531,749
/ FILING DATE:
/ CLASSIFICATION: 536
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/531,747
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Fugit, Donna R.
/ REGISTRATION NUMBER: 32,135
/ REFERENCE/DOCKET NUMBER: P-3462
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/
US-08-531-749-4
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 97;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1094 TTGACGCTAATTATGTA 1110
Db 1 UUGAAAGUUAUUGUA 17

RESULT 98
US-08-781-432-4/c
/ Sequence 4, Application US/08781432
/ Patent No. 5756702
/ GENERAL INFORMATION:
/ APPLICANT: Lohman, Kenton L.
/ APPLICANT: Ostrova, Natalie V.
/ APPLICANT: Van Cleve, Mark
/ APPLICANT: Reid, Robert A.
/ TITLE OF INVENTION: DETECTION OF NUCLEIC ACIDS IN CELLS BY
/ NUMBER OF SEQUENCES: 14
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Richard J. Rodrick, Becton Dickinson and
/ COMPANY:
/ STREET: 1 Becton Drive
/ CITY: Franklin Lakes
/ STATE: NJ
/ COUNTRY: US
/ ZIP: 07417
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/781,432
/ FILING DATE:
/ CLASSIFICATION: 536
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/531,747
/ FILING DATE:
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Fugit, Donna R.
/ REGISTRATION NUMBER: 32,135
/ REFERENCE/DOCKET NUMBER: P-3462
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/
US-08-781-432-4
Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 97;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1094 TTGACGCTAATTATGTA 1110
Db 1 UUGAAAGUUAUUGUA 17

RESULT 99
US-08-435-628-2029
/ Sequence 2029, Application US/08435628
/ Patent No. 5817796
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Dan T.
/ APPLICANT: Draper, Kenneth
/ APPLICANT: McSwiggen, James
/ APPLICANT: Jarvis, Thale
```

;; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
;; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
;; TITLE OF INVENTION: CANCER USING RIBOZYMES
;; NUMBER OF SEQUENCES: 2627
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Suite 4700
;; STATE: Los Angeles
;; COUNTRY: California
;; ZIP: 90071
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/435,628
;; FILING DATE: 05-MAY-1995
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 08/373,124
;; FILING DATE: January 13, 1995
;; APPLICATION NUMBER: 08/245,466
;; FILING DATE: May 18, 1994
;; APPLICATION NUMBER: 08/192,943
;; FILING DATE: February 7, 1994
;; APPLICATION NUMBER: 07/987,132
;; FILING DATE: December 7, 1992
;; APPLICATION NUMBER: 07/936,422
;; FILING DATE: August 26, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 209/035
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 2029:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-435-628--2029

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 47.1%; Pred. No. 97;
Matches 8; Conservative 7; Mismatches 2; Indels 0; Gaps 0;

QY 1094 TTGAACGTAAATGTGTA 1110
::|||::|::|::|
Db 1 UUGAAGUAUUAUGUA 17

RESULT 100
US-08-985-162-17/c
; Sequence 17, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162

;; STREET: 633 West Fifth Street
;; STREET: Suite 4700
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: FastSeq for Windows 2.0
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/985,162
;; FILING DATE: 04 December 1997
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/036,476
;; FILING DATE: 31 January 1997
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 230/107
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 17:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-985-162-17

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 629 AGCTCCAGGAGCTCTGC 645
||| ||||| |||||
Db 17 AGGCCAGGAGGCTGC 1

RESULT 101
US-08-985-162-645/c
; Sequence 645, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162

; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 645:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-985-162-645

Query Match 1.0%; Score 13.8; DB 1; Length 17;
Best Local Similarity 88.2%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 916 CTAAGGAGATGGCAGA 932
DB 17 CTAAGGAGATTTCAGA 1

RESULT 102

US-08-964-020-2/c
; Sequence 2, Application US/08964020
; Patent No. 6077669
; GENERAL INFORMATION:

; APPLICANT: Vonk, Glenn P.
; APPLICANT: Little, Michael C.
; TITLE OF INVENTION: Kit and Method for Fluorescence Based
; NUMBER OF SEQUENCES: 20
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Richard J. Rodrick - Becton, Dickinson and
; ADDRESSEE: Company
; STREET: 1 Becton Drive
; CITY: Franklin Lakes
; STATE: NJ
; COUNTRY: USA
; ZIP: 07417

COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/964,020
; FILING DATE:

CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:
; NAME: Hightet, David W.
; REGISTRATION NUMBER: 30,265
; REFERENCE/DOCKET NUMBER: p-4025
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (201) 847-5317
; TELEFAX: (201) 848-9228

INFORMATION FOR SEQ ID NO: 2:

; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-964-020-2

Query Match

1.0%; Score 13.8; DB 1; Length 17;

Best Local Similarity 88.2%; Pred. No. 97;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 274 ATCAAAGAGGAAGCAGC 290
DB 17 ATCAATGAGGAAGCTGC 1

RESULT 103

US-09-474-432B-684
; Sequence 684, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:

; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn

; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucle
; FILE REFERENCE: MBHB00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19

; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29

; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28

; NUMBER OF SEQ ID NOS: 1526

; SOFTWARE: Patent in version 3.0

; SEQ ID NO 684

; LENGTH: 17

; TYPE: RNA

; ORGANISM: Homo sapiens

US-09-474-432B-684

Query Match

Best Local Similarity 1.0%; Score 13.8; DB 1; Length 17;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 517 GCCAACCTGCCGAGGA 533
DB 1 GCCAACCGCCAGAGGA 17

RESULT 104

US-08-585-684B-2548/c
; Sequence 2548, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES

; NUMBER OF SEQUENCES: 2751

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

; STREET: 633 West Fifth Street

; CITY: Los Angeles

; STATE: California

; COUNTRY: U.S.A.

; ZIP: 90071

; COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

; MEDIUM TYPE: storage


```
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2548:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-585-684B-2548

Query Match          1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1157 GGAAGTAAAGCAGCTAA 1173
Db 18 GGAAGCAAGCAGCTAA 2
```

```
RESULT 105
US-08-702-105A-33/c
; Sequence 33, Application US/08702105A
; Patent No. 5908839
; GENERAL INFORMATION:
; APPLICANT: Levitt, Roy C.
; APPLICANT: Maloy, W. Lee
; APPLICANT: Kari, U. Prasad
; APPLICANT: Nicolaides, Nicholas C.
; TITLE OF INVENTION: Asthma Associated Factors As Targets For
; TITLE OF INVENTION: Treating Atopic Allergies Including Asthma And Related
; TITLE OF INVENTION: Disorders
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner L.L.P.
; STREET: 1300 I Street N.W., Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/702,105A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/874,503
; FILING DATE: 13-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B.
; REGISTRATION NUMBER: 32984
; REFERENCE/DOCKET NUMBER: 05387.0056-01000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
```

```
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-702-105A-33

Query Match          1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 464 GCAGCCTGCAGGGGAG 480
Db 17 GTAGGCTGCAGGGGAG 1

RESULT 106
US-08-702-110A-33/c
; Sequence 33, Application US/08702110A
; Patent No. 6037149
; GENERAL INFORMATION:
; APPLICANT: Levitt, Roy C.
; APPLICANT: Maloy, W. Lee
; APPLICANT: Kari, U. Prasad
; APPLICANT: Nicolaides, Nicholas C.
; TITLE OF INVENTION: Asthma Associated Factors As Targets For
; TITLE OF INVENTION: Treating Atopic Allergies Including Asthma And Related
; TITLE OF INVENTION: Disorders
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner L.L.P.
; STREET: 1300 I Street N.W., Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/702,110A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/874,503
; FILING DATE: 13-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B.
; REGISTRATION NUMBER: 32984
; REFERENCE/DOCKET NUMBER: 05387.0056-01000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4000
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-702-110A-33

Query Match          1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 464 GCAGCCTGCAGGGGAG 480
```


RESULT 110

US-08-679-645-583
 ; Sequence 583, Application US/08679645
 ; Patent No. 6350934
 ; GENERAL INFORMATION:
 ; APPLICANT: Zwick, Michael G.
 ; APPLICANT: Edington, Brent E.
 ; APPLICANT: McSwiggen, James A.
 ; APPLICANT: Merlo, Patricia Ann Owens
 ; APPLICANT: Guo, Lining
 ; APPLICANT: Skokut, Thomas A.
 ; APPLICANT: Young, Scott A.
 ; APPLICANT: Folkerts, Otto
 ; APPLICANT: Merlo, Donald J.
 ; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
 ; MODULATION OF GENE EXPRESSION
 ; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
 ; NUMBER OF SEQUENCES: 1263
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: Lyon & Lyon
 ; STREET: 633 West Fifth Street
 ; STREET: Suite 4700
 ; CITY: Los Angeles
 ; STATE: California
 ; COUNTRY: U.S.A.
 ; ZIP: 90071-2066
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 ; MEDIUM TYPE: storage
 ; COMPUTER: IBM Compatible
 ; OPERATING SYSTEM: IBM P.C. DOS 5.0
 ; SOFTWARE: Word Perfect 5.1
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/679,645
 ; FILING DATE: July 12, 1996
 ; CLASSIFICATION: 800
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: 60/001,135
 ; FILING DATE: July 13, 1995
 ; APPLICATION NUMBER: 08/300,726
 ; FILING DATE: September 2, 1994
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: Warburg, Richard J.
 ; REGISTRATION NUMBER: 32,327
 ; REFERENCE/DOCKET NUMBER: 219/247
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (213) 489-1600
 ; TELEFAX: (213) 955-0440
 ; TELEX: 67-3510
 ; INFORMATION FOR SEQ ID NO: 583:
 ; SEQUENCE CHARACTERISTICS:
 ; LENGTH: 18 base pairs
 ; TYPE: nucleic acid
 ; STRANDEDNESS: single
 ; TOPOLOGY: linear
 ; US-08-679-645-583

Query Match 1.0%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 70.6%; Pred. No. 1.1e+02;
 Matches 12; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 890 AGCTGCGGTACAGCGTG 906

Db 1 AGCUGCGGUACGCCUG 17

RESULT 111

US-08-535-249-98
 ; Sequence 98, Application US/08535249
 ; Patent No. 6455689
 ; GENERAL INFORMATION:

APPLICANT: Schlingensiepen, Georg-Ferdinand
 APPLICANT: Brysch, Wolfgang
 APPLICANT: Schlingensiepen, Karl-Hermann
 APPLICANT: Schlingensiepen, Reimar
 APPLICANT: Bogdahn, Ulrich
 TITLE OF INVENTION: Antisense-oligonucleotides for the treatment of
 immunosuppressive effect of transforming-growth-factor beta
 NUMBER OF SEQUENCES: 137
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Jacobson, Price, Holman & Stern
 STREET: 400 Seventh St. N.W.
 CITY: Washington D.C.
 COUNTRY: U.S.A.
 ZIP: 20004
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/535,249
 FILING DATE:
 CLASSIFICATION: 514
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER: EP 93 107 089.0
 FILING DATE: 30-APR-1993
 PRIOR APPLICATION DATA: EP 93 107 849.7
 FILING DATE: 13-MAY-1993
 ATTORNEY/AGENT INFORMATION:
 NAME: Player, William E.
 REGISTRATION NUMBER: 31,409
 REFERENCE/DOCKET NUMBER: 10577/P58418
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (202) 638-6666
 TELEFAX: (202) 393-5350
 TELEX: RCA 248593 IDEA UR
 INFORMATION FOR SEQ ID NO: 98:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 18 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: unknown
 TOPOLOGY: unknown
 MOLECULE TYPE: DNA (genomic)
 ANTI-SENSE: YES
 US-08-535-249-98

Query Match 1.0%; Score 13.8; DB 1; Length 18;
 Best Local Similarity 88.2%; Pred. No. 1.1e+02;
 Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1018 AGATGGTGCACAAAGTGC 1034
 Db 2 AGATGGTACAAAAGTGC 18

RESULT 112
 US-09-091-952A-193
 ; Sequence 193, Application US/09091952A
 ; Patent No. 6458532
 ; GENERAL INFORMATION:
 ; APPLICANT: Detera-Wadleigh, Sevilla D.
 ; APPLICANT: Gershon, Elliot S.
 ; Badner, Judith A.
 ; Goldin, Lynn R.
 ; Berrettini, Wade H.
 ; Yoshikawa, Takeo
 ; Sanders, Alan R.
 ; Esterling, Lisa E.
 ; TITLE OF INVENTION: Chromosomal Markers and Diagnostic
 ; Tests for Manic-Depressive Illness
 ; NUMBER OF SEQUENCES: 197
 ; CORRESPONDENCE ADDRESS:

```
;
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/091,952A
; FILING DATE: 19-Apr-1999
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/029,278
; FILING DATE: 28-OCT-1996
; APPLICATION NUMBER: PCT/US97/19381
; FILING DATE: 28-OCT-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, Timothy L.
; REGISTRATION NUMBER: 35,367
; REFERENCE/DOCKET NUMBER: 015280-297100US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; TELEX: <Unknown>
; INFORMATION FOR SEQ ID NO: 193:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: -
; LOCATION: 1...18
; OTHER INFORMATION: Clone 47 reverse primer
; SEQUENCE DESCRIPTION: SEQ ID NO: 193:
US-09-091-952A-193

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1319 GTGCTTTCTAGACTTT 1335
Db 2 GTGCTTCTGAGCTCTT 18

RESULT 113
US-09-422-978-4727
; Sequence 4727, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 4727
; LENGTH: 18
; TYPE: DNA
```

```
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-17363 for SEQ 793,
US-09-422-978-4727

Query Match 1.0%; Score 13.8; DB 1; Length 18;
Best Local Similarity 88.2%; Pred. No. 1.1e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 935 TGGAGAGAGGTTGTGAG 951
Db 2 TGGAGAGAGGTTGTG 18

RESULT 114
US-07-741-940-49/c
; Sequence 49, Application US/07741940
; Patent No. 5352775
; GENERAL INFORMATION:
; APPLICANT: ALBERTSEN, HANS
; APPLICANT: ANAND, RAKESH
; APPLICANT: CARLSON, MARY
; APPLICANT: GRODEN, JOANNA
; APPLICANT: HEDGE, PHILIP J.
; APPLICANT: JOSLYN, GREGG
; APPLICANT: KINZLER, KENNETH
; APPLICANT: MARKHAM, ALEXANDER F.
; APPLICANT: NAKAMURA, YUSUKE
; APPLICANT: THLIVERIS, ANDREW
; TITLE OF INVENTION: INHERITED AND SOMATIC MUTATIONS OF APC
; TITLE OF INVENTION: GENE IN COLORECTAL CANCER IN HUMANS
; NUMBER OF SEQUENCES: 94
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner, Birch, McKie & Beckett
; STREET: 1001 G Street, NW
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20001-4598
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/741,940
; FILING DATE: 19920109
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Kagan, Sarah A.
; REGISTRATION NUMBER: 32,141
; REFERENCE/DOCKET NUMBER: 1107.035574
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-508-9100
; TELEFAX: 202-508-9299
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
US-07-741-940-49

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 100 ACAACCCCGAGCGCA 116
```

```
Db      ||||| ||||| ||||| |||||
17 ACAACCCGAGGCGCA 1

RESULT 115
US-08-289-548A-49/c
; Sequence 49, Application US/08289548A
; Patent No. 5648212
; GENERAL INFORMATION:
; APPLICANT: ALBERTSEN, HANS
; APPLICANT: ANAND, RAKESH
; APPLICANT: CARLSON, MARY
; APPLICANT: GRODEN, JOANNA
; APPLICANT: HEDGE, PHILIP J.
; APPLICANT: JOSLYN, GEOFF
; APPLICANT: KINZLER, KENNETH
; APPLICANT: MARKHAM, ALEXANDER F.
; APPLICANT: NAKAMURA, YUSUKE
; APPLICANT: THLIVERIS, ANDREW
; TITLE OF INVENTION: INHERITED AND SOMATIC MUTATIONS OF APC
; TITLE OF INVENTION: GENE IN COLORECTAL CANCER IN HUMANS
; NUMBER OF SEQUENCES: 102
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Allegretti, LTD
; STREET: 1001 G Street, NW
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20001-4598
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/289,548A
; FILING DATE: 12-AUG-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Kagan, Sarah A.
; REGISTRATION NUMBER: 32,141
; REFERENCE/DOCKET NUMBER: 1107.46943
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-508-9100
; TELEFAX: 202-508-9299
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
US-08-289-548A-49

Query Match      1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      100 ACAACCCGAGGCGCA 116
Db      ||||| ||||| ||||| |||||
17 ACAACCCGAGGCGCA 1

RESULT 116
US-08-452-654-49/c
; Sequence 49, Application US/08452654
; Patent No. 5691454
; GENERAL INFORMATION:
; APPLICANT: ALBERTSEN, HANS
; APPLICANT: ANAND, RAKESH
; APPLICANT: CARLSON, MARY
; APPLICANT: GRODEN, JOANNA
; APPLICANT: HEDGE, PHILIP J.
; APPLICANT: JOSLYN, GEOFF
; APPLICANT: KINZLER, KENNETH
; APPLICANT: MARKHAM, ALEXANDER F.
; APPLICANT: NAKAMURA, YUSUKE
; APPLICANT: THLIVERIS, ANDREW
; TITLE OF INVENTION: INHERITED AND SOMATIC MUTATIONS OF APC
; TITLE OF INVENTION: GENE IN COLORECTAL CANCER IN HUMANS
; NUMBER OF SEQUENCES: 94
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner, Birch, McKie & Beckett
; STREET: 1001 G Street, NW
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20001-4598
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/452,654
; FILING DATE: 25-MAY-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/741,940
; FILING DATE: 08-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Kagan, Sarah A.
; REGISTRATION NUMBER: 32,141
; REFERENCE/DOCKET NUMBER: 1107.035574
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-508-9100
; TELEFAX: 202-508-9299
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
US-08-452-654-49

Query Match      1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      100 ACAACCCGAGGCGCA 116
Db      ||||| ||||| ||||| |||||
17 ACAACCCGAGGCGCA 1

RESULT 117
US-08-452-655B-49/c
; Sequence 49, Application US/08452655B
; Patent No. 5783666
; GENERAL INFORMATION:
; APPLICANT: ALBERTSEN, HANS
; APPLICANT: ANAND, RAKESH
; APPLICANT: CARLSON, MARY
; APPLICANT: GRODEN, JOANNA
; APPLICANT: HEDGE, PHILIP J.
; APPLICANT: JOSLYN, GEOFF
; APPLICANT: KINZLER, KENNETH
; APPLICANT: MARKHAM, ALEXANDER F.
; APPLICANT: NAKAMURA, YUSUKE
; APPLICANT: THLIVERIS, ANDREW
; TITLE OF INVENTION: INHERITED AND SOMATIC MUTATIONS OF APC
; TITLE OF INVENTION: GENE IN COLORECTAL CANCER IN HUMANS
; NUMBER OF SEQUENCES: 94
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner, Birch, McKie & Beckett
; STREET: 1001 G Street, NW
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20001-4598
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/452,654
; FILING DATE: 25-MAY-1995
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/741,940
; FILING DATE: 08-AUG-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: Kagan, Sarah A.
; REGISTRATION NUMBER: 32,141
; REFERENCE/DOCKET NUMBER: 1107.035574
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-508-9100
; TELEFAX: 202-508-9299
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cdna
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
US-08-452-654-49

Query Match      1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy      100 ACAACCCGAGGCGCA 116
Db      ||||| ||||| ||||| |||||
17 ACAACCCGAGGCGCA 1
```

```
/
/
/ NUMBER OF SEQUENCES: 102
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Banner & Witcoff, Ltd.
/ STREET: 1001 G Street, NW
/ CITY: Washington
/ STATE: D.C.
/ COUNTRY: USA
/ ZIP: 20001-4598
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/452,655B
/ FILING DATE: 25-MAY-1995
/ CLASSIFICATION: 530
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/289,548
/ FILING DATE: 12-AUG-1994
/ APPLICATION NUMBER: US 07/741,940
/ FILING DATE: 08-AUG-1991
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Kagan, Sarah A.
/ REGISTRATION NUMBER: 32,141
/ REFERENCE/DOCKET NUMBER: 1107.49964
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 202-508-9100
/ TELEFAX: 202-508-9299
/ INFORMATION FOR SEQ ID NO: 49:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: cdna
/ ORIGINAL SOURCE:
/ ORGANISM: Homo sapiens
/
/ US-08-452-655B-49
/
/ Query Match 1.0%; Score 13.8; DB 1; Length 19;
/ Best Local Similarity 88.2%; Pred. No. 1.3e+02;
/ Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 100 ACAACCCGAGCGCA 116
/ Db 17 ACAACCCGAGCGCA 1
/
/ RESULT 118
/ US-08-468-037A-33/c
/ Sequence 33, Application US/08468037A
/ Patent No. 5859221
/ GENERAL INFORMATION:
/ APPLICANT: Phillip Dan Cook
/ APPLICANT: A. Kawasaki
/ TITLE OF INVENTION: 2'-Modified Oligonucleotides
/ NUMBER OF SEQUENCES: 37
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5859221ris
/ STREET: One Liberty Place - 46th Floor
/ CITY: Philadelphia
/ STATE: PA
/ COUNTRY: U.S.A.
/ ZIP: 19103
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5 inch disk, 720 Kb
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: WordPerfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/471,973A
/ FILING DATE: 06-JUN-1995
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 835,932
/ FILING DATE: 05-MAR-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Joseph Lucci
/ REGISTRATION NUMBER: 33,307
/ REFERENCE/DOCKET NUMBER: ISIS-2005
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 215-568-3100
/ TELEFAX: 215-568-3439
/ INFORMATION FOR SEQ ID NO: 33:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19 bases
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-08-471-973A-33
/
/ Query Match 1.0%; Score 13.8; DB 1; Length 19;
/
/ NUMBER OF SEQUENCES: 102
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Banner & Witcoff, Ltd.
/ STREET: 1001 G Street, NW
/ CITY: Washington
/ STATE: D.C.
/ COUNTRY: USA
/ ZIP: 20001-4598
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/452,655B
/ FILING DATE: 25-MAY-1995
/ CLASSIFICATION: 530
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 08/289,548
/ FILING DATE: 12-AUG-1994
/ APPLICATION NUMBER: US 07/741,940
/ FILING DATE: 08-AUG-1991
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Kagan, Sarah A.
/ REGISTRATION NUMBER: 32,141
/ REFERENCE/DOCKET NUMBER: 1107.49964
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 202-508-9100
/ TELEFAX: 202-508-9299
/ INFORMATION FOR SEQ ID NO: 49:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: cdna
/ ORIGINAL SOURCE:
/ ORGANISM: Homo sapiens
/
/ US-08-452-655B-49
/
/ Query Match 1.0%; Score 13.8; DB 1; Length 19;
/ Best Local Similarity 88.2%; Pred. No. 1.3e+02;
/ Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 100 ACAACCCGAGCGCA 116
/ Db 17 ACAACCCGAGCGCA 1
/
/ RESULT 119
/ US-08-471-973A-33/c
/ Sequence 33, Application US/08471973A
/ Patent No. 5872232
/ GENERAL INFORMATION:
/ APPLICANT: Phillip Dan Cook
/ APPLICANT: Andrew Kawasaki
/ TITLE OF INVENTION: Sugar Modified Oligonucleotides
/ NUMBER OF SEQUENCES: 37
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5872232ris
/ STREET: One Liberty Place - 46th Floor
/ CITY: Philadelphia
/ STATE: PA
/ COUNTRY: U.S.A.
/ ZIP: 19103
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5 inch disk, 720 Kb
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: WordPerfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/471,973A
/ FILING DATE: 06-JUN-1995
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 835,932
/ FILING DATE: 05-MAR-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Joseph Lucci
/ REGISTRATION NUMBER: 33,307
/ REFERENCE/DOCKET NUMBER: ISIS-2005
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 215-568-3100
/ TELEFAX: 215-568-3439
/ INFORMATION FOR SEQ ID NO: 33:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19 bases
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-08-471-973A-33
/
/ Query Match 1.0%; Score 13.8; DB 1; Length 19;
/
/ FILING DATE: 06-JUN-1995
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 835,932
/ FILING DATE: 05-MAR-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Joseph Lucci
/ REGISTRATION NUMBER: 33,307
/ REFERENCE/DOCKET NUMBER: ISIS-2004
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 215-568-3100
/ TELEFAX: 215-568-3439
/ INFORMATION FOR SEQ ID NO: 33:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19 bases
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-08-468-037A-33
/
/ Query Match 1.0%; Score 13.8; DB 1; Length 19;
/ Best Local Similarity 88.2%; Pred. No. 1.3e+02;
/ Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
/
/ QY 1141 GCGTTTTTCTTTTG 1157
/ Db 19 GCGTTTTTCTTTTG 3
/
/ RESULT 119
/ US-08-471-973A-33/c
/ Sequence 33, Application US/08471973A
/ Patent No. 5872232
/ GENERAL INFORMATION:
/ APPLICANT: Phillip Dan Cook
/ APPLICANT: Andrew Kawasaki
/ TITLE OF INVENTION: Sugar Modified Oligonucleotides
/ NUMBER OF SEQUENCES: 37
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5872232ris
/ STREET: One Liberty Place - 46th Floor
/ CITY: Philadelphia
/ STATE: PA
/ COUNTRY: U.S.A.
/ ZIP: 19103
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5 inch disk, 720 Kb
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: WordPerfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/471,973A
/ FILING DATE: 06-JUN-1995
/ CLASSIFICATION: 514
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 835,932
/ FILING DATE: 05-MAR-1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Joseph Lucci
/ REGISTRATION NUMBER: 33,307
/ REFERENCE/DOCKET NUMBER: ISIS-2005
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 215-568-3100
/ TELEFAX: 215-568-3439
/ INFORMATION FOR SEQ ID NO: 33:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19 bases
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/
/ US-08-471-973A-33
/
/ Query Match 1.0%; Score 13.8; DB 1; Length 19;
```

Best Local Similarity 88.2%; Pred. No. 1.3e+02; Indels 0; Gaps 0;
Matches 15; Conservative 0; Mismatches 2;

QY 1141 GCCTTTTCTTTTG 1157
Db 19 GCGTTTTTTTTTG 3

RESULT 120

US-08-465-880-28/c
; Sequence 28, Application US/08465880
; Patent No. 5955589
; GENERAL INFORMATION:
; APPLICANT: Philip Dan Cook
; TITLE OF INVENTION: Gapped 2' Modified Oligonucleotides
; NUMBER OF SEQUENCES: 28
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 5955589ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103

COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/465,880
; FILING DATE: Herewith
; CLASSIFICATION: 514

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 244,993
; FILING DATE: 21-JUN-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci

; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2002
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439

; INFORMATION FOR SEQ ID NO: 28:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-465-880-28

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTCTTTTG 1157
Db 19 GCGTTTTTTTTTG 3

RESULT 121

US-09-035-357-33/c
; Sequence 33, Application US/09035357
; Patent No. 6005087

; GENERAL INFORMATION:
; APPLICANT: Phillip Dan Cook
; APPLICANT: A. Kawasaki
; TITLE OF INVENTION: 2'-Modified Oligonucleotides
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6005087ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA

; COUNTRY: U.S.A.
; ZIP: 19103
COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/035,357
; FILING DATE:

; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/468,037
; FILING DATE:

; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2004

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439

; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-09-035-357-33

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTCTTTTG 1157
Db 19 GCGTTTTTTTTTG 3

RESULT 122

US-08-450-582-49/c
; Sequence 49, Application US/08450582
; Patent No. 6114124

; GENERAL INFORMATION:

; APPLICANT: ALBERTSEN, HANS
; APPLICANT: ANAND, RAKESH
; APPLICANT: CARLSON, MARY
; APPLICANT: GRODEN, JOANNA
; APPLICANT: HEDGE, PHILIP J.
; APPLICANT: JOSLYN, GEOFF

; APPLICANT: KINZLER, KENNETH
; APPLICANT: MARKHAM, ALEXANDER F.
; APPLICANT: NAKAMURA, YUSUKE
; APPLICANT: THLIVERIS, ANDREW

; TITLE OF INVENTION: INHERITED AND SOMATIC MUTATIONS OF APC
; NUMBER OF SEQUENCES: 102
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Witcoff, Ltd.
; STREET: 1001 G Street, NW
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA

; ZIP: 20001-4598

COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA: US/08/450,582
; APPLICATION NUMBER: US/08/450,582
; FILING DATE:
; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

```
/ APPLICATION NUMBER: US 08/452,655
/ FILING DATE: 25-MAY-1995
/ APPLICATION NUMBER: US 08/289,548
/ FILING DATE: 12-AUG-1994
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: US 07/741,940
/ FILING DATE: 08-AUG-1991
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Kagan, Sarah A.
/ REGISTRATION NUMBER: 32,141
/ REFERENCE/DOCKET NUMBER: 1107.49964
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 202-508-9100
/ TELEFAX: 202-508-9299
/ INFORMATION FOR SEQ ID NO: 49:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 19 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: cDNA
/ ORIGINAL SOURCE:
/ ORGANISM: Homo sapiens
/ US-08-450-582-49

Query Match
Best Local Similarity 1.0%; Score 13.8; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 100 ACAACCCCGAGCGCA 116
Db 17 ACAACCCCGAGCGCA 1

RESULT 123
US-09-016-520-4/c
Sequence 4, Application US/09016520A
Patent No. 6127533
GENERAL INFORMATION:
/ APPLICANT: Cook, Phillip D
/ APPLICANT: Manoharan, Muthiah
/ APPLICANT: Kawasaki, Andrew
/ TITLE OF INVENTION: Aminoxy-Modified Oligonucleotides
/ FILE REFERENCE: ISIS2824
/ CURRENT APPLICATION NUMBER: US/09/016,520A
/ CURRENT FILING DATE: 1998-01-30
/ EARLIER APPLICATION NUMBER: 60/037,143
/ EARLIER FILING DATE: 1997-02-14
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 4
/ LENGTH: 19
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-016-520-4

Query Match
Best Local Similarity 1.0%; Score 13.8; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTCTCTTTTG 1157
Db 19 GCGTTTTTTTTTTTG 3

RESULT 124
US-09-144-611-12/c
Sequence 12, Application US/09144611A
Patent No. 6146829
GENERAL INFORMATION:
/ APPLICANT: Cook, Phillip D
/ APPLICANT: Manoharan, Muthiah
/ APPLICANT: Kawasaki, Andrew
/ TITLE OF INVENTION: Aminoxy-Modified Oligonucleotides
/ FILE REFERENCE: ISIS2824
/ CURRENT APPLICATION NUMBER: US/09/144,611A
/ FILING DATE: 1998-08-31
/ PRIOR APPLICATION NUMBER: 08/861,306
/ PRIOR FILING DATE: 1997-04-21
/ NUMBER OF SEQ ID NOS: 12
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 12
/ LENGTH: 19
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: No. 6146829el
US-09-144-611-12

Query Match
Best Local Similarity 1.0%; Score 13.8; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTCTCTTTTG 1157
Db 19 GCGTTTTTTTTTTTG 3

RESULT 125
US-09-130-973-4/c
Sequence 4, Application US/09130973
Patent No. 6172209
GENERAL INFORMATION:
/ APPLICANT: Manoharan, Muthiah
/ APPLICANT: Cook, Phillip Dan
/ APPLICANT: Prakash, Thazha P
/ APPLICANT: Kawasaki, Andrew M
/ TITLE OF INVENTION: Aminoxy-Modified Oligonucleotides And Methods For
/ TITLE OF INVENTION: Making Same
/ FILE REFERENCE: ISIS2955
/ CURRENT APPLICATION NUMBER: US/09/130,973
/ CURRENT FILING DATE: 1998-08-07
/ NUMBER OF SEQ ID NOS: 58
/ SOFTWARE: PatentIn Ver. 2.1
/ SEQ ID NO 4
/ LENGTH: 19
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: Description of Artificial Sequence: No. 6172209el
US-09-130-973-4

Query Match
Best Local Similarity 1.0%; Score 13.8; DB 1; Length 19;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTCTCTTTTG 1157
Db 19 GCGTTTTTTTTTTTG 3

RESULT 126
US-09-477-902-4/c
Sequence 4, Application US/09477902
Patent No. 6194598
GENERAL INFORMATION:
/ APPLICANT: Cook, Phillip D
/ APPLICANT: Manoharan, Muthiah
/ APPLICANT: Kawasaki, Andrew
/ TITLE OF INVENTION: Aminoxy-Modified Oligonucleotides
/ FILE REFERENCE: ISIS2824
/ CURRENT APPLICATION NUMBER: US/09/477,902
```



```
; CURRENT FILING DATE: 2000-01-05
; PRIOR APPLICATION NUMBER: 09/016,520
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: 60/037,143
; PRIOR FILING DATE: 1997-02-14
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: No. 6326199el Sequence
US-09-453-514A-12

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTTCCTTTTG 1157
Db 19 GCGTTTTTTTTTTTG 3

RESULT 127
US-09-315-886C-32/c
; Sequence 32, Application US/09315886C
; Patent No. 6225063
; GENERAL INFORMATION:
; APPLICANT: Khvorova, Anastasia
; TITLE OF INVENTION: RNA Channels in Biological Membranes
; FILE REFERENCE: UTC-03444
; CURRENT APPLICATION NUMBER: US/09/315,886C
; CURRENT FILING DATE: 1999-05-20
; PRIOR APPLICATION NUMBER: 60/086,492
; PRIOR FILING DATE: 1998-05-22
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 32
; LENGTH: 19
; TYPE: RNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: Synthetic
US-09-315-886C-32

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 196 CACCCGACGCGCAGCA 212
Db 17 CACCCGACGCGCTAGCA 1

RESULT 128
US-09-453-514A-12/c
; Sequence 12, Application US/09453514A
; Patent No. 6326199
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip Dan
; APPLICANT: Monia, Brett P.
; TITLE OF INVENTION: Gapped 2-Modified Oligonucleotides
; FILE REFERENCE: ISIS-4291
; CURRENT APPLICATION NUMBER: US/09/453,514A
; CURRENT FILING DATE: 1999-12-01
; PRIOR APPLICATION NUMBER: 09/144,611
; PRIOR FILING DATE: 1998-08-31
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 12

; CURRENT FILING DATE: 2000-01-05
; PRIOR APPLICATION NUMBER: 09/016,520
; PRIOR FILING DATE: 1998-01-30
; PRIOR APPLICATION NUMBER: 60/037,143
; PRIOR FILING DATE: 1997-02-14
; NUMBER OF SEQ ID NOS: 47
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 4
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; NAME/KEY: misc feature
; OTHER INFORMATION: No. 6326199el Sequence
US-09-453-514A-12

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTTCCTTTTG 1157
Db 19 GCGTTTTTTTTTTTG 3

RESULT 129
US-09-135-202-33/c
; Sequence 33, Application US/09135202
; Patent No. 6399754
; GENERAL INFORMATION:
; APPLICANT: Phillip Dan Cook
; APPLICANT: Andrew Kawasaki
; TITLE OF INVENTION: Sugar Modified Oligonucleotides
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 6399754ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/135,202
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/471,973
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2005
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-135-202-33

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTTCCTTTTG 1157
Db 19 GCGTTTTTTTTTTTG 3

RESULT 130
US-08-449-731-49/c
; Sequence 49, Application US/08449731
; Patent No. 6413727
```

GENERAL INFORMATION:
; APPLICANT: ALBERTSEN, HANS
; ANAND, RAKESH
; CARLSON, MARY
; GRODEN, JOANNA
; HEDGE, PHILIP J.
; JOSLYN, GEOFF
; KINZLER, KENNETH
; MARKHAM, ALEXANDER F.
; NAKAMURA, YUSUKE
; THLIVERTIS, ANDREW
; TITLE OF INVENTION: INHERITED AND SOMATIC MUTATIONS OF APC
; GENE IN COLORECTAL CANCER IN HUMANS
; NUMBER OF SEQUENCES: 102
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Banner & Allegretti, LTD
; STREET: 1001 G Street, NW
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20001-4598
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/449,731
; FILING DATE: 25-May-1995
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/289,548
; FILING DATE: 12-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Kagan, Sarah A.
; REGISTRATION NUMBER: 32,141
; REFERENCE/DOCKET NUMBER: 1107.46943
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-508-9100
; TELEFAX: 202-508-9299
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; ORIGINAL SOURCE:
; ORGANISM: Homo sapiens
; SEQUENCE DESCRIPTION: SEQ ID NO: 49:
US-08-449-731-49
Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 100 ACAACCCGAGGCGCA 116
Db 17 ACACCCAGGAGCCGCA 1
RESULT 131
US-08-802-331-29/c
; Sequence 29, Application US/08802331
; Patent No. 6451991
; GENERAL INFORMATION:
; APPLICANT: Cook, Phillip D.
; APPLICANT: Monia, Brett
; APPLICANT: Martin, Pierre
; APPLICANT: Altman, Karl-Heinz
; TITLE OF INVENTION: Sugar-Modified Gapped Oligonucleotides
; FILE REFERENCE: ISN00083
; CURRENT APPLICATION NUMBER: US/08/802,331

US-08-802-331-29
; CURRENT FILING DATE: 1997-02-11
; NUMBER OF SEQ ID NOS: 32
; SOFTWARE: Patent in version 3.1
; SEQ ID NO 29
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: No. 6451991el Sequence
Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 1141 GCCTTTTCTTTTGTG 1157
Db 19 GCGTTTTTTTTTTTG 3
RESULT 132
US-09-375-318-29/c
; Sequence 29, Application US/09375318
; Patent No. 6468791
; GENERAL INFORMATION:
; APPLICANT: Tanzi, Rudolph E.
; Schellenberg, Gerard D.
; Masco, Wilma
; Levy-Lahad, Ephrat
; Bird, Thomas D.
; Galas, David J.
; TITLE OF INVENTION: CHROMOSOME 1 GENE AND GENE PRODUCTS RELATED TO
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BEERY LLP
; STREET: 701 Fifth Ave, Suite 6300
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/375,318
; FILING DATE: 16-Aug-1999
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Verna, James M.
; REGISTRATION NUMBER: 33,287
; REFERENCE/DOCKET NUMBER: 920010.571C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 29:
US-09-375-318-29
Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 581 CCTCCGTCGCCCCC 597
Db 17 CTCCTCGTCGCCAC 1

```
RESULT 133
US-09-375-318-43/c
; Sequence 43, Application US/09375318
; Patent No. 6468791
; GENERAL INFORMATION:
; APPLICANT: Tanzi, Rudolph E.
; Schellenberg, Gerard D.
; Wasco, Wilma
; Levy-Lahad, Ephrat
; Bird, Thomas D.
; Galas, David J.
; TITLE OF INVENTION: CHROMOSOME 1 GENE AND GENE PRODUCTS RELATED TO
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED AND BERRY LLP
; STREET: 701 Fifth Ave, Suite 6300
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patenlin Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/375,318
; FILING DATE: 16-Aug-1999
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Verna, James M.
; REGISTRATION NUMBER: 33,287
; REFERENCE/DOCKET NUMBER: 920010.571C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4300
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 43:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; SEQUENCE DESCRIPTION: SEQ ID NO: 43:
US-09-375-318-43
Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 581 CCCTCCGCTGCGCCCC 597
Db 17 CTCTCCGCTGCGCCAC 1

RESULT 134
US-09-389-283-33/c
; Sequence 33, Application US/09389283
; Patent No. 6531584
; GENERAL INFORMATION:
; APPLICANT: Phillip Dan Cook
; APPLICANT: A. Kawasaki
; TITLE OF INVENTION: 2'-Modified Oligonucleotides
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz & No. 6531584ris
; STREET: One Liberty Place - 46th Floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: U.S.A.
; ZIP: 19103

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5 inch disk, 720 Kb
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/389,283
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION NUMBER: 09/035,357
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph Lucci
; REGISTRATION NUMBER: 33,307
; REFERENCE/DOCKET NUMBER: ISIS-2004
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 215-568-3100
; TELEFAX: 215-568-3439
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 bases
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-389-283-33

Query Match 1.0%; Score 13.8; DB 1; Length 19;
Best Local Similarity 88.2%; Pred. No. 1.3e+02;
Matches 15; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCGTTTTTCTCTTTTG 1157
Db 19 GCGTTTTTCTCTTTTG 3

RESULT 135
US-09-302-681-76
; Sequence 76, Application US/09302681
; Patent No. 6441149
; GENERAL INFORMATION:
; APPLICANT: Herinstdat, Corrina
; APPLICANT: Ghosh, Soumitra S.
; APPLICANT: Clevenger, William
; APPLICANT: Fahy, Eoin E.
; APPLICANT: Davis, Robert E.
; TITLE OF INVENTION: DIAGNOSTIC METHOD BASED ON
; TITLE OF INVENTION: QUANTIFICATION OF EXTRAMITOCHONDRIAL DNA
; FILE REFERENCE: 660088.416C1
; CURRENT APPLICATION NUMBER: US/09/302,681
; CURRENT FILING DATE: 1999-04-30
; NUMBER OF SEQ ID NOS: 108
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 76
; LENGTH: 21
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Oligonucleotide primer corresponding to NADH
; OTHER INFORMATION: dehydrogenase encoding mitochondrial DNA
US-09-302-681-76

Query Match 1.0%; Score 13.6; DB 1; Length 21;
Best Local Similarity 80.0%; Pred. No. 1.8e+02;
Matches 16; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 268 TGGCTGATCAAGAGGAAGC 287
Db 2 TGGCTGATCAAGAGTATGC 21

RESULT 136
US-08-832-021-49
```

; Sequence 49, Application US/08832021

; Patent No. 6045998

; GENERAL INFORMATION:

; APPLICANT: Combates, N.

; APPLICANT: Pardini, J.

; APPLICANT: Parimoo, S.

; APPLICANT: Prouty, S.

; APPLICANT: Stenn, K.

; TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY

; FILE REFERENCE: JBP-382

; CURRENT APPLICATION NUMBER: US/08/832,021

; CURRENT FILING DATE: 1997-04-02

; NUMBER OF SEQ ID NOS: 64

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 49

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: primer

US-08-832-021-49

Query Match

Best Local Similarity 1.0%; Score 13.4; DB 1; Length 15;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGA 1159

DB 1 TTTTTCCTTTTGA 15

RESULT 137

US-08-445-515-37

; Sequence 37, Application US/08445515

; Patent No. 6043088

; GENERAL INFORMATION:

; APPLICANT: Bookstein, Robert

; APPLICANT: Isaacs, William B.

; TITLE OF INVENTION: A No. 6043088el Prostate/Colon Tumor Suppressor

; TITLE OF INVENTION: Gene Located on Human Chromosome 8

; NUMBER OF SEQUENCES: 59

; CORRESPONDENCE ADDRESS:

; ADDRESS: Campbell and Flores

; STREET: 4370 La Jolla Village Drive, Suite 700

; CITY: San Diego

; STATE: California

; COUNTRY: USA

; ZIP: 92122

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.25

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/445,515

; FILING DATE:

; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:

; NAME: Campbell, Cathryn A.

; REGISTRATION NUMBER: 31,815

; REFERENCE/DOCKET NUMBER: P-CJ 1607

; TELEPHONE: (619) 535-9001

; TELEFAX: (619) 535-8949

; INFORMATION FOR SEQ ID NO: 37:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 17 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

US-08-445-515-37

Query Match

1.0%; Score 13.4; DB 1; Length 17;

Best Local Similarity 93.3%; Pred. No. 1.2e+02;

Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 237 GGCACTGTCATCTGG 251

DB 3 GGCACTGTCATCTGG 17

RESULT 138

US-09-996-243-493

; Sequence 493, Application US/09996243

; Patent No. 6478825

; GENERAL INFORMATION:

; APPLICANT: Ashkenazi, Avi J.

; APPLICANT: Baker, Kevin P.

; APPLICANT: Botstein, David

; APPLICANT: Desnoyers, Luc

; APPLICANT: Eaton, Dan L.

; APPLICANT: Ferrara, Napoleone

; APPLICANT: Fong, Sherman

; APPLICANT: Gerber, Hanspeter

; APPLICANT: Gerritsen, Mary E.

; APPLICANT: Goddard, Audrey

; APPLICANT: Godowski, Paul J.

; APPLICANT: Grimaldi, J. Christopher

; APPLICANT: Gurney, Austin L.

; APPLICANT: Kijavir, Ivar J.

; APPLICANT: Napier, Mary A.

; APPLICANT: Pan, James

; APPLICANT: Paoni, Nicholas F.

; APPLICANT: Roy, Margaret Ann

; APPLICANT: Stewart, Timothy A.

; APPLICANT: Tumas, Daniel

; APPLICANT: Watanabe, Colin K.

; APPLICANT: Williams, P. Mickey

; APPLICANT: Wood, William I.

; APPLICANT: Zhang, Zemin

; TITLE OF INVENTION: Secreted and Transmembrane Polypeptides and Nucleic

; TITLE OF INVENTION: Acids Encoding the Same

; FILE REFERENCE: P2730P13

; CURRENT APPLICATION NUMBER: US/09/996,243

; CURRENT FILING DATE: 2001-11-14

; PRIOR APPLICATION NUMBER: 60/049787

; PRIOR FILING DATE: 1997-06-16

; PRIOR APPLICATION NUMBER: 60/062250

; PRIOR FILING DATE: 1997-10-17

; PRIOR APPLICATION NUMBER: 60/065186

; PRIOR FILING DATE: 1997-11-12

; PRIOR APPLICATION NUMBER: 60/065311

; PRIOR FILING DATE: 1997-11-13

; PRIOR APPLICATION NUMBER: 60/066770

; PRIOR FILING DATE: 1997-11-24

; PRIOR APPLICATION NUMBER: 60/075945

; PRIOR FILING DATE: 1998-02-25

; PRIOR APPLICATION NUMBER: 60/078910

; PRIOR FILING DATE: 1998-03-20

; PRIOR APPLICATION NUMBER: 60/083322

; PRIOR FILING DATE: 1998-04-28

; PRIOR APPLICATION NUMBER: 60/084600

; PRIOR FILING DATE: 1998-05-07

; PRIOR APPLICATION NUMBER: 60/087106

; PRIOR FILING DATE: 1998-05-28

; PRIOR APPLICATION NUMBER: 60/087607

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087609

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087759

; PRIOR FILING DATE: 1998-06-02

; PRIOR APPLICATION NUMBER: 60/087827

; PRIOR FILING DATE: 1998-06-03

; PRIOR APPLICATION NUMBER: 60/088021

; PRIOR FILING DATE: 1998-06-04

; PRIOR APPLICATION NUMBER: 60/088025

; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088026
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088028
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088029
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088030
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088033
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088326
; PRIOR FILING DATE: 1998-06-04
; PRIOR APPLICATION NUMBER: 60/088167
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088202
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088212
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088217
; PRIOR FILING DATE: 1998-06-05
; PRIOR APPLICATION NUMBER: 60/088655
; PRIOR FILING DATE: 1998-06-09
; PRIOR APPLICATION NUMBER: 60/088734
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088738
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088742
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088810
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088824
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088826
; PRIOR FILING DATE: 1998-06-10
; PRIOR APPLICATION NUMBER: 60/088858
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088861
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/088876
; PRIOR FILING DATE: 1998-06-11
; PRIOR APPLICATION NUMBER: 60/089105
; PRIOR FILING DATE: 1998-06-12
; PRIOR APPLICATION NUMBER: 60/089440
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089512
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089514
; PRIOR FILING DATE: 1998-06-16
; PRIOR APPLICATION NUMBER: 60/089532
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089538
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089598
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089599
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089600
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089653
; PRIOR FILING DATE: 1998-06-17
; PRIOR APPLICATION NUMBER: 60/089801
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089907
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089908
; PRIOR FILING DATE: 1998-06-18
; PRIOR APPLICATION NUMBER: 60/089947
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089948
; PRIOR FILING DATE: 1998-06-19
; PRIOR APPLICATION NUMBER: 60/089952
; PRIOR FILING DATE: 1998-06-19

; PRIOR APPLICATION NUMBER: 60/090246
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090252
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090254
; PRIOR FILING DATE: 1998-06-22
; PRIOR APPLICATION NUMBER: 60/090349
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090355
; PRIOR FILING DATE: 1998-06-23
; PRIOR APPLICATION NUMBER: 60/090429
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090431
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090435
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090444
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090445
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090472
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090535
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090540
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090542
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090557
; PRIOR FILING DATE: 1998-06-24
; PRIOR APPLICATION NUMBER: 60/090676
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090678
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090690
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090694
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090695
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090696
; PRIOR FILING DATE: 1998-06-25
; PRIOR APPLICATION NUMBER: 60/090862
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/090863
; PRIOR FILING DATE: 1998-06-26
; PRIOR APPLICATION NUMBER: 60/091360
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091478
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091544
; PRIOR FILING DATE: 1998-07-01
; PRIOR APPLICATION NUMBER: 60/091519
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091626
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091633
; PRIOR FILING DATE: 1998-07-02
; PRIOR APPLICATION NUMBER: 60/091978
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/091982
; PRIOR FILING DATE: 1998-07-07
; PRIOR APPLICATION NUMBER: 60/092182
; PRIOR FILING DATE: 1998-07-09

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 93.3%; Pred.No. 1.2e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 494 GTGTGACGCTCTTG 508

Db 1 GTGGCAGCGCTCTTG 15

RESULT 139
US-09-371-772B-5187
; Sequence 5187, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5187
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5187

Query Match 1.0%; Score 13.4; DB 1; Length 17;
Best Local Similarity 66.7%; Pred. No. 1.2e+02;
Matches 10; Conservative 4; Mismatches 1; Indels 0; Gaps 0;
QY 1154 TTGGAAGTAAGCA 1168
:::|||||:|||||
Db 1 UUUGAACUAAAGCA 15

RESULT 140
US-08-585-684B-2595
; Sequence 2595, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585,684B
; FILING DATE: January 16, 1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2595:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-2595

Query Match 1.0%; Score 13.4; DB 1; Length 18;
Best Local Similarity 33.3%; Pred. No. 1.4e+02;
Matches 5; Conservative 9; Mismatches 1; Indels 0; Gaps 0;
QY 1111 GTTTCCTGTTAAAT 1125
|:::|:::|:::|:::|
Db 1 GUUUCUGUCUAAU 15

RESULT 141
US-09-213-768-47/c
; Sequence 47, Application US/09213768
; Patent No. 5985664
; GENERAL INFORMATION:
; APPLICANT: Brenda F. Baker
; APPLICANT: Lex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF SENTRIN EXPRESSION
; FILE REFERENCE: RTS-0026
; CURRENT APPLICATION NUMBER: US/09/213,768
; CURRENT FILING DATE: 1998-12-17
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 47
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-213-768-47

Query Match 1.0%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;
QY 440 GAAAGTTGCTGAAGT 454
||||| |
Db 18 GAAAGTTACTGAAGT 4

RESULT 142
US-09-205-921-18/c
; Sequence 18, Application US/09205921A
; Patent No. 6008048
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: ex M. Cowsett
; TITLE OF INVENTION: ANTISENSE MODULATION OF EGR-1 EXPRESSION
; FILE REFERENCE: RTS-0028
; CURRENT APPLICATION NUMBER: US/09/205,921A
; CURRENT FILING DATE: 1998-12-04
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 18
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-205-921-18

Query Match 1.0%; Score 13.4; DB 1; Length 18;
Best Local Similarity 93.3%; Pred. No. 1.4e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

NAME: Smith, William M.
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 14643-5
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-543-9600
TELEFAX: 415-543-5043
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-07-834-539A-8

Query Match 1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 391 GTGGCAGCAATGGCC 405
Db 4 GTGGCGCAATGGCC 18

RESULT 147
US-08-053-131-16
Sequence 16, Application US/08053131
Patent No. 5661016
GENERAL INFORMATION:
APPLICANT: Lomborg, Nils
TITLE OF INVENTION: Transgenic No. 5661016-Human Animals for
Producing Heterologous Antibodies
NUMBER OF SEQUENCES: 197
CORRESPONDENCE ADDRESS:
ADDRESSEE: Townsend and Townsend Kourie and Crew
STREET: One Market Plaza, Steuart Tower, Suite 200
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94105

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/053,131
FILING DATE: 26-APR-1993
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/990,860
FILING DATE: 16-DEC-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/810,279
FILING DATE: 17-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/853,408
FILING DATE: 18-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M.
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 14643-9-3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-326-2400
TELEFAX: 415-326-2422
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (primer)

US-08-053-131-16

Query Match 1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 391 GTGGCAGCAATGGCC 405
Db 4 GTGGCGCAATGGCC 18

RESULT 148
US-08-645-641-16
Sequence 16, Application US/08645641
Patent No. 5719032
GENERAL INFORMATION:
APPLICANT: Lomborg, Nils
TITLE OF INVENTION: Transgenic No. 5719032-Human Animals for
Producing Heterologous Antibodies
NUMBER OF SEQUENCES: 150
CORRESPONDENCE ADDRESS:
ADDRESSEE: William M. Smith
STREET: Two Embarcadero Center, 8th Floor
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-3834

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/645,641
FILING DATE: 20-MAY-1996
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/904,068
FILING DATE: 23-JUN-1992
ATTORNEY/AGENT INFORMATION:
NAME: Smith, William M.
REGISTRATION NUMBER: 30,223
REFERENCE/DOCKET NUMBER: 14643-000913
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-326-2400
TELEFAX: 415-326-2422
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 19 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (primer)
US-08-645-641-16

Query Match 1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 391 GTGGCAGCAATGGCC 405
Db 4 GTGGCGCAATGGCC 18

RESULT 149
US-07-853-408B-16
Sequence 16, Application US/07853408B
Patent No. 5789650
GENERAL INFORMATION:
APPLICANT: Lomborg, Nils
TITLE OF INVENTION: Transgenic No. 5789650-Human Animals for

;; TITLE OF INVENTION: Producing Heterologous Antibodies
;; NUMBER OF SEQUENCES: 150
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: William M. Smith
;; STREET: One Market Plaza, Steuart Tower, Suite 2000
;; CITY: San Francisco
;; STATE: California
;; COUNTRY: USA
;; ZIP: 94105
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; OPERATING SYSTEM: IBM PC compatible
;; SOFTWARE: PatentIn Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/07/853,408B
;; FILING DATE: 19920318
;; CLASSIFICATION: 800
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Smith, William M.
;; REGISTRATION NUMBER: 30,223
;; REFERENCE/DOCKET NUMBER: 14643-9
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 415-326-2400
;; TELEFAX: 415-326-2422
;; INFORMATION FOR SEQ ID NO: 16:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 19 base pairs
;; TYPE: NUCLEIC ACID
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (primer)
;; US-07-853-408B-16

Query Match 1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 391 GTGGCAGCAATGGCC 405
Db 4 GTGGCCGCAATGGCC 18

RESULT 150
US-08-096-762-16
; Sequence 16, Application US/08096762
; Patent No. 5614318
; GENERAL INFORMATION:
; APPLICANT: Lonberg, Nils
; APPLICANT: Kay, Robert M.
; TITLE OF INVENTION: Transgenic No. 5814318-Human Animals for
; TITLE OF INVENTION: Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 210
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourie and Crew
; STREET: One Market Plaza, Steuart Tower, Suite 200
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/096,762
; FILING DATE: 22-JUL-1993
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/053,131
; FILING DATE: 26-APR-1993
; PRIOR APPLICATION DATA:

;; APPLICATION NUMBER: US 07/990,860
;; FILING DATE: 16-DEC-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/904,068
;; FILING DATE: 23-JUN-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/853,408
;; FILING DATE: 18-MAR-1992
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 07/810,279
;; FILING DATE: 17-DEC-1991
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Smith, William M.
;; REGISTRATION NUMBER: 30,223
;; REFERENCE/DOCKET NUMBER: 14643-9-4
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 415-326-2400
;; TELEFAX: 415-326-2422
;; INFORMATION FOR SEQ ID NO: 16:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 19 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (primer)
;; US-08-096-762-16

Query Match 1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 391 GTGGCAGCAATGGCC 405
Db 4 GTGGCCGCAATGGCC 18

RESULT 151
US-08-800-353-8
; Sequence 8, Application US/08800353
; Patent No. 5874299
; GENERAL INFORMATION:
; APPLICANT: Lonberg, Nils
; APPLICANT: Kay, Robert M.
; TITLE OF INVENTION: Transgenic No. 5874299-Human Animals Capable of
; TITLE OF INVENTION: Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 77
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: William M. Smith
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/800,353
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/07/834,539
; FILING DATE: 1992-02-05
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 14643-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-543-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 8:

```
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-800-353-8
Query Match          1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      391 GTGGCAGCAATGCC 405
Db      4 GTGGCGCAATGCC 18

RESULT 152
US-08-308-865-16
; Sequence 16, Application US/08308865
; Patent No. 5877397
; GENERAL INFORMATION:
; APPLICANT: Lonberg, Nils
; TITLE OF INVENTION: Transgenic No. 5877397-Human Animals for
; TITLE OF INVENTION: Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 150
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: William M. Smith
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 23-JUN-1992
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/145,707
; FILING DATE: 23-JUN-1992
; APPLICATION NUMBER: US 07/904,068
; FILING DATE: 18-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 14643-9-1-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)
US-08-308-865-16
Query Match          1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      391 GTGGCAGCAATGCC 405
Db      4 GTGGCGCAATGCC 18

RESULT 153
US-09-042-353-184
; Sequence 184, Application US/09042353
; Patent No. 6255458
; GENERAL INFORMATION:
; APPLICANT: Lonberg, Nils
; APPLICANT: Kay, Robert M.
; TITLE OF INVENTION: Transgenic No. 6255458-Human Animals for
; TITLE OF INVENTION: Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 421
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; FILING DATE: 13-MAR-1998
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/810,279
; FILING DATE: 17-DEC-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/853,408
; FILING DATE: 18-MAR-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/904,068
; FILING DATE: 23-JUN-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/990,860
; FILING DATE: 16-DEC-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/053,131
; FILING DATE: 26-APR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/096,762
; FILING DATE: 22-JUL-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/155,301
; FILING DATE: 18-NOV-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/161,739
; FILING DATE: 03-DEC-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/165,699
; FILING DATE: 10-DEC-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/209,741
; FILING DATE: 09-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/352,322
; FILING DATE: 07-DEC-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/544,404
; FILING DATE: 10-OCT-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/728,463
; FILING DATE: 10-OCT-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO PCT/US96/16433
; FILING DATE: 10-OCT-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/758,417
; FILING DATE: 02-DEC-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO PCT/US97/21803
```

```
; FILING DATE: 01-DEC-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Apple, Randolph T.
; REGISTRATION NUMBER: 36,429
; REFERENCE/DOCKET NUMBER: 014643-009040US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 184:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-09-042-353-184

Query Match          1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      391 GTGGCAGCAATGGCC 405
Db      4 GTGGCGCAATGGCC 18

RESULT 154
US-08-758-417A-32
; Sequence 32, Application US/08758417A
; Patent No. 6300129
; GENERAL INFORMATION:
; APPLICANT: Lonberg, Nils
; Kay, Robert M.
; TITLE OF INVENTION: Transgenic No. 6300129-Human Animals for
; Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 417
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend and Crew LLP
; STREET: Two Embarcadero Center, Eighth Floor
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-3834
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,417A
; FILING DATE: 02-Dec-1996
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/728,463
; FILING DATE: 10-OCT-1996
; APPLICATION NUMBER: US 08/544,404
; FILING DATE: 10-OCT-1995
; APPLICATION NUMBER: US 08/352,322
; FILING DATE: 07-DEC-1994
; APPLICATION NUMBER: US 08/209,741
; FILING DATE: 09-MAR-1994
; APPLICATION NUMBER: US 08/165,699
; FILING DATE: 10-DEC-1993
; APPLICATION NUMBER: US 08/161,739
; FILING DATE: 03-DEC-1993
; APPLICATION NUMBER: US 08/155,301
; FILING DATE: 18-NOV-1993
; APPLICATION NUMBER: US 08/096,762
; FILING DATE: 22-JUL-1993
; APPLICATION NUMBER: US 08/053,131
; FILING DATE: 26-APR-1993
; APPLICATION NUMBER: US 07/990,860
; FILING DATE: 16-DEC-1992
```

```
; ATTORNEY/AGENT INFORMATION:
; NAME: Serafini, Andrew T.
; REGISTRATION NUMBER: 41,303
; REFERENCE/DOCKET NUMBER: 014643-009030US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 576-0200
; TELEFAX: (415) 576-0300
; INFORMATION FOR SEQ ID NO: 32:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; SEQUENCE DESCRIPTION: SEQ ID NO: 32:
US-08-758-417A-32

Query Match          1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      391 GTGGCAGCAATGGCC 405
Db      4 GTGGCGCAATGGCC 18

RESULT 155
US-09-517-467B-9
; Sequence 9, Application US/09517467B
; Patent No. 6451602
; GENERAL INFORMATION:
; APPLICANT: Ian Popoff
; APPLICANT: Lex M. Cowbert
; TITLE OF INVENTION: ANTISENSE MODULATION OF PARP EXPRESSION
; FILE REFERENCE: RTS-0150
; CURRENT APPLICATION NUMBER: US/09/517,467B
; CURRENT FILING DATE: 2001-03-02
; PRIOR APPLICATION NUMBER: 09/517,467
; PRIOR FILING DATE: 2000-03-02
; NUMBER OF SEQ ID NOS: 345
; SEQ ID NO 9
; LENGTH: 19
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: PCR Primer
; US-09-517-467B-9

Query Match          1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY      229 CAGCCTCAGGCATCT 243
Db      5 CAGCCACAGGCATCT 19

RESULT 156
PCT-US92-06185-8
; Sequence 8, Application PC/TUS9206185
; GENERAL INFORMATION:
; APPLICANT: Lonberg, Nils
; APPLICANT: Kay, Robert M.
; TITLE OF INVENTION: Transgenic Non-Human Animals Capable of
; Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 75
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: William M. Smith
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
```

```

;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/06185
; FILING DATE: 19910828
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 87654
; REFERENCE/DOCKET NUMBER: 14643-5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-543-9600
; TELEFAX: 415-543-5043
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; PCT-US92-06185-8

Query Match 1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 391 GTGGCGCAATGGCC 405
Db 4 GTGGCGCAATGGCC 18

RESULT 157
PCT-US92-10983-16
; Sequence 16, Application PC/TUS9210983
; GENERAL INFORMATION:
; APPLICANT: Lonberg, Nils
; APPLICANT: Kay, Robert M.
; TITLE OF INVENTION: Transgenic Non-Human Animals for
; TITLE OF INVENTION: Producing Heterologous Antibodies
; NUMBER OF SEQUENCES: 152
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: William M. Smith
; STREET: One Market Plaza, Steuart Tower, Suite 2000
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94105
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US92/10983
; FILING DATE: 19921217
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Smith, William M.
; REGISTRATION NUMBER: 30,223
; REFERENCE/DOCKET NUMBER: 14643-9-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-326-2400
; TELEFAX: 415-326-2422
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 19 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (primer)

PCT-US92-10983-16
Query Match 1.0%; Score 13.4; DB 1; Length 19;
Best Local Similarity 93.3%; Pred. No. 1.5e+02;
Matches 14; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 391 GTGGCGCAATGGCC 405
Db 4 GTGGCGCAATGGCC 18

RESULT 158
US-07-759-841C-2
; Sequence 2, Application US/07759841C
; Patent No. 5618796
; GENERAL INFORMATION:
; APPLICANT: Iversen, Patrick L.
; TITLE OF INVENTION: No. 5618796el Metal Binding Agents, and
; TITLE OF INVENTION: Methods and Compositions for Their
; TITLE OF INVENTION: Use to Treat Metal Toxicity
; NUMBER OF SEQUENCES: 3
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: John P. Floyd, Esq.
; STREET: P.O. Box 3609
; CITY: Williamsburg
; STATE: Virginia
; COUNTRY: USA
; ZIP: 23187-3609
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 5.25 inch, 360 Kb storage
; COMPUTER: IBM-compatible 486/33
; OPERATING SYSTEM: MS-DOS 5.0
; SOFTWARE: WordPerfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/759,841C
; FILING DATE: 12 September 1991
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA: none
; ATTORNEY/AGENT INFORMATION:
; NAME: Floyd, John P.
; REGISTRATION NUMBER: 19,528
; REFERENCE/DOCKET NUMBER: 63031
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (804) 220-0930
; TELEFAX: (804) 220-0930
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 nucleotide bases
; TYPE: nucleic acid
; STRANDEDNESS: single stranded
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA to a mRNA
; HYPOTHETICAL: no
; ANTI-SENSE: yes
; POSITION IN GENOME:
; CHROMOSOME/SEGMENT: 16q21-q22.1.
; MAP POSITION: 844 through 861
; UNITS:
; PUBLICATION INFORMATION:
; AUTHORS: Karin, M., and Richards, R. I.
; TITLE: Human metallothionein genes-primary
; TITLE: structure of the Metallothionein-II gene and
; TITLE: a related processed gene
; JOURNAL: Nature
; VOLUME: 299
; ISSUE: 43
; PAGES: 797
; DATE: 1982
; US-07-759-841C-2

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;
```

QY 525 GCCGAGGAGCAGCTGGG 542
Db 1 GGCGCAGGAGCAGTTGGG 18

RESULT 159

US-07-759-841C-3/c
; Sequence 3, Application US/07759841C
; Patent No. 5618796

GENERAL INFORMATION:

; APPLICANT: Iversen, Patrick L.
; TITLE OF INVENTION: No. 5618796el Metal Binding Agents, and
; TITLE OF INVENTION: Methods and Compositions for Their
; TITLE OF INVENTION: Use to Treat Metal Toxicity

; NUMBER OF SEQUENCES: 3

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: John P. Floyd, Esq.

; STREET: P.O. Box 3609

; CITY: Williamsburg

; STATE: Virginia

; COUNTRY: USA

; ZIP: 23187-3609

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette, 5.25 inch, 360 Kb storage

; COMPUTER: IBM-compatible 486/33

; OPERATING SYSTEM: MS-DOS 5.0

; SOFTWARE: WordPerfect 5.1

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/07759,841C

; FILING DATE: 12 September 1991

; CLASSIFICATION: 514

; PRIOR APPLICATION DATA: none

; ATTORNEY/AGENT INFORMATION:

; NAME: Floyd, John P.

; REGISTRATION NUMBER: 19,528

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: (804) 220-0930

; TELEFAX: (804) 220-0930

; INFORMATION FOR SEQ ID NO: 3:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 18 nucleotide bases

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: cDNA to a mRNA

; HYPOTHETICAL: no

; ANTI-SENSE: yes

; POSITION IN GENOME:

; CHROMOSOME/SEGMENT: 16q21-q22.1.

; MAP POSITION: 844 through 861

; UNITS:

; PUBLICATION INFORMATION:

; AUTHORS: Karin, M., and Richards, R. I.

; TITLE: Human metallothionein genes-primary

; TITLE: structure of the Metallothionein-II gene and

; TITLE: a related processed gene

; JOURNAL: Nature

; VOLUME: 239

; ISSUE: 43

; PAGES: 797

; DATE: 1982

US-07-759-841C-3

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 525 GCCGAGGAGCAGCTGGG 542
Db 18 GGCGCAGGAGCAGTTGGG 1

RESULT 160

US-09-339-964-33

; Sequence 33, Application US/09339964

; Patent No. 6025198

; GENERAL INFORMATION:

; APPLICANT: C. Frank Bennett

; APPLICANT: Lex M. Cowsett

; TITLE OF INVENTION: ANTISENSE MODULATION OF SHIP-2 EXPRESSION

; FILE REFERENCE: RTS-0065

; CURRENT APPLICATION NUMBER: US/09/339,964

; CURRENT FILING DATE: 1999-06-25

; NUMBER OF SEQ ID NOS: 47

; SEQ ID NO 33

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-339-964-33

Query Match 1.0%; Score 13.2; DB 1; Length 18;

Best Local Similarity 83.3%; Pred. No. 1.5e+02;

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 869 TCCCCACAGCCCAAGTTCC 886

Db 1 TCCCCACTGCCCACTTCC 18

RESULT 161

US-09-339-993-23/c

; Sequence 23, Application US/09339993A

; Patent No. 6040179

; GENERAL INFORMATION:

; APPLICANT: Lex M. Cowsett

; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-I2 EXPRESSION

; FILE REFERENCE: RTS-0064

; CURRENT APPLICATION NUMBER: US/09/339,993A

; CURRENT FILING DATE: 1999-06-25

; NUMBER OF SEQ ID NOS: 47

; SEQ ID NO 23

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-339-993-23

Query Match 1.0%; Score 13.2; DB 1; Length 18;

Best Local Similarity 83.3%; Pred. No. 1.5e+02;

Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 860 GCTTTGAGGTCCCCACAG 877

Db 18 GCTTTGAGGCGCTCACAG 1

RESULT 162

US-09-073-465-7/c

; Sequence 7, Application US/09073465

; Patent No. 6054278

; GENERAL INFORMATION:

; APPLICANT: DODGE, Deborah E

; APPLICANT: SMITH, Doug

; TITLE OF INVENTION: RIBOSOMAL RNA GENE POLYMORPHISM BASED MICROORGANISM

; TITLE OF INVENTION: IDENTIFICATION

; FILE REFERENCE: 4343 US

; CURRENT APPLICATION NUMBER: US/09/073,465

; CURRENT FILING DATE: 1998-05-05

; NUMBER OF SEQ ID NOS: 17

; SOFTWARE: PatentIn Ver. 2.1

; SEQ ID NO 7

```
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Bacterial
US-09-073-465-7

Query Match          1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      882 GTTCAGAGCTGGGTA 899
Db      18 GTGCAGAGCGCGGTA 1

RESULT 163
US-09-339-775-31/C
; Sequence 31, Application US/09339775
; Patent No. 6063626
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowert
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-I3 EXPRESSION
; FILE REFERENCE: RFS-0069
; CURRENT APPLICATION NUMBER: US/09/339,775
; CURRENT FILING DATE: 1999-06-24
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 31
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-339-775-31

Query Match          1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      973 CTCACCTGACAGTCCCA 990
Db      18 CTCACCTGACCTGTGCCA 1

RESULT 164
US-09-199-859-14
; Sequence 14, Application US/09199859
; Patent No. 6063008
; GENERAL INFORMATION:
; APPLICANT: C. Frank Bennett
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowert
; TITLE OF INVENTION: ANTISENSE MODULATION OF NF-KAPPA-B P65 SUBUNIT EXPRESSION
; FILE REFERENCE: RFS-0025
; CURRENT APPLICATION NUMBER: US/09/199,859
; CURRENT FILING DATE: 1998-11-25
; NUMBER OF SEQ ID NOS: 47
; SEQ ID NO 14
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-199-859-14

Query Match          1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      1300 CTTGGCCCATGTAGCCA 1317
Db      1 CTTGGTCTCTGTAGCCA 18
```

```
RESULT 165
US-08-795-430-31
; Sequence 31, Application US/08795430
; Patent No. 6130071
; GENERAL INFORMATION:
; APPLICANT: Alitalo, Kari
; APPLICANT: Joukov, Vladimir
; TITLE OF INVENTION: Vascular Endothelial Growth Factor C (VEGF-C)
; TITLE OF INVENTION: Protein and Gene, Mutants Thereof, and Uses Thereof
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/795,430
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/FI96/00427
; FILING DATE: 01-AUG-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/671,573
; FILING DATE: 28-JUN-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/601,132
; FILING DATE: 14-FEB-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,895
; FILING DATE: 12-JAN-1996
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/510,133
; FILING DATE: 01-AUG-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/340,011
; FILING DATE: 14-NOV-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Gass, David A.
; REGISTRATION NUMBER: 38,153
; REFERENCE/DOCKET NUMBER: 28967/33691
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-795-430-31

Query Match          1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY      380 TTCCTCCAGAGTGGCAG 397
Db      1 TTCCTCCAAAGGTGTGAG 18

RESULT 166
US-09-487-444-10
```

; Sequence 10, Application US/09487444
; Patent No. 6159697
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowser
; TITLE OF INVENTION: ANTISENSE MODULATION OF SMAD7 EXPRESSION
; FILE REFERENCE: RTS-0133
; CURRENT APPLICATION NUMBER: US/09/487,444
; CURRENT FILING DATE: 2000-01-19
; NUMBER OF SEQ ID NOS: 49
; SEQ ID NO 10
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-487-444-10

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 583 CTCGGTGTGCCCCCACC 600
|||||
Db 1 CTCGGTGTGCCCCCACC 18

RESULT 167

US-09-338-907-354
; Sequence 354, Application US/09338907
; Patent No. 6265546
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilya, Chumakov
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: PROSTATE CANCER GENE
; FILE REFERENCE: GENSET.18CP1C
; CURRENT APPLICATION NUMBER: US/09/338,907
; CURRENT FILING DATE: 1999-06-23
; EARLIER APPLICATION NUMBER: 08/996,306
; EARLIER FILING DATE: 1997-12-22
; EARLIER APPLICATION NUMBER: 60/099,658
; EARLIER FILING DATE: 1998-09-09
; EARLIER APPLICATION NUMBER: 09/218,207
; EARLIER FILING DATE: 1998-12-22
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm
; SEQ ID NO 354
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer for SEQ 218, SEQ 295, SEQ 219, SEQ
US-09-338-907-354

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 869 TCCCCACAGCCCAAGTTC 886
|||||
Db 1 TCCCCACAGCTAAGGCC 18

RESULT 168

US-09-218-207-354
; Sequence 354, Application US/09218207
; Patent No. 6346381
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel

; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilya, Chumakov
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: Prostate cancer gene
; FILE REFERENCE: GENSET.018CP1
; CURRENT APPLICATION NUMBER: US/09/218,207
; CURRENT FILING DATE: 1998-12-22
; EARLIER APPLICATION NUMBER: 08/996,306
; EARLIER FILING DATE: 1997-12-22
; EARLIER APPLICATION NUMBER: 60/099,658
; EARLIER FILING DATE: 1998-09-09
; NUMBER OF SEQ ID NOS: 578
; SOFTWARE: Patent.pm
; SEQ ID NO 354
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer for SEQ 218, SEQ 295, SEQ 219, SE
US-09-218-207-354

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 869 TCCCCACAGCCCAAGTTC 886
|||||
Db 1 TCCCCACAGCTAAGGCC 18

RESULT 169

US-08-584-040-2983
; Sequence 2983, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:

```
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2983:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-2983

Query Match
Best Local Similarity 1.0%; Score 13.2; DB 1; Length 18;
Matches 13; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 142 CCGCTCGGCTCGCTCCG 159
Db 1 CCUCGCGCUCUCCCG 18

RESULT 170
US-08-584-040-4454
; Sequence 4454, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 4454:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-4454

Query Match
Best Local Similarity 1.0%; Score 13.2; DB 1; Length 18;
Matches 13; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 142 CCGCTCGGCTCGCTCCG 159
Db 1 CCUCGCGCUCUCCCG 18

RESULT 171
US-08-584-040-8393
; Sequence 8393, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 8393:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-8393

Query Match
Best Local Similarity 1.0%; Score 13.2; DB 1; Length 18;
Matches 11; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1053 CAGCCCTGCGCTTCCCAT 1070
Db 1 CAGGCCUGACCUUCGCAU 18

RESULT 172
US-09-355-700-31
; Sequence 31, Application US/09355700
; Patent No. 6361946
```



```

; GENERAL INFORMATION:
; APPLICANT: Ludwig Institute for Cancer Research
; Helinski University Licensing
; Aitaio, Kari (U.S. only)
; Joukov, Vladimir (U.S. only)
; TITLE OF INVENTION: Vascular Endothelial Growth Factor C (VEGF-C)
; Protein and Gene, Mutants Thereof, and Uses Thereof
; NUMBER OF SEQUENCES: 59
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Marshall, O'Toole, Gerstein, Murray & Borun
; STREET: 6300 Sears Tower, 233 South Wacker Drive
; CITY: Chicago
; STATE: Illinois
; COUNTRY: United States of America
; ZIP: 60606-6402
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/355,700
; FILING DATE: 05-NOV-1994
; CLASSIFICATION: <Unknown>
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/795,430
; FILING DATE: 05-FEB-1997
; APPLICATION NUMBER: PCT/EP96/00427
; FILING DATE: 01-AUG-1996
; APPLICATION NUMBER: 08/671,573
; FILING DATE: 28-JUN-1996
; APPLICATION NUMBER: 08/601,132
; FILING DATE: 14-FEB-1996
; APPLICATION NUMBER: 08/585,895
; FILING DATE: 12-JAN-1996
; APPLICATION NUMBER: 08/510,133
; FILING DATE: 01-AUG-1995
; APPLICATION NUMBER: 08/340,011
; FILING DATE: 14-NOV-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Gass, David A.
; REGISTRATION NUMBER: 38,153
; REFERENCE/DOCKET NUMBER: 28967/34140
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 312/474-6300
; TELEFAX: 312/474-0448
; TELEX: 25-3856
; INFORMATION FOR SEQ ID NO: 31:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; SEQUENCE DESCRIPTION: SEQ ID NO: 31:
US-09-355-700-31

```

```

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 380 TTCTCCAGAGGTGGCAG 397
Db 1 TTCTCCAAAGGTGTCTAG 18

```

```

RESULT 173
US-09-167-109-8
; Sequence 8, Application US/09167109
; GENERAL INFORMATION:
; APPLICANT: Baker, Brenda F.
; APPLICANT: Cowser, Lex M.

```

```

; APPLICANT: Monia, Brett P.
; APPLICANT: Xu, Xiaoxing S.
; TITLE OF INVENTION: ANTISENSE MODULATION OF TRAF EXPRESSION
; FILE REFERENCE: ISPH-0321
; CURRENT APPLICATION NUMBER: US/09/167,109
; CURRENT FILING DATE: 1998-10-06
; NUMBER OF SEQ ID NOS: 228
; SEQ ID NO 8
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: antisense sequence
US-09-167-109-8

```

```

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 471 GCAGGGGAGGACTGCCG 488
Db 1 GCCGGCGAGGACTGCTG 18

```

```

RESULT 174
US-08-275-951-33
; Sequence 33, Application US/08275951
; Patent No. 6451968
; GENERAL INFORMATION:
; APPLICANT: Egholm, Michael
; APPLICANT: Kiely, John
; APPLICANT: Griffin, Michael
; APPLICANT: Coull, James M.
; APPLICANT: Neilsen, Peter
; APPLICANT: Buchardt, Ole
; APPLICANT: Dueholm, Kim L.
; APPLICANT: Christensen, Leif
; TITLE OF INVENTION: Linked Peptide Nucleic Acids
; FILE REFERENCE: ISIS1577
; CURRENT APPLICATION NUMBER: US/08/275,951
; CURRENT FILING DATE: 1994-07-15
; PRIOR APPLICATION NUMBER: 08/108,591
; PRIOR FILING DATE: 1993-11-22
; PRIOR APPLICATION NUMBER: 08/088,658
; PRIOR FILING DATE: 1993-07-02
; PRIOR APPLICATION NUMBER: 08/088,661
; PRIOR FILING DATE: 1993-07-02
; PRIOR APPLICATION NUMBER: PCT/EP92/01219
; PRIOR FILING DATE: 1992-05-22
; PRIOR APPLICATION NUMBER: 986/91
; PRIOR FILING DATE: 1991-05-22
; PRIOR APPLICATION NUMBER: 987/91
; PRIOR FILING DATE: 1991-05-24
; PRIOR APPLICATION NUMBER: 510/92
; PRIOR FILING DATE: 1991-04-15
; NUMBER OF SEQ ID NOS: 65
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 33
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: No. 6451968el Sequence
; NAME/KEY: misc_feature
; LOCATION: (9)..(10)
; OTHER INFORMATION: Lysine, Amino Hexanoic Acid, Lysine, Amino
; OTHER INFORMATION: Hexanoic Acid, Lysine Linkage
US-08-275-951-33

```

```

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

QY 1138 TATGCTTTTCTTTT 1155
DB 1 TTTCTTTTCTTTT 18

RESULT 175

US-09-422-978-6039/c
; Sequence 6039, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET 020CP1
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 6039
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-8571 for SEQ 2105,
US-09-422-978-6039

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 83.3%; Pred. No. 1.5e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 56 CTCCTCAATTACCACAT 73
DB 18 CTCCTCTTATCCACAT 1

RESULT 176

US-09-371-772B-1411
; Sequence 1411, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1411
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1411

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 72.2%; Pred. No. 1.5e+02;
Matches 13; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 142 CCGCTCGGCTCGCTCCG 159
DB 1 CCTCUGGCGUCGCCCG 18

RESULT 177

US-09-371-772B-2167
; Sequence 2167, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2167
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-2167

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 61.1%; Pred. No. 1.5e+02;
Matches 11; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1239 GCTGGACGTGGCCATGTG 1256
DB 1 GCUGGCCGUGCCCGUG 18

RESULT 178

US-09-371-772B-4049
; Sequence 4049, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4049
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-4049

Query Match 1.0%; Score 13.2; DB 1; Length 18;
Best Local Similarity 61.1%; Pred. No. 1.5e+02;
Matches 11; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1053 CAGCCCTGGCTTCCCAT 1070
Db 1 CAGGCCUGACCUUGCGCAU 18

RESULT 179

US-08-450-905B-134/c
; Sequence 134, Application US/08450905B
; Patent No. 5856301
; GENERAL INFORMATION:
; APPLICANT:
; TITLE OF INVENTION: Stem Cell Inhibiting Proteins
; NUMBER OF SEQUENCES: 178
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE and DORR
; STREET: 60 State Street
; CITY: Boston
; STATE: MA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/450,905B
; FILING DATE: 26-MAR-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/982,759
; FILING DATE: 08-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9127319.3
; FILING DATE: 23-DEC-1991
; APPLICATION DATA:
; APPLICATION NUMBER: GB 9221587.0
; FILING DATE: 14-OCT-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: BAKER, HOLLIE L.
; REGISTRATION NUMBER: 31,321
; REFERENCE/DOCKET NUMBER: 102.378.120DV-2
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-526-6110
; TELEFAX: 617-526-5000
; INFORMATION FOR SEQ ID NO: 134:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..20
; OTHER INFORMATION: /product= "BB9513 oligomer"
US-08-450-905B-134

Query Match 1.0%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 820 GTCTGTGATGCAGCTGAAG 837
Db 20 GTGCTGACGCATCTGAAG 3

RESULT 180

US-07-982-759F-134/c
; Sequence 134, Application US/07982759F
; Patent No. 6057123
; GENERAL INFORMATION:
; APPLICANT: CRAIG, Stewart
; APPLICANT: GEORGE, Michael
; APPLICANT: EDWARDS, Richard Mark

; APPLICANT: CZAPLEWSKI, Lloyd George
; APPLICANT: GILBERT, Richard
; TITLE OF INVENTION: Stem Cell Inhibiting Proteins
; NUMBER OF SEQUENCES: 178
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE and DORR LLP
; STREET: 60 State Street
; CITY: Boston
; STATE: MA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/07/982,759F
; FILING DATE: 08-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9127319.3
; FILING DATE: 23-DEC-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9221587.0
; FILING DATE: 14-OCT-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: BAKER, HOLLIE L.
; REGISTRATION NUMBER: 31,321
; REFERENCE/DOCKET NUMBER: 102378.120
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-526-6000
; TELEFAX: 617-526-5000
; INFORMATION FOR SEQ ID NO: 134:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 20 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1..20
; OTHER INFORMATION: /product= "BB9513 oligomer"
US-07-982-759F-134

Query Match 1.0%; Score 13.2; DB 1; Length 20;
Best Local Similarity 83.3%; Pred. No. 1.9e+02;
Matches 15; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 820 GTCTGTGATGCAGCTGAAG 837
Db 20 GTGCTGACGCATCTGAAG 3

RESULT 181

US-08-291-932A-311
; Sequence 311, Application US/08291932A
; Patent No. 5658780
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

```

; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/291.932A
; FILING DATE: August 15, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/157
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 311:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-291-932A-311

```

```

Query Match 1.0%; Score 13; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.1e+02;
Matches 12; Conservative 1; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 1066 CCATCAGGAGG 1078
Db 3 CCATCAGGAGG 15

```

```

RESULT 182
US-08-152-313-111
; Sequence 111, Application US/08152313
; Patent No. 5561041
; GENERAL INFORMATION:
; APPLICANT: Sidransky, David
; TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION BY
; TITLE OF INVENTION: ANALYSIS OF SPUTUM
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Spensley Horn Juba & Lubitz
; STREET: 1880 Century Park East, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90067
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/152.313
; FILING DATE: 12-NOV-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Wetherell, Jr., Ph.D., John R.,
; REGISTRATION NUMBER: 31,678
; REFERENCE/DOCKET NUMBER: FD-2912
; TELECOMMUNICATION INFORMATION:

```

```

; TELEPHONE: (619) 455-5100
; TELEFAX: (619) 455-5110
; INFORMATION FOR SEQ ID NO: 111:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..17
; US-08-152-313-111

```

Two

```

Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 589 CTGCCCCCACCACCA 601
Db 2 CTGCCCCCACCACCA 14

```

```

RESULT 183
US-08-250-740-23
; Sequence 23, Application US/08250740
; Patent No. 5686240
; GENERAL INFORMATION:
; APPLICANT: Schuchman, Edward H.
; APPLICANT: Desnick, Robert J.
; TITLE OF INVENTION: Acid Sphingomyelinase Gene and Diagnosis
; TITLE OF INVENTION: of Niemann-Pick Disease
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: USA
; ZIP: 10036
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/250,740
; FILING DATE: 27-MAY-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Coruzzi, Laura A.
; REGISTRATION NUMBER: 30742
; REFERENCE/DOCKET NUMBER: 6923-038
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 790-9090
; TELEFAX: (212) 869-8864
; TELEX: 66141 PENNIE
; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; US-08-250-740-23

```

```

Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

QY 631 CTCGAGGAGCTCT 643
Db 5 CTCGAGGAGCTCT 17

```

RESULT 184
US-08-579-223-111
; Sequence 111, Application US/08579223
; Patent No. 5726019
; GENERAL INFORMATION:
; APPLICANT: Sidransky, David
; TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION BY
; TITLE OF INVENTION: ANALYSIS OF SPUTUM
; NUMBER OF SEQUENCES: 128
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Spensley Horn Jubas & Lubitz
; STREET: 1860 Century Park East, Suite 500
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90067
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; FILING DATE: 28-DEC-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/152,313
; FILING DATE: 12-NOV-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Wetherell, Jr., Ph.D., John R.,
; REGISTRATION NUMBER: 31,678
; REFERENCE/DOCKET NUMBER: PD-2912
; TELEPHONE: (619) 455-5100
; TELEFAX: (619) 455-5110
; INFORMATION FOR SEQ ID NO: 111:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: Nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..17
US-08-579-223-111
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 589 CTGCCCCCACCACCA 601
DB 2 CTGCCCCCACCACCA 14
RESULT 185
US-07-695-472B-29
; Sequence 29, Application US/07695472B
; Patent No. 5773278
; GENERAL INFORMATION:
; APPLICANT: Schuchman, Edward H.
; APPLICANT: Desnick, Robert J.
; TITLE OF INVENTION: The Acid Sphingomyelinase Gene and
; TITLE OF INVENTION: Diagnosis of Niemann-Pick Disease
; NUMBER OF SEQUENCES: 36
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Pennie & Edmonds
; STREET: 1155 Avenue of the Americas
; CITY: New York
; STATE: New York

COUNTRY: U.S.A.
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/695,472B
FILING DATE: 19910503
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Mistrock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 6923-014
TELEPHONE: (212) 790-9090
TELEFAX: (212) 7908864/9741
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: NUCLEIC ACID
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: DNA
US-07-695-472B-29
Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;
QY 631 CTCGAGGAGCTCT 643
DB 5 CTCGAGGAGCTCT 17
RESULT 186
US-08-985-162-4/C
; Sequence 4, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 4:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-4

Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 200 CGGACGCCGACGA 212
DB 17 CGGACGCCGACGA 5

RESULT 187

US-09-106-375-29
Sequence 29, Application US/09106375
Patent No. 6541218
GENERAL INFORMATION:
APPLICANT: Schuchman, Edward H.
APPLICANT: Desnick, Robert J.
TITLE OF INVENTION: The Acid Sphingomyelinase Gene and
TITLE OF INVENTION: Diagnosis of Niemann-Pick Disease
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Pennie & Edmonds
STREET: 1155 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/106,375
FILING DATE:

CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/695,472
FILING DATE: 03-MAY-1991
ATTORNEY/AGENT INFORMATION:
NAME: Mirock, S. Leslie
REGISTRATION NUMBER: 18,872
REFERENCE/DOCKET NUMBER: 6923-014
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 790-9090
TELEFAX: (212) 790864/9741
TELEX: 66141 PENNIE
INFORMATION FOR SEQ ID NO: 29:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: unknown
MOLECULE TYPE: DNA
US-09-106-375-29

Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 631 CTCGAGGAGCTCT 643
DB 5 CTCGAGGAGCTCT 17

RESULT 188

PCT-US94-12947A-111
Sequence 111, Application PC/TUS9412947A
GENERAL INFORMATION:
APPLICANT: The Johns Hopkins University School of Medicine
TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION BY
TITLE OF INVENTION: ANALYSIS OF SPUTUM
NUMBER OF SEQUENCES: 128
CORRESPONDENCE ADDRESS:
ADDRESSEE: Spensley Horn Jubas & Lubitz
STREET: 1880 Century Park East, Suite 500
CITY: Los Angeles
STATE: California
COUNTRY: USA
ZIP: 90067
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US94/12947A
FILING DATE: 10-NOV-1994
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Haile, Ph.D., Lisa A.
REGISTRATION NUMBER: P-38,347
REFERENCE/DOCKET NUMBER: PD-2912
TELECOMMUNICATION INFORMATION:
TELEPHONE: (619) 455-5100
TELEFAX: (619) 455-5110
INFORMATION FOR SEQ ID NO: 111:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
FEATURE:
NAME/KEY: CDS
LOCATION: 1..17
PCT-US94-12947A-111

Query Match 1.0%; Score 13; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 589 CTGCCCCCACCACCA 601
DB 2 CTGCCCCCACCACCA 14

RESULT 189

US-08-469-802B-13/c
Sequence 13, Application US/08469802B
Patent No. 5741645
GENERAL INFORMATION:
APPLICANT: Orr, Harry T.
APPLICANT: Rannu, Laura P.W.
APPLICANT: Chung, Ming-Yi
APPLICANT: Zoghbi, Huda Y.
TITLE OF INVENTION: Gene Sequence for Spinocerebellar Ataxia
Patent No. 5741645
TITLE OF INVENTION: Type 1 and Method for Diagnosis
NUMBER OF SEQUENCES: 47
CORRESPONDENCE ADDRESS:
ADDRESSEE: Mueeting, Raasch, Gebhardt & Schwappach, P.A.
STREET: 119 No. 5741645th Fourth Street, Suite 203

CITY: Minneapolis
STATE: MN
COUNTRY: USA
ZIP: 55401
COMPUTER READABLE FORM: disk
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/469,802B
FILING DATE: 06-JUN-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Mueiting, Ann M.
REGISTRATION NUMBER: 33,977
REFERENCE/DOCKET NUMBER: 110.00030101
TELECOMMUNICATION INFORMATION:
TELEPHONE: 612-305-1217
TELEFAX: 612-305-1225
INFORMATION FOR SEQ ID NO: 13:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-469-802B-13

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 592 CCCCCCACCAGCC 604
DB 18 CCCCCCACCAGCC 6

RESULT 190
US-08-267-803B-31/c
Sequence 31, Application US/08267803B
Patent No. 5834183
GENERAL INFORMATION:
APPLICANT: Orr, Harry T.
APPLICANT: Ranum, Laura P.W.
APPLICANT: Chung, Ming-yi
APPLICANT: Zoghbi, Huda Y.
TITLE OF INVENTION: Gene Sequence for Spinocerebellar Ataxia
Patent No. 5834183
TITLE OF INVENTION: Type 1 and Method for Diagnosis
NUMBER OF SEQUENCES: 85
CORRESPONDENCE ADDRESS:
ADDRESSEE: Mueiting, Raasch, Gebhardt & Schwappach, P.A.
STREET: P.O. Box 581415
CITY: Minneapolis
STATE: MN
COUNTRY: USA
ZIP: 55458-1415
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/267,803B
FILING DATE: 28-JUN-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: McCormack, Myra H.
REGISTRATION NUMBER: 36,602
REFERENCE/DOCKET NUMBER: 110.00030120
TELECOMMUNICATION INFORMATION:
TELEPHONE: 612-305-1217

TELEFAX: 612-305-1228
INFORMATION FOR SEQ ID NO: 31:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-267-803B-31

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 592 CCCCCCACCAGCC 604
DB 18 CCCCCCACCAGCC 6

RESULT 191
US-08-450-905B-135/c
Sequence 135, Application US/08450905B
Patent No. 5856301
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: Stem Cell Inhibiting Proteins
NUMBER OF SEQUENCES: 178
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hale and Dorr
STREET: 60 State Street
CITY: Boston
STATE: MA
ZIP: 02109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/450,905B
FILING DATE: 26-MAR-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 07/982,759
FILING DATE: 08-MAR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9127319.3
FILING DATE: 23-DEC-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: GB 9221587.0
FILING DATE: 14-OCT-1992
ATTORNEY/AGENT INFORMATION:
NAME: Baker, Hollie L.
REGISTRATION NUMBER: 31,321
REFERENCE/DOCKET NUMBER: 102.378.120DV-2
TELECOMMUNICATION INFORMATION:
TELEPHONE: 617-526-6110
TELEFAX: 617-526-5000
INFORMATION FOR SEQ ID NO: 135:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
FEATURE:
NAME/KEY: misc feature
LOCATION: 1..18
OTHER INFORMATION: /product= "BB9516 oligomer"

US-08-450-905B-135
Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
QY 746 ATGTTGCTGACTT 758
Db 14 ATGTTGCTGACTT 2

RESULT 192
US-09-205-860-29
; Sequence 29, Application US/09205860
; Patent No. 5981732
; GENERAL INFORMATION:
; APPLICANT: Lex M. Cowert
; TITLE OF INVENTION: ANTISENSE MODULATION OF G-ALPHA-13 EXPRESSION
; FILE REFERENCE: RTS-0031
; CURRENT APPLICATION NUMBER: US/09/205,860
; CURRENT FILING DATE: 1998-12-04
; NUMBER OF SEQ ID NOS: 87
; SEQ ID NO 29
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-205-860-29

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 718 GCCCAGCAGCAGG 730
Db 4 GCCCAGCAGCAGG 16

RESULT 193
US-07-982-759F-135/c
; Sequence 135, Application US/07982759F
; Patent No. 6057123
; GENERAL INFORMATION:
; APPLICANT: CRAIG, Stewart
; APPLICANT: GEORGE, Michael
; APPLICANT: EDWARDS, Richard Mark
; APPLICANT: CZAPLEWSKI, Lloyd George
; APPLICANT: GILBERT, Richard
; TITLE OF INVENTION: Stem Cell Inhibiting Proteins
; NUMBER OF SEQUENCES: 178
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: HALE and DORR LLP
; STREET: 60 State Street
; CITY: Boston
; STATE: MA
; ZIP: 02109
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; APPLICATION NUMBER: US/07/982,759F
; FILING DATE: 08-MAR-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9127319.3
; FILING DATE: 23-DEC-1991
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: GB 9221587.0
; FILING DATE: 14-OCT-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: BAKER, HOLLIE L.
; REGISTRATION NUMBER: 31,321
; REFERENCE/DOCKET NUMBER: 102378.120
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 617-526-6000
; TELEFAX: 617-526-5000
```

```
; INFORMATION FOR SEQ ID NO: 135:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; FEATURE:
; NAME/KEY: misc feature
; LOCATION: 1..18
; OTHER INFORMATION: /product= "BB9516 oligomer"
US-07-982-759F-135

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 746 ATGTTGCTGACTT 758
Db 14 ATGTTGCTGACTT 2

RESULT 194
US-09-422-978-8784/c
; Sequence 8784, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 8784
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-18221 for SEQ 919, in comple
US-09-422-978-8784

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1140 TGCCTTTTCTTCT 1152
Db 17 TGCCTTTTCTTCT 5

RESULT 195
PCT-US91-03680-4
; Sequence 4, Application PC/TUS9103680
; GENERAL INFORMATION:
; APPLICANT: Matteucci, Mark D.
; APPLICANT: Krawczyk, Steven
; TITLE OF INVENTION: SEQUENCE-SPECIFIC NONPHOTOACTIVATED
; TITLE OF INVENTION: CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
; TITLE OF INVENTION: DUPLEX DNA
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 545 Middlefield Road, Suite 200
```



```

; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/03680
; FILING DATE: 19910524
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murashige, Kate H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 4610-0011.40
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-327-7250
; TELEFAX: 415-327-2951
; TELEX: 706141
;
; INFORMATION FOR SEQ ID NO: 4:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 1
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "N4,N4-ethanocytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 9
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "5-methylcytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 15
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "5-methylcytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 18
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "1,3-propanediol"
; PCT-US91-03680-4

```

```

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTT 1156
Db 2 TTTTTCCTTTT 14

```

```

RESULT 196
PCT-US91-03680-5
; Sequence 5, Application PC/TUS9103680
; GENERAL INFORMATION:
; APPLICANT: Matteucci, Mark D.
; APPLICANT: Krawczyk, Steven
; TITLE OF INVENTION: SEQUENCE-SPECIFIC NONPHOTOACTIVATED
; TITLE OF INVENTION: CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
; TITLE OF INVENTION: DUPLEX DNA
; NUMBER OF SEQUENCES: 159
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
; STATE: California

```

```

; COUNTRY: USA
; ZIP: 94025
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/03680
; FILING DATE: 19910524
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murashige, Kate H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 4610-0011.40
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-327-7250
; TELEFAX: 415-327-2951
; TELEX: 706141
;
; INFORMATION FOR SEQ ID NO: 5:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 8
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "5-methylcytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 14
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "5-methylcytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 17
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "N4,N4-ethanocytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 18
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "1,3-propanediol"
; PCT-US91-03680-5

```

```

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTT 1156
Db 1 TTTTTCCTTTT 13

```

```

RESULT 197
PCT-US95-04094-19/c
; Sequence 19, Application PC/TUS9504094
; GENERAL INFORMATION:
; APPLICANT: ALMS, William
; APPLICANT: WHITE, Barbara
; TITLE OF INVENTION: HUMAN INTERLEUKIN VARIANTS GENERATED BY
; TITLE OF INVENTION: ALTERNATIVE SPLICING
; NUMBER OF SEQUENCES: 22
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Burns, Doane, Swecker & Mathis
; STREET: P.O. Box 1404
; CITY: Alexandria
; STATE: Virginia
; COUNTRY: United States
; ZIP: 22313-1404
; COMPUTER READABLE FORM:

```

MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/04094
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/224,010
FILING DATE: 06-APR-1994
ATTORNEY/AGENT INFORMATION:
NAME: Crane-Feury, Sharon E
REGISTRATION NUMBER: 36,113
REFERENCE/DOCKET NUMBER: 028754-001
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-2021
INFORMATION FOR SEQ ID NO: 19:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US95-04094-19

Query Match 1.0%; Score 13; DB 1; Length 18;
Best Local Similarity 100.0%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 379 CTTCTCTCCAGG 391

Db 13 CTTCTCTCCAGG 1

RESULT 198

US-09-364-539-10
Sequence 10, Application US/09364539B
Patent No. 6344321
GENERAL INFORMATION:
APPLICANT: Rabin, Ross
APPLICANT: Lochrie, Michael
APPLICANT: Janjic, Nebojsa
APPLICANT: Gold, Larry
TITLE OF INVENTION: Nucleic Acid Ligands Which Bind to Hepatocyte Growth
TITLE OF INVENTION: Factor/Scatter Factor (HGF/SF) or its Receptor C-Met
FILE REFERENCE: NEX83
CURRENT APPLICATION NUMBER: US/09/364,539B
CURRENT FILING DATE: 1999-07-29
NUMBER OF SEQ ID NOS: 192
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 10
LENGTH: 16
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic
OTHER INFORMATION: Sequence
FEATURE:
NAME/KEY: modified base
LOCATION: (1)...(16)
OTHER INFORMATION: Purines and pyrimidines are 2'OMe; purines and
OTHER INFORMATION: pyrimidines at positions 1-4 are DNA; purines and
OTHER INFORMATION: pyrimidines at positions 5-16 are RNA.
US-09-364-539-10

Query Match 0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 75.0%; Pred. No. 1.4e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 297 GTCTGCTGGGGCT 312

|||||:|:|:|:

Db 1 GTCTGCGAGGGGCU 16

RESULT 199

US-09-371-772B-5925
Sequence 5925, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MEH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 5925
LENGTH: 16
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-5925

Query Match 0.9%; Score 12.8; DB 1; Length 16;
Best Local Similarity 56.2%; Pred. No. 1.4e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1311 GTAGCCAGGTGCTTTT 1326

Db 1 GGAGCCAGCGCUUUU 16

RESULT 200

US-08-373-124A-420
Sequence 420, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943

; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 420:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-373-124A-420

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. NO. 1.6e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

Qy 795 CTTGCTCGTCCTCG 810
Db 2 CCUGGCUCCUACCG 17

RESULT 201
US-08-373-124A-2031
; Sequence 2031, Application US/08373124A
; Patent No. 5646042
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/373,124A
; FILING DATE: January 13, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035

; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2031:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-373-124A-2031

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. NO. 1.6e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

Qy 1095 TGAACGTAATTATGTA 1110
Db 1 UGAAAGUUAUUAUGA 16

RESULT 202
US-08-758-306-655
; Sequence 655, Application US/08758306
; Patent No. 5807743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 655:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-758-306-655

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. NO. 1.6e+02;

Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 227 CTCAGCTCCAGGCATC 242
|:|||||
Db 1 CUGAGCCUCCAGGCAAC 16

RESULT 203

US-08-758-306-721
; Sequence 721, Application US/08758306
; Patent No. 5807743

GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: McSwiggen, James A.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION NUMBER:

ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 721:

; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-758-306-721

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.6e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 625 GACCAGCTCCAGGAGC 640
|:|||||
Db 1 GUCCAGCUCAGGAGC 16

RESULT 204

US-08-435-628-420
; Sequence 420, Application US/08435628
; Patent No. 5817796

GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth

; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

COMPUTER READABLE FORM:

; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/435,628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994

; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992

; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:

; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 420:

; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-435-628-420

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 1.6e+02;
Matches 10; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 795 CCTGGCTCGCTCCCTG 810
|:|||||
Db 2 CCUGGCUCCUACUG 17

RESULT 205

US-08-435-628-2031
; Sequence 2031, Application US/08435628
; Patent No. 5817796

GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwiggen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627

;;
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2031:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-2031

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.6e+02;
Matches 8; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 1095 TGAACGTAATATCTA 1110
DB 1 UGAAGUUAUUGUA 16
RESULT 206
US-08-292-620A-1727/c
Sequence 1727, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
RELATED TO LEVELS OF
INTRACELLULAR ADHESION
MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street

;;
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1727:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1727

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 334 CCTGGTGATAGTCACA 349
DB 17 CCTGGTGATAGTCACCA 2

RESULT 207
US-08-292-620A-1937/c
Sequence 1937, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
RELATED TO LEVELS OF
INTRACELLULAR ADHESION
MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

;/ MEDIUM TYPE: storage
;/ COMPUTER: IBM Compatible
;/ OPERATING SYSTEM: IBM P.C. DOS 5.0
;/ SOFTWARE: Word Perfect 5.1
;/ CURRENT APPLICATION DATA:
;/ APPLICATION NUMBER: US/08/292,620A
;/ FILING DATE: August 17, 1994
;/ CLASSIFICATION: 435
;/ PRIOR APPLICATION DATA:
;/ PRIOR APPLICATION DATA: including application
;/ PRIOR APPLICATION DATA: described below:
;/ APPLICATION NUMBER: 08/008,895
;/ FILING DATE: January 19, 1993
;/ APPLICATION NUMBER: 07/989,849
;/ FILING DATE: December 7, 1992
;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Warburg, Richard J.
;/ REGISTRATION NUMBER: 32,327
;/ REFERENCE/DOCKET NUMBER: 208/149
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: (213) 489-1600
;/ TELEX: 67-3510
;/ INFORMATION FOR SEQ ID NO: 1937:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 17 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ US-08-292-620A-1937

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 334 CCTGGTGATGATGACCA 349
Db 17 CCTGGTGATGATGACCA 2

RESULT 208
US-08-765-783A-79
; Sequence 79, Application US/08/765783A
; Patent No. 5994524
; GENERAL INFORMATION:
; APPLICANT: Matsushima, Kouji
; APPLICANT: Matsumoto, Yoshihiro
; APPLICANT: Yamada, Yoshiki
; APPLICANT: Sato, Koh
; APPLICANT: Tsuchiya, Masayuki
; APPLICANT: Yamazaki, Tatsumi
; TITLE OF INVENTION: Reshaped Human Antibody to
; TITLE OF INVENTION: Interleukin-8
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSER: MORRISON & FORSTER
; STREET: 2000 Pennsylvania Avenue, NW, suite 5500
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20006-1888
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSEQ for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/765,783A
; FILING DATE: 07-MAR-1997
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:

two

;/ ATTORNEY/AGENT INFORMATION:
;/ NAME: Murashige, Kate H
;/ REGISTRATION NUMBER: 29,959
;/ REFERENCE/DOCKET NUMBER: 35029-20001.20
;/ TELECOMMUNICATION INFORMATION:
;/ TELEPHONE: 202-887-1500
;/ TELEFAX: 202-822-0168
;/ TELEX:
;/ INFORMATION FOR SEQ ID NO: 79:
;/ SEQUENCE CHARACTERISTICS:
;/ LENGTH: 17 base pairs
;/ TYPE: nucleic acid
;/ STRANDEDNESS: single
;/ TOPOLOGY: linear
;/ FEATURE:
;/ NAME/KEY: Other
;/ LOCATION: 1...17
;/ OTHER INFORMATION: HIP sequence
;/ US-08-765-783A-79

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 870 CCCACAGCCAGTTC 885
Db 2 CCCAAAGCCAGGTC 17

RESULT 209
US-08-985-162-452
; Sequence 452, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 452:
; SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-452

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 75.0%; Pred. No. 1.6e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 574 CAGCAGGCCCTCCGTC 589
|||||:|:|:|:
Db 1 CAGCAGGCCCTCCCAUC 16

RESULT 210

US-09-071-845-1727/c
Sequence 1727, Application US/09071845
Patent No. 6132967

GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1727:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-1727

Query Match

0.9%; Score 12.8; DB 1; Length 17;

Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 334 CCTGGTGATAGTCACA 349
|||||:|:|:|:
Db 17 CCTGGTGATAGTCACA 2

RESULT 211

US-09-071-845-1937/c
Sequence 1937, Application US/09071845
Patent No. 6132967

GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage

COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:

CLASSIFICATION:

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1937:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-1937

Query Match

0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 334 CCTGGTGATAGTCACA 349
|||||:|:|:|:
Db 17 CCTGGTGATAGTCACA 2

RESULT 212
US-09-416-557-79
; Sequence 79, Application US/09416557
; Patent No. 6245894
; GENERAL INFORMATION:
; APPLICANT: Matsushima, Kouji
; APPLICANT: Matsumoto, Yoshihiro
; APPLICANT: Yamada, Yoshiki
; APPLICANT: Sato, Koh
; APPLICANT: Tsuchiya, Masayuki
; APPLICANT: Yamazaki, Tatsumi
; TITLE OF INVENTION: Reshaped Human Antibody to
; NUMBER OF SEQUENCES: 105
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FORSTER
; STREET: 2000 Pennsylvania Avenue, NW, suite 5500
; CITY: Washington
; STATE: DC
; COUNTRY: USA
; ZIP: 20006-1888
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/416,557
; FILING DATE: 12-October-1999
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/765,783
; FILING DATE: 7-March-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Muraahice, Kate H
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 35029-20001.10
; TELEPHONE: 202-887-1500
; TELEFAX: 202-822-0168
; TELEX:
; INFORMATION FOR SEQ ID NO: 79:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: Other
; LOCATION: 1...17
; OTHER INFORMATION: HIP sequence
US-09-416-557-79

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 870 CCCACAGCCCAAGTTC 885
Db 2 CCCCAAGCCCAAGTTC 17

RESULT 213
US-08-584-040-4374/c
; Sequence 4374, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE

; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 4374:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-4374

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
Qy 41 CAAAATCTTAGCATAC 56
Db 17 CAAAATCTTAGCAGAC 2

RESULT 214
US-08-584-040-7924
; Sequence 7924, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.

ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 7924:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7924

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.6e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 47 CTTAGCATCTCTCA 62
Db 1 CUUCGCAUACUGCUCA 16

RESULT 215
US-08-679-645-75
Sequence 75, Application US/08679645
Patent No. 6350934
GENERAL INFORMATION:
APPLICANT: Zwick, Michael G.
APPLICANT: Edington, Brent E.
APPLICANT: McSwiggen, James A.
APPLICANT: Merlo, Patricia Ann Owens
APPLICANT: Guo, Lining
APPLICANT: Skokut, Thomas A.
APPLICANT: Young, Scott A.
APPLICANT: Folkerts, Otto
APPLICANT: Merlo, Donald J.
TITLE OF INVENTION: COMPOSITION AND METHODS FOR
TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
NUMBER OF SEQUENCES: 1263
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/679,645

FILING DATE: July 12, 1996
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/001,135
FILING DATE: July 13, 1995
APPLICATION NUMBER: 08/300,726
FILING DATE: September 2, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 219/247
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 75:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-679-645-75

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 68.8%; Pred. No. 1.6e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY 891 GCTGCGGTACAGCGTG 906
Db 1 GCUGCGGUACGCCUG 16

RESULT 216
US-08-679-645-886
Sequence 886, Application US/08679645
Patent No. 6350934
GENERAL INFORMATION:
APPLICANT: Zwick, Michael G.
APPLICANT: Edington, Brent E.
APPLICANT: McSwiggen, James A.
APPLICANT: Merlo, Patricia Ann Owens
APPLICANT: Guo, Lining
APPLICANT: Skokut, Thomas A.
APPLICANT: Young, Scott A.
APPLICANT: Folkerts, Otto
APPLICANT: Merlo, Donald J.
TITLE OF INVENTION: COMPOSITION AND METHODS FOR
TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
NUMBER OF SEQUENCES: 1263
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/679,645
FILING DATE: July 12, 1996
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/001,135
FILING DATE: July 13, 1995
APPLICATION NUMBER: 08/300,726
FILING DATE: September 2, 1994

ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 219/247
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 886:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-679-645-886

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 31.2%; Pred. No. 1.6e+02;
Matches 5; Conservative 9; Mismatches 2; Indels 0; Gaps 0;

Qy 1103 ATTATGTTCTG 1118
Db 2 AUUUUUAUUUUCUG 17
||:|:|:|:|:|

RESULT 217

US-09-474-432B-388
Sequence 388, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Beigelman, Leo
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
APPLICANT: Zimen, Shawn
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
FILE REFERENCE: MBH00-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
CURRENT FILING DATE: 1999-12-19
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511
NUMBER OF SEQ ID NOS: 1526
SOFTWARE: Patent in version 3.0
SEQ ID NO 388
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-474-432B-388

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.6e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 589 CTGCCCCCGCCAGCC 604
Db 2 CUGCCCGCUCAGCC 17
|:|:|:|:|:|

RESULT 218

US-09-371-772B-2141/c
Sequence 2141, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: Patent in version 3.0
SEQ ID NO 2141
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-2141

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 41 CAAATCTTAGCATAC 56
Db 17 CAAATCTGAGCAGAC 2
|||||

RESULT 219

US-09-371-772B-3707
Sequence 3707, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
FILE REFERENCE: MBH00,876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: Patent in version 3.0
SEQ ID NO 3707
LENGTH: 17
TYPE: RNA
ORGANISM: Mus sp.
US-09-371-772B-3707

Query Match 0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 56.2%; Pred. No. 1.6e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

Qy 47 CTTAGCATCTCCTCA 62
Db 1 CUUGCAUACUGCUCA 16
|:|:|:|:|:|

RESULT 220

US-09-371-772B-4175
Sequence 4175, Application US/09371772B
Patent No. 6566127
GENERAL INFORMATION:
APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam

```

; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4175
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-4175

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.6e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 727 CAGGGGGCTGCTGC 742
Db 1 CAGCGGGCCUGCGGC 16

RESULT 221
US-09-371-772B-6941/c
; Sequence 6941, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6941
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-6941

Query Match      0.9%; Score 12.8; DB 1; Length 17;
Best Local Similarity 87.5%; Pred. No. 1.6e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 41 CAAATCTAGCATAC 56
Db 16 CAAATCTAGCATAC 1

RESULT 222
US-08-219-842-52
; Sequence 52, Application US/08219842
; Patent No. 5565323
; GENERAL INFORMATION:
; APPLICANT: Parker, W. D.
; APPLICANT: Herrnstadt, Corinna
; TITLE OF INVENTION: Diagnostic and Therapeutic Compositions
; TITLE OF INVENTION: for Alzheimer's Disease

```

```

; TITLE OF INVENTION: for Alzheimer's Disease
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Campbell and Flores
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: USA
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/219,842
; FILING DATE: 30-MAR-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-AG 9504
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 535-9001
; TELEFAX: (619) 535-8949
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-219-842-52

Query Match      0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 590 TGCCCCCACCAGCT 605
Db 1 TGCCCCCACCAGCT 16

RESULT 223
US-08-219-842-85/c
; Sequence 85, Application US/08219842
; Patent No. 5565323
; GENERAL INFORMATION:
; APPLICANT: Parker, W. D.
; APPLICANT: Herrnstadt, Corinna
; TITLE OF INVENTION: Diagnostic and Therapeutic Compositions
; TITLE OF INVENTION: for Alzheimer's Disease
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Campbell and Flores
; STREET: 4370 La Jolla Village Drive, Suite 700
; CITY: San Diego
; STATE: California
; COUNTRY: USA
; ZIP: 92122
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/219,842
; FILING DATE: 30-MAR-1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Campbell, Cathryn A.
; REGISTRATION NUMBER: 31,815
; REFERENCE/DOCKET NUMBER: P-AG 9504
; TELECOMMUNICATION INFORMATION:

```

TELEPHONE: (619) 535-9001
 TELEFAX: (619) 535-8949
 INFORMATION FOR SEQ ID NO: 85:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 18 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-219-842-85

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 590 TGCCCCCACCACGCT 605
 Db 18 TGCCCGCCACCATCT 3

RESULT 224

US-08-363-240A-1187/c
 ; Sequence 1187, Application US/08363240A
 ; Patent No. 5705388

GENERAL INFORMATION:
 APPLICANT: Couture, Larry
 APPLICANT: McSwiggen, James
 APPLICANT: Bisgaier, Charles
 APPLICANT: Pape, Michael
 TITLE OF INVENTION: METHOD AND REAGENT FOR
 TITLE OF INVENTION: PREVENTION, INHIBITION OF
 TITLE OF INVENTION: PROGRESSION AND REGRESSION
 TITLE OF INVENTION: OF VASCULAR DISEASES
 NUMBER OF SEQUENCES: 1243
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street
 STREET: Suite 4700
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage
 COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: Word Perfect 5.1
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/363,240A
 FILING DATE: December 23, 1994
 PRIOR APPLICATION DATA:
 APPLICATION NUMBER:
 FILING DATE:
 ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard
 REGISTRATION NUMBER: 32,327
 REFERENCE/DOCKET NUMBER: 210/096
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440
 TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1187:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 18 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-363-240A-1187

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 924 GATGGCAGATCTGGAG 939
 Db 18 GGTGGCTGATCTGGAG 3

RESULT 225

US-08-451-096-52
 ; Sequence 52, Application US/08451096
 ; Patent No. 5760205

GENERAL INFORMATION:
 APPLICANT: Parker, W. D.
 APPLICANT: Herrnstadt, Corinna
 TITLE OF INVENTION: Diagnostic and Therapeutic Compositions
 TITLE OF INVENTION: for Alzheimer's Disease
 NUMBER OF SEQUENCES: 95
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Campbell and Flores
 STREET: 4370 La Jolla Village Drive, Suite 700
 CITY: San Diego
 STATE: California
 COUNTRY: USA
 ZIP: 92122

COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 COMPUTER: IBM PC compatible
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.25
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/451,096
 FILING DATE:
 CLASSIFICATION: 435

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/219,842
 FILING DATE: 30-MAR-1994
 ATTORNEY/AGENT INFORMATION:
 NAME: Campbell, Cathryn A.
 REGISTRATION NUMBER: 31,815
 REFERENCE/DOCKET NUMBER: P-AG 9504
 TELECOMMUNICATION INFORMATION:
 TELEPHONE: (619) 535-9001
 TELEFAX: (619) 535-8949
 INFORMATION FOR SEQ ID NO: 52:
 SEQUENCE CHARACTERISTICS:
 LENGTH: 18 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 US-08-451-096-52

Query Match 0.9%; Score 12.8; DB 1; Length 18;
 Best Local Similarity 87.5%; Pred. No. 1.8e+02;
 Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 590 TGCCCCCACCACGCT 605
 Db 1 TGCCCGCCACCATCT 16

RESULT 226

US-08-451-096-85/c
 ; Sequence 85, Application US/08451096
 ; Patent No. 5760205

GENERAL INFORMATION:
 APPLICANT: Parker, W. D.
 APPLICANT: Herrnstadt, Corinna
 TITLE OF INVENTION: Diagnostic and Therapeutic Compositions
 TITLE OF INVENTION: for Alzheimer's Disease
 NUMBER OF SEQUENCES: 95
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Campbell and Flores
 STREET: 4370 La Jolla Village Drive, Suite 700
 CITY: San Diego
 STATE: California


```

Qy 879 CAAGTTCAGGAGCTG 894
Db 3 CACGCTCCAGGAGCTG 18

RESULT 229
US-08-758-306-971
; Sequence 971, Application US/08758306
; Patent No. 5807743
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES
; TITLE OF INVENTION: ASSOCIATED WITH
; TITLE OF INVENTION: INTERLEUKIN-2 RECEPTOR
; TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION
; NUMBER OF SEQUENCES: 1379
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/758,306
; FILING DATE: December 3, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 212/132
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 971:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-758-306-971

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 81.2%; Pred. No. 1.8e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 625 GACGAGTCCAGGAGC 640
Db 3 GUCCAGTCCAGGAGC 18

RESULT 230
US-08-411-098-35/c
; Sequence 35, Application US/08411098
; Patent No. 5830755
; GENERAL INFORMATION:
; APPLICANT: HWU, PATRICK; NISHIMURA,
; APPLICANT: MICHAEL; ROSENBERG, STEVEN A.
; TITLE OF INVENTION: T-CELL RECEPTORS AND

```

```

; TITLE OF INVENTION: THEIR USE IN THERAPEUTIC AND DIAGNOSTIC
; TITLE OF INVENTION: METHODS
; NUMBER OF SEQUENCES: 39
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORGAN & FINNEGAN, L.L.P.
; STREET: 345 PARK AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10154
; COMPUTER READABLE FORM:
; MEDIUM TYPE: FLOPPY DISK
; COMPUTER: IBM PC COMPATIBLE
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: ASCII
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/411.098
; FILING DATE: 27-MAR-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: CAROL M. GRUPPEL
; REGISTRATION NUMBER: 37,341
; REFERENCE/DOCKET NUMBER: 2026-4188
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (212) 758-4800
; TELEFAX: (212) 751-6849
; TELEX: 421792
; INFORMATION FOR SEQ ID NO: 35:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18
; TYPE: NUCLEOTIDE
; STRANDEDNESS: SINGLE
; TOPOLOGY: UNKNOWN
; US-08-411-098-35

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 728 AGGGGGCTGGCTGCC 743
Db 16 AGGGGCTCTGTCTGCC 1

RESULT 231
US-08-880-557-18
; Sequence 18, Application US/08880557
; Patent No. 5876988
; GENERAL INFORMATION:
; APPLICANT: SELTEN, GERARDUS CORNELIUS MAIA
; APPLICANT: SWINKELS, BART WILLEM
; APPLICANT: VAN GORCOM, ROBERTUS
; APPLICANT: FRANCISCUS MARIA
; TITLE OF INVENTION: SELECTION MARKER GENE FREE RECOMBINANT
; TITLE OF INVENTION: STRAINS: A METHOD FOR OBTAINING THEM AND THE USE OF THESE
; NUMBER OF SEQUENCES: 37
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 2000 Pennsylvania Ave. N.W., Suite 5500
; CITY: Washington, D.C.
; COUNTRY: USA
; ZIP: 20006-1888
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/880,557
; FILING DATE: 23-JUN-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:

```

APPLICATION NUMBER: US 08/279,980
FILING DATE: 22-JUL-1994
ATTORNEY/AGENT INFORMATION:
NAME: MURASHIGE, KATE H.
REGISTRATION NUMBER: 29,959
REFERENCE/DOCKET NUMBER: 4615-0042.00
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 887-1500
TELEFAX: (202) 887-0763
TELEX: 90-4030
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
IMMEDIATE SOURCE:
CLONE: AB3781
US-08-880-557-18

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 368 TGGGGCCCGAGTTC 383
DB 3 TTGGGGCCCGAGGCTC 18

RESULT 232
US-08-990-818-39
Sequence 39, Application US/08990818
Patent No. 5910432
GENERAL INFORMATION:
APPLICANT: ITO, Kiyoshi
APPLICANT: YAMAKI, Toshifumi
APPLICANT: ARII, Teruo
APPLICANT: TSURUOKA, Miyuki
APPLICANT: NAKAMURA, Takeshi
TITLE OF INVENTION: NOVEL NITRILE HYDRATASE
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSER: BURNS, DOANE, SWECKER & MATHIS
STREET: P.O. Box 1404
CITY: Alexandria
STATE: Virginia
COUNTRY: United States
ZIP: 22313-1404
COMPUTER READABLE FORM:
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/990,818
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/800,751
FILING DATE:
FILING DATE: 14-FEB-1996
ATTORNEY/AGENT INFORMATION:
NAME: Teskin, Robin L.
REGISTRATION NUMBER: 35,030
REFERENCE/DOCKET NUMBER: 028022-007
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-2021
INFORMATION FOR SEQ ID NO: 39:

SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "synthetic DNA"
US-08-990-818-39

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 879 CAAATTCAGGAGCTG 894
DB 3 CACGATCCAGGAGCTG 18

RESULT 233
US-08-990-818-40
Sequence 40, Application US/08990818
Patent No. 5910432
GENERAL INFORMATION:
APPLICANT: ITO, Kiyoshi
APPLICANT: YAMAKI, Toshifumi
APPLICANT: ARII, Teruo
APPLICANT: TSURUOKA, Miyuki
APPLICANT: NAKAMURA, Takeshi
TITLE OF INVENTION: NOVEL NITRILE HYDRATASE
NUMBER OF SEQUENCES: 42
CORRESPONDENCE ADDRESS:
ADDRESSER: BURNS, DOANE, SWECKER & MATHIS
STREET: P.O. Box 1404
CITY: Alexandria
STATE: Virginia
COUNTRY: United States
ZIP: 22313-1404
COMPUTER READABLE FORM:
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/990,818
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/800,751
FILING DATE:
FILING DATE: 14-FEB-1996
ATTORNEY/AGENT INFORMATION:
NAME: Teskin, Robin L.
REGISTRATION NUMBER: 35,030
REFERENCE/DOCKET NUMBER: 028022-007
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 836-6620
TELEFAX: (703) 836-2021
INFORMATION FOR SEQ ID NO: 40:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "synthetic DNA"
US-08-990-818-40

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 879 CAAATTCAGGAGCTG 894

RESULT 235
 US-09-189-583-18
 ; Sequence 18, Application US/09189583
 ; Patent No. 6063614
 ; GENERAL INFORMATION:
 ; APPLICANT: SELTEN, GERARDUS CORNELIUS MAIA
 ; APPLICANT: SWINKELS, BART WILLEM
 ; APPLICANT: VAN GORCOM, ROBERTUS
 ; APPLICANT: FRANCISCUS MARIA
 ; TITLE OF INVENTION: SELECTION MARKER GENE FREE RECOMBINANT
 ; TITLE OF INVENTION: STRAINS: A METHOD FOR OBTAINING THEM AND THE USE OF THESE
 ; TITLE OF INVENTION: STRAINS
 ; NUMBER OF SEQUENCES: 37
 ; CORRESPONDENCE ADDRESS:
 ; ADDRESSEE: MORRISON & FOERSTER
 ; STREET: 2000 Pennsylvania Ave. N.W., Suite 5500
 ; CITY: Washington, D.C.
 ; COUNTRY: USA
 ; ZIP: 20006-1888
 ; COMPUTER READABLE FORM:
 ; MEDIUM TYPE: Floppy disk
 ; COMPUTER: IBM PC compatible
 ; OPERATING SYSTEM: PC-DOS/MS-DOS
 ; SOFTWARE: PatentIn Release #1.0, Version #1.25
 ; CURRENT APPLICATION DATA:
 ; APPLICATION NUMBER: US/09/189,583
 ; FILING DATE:
 ; CLASSIFICATION:
 ; PRIOR APPLICATION DATA:
 ; APPLICATION NUMBER: US/08/880,557
 ; FILING DATE: 23-JUN-1997
 ; APPLICATION NUMBER: US 08/279,980
 ; FILING DATE: 22-JUL-1994
 ; ATTORNEY/AGENT INFORMATION:
 ; NAME: MURASHIGE, KATE H.
 ; REGISTRATION NUMBER: 29,959
 ; REFERENCE/DOCKET NUMBER: 4615-0042.00
 ; TELECOMMUNICATION INFORMATION:
 ; TELEPHONE: (202) 887-1500


```
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-08-413-740A-28

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 18;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 590 TGCCCCCACCACGCT 605
Db 1 TGCCCCCACCACGCT 16

RESULT 237
US-09-474-922A-85
; Sequence 85, Application US/09474922A
; Patent No. 6187586
; GENERAL INFORMATION:
; APPLICANT: Brett P. Monia
; APPLICANT: Lex M. Cowsett
; APPLICANT: Richard A. Roth
; TITLE OF INVENTION: ANTISENSE MODULATION OF Akt-3 EXPRESSION
; FILE REFERENCE: RUS-0036
; CURRENT APPLICATION NUMBER: US/09/474,922A
; CURRENT FILING DATE: 1999-12-29
; NUMBER OF SEQ ID NOS: 89
; SEQ ID NO 85
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Antisense Oligonucleotide
US-09-474-922A-85

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 18;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 375 CCAGCTTCTCCAGAG 390
Db 2 CCAGTTATCTCCAGAG 17

RESULT 238
US-08-584-040-3044
; Sequence 3044, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
```

```
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3044:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-3044

Query Match
Best Local Similarity 0.9%; Score 12.8; DB 1; Length 18;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1311 GTAGCCAGGTGCTTTT 1326
Db 1 GGAGCCAGCGCUUUT 16

RESULT 239
US-08-584-040-8378
; Sequence 8378, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
```

```
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 8378:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-8378

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1311 GTAGCCAGGTGTTT 1326
Db 1 GGAGCCAGCUCUUU 16

RESULT 240
US-08-679-645-609/c
; Sequence 609, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; TITLE OF INVENTION: IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 609:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
```

```
; TOPOLOGY: linear
US-08-679-645-609

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 884 TCCAGGAGCTCGGTA 899
Db 16 TCCATGAGCTCGGGA 1

RESULT 241
US-08-679-645-629
; Sequence 629, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; TITLE OF INVENTION: IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 629:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-679-645-629

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 68.8%; Pred. No. 1.8e+02;
Matches 11; Conservative 3; Mismatches 2; Indels 0; Gaps 0;
```

QY 220 CGAGCTCTCAGCCTC 235
Db 2 CGUGGUCGACGCCUC 17

RESULT 242

US-08-614-151-51
; Sequence 51, Application US/08614151
; Patent No. 6436635

; GENERAL INFORMATION:

; APPLICANT: FU Dong-Jing
; APPLICANT: CANTOR, Charles R.

; APPLICANT: KOSTER, Hubert

; APPLICANT: SMITH, Cassandra L.

; TITLE OF INVENTION: SOLID PHASE SEQUENCING OF DOUBLE-STRANDED NUCLEIC ACID

; NUMBER OF SEQUENCES: 53

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: BAKER & BOTS, L.L.P.

; STREET: 1299 Pennsylvania Avenue, N.W.

; CITY: Washington

; STATE: DC

; COUNTRY: USA

; ZIP: 20004-2400

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Diskette

; COMPUTER: IBM Compatible

; OPERATING SYSTEM: DOS

; SOFTWARE: FastSeq Version 1.5

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/08/614,151

; FILING DATE: 12-MAR-1996

; CLASSIFICATION: 435

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: 08/420,009

; FILING DATE: 11-APR-1995

; APPLICATION NUMBER: 08/110,691

; FILING DATE: 23-AUG-1993

; APPLICATION NUMBER: 07/972,012

; FILING DATE: 06-NOV-1992

; ATTORNEY/AGENT INFORMATION:

; NAME: Remenick, James

; REGISTRATION NUMBER: 36,902

; REFERENCE/DOCKET NUMBER: 16865-0276

; TELECOMMUNICATION INFORMATION:

; TELEPHONE: 202-639-7700

; TELEFAX: 202-639-7890

; TELEX:

; INFORMATION FOR SEQ ID NO: 51:

; SEQUENCE CHARACTERISTICS:

; LENGTH: 18 base pairs

; TYPE: nucleic acid

; STRANDEDNESS: single

; TOPOLOGY: linear

; MOLECULE TYPE: cDNA

; HYPOTHETICAL: NO

; ANTI-SENSE: NO

; FRAGMENT TYPE:

; ORIGINAL SOURCE:

US-08-614-151-51

Query Match

Best Local Similarity 0.9%; Score 12.8; DB 1; Length 18;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 409 CTACTAGGGGACCTAG 424

Db 1 CTACTAGGGTCCCTAG 16

RESULT 243

US-09-920-760-14

; Sequence 14, Application US/09920760

; Patent No. 6492173

; GENERAL INFORMATION:

; APPLICANT: Lex M. Cowsett

; TITLE OF INVENTION: ANTISENSE MODULATION OF CYCLIN D2 EXPRESSION

; FILE REFERENCE: RTS-0275

; CURRENT APPLICATION NUMBER: US/09/920,760

; CURRENT FILING DATE: 2001-08-01

; NUMBER OF SEQ ID NOS: 89

; SEQ ID NO 14

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Antisense Oligonucleotide

US-09-920-760-14

Query Match

Best Local Similarity 0.9%; Score 12.8; DB 1; Length 18;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGGAA 1160

Db 3 TTTTGTCTTTTGGAA 18

RESULT 244

US-09-077-619-17

; Sequence 17, Application US/09077619

; Patent No. 6500614

; GENERAL INFORMATION:

; APPLICANT: ARGUELLO, Rafael

; APPLICANT: AVAKIAN, Hovanes

; APPLICANT: MADRIGAL, Alejandro

; TITLE OF INVENTION: METHOD FOR IDENTIFYING AN UNKNOWN ALLELE

; FILE REFERENCE: 028979/0104

; CURRENT APPLICATION NUMBER: US/09/077,619

; PRIOR FILING DATE: 2000-03-31

; PRIOR APPLICATION NUMBER: PCT/GB96/02959

; PRIOR FILING DATE: 1996-11-29

; PRIOR APPLICATION NUMBER: GB 9524381.2

; PRIOR FILING DATE: 1995-11-29

; NUMBER OF SEQ ID NOS: 46

; SOFTWARE: PatentIn version 3.0

; SEQ ID NO 17

; LENGTH: 18

; TYPE: DNA

; ORGANISM: Homo sapiens

US-09-077-619-17

Query Match

Best Local Similarity 0.9%; Score 12.8; DB 1; Length 18;

Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 531 GGAGCAGCTGGTGCC 546

Db 1 GGAGCAGCTGAGAGCC 16

RESULT 245

US-09-422-978-7504

; Sequence 7504, Application US/09422978

; Patent No. 6537751

; GENERAL INFORMATION:

; APPLICANT: Cohen, Daniel

; APPLICANT: Blumenfeld, Marta

; APPLICANT: Chumakov, Ilya

; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...

; FILE REFERENCE: GENSET.020CPI

; CURRENT APPLICATION NUMBER: US/09/422,978

; CURRENT FILING DATE: 1999-10-20

; EARLIER APPLICATION NUMBER: US 09/298,850

; EARLIER FILING DATE: 1999-04-21

; EARLIER APPLICATION NUMBER: US 60/109,732

; EARLIER FILING DATE: 1998-11-23

```
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 7504
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: upstream amplification primer 99-6071 for SEQ 3570,
US-09-422-978-7504

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 850 TCAGCATACGCTTGG 865
Db 3 TCAGCATACGCTTGG 18

RESULT 246
US-09-422-978-11175
; Sequence 11175, Application US/09422978
; Patent No. 6537751
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Chumakov, Ilya
; TITLE OF INVENTION: Biallelic markers for use in constructing a high density...
; FILE REFERENCE: GENSET.020CPI
; CURRENT APPLICATION NUMBER: US/09/422,978
; CURRENT FILING DATE: 1999-10-20
; EARLIER APPLICATION NUMBER: US 09/298,850
; EARLIER FILING DATE: 1999-04-21
; EARLIER APPLICATION NUMBER: US 60/109,732
; EARLIER FILING DATE: 1998-11-23
; EARLIER APPLICATION NUMBER: US 60/082,614
; EARLIER FILING DATE: 1998-04-21
; NUMBER OF SEQ ID NOS: 11796
; SEQ ID NO 11175
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Homo Sapiens
; FEATURE:
; NAME/KEY: primer_bind
; LOCATION: 1..18
; OTHER INFORMATION: downstream amplification primer 99-3147 for SEQ 3310, in compleme
US-09-422-978-11175

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 955 ACAGTCAGGACTGAC 970
Db 3 ACAGTCAGGACTGAC 18

RESULT 247
US-09-742-373-6
; Sequence 6, Application US/09742373
; Patent No. 6562946
; GENERAL INFORMATION:
; APPLICANT: Althaus, Harald
; APPLICANT: Hauser, Hans-Peter
; TITLE OF INVENTION: Human Procalcitonin and the Preparation and Use Thereof
; FILE REFERENCE: 05552.1445-00
; CURRENT APPLICATION NUMBER: US/09/742,373
; CURRENT FILING DATE: 2000-12-22
; PRIOR APPLICATION NUMBER: 19962434.8
; PRIOR FILING DATE: 1999-12-22
```

```
; PRIOR APPLICATION NUMBER: 10016278.9
; PRIOR FILING DATE: 2000-04-03
; PRIOR APPLICATION NUMBER: 10027954.6
; PRIOR FILING DATE: 2000-06-08
; NUMBER OF SEQ ID NOS: 12
; SOFTWARE: PatentIn Ver. 2.1
; SEQ ID NO 6
; LENGTH: 18
; TYPE: DNA
; ORGANISM: Unknown Organism
; FEATURE:
; OTHER INFORMATION: Description of Unknown Organism: Primer, non
; OTHER INFORMATION: genomic DNA
US-09-742-373-6

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 833 TCAGCTTTCAGATGG 848
Db 2 TCAGCTTTCAGATGG 17

RESULT 248
US-09-371-772B-1472
; Sequence 1472, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; FILE REFERENCE: MBHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1472
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1472

Query Match          0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1311 GTAGCCAGTCTTTT 1326
Db 1 GGAGCCAGCUCUUU 16

RESULT 249
US-09-371-772B-4034
; Sequence 4034, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; FILE REFERENCE: MBHB00,876-J (237/198)
```

;; CURRENT APPLICATION NUMBER: US/09/371,772B
;; PRIOR FILING DATE: 1999-08-10
;; PRIOR APPLICATION NUMBER: US 60/005,974
;; PRIOR FILING DATE: 1995-10-26
;; PRIOR APPLICATION NUMBER: US 08/584,040
;; PRIOR FILING DATE: 1996-01-08
;; NUMBER OF SEQ ID NOS: 14225
;; SOFTWARE: PatentIn version 3.0
;; SEQ ID NO 4034
;; LENGTH: 18
;; TYPE: RNA
;; ORGANISM: Mus sp.
US-09-371-772B-4034

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 56.2%; Pred. No. 1.8e+02;
Matches 9; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1311 GTAGCCAGGTGCTTT 1326
| | | | | : | | | | : | | | | : | | | | :
Db 1 GGAGCCAGCGCUUU 16

RESULT 250
PCT-US93-12600-16
;; Sequence 16, Application PC/TUS9312600
;; GENERAL INFORMATION:
;; APPLICANT: Denner, Larry A.
;; APPLICANT: Reese, Ajay A.
;; APPLICANT: Dixon, Richard A.F.
;; TITLE OF INVENTION: ANTISENSE MOLECULES DIRECTED AGAINST A
;; NUMBER OF SEQUENCES: 29
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Dressler, Goldsmith, Shore &
;; ADDRESSEE: Milramow, Ltd.
;; STREET: 180 North Stetson, Suite 4700
;; CITY: Chicago
;; STATE: Illinois
;; COUNTRY: USA
;; ZIP: 60601
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US93/12600
FILING DATE: 28-DEC-1993
CLASSIFICATION:
PRIORITY APPLICATION DATA:
APPLICATION NUMBER: US 07/999,706
FILING DATE: December 31, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Katz, Martin L.
REGISTRATION NUMBER: 25,011
TELEPHONE: (312) 616-5400
TELEFAX: (312) 616-5460
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US93-12600-16

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 870 CCCACAGCCAGTTC 885

Db 2 CCCACATCCAGTTC 17

RESULT 251
PCT-US95-04063-28
;; Sequence 28, Application PC/TUS9504063
;; GENERAL INFORMATION:
;; APPLICANT: HERRNSTADT, CORINNA
;; APPLICANT: PARKER, WILLIAM D.
;; APPLICANT: DAVIS, ROBERT
;; APPLICANT: MILLER, SCOTT W.
;; TITLE OF INVENTION: Diagnosis, Therapy and Cellular and
;; TITLE OF INVENTION: Animal Models for Diseases Associated With Mitochondrial
;; NUMBER OF SEQUENCES: 206
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Kenyon & Kenyon
;; STREET: 1025 Connecticut Avenue, N.W.
;; CITY: Washington
;; STATE: DC
;; COUNTRY: USA
;; ZIP: 20036-5405
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/04063
FILING DATE: 30-MAR-1995
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Bonham, David B.
REGISTRATION NUMBER: 34297
REFERENCE/DOCKET NUMBER: 2105/7
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 429-1776
TELEFAX: (202) 429-0796
INFORMATION FOR SEQ ID NO: 28:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
HYPOTHETICAL: NO
ANTI-SENSE: NO
PCT-US95-04063-28

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 590 TGCCCCCACCAGCCT 605
| | | | | : | | | | : | | | | : | | | | :
Db 1 TGCCCCCACCAGTCT 16

RESULT 252
5182195-70/c
;; Patent No. 5182195
;; APPLICANT: NAKAHAMA, KAZUO, KAISHO, YOSHITAKO, YOSHIMURA, KOJI
;; TITLE OF INVENTION: METHOD FOR INCREASING USING PROTEASE
;; DEFICIENT YEASTS
;; NUMBER OF SEQUENCES: 71
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/269,140
;; FILING DATE: 09-NOV-1988
;; SEQ ID NO: 70:
;; LENGTH: 18
5182195-70

Query Match 0.9%; Score 12.8; DB 1; Length 18;
Best Local Similarity 87.5%; Pred. No. 1.8e+02;
Matches 14; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 473 AGGGGAGAGCTGCCG 488
DB 18 ATGGGGGAGCTGCCG 3

RESULT 253

US-08-882-649A-7/c
; Sequence 7, Application US/08882649A
; Patent No. 6344316

GENERAL INFORMATION:

APPLICANT: Lockhart, David J.

Chee, Mark
Gunderson, Kevin
Chaoqiang, Lai
Wodicka, Lisa
Cronin, Maureen T.
Lee, Danny
Tran, Huu M.
Matsuzaki, Hajime
McGall, Glenn H.

TITLE OF INVENTION: NUCLEIC ACID ANALYSIS TECHNIQUES

NUMBER OF SEQUENCES: 32

CORRESPONDENCE ADDRESS:

ADDRESS: Joe Liebeschuetz
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: CA

COUNTRY: USA

ZIP: 94111-3834

COMPUTER READABLE FORM:

MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible

OPERATING SYSTEM: PC-DOS/MS-DOS

SOFTWARE: Patent In Release #1.0, Version #1.30

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/882,649A

FILING DATE: 25-JUN-1997

CLASSIFICATION: 435-006.000

PRIOR APPLICATION DATA:

APPLICATION NUMBER: US 60/010,471

FILING DATE: 23-JAN-1996

APPLICATION NUMBER: US 60/035,170

FILING DATE: 09-JAN-1997

APPLICATION NUMBER: PCT/US97/01603

FILING DATE: 22-JAN-1997

ATTORNEY/AGENT INFORMATION:

NAME: Liebeschuetz, Joe

REGISTRATION NUMBER: 37,505

REFERENCE/DOCKET NUMBER: 018547-019410US

TELECOMMUNICATION INFORMATION:

TELEPHONE: (415) 576-0200

TELEFAX: (415) 576-0300

INFORMATION FOR SEQ ID NO: 7:

SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

MOLECULE TYPE: DNA (genomic)

HYPOTHETICAL: YES

FEATURES:

SEQUENCE DESCRIPTION: SEQ ID NO: 7:

US-08-882-649A-7

Query Match

Best Local Similarity 86.7%; Score 12.6; DB 1; Length 15;
Matches 13; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTGG 1158

DB 15 TTTTTCCTTTTGG 1

RESULT 254

US-09-661-753-55/c
; Sequence 55, Application US/09661753
; Patent No. 6436909

GENERAL INFORMATION:

APPLICANT: Nicholas M. Dean

APPLICANT: Susan F. Murray

TITLE OF INVENTION: ANTISENSE MODULATION OF TRANSFORMING GROWTH FACTOR BETA

FILE REFERENCE: ISH-0498

CURRENT APPLICATION NUMBER: US/09/661,753

CURRENT FILING DATE: 2000-09-14

EARLIER APPLICATION NUMBER: 60/154,546

EARLIER FILING DATE: 1999-09-17

NUMBER OF SEQ ID NOS: 68

SEQ ID NO 55

LENGTH: 20

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Antisense Oligonucleotide

US-09-661-753-55

Query Match

Best Local Similarity 0.9%; Score 12.6; DB 1; Length 20;

Matches 15; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 238 GCATCTGCATCTGGGACCG 256

DB 20 GCTCTGCATCTGGTCCCG 2

RESULT 255

US-08-832-021-15
; Sequence 15, Application US/08832021
; Patent No. 6045998

GENERAL INFORMATION:

APPLICANT: Combates, N.

APPLICANT: Pardinas, J.

APPLICANT: Patimco, S.

APPLICANT: Prouty, S.

APPLICANT: Stenn, K.

TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY

FILE REFERENCE: JEP-382

CURRENT APPLICATION NUMBER: US/08/832,021

CURRENT FILING DATE: 1997-04-02

NUMBER OF SEQ ID NOS: 64

SOFTWARE: Patent In Ver. 2.0

SEQ ID NO 15

LENGTH: 14

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: primer

US-08-832-021-15

Query Match

Best Local Similarity 0.9%; Score 12.4; DB 1; Length 14;

Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGG 1158

DB 1 TTTTTCCTTTTGG 14

RESULT 256

US-08-985-162-1842
; Sequence 1842, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:

APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1842:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-1842

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 85.7%; Pred. No. 1.2e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 1050 CGACAGCCCTGGCC 1063
|||||
Db 1 CGACAGCCCGGCC 14

RESULT 257
US-08-724-466B-12
Sequence 12, Application US/08724466B
Patent No. 6063606
GENERAL INFORMATION:
APPLICANT: Petkovich, P. Martin, White, Jay A.,
APPLICANT: Beckett, Barbara R., Jones, Glenville
TITLE OF INVENTION: Retinoid Metabolizing Protein
NUMBER OF SEQUENCES: 30
CORRESPONDENCE ADDRESS:
ADDRESSEE: Blake, Cassels & Graydon
STREET: Box 25, Commerce Court West
CITY: Toronto
ZIP: M5L 1A9
COUNTRY: Canada
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3 1/2 inch, 1.4 Mb storage
COMPUTER: COMPAQ, IBM PC compatible
OPERATING SYSTEM: MS-DOS 5.1

SOFTWARE: WORD PERFECT
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/724,466B
FILING DATE: October 1, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/667,546
FILING DATE: June 21, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Hunt, John C.
REGISTRATION NUMBER: 36,424
REFERENCE/DOCKET NUMBER: 50767/00004
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 863-4344
TELEFAX: (416) 863-2653
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-724-466B-12

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTCTTTTGG 1158
|||||
Db 1 TTTTCTTTTGG 14

RESULT 258
US-08-882-164D-12
Sequence 12, Application US/08882164D
Patent No. 6306624
GENERAL INFORMATION:
APPLICANT: Petkovich, P. Martin, White, Jay A.,
APPLICANT: Beckett, Barbara R., Jones, Glenville
TITLE OF INVENTION: Retinoid Metabolizing Protein
NUMBER OF SEQUENCES: 43
CORRESPONDENCE ADDRESS:
ADDRESSEE: Blake, Cassels & Graydon
STREET: Box 25, Commerce Court West
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5L 1A9
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette, 3 1/2 inch, 1.4 Mb storage
COMPUTER: COMPAQ, IBM PC compatible
OPERATING SYSTEM: MS-DOS 5.1
SOFTWARE: WORD PERFECT
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/882,164D
FILING DATE: June 25, 1997
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/667,546
FILING DATE: June 21, 1996
APPLICATION NUMBER: 08/724,466
FILING DATE: October 1, 1996
ATTORNEY/AGENT INFORMATION:
NAME: Hunt, John C.
REGISTRATION NUMBER: 36,424
REFERENCE/DOCKET NUMBER: 50767/00010
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 863-4344
TELEFAX: (416) 863-2653
INFORMATION FOR SEQ ID NO: 12:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-882-164D-12

Query Match 0.9%; Score 12.4; DB 1; Length 14;
Best Local Similarity 92.9%; Pred. No. 1.2e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTG 1158
|||||
Db 1 TTTTTCCTTTTG 14

RESULT 259

US-08-319-492B-23/c
; Sequence 23, Application US/08319492B
; Patent No. 5616488

; GENERAL INFORMATION:
; APPLICANT: Sullivan, Sean M.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggan, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: RIBOZYME TREATMENT OF DISEASES
; TITLE OF INVENTION: OF IL-5
; TITLE OF INVENTION: OF IL-5
; NUMBER OF SEQUENCES: 751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/319,492B
; FILING DATE: October 7, 1994

; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992

; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/276
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 23:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear

US-08-319-492B-23

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 628 CAGCTCCAGGAGCT 641
|||||
Db 15 CAGCTCCAGGAGCT 2

RESULT 260

US-08-863-639A-7/c
; Sequence 7, Application US/08863639A
; Patent No. 5961185

; GENERAL INFORMATION:
; APPLICANT: Matson, Robert S.
; APPLICANT: Coassin, Peter J.
; APPLICANT: Rampal, Jang B.
; APPLICANT: Caskey, C. F.
; TITLE OF INVENTION: OLIGONUCLEOTIDE REPEAT ARRAYS
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Sheldon & Mak
; STREET: 225 South Lake Avenue, 9th Floor
; CITY: Pasadena
; STATE: CA
; COUNTRY: USA
; ZIP: 91101

; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette, 3.50 inch, 1.44 Mb storage
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 95
; SOFTWARE: Corel WordPerfect 8 version
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/863,639A
; FILING DATE: May 28, 1997
; CLASSIFICATION: 435

; ATTORNEY/AGENT INFORMATION:
; NAME: Joseph E. Mueth
; REGISTRATION NUMBER: 20,532
; REFERENCE/DOCKET NUMBER: 11859-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (626) 796-4000
; TELEFAX: (626) 795-6321
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid
; US-08-863-639A-7

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTG 1157
|||||
Db 15 TTTTTCCTTTTG 2

RESULT 261

US-08-832-021-50
; Sequence 50, Application US/08832021
; Patent No. 6045998

; GENERAL INFORMATION:
; APPLICANT: Combates, N.
; APPLICANT: Pardini, J.
; APPLICANT: Parimoo, S.
; APPLICANT: Prouty, S.
; APPLICANT: Stenn, K.
; TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
; FILE REFERENCE: JBP-382
; CURRENT APPLICATION NUMBER: US/08/832,021
; CURRENT FILING DATE: 1997-04-02
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 50
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-50

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGG 1158
Db 1 TTTTTCCTTTTGG 14

RESULT 262

US-08-832-021-51
Sequence 51, Application US/08832021
Patent No. 6045998
GENERAL INFORMATION:
APPLICANT: Combates, N.
APPLICANT: Pardini, J.
APPLICANT: Parimoo, S.
APPLICANT: Prouty, S.
APPLICANT: Stenn, K.
TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
FILE REFERENCE: JBP-382
CURRENT APPLICATION NUMBER: US/08/832,021
CURRENT FILING DATE: 1997-04-02
NUMBER OF SEQ ID NOS: 64
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 51
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-51

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGG 1158
Db 1 TTTTTCCTTTTGG 14

RESULT 263

US-08-832-021-52
Sequence 52, Application US/08832021
Patent No. 6045998
GENERAL INFORMATION:
APPLICANT: Combates, N.
APPLICANT: Pardini, J.
APPLICANT: Parimoo, S.
APPLICANT: Prouty, S.
APPLICANT: Stenn, K.
TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
FILE REFERENCE: JBP-382
CURRENT APPLICATION NUMBER: US/08/832,021
CURRENT FILING DATE: 1997-04-02
NUMBER OF SEQ ID NOS: 64
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 52
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-52

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGG 1158
Db 1 TTTTTCCTTTTGG 14

RESULT 264

US-08-275-951-31
Sequence 31, Application US/08275951
Patent No. 6451968
GENERAL INFORMATION:
APPLICANT: Egholm, Michael
APPLICANT: Kiely, John
APPLICANT: Griffin, Michael
APPLICANT: Coull, James M.
APPLICANT: Neilsen, Peter
APPLICANT: Buchardt, Ole
APPLICANT: Dueholm, Kim L.
APPLICANT: Christensen, Leif
TITLE OF INVENTION: Linked Peptide Nucleic Acids
FILE REFERENCE: ISIS1577
CURRENT APPLICATION NUMBER: US/08/275,951
CURRENT FILING DATE: 1994-07-15
PRIOR APPLICATION NUMBER: 08/108,591
PRIOR FILING DATE: 1993-11-22
PRIOR APPLICATION NUMBER: 08/088,658
PRIOR FILING DATE: 1993-07-02
PRIOR APPLICATION NUMBER: 08/088,661
PRIOR FILING DATE: 1993-07-02
PRIOR APPLICATION NUMBER: PCT/EP92/01219
PRIOR FILING DATE: 1992-05-22
PRIOR APPLICATION NUMBER: 986/91
PRIOR FILING DATE: 1991-05-22
PRIOR APPLICATION NUMBER: 987/91
PRIOR FILING DATE: 1991-05-24
PRIOR APPLICATION NUMBER: 510/92
PRIOR FILING DATE: 1991-04-15
NUMBER OF SEQ ID NOS: 65
SOFTWARE: PatentIn Ver. 2.1
SEQ ID NO 31
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: No. 6451968el Sequence
NAME/KEY: misc feature
LOCATION: (6)..(7)
OTHER INFORMATION: Lysine, Amino Hexanoic Acid, Lysine, Amino Hexanoic Acid, Lysine Linkage
OTHER INFORMATION: Hexanoic Acid, Lysine Linkage
US-08-275-951-31

Query Match 0.9%; Score 12.4; DB 1; Length 15;
Best Local Similarity 92.9%; Pred. No. 1.4e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1142 CCTTTTTCCTTTT 1155
Db 2 CCTTTTTCCTTTT 15

RESULT 265

US-08-087-387-6
Sequence 6, Application US/08087387
Patent No. 5473060
GENERAL INFORMATION:
APPLICANT: Sergei M. Gryaznov
TITLE OF INVENTION: Oligonucleotide clamps having diagnostic and therapeutic app
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSEE: Stephen C. Macevicz, Lynx Therapeutics
STREET: 465 Lincoln Centre Drive
CITY: Foster City
STATE: California
COUNTRY: USA

ZIP: 94404
COMPUTER READABLE FORM:
MEDIUM TYPE: 5.25 inch diskette
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 3.1/DOS 5.0
SOFTWARE: Microsoft Word for Windows, vers. 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/087,387
FILING DATE: 19930702
CLASSIFICATION: 435
PRIOR APPLICATION NUMBER:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Stephen C. Macevitz
REGISTRATION NUMBER: 30,285
REFERENCE/DOCKET NUMBER: 104
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 358-7855
TELEFAX: (415) 358-7794
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-087-387-6

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1143 CTTTTTTCTTTTT 1156
Db 2 CTTTTTTTTTTTT 15

RESULT 266
US-08-061-697-23/c
Sequence 23, Application US/08061697
Patent No. 5498696
GENERAL INFORMATION:
APPLICANT: Brown, Michael S.; Briggs, Michael R.; Wang,
APPLICANT: Xiaodong; Goldstein, Joseph L.
TITLE OF INVENTION: Sterol Regulatory Element Binding Proteins
TITLE OF INVENTION: and Their Use in Screening Assays
NUMBER OF SEQUENCES: 36
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P. O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: USA
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/061,697
FILING DATE: Concurrently Herewith
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Parker, David L.
REGISTRATION NUMBER: 32,165
REFERENCE/DOCKET NUMBER: UTSD:347/PAR
TELECOMMUNICATION INFORMATION:
TELEPHONE: (512) 320-7200
TELEFAX: (512) 474-7577
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs

TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-061-697-23

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 471 GCAGGGGGAGGACT 484
Db 16 GCAGGGGGAGGACT 3

RESULT 267
US-08-131-365B-23/c
Sequence 23, Application US/08131365B
Patent No. 5527690
GENERAL INFORMATION:
APPLICANT: Brown, Michael S.
APPLICANT: Briggs, Michael R.
APPLICANT: Wang, Xiaodong
APPLICANT: Goldstein, Joseph L.
TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING
TITLE OF INVENTION: TO STEROL REGULATORY ELEMENT BINDING
TITLE OF INVENTION: PROTEINS
NUMBER OF SEQUENCES: 64
CORRESPONDENCE ADDRESS:
ADDRESSEE: Arnold, White & Durkee
STREET: P. O. Box 4433
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77210
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/131,365B
FILING DATE: 01-OCT-1993
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Parker, David L.
REGISTRATION NUMBER: 32,165
REFERENCE/DOCKET NUMBER: UTSD:372/PAR
TELECOMMUNICATION INFORMATION:
TELEPHONE: (512) 418-3000
TELEFAX: (512) 474-7577
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "DNA"
US-08-131-365B-23

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 471 GCAGGGGGAGGACT 484
Db 16 GCAGGGGGAGGACT 3

RESULT 268
US-08-455-627-6
Sequence 6, Application US/08455627

```
/ Patent No. 5571677
/ GENERAL INFORMATION:
/ APPLICANT: Sergei M. Gryaznov
/ TITLE OF INVENTION: Convergent Synthesis of Branched and Multiply
/ TITLE OF INVENTION: Connected Macromolecular Structures
/ NUMBER OF SEQUENCES: 26
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Cooley Godward LLP
/ STREET: Five Palo Alto Square, 3000 El Camino Real
/ CITY: Palo Alto
/ STATE: California
/ COUNTRY: USA
/ ZIP: 94306-2155
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/455,627
/ FILING DATE: 31-MAY-1995
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Nakamura, Jackie N.
/ REGISTRATION NUMBER: 35,966
/ REFERENCE/DOCKET NUMBER: LYNX-003/01 US
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-843-5000
/ TELEFAX: 415-857-0663
/ INFORMATION FOR SEQ ID NO: 6:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 nucleotides
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA
US-08-455-627-6

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1143 CTTTTCCTTTT 1156
Db 2 CTTTTCCTTTT 15

RESULT 269
US-08-284-484A-4/c
/ Sequence 4, Application US/08284484A
/ Patent No. 5639873
/ GENERAL INFORMATION:
/ APPLICANT: Barascut, et al.
/ TITLE OF INVENTION: Oligothionucleotides
/ NUMBER OF SEQUENCES: 5
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Woodcock Washburn Kurtz Mackiewicz and No. 5639873ris
/ STREET: One Liberty Place - 46th Floor
/ CITY: Philadelphia
/ STATE: PA
/ COUNTRY: U.S.A.
/ ZIP: 19103
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5 inch disk, 720 Kb
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: WordPerfect 5.1
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/284,484A
/ FILING DATE: 04-AUG-1994
/ CLASSIFICATION: 536
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Paul K. Legaard
```

```
/ REGISTRATION NUMBER: 38,534
/ REFERENCE/DOCKET NUMBER: MSWA-0001
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 215-568-3100
/ TELEFAX: 215-568-3439
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 bases
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-284-484A-4

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGG 1158
Db 14 TTTTTCCTTTTGG 1

RESULT 270
US-08-461-271-6
/ Sequence 6, Application US/08461271
/ Patent No. 5741643
/ TELECOMMUNICATION INFORMATION:
/ GENERAL INFORMATION:
/ APPLICANT: Sergei M. Gryaznov
/ TITLE OF INVENTION: Oligonucleotide clamps having diagnostic
/ TITLE OF INVENTION: and therapeutic applications
/ NUMBER OF SEQUENCES: 6
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Stephen C. Macevicz, Lynx Therapeutics
/ STREET: 465 Lincoln Centre Drive
/ CITY: Foster City
/ STATE: California
/ COUNTRY: USA
/ ZIP: 94404
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 5.25 inch diskette
/ COMPUTER: IBM compatible
/ OPERATING SYSTEM: Windows 3.1/DOS 5.0
/ SOFTWARE: Microsoft Word for Windows, vers. 2.0
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/461,271
/ FILING DATE:
/ CLASSIFICATION: 435
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/087,387
/ FILING DATE: 2-Jul-93
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Stephen C. Macevicz
/ REGISTRATION NUMBER: 30,285
/ REFERENCE/DOCKET NUMBER: 104
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (415) 358-7855
/ TELEFAX: (415) 358-7794
/ INFORMATION FOR SEQ ID NO: 6:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 nucleotides
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-461-271-6

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1143 CTTTTCCTTTT 1156
Db 2 CTTTTCCTTTT 15
```

RESULT 271
US-08-713-685A-6
; Sequence 6, Application US/08713685A
; Patent No. 5817795
; GENERAL INFORMATION:
; APPLICANT: Sergei M. Gryaznov
; TITLE OF INVENTION: Oligonucleotide clamps having diagnostic
; TITLE OF INVENTION: and therapeutic applications
; NUMBER OF SEQUENCES: 6
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Stephen C. Macevitz, Lynx Therapeutics
; STREET: 465 Lincoln Centre Drive
; CITY: Foster City
; STATE: California
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 5.25 inch diskette
; COMPUTER: IBM compatible
; OPERATING SYSTEM: Windows 3.1/DOS 5.0
; SOFTWARE: Microsoft Word for Windows, vers. 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/713.685A
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/461,271
; FILING DATE:
; APPLICATION NUMBER: 08/087,387
; FILING DATE: 2-Jul-93
; ATTORNEY/AGENT INFORMATION:
; NAME: Stephen C. Macevitz
; REGISTRATION NUMBER: 30,285
; REFERENCE/DOCKET NUMBER: 104
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 358-7855
; TELEFAX: (415) 358-7794
; INFORMATION FOR SEQ ID NO: 6:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 nucleotides
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-713-685A-6

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1143 CTTTTTCTTTTT 1156
Db 2 CTTTTTCTTTTT 15

RESULT 272
US-08-689-856-6
; Sequence 6, Application US/08689856
; Patent No. 5830658
; GENERAL INFORMATION:
; APPLICANT: Sergei M. Gryaznov
; TITLE OF INVENTION: Convergent Synthesis of Branched and Multiply
; TITLE OF INVENTION: Connected Macromolecular Structures
; NUMBER OF SEQUENCES: 26
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooley Godward LLP
; STREET: Five Palo Alto Square, 3000 El Camino Real
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94306-2155
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/689,856
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/455,627
FILING DATE: 31-MAY-1995
ATTORNEY/AGENT INFORMATION:
NAME: Nakamura, Jackie N.
REGISTRATION NUMBER: 35,966
REFERENCE/DOCKET NUMBER: LYNX-003/01 US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-843-5000
TELEFAX: 415-857-0663
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA
US-08-689-856-6

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1143 CTTTTTCTTTTT 1156
Db 2 CTTTTTCTTTTT 15

RESULT 273
US-08-668-123-23/c
; Sequence 23, Application US/08668123
; Patent No. 5891631
; GENERAL INFORMATION:
; APPLICANT: Brown, Michael S.
; APPLICANT: Briggs, Michael R.
; APPLICANT: Wang, Xiaodong
; APPLICANT: Goldstein, Joseph L.
; TITLE OF INVENTION: METHODS AND COMPOSITIONS RELATING
; TITLE OF INVENTION: TO STEROL REGULATORY ELEMENT BINDING
; NUMBER OF SEQUENCES: 64
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Arnold, White & Durkee
; STREET: P.O. Box 4433
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77210
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/668,123
; FILING DATE: 14-JUN-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/131,365
; FILING DATE: 01-OCT-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Parker, David L.
; REGISTRATION NUMBER: 32,165
; REFERENCE/DOCKET NUMBER: UTSD:372/PAR
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (512) 418-3000

TELEFAX: (512) 474-7577
INFORMATION FOR SEQ ID NO: 23:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "DNA"
US-08-668-123-23

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 471 GCAGGGGGAGGACT 484
Db 16 GCAGGGGGAGGACT 3

RESULT 274
US-09-070-477-6
Sequence 6, Application US/09070477
Patent No. 6048974
GENERAL INFORMATION:
APPLICANT: Sergei M. Gryaznov
TITLE OF INVENTION: Oligonucleotide clamps having diagnostic
TITLE OF INVENTION: and therapeutic applications
NUMBER OF SEQUENCES: 6
CORRESPONDENCE ADDRESS:
ADDRESSEE: Stephen C. Macevicz, Lynx Therapeutics
STREET: 465 Lincoln Centre Drive
CITY: Foster City
STATE: California
COUNTRY: USA
ZIP: 94404
COMPUTER READABLE FORM:
MEDIUM TYPE: 5.25 inch diskette
COMPUTER: IBM compatible
OPERATING SYSTEM: Windows 3.1/DOS 5.0
SOFTWARE: Microsoft Word for Windows, vers. 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/070,477
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/713,685
FILING DATE:
APPLICATION NUMBER: 08/461,271
FILING DATE:
APPLICATION NUMBER: 08/087,387
FILING DATE: 2-Jul-93
NAME: Stephen C. Macevicz
ATTORNEY/AGENT INFORMATION:
REGISTRATION NUMBER: 30,285
REFERENCE/DOCKET NUMBER: 104
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 358-7855
TELEFAX: (415) 358-7794
INFORMATION FOR SEQ ID NO: 6:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 nucleotides
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-070-477-6

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1143 CTTTTTTCTTTT 1156
TTTTTTTTTTTTTTTT

Db 2 CTTTTTTTTTTTTT 15

RESULT 275
5256545-4/c
Patent No. 5256545
APPLICANT: BROWN, MICHAEL S.;GOLDSTEIN, JOSEPH L.;RUSSELL,
DAVID W.;SUDHOF, THOMAS C.
TITLE OF INVENTION: STEROL REGULATORY ELEMENTS
NUMBER OF SEQUENCES: 42
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/425,852
FILING DATE: 20-OCT-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 33,330
FILING DATE: 30-MAR-1987
APPLICATION NUMBER: 33,081
FILING DATE: 30-MAR-1987
SEQ ID NO:4:
LENGTH: 16
5256545-4

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 471 GCAGGGGGAGGACT 484
Db 16 GCAGGGGGAGGACT 3

RESULT 276
5256545-33
Patent No. 5256545
APPLICANT: BROWN, MICHAEL S.;GOLDSTEIN, JOSEPH L.;RUSSELL,
DAVID W.;SUDHOF, THOMAS C.
TITLE OF INVENTION: STEROL REGULATORY ELEMENTS
NUMBER OF SEQUENCES: 42
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/425,852
FILING DATE: 20-OCT-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 33,330
FILING DATE: 30-MAR-1987
APPLICATION NUMBER: 33,081
FILING DATE: 30-MAR-1987
SEQ ID NO:33:
LENGTH: 16
5256545-33

Query Match 0.9%; Score 12.4; DB 1; Length 16;
Best Local Similarity 92.9%; Pred. No. 1.7e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 471 GCAGGGGGAGGACT 484
Db 1 GCAGGGGGAGGACT 14

RESULT 277
US-08-373-124A-338/c
Sequence 338, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 338:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-338

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 2 GGCAGGCGAGTTGAG 15
Db 15 GGCAGGCGAGTTGAG 2

RESULT 278
US-08-373-124A-2047
Sequence 2047, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2047:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-2047

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 1118 GTTTAATTGAAAAA 1131
Db 4 GUUUUUUGAAAAA 17

RESULT 279
US-08-373-124A-2049
Sequence 2049, Application US/08373124A
Patent No. 5646042
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TREATMENT OF RESTENOSIS AND
CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/373,124A
FILING DATE: January 13, 1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/245,466

```

FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 2049:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-373-124A-2049

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 1118 GTTAAATTGAAAAA 1131
DB 2 GUUUUUGAAAAA 15

RESULT 280
US-08-261-822A-30/c
Sequence 30, Application US/08261822A
Patent No. 5650553
GENERAL INFORMATION:
APPLICANT: Ecker, Joseph R. et al.
TITLE OF INVENTION: Plant Genes for Sensitivity to Ethylene
TITLE OF INVENTION: and Pathogens
NUMBER OF SEQUENCES: 82
CORRESPONDENCE ADDRESS:
ADDRESSER: Woodcock, Washburn, Kurtz, Mackiewicz & No. 5650553ris
STREET: One Liberty Place, 46th floor
CITY: Philadelphia
STATE: PA
COUNTRY: USA
ZIP: 19103
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/261,822A
FILING DATE: 17-JUN-1994
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Beardell, Lori Y.
REGISTRATION NUMBER: 34,293
TELECOMMUNICATION INFORMATION:
TELEPHONE: (215) 568-3100
TELEFAX: (215) 568-3439
INFORMATION FOR SEQ ID NO: 30:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: YES
US-08-261-822A-30

```

```

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 648 CCCCCAAGACCTGG 661
DB 17 CCACCAAGACCTGG 4

RESULT 281
US-08-435-628-338/c
Sequence 338, Application US/08435628
Patent No. 5817796
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth
APPLICANT: McSwiggen, James
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
TITLE OF INVENTION: CANCER USING RIBOZYMES
NUMBER OF SEQUENCES: 2627
CORRESPONDENCE ADDRESS:
ADDRESSER: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,628
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/373,124
FILING DATE: January 13, 1995
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 08/192,943
FILING DATE: February 7, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
APPLICATION NUMBER: 07/936,422
FILING DATE: August 26, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 209/035
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 338:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-628-338

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

Db ||||| |||||
15 GCAGGGAGTTGAG 2

RESULT 282
US-08-435-628-2047
; Sequence 2047, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwigen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435.628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2047:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-2047

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1118 GTTTAATTGAAAAA 1131
|:::|:::|:::|:::|:::|
Db 4 GUUUUAUUGAAAAA 17

RESULT 283
US-08-435-628-2049

; Sequence 2049, Application US/08435628
; Patent No. 5817796
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth
; APPLICANT: McSwigen, James
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHODS AND COMPOSITIONS FOR
; TITLE OF INVENTION: TREATMENT OF RESTENOSIS AND
; TITLE OF INVENTION: CANCER USING RIBOZYMES
; NUMBER OF SEQUENCES: 2627
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/435.628
; FILING DATE: 05-MAY-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/373,124
; FILING DATE: January 13, 1995
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 08/192,943
; FILING DATE: February 7, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; APPLICATION NUMBER: 07/936,422
; FILING DATE: August 26, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/035
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2049:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-435-628-2049

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1118 GTTTAATTGAAAAA 1131
|:::|:::|:::|:::|:::|
Db 2 GUUUUAUUGAAAAA 15

RESULT 284
US-08-485-611A-9
; Sequence 9, Application US/08485611A
; Patent No. 5849482
; GENERAL INFORMATION:
; APPLICANT: Meyer, Jr., Rich B.
; APPLICANT: Gamber, Howard B.
; APPLICANT: Kutayavin, Igor V.

APPLICANT: Gall, Alexander A.
APPLICANT: Petrie, Charles R.
APPLICANT: Tabone, John C.
APPLICANT: Hurst, Gerald D.
TITLE OF INVENTION: CROSSLINKING OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 29
CORRESPONDENCE ADDRESS:
ADDRESSER: Klein & Szekeres
STREET: 4199 Campus Drive, Suite 700
CITY: Irvine
STATE: CA
COUNTRY: USA
ZIP: 92715
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,611A
FILING DATE: 07-JUN-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/226,949
FILING DATE: 27-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/011,482
FILING DATE: 26-JAN-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/334,490
FILING DATE: 04-NOV-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/049,807
FILING DATE: 20-APR-1993
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/353,857
FILING DATE: 18-MAY-1989
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/250,474
FILING DATE: 28-SEP-1988
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/178,733
FILING DATE: 07-JAN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/748,138
FILING DATE: 21-AUG-1991
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/353,857
FILING DATE: 18-MAY-1989
ATTORNEY/AGENT INFORMATION:
NAME: Szekeres, Gabor L.
REGISTRATION NUMBER: 28,675
REFERENCE/DOCKET NUMBER: 491-11-CIP
TELECOMMUNICATION INFORMATION:
TELEPHONE: 714-854-5502
TELEFAX: 714-854-4897
INFORMATION FOR SEQ ID NO: 9:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-485-611A-9

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 81.2%; Pred. No. 1.9e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1147 TTTTCTTTTGGAGT 1162
Db 1 TTTTCTTTTGGGGT 16

RESULT 285
US-08-985-162-118
Sequence 118, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
FILING DATE: 31 January 1997
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 118:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-118

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.9e+02;
Matches 7; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1099 CGTAATTATGTAGT 1112
Db 3 CGUAAUUAUGUGGU 16

RESULT 286
US-08-985-162-119
Sequence 119, Application US/08985162
Patent No. 6057156
GENERAL INFORMATION:
APPLICANT: Akhtar, Saghir
APPLICANT: Fell, Patricia
APPLICANT: McSwiggen, James
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
TITLE OF INVENTION: FACTOR RECEPTORS
NUMBER OF SEQUENCES: 1877
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ for Windows 2.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/985,162
FILING DATE: 04 December 1997
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/036,476
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 230/107
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 119:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-985-162-119

Query Match: 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 50.0%; Pred. No. 1.9e+02;
Matches 7; Conservative 6; Mismatches 1; Indels 0; Gaps 0;

QY 1099 CCGAUAUUGUGGU 1112
|||:|:|:|:
DB 2 CGAUAUUGUGGU 15

RESULT 287
US-08-998-099-95
Sequence 95, Application US/08998099A
Patent No. 6103890
GENERAL INFORMATION:
APPLICANT: JARVIS, THALE
APPLICANT: MCSWIGGEN, JAMES A.
TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES
TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF C-FOS
FILE REFERENCE: 231/175
CURRENT APPLICATION NUMBER: US/08/998,099A
CURRENT FILING DATE: 1997-12-24
EARLIER APPLICATION NUMBER: 60/037,658
EARLIER FILING DATE: 1997-01-23
EARLIER APPLICATION NUMBER: 08/373,124
EARLIER FILING DATE: 1995-01-13
EARLIER APPLICATION NUMBER: 08/245,466
EARLIER FILING DATE: 1994-05-18
NUMBER OF SEQ ID NOS: 375
SOFTWARE: FastSEQ for Windows Version 3.0
SEQ ID NO 95
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-08-998-099-95

Query Match: 0.9%; Score 12.4; DB 1; Length 17;

Best Local Similarity 71.4%; Pred. No. 1.9e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 56 CTCCTCAATTACCC 69
|:|:|:|:|:|:|:
DB 4 CUCCUCAUGACCC 17

RESULT 288
US-09-017-974-79
Sequence 79, Application US/09017974
Patent No. 6288042
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.
APPLICANT: Ojwang, Joshua O.
APPLICANT: Hogan, Michael E.
APPLICANT: Wallace, Thomas L.
APPLICANT: Cossam, Paul A.
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
TITLE OF INVENTION: Tetrad Forming Oligonucleotides
NUMBER OF SEQUENCES: 88
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Taylor, P.C.
STREET: 600 Travis, Suite 1800
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: MS Word 97 (saved as .txt file)
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/017,974
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/037,374
FILING DATE: 04-FEB-97
APPLICATION NUMBER:
FILING DATE: 09-DEC-97
ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06223
TELECOMMUNICATION INFORMATION:
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008
INFORMATION FOR SEQ ID NO: 79:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-017-974-79

Query Match: 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 762 GTGGCGGGTGGATG 775
|||:|:|:|:|:|:|:
DB 1 GTGGCGGGTGGATG 14

RESULT 289
US-08-682-255A-79
Sequence 79, Application US/08682255A
Patent No. 6323185
GENERAL INFORMATION:
APPLICANT: Rando, Robert F.

```

; APPLICANT: Fennwald, Susan
; APPLICANT: Zendegeu, Joseph G.
; APPLICANT: Ojwang, Joshua O.
; APPLICANT: Hogan, Michael E.
; APPLICANT: Pommer, Yves
; APPLICANT: Mazunder, Abbiilit
; TITLE OF INVENTION: Anti-viral Guanosine-Rich
; TITLE OF INVENTION: Oligonucleotides
; NUMBER OF SEQUENCES: 87
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Conley, Rose & Tayon, P.C.
; STREET: 600 Travis, Suite 1850
; CITY: Houston
; STATE: Texas
; COUNTRY: U.S.A.
; ZIP: 77002-2912
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: MS Windows 95
; SOFTWARE: MS Word 97 (saved as .txt file)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/682,255A
; FILING DATE: 17-JULY-1996
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/535,168
; FILING DATE: 23-OCT-95
; APPLICATION NUMBER: 60/001,505
; FILING DATE: 19-JULY-95
; APPLICATION NUMBER: 60/014,007
; FILING DATE: 25-MARCH-96
; APPLICATION NUMBER: 60/013,688
; FILING DATE: 19-MARCH-96
; APPLICATION NUMBER: 60/015,714
; FILING DATE: 17-APRIL-96
; APPLICATION NUMBER: 60/016,271
; FILING DATE: 23-APRIL-96
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcdaniel, C. Steven
; REGISTRATION NUMBER: 33,962
; REFERENCE/DOCKET NUMBER: 1472-06214
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 713/238-8010
; TELEFAX: 713/238-8008
; INFORMATION FOR SEQ ID NO: 79:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-682-255A-79

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 762 GTGCGGGTGGATG 775
Db 1 GTGCGGGTGGGTG 14

RESULT 290
US-08-682-255A-79
; Sequence 2256, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
```

```

; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2256:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-2256

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 1.9e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;

QY 1155 TTGGAGTAAGCA 1168
Db 1 UUGGAACUAAAGCA 14

RESULT 291
US-08-584-040-2547
; Sequence 2547, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
```


TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels

Qy 23 AAACCAACCCAGC 36
|||
Db 14 AAACCAACCCCTGC 1

RESULT 297

US-08-679-645-139/c
; Sequence 139, Application US/08679645
; Patent No. 6350934

REFERENCE: MERIC, Donald J.
 TITLE OF INVENTION: COMPOSITION AND METHODS FOR
 TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
 TITLE OF INVENTION: IN PLANTS
 NUMBER OF SEQUENCES: 1263
 CORRESPONDENCE ADDRESS:
 ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street

STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: 5.25"
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/679,645
FILING DATE: July 12, 1996
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/001,135
FILING DATE: July 13, 1995
APPLICATION NUMBER: 08/300,726
FILING DATE: September 2, 1994
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 219/247
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 139:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-679-645-139

```
Query Match      0.9%;      Score 12.4; DB 1;      Length 17;
Best Local Similarity 92.9%;      Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels
```

Qy 884 TCCAGGAGCTGCGG 897
||| ||| ||| ||| |||
Db 14 TCCATGAGCTGCGG 1

RESULT 298

US-09-429-130-79
; Sequence 79, Application US/09429130
; Patent No. 6355785

607015, 744
TITLE OF INVENTION: Anti-Viral Guanosine-Rich
Oligonucleotides
NUMBER OF SEQUENCES: 87
CORRESPONDENCE ADDRESS:
ADDRESSEE: Conley, Rose & Tayon, P.C.
STREET: 600 Travis, Suite 1850
CITY: Houston
STATE: Texas
COUNTRY: U.S.A.
ZIP: 77002-2912
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: MS Windows 95
SOFTWARE: MS Word 97 (saved as .txt file)

CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/429,130
FILING DATE: 28-Oct-1999
CLASSIFICATION: <Unknown>
19-JULY-95
25-MARCH-96
19-MARCH-96
17-APRIL-96
23-APRIL-96

PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/682,255
FILING DATE: <Unknown>
APPLICATION NUMBER: 60/001,505
FILING DATE: 19-JULY-95
APPLICATION NUMBER: 60/014,007
FILING DATE: 25-MARCH-96
APPLICATION NUMBER: 60/013,688
FILING DATE: 19-MARCH-96
APPLICATION NUMBER: 60/016,271
FILING DATE: 17-APRIL-96

ATTORNEY/AGENT INFORMATION:
NAME: McDaniel, C. Steven
REGISTRATION NUMBER: 33,962
REFERENCE/DOCKET NUMBER: 1472-06214
TELEPHONE: 713/238-8010
TELEFAX: 713/238-8008

INFORMATION FOR SEQ ID NO: 79:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
SEQUENCE DESCRIPTION: SEQ ID NO: 79:
US-09-429-130-79

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 762 GTGGCGGGTGGATG 775
|||||
Db 1 GTGGCGGGTGGTG 14

RESULT 299
US-09-788-338-3
Sequence 3, Application US/09788338
Patent No. 6485916
GENERAL INFORMATION:
APPLICANT: MURAMATSU, TAKAMICHI
APPLICANT: FUJITA, TAKESHI
APPLICANT: KIYAMA, MASAHARU
APPLICANT: IRIE, TAKASHI
TITLE OF INVENTION: PREPARATION METHOD OF NUCLEIC ACID SAMPLE FOR RARE
TITLE OF INVENTION: EXPRESSED GENES AND ANALYZING METHOD USING THE PREPARED
TITLE OF INVENTION: NUCLEIC ACID SAMPLES THEREBY
FILE REFERENCE: NIT-129-02
CURRENT APPLICATION NUMBER: US/09/788,338
CURRENT FILING DATE: 2001-02-21
PRIOR APPLICATION NUMBER: 09/313,637
PRIOR FILING DATE: 1999-05-18
PRIOR APPLICATION NUMBER: JP 10-153651
PRIOR FILING DATE: 1998-05-20
NUMBER OF SEQ ID NOS: 4
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 3
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Synthetic DNA

US-09-788-338-3

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTG 1157
|||||
Db 4 TTTTTCCTTTTG 17

RESULT 300
US-09-300-958A-64
Sequence 64, Application US/09300958A
Patent No. 6495319
GENERAL INFORMATION:
APPLICANT: McClelland, Michael
APPLICANT: Welsh, John
APPLICANT: Trenkle, Thomas
TITLE OF INVENTION: Reduced Complexity Nucleic Acid Targets and Methods of
TITLE OF INVENTION: Using Same
FILE REFERENCE: P-PH 3457
CURRENT APPLICATION NUMBER: US/09/300,958A
CURRENT FILING DATE: 1999-04-27
PRIOR APPLICATION NUMBER: 60/083,331
PRIOR FILING DATE: 1998-04-27
PRIOR APPLICATION NUMBER: 60/098,070
PRIOR FILING DATE: 1998-08-27
PRIOR APPLICATION NUMBER: 60/118,624
PRIOR FILING DATE: 1999-02-04
NUMBER OF SEQ ID NOS: 85
SOFTWARE: PatentIn Ver. 2.0
SEQ ID NO 64
LENGTH: 17
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Description of Artificial Sequence: Primer
US-09-300-958A-64

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTG 1157
|||||
Db 4 TTTTTCCTTTTG 17

RESULT 301
US-09-474-432B-409
Sequence 409, Application US/09474432B
Patent No. 6528640
GENERAL INFORMATION:
APPLICANT: Beigelman, Leo
APPLICANT: Burgin, Alex
APPLICANT: Beaudry, Amber
APPLICANT: Karpeisky, Alex
APPLICANT: Adamic, Jasenka
APPLICANT: Sweedler, David
APPLICANT: Zinnen, Shawn
TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucle
FILE REFERENCE: MBH00-831-B (247/276)
CURRENT APPLICATION NUMBER: US/09/474,432B
CURRENT FILING DATE: 1999-12-19
PRIOR APPLICATION NUMBER: US 60/064,866
PRIOR FILING DATE: 1997-11-05
PRIOR APPLICATION NUMBER: US 60/084,727
PRIOR FILING DATE: 1998-04-29
PRIOR APPLICATION NUMBER: US 09/186,675
PRIOR FILING DATE: 1998-11-04
PRIOR APPLICATION NUMBER: US 09/301,511

```

; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 409
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-409

Query Match          0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 1.9e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

Qy 477 GGAGGACTGGCGAG 490
Db 1 GGAGGAUCCGAG 14

RESULT 302
US-09-474-432B-421
; Sequence 421, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleot
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 421
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-421

Query Match          0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

Qy 1297 CAGCCTGGCCGCAT 1310
Db 2 CAGCCUUGCCCAU 15

RESULT 303
US-09-474-432B-557
; Sequence 557, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn

```

```

; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucle
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 557
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-557

Query Match          0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 21.4%; Pred. No. 1.9e+02;
Matches 3; Conservative 10; Mismatches 1; Indels 0; Gaps 0;

Qy 1112 TTTTCTGTTTAAT 1125
Db 3 UUUUCUGUUUGUU 16

RESULT 304
US-09-474-432B-815/c
; Sequence 815, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucle
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 815
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-815

Query Match          0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 867 GGTCCCCACACGCCA 880
Db 17 GGTCCCCACACGCCA 4

RESULT 305
US-09-371-772B-801

```


; Sequence 801, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 801
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-801

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 1.9e+02;
Matches 10; Conservative 3; Mismatches 1; Indels 0; Gaps 0;
QY 1155 TTGGAAGTAAAGCA 1168
:||||:|||||
Db 1 UUGGAACUAAAGCA 14

RESULT 306
US-09-371-772B-1071
; Sequence 1071, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1071
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1071

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 71.4%; Pred. No. 1.9e+02;
Matches 1; Conservative 12; Mismatches 1; Indels 0; Gaps 0;
QY 1143 CTTTTCCTTTT 1156
|:|||||:|
Db 4 CUUUUUUUUUUU 17

RESULT 307
US-09-371-772B-1072
; Sequence 1072, Application US/09371772B

; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1072
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1072

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 71.1%; Pred. No. 1.9e+02;
Matches 1; Conservative 12; Mismatches 1; Indels 0; Gaps 0;
QY 1143 CTTTTCCTTTT 1156
|:|||||:|
Db 3 CUUUUUUUUUUU 16

RESULT 308
US-09-371-772B-1073
; Sequence 1073, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1073
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1073

Query Match 0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 71.1%; Pred. No. 1.9e+02;
Matches 1; Conservative 12; Mismatches 1; Indels 0; Gaps 0;
QY 1143 CTTTTCCTTTT 1156
|:|||||:|
Db 2 CUUUUUUUUUUU 15

RESULT 309
US-09-371-772B-1074
; Sequence 1074, Application US/09371772B
; Patent No. 6566127

```

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1074
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1074

```

```

Query Match      0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 7.1%; Pred. No. 1.9e+02;
Matches 1; Conservative 12; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 1143 CTTTTCCTTTTCTTTT 1156
      |||:|||||:|||||
DB 1 CUUUUUUUUUUUU 14

```

```

RESULT 310
US-09-371-772B-2845/c
; Sequence 2845, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2845
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2845

```

```

Query Match      0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 23 AAACCAAAACCCGCGC 36
      |||:|||||:|||||
DB 15 AAACCAAAACCCCTGC 2

```

```

RESULT 311
US-09-371-772B-2846/c
; Sequence 2846, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:

```

```

; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 2846
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-2846

```

```

Query Match      0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 92.9%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 23 AAACCAAAACCCGCGC 36
      |||:|||||:|||||
DB 14 AAACCAAAACCCCTGC 1

```

```

RESULT 312
US-09-371-772B-5053
; Sequence 5053, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5053
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5053

```

```

Query Match      0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 1.9e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

```

```

QY 687 TGGGAGCCGCGCGC 700
      |||:|||||:|||||
DB 2 UGGGAGCCGCGCUGC 15

```

```

RESULT 313
US-09-371-772B-5054
; Sequence 5054, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.

```

```
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 5054
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5054

Query Match          0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 85.7%; Pred. No. 1.9e+02;
Matches 12; Conservative 1; Mismatches 1; Indels 0; Gaps 0;

QY 687 TGGGAGCCAGCGGC 700
Db 1 UGGGAGCCAGCGUC 14

RESULT 314
US-09-371-772B-5055
; Sequence 5055, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 5055
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5055

Query Match          0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 57.1%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 1313 AGCCAGGTCGTTT 1326
Db 2 AGCCAGCUGCUUUU 15

RESULT 315
US-09-371-772B-6554
; Sequence 6554, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
```

```
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: Patentin version 3.0
; SEQ ID NO 6554
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6554

Query Match          0.9%; Score 12.4; DB 1; Length 17;
Best Local Similarity 78.6%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 1; Indels 0; Gaps 0;

QY 550 CTGGCAGGCATGCA 583
Db 4 CUGCCAGGCAUGCA 17

RESULT 316
PCT-US95-07744A-30/c
; Sequence 30, Application PC/TUS9507744A
; GENERAL INFORMATION:
; APPLICANT: Trustees of The University of Pennsylvania
; TITLE OF INVENTION: Plant Genes for Sensitivity to Ethylene
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Woodcock, Washburn, Kurtz, Mackiewicz & Norris
; STREET: One Liberty Place, 46th floor
; CITY: Philadelphia
; STATE: PA
; COUNTRY: USA
; ZIP: 19103
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US95/07744A
; FILING DATE: 15-JUNE-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/261,822
; FILING DATE: June 17, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Beardell, Lori Y.
; REGISTRATION NUMBER: 34,293
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (215) 568-3100
; TELEFAX: (215) 568-3439
; INFORMATION FOR SEQ ID NO: 30:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: YES
PCT-US95-07744A-30
```

```
;
;
; REFERENCE/DOCKET NUMBER: 0372/09696
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212/527-7700
; TELEFAX: 212/753-6237
; TELEX: 236687
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; ORIGINAL SOURCE:
; ORGANISM: Homo sapien
; IMMEDIATE SOURCE:
; CLONE: 711+1GTN
; US-08-281-940-49

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 92.4%; Pred. No. 2.1e+02;
Matches 13; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 648 CCCCCAAGACCTGG 661
Db 17 CCACCAAGACCTGG 4

RESULT 317
US-09-371-772B-5055/c
; Sequence 5055, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyne Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MH000,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371.772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5055
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-09-371-772B-5055

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1027 CAAAGTCAGCTGACTC 1043
Db 17 CAAAAGCAGCTGGCTC 1

RESULT 318
US-08-281-940-49/c
; Sequence 49, Application US/08281940
; Patent No. 5589330
; GENERAL INFORMATION:
; APPLICANT: SHUBER, ANTHONY P.
; TITLE OF INVENTION: METHOD FOR MULTIPLE ALLELE-SPECIFIC
; TITLE OF INVENTION: DISEASE ANALYSIS
; NUMBER OF SEQUENCES: 65
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: DARBY & DARBY P.C.
; STREET: 805 THIRD AVENUE
; CITY: NEW YORK
; STATE: NEW YORK
; COUNTRY: USA
; ZIP: 10022
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/281,940
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: LUDWIG, S. PETER
; TELEPHONE: (212) 555-0440
; TELEFAX: 67-3510
; INFORMATION FOR SEQ ID NO: 25351
```

```
;
;
; REFERENCE/DOCKET NUMBER: 0372/09696
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 212/527-7700
; TELEFAX: 212/753-6237
; TELEX: 236687
; INFORMATION FOR SEQ ID NO: 49:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; ORIGINAL SOURCE:
; ORGANISM: Homo sapien
; IMMEDIATE SOURCE:
; CLONE: 711+1GTN
; US-08-281-940-49

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 441 AAAGTTGCTGAAGTTTG 457
Db 17 AAATTGATGAAGTATG 1

RESULT 319
US-08-390-850-589/c
; Sequence 589, Application US/08390850
; Patent No. 5612215
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Gustofson, John
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
; TITLE OF INVENTION: OF ARTHRITIC CONDITIONS
; NUMBER OF SEQUENCES: 1151
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/390,850
; FILING DATE: February 17, 1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/354,920
; FILING DATE: December 13, 1994
; APPLICATION NUMBER: 08/152,487
; FILING DATE: No. 5612215ember 12, 1993
; APPLICATION NUMBER: 07/989,848
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 211/084
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 589:
```

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-390-850-589

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 365 TCTTGGGGCCAGCTT 381
||||| :|||
Db 17 TCTTGGGTAAACAGCTT 1

RESULT 320

US-08-390-850-590/c

; Sequence 590, Application US/08390850
; Patent No. 5612215

GENERAL INFORMATION:

APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.

TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT

TITLE OF INVENTION: OF ARTHRITIC CONDITIONS

NUMBER OF SEQUENCES: 1151

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSEQ Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/390,850

FILING DATE: February 17, 1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/354,920

FILING DATE: December 13, 1994

APPLICATION NUMBER: 08/152,487

FILING DATE: No. 5612215ember 12, 1993

APPLICATION NUMBER: 07/989,848

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 211/084

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 590:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-390-850-590

Query Match

0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 364 TCTTGGGGCCAGCT 380
||||| :|||
Db 17 TCTTGGGTAAACAGCT 1

RESULT 321

US-08-390-850-592

; Sequence 592, Application US/08390850
; Patent No. 5612215

GENERAL INFORMATION:

APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.

TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT

TITLE OF INVENTION: OF ARTHRITIC CONDITIONS

NUMBER OF SEQUENCES: 1151

CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSEQ Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/390,850

FILING DATE: February 17, 1995

PRIOR APPLICATION DATA:

APPLICATION NUMBER: 08/354,920

FILING DATE: December 13, 1994

APPLICATION NUMBER: 08/152,487

FILING DATE: No. 5612215ember 12, 1993

APPLICATION NUMBER: 07/989,848

FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 211/084

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 592:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-390-850-592

Query Match

0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.1e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1056 CCTGTGCTTCCCATCA 1072
||||| :|||
Db 1 CCUGGGUUCUUCA 17

RESULT 322

US-08-435-634-589/c

; Sequence 589, Application US/08435634
; Patent No. 5731295

GENERAL INFORMATION:

APPLICANT: Draper, Kenneth G.

APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 589:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-589

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 365 TTCTGGGGGCCAGCTT 381
DB 17 TCCTGGGTAAACCAGTT 1

RESULT 323
US-08-435-634-590/c
Sequence 590, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSEQ Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435,634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 590:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-590

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 364 TTCTGGGGGCCAGCT 380
DB 17 TCCTGGGTAAACCAGCT 1

RESULT 324
US-08-435-634-592
Sequence 592, Application US/08435634
Patent No. 5731295
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Gustofson, John
APPLICANT: Stinchcomb, Dan T.
TITLE OF INVENTION: METHOD AND REAGENT FOR TREATMENT
NUMBER OF SEQUENCES: 1151
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/435.634
FILING DATE: 05-MAY-1995
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/390,850
FILING DATE: February 17, 1995
APPLICATION NUMBER: 08/354,920
FILING DATE: December 13, 1994
APPLICATION NUMBER: 08/152,487
FILING DATE: No. 5731295ember 12, 1993
APPLICATION NUMBER: 07/989,848
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 211/084
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 592:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-435-634-592

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.1e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1056 CCCTGGGCTTCCCATCA 1072
|||:|:|:|:|:|:|:|:|:|:
Db 1 CCCUGGGUUCUUUCA 17

RESULT 325
US-08-466-033-104
; Sequence 104, Application US/08466033
; Patent No. 5766840
; GENERAL INFORMATION:
; APPLICANT: Kim, Jungshuh P.
; APPLICANT: Wages, John
; APPLICANT: Young, LaVonne M.
; APPLICANT: Fry, Kirk E.
; APPLICANT: Linnen, Jeffrey M.
; TITLE OF INVENTION: Hepatitis G Virus and Molecular
; TITLE OF INVENTION: Cloning Thereof
; NUMBER OF SEQUENCES: 277
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dehlinger & Associates
; STREET: 350 Cambridge Ave., Suite 250
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,033
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/389,886
; FILING DATE: 15-FEB-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/357,509
; FILING DATE: 16-DEC-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/329,729
; FILING DATE: 26-OCT-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/344,271
; FILING DATE: 23-NOV-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/285,558
; FILING DATE: 03-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/285,543
; FILING DATE: 03-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/246,985
; FILING DATE: 20-MAY-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Fabian, Gary R.
; REGISTRATION NUMBER: 33,875
; REFERENCE/DOCKET NUMBER: 4600-0201.36/G100P11
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 324-0880
; TELEFAX: (415) 324-0960
; INFORMATION FOR SEQ ID NO: 104:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: both
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: Primer PGEX-R
; US-08-466-033-104

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 625 GACCAGCTCCGAGGCT 641
|||||:|:|:|:|:|:|:|:|:|:
Db 1 GACCGTCTCCGGAGCT 17

RESULT 326
US-08-444-733-104
; Sequence 104, Application US/08444733
; Patent No. 5824507
; GENERAL INFORMATION:
; APPLICANT: Kim, Jungshuh P.
; APPLICANT: Wages, John
; APPLICANT: Young, LaVonne M.
; APPLICANT: Fry, Kirk E.
; APPLICANT: Linnen, Jeffrey M.
; TITLE OF INVENTION: Hepatitis G Virus and Molecular
; TITLE OF INVENTION: Cloning Thereof
; NUMBER OF SEQUENCES: 277
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dehlinger & Associates
; STREET: 350 Cambridge Ave., Suite 250
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/466,033
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:

SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/444,733
FILING DATE:
CLASSIFICATION: 435
PRIOR APPLICATION DATA: US 08/389,886
APPLICATION NUMBER: 15-FEB-1995
FILING DATE: 15-FEB-1995
PRIOR APPLICATION DATA: US 08/357,509
APPLICATION NUMBER: 16-DEC-1994
FILING DATE: 16-DEC-1994
PRIOR APPLICATION DATA: US 08/329,729
APPLICATION NUMBER: 26-OCT-1994
FILING DATE: 26-OCT-1994
PRIOR APPLICATION DATA: US 08/344,271
APPLICATION NUMBER: 23-NOV-1994
FILING DATE: 23-NOV-1994
PRIOR APPLICATION DATA: US 08/285,558
APPLICATION NUMBER: 03-AUG-1994
FILING DATE: 03-AUG-1994
PRIOR APPLICATION DATA: US 08/285,543
APPLICATION NUMBER: 03-AUG-1994
FILING DATE: 03-AUG-1994
PRIOR APPLICATION DATA: US 08/246,985
APPLICATION NUMBER: 20-MAY-1994
FILING DATE: 20-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-0201.36/G100P11
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 104:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Primer PGEX-R
US-08-444-733-104

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 625 GACCAGCTCCAGGAGCT 641
Db 1 GACCCTCTCCGGAGCT 17

RESULT 327
US-08-710-134-49/c
Sequence 49, Application US/08710134
Patent No. 5834181
GENERAL INFORMATION:
APPLICANT: SHUBER, ANTHONY P.
TITLE OF INVENTION: HIGH THROUGHPUT SCREENING METHOD FOR
SEQUENCES OR GENETIC ALTERATIONS IN NUCLEIC ACIDS
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genzyme Corporation
STREET: One Mountain Road
CITY: Framingham
STATE: Massachusetts
COUNTRY: USA
ZIP: 01701
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk

COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/710,134
FILING DATE: 13-SEP-1996
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Dugan, Deborah A.
REGISTRATION NUMBER: 37,315
REFERENCE/DOCKET NUMBER: IG5-8.1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 508-872-8400
TELEFAX: 508-872-5415
INFORMATION FOR SEQ ID NO: 49:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Oligonucleotides"
US-08-710-134-49

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 441 AAAGTTGCTGAAGTTTG 457
Db 17 AAATTTGATGAAGTATG 1

RESULT 328
US-08-292-620A-1644/c
Sequence 1644, Application US/08292620A
Patent No. 5837542
GENERAL INFORMATION:
APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
RELATED TO LEVELS OF
INTRACELLULAR ADHESION
MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
described below:
PRIOR APPLICATION DATA: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849

/ FILING DATE: December 7, 1992
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 208/149
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 1644:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-292-620A-1644

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 623 GGCACCGAGTCCAGGAG 639
Db 17 GGCACCGAGGACCGAG 1

RESULT 329
US-08-292-620A-1697
; Sequence 1697, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600

two

/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 1697:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
US-08-292-620A-1697

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 961 CAGGACTGACCCCTCAC 977
Db 1 CAGCAUUAUCCCUAC 17

RESULT 330
US-08-292-620A-1700/c
; Sequence 1700, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1700:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single

two

```

; TOPOLOGY: linear
US-08-292-620A-1700

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 623 GGGACCAAGCTCCAGGAG 639
Db 17 GCGACCAAGCTCCAGGAG 1

RESULT 331
US-08-292-620A-1707/c
; Sequence 1707, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1707:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-1707

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

Qy 623 GGGACCAAGCTCCAGGAG 639
Db 17 GCGACCAAGCTCCAGGAG 1

RESULT 332
US-08-292-620A-1743/c
; Sequence 1743, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1743:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-1743

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

; Sequence 1796, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1796:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-1796

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 623 GGGACCAAGCTCCAGGAG 639
Db 17 GCGACCAAGGACCAAGGAG 1

RESULT 334
US-08-292-620A-1873/c
; Sequence 1873, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan

; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1873:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-292-620A-1873

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 623 GGGACCAAGCTCCAGGAG 639
Db 17 GCGACCAAGGACCAAGGAG 1

RESULT 335
US-08-292-620A-1934/c
; Sequence 1934, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390

two

two

```

CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
STATE: Los Angeles
COUNTRY: California
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/969,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1934:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1934

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 623 GGGACCAGCTCCAGGAG 639
Db 17 GGGACCAGGACCAGGAG 1

RESULT 336
US-08-485-885-49/c
Sequence 49, Application US/08485885
Patent No. 5849483
GENERAL INFORMATION:
APPLICANT: SHUBER, ANTHONY P.
TITLE OF INVENTION: HIGH THROUGHPUT SCREENING METHOD FOR
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: Genzyme Corporation
STREET: One Mountain Road
CITY: Framingham
STATE: Massachusetts
COUNTRY: USA
ZIP: 01701
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/485,885

```

```

FILING DATE: 07-JUN-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Dugan, Deborah A.
REGISTRATION NUMBER: 37,315
REFERENCE/DOCKET NUMBER: GEN4-12.1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 508-872-8400
TELEFAX: 508-872-5415
INFORMATION FOR SEQ ID NO: 49:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Oligonucleotides"
US-08-485-885-49

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 441 AAGTTGCTGAAGTTTG 457
Db 17 AAATTTGATGAAGTATG 1

RESULT 337
US-08-464-134-104
Sequence 104, Application US/08464134
Patent No. 5849532
GENERAL INFORMATION:
APPLICANT: Kim, Jungshuh P.
APPLICANT: Wages, John
APPLICANT: Young, LaVonne M.
APPLICANT: Fry, Kirk E.
APPLICANT: Linnen, Jeffrey M.
TITLE OF INVENTION: Hepatitis G Virus and Molecular
NUMBER OF SEQUENCES: 277
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dehlinger & Associates
STREET: 350 Cambridge Ave., Suite 250
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/464,134
FILING DATE:
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/389,886
FILING DATE: 15-FEB-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/357,509
FILING DATE: 16-DEC-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/329,729
FILING DATE: 26-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/344,271
FILING DATE: 23-NOV-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/285,558
FILING DATE: 03-AUG-1994
PRIOR APPLICATION DATA:

```

```

; APPLICATION NUMBER: US 08/285,543
; FILING DATE: 03-AUG-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/246,985
; FILING DATE: 20-MAY-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Fabian, Gary R.
; REGISTRATION NUMBER: 33,875
; REFERENCE/DOCKET NUMBER: 4600-0201.36/G100P11
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 324-0880
; TELEFAX: (415) 324-0960
; INFORMATION FOR SEQ ID NO: 104:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: both
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: Primer PGEX-R
; US-08-461-134-104

```

```

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY      625 GACCAGCTCCAGGAGCT 641
Db      1 GACCGTCTCCGGAGCT 17

```

```

RESULT 338
US-08-461-361-104
; Sequence 104, Application US/08461361
; Patent No. 5856134
; GENERAL INFORMATION:
; APPLICANT: Kim, Jungshuh P.
; APPLICANT: Wages, John
; APPLICANT: Young, LaVonne M.
; APPLICANT: Fry, Kirk E.
; APPLICANT: Linnen, Jeffrey M.
; TITLE OF INVENTION: Hepatitis G Virus and Molecular
; Cloning Thereof
; NUMBER OF SEQUENCES: 277
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dehlinger & Associates
; STREET: 350 Cambridge Ave., Suite 250
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/461,361
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/389,886
; FILING DATE: 15-FEB-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/357,509
; FILING DATE: 16-DEC-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/329,729
; FILING DATE: 26-OCT-1994
; PRIOR APPLICATION DATA:

```

```

; APPLICATION NUMBER: US 08/344,271
; FILING DATE: 23-NOV-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/285,558
; FILING DATE: 03-AUG-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Fabian, Gary R.
; REGISTRATION NUMBER: 33,875
; REFERENCE/DOCKET NUMBER: 4600-0201.36/G100P11
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 324-0880
; TELEFAX: (415) 324-0960
; INFORMATION FOR SEQ ID NO: 104:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: both
; TOPOLOGY: linear
; MOLECULE TYPE: DNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
; ORIGINAL SOURCE:
; INDIVIDUAL ISOLATE: Primer PGEX-R
; US-08-461-361-104

```

```

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY      625 GACCAGCTCCAGGAGCT 641
Db      1 GACCGTCTCCGGAGCT 17

```

```

RESULT 339
US-08-485-910-104
; Sequence 104, Application US/08485910
; Patent No. 5874563
; GENERAL INFORMATION:
; APPLICANT: Kim, Jungshuh P.
; APPLICANT: Wages, John
; APPLICANT: Young, LaVonne M.
; APPLICANT: Fry, Kirk E.
; APPLICANT: Linnen, Jeffrey M.
; TITLE OF INVENTION: Hepatitis G Virus and Molecular
; Cloning Thereof
; NUMBER OF SEQUENCES: 277
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Dehlinger & Associates
; STREET: 350 Cambridge Ave., Suite 250
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/485,910
; FILING DATE:
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/389,886
; FILING DATE: 15-FEB-1995
; PRIOR APPLICATION DATA:

```

APPLICATION NUMBER: US 08/357,509
FILING DATE: 16-DEC-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/329,729
FILING DATE: 26-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/344,271
FILING DATE: 23-NOV-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/285,558
FILING DATE: 03-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/285,543
FILING DATE: 03-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/246,985
FILING DATE: 20-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-0201.36/G100P11
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 104:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: linear
MOLECULE TYPE: DNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Primer PGEX-R
US-08-485-910-104

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 625 GACCGCTCCGGAGCT 641
Db 1 GACCGCTCCGGAGCT 17

RESULT 340
US-08-474-450A-62
Sequence 62, Application US/08474450A
Patent No. 5882856
GENERAL INFORMATION:
APPLICANT: SHUBER, ANTHONY P.
TITLE OF INVENTION: UNIVERSAL PRIMER SEQUENCE FOR MULTIPLEX
TITLE OF INVENTION: DNA AMPLIFICATION
NUMBER OF SEQUENCES: 65
CORRESPONDENCE ADDRESS:
ADDRESSEE: RAE-VENTER LAW GROUP
STREET: 260 Sheridan Ave., Ste. 440
CITY: Palo Alto
STATE: California
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/474,450A
FILING DATE: 7-JUNE-1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Rae-Venter, Barbara

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;

REGISTRATION NUMBER: 32,750
REFERENCE/DOCKET NUMBER: GECO.001.000S
TELECOMMUNICATION INFORMATION:
TELEPHONE: (650) 328-4400
TELEFAX: (650) 328-4477
INFORMATION FOR SEQ ID NO: 62:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "WT-1 PRIMER SEQUENCE - N"
US-08-474-450A-62

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 386 CACAGGTGGCAGCAATG 402
Db 1 CACAGGTGGCAGCAATG 17

RESULT 341
US-08-798-738-10/c
Sequence 10, Application US/08798738
Patent No. 5885833
GENERAL INFORMATION:
APPLICANT: MUELLER, Rolf
APPLICANT: ZWICKER, Joerk
APPLICANT: SEDLACEK, Hans-Herald
TITLE OF INVENTION: NUCLEIC ACID CONSTRUCTS FOR THE CELL
TITLE OF INVENTION: CYCLE-REGULATED EXPRESSION OF GENES AND THERAPEUTIC
TITLE OF INVENTION: METHODS OF UTILIZING SUCH CONSTRUCTS
NUMBER OF SEQUENCES: 20
CORRESPONDENCE ADDRESS:
ADDRESSEE: Foley & Lardner
STREET: 3000 K Street, N.W., Suite 500
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20007-5109
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/798,738
FILING DATE: 13-FEB-1997
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: DE 19605274.2
FILING DATE: 13-FEB-1996
ATTORNEY/AGENT INFORMATION:
NAME: GRANADOS, Patricia D.
REGISTRATION NUMBER: 33,683
REFERENCE/DOCKET NUMBER: 18748/318
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 672-5300
TELEFAX: (202) 672-5399
TELEX: 904136
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-798-738-10

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 598 ACCAGCCTGAAGCCTGA 614
| | | | | | | | | | | | | | | |
Db 17 AGCAGCCTGAGTCCTGA 1

RESULT 342

US-08-484-661A-17
; Sequence 17, Application US/08484661A
; Patent No. 6001645
; GENERAL INFORMATION:
; APPLICANT: SLATER, MICHAEL R.
; APPLICANT: HARTNETT, JAMES R.
; APPLICANT: HUANG, FEN
; APPLICANT: BOLCHAKOVA, ELENA
; TITLE OF INVENTION: MODIFIED THERMOPHILIC DNA POLYMERASES
; TITLE OF INVENTION: FROM THERMOTOGA NEAPOLITANA
; NUMBER OF SEQUENCES: 51
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MEDLEN & CARROLL
; STREET: 220 MONTGOMERY STREET, SUITE 2200
; CITY: SAN FRANCISCO
; STATE: CALIFORNIA
; COUNTRY: UNITED STATES OF AMERICA
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/484,661A
; FILING DATE: 07-JUN-1995
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: INGOLIA, DIANE E.
; REGISTRATION NUMBER: 40,027
; REFERENCE/DOCKET NUMBER: PRMG-01175
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-484-661A-17

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1199 GACCTTACACCTCCCC 1215
| | | | | | | | | | | | | | | |
Db 1 GACCTTACACCTCCTC 17

RESULT 343

US-08-181-664-64/C
; Sequence 64, Application US/08181664
; Patent No. 6025127
; GENERAL INFORMATION:
; APPLICANT: Sidransky, David
; TITLE OF INVENTION: NUCLEIC ACID MUTATION DETECTION IN
; TITLE OF INVENTION: HISTOLOGIC TISSUE
; NUMBER OF SEQUENCES: 82
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Spensley Horn Jubas & Lubitz
; STREET: 1880 Century Park East, Suite 500
; CITY: Los Angeles

; STATE: California
; COUNTRY: USA
; ZIP: 90067
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/181,664
; FILING DATE: JANUARY 14, 1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Wetherell, Jr., Ph.D., John R.
; REGISTRATION NUMBER: 31,678
; REFERENCE/DOCKET NUMBER: PD-3055
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (619) 455-5100
; TELEFAX: (619) 455-5110
; INFORMATION FOR SEQ ID NO: 64:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; FEATURE:
; NAME/KEY: CDS
; LOCATION: 1..17
US-08-181-664-64

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1039 GACTCTTCCCGACGACG 1055
| | | | | | | | | | | | | | | |
Db 17 GTCTCTCCCGACGACG 1

RESULT 344

US-08-985-162-85/c
; Sequence 85, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476

```

; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 85:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-985-162-85

Query Match      0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1216 TTCCCTGTACATTGTC 1232
Db 17 TTTCCTGTAATTCTC 1

RESULT 345
US-08-985-162-104/c
; Sequence 104, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 104:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-985-162-293

Query Match      0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 645 CATCCCCCAAGACCTGG 661
Db 17 CAGCCTTCAAGACCTGG 1

RESULT 347
US-08-985-162-293
```

```

; TOPOLOGY: linear
; US-08-985-162-104

Query Match      0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 629 AGCTCCAGGAGCTCTGC 645
Db 17 AGCGCCCGGAGCACTGC 1

RESULT 346
US-08-985-162-237/c
; Sequence 237, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMATIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 237:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-985-162-237

Query Match      0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 645 CATCCCCCAAGACCTGG 661
Db 17 CAGCCTTCAAGACCTGG 1

RESULT 347
US-08-985-162-293
```



```
; Sequence 293, Application US/08985162
; Patent No. 6057156
; GENERAL INFORMATION:
; APPLICANT: Akhtar, Saghir
; APPLICANT: Fell, Patricia
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT
; TITLE OF INVENTION: OF DISEASES OR CONDITIONS RELATED
; TITLE OF INVENTION: TO LEVELS OF EPIDERMAL GROWTH
; TITLE OF INVENTION: FACTOR RECEPTORS
; NUMBER OF SEQUENCES: 1877
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq for Windows 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/985,162
; FILING DATE: 04 December 1997
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/036,476
; FILING DATE: 31 January 1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 230/107
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 293:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-985-162-293

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 577 CAGGCCCTCCGCTCTGCC 593
Db 1 CAUGGCCUUCGCGGCC 17

RESULT 348
US-08-656-664-17
; Sequence 17, Application US/08656664
; Patent No. 6077864
; GENERAL INFORMATION:
; APPLICANT: Slater, Michael R.
; APPLICANT: Huang, Fen
; APPLICANT: Hartnett, James R.
; APPLICANT: Bolchakova, Elena
; APPLICANT: Storts, Douglas R.
; APPLICANT: Otto, Paul
; TITLE OF INVENTION: THERMOPHILIC DNA POLYMERASES FROM
; TITLE OF INVENTION: THERMOTOGA NEAPOLIITANA
; NUMBER OF SEQUENCES: 57
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Medlen & Carroll
```

```
; STREET: 220 Montgomery Street, Suite 2200
; CITY: San Francisco
; STATE: California
; COUNTRY: United States Of America
; ZIP: 94104
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/656,664
; FILING DATE: 31-MAY-1996
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Ingolia, Diane E.
; REGISTRATION NUMBER: 40,027
; REFERENCE/DOCKET NUMBER: PRMG-02185
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 705-8410
; TELEFAX: (415) 397-8338
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-656-664-17

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1199 GACCTTCACACCTCCCC 1215
Db 1 GACCTTCACAGGCTC 17

RESULT 349
US-08-998-099-82
; Sequence 82, Application US/08998099A
; Patent No. 6103890
; GENERAL INFORMATION:
; APPLICANT: JARVIS, THALE
; APPLICANT: MCSWIGGEN, JAMES A.
; APPLICANT: STINCHCOMB, DAN T.
; TITLE OF INVENTION: ENZYMAIC NUCLEIC ACID TREATMENT OF DISEASES
; TITLE OF INVENTION: OR CONDITIONS RELATED TO LEVELS OF C-POS
; FILE REFERENCE: 231/175
; CURRENT APPLICATION NUMBER: US/08/998,099A
; CURRENT FILING DATE: 1997-12-24
; EARLIER APPLICATION NUMBER: 60/037,658
; EARLIER FILING DATE: 1997-01-23
; EARLIER APPLICATION NUMBER: 08/373,124
; EARLIER FILING DATE: 1995-01-13
; EARLIER APPLICATION NUMBER: 08/245,466
; EARLIER FILING DATE: 1994-05-18
; NUMBER OF SEQ ID NOS: 375
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 82
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; US-08-998-099-82

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 1057 CTTGGCCTTCCCATCAG 1073
Db 1 CCUGGGCUUCCAGAG 17
```

RESULT 350
US-09-071-845-1644/c
; Sequence 1644, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1644:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-1644

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 623 GGGACCGAGCTCCAGGAG 639
Db 17 GCGACCGAGCGACGAG 1

RESULT 351
US-09-071-845-1697
; Sequence 1697, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:

; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1697:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-1697

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 961 CAGGACTGACCCCTGAC 977
Db 1 CAGCAUUUACCCCUAC 17

RESULT 352
US-09-071-845-1700/c
; Sequence 1700, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:

; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS

;; TITLE OF INVENTION: RELATED TO LEVELS OF
;; TITLE OF INVENTION: INTRACELLULAR ADHESION
;; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
;; NUMBER OF SEQUENCES: 2390
;; CORRESPONDENCE ADDRESS:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/071,845
;; FILING DATE:
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/08/292,620
;; FILING DATE: August 17, 1994
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/149
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1700:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-09-071-845-1700

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 623 GGGACCAGCTCCAGGAG 639
Db 17 GCGACCAGGACCAGGAG 1

RESULT 353
US-09-071-845-1707/c
; Sequence 1707, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street

;; STREET: Suite 4700
;; CITY: Los Angeles
;; STATE: California
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/09/071,845
;; FILING DATE:
;; CLASSIFICATION:
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US/08/292,620
;; FILING DATE: August 17, 1994
;; APPLICATION NUMBER: 08/008,895
;; FILING DATE: January 19, 1993
;; APPLICATION NUMBER: 07/989,849
;; FILING DATE: December 7, 1992
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 208/149
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 1707:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-09-071-845-1707

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 623 GGGACCAGCTCCAGGAG 639
Db 17 GCGACCAGGACCAGGAG 1

RESULT 354
US-09-071-845-1743/c
; Sequence 1743, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

```

; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1743:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-1743

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 623 GGGACCAGCTCCAGGAG 639
Db 17 GCGACCAGGACCAGGAG 1

RESULT 355
US-09-071-845-1796/c
; Sequence 1796, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:

```

```

; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1796:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-09-071-845-1796

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 623 GGGACCAGCTCCAGGAG 639
Db 17 GCGACCAGGACCAGGAG 1

RESULT 356
US-09-071-845-1873/c
; Sequence 1873, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849

```

; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1873:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-1873

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 623 GGCACCGACTCCAGGAG 639
Db 17 GCGACCGAGCCAGGAG 1

RESULT 357
US-09-071-845-1934/c
; Sequence 1934, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Strinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600

; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1934:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-1934

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 623 GGCACCGACTCCAGGAG 639
Db 17 GCGACCGAGCCAGGAG 1

RESULT 358
US-08-961-810-104/c
; Sequence 104, Application US/08961810
; Patent No. 6165713
; GENERAL INFORMATION:
; APPLICANT: Liskay, Robert M.
; APPLICANT: Bronner, C. Eric
; APPLICANT: Baker, Sean M.
; APPLICANT: Bollag, Roni J.
; APPLICANT: Kolodner, Richard D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS RELATING TO DNA
; TITLE OF INVENTION: MISMATCH REPAIR GENES
; NUMBER OF SEQUENCES: 134
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kollisch, Hartwell, Dickinson, McCormack &
; STREET: 520 S.W. Yamhill Street, Suite 200
; CITY: Portland
; STATE: Oregon
; COUNTRY: U.S.A.
; ZIP: 97204
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/961,810
; FILING DATE:
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Rysselberghe, Pierre C.
; REGISTRATION NUMBER: 33,557
; REFERENCE/DOCKET NUMBER: OHSU 306B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (503) 224-6655
; TELEFAX: (503) 295-6679
; TELEX: 360619
; INFORMATION FOR SEQ ID NO: 104:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: /note= "primers directed to genomic
; OTHER INFORMATION: intron DNA"
US-08-961-810-104

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```
QY 941 AGAGGTGTGAGCCGAGA 957
D5 17 AGACGTGAGAGCCCGAGA 1

RESULT 359
US-08-352-902D-104/c
; Sequence 104, Application US/08352902D
; Patent No. 6191288
; GENERAL INFORMATION:
; APPLICANT: Liskay, Robert M.
; Bronner, C. Eric
; Baker, Sean M.
; Bollag, Roni J.
; Kolodner, Richard D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS RELATING TO DNA
; CORRESPONDENCE ADDRESS:
; ADDRESSER: Kollisch, Hartwell, Dickinson, McCormack &
; Heuser
; STREET: 520 S.W. Yamhill Street, Suite 200
; CITY: Portland
; STATE: Oregon
; COUNTRY: U.S.A.
; ZIP: 97204
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/352,902D
; FILING DATE: 09-Dec-1994
; CLASSIFICATION: <Unknown>
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Rysselberghe, Pierre C.
; REGISTRATION NUMBER: 33,557
; REFERENCE/DOCKET NUMBER: OHSU 306B
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (503) 224-6655
; TELEFAX: (503) 295-6679
; INTRON DNA
; INFORMATION FOR SEQ ID NO: 104:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: /note= "primers directed to genomic
; intron DNA"
; SEQUENCE DESCRIPTION: SEQ ID NO: 104:
US-08-352-902D-104

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 941 AGAGGTGTGAGCCGAGA 957
D5 17 AGACGTGAGAGCCCGAGA 1

RESULT 360
US-08-983-466-93
; Sequence 93, Application US/08983466
; Patent No. 6207372
; GENERAL INFORMATION:
; APPLICANT: SHUBER, ANTHONY P.
```

```
; TITLE OF INVENTION: UNIVERSAL PRIMER SEQUENCE FOR MULTIPLEX
; TITLE OF INVENTION: DNA AMPLIFICATION
; NUMBER OF SEQUENCES: 95
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: RAE-VENTER LAW GROUP
; STREET: 260 Sheridan Ave., Ste. 440
; CITY: Palo Alto
; STATE: California
; COUNTRY: USA
; ZIP: 94306
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/983,466
; FILING DATE: 10-FEB-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/474,450
; FILING DATE: 07-JUNE-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: WO96/41012
; FILING DATE: 06-JUNE-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Rae-Venter, Barbara
; REGISTRATION NUMBER: 32,750
; REFERENCE/DOCKET NUMBER: GECO.001.01US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650) 328-4400
; TELEFAX: (650) 328-4477
; INFORMATION FOR SEQ ID NO: 93:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "WT-1 PRIMER SEQUENCE - N"
US-08-983-466-93

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 386 CAGAGTGGCAGCAATG 402
D5 1 CACAGCTGCCAGCAATG 17

RESULT 361
US-09-091-590A-26
; Sequence 26, Application US/09091590A
; Patent No. 6242574
; GENERAL INFORMATION:
; APPLICANT: Nielsen, Klaus
; APPLICANT: Kroll Kristensen, Anne
; APPLICANT: Brunstedt, Jame
; TITLE OF INVENTION: Anti-Microbial Proteins
; FILE REFERENCE: S-137-1101/NA/A/SGS/PCT
; CURRENT APPLICATION NUMBER: US/09/091,590A
; CURRENT FILING DATE: 1999-05-06
; PRIOR APPLICATION NUMBER: PCT/EP96/05765
; PRIOR FILING DATE: 1996-12-20
; PRIOR APPLICATION NUMBER: GB 9526238.2
; PRIOR FILING DATE: 1995-12-21
; NUMBER OF SEQ ID NOS: 35
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 26
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial/Unknown
```

```

; FEATURE:
; NAME/KEY: misc feature
; LOCATION: (1)..(17)
; OTHER INFORMATION: primer
; NAME/KEY: misc feature
; LOCATION: (1)..(17)
; OTHER INFORMATION: n = a, t, c, or g
US-09-091-590A-25

```

```

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 294 AATGTCGTCTGTGGGG 310
Db 1 AATGTCGTCTGTGGGG 17

```

```

RESULT 362
US-09-021-701-53/c
; Sequence 53, Application US/09021701
; Patent No. 6251588
; GENERAL INFORMATION:
; APPLICANT: Shannon, Karen W.
; APPLICANT: Wolber, Paul K.
; APPLICANT: Delenstarr, Glenda C.
; APPLICANT: Webb, Peter G.
; APPLICANT: Kincaid, Robert H.
; TITLE OF INVENTION: Methods for evaluating oligonucleotide
; NUMBER OF SEQUENCES: 1165
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard Company M/S 20
; STREET: 3000 Hanover Street
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/021,701
; FILING DATE: 10-FEB-1998
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Choi, Wendy A.
; REGISTRATION NUMBER: 36,697
; REFERENCE/DOCKET NUMBER: 10971464-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-236-2386
; TELEFAX: 650-852-8063
; INFORMATION FOR SEQ ID NO: 53:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-09-021-701-53

```

```

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 1249 GCCATGTGAGGCCAGGT 1265
Db 17 GCCCTGTGGGCAAGGT 1

```

```

RESULT 363
US-09-021-701-111
; Sequence 111, Application US/09021701
; Patent No. 6251588
; GENERAL INFORMATION:
; APPLICANT: Shannon, Karen W.
; APPLICANT: Wolber, Paul K.
; APPLICANT: Delenstarr, Glenda C.
; APPLICANT: Webb, Peter G.
; APPLICANT: Kincaid, Robert H.
; TITLE OF INVENTION: Methods for evaluating oligonucleotide
; NUMBER OF SEQUENCES: 1165
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Records Manager, Legal Department, Hewlett-Packard Company M/S 20
; STREET: 3000 Hanover Street
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/021,701
; FILING DATE: 10-FEB-1998
; CLASSIFICATION:
; ATTORNEY/AGENT INFORMATION:
; NAME: Choi, Wendy A.
; REGISTRATION NUMBER: 36,697
; REFERENCE/DOCKET NUMBER: 10971464-1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 650-236-2386
; TELEFAX: 650-852-8063
; INFORMATION FOR SEQ ID NO: 111:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; HYPOTHETICAL: NO
; ANTI-SENSE: NO
US-09-021-701-111

```

```

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

```

```

QY 296 TGTCTCTCTGTGGGGCT 312
Db 1 TGTCTCTCTGTGGGGAT 17

```

```

RESULT 364
US-09-338-907-84/c
; Sequence 84, Application US/09338907
; Patent No. 6265546
; GENERAL INFORMATION:
; APPLICANT: Cohen, Daniel
; APPLICANT: Blumenfeld, Marta
; APPLICANT: Ilya, Chumakov
; APPLICANT: Bougueleret, Lydie
; TITLE OF INVENTION: PROSTATE CANCER GENE
; FILE REFERENCE: GENSET.18C1CP
; CURRENT APPLICATION NUMBER: US/09/338,907
; CURRENT FILING DATE: 1999-06-23
; EARLIER APPLICATION NUMBER: 08/996,306
; EARLIER FILING DATE: 1997-12-22
; EARLIER APPLICATION NUMBER: 60/099,658

```



```
;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1922:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-1922

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 432 CACGTTCAAGAAGTTGC 448
Db 17 CACGTTCAAGTGGTGC 1

RESULT 368
US-08-584-040-2028
; Sequence 2028, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2224:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
```

```
;
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2028:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-584-040-2028

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 843 AGATGGGTGACATACC 859
Db 1 AGGUGGUCUCCAUACC 17

RESULT 369
US-08-584-040-2224/c
; Sequence 2224, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2224:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
```

;
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-2224

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 480 GGACTCCGAGCGTG 496
Db 17 GGACTCCGAGATG 1

RESULT 370

US-08-584-040-2554
; Sequence 2554, Application US/08584040
; Patent No. 6346398

; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 2554:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-2554

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 11.8%; Pred. No. 2.1e+02;
Matches 2; Conservative 12; Mismatches 3; Indels 0; Gaps 0;

Qy 1144 TTTTTCCTTTTGAA 1160
Db 1 UUUUUUUUUUUUCAA 17

RESULT 371

US-08-584-040-3739
; Sequence 3739, Application US/08584040
; Patent No. 6346398

; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 3739:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-3739

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.1e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1240 CTGACGTGCGCCGATG 1256
Db 1 CUGGCGGCGCCGUG 17

RESULT 372

US-08-584-040-3840
; Sequence 3840, Application US/08584040
; Patent No. 6346398

; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE

;; TITLE OF INVENTION: TREATMENT OF DISEASES OR
;; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
;; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
;; TITLE OF INVENTION: GROWTH FACTOR
;; NUMBER OF SEQUENCES: 8502
;; CORRESPONDENCE ADDRESSES:
;; ADDRESSEE: Lyon & Lyon
;; STREET: 633 West Fifth Street
;; CITY: Suite 4700
;; STATE: Los Angeles
;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/584,040
;; FILING DATE: January 11, 1996
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/005,974
;; FILING DATE: October 26, 1995
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 218/064
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 3840:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-584-040-3840

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.1e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1073 GGCAAGGCTTTCAGTGA 1089
||| | : : : :
Db 1 GGCAUGGUCUUCUGA 17

RESULT 373
US-08-584-040-3911
; Sequence 3911, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.

;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/584,040
;; FILING DATE: January 11, 1996
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/005,974
;; FILING DATE: October 26, 1995
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 218/064
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 3911:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-08-584-040-3911

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 23.5%; Pred. No. 2.1e+02;
Matches 4; Conservative 10; Mismatches 3; Indels 0; Gaps 0;

QY 1142 CTTTTCCTTTTCG 1158
||: : : :
Db 1 CCUUUGUCUUUG 17

RESULT 374
US-08-584-040-3912
; Sequence 3912, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/584,040
;; FILING DATE: January 11, 1996
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:

```
/ APPLICATION NUMBER: 60/005,974
/ FILING DATE: October 26, 1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard J.
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 218/064
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 3912:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 17 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-584-040-3912

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 29.4%; Pred. No. 2.1e+02;
Matches 5; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

QY 1146 TTTTCTTTTGAAGT 1162
Db 1 UUGUUGUUUGGAAGU 17

RESULT 375
US-08-584-040-5441
; Sequence 5441, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5441:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
/ US-08-584-040-5441

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 457 GTGGTCAGCAGCTGCA 473
Db 1 GGCAUGGUCUUCUGUGA 17

RESULT 376
US-08-584-040-5837/c
; Sequence 5837, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5837:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
/ US-08-584-040-5837

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 457 GTGGTCAGCAGCTGCA 473
Db 1 GGCAUGGUCUUCUGUGA 17
```

Db 17 GTAGTCAGAGCCCGCA 1

RESULT 377
US-08-584-040-5925/c
; Sequence 5925, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 5925:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-5925

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 881 AGTTCAGAGCTGCGG 897
Db 17 ATTTCAGAGTGGGG 1

RESULT 378
US-08-584-040-7260/c
; Sequence 7260, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 878 CCAAGTTCAGAGCTG 894
Db 17 CCAAGGTCAAGGTGCTG 1

RESULT 379
US-08-584-040-7406/c
; Sequence 7406, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 878 CCAAGTTCAGAGCTG 894
Db 17 CCAAGGTCAAGGTGCTG 1

RESULT 379
US-08-584-040-7406/c
; Sequence 7406, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California

;; COUNTRY: U.S.A.
;; ZIP: 90071-2066
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
;; MEDIUM TYPE: storage
;; COMPUTER: IBM Compatible
;; OPERATING SYSTEM: IBM P.C. DOS 5.0
;; SOFTWARE: Word Perfect 5.1
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/584,040
;; FILING DATE: January 11, 1996
;; CLASSIFICATION: 514
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/005,974
;; FILING DATE: October 26, 1995
;; NAME: Warburg, Richard J.
;; ATTORNEY/AGENT INFORMATION:
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 218/064
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 7406:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-584-040-7406

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1327 GTAGATCTGTGTTTCA 1343
Db 17 GTAGATCTGTGTTTCA 1

RESULT 380
US-08-584-040-7591
; Sequence 7591, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: 60/005,974
;; FILING DATE: October 26, 1995
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Warburg, Richard J.
;; REGISTRATION NUMBER: 32,327
;; REFERENCE/DOCKET NUMBER: 218/064
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 7591:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 17 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
US-08-584-040-7591

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.1e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 234 TCAGGCATCTGCATCTG 250
Db 1 UCAAGCCUCUGCAUUG 17

RESULT 381
US-08-584-040-7877
; Sequence 7877, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 7877:

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.1e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

QY 939 GAAGAGGTGTGAGCGCA 955
|||||:|||||
Db 1 GAAGAAGUUCGAGCGCA 17

RESULT 383
US-08-679-645-216
; Sequence 216, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; TITLE OF INVENTION: IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 216:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-679-645-216

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 221 GAGTCCTCAGCCTCAG 237
|||||:|||||
Db 1 GUGCUGCUCAGCCCGG 17

SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-7877

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 941 AGAGGTGTGAGCGCAGA 957
|||||:|||||
Db 1 AGAGGUAUCAGAGCAGA 17

RESULT 382
US-08-679-645-147
; Sequence 147, Application US/08679645
; Patent No. 6350934
; GENERAL INFORMATION:
; APPLICANT: Zwick, Michael G.
; APPLICANT: Edington, Brent E.
; APPLICANT: McSwiggen, James A.
; APPLICANT: Merlo, Patricia Ann Owens
; APPLICANT: Guo, Lining
; APPLICANT: Skokut, Thomas A.
; APPLICANT: Young, Scott A.
; APPLICANT: Folkerts, Otto
; APPLICANT: Merlo, Donald J.
; TITLE OF INVENTION: COMPOSITION AND METHODS FOR
; TITLE OF INVENTION: MODULATION OF GENE EXPRESSION
; TITLE OF INVENTION: IN PLANTS
; NUMBER OF SEQUENCES: 1263
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/679,645
; FILING DATE: July 12, 1996
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/001,135
; FILING DATE: July 13, 1995
; APPLICATION NUMBER: 08/300,726
; FILING DATE: September 2, 1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 147:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-679-645-147

; APPLICANT: Zinnen, Shawn
 ; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
 ; FILE REFERENCE: MBH00-831-B (247/276)
 ; CURRENT APPLICATION NUMBER: US/09/474,432B
 ; CURRENT FILING DATE: 1999-12-19
 ; PRIOR APPLICATION NUMBER: US 60/064,866
 ; PRIOR FILING DATE: 1997-11-05
 ; PRIOR APPLICATION NUMBER: US 60/084,727
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: US 09/186,675
 ; PRIOR FILING DATE: 1998-11-04
 ; PRIOR APPLICATION NUMBER: US 09/301,511
 ; PRIOR FILING DATE: 1999-04-28
 ; NUMBER OF SEQ ID NOS: 1526
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 355
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 ; ORGANISM: Homo sapiens
 US-09-474-432B-355

Query Match 0.9%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 82.4%; Pred. No. 2.1e+02;
 Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 719 CCACGACGACGGGGCC 735
 DB 17 CCACGACGACGGGGCC 1

RESULT 387
 US-09-474-432B-479
 ; Sequence 479, Application US/09474432B
 ; Patent No. 6528640
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Beigelman, Leo
 ; APPLICANT: Burgin, Alex
 ; APPLICANT: Beaudry, Amber
 ; APPLICANT: Karpeisky, Alex
 ; APPLICANT: Adamic, Jasenka
 ; APPLICANT: Sweedler, David
 ; APPLICANT: Zinnen, Shawn
 ; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
 ; FILE REFERENCE: MBH00-831-B (247/276)
 ; CURRENT APPLICATION NUMBER: US/09/474,432B
 ; CURRENT FILING DATE: 1999-12-19
 ; PRIOR APPLICATION NUMBER: US 60/064,866
 ; PRIOR FILING DATE: 1997-11-05
 ; PRIOR APPLICATION NUMBER: US 60/084,727
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: US 09/186,675
 ; PRIOR FILING DATE: 1998-11-04
 ; PRIOR APPLICATION NUMBER: US 09/301,511
 ; PRIOR FILING DATE: 1999-04-28
 ; NUMBER OF SEQ ID NOS: 1526
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 479
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 ; ORGANISM: Homo sapiens
 US-09-474-432B-479

Query Match 0.9%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 58.8%; Pred. No. 2.1e+02;
 Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 1240 CTGACGTCGCGCATGTG 1256
 DB 1 CUGGACGCGCGCAGUG 17

RESULT 388

US-09-474-432B-605
 ; Sequence 605, Application US/09474432B
 ; Patent No. 6528640
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Beigelman, Leo
 ; APPLICANT: Burgin, Alex
 ; APPLICANT: Beaudry, Amber
 ; APPLICANT: Karpeisky, Alex
 ; APPLICANT: Adamic, Jasenka
 ; APPLICANT: Sweedler, David
 ; APPLICANT: Zinnen, Shawn
 ; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
 ; FILE REFERENCE: MBH00-831-B (247/276)
 ; CURRENT APPLICATION NUMBER: US/09/474,432B
 ; CURRENT FILING DATE: 1999-12-19
 ; PRIOR APPLICATION NUMBER: US 60/064,866
 ; PRIOR FILING DATE: 1997-11-05
 ; PRIOR APPLICATION NUMBER: US 60/084,727
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: US 09/186,675
 ; PRIOR FILING DATE: 1998-11-04
 ; PRIOR APPLICATION NUMBER: US 09/301,511
 ; PRIOR FILING DATE: 1999-04-28
 ; NUMBER OF SEQ ID NOS: 1526
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 605
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 ; ORGANISM: Homo sapiens
 US-09-474-432B-605

Query Match 0.9%; Score 12.2; DB 1; Length 17;
 Best Local Similarity 70.6%; Pred. No. 2.1e+02;
 Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 523 CTGCGGAGGAGCAGCT 539
 DB 1 CUGGCGGAGGAGCAGCT 17

RESULT 389
 US-09-474-432B-727
 ; Sequence 727, Application US/09474432B
 ; Patent No. 6528640
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Beigelman, Leo
 ; APPLICANT: Burgin, Alex
 ; APPLICANT: Beaudry, Amber
 ; APPLICANT: Karpeisky, Alex
 ; APPLICANT: Adamic, Jasenka
 ; APPLICANT: Sweedler, David
 ; APPLICANT: Zinnen, Shawn
 ; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
 ; FILE REFERENCE: MBH00-831-B (247/276)
 ; CURRENT APPLICATION NUMBER: US/09/474,432B
 ; CURRENT FILING DATE: 1999-12-19
 ; PRIOR APPLICATION NUMBER: US 60/064,866
 ; PRIOR FILING DATE: 1997-11-05
 ; PRIOR APPLICATION NUMBER: US 60/084,727
 ; PRIOR FILING DATE: 1998-04-29
 ; PRIOR APPLICATION NUMBER: US 09/186,675
 ; PRIOR FILING DATE: 1998-11-04
 ; PRIOR APPLICATION NUMBER: US 09/301,511
 ; PRIOR FILING DATE: 1999-04-28
 ; NUMBER OF SEQ ID NOS: 1526
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 727
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 ; ORGANISM: Homo sapiens
 US-09-474-432B-727

```

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.1e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

Qy 1238 TCGTGGACGTGGCCATG 1254
      :||:||||:||||:|
Db 1 UGCGUGGUGGUCUUG 17

RESULT 390
US-09-474-432B-776
; Sequence 776, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29
; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 776
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-776

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

Qy 1018 AGATGGTGCCAAAGTGC 1034
      |||:||||:||||:|
Db 1 AGAUGGGGCGCAAGGUGC 17

RESULT 391
US-09-474-432B-831
; Sequence 831, Application US/09474432B
; Patent No. 6528640
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Beigelman, Leo
; APPLICANT: Burgin, Alex
; APPLICANT: Beaudry, Amber
; APPLICANT: Karpeisky, Alex
; APPLICANT: Adamic, Jasenka
; APPLICANT: Sweedler, David
; APPLICANT: Zinnen, Shawn
; TITLE OF INVENTION: Nucleotide triphosphate and their incorporation into oligonucleotides
; FILE REFERENCE: MBH00-831-B (247/276)
; CURRENT APPLICATION NUMBER: US/09/474,432B
; CURRENT FILING DATE: 1999-12-19
; PRIOR APPLICATION NUMBER: US 60/064,866
; PRIOR FILING DATE: 1997-11-05
; PRIOR APPLICATION NUMBER: US 60/084,727
; PRIOR FILING DATE: 1998-04-29

```

```

; PRIOR APPLICATION NUMBER: US 09/186,675
; PRIOR FILING DATE: 1998-11-04
; PRIOR APPLICATION NUMBER: US 09/301,511
; PRIOR FILING DATE: 1999-04-28
; NUMBER OF SEQ ID NOS: 1526
; SOFTWARE: Patent in version 3.0
; SEQ ID NO 831
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-474-432B-831

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 76.5%; Pred. No. 2.1e+02;
Matches 13; Conservative 1; Mismatches 3; Indels 0; Gaps 0;

Qy 894 GCGGTACAGCGTGGCCC 910
      |||:||||:||||:|
Db 1 GCGGUCACAGGAGGACC 17

RESULT 392
US-09-265-503B-104/c
; Sequence 104, Application US/09265503B
; Patent No. 6538108
; GENERAL INFORMATION:
; APPLICANT: Liskay, Robert M.
; APPLICANT: Bronner, C. Eric
; APPLICANT: Baker, Sean M.
; APPLICANT: Bollag, Roni J.
; APPLICANT: Kolodner, Richard D.
; TITLE OF INVENTION: COMPOSITIONS AND METHODS
; TITLE OF INVENTION: RELATING TO DNA MISMATCH REPAIR GENES
; NUMBER OF SEQUENCES: 148
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Kolisch, Hartwell, Dickinson, McCormack & Heuser
; STREET: 520 S.W. Yamhill Street, Suite 200
; CITY: Portland
; STATE: Oregon
; COUNTRY: U.S.A.
; ZIP: 97204
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/265,503B
; FILING DATE: March 10, 1999
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Van Rysselberghe, Pierre C.
; REGISTRATION NUMBER: 33,557
; REFERENCE/DOCKET NUMBER: OHSU 306D
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (503) 224-6655
; TELEFAX: (503) 295-6679
; TELEX: 360619
; INFORMATION FOR SEQ ID NO: 104:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: misc_feature
; LOCATION: 1
; OTHER INFORMATION: /note= "primers directed to genomic
; OTHER INFORMATION: intron DNA"
; US-09-265-503B-104

Query Match          0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;

```

Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 941 AGAGGTGTGAGCCGAGA 957
||| ||| ||| ||| ||| ||| |||
Db 17 AGACGTGAGAGCCGAGA 1

RESULT 393

US-09-371-772B-454
; Sequence 454, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 454
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-454

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 58.8%; Pred. No. 2.1e+02;
Matches 10; Conservative 4; Mismatches 3; Indels 0; Gaps 0;

QY 234 TCAGGCATCTGCTCTG 250
:|| ||| ||| ||| ||| ||| |||
Db 1 UCAAGCAUCAUCAUUG 17

RESULT 394

US-09-371-772B-467/c
; Sequence 467, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 467
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-467

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 432 CACGTTCAAGATTGC 448
||| ||| ||| ||| ||| ||| |||
Db 17 CACGTTCAAGATTGGTC 1

RESULT 395

US-09-371-772B-573
; Sequence 573, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions F
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 573
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-573

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

QY 843 AGATGGGTCTCAGCATACC 859
||| ||| ||| ||| ||| ||| |||
Db 1 AGGUGGUCUCCAUACC 17

RESULT 396

US-09-371-772B-769/c
; Sequence 769, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions I
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 769
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-769

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 480 GGACTGCCGAGACGGTG 496
|||
Db 17 GGACTCCCGAGATGTTG 1

RESULT 397
 US-09-371-772B-1078
 ; Sequence 1078, Application US/09371772B
 ; Patent No. 6566127
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MEBH00.876-J (237/198)
 ; CURRENT APPLICATION NUMBER: US/09/371,772B
 ; CURRENT FILING DATE: 1999-08-10
 ; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 1078
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 ; US-09-371-772B-1078

RESULT 398

US-09-371-772B-1506

Sequence 1506, Application US/09371772B

Patent No. 6566127

GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.

APPLICANT: Pavco, Pam

APPLICANT: McSwiggen, Jim

APPLICANT: Stinchcomb, Dan

APPLICANT: Escobedo, Jaime

TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Regulation of Endothelial Growth Factor Receptor

TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor

FILE REFERENCE: MEHB00.876-J (237/198)

CURRENT APPLICATION NUMBER: US/09/371.772B

CURRENT FILING DATE: 1999-08-10

PRIOR APPLICATION NUMBER: US 60/005,974

PRIOR FILING DATE: 1995-10-26

PRIOR APPLICATION NUMBER: US 08/584,040

PRIOR FILING DATE: 1996-01-08

NUMBER OF SEQ ID NOS: 14225

SOFTWARE: PatentIn version 3.0

SEQ ID NO 1506

LENGTH: 17

TYPE: RNA

ORGANISM: Homo sapiens

US-09-371-772B-1506

```

|:||:||:||:||:||
Db      1  CUGCCGCGCCCTGUG  17

RESULT 399
US-09-371-772B-1607
; Sequence 1607, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions F
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371.772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1607
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1607

```

RESULT 400
 US-09-371-772B-1678
 ; Sequence 1678, Application US/09371772B
 ; Patent No. 6566127
 ; GENERAL INFORMATION:
 ; APPLICANT: Ribozyme Pharmaceuticals, Inc.
 ; APPLICANT: Pavco, Pam
 ; APPLICANT: McSwiggen, Jim
 ; APPLICANT: Stinchcomb, Dan
 ; APPLICANT: Escobedo, Jaime
 ; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions R
 ; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
 ; FILE REFERENCE: MBH00,876-J (237/198)
 ; CURRENT APPLICATION NUMBER: US/09/371,772B
 ; CURRENT FILING DATE: 1999-08-10
 ; PRIOR APPLICATION NUMBER: US 60/005,974
 ; PRIOR FILING DATE: 1995-10-26
 ; PRIOR APPLICATION NUMBER: US 08/584,040
 ; PRIOR FILING DATE: 1996-01-08
 ; NUMBER OF SEQ ID NOS: 14225
 ; SOFTWARE: PatentIn version 3.0
 ; SEQ ID NO 1678
 ; LENGTH: 17
 ; TYPE: RNA
 ; ORGANISM: Homo sapiens
 US-09-371-772B-1678

```

Query Match      0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 23.5%; Pred. No. 2.1e+03;
Matches 4; Conservative 10; Mismatches 3; Indels 0; Gaps 0;

Qy      1142  CCTTTTTCCTTTTGG 1158
          ||:::: :: ::::||

```


RESULT 405

US-09-371-772B-3213/c
; Sequence 3213, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3213
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3213

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1327 GTAGATCTTGTGTTTCA 1343
Db 17 GTAGATCTGAGTTTCA 1

RESULT 406

US-09-371-772B-3387
; Sequence 3387, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3387
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3387

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 52.9%; Pred. No. 2.1e+02;
Matches 9; Conservative 5; Mismatches 3; Indels 0; Gaps 0;

QY 234 TCAGGCATCTGCATCTG 250
Db 1 UCAAGCCUCUGCAUTUG 17

RESULT 407

US-09-371-772B-3660
; Sequence 3660, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions F
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 3660
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-3660

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 941 AGAGGTGTGAGCGCAGA 957
Db 1 AGAGGUACAGAGCAGA 17

RESULT 408

US-09-371-772B-4161
; Sequence 4161, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions F
; FILE REFERENCE: MBH00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4161
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Mus sp.
US-09-371-772B-4161

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 70.6%; Pred. No. 2.1e+02;
Matches 12; Conservative 2; Mismatches 3; Indels 0; Gaps 0;

QY 143 CGCTCGGCTCCGCTCCG 159
Db 1 CUCUGGCGCUCUCCCCG 17

RESULT 409

US-09-371-772B-4457/c
; Sequence 4457, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4457
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4457

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1327 GTAGATCTTGTTGTTCA 1343
||| ||||| ||||| |||||
Db 17 GTAAATCTGGGGTTTCA 1

RESULT 410
US-09-371-772B-4643/c
; Sequence 4643, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4643
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4643

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 1079 CTCCTCAGTGAGTGTTT 1095
||||| ||||| ||||| |||||
Db 17 CTCCTCTGTGACTCTTT 1

RESULT 411
US-09-371-772B-4722

; Sequence 4722, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4722
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-4722

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 64.7%; Pred. No. 2.1e+02;
Matches 11; Conservative 3; Mismatches 3; Indels 0; Gaps 0;

Qy 235 CAGGCATCTGCATCTGG 251
||| ||||| ||||| |||||
Db 1 CAAGCAUCAGCAUUGG 17

RESULT 412
US-09-371-772B-5116/c
; Sequence 5116, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; PRIOR FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5116
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5116

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 956 GACTGCAGGACTGACCC 972
||||| ||||| ||||| |||||
Db 17 GGCTGCAGGCTGGCCC 1

RESULT 413
US-09-371-772B-5579/c
; Sequence 5579, Application US/09371772B

; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 5579
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-5579

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1146 TTTTCTTTTGGAGT 1162
|||
Db 17 TTTTCTTTTGAAT 1

RESULT 414
US-09-371-772B-6296
; Sequence 6296, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Re
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6296
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6296

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 29.4%; Pred. No. 2.1e+02;
Matches 5; Conservative 9; Mismatches 3; Indels 0; Gaps 0;

QY 1145 TTTTCTTTTGGAG 1161
::: :
Db 1 UUUUGUUCUUUGAAG 17

RESULT 415
US-09-371-772B-6439/c
; Sequence 6439, Application US/09371772B
; Patent No. 6566127

; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions F
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6439
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6439

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 299 CTGCTCGGGGCTGCA 315
|||
Db 17 CTGCTCAGTGGGCTGCA 1

RESULT 416
US-09-371-772B-6624/c
; Sequence 6624, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions F
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 6624
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-6624

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 742 CCGCATGTTGCTGACTT 758
|||
Db 17 CTGCAAGTTGCTGCTT 1

RESULT 417
US-09-371-772B-6701/c
; Sequence 6701, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:

APPLICANT: Ribozyme Pharmaceuticals, Inc.
APPLICANT: Pavco, Pam
APPLICANT: McSwiggen, Jim
APPLICANT: Stinchcomb, Dan
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions Related to the Growth of Vascular Endothelial Growth Factor Receptor
FILE REFERENCE: MEHB00, 876-J (237/198)
CURRENT APPLICATION NUMBER: US/09/371,772B
CURRENT FILING DATE: 1999-08-10
PRIOR APPLICATION NUMBER: US 60/005,974
PRIOR FILING DATE: 1995-10-26
PRIOR APPLICATION NUMBER: US 08/584,040
PRIOR FILING DATE: 1996-01-08
NUMBER OF SEQ ID NOS: 14225
SOFTWARE: PatentIn version 3.0
SEQ ID NO 6701
LENGTH: 17
TYPE: RNA
ORGANISM: Homo sapiens
US-09-371-772B-6701

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 260 TCGTGGGCTGGCTGATC 276
||| |||||
Db 17 TCCAGAGCTGGCTGAGC 1

RESULT 418
PCT-US95-06266-87
Sequence 87, Application PC/TUS9506266
GENERAL INFORMATION:
APPLICANT:
TITLE OF INVENTION: Detection of Viral Antigens Coded by Reverse Reading Frames
NUMBER OF SEQUENCES: 157
CORRESPONDENCE ADDRESS:
ADDRESSEE: Dehlinger & Associates
STREET: 350 Cambridge Avenue, Suite 250
CITY: Palo Alto
STATE: CA
COUNTRY: USA
ZIP: 94306
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/06266
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/246,985
FILING DATE: 20-MAY-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/285,561
FILING DATE: 03-AUG-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/329,729
FILING DATE: 26-OCT-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/344,271
FILING DATE: 23-NOV-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/357,509
FILING DATE: 16-DEC-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/389,886
FILING DATE: 15-FEB-1995

ATTORNEY/AGENT INFORMATION:
NAME: Fabian, Gary R.
REGISTRATION NUMBER: 33,875
REFERENCE/DOCKET NUMBER: 4600-0202.41
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 324-0880
TELEFAX: (415) 324-0960
INFORMATION FOR SEQ ID NO: 87:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: linear
MOLECULE TYPE: cDNA to mRNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
INDIVIDUAL ISOLATE: Primer FGEX-R
PCT-US95-06266-87

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 625 GACCAGCTCCAGGAGCT 641
||| |||||
Db 1 GACCGTCTCCGGAGCT 17

RESULT 419
PCT-US96-09641-17
Sequence 17, Application PC/TUS9609641
GENERAL INFORMATION:
APPLICANT: Slater, Michael R.
APPLICANT: Huang, Fen
APPLICANT: Hartnett, James R.
APPLICANT: Bolchakova, Elena
APPLICANT: Stotts, Douglas R.
APPLICANT: Otto, Paul
TITLE OF INVENTION: THERMOPHILIC DNA POLYMERASES FROM THERMOTOGA NEAPOLITANA
NUMBER OF SEQUENCES: 57
CORRESPONDENCE ADDRESS:
ADDRESSEE: Medlen & Carroll
STREET: 220 Montgomery Street, Suite 2200
CITY: San Francisco
STATE: California
COUNTRY: United States Of America
ZIP: 94104
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US96/09641
FILING DATE: 31-MAY-1996
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: Ingolia, Diane E.
REGISTRATION NUMBER: 40,027
REFERENCE/DOCKET NUMBER: PRMG-02185
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 705-8410
TELEFAX: (415) 397-8338
INFORMATION FOR SEQ ID NO: 17:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US96-09641-17

Query Match 0.9%; Score 12.2; DB 1; Length 17;
Best Local Similarity 82.4%; Pred. No. 2.1e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1199 GACCTTCACACCTCCCC 1215
|||||
DB 1 GACCTTGACAGCTCCTC 17

RESULT 420
US-08-584-040-3044/c
; Sequence 3044, Application US/08584040
; Patent No. 6346398
; GENERAL INFORMATION:
; APPLICANT: Pavco, Pamela
; APPLICANT: McSwiggen, James
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: TREATMENT OF DISEASES OR
; TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
; TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
; TITLE OF INVENTION: GROWTH FACTOR
; NUMBER OF SEQUENCES: 8502
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/584,040
; FILING DATE: January 11, 1996
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/005,974
; FILING DATE: October 26, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/064
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 3044:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-584-040-3044

Query Match 0.9%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1027 CAAAGTGCAGCTGACTC 1043
|||||
DB 18 CAAAAGCAGCTGGCTC 2

RESULT 421
US-09-371-772B-1472/c

; Sequence 1472, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions F
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 1472
; LENGTH: 18
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-1472

Query Match 0.9%; Score 12.2; DB 1; Length 18;
Best Local Similarity 82.4%; Pred. No. 2.4e+02;
Matches 14; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

QY 1027 CAAAGTGCAGCTGACTC 1043
|||||
DB 18 CAAAAGCAGCTGGCTC 2

RESULT 422
US-08-214-603-11/c
; Sequence 11, Application US/08214603
; Patent No. 5596091
; GENERAL INFORMATION:
; APPLICANT: SWITZER, Christopher
; TITLE OF INVENTION: NOVEL ANTISENSE OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Townsend and Townsend Kourie and Crew
; STREET: Steuart Street Tower, One Market Plaza
; CITY: San Francisco
; STATE: California
; COUNTRY: US
; ZIP: 94105-1493
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/214,603
; FILING DATE: 18-MAR-1994
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Kezer, William B.
; REGISTRATION NUMBER: 37,369
; REFERENCE/DOCKET NUMBER: 2307E-0521000S
; TELEPHONE: (415) 543-9600
; TELEFAX: (415) 543-5043
; INFORMATION FOR SEQ ID NO: 11:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 12 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "Oligodeoxynucleotide"

us0904568-3.rni

Thu Jan 8 16:51:56 2004

US-08-214-603-11

Query Match 0.9%; Score 12; DB 1; Length 12;
Best Local Similarity 100.0%; Pred. No. 1e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1144 TTTTTCCTTT 1155
Db 12 TTTTTCCTTT 1

RESULT 423
US-08-242-664-14/c
; Sequence 14, Application US/08242664
; Patent No. 5571937
; GENERAL INFORMATION:
; APPLICANT: Watanabe, Kyoichi A.
; APPLICANT: Ren, Wu-Yun
; APPLICANT: Wei, Roger
; TITLE OF INVENTION: Complementary DNA and Toxins
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham
; STREET: 30 Rockefeller Plaza
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10112

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44Mb
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/242,664
FILING DATE: May 12, 1994
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44683
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-977-9550
TELEFAX: 212-664-0525
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-242-664-14

Query Match 0.9%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1145 TTTTTCCTTT 1156
Db 13 TTTTTCCTTT 2

RESULT 424
US-08-484-138-14/c
; Sequence 14, Application US/08484138
; Patent No. 5652350
; GENERAL INFORMATION:
; APPLICANT: Watanabe, Kyoichi A.
; APPLICANT: Ren, Wu-Yun
; APPLICANT: Wei, Roger
; TITLE OF INVENTION: Complementary DNA and Toxins
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:

ADDRESSEE: Cooper & Dunham LLP
STREET: 1185 Avenue of the Americas
CITY: New York
STATE: New York
COUNTRY: U.S.A.
ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44Mb
COMPUTER: IBM PC
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/484,138
FILING DATE: June 7, 1995
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44683-Z/JPW/MJG
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-977-9550
TELEFAX: 212-664-0525
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-484-138-14

Query Match 0.9%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1145 TTTTTCCTTT 1156
Db 13 TTTTTCCTTT 2

RESULT 425
PCT-US95-06379-14/c
; Sequence 14, Application PC/TUS9506379
; GENERAL INFORMATION:
; APPLICANT: Watanabe, Kyoichi A.
; APPLICANT: Ren, Wu-Yun
; APPLICANT: Wei, Roger
; TITLE OF INVENTION: Complementary DNA and Toxins
; NUMBER OF SEQUENCES: 43
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Cooper & Dunham LLP
; STREET: 1185 Avenue of the Americas
; CITY: New York
; STATE: New York
; COUNTRY: U.S.A.
; ZIP: 10036
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5 inch 1.44Mb
COMPUTER: IBM PC
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.24
CURRENT APPLICATION DATA:
APPLICATION NUMBER: PCT/US95/06379
FILING DATE: May 13, 1994
CLASSIFICATION:
ATTORNEY/AGENT INFORMATION:
NAME: White, John P.
REGISTRATION NUMBER: 28,678
REFERENCE/DOCKET NUMBER: 44683-PCT
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-278-0400
TELEFAX: 212-391-0526
INFORMATION FOR SEQ ID NO: 14:

SEQUENCE CHARACTERISTICS:
LENGTH: 13 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
PCT-US95-06379-14

Query Match 0.9%; Score 12; DB 1; Length 13;
Best Local Similarity 100.0%; Pred. No. 1.2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTT 1156
DB 13 TTTTTCCTTTT 2

RESULT 426
US-08-146-010A-8
; Sequence 8, Application US/08146010A
; Patent No. 5591577
; GENERAL INFORMATION:
; APPLICANT: TSUCHIYA, MAKOTO
; APPLICANT: MORIYA, MIKO
; APPLICANT: MIWA, KIYOSHI
; TITLE OF INVENTION: MOBILE GENETIC ELEMENT ORIGINATED FROM
; TITLE OF INVENTION: BREVI BACTERIUM STRAIN
; NUMBER OF SEQUENCES: 9
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT
; STREET: 1755 S. JEFFERSON DAVIS HIGHWAY, FOURTH FLOOR
; CITY: ARLINGTON
; STATE: VIRGINIA
; COUNTRY: USA
; ZIP: 22202

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/146.010A
FILING DATE: 12-NOV-1993
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 52694/92
FILING DATE: 11-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NORMAN F
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 10-649-0
TELEPHONE: (703) 413-3000
TELEFAX: (703) 413-2220
TELEX: 248855 OPAT UR
INFORMATION FOR SEQ ID NO: 8:

SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
ORIGINAL SOURCE:
ORGANISM: Brevibacterium lactofermentum
STRAIN: AJ2256
US-08-146-010A-8

Query Match 0.9%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 963 GGACTGACCCCT 974
DB 13 TTTTTCCTTTT 2

Db 2 GGACTGACCCCT 13

RESULT 427

US-08-683-839B-15/c
; Sequence 15, Application US/08683839B
; Patent No. 5744326
; GENERAL INFORMATION:
; APPLICANT: ILL, Charles . R. et al.
; TITLE OF INVENTION: Use of Viral Cis-Acting Post-Transcriptional
; TITLE OF INVENTION: Regulatory Sequences To Increase Expression of
; TITLE OF INVENTION: Intronless Genes Containing Near-Consensus Splice Sites
; NUMBER OF SEQUENCES: 18
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: LAHIVE & COCKFIELD
; STREET: 60 State Street, suite 510
; CITY: Boston
; STATE: Massachusetts
; COUNTRY: USA
; ZIP: 02109-1875

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/683,839B
FILING DATE: 11-MARCH-1996
CLASSIFICATION: 435

PRIOR APPLICATION DATA:
APPLICATION NUMBER:
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Remillard, Jane E.
REGISTRATION NUMBER: 38,872
REFERENCE/DOCKET NUMBER: TII-138
TELECOMMUNICATION INFORMATION:
TELEPHONE: (617)227-7400
TELEFAX: (617)227-5941
INFORMATION FOR SEQ ID NO: 15:

SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-683-839B-15

Query Match 0.9%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1125 TGAAGAGAGAG 1136
DB 12 TGAAGAGAGAG 1

RESULT 428

US-08-674-168-10
; Sequence 10, Application US/08674168
; Patent No. 5804414
; GENERAL INFORMATION:
; APPLICANT: MORIYA, Mika
; APPLICANT: MATSUI, Hiroshi
; APPLICANT: YOKOZEKI, Kenzo
; APPLICANT: HIRANO, Seiko
; APPLICANT: HAYAKAWA, Atsushi
; APPLICANT: IZUI, Masako
; APPLICANT: SUGIMOTO, Masakazu
; TITLE OF INVENTION: METHOD OF AMPLIFYING GENE USING
; TITLE OF INVENTION: ARTIFICIAL TRANSPOSON
; NUMBER OF SEQUENCES: 32
; CORRESPONDENCE ADDRESS:

ADDRESSEE: OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT,
ADDRESS: P.C.
STREET: 1755 JEFFERSON DAVIS HIGHWAY, SUITE # 400
CITY: ARLINGTON
STATE: VIRGINIA
COUNTRY: USA
ZIP: 22202
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/674,168
FILING DATE: 01-JUL-1996
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP 7-166541
FILING DATE: 30-JUN-1995
ATTORNEY/AGENT INFORMATION:
NAME: OBLON, NORMAN F.
REGISTRATION NUMBER: 24,618
REFERENCE/DOCKET NUMBER: 10-810-0
TELEPHONE: (703) 413-3000
TELEFAX: (703) 413-2220
TELEX: 248855 OPAT UR
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Brevibacterium lactofermentum
STRAIN: AJ12036
US-08-674-168-10

Query Match 0.9%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 963 GGACTGACCCCT 974
|||||
Db 2 GGACTGACCCCT 13

RESULT 429
US-08-846-021A-14
Sequence 14, Application US/08846021A
Patent No. 5948682
GENERAL INFORMATION:
APPLICANT: Moloney, Maurice M.
TITLE OF INVENTION: Preparation of Heterologous Proteins on
TITLE OF INVENTION: Oil Bodies
NUMBER OF SEQUENCES: 31
CORRESPONDENCE ADDRESS:
ADDRESSEE: BERESKIN & PARR
STREET: 40 King Street West
CITY: Toronto
STATE: Ontario
COUNTRY: Canada
ZIP: M5H 3Y2
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/846,021A

FILING DATE: April 25, 1997
CLASSIFICATION: 800
ATTORNEY/AGENT INFORMATION:
NAME: Gravelle, Micheline
REGISTRATION NUMBER: 40,261
REFERENCE/DOCKET NUMBER: 9369-039
TELECOMMUNICATION INFORMATION:
TELEPHONE: (416) 364-7311
TELEFAX: (416) 361-1398
INFORMATION FOR SEQ ID NO: 14:
SEQUENCE CHARACTERISTICS:
LENGTH: 14 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-846-021A-14

Query Match 0.9%; Score 12; DB 1; Length 14;
Best Local Similarity 100.0%; Pred. No. 1.5e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 393 GGCAGCAATGCG 404
|||||
Db 2 GGCAGCAATGCG 13

RESULT 430
US-08-365-189-10
Sequence 10, Application US/08365189
Patent No. 5514576
GENERAL INFORMATION:
APPLICANT: Bower, Patricia A.
TITLE OF INVENTION: Cloned Pullulanase
NUMBER OF SEQUENCES: 14
CORRESPONDENCE ADDRESS:
ADDRESSEE: Quarles & Brady
STREET: 411 East Wisconsin Avenue
CITY: Milwaukee
STATE: Wisconsin
COUNTRY: U.S.A.
ZIP: 53202-4497
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/365,189
FILING DATE:

CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/132,648
FILING DATE: October 5, 1993
ATTORNEY/AGENT INFORMATION:
NAME: Ryser, David G.
REGISTRATION NUMBER: 36,407
REFERENCE/DOCKET NUMBER: 66-005-9367-4
TELECOMMUNICATION INFORMATION:
TELEPHONE: (414) 277-5717
TELEFAX: (414) 271-3552
INFORMATION FOR SEQ ID NO: 10:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
FEATURE:
NAME/KEY: CDS
LOCATION: 1..15
US-08-365-189-10

```
Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      831 GCTGAAGCTTTC 842
DB      4 GCTGAAGCTTTC 15

RESULT 431
US-08-208-886C-29/c
; Sequence 29, Application US/08208886C
; Patent No. 5597710
; GENERAL INFORMATION:
; APPLICANT: Dalié, Barbara
; APPLICANT: Miller, Kenneth
; APPLICANT: Murgolo, Nicholas
; APPLICANT: Tindall, Stephen
; TITLE OF INVENTION: Humanized Monoclonal Antibodies Against Human Interleukin-4
; NUMBER OF SEQUENCES: 88
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Schering-Plough Corporation
; STREET: 2000 Galloping Hill Road
; CITY: Kenilworth
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07033-0530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Apple Macintosh
; OPERATING SYSTEM: Macintosh 7.1
; SOFTWARE: Microsoft Word 5.1a
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/208,886C
; FILING DATE: March 10, 1994
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Foulke, Cynthia L.
; REGISTRATION NUMBER: 32,364
; REFERENCE/DOCKET NUMBER: JB0429
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 908 298 2987
; TELEFAX: 908 298 5388
; INFORMATION FOR SEQ ID NO: 29:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-208-886C-29

Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      463 AGCAGCCTGCAG 474
DB      15 AGCAGCCTGCAG 4

RESULT 432
US-08-704-744-29/c
; Sequence 29, Application US/08704744
; Patent No. 5705154
; GENERAL INFORMATION:
; APPLICANT: Dalié, Barbara
; APPLICANT: Miller, Kenneth
; APPLICANT: Murgolo, Nicholas
; APPLICANT: Tindall, Stephen
; TITLE OF INVENTION: Humanized Monoclonal Antibodies Against Human Interleukin-4

Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY      463 AGCAGCCTGCAG 474
DB      15 AGCAGCCTGCAG 4

RESULT 433
US-08-469-557-29/c
; Sequence 29, Application US/08469557
; Patent No. 5770403
; GENERAL INFORMATION:
; APPLICANT: Dalié, Barbara
; APPLICANT: Le, Hung
; APPLICANT: Miller, Kenneth
; APPLICANT: Murgolo, Nicholas
; APPLICANT: Nguyen, Hanh
; APPLICANT: Tindall, Stephen
; APPLICANT: Zavodny, Paul
; TITLE OF INVENTION: Cloning and Expression of
; TITLE OF INVENTION: Humanized Monoclonal Antibodies
; TITLE OF INVENTION: Against Human Interleukin-4
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Schering-Plough Corporation
; STREET: 2000 Galloping Hill Road
; CITY: Kenilworth
; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07033-0530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: Apple Macintosh
```

```

; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: Microsoft Word 5.1A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/469,557
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 424
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/290,793
; FILING DATE: August 16, 1994
; APPLICATION NUMBER: PCT/US93/01301
; FILING DATE: 19-FEB-1992
; APPLICATION NUMBER: US 07/841,659
; FILING DATE: 19-FEB-1992
; APPLICATION NUMBER: US 07/782,784
; FILING DATE: 24-OCT-1991
; APPLICATION NUMBER: US 07/499,327
; FILING DATE: 21-MAY-1990
; APPLICATION NUMBER: PCT/US88/03631
; FILING DATE: 21-OCT-1988
; APPLICATION NUMBER: US 07/655,966
; FILING DATE: 14-FEB-1991
; APPLICATION NUMBER: US 07/113,623
; FILING DATE: 26-OCT-1987
; APPLICATION NUMBER: US 06/881,553
; FILING DATE: 03-JUL-1986
; APPLICATION NUMBER: US 06/843,958
; FILING DATE: 25-MAR-1986
; APPLICATION NUMBER: US 06/799,668
; FILING DATE: 19-NOV-1985
; ATTORNEY/AGENT INFORMATION:
; NAME: Foulke, Cynthia L.
; REGISTRATION NUMBER: 32,364
; REFERENCE/DOCKET NUMBER: 2409K7
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 908 298-2987
; TELEFAX: 908-298-5388
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-469-557-29

```

```

Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 463 AGCAGCCTGCAG 474
Db 15 AGCAGCCTGCAG 4

```

```

RESULT 434
US-08-290-793B-29/c
; Sequence 29, Application US/08290793B
; Patent No. 5863537
; GENERAL INFORMATION:
; APPLICANT: Dalie, Barbara
; APPLICANT: Le, Hung
; APPLICANT: Miller, Kenneth
; APPLICANT: Murgolo, Nicholas
; APPLICANT: Nguyen, Hanh
; APPLICANT: Tindall, Stephen
; APPLICANT: Zavodny, Paul
; TITLE OF INVENTION: Cloning and Expression of
; TITLE OF INVENTION: Humanized Monoclonal Antibodies
; TITLE OF INVENTION: Against Human Interleukin-4
; NUMBER OF SEQUENCES: 69
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Schering-Plough Corporation
; STREET: 2000 Galloping Hill Road
; CITY: Kenilworth

```

```

; STATE: New Jersey
; COUNTRY: USA
; ZIP: 07033-0530
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; OPERATING SYSTEM: Macintosh 6.0.5
; SOFTWARE: Microsoft Word 5.1A
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/290,793B
; FILING DATE: August 16, 1994
; APPLICATION NUMBER: PCT/US93/01301
; FILING DATE: 19-FEB-1992
; APPLICATION NUMBER: US 07/841,659
; FILING DATE: 19-FEB-1992
; APPLICATION NUMBER: US 07/782,784
; FILING DATE: 24-OCT-1991
; APPLICATION NUMBER: US 07/499,327
; FILING DATE: 21-MAY-1990
; APPLICATION NUMBER: PCT/US88/03631
; FILING DATE: 21-OCT-1988
; APPLICATION NUMBER: US 07/655,966
; FILING DATE: 14-FEB-1991
; APPLICATION NUMBER: US 07/113,623
; FILING DATE: 26-OCT-1987
; APPLICATION NUMBER: US 06/881,553
; FILING DATE: 03-JUL-1986
; APPLICATION NUMBER: US 06/843,958
; FILING DATE: 25-MAR-1986
; APPLICATION NUMBER: US 06/799,668
; FILING DATE: 19-NOV-1985
; ATTORNEY/AGENT INFORMATION:
; NAME: Foulke, Cynthia L.
; REGISTRATION NUMBER: 32,364
; REFERENCE/DOCKET NUMBER: 2409K7
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 908 298-2987
; TELEFAX: 908-298-5388
; INFORMATION FOR SEQ ID NO: 29:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-290-793B-29

```

```

Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```

```

Qy 463 AGCAGCCTGCAG 474
Db 15 AGCAGCCTGCAG 4

```

```

RESULT 435
US-08-606-505B-62
; Sequence 62, Application US/08606505B
; Patent No. 6114601
; GENERAL INFORMATION:
; APPLICANT: KIKUCHI, Yasuhiro
; APPLICANT: KIYOKAWA, Shigeto
; APPLICANT: SHIMADA, Yukinisa
; APPLICANT: OHBAYASHI, Masaya
; APPLICANT: SHIMADA, Ritsuko
; APPLICANT: OKINAKA, Yasushi
; TITLE OF INVENTION: NOVEL PLANT GENES
; NUMBER OF SEQUENCES: 67
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FITZPATRICK, CELLA, HARPER & SCINTO
; STREET: 30 Rockefeller Plaza
; CITY: New York

```

STATE: New York
COUNTRY: U.S.A.
ZIP: 10112-3801
COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette - 3.50 inch, 720 Kb storage.
COMPUTER: IBM PS/IV
OPERATING SYSTEM: MS-DOS Ver3.30
SOFTWARE: PATENT AID Ver1.0
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/606,505B
FILING DATE: 23-MAR-1996

PRIOR APPLICATION DATA:
APPLICATION NUMBER: JP44963/92
FILING DATE: 02-MAR-1992
ATTORNEY/AGENT INFORMATION:
NAME: Perry, Lawrence S.
REGISTRATION NUMBER: 31865
TELECOMMUNICATION INFORMATION:
TELEPHONE: 212-218-2100
TELEFAX: 212-218-2200

INFORMATION FOR SEQ ID NO: 62 :
LENGTH: 15 base pairs
TYPE: nucleic acid
TOPOLOGY: linear
STRANDEDNESS: single
MOLECULE TYPE: Other nucleic acid
DESCRIPTION: Synthetic DNA

US-08-606-505B-62

Query Match 0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1233 TTGGTGTCTGGA 1244

Db 4 TTGGTGTCTGGA 15

RESULT 436

US-09-115-446-3
Sequence 3, Application US/09115446
Patent No. 6165719

GENERAL INFORMATION:
APPLICANT: Chandy, George K.

APPLICANT: Gargus, Jay J.

APPLICANT: Gutman, George

APPLICANT: Fantino, Emmanuelle

APPLICANT: Kalman, Katarin

TITLE OF INVENTION: hKCA3/KCNN3 SMALL CONDUCTANCE CALCIUM
TITLE OF INVENTION: ACTIVATED POTASSIUM CHANNEL: A DIAGNOSTIC

FILE REFERENCE: 07306/014001

CURRENT APPLICATION NUMBER: US/09/115,446

EARLIER FILING DATE: 1998-07-14

EARLIER APPLICATION NUMBER: 60/052,556

EARLIER FILING DATE: 1997-07-15

EARLIER APPLICATION NUMBER: 60/070,741

NUMBER OF SEQ ID NOS: 15

SOFTWARE: FastSEQ for Windows Version 4.0

SEQ ID NO 3

LENGTH: 15

TYPE: DNA

ORGANISM: Homo sapiens

US-09-115-446-3

Query Match 0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTT 1156

TTTTTCTTTT

Db 1 TTTTTCCTTTT 12

RESULT 437

US-09-177-359-26/c

Sequence 26, Application US/09177359B

Patent No. 6183963

GENERAL INFORMATION:

APPLICANT: SINNETT, Daniel

APPLICANT: LABUDA, Damian

TITLE OF INVENTION: DETECTION OF CYP1A1, CYP3A4, CYP2D6 AND

TITLE OF INVENTION: NAT2 VARIANTS BY PCR-ALLELE-SPECIFIC OLIGONUCLEOTIDE (ASO)

TITLE OF INVENTION: ASSAY

FILE REFERENCE: 12667-17"US" FC/ld

CURRENT APPLICATION NUMBER: US/09/177,359B

CURRENT FILING DATE: 1998-10-23

NUMBER OF SEQ ID NOS: 37

SOFTWARE: FastSEQ for Windows Version 3.0

SEQ ID NO 26

LENGTH: 15

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: cDNA for use as probes

US-09-177-359-26

Query Match 0.9%; Score 12; DB 1; Length 15;

Best Local Similarity 100.0%; Pred. No. 1.8e+02;

Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 257 ACCTCTGGGCT 268

Db 14 ACCTCTGGGCT 3

RESULT 438

US-09-616-990-62

Sequence 62, Application US/09616990

Patent No. 6232109

GENERAL INFORMATION:

APPLICANT: KIKUCHI, Yasuhiro

APPLICANT: KIYOKAWA, Shigeto

APPLICANT: SHIMADA, Yukihisa

APPLICANT: OHBAYASHI, Masayo

APPLICANT: SHIMADA, Ritsuko

APPLICANT: OKINAKA, Yasushi

TITLE OF INVENTION: NOVEL PLANT GENES

NUMBER OF SEQUENCES: 67

CORRESPONDENCE ADDRESS:

ADDRESSEE: FITZPATRICK, CELLA, HARPER & SCINTO

STREET: 30 Rockefeller Plaza

CITY: New York

STATE: New York

COUNTRY: U.S.A.

ZIP: 10112-3801

MEDIUM TYPE: Diskette - 3.50 inch, 720 Kb storage.

COMPUTER: IBM PS/IV

OPERATING SYSTEM: MS-DOS Ver3.30

SOFTWARE: PATENT AID Ver1.0

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/09/616,990

FILING DATE: 14-Jul-2000

PRIOR APPLICATION DATA:

APPLICATION NUMBER: JP44963/92

FILING DATE: 02-MAR-1992

ATTORNEY/AGENT INFORMATION:

NAME: Perry, Lawrence S.

REGISTRATION NUMBER: 31865

TELECOMMUNICATION INFORMATION:

TELEPHONE: 212-218-2100

TELEFAX: 212-218-2200

INFORMATION FOR SEQ ID NO: 62 :


```
/ ; SEQUENCE CHARACTERISTICS:
/ ; LENGTH: 15 base pairs
/ ; TYPE: nucleic acid
/ ; STRANDEDNESS: single
/ ; TOPOLOGY: linear
/ ; MOLECULE TYPE: Other nucleic acid
/ ; DESCRIPTION: Synthetic DNA
/ ; SEQUENCE DESCRIPTION: SEQ ID NO: 62
US-09-616-990-62

Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 100.0%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 1233 TTTGGTGTGGA 1244
Db 4 TTTGGTGTGGA 15

RESULT 439
US-08-812-951B-1
; Sequence 1, Application US/08812951B
; Patent No. 6297006
; GENERAL INFORMATION:
; APPLICANT: Drmanac, Radoje T.
; APPLICANT: Drmanac, Snezana
; APPLICANT: Hou, Aaron
; APPLICANT: Houser, Brian
; TITLE OF INVENTION: Methods and Compositions for
; TITLE OF INVENTION: Detection or Quantification of Nucleic Acid Species
; NUMBER OF SEQUENCES: 15
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: McCutchen, Doyle, Brown & Enersen LLP
; STREET: Three Embarcadero Center
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/812,951B
; FILING DATE: 04-MAR-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US08/784747
; FILING DATE: 16-JAN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Kumamoto, Andrew A
; REGISTRATION NUMBER: 40,690
; REFERENCE/DOCKET NUMBER: 20411-701
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-393-2000
; TELEFAX: 415-393-2286
; TELEX:
; INFORMATION FOR SEQ ID NO: 1:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-812-951B-2

Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Qy 1146 TTTTCTTTTGG 1158
Db 13 TTTTNTTTTGG 1

RESULT 441
US-08-784-747-2
; Sequence 2, Application US/08784747
; Patent No. 6309824
; GENERAL INFORMATION:
; APPLICANT: Drmanac, Radoje T.
; TITLE OF INVENTION: Methods and Compositions for
; TITLE OF INVENTION: Detection or Quantification of Nucleic Acid Species
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: McCutchen, Doyle, Brown & Enersen LLP
; STREET: Three Embarcadero Center
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
```

```

;
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/784,747
; FILING DATE: 16-JAN-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kumamoto, Andrew A
; REGISTRATION NUMBER: 40,690
; REFERENCE/DOCKET NUMBER: 20411-709
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-393-2000
; TELEFAX: 415-393-2286
; TELEX:
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-784-747-2

Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1146 TTTTCTTTTGG 1158
Db 3 TTTTNTTTTGG 15

RESULT 442
US-08-784-747-3/c
; Sequence 3, Application US/08784747
; Patent No. 6309824
; GENERAL INFORMATION:
; APPLICANT: Drmanac, Radoje T.
; TITLE OF INVENTION: Methods and Compositions for
; DETECTION OR QUANTIFICATION OF NUCLEIC ACID SPECIES
; NUMBER OF SEQUENCES: 13
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: McCutchen, Doyle, Brown & Enersen LLP
; STREET: Three Embarcadero Center
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Diskette
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: DOS
; SOFTWARE: FastSeq for Windows Version 2.0
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/784,747
; FILING DATE: 16-JAN-1997
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Kumamoto, Andrew A
; REGISTRATION NUMBER: 40,690
; REFERENCE/DOCKET NUMBER: 20411-709
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-393-2000
; TELEFAX: 415-393-2286

```

```

;
; TELEX:
; INFORMATION FOR SEQ ID NO: 3:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-784-747-3

Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1146 TTTTCTTTTGG 1158
Db 13 TTTTNTTTTGG 1

RESULT 443
US-09-409-778-9
; Sequence 9, Application US/09409778
; Patent No. 6472173
; GENERAL INFORMATION:
; APPLICANT: Yeung, George
; TITLE OF INVENTION: A NOVEL CHEMOKINE RECEPTOR OBTAINED FROM
; A CDNA LIBRARY OF FETAL LIVER-SPLEEN
; FILE REFERENCE: 20411-742CON2 (now 28110/36057B)
; CURRENT APPLICATION NUMBER: US/09/409,778
; CURRENT FILING DATE: 1999-09-22
; PRIOR APPLICATION NUMBER: PCT/US99/12829
; PRIOR FILING DATE: 1999-06-29
; PRIOR APPLICATION NUMBER: US 09/236,166
; PRIOR FILING DATE: 1999-01-22
; PRIOR APPLICATION NUMBER: US 09/106,800
; PRIOR FILING DATE: 1998-06-26
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 9
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Exemplary oligonucleotide primer used in sequence assembly proc.
; NAME/KEY: Misc_feature
; LOCATION: (8)...(8)
; OTHER INFORMATION: n = A, T, C, G or 1-(2-deoxy-D-ribofuranosyl)-3-nitropyrolo
; US-09-409-778-9

Query Match          0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1146 TTTTCTTTTGG 1158
Db 3 TTTTNTTTTGG 15

RESULT 444
US-09-409-778-10/c
; Sequence 10, Application US/09409778
; Patent No. 6472173
; GENERAL INFORMATION:
; APPLICANT: Yeung, George
; TITLE OF INVENTION: A NOVEL CHEMOKINE RECEPTOR OBTAINED FROM
; A CDNA LIBRARY OF FETAL LIVER-SPLEEN
; FILE REFERENCE: 20411-742CON2 (now 28110/36057B)
; CURRENT APPLICATION NUMBER: US/09/409,778
; CURRENT FILING DATE: 1999-09-22
; PRIOR APPLICATION NUMBER: PCT/US99/12829
; PRIOR FILING DATE: 1999-06-29
; PRIOR APPLICATION NUMBER: US 09/236,166

```

PRIOR FILING DATE: 1999-01-22
PRIOR APPLICATION NUMBER: US 09/106,800
PRIOR FILING DATE: 1998-06-26
NUMBER OF SEQ ID NOS: 25
SOFTWARE: FastSeq for Windows Version 3.0
SEQ ID NO 10
LENGTH: 15
TYPE: DNA
ORGANISM: Artificial Sequence
FEATURE:
OTHER INFORMATION: Exemplary oligonucleotide primer used in sequence assembly process
NAME/KEY: misc(feature)
LOCATION: (8)...(8)
OTHER INFORMATION: n = A, T, C, G or 1-(2-deoxy-D-ribofuranosyl)-3-nitropyrrrole
US-09-409-778-10

Query Match 0.9%; Score 12; DB 1; Length 15;
Best Local Similarity 92.3%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1146 TTTTCTTTTGG 1158
DB 13 TTTTNTTTTGG 1

RESULT 445

US-08-232-087A-5/c
Sequence 5, Application US/08232087A
Patent No. 5866372
GENERAL INFORMATION:
APPLICANT: Stein, Harald
APPLICANT: D r kop, Horst
APPLICANT: Latza, Ute
TITLE OF INVENTION: Lymphoid CD30-Antigen
NUMBER OF SEQUENCES: 11
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch, LLP
STREET: 8110 Gatehouse Road, Suite 500 East
CITY: Falls Church
STATE: Virginia
COUNTRY: U.S.A.
ZIP: 22042

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/232,087A
FILING DATE: 08-SEP-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Murphy Jr., Gerald M.
REGISTRATION NUMBER: 28,977
REFERENCE/DOCKET NUMBER: 756-103P
TELECOMMUNICATION INFORMATION:
TELEPHONE: (703) 205-8000
TELEFAX: (703) 205-8050
TELEX: 248345

INFORMATION FOR SEQ ID NO: 5:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
HYPOTHETICAL: NO
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Homo sapiens

US-08-232-087A-5
Query Match 0.9%; Score 12; DB 1; Length 16;
Best Local Similarity 92.3%; Pred. No. 1.8e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

Best Local Similarity 100.0%; Pred. No. 2e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 576 GCAGGCCCTCCG 587
DB 15 GCAGGCCCTCCG 4

RESULT 446

US-08-882-649A-8
Sequence 8, Application US/08882649A
Patent No. 6344316
GENERAL INFORMATION:
APPLICANT: Lockhart, David J.
Chee, Mark
Gunderson, Kevin
Chaoqiang, Lai
Wodicka, Lisa
Cronin, Maureen T.
Lee, Danny
Tran, Huu M.
Matsuzaki, Hajime
McGall, Glenn H.
TITLE OF INVENTION: NUCLEIC ACID ANALYSIS TECHNIQUES
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: Joe Liebeschuetz
STREET: Two Embarcadero Center, Eighth Floor
CITY: San Francisco
STATE: CA
COUNTRY: USA
ZIP: 94111-3834

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/882,649A
FILING DATE: 25-Jun-1997
CLASSIFICATION: 435-006.000
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 60/010,471
FILING DATE: 23-JAN-1996
APPLICATION NUMBER: US 60/035,170
FILING DATE: 09-JAN-1997
APPLICATION NUMBER: PCT/US97/01603
FILING DATE: 22-JAN-1997
ATTORNEY/AGENT INFORMATION:
NAME: Liebeschuetz, Joe
REGISTRATION NUMBER: 37,505
REFERENCE/DOCKET NUMBER: 018547-019410US
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 576-0200
TELEFAX: (415) 576-0300

INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: YES
FEATURES:
SEQUENCE DESCRIPTION: SEQ ID NO: 8:
US-08-882-649A-8

Query Match 0.9%; Score 12; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2e+02;
Matches 13; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1141 GCCTTTTCTTTT 1156
: ||||| |||||

Db 1 GVVTTTTTTTTTTTTT 16

RESULT 447

US-08-758-306-649

Sequence 649, Application US/08758306

Patent No. 5807743

GENERAL INFORMATION:

APPLICANT: Stinchcomb, Dan T.

TITLE OF INVENTION: METHOD AND REAGENT FOR THE TREATMENT OF DISEASES ASSOCIATED WITH INTERLEUKIN-2 RECEPTOR

TITLE OF INVENTION: GAMMA-CHAIN EXPRESSION

NUMBER OF SEQUENCES: 1379

CORRESPONDENCE ADDRESSES:

ADDRESSEE: Lyon & Lyon

STREET: 633 West Fifth Street

STREET: Suite 4700

CITY: Los Angeles

STATE: California

COUNTRY: U.S.A.

ZIP: 90071-2066

COMPUTER READABLE FORM:

MEDIUM TYPE: 3.5" Diskette, 1.44 Mb

MEDIUM TYPE: storage

COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0

SOFTWARE: FastSeq version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/758,306

FILING DATE: December 3, 1996

CLASSIFICATION: 514

PRIOR APPLICATION DATA:

APPLICATION NUMBER:

FILING DATE:

ATTORNEY/AGENT INFORMATION:

NAME: Warburg, Richard J.

REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 212/132

TELECOMMUNICATION INFORMATION:

TELEPHONE: (213) 489-1600

TELEFAX: (213) 955-0440

TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 649:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: linear

US-08-758-306-649

Query Match 0.9%; Score 12; DB 1; Length 17;

Best Local Similarity 66.7%; Pred. No. 2.3e+02;

Matches 8; Conservative 4; Mismatches 0; Indels 0; Gaps 0;

Qy 83 AATAGCAGTCTT 94

Db 6 AAUAGCAGUUCU 17

RESULT 448

US-09-328-501-14

Sequence 14, Application US/09328501A

Patent No. 6258581

GENERAL INFORMATION:

APPLICANT: OKINO, No. 6258581omu

TITLE OF INVENTION: ITO, Makoto

FILE REFERENCE: 1422-0377P

CURRENT APPLICATION NUMBER: US/09/328,501A

CURRENT FILING DATE: 1999-06-09

EARLIER APPLICATION NUMBER: 10-234769 JAPAN

EARLIER FILING DATE: 1998-08-20

NUMBER OF SEQ ID NOS: 18

SOFTWARE: PatentIn Ver. 2.1

SEQ ID NO 14

LENGTH: 17

TYPE: DNA

ORGANISM: Artificial Sequence

FEATURE:

OTHER INFORMATION: Description of Artificial Sequence: Designed

OTHER INFORMATION: oligonucleotide based on the amino acid sequence

OTHER INFORMATION: represented in SEQ ID NO:4.

FEATURE:

OTHER INFORMATION: any n or Xaa = Unknown

US-09-328-501-14

Query Match 0.9%; Score 12; DB 1; Length 17;

Best Local Similarity 62.5%; Pred. No. 2.3e+02;

Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

Qy 629 AGTCCAGAGCTCTG 644

Db 2 AGTYCASRASCCTVG 17

RESULT 449

US-08-984-709A-45

Sequence 45, Application US/08984709A

Patent No. 6320032

GENERAL INFORMATION:

APPLICANT: Williams, Mark E.

APPLICANT: Stauderman, Kenneth A.

APPLICANT: Harpold, Michael M.

TITLE OF INVENTION: HUMAN CALCIUM CHANNEL COMPOSITIONS AND

TITLE OF INVENTION: METHODS

NUMBER OF SEQUENCES: 52

CORRESPONDENCE ADDRESS:

ADDRESSEE: Heller Ehrman White & McAuliffe

STREET: 4250 Executive Square, Suite 700

CITY: La Jolla

STATE: California

COUNTRY: US

ZIP: 92037

COMPUTER READABLE FORM:

MEDIUM TYPE: Diskette

COMPUTER: IBM Compatible

OPERATING SYSTEM: DOS

SOFTWARE: FastSeq Version 1.5

CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/984,709A

FILING DATE: 02-DEC-1997

CLASSIFICATION: 435

ATTORNEY/AGENT INFORMATION:

NAME: Seidman, Stephanie L.

REGISTRATION NUMBER: 33,779

REFERENCE/DOCKET NUMBER: 24735-9815 (formerly 6362-9815)

TELECOMMUNICATION INFORMATION:

TELEPHONE: (619) 450-8400

TELEFAX: (619) 587-5360

INFORMATION FOR SEQ ID NO: 45:

SEQUENCE CHARACTERISTICS:

LENGTH: 17 base pairs

TYPE: nucleic acid

STRANDEDNESS: single

TOPOLOGY: unknown

MOLECULE TYPE: cdna

HYPOTHETICAL: NO

ANTI-SENSE: NO

FRAGMENT TYPE: NO

ORIGINAL SOURCE:

US-08-984-709A-45

Query Match 0.9%; Score 12; DB 1; Length 17;

Best Local Similarity 75.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 323 ACTGCATCATCTGG 338
| |||:|:| ||||
Db 1 AACTGYATVACCTGG 16

RESULT 450

US-08-584-040-1844/c
; Sequence 1844, Application US/08584040
; Patent No. 6346398

GENERAL INFORMATION:

APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1844:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-1844

Query Match 0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 909 CCTGGTCCTAAA 920
| |||:|:| ||||
Db 17 CCTGGTCCTAAA 6

RESULT 451

US-08-584-040-7538/c
; Sequence 7538, Application US/08584040
; Patent No. 6346398

GENERAL INFORMATION:

APPLICANT: Pavco, Pamela
APPLICANT: McSwiggen, James
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Escobedo, Jaime
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
TREATMENT OF DISEASES OR
TITLE OF INVENTION: CONDITIONS RELATED TO LEVELS
TITLE OF INVENTION: OF VASCULAR ENDOTHELIAL
TITLE OF INVENTION: GROWTH FACTOR
NUMBER OF SEQUENCES: 8502
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/584,040
FILING DATE: January 11, 1996
CLASSIFICATION: 514
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/005,974
FILING DATE: October 26, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/064
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 7538:
SEQUENCE CHARACTERISTICS:
LENGTH: 17 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-584-040-7538

Query Match 0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 909 CCTGGTCCTAAA 920
| |||:|:| ||||
Db 17 CCTGGTCCTAAA 6

RESULT 452

US-09-537-720B-15/c
; Sequence 15, Application US/09537720B
; Patent No. 6376184

GENERAL INFORMATION:
APPLICANT: Laboratory of Molecular Biophotonics
TITLE OF INVENTION: Method for gene analysis
FILE REFERENCE: 400595
CURRENT APPLICATION NUMBER: US/09/537,720B
CURRENT FILING DATE: 2000-03-30
PRIOR APPLICATION NUMBER: JPI2/22630
PRIOR FILING DATE: 2000-01-31
NUMBER OF SEQ ID NOS: 16
SOFTWARE: Patent in version 3.1
SEQ ID NO 15
LENGTH: 17

```
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Predicted Sequence
; NAME/KEY: misc_feature
; OTHER INFORMATION: Part of the template
US-09-537-720B-15

Query Match          0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 1296 TCAGCCTGGCCC 1307
Db 14 TCAGCCTGGCCC 3

RESULT 453
US-08-937-067-17
; Sequence 17, Application US/08937067
; Patent No. 6433155
; GENERAL INFORMATION:
; APPLICANT: Umansky, Samuil
; APPLICANT: Melkonyan, Hovsep
; TITLE OF INVENTION: A FAMILY OF GENES ENCODING
; TITLE OF INVENTION: APOPTOSIS-RELATED PEPTIDES; PEPTIDES ENCODED THEREBY AND
; TITLE OF INVENTION: METHODS OF USE THEREOF
; NUMBER OF SEQUENCES: 19
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: MORRISON & FOERSTER
; STREET: 755 Page Mill Road
; CITY: Palo Alto
; STATE: CA
; COUNTRY: USA
; ZIP: 94304-1018
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA: US/08/937,067
; FILING DATE:
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: Lehnhardt, Susan K.
; REGISTRATION NUMBER: 33,943
; REFERENCE/DOCKET NUMBER: 23647-20018.00
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (650) 813-5600
; TELEFAX: (650) 494-0792
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-937-067-17

Query Match          0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 80.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTGG 1158
Db 3 TTTTTCCTTTTNS 17

RESULT 454
US-09-777-710A-14
; Sequence 14, Application US/0977710A
; Patent No. 6489117
; GENERAL INFORMATION:
; APPLICANT: OKINO, No. 6489117omui et al.
; TITLE OF INVENTION: CERAMIDASE GENE
; FILE REFERENCE: 1422-0458P
; CURRENT APPLICATION NUMBER: US/09/777,710A
; CURRENT FILING DATE: 2001-02-07
; NUMBER OF SEQ ID NOS: 18
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 14
; LENGTH: 17
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Designed oligonucleotide based on the amino acid sequence
; OTHER INFORMATION: represented in SEQ ID NO:4
US-09-777-710A-14

Query Match          0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 62.5%; Pred. No. 2.3e+02;
Matches 10; Conservative 5; Mismatches 1; Indels 0; Gaps 0;

QY 629 AGCTCAGGAGCTCTG 644
Db 2 AGCTCAGGAGCTCTG 17

RESULT 455
US-09-371-772B-389/c
; Sequence 389, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
; FILE REFERENCE: MEHB00,876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 389
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
US-09-371-772B-389

Query Match          0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 909 CCTGGTCCTAAA 920
Db 17 CCTGGTCCTAAA 6

RESULT 456
US-09-371-772B-4638/c
; Sequence 4638, Application US/09371772B
; Patent No. 6566127
; GENERAL INFORMATION:
; APPLICANT: Ribozyme Pharmaceuticals, Inc.
; APPLICANT: Pavco, Pam
; APPLICANT: McSwiggen, Jim
; APPLICANT: Stinchcomb, Dan
; APPLICANT: Escobedo, Jaime
; TITLE OF INVENTION: Method and Reagent for the Treatment of Diseases or Conditions
; TITLE OF INVENTION: Levels of Vascular Endothelial Growth Factor Receptor
```

```

; FILE REFERENCE: MEHB00.876-J (237/198)
; CURRENT APPLICATION NUMBER: US/09/371,772B
; CURRENT FILING DATE: 1999-08-10
; PRIOR APPLICATION NUMBER: US 60/005,974
; PRIOR FILING DATE: 1995-10-26
; PRIOR APPLICATION NUMBER: US 08/584,040
; PRIOR FILING DATE: 1996-01-08
; NUMBER OF SEQ ID NOS: 14225
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 4638
; LENGTH: 17
; TYPE: RNA
; ORGANISM: Homo sapiens
; ORGANISM: Homo sapiens
US-09-371-772B-4638

Query Match          0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 100.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

QY 909 CCTGGTCCTAAA 920
DB 12 CCTGGTCCTAAA 1

RESULT 457
PCT-US91-03680-7
; Sequence 7, Application PC/TUS9103680
; GENERAL INFORMATION:
; APPLICANT: Matteucci, Mark D.
; APPLICANT: Krawczyk, Steven
; TITLE OF INVENTION: SEQUENCE-SPECIFIC NONPHOTOACTIVATED
; TITLE OF INVENTION: CROSSLINKING AGENTS WHICH BIND TO THE MAJOR GROOVE OF
; TITLE OF INVENTION: DUPLEX DNA
; NUMBER OF SEQUENCES: 158
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Morrison & Foerster
; STREET: 545 Middlefield Road, Suite 200
; CITY: Menlo Park
; STATE: California
; COUNTRY: USA
; ZIP: 94025
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/03680
; FILING DATE: 19910524
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Murashige, Kate H.
; REGISTRATION NUMBER: 29,959
; REFERENCE/DOCKET NUMBER: 4610-0011.40
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 415-327-7250
; TELEFAX: 415-327-2951
; TELEX: 706141
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 17 base pairs
; TYPE: NUCLEIC ACID
; STRANDEDNESS: single
; TOPOLOGY: linear
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 8
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "N4,N4-ethanocytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 14
; OTHER INFORMATION: /mod_base= OTHER

```

```

; OTHER INFORMATION: /note= "5-methylcytosine"
; FEATURE:
; NAME/KEY: modified_base
; LOCATION: 17
; OTHER INFORMATION: /mod_base= OTHER
; OTHER INFORMATION: /note= "1,3-propanediol"
PCT-US91-03680-7

Query Match          0.9%; Score 12; DB 1; Length 17;
Best Local Similarity 92.3%; Pred. No. 2.3e+02;
Matches 12; Conservative 0; Mismatches 1; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTT 1156
DB 1 TTTTTCCTTTT 13

RESULT 458
US-08-041-599-2
; Sequence 2, Application US/08041599
; Patent No. 5393877
; GENERAL INFORMATION:
; APPLICANT: McLEAN, MICHAEL J.
; APPLICANT: HOLLAND, DAVID
; APPLICANT: GARMAN, ANDREW J.
; APPLICANT: SHEPPARD, ROBERT C.
; TITLE OF INVENTION: SYNTHESIS OF OLIGONUCLEOTIDES
; NUMBER OF SEQUENCES: 2
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CUSHMAN, DARBY & CUSHMAN
; STREET: 1100 NEW YORK AVENUE, N.W.
; CITY: WASHINGTON
; STATE: D.C.
; COUNTRY: U.S.A.
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/041,599
; FILING DATE: 19930405
; CLASSIFICATION: 536
; ATTORNEY/AGENT INFORMATION:
; NAME: KOKULIS, PAUL N.
; REGISTRATION NUMBER: 16,773
; REFERENCE/DOCKET NUMBER: 202706/SBI36848/US
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 202-861-3000
; TELEFAX: 202-822-0944
; INFORMATION FOR SEQ ID NO: 2:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
US-08-041-599-2

Query Match          0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGA 1159
DB 1 TTTTTCCTTTTGA 15

RESULT 459
US-08-127-954-50
; Sequence 50, Application US/08127954
; Patent No. 5451512

```

GENERAL INFORMATION:
APPLICANT: Apple, Raymond J.
APPLICANT: Bugawan, Teodorica L.
APPLICANT: Erlich, Henry A.
TITLE OF INVENTION: Methods and Reagents for HLA Class I A
TITLE OF INVENTION: Locus DNA Typing
NUMBER OF SEQUENCES: 173
CORRESPONDENCE ADDRESS:
ADDRESSEE: Hoffmann-La Roche Inc.
STREET: 340 Kingsland Street
CITY: Nutley
STATE: New Jersey
COUNTRY: U.S.A.
ZIP: 07110-1199
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/127,954
FILING DATE:
CLASSIFICATION: 436
ATTORNEY/AGENT INFORMATION:
NAME: Petry, Douglas A.
REGISTRATION NUMBER: 35,321
REFERENCE/DOCKET NUMBER: 8873
TELECOMMUNICATION INFORMATION:
TELEPHONE: (510) 814-2974
TELEFAX: (510) 814-2977
INFORMATION FOR SEQ ID NO: 50:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-127-954-50

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 113 CGGAGACCGTCCACA 127
Db 1 CGGAGCCCGTCCACA 15

RESULT 460
US-08-337-025-2
Sequence 2, Application US/08337025
Patent No. 5552535
GENERAL INFORMATION:
APPLICANT: McLEAN, MICHAEL J.
APPLICANT: HOLLAND, DAVID
APPLICANT: GARMAN, ANDREW J.
APPLICANT: SHEPPARD, ROBERT C.
TITLE OF INVENTION: SYNTHESIS OF OLIGONUCLEOTIDES
NUMBER OF SEQUENCES: 2
CORRESPONDENCE ADDRESS:
ADDRESSEE: CUSHMAN, DARRY & CUSHMAN
STREET: 1100 NEW YORK AVENUE, N.W.
CITY: WASHINGTON
STATE: D.C.
COUNTRY: U.S.A.
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/337,025

FILING DATE: 07-NOV-1994
CLASSIFICATION: 536
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/041,599
FILING DATE: 05-APR-1993
ATTORNEY/AGENT INFORMATION:
NAME: BIRD, DONALD J.
REGISTRATION NUMBER: 25,323
REFERENCE/DOCKET NUMBER: 202706/SBI36848/US
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-861-3000
TELEFAX: 202-822-0944
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-337-025-2

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1145 TTTTTCCTTTTTCGA 1159
Db 1 TTTTTCCTTTTTCGA 15

RESULT 461
US-08-276-099A-8
Sequence 8, Application US/08276099A
Patent No. 5591825
GENERAL INFORMATION:
APPLICANT: McKnight, Steven L
APPLICANT: Hou, Jinzhao
TITLE OF INVENTION: INTERLEUKIN-4 SIGNAL TRANSDUCERS AND
TITLE OF INVENTION: BINDING ASSAYS
NUMBER OF SEQUENCES: 17
CORRESPONDENCE ADDRESS:
ADDRESSEE: FLEHR, HOHBACH, TEST, ALBRITTON & HERBERT
STREET: 4 Embarcadero Center, Suite 3400
CITY: San Francisco
STATE: California
COUNTRY: USA
ZIP: 94111-4187
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/276,099A
FILING DATE: 15-JUL-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Osman, Richard Aron
REGISTRATION NUMBER: 36,627
REFERENCE/DOCKET NUMBER: A-59451-1/RAO
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 781-1989
TELEFAX: (415) 398-3249
TELEX: 910 277299
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: CDNA
US-08-276-099A-8

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 835 AAGCTTTCAGATGGG 849
Db 1 AAGGTTTCAGAGGG 15

RESULT 462
US-08-182-968A-201
; Sequence 201, Application US/08182968A
; Patent No. 5610054
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 497
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/182,968A
; FILING DATE: 13-JANUARY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 07/892,888
; FILING DATE: 14-MAY-1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 205/277
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 201:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-182-968A-201

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1190 TGAGTGTTCAGCTT 1204
Db 1 UGUGUGUUGACCGG 15

RESULT 463
US-08-291-932A-33/c
; Sequence 33, Application US/08291932A
; Patent No. 5658780
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF

; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California
; ZIP: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/291,932A
; FILING DATE: August 15, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/157
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-291-932A-33

Two

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 6 GGCGAGTTCAGGTGGA 20
Db 15 GGCGCGTTCAGGTGGA 1

RESULT 464
US-08-291-932A-378/c
; Sequence 378, Application US/08291932A
; Patent No. 5658780
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: California

```

; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/291,932A
; FILING DATE: August 15, 1994
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/245,466
; FILING DATE: May 18, 1994
; APPLICATION NUMBER: 07/987,132
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/157
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 378:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-291-932A-378

```

Two

```

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 528 GGAGGAGGAGCTGGG 542
Db 15 GGAGGAGGAGCTGGG 1

```

```

RESULT 465
US-08-334-847-570
; Sequence 570, Application US/08334847
; Patent No. 5693532
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Draper, Kenneth
; APPLICANT: Pavco, Pam
; APPLICANT: Woolf, Tod
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING RESPIRATORY
; TITLE OF INVENTION: SYNCYTIAL VIRUS
; NUMBER OF SEQUENCES: 909
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/334,847

```

```

; FILING DATE: No. 5693532ember 4, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/032
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 570:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-334-847-570

```

```

Query Match 0.9%; Score 11.8; DB 1; length 15;
Best Local Similarity 20.0%; Pred. No. 1.9e+02;
Matches 3; Conservative 10; Mismatches 2; Indels 0; Gaps 0;

```

```

QY 1144 TTTTTCCTTTTGG 1158
Db 1 UUUUGUUCUUUUUGG 15

```

```

RESULT 466
US-08-334-847-606
; Sequence 606, Application US/08334847
; Patent No. 5693532
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Draper, Kenneth
; APPLICANT: Pavco, Pam
; APPLICANT: Woolf, Tod
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING RESPIRATORY
; TITLE OF INVENTION: SYNCYTIAL VIRUS
; NUMBER OF SEQUENCES: 909
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/334,847
; FILING DATE: No. 5693532ember 4, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/032
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 606:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs

```

```

; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-334-847-606

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 46.7%; Pred. No. 1.9e+02;
Matches 7; Conservative 6; Mismatches 2; Indels 0; Gaps 0;

QY 442 AAGTTGCTGAAGTTT 456
Db 1 AAGUUGUAGGAGUU 15

RESULT 467
US-08-334-847-631
; Sequence 631, Application US/08334847
; Patent No. 5693532
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Draper, Kenneth
; APPLICANT: Pavco, Pam
; APPLICANT: Woolf, Tod
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING RESPIRATORY
; TITLE OF INVENTION: SYNCYTIAL VIRUS
; NUMBER OF SEQUENCES: 909
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER READABLE FORM:
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/334,847
; FILING DATE: No. 5693532ember 4, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/032
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 631:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-334-847-631

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 60.0%; Pred. No. 1.9e+02;
Matches 9; Conservative 4; Mismatches 2; Indels 0; Gaps 0;

QY 972 CCTCACTTGACCACT 986
Db 1 CCUCACUUCUCCAGU 15

RESULT 468
US-08-334-847-631
; Sequence 631, Application US/08334847
; Patent No. 5693532
; GENERAL INFORMATION:
; APPLICANT: McSwiggen, James
; APPLICANT: Draper, Kenneth
; APPLICANT: Pavco, Pam
; APPLICANT: Woolf, Tod
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING RESPIRATORY
; TITLE OF INVENTION: SYNCYTIAL VIRUS
; NUMBER OF SEQUENCES: 909
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER READABLE FORM:
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/334,847
; FILING DATE: No. 5693532ember 4, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 209/032
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 631:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-334-847-631

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.9e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 307 GGGGCTGCAACTCCA 321
Db 1 GGGGCUUCACACCA 15

RESULT 469
US-08-363-240A-541/c
; Sequence 541, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 142:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-363-240A-142

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 80.0%; Pred. No. 1.9e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

QY 307 GGGGCTGCAACTCCA 321
Db 1 GGGGCUUCACACCA 15

RESULT 469
US-08-363-240A-541/c
; Sequence 541, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 142:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-363-240A-142
```

```

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION NUMBER:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 541:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-541

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 924 GATGCAGATCTGGA 938
Db 15 GGTGCTGATCTGGA 1

RESULT 470
US-08-363-240A-658/c
; Sequence 658, Application US/08363240A
; Patent No. 5705388
; GENERAL INFORMATION:
; APPLICANT: Couture, Larry
; APPLICANT: McSwiggen, James
; APPLICANT: Bisgaier, Charles
; APPLICANT: Pape, Michael
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: PREVENTION, INHIBITION OF
; TITLE OF INVENTION: PROGRESSION AND REGRESSION
; TITLE OF INVENTION: OF VASCULAR DISEASES
; NUMBER OF SEQUENCES: 1243
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:

```

```

; APPLICATION NUMBER: US/08/363,240A
; FILING DATE: December 23, 1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER:
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 210/096
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 658:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-363-240A-658

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1 GGGCAGGCAGTTGAG 15
Db 15 GGCAGGGAGTTGAG 1

RESULT 471
US-08-781-890-8
; Sequence 8, Application US/08781890
; Patent No. 5710266
; GENERAL INFORMATION:
; APPLICANT: McKnight, Steven L
; APPLICANT: Hou, Jizhao
; TITLE OF INVENTION: INTERLEUKIN-4 SIGNAL TRANSDUCERS AND
; TITLE OF INVENTION: BINDING ASSAYS
; NUMBER OF SEQUENCES: 17
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: FLEHR, HOEBACH, TEST, ALBRITTON & HERBERT
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: California
; COUNTRY: USA
; ZIP: 94111-4187
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/781,890
; FILING DATE: 05-JAN-1997
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/276,099
; FILING DATE: 15-JUL-1994
; ATTORNEY/AGENT INFORMATION:
; NAME: Osman, Richard Aron
; REGISTRATION NUMBER: 36,627
; REFERENCE/DOCKET NUMBER: A-59451-1/RAO
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415) 781-1989
; TELEFAX: (415) 398-3249
; TELEX: 910 277299
; INFORMATION FOR SEQ ID NO: 8:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear

```

```

; MOLECULE TYPE: cDNA
US-08-781-890-8

Query Match      0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      835 AGCTTTCAGATGGG 849
Db      1 AAGTTTTCAGAGGG 15

RESULT 472
US-08-471-033-34/c
; Sequence 34, Application US/08471033
; Patent No. 5770696
; GENERAL INFORMATION:
; APPLICANT: Warren, Gregory W
; APPLICANT: Koziel, Michael G
; APPLICANT: Mullins, Martha A
; APPLICANT: Nye, Gordon J
; APPLICANT: Carr, Brian
; APPLICANT: Desai, Nalini M
; APPLICANT: Kostichka, N. Kristy
; APPLICANT: Duck, Nicholas B
; APPLICANT: Estruch, Juan J
; TITLE OF INVENTION: No. 5770696el Pesticidal Proteins and Strains
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CIBA-GEIGY Corporation
; STREET: 7 Skyline Drive
; CITY: Hawthorne
; STATE: NY
; COUNTRY: USA
; ZIP: 10532
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patentin Release #1.0, Version #1.30B
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/471,033
; FILING DATE:
; CLASSIFICATION: 530
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/314,594
; FILING DATE: 09-SEP-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/218,018
; FILING DATE: 23-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/037,057
; FILING DATE: 25-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Pace, Gary M.
; REGISTRATION NUMBER: P-40,403
; REFERENCE/DOCKET NUMBER: CGC 1695/CIP3/DIV7 - SQLv3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-541-8582
; TELEFAX: 919-541-8689
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "reverse primer used to make
; DESCRIPTION: pCIB5526"
; HYPOTHETICAL: NO
US-08-471-033-34

Query Match      0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

; MOLECULE TYPE: cDNA
US-08-781-890-8

Query Match      0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      826 ATGCAGCTGAGCTT 840
Db      15 AAGGAGCTGAGCTT 1

RESULT 473
US-08-292-620A-74
; Sequence 74, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Suite 4700
; STATE: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620A
; FILING DATE: August 17, 1994
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION DATA: including application
; PRIOR APPLICATION DATA: described below:
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 74:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-292-620A-74

Query Match      0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY      908 CCGTGGTCTTAAAGG 922
Db      1 CCGGGGCUUAGAGG 15

```

RESULT 474

US-08-292-620A-105/c
; Sequence 105, Application US/08292620A
; Patent No. 5837542

GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 105:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-292-620A-105

two

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 308 GGGCTGCACTCCAT 322

Db 15 GGGCTGGACCCCAT 1

RESULT 475

US-08-292-620A-393/c
; Sequence 393, Application US/08292620A
; Patent No. 5837542

GENERAL INFORMATION:

APPLICANT: Susan Grimm

APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 393:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear

US-08-292-620A-393

two

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1260 CCAGGTTGAGGCCT 1274

Db 15 CCAGGCTGAGGTCCT 1

RESULT 476

US-08-292-620A-656/c
; Sequence 656, Application US/08292620A
; Patent No. 5837542

GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF

TITLE OF INVENTION: INTRACELLULAR ADHESION
 TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
 NUMBER OF SEQUENCES: 2390
 CORRESPONDENCE ADDRESS:

ADDRESSEE: Lyon & Lyon
 STREET: 633 West Fifth Street
 STREET: Suite 4700
 CITY: Los Angeles
 STATE: California
 COUNTRY: U.S.A.
 ZIP: 90071-2066

COMPUTER READABLE FORM:
 MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
 MEDIUM TYPE: storage

COMPUTER: IBM Compatible
 OPERATING SYSTEM: IBM P.C. DOS 5.0
 SOFTWARE: Word Perfect 5.1

CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/292,620A
 FILING DATE: August 17, 1994

CLASSIFICATION: 435

PRIOR APPLICATION DATA: including application
 PRIOR APPLICATION DATA: described below:

APPLICATION NUMBER: 08/008,895
 FILING DATE: January 19, 1993
 APPLICATION NUMBER: 07/989,849
 FILING DATE: December 7, 1992

ATTORNEY/AGENT INFORMATION:
 NAME: Warburg, Richard J.
 REGISTRATION NUMBER: 32,327

REFERENCE/DOCKET NUMBER: 208/149
 TELEPHONE: (213) 489-1600
 TELEFAX: (213) 955-0440

TELEX: 67-3510
 INFORMATION FOR SEQ ID NO: 656:
 SEQUENCE CHARACTERISTICS:

LENGTH: 15 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear

US-08-292-620A-656

Query Match 0.9%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 1.9e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1260 CCAGGTTGAGCCCT 1274
 Db 15 CCAGGCTGAGCTCT 1

RESULT 477

US-08-471-044-34/c
 Sequence 34, Application US/08471044
 Patent No. 5840868

GENERAL INFORMATION:

APPLICANT: Warren, Gregory W
 APPLICANT: Koziel, Michael G
 APPLICANT: Mullins, Martha A
 APPLICANT: Nye, Gordon J
 APPLICANT: Carr, Brian
 APPLICANT: Desai, Nalini M
 APPLICANT: Kostichka, N. Kristy
 APPLICANT: Duck, Nicholas B
 APPLICANT: Estruch, Juan J

TITLE OF INVENTION: No. 5840868el Pesticidal Proteins and Strains
 NUMBER OF SEQUENCES: 50

CORRESPONDENCE ADDRESS:

ADDRESSEE: CIBA-GEIGY Corporation
 STREET: 7 Skyline Drive
 CITY: Hawthorne

STATE: NY
 COUNTRY: USA
 ZIP: 10532
 COMPUTER READABLE FORM:
 MEDIUM TYPE: Floppy disk
 OPERATING SYSTEM: PC-DOS/MS-DOS
 SOFTWARE: PatentIn Release #1.0, Version #1.30B
 CURRENT APPLICATION DATA:
 APPLICATION NUMBER: US/08/471,044
 FILING DATE: 06-JUN-1995

CLASSIFICATION: 800

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/463,483
 FILING DATE: 05-JUN-1995

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/314,594
 FILING DATE: 09-SEP-1994

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/218,018
 FILING DATE: 23-MAR-1994

PRIOR APPLICATION DATA:
 APPLICATION NUMBER: US 08/037,057
 FILING DATE: 25-MAR-1993

ATTORNEY/AGENT INFORMATION:
 NAME: Pace, Gary M.
 REGISTRATION NUMBER: 40,403

REFERENCE/DOCKET NUMBER: CGC 1695/CIP3/DIV6 - SQLv3
 TELEPHONE: 919-541-8582
 TELEFAX: 919-541-8689

INFORMATION FOR SEQ ID NO: 34:

SEQUENCE CHARACTERISTICS:
 LENGTH: 15 base pairs
 TYPE: nucleic acid
 STRANDEDNESS: single
 TOPOLOGY: linear
 MOLECULE TYPE: other nucleic acid
 DESCRIPTION: /desc = "reverse primer used to make
 HYPOTHETICAL: NO

US-08-471-044-34

Query Match 0.9%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 1.9e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 ATGCAGCTGAAGCTT 840
 Db 15 AAGGAGCTGAAGCTT 1

RESULT 478

US-08-463-483A-34/c
 Sequence 34, Application US/08463483A
 Patent No. 5849870

GENERAL INFORMATION:

APPLICANT: Warren, Gregory W
 APPLICANT: Koziel, Michael G
 APPLICANT: Mullins, Martha A
 APPLICANT: Nye, Gordon J
 APPLICANT: Carr, Brian
 APPLICANT: Desai, Nalini M
 APPLICANT: Kostichka, N. Kristy
 APPLICANT: Duck, Nicholas B
 APPLICANT: Estruch, Juan J

TITLE OF INVENTION: No. 5849870el Pesticidal Proteins and Strains
 NUMBER OF SEQUENCES: 50

CORRESPONDENCE ADDRESS:

ADDRESSEE: CIBA-GEIGY Corporation
 STREET: 7 Skyline Drive
 CITY: Hawthorne
 STATE: NY

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 07/968,436
FILING DATE: 29 OCT 1992
ATTORNEY/AGENT INFORMATION:
NAME: Handelman, Joseph H.
REGISTRATION NUMBER: 26,179
REFERENCE/DOCKET NUMBER: U9518-6
TELEPHONE: (attorney) (212) 708-1880
TELEFAX: (attorney) (212) 246-8959
INFORMATION FOR SEQ ID NO: 87:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: Nucleic Acid
STRANDEDNESS: double stranded
TOPOLOGY: linear
MOLECULE TYPE: Genomic DNA
DESCRIPTION: retinoblastoma gene (Accession #
DESCRIPTION: M33647, J02994) nucleotides 4062 to 4076
HYPOTHETICAL: No
ANTI-SENSE: No
ORIGINAL SOURCE:
ORGANISM: Homo sapiens
POSITION IN GENOME:
CHROMOSOME/SEGMENT: chromosome 13
MAP POSITION: 13q14.2
PUBLICATION INFORMATION:
AUTHORS: Friend, S H, Horowitz, J M, Gerber, M R,
AUTHORS: Wang X F, Bogenmann, E, Li, F P, Weinberg,
AUTHORS: R A.
TITLE: Deletions of a DNA sequence
TITLE: in retinoblastomas and mesenchymal tumors:
TITLE: Organization of the sequence and its encoded
TITLE: Protein
JOURNAL: Proceedings of the National Academy of
JOURNAL: Sciences, USA
VOLUME: 84
PAGES: 9059-9063
DATE: 1987
RELEVANT RESIDUES IN SEQ ID NO: 87 :FROM 1 TO 15
US-08-173-489C-87

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1202 CTTCCACCTCCCT 1216
| | | | |
Db 1 CTTCCCTCCCT 15

RESULT 481
US-08-471-046A-34/C
Sequence 34, Application US/08471046A
Patent No. 5866326
GENERAL INFORMATION:
APPLICANT: Warren, Gregory W
APPLICANT: Koziel, Michael G
APPLICANT: Mullins, Martha A
APPLICANT: Nye, Gordon J
APPLICANT: Carr, Brian
APPLICANT: Desai, Nalini M
APPLICANT: Kostichka, N. Kristy
APPLICANT: Duck, Nicholas B
APPLICANT: Estruch, Juan J
TITLE OF INVENTION: Method For Isolating Vegetative Insecticidal
TITLE OF INVENTION: Protein Genes
NUMBER OF SEQUENCES: 50
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 5866326artis Corporation
STREET: 3054 Cornwallis Road
CITY: Research Triangle Park
STATE: NC

COUNTRY: USA
ZIP: 27709
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30B
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/471,046A
FILING DATE: 06-JUN-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/463,483
FILING DATE: 05-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/314,594
FILING DATE: 09-SEP-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/218,018
FILING DATE: 23-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/037,057
FILING DATE: 25-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Weigs, J Timothy
REGISTRATION NUMBER: 38,241
REFERENCE/DOCKET NUMBER: CGC1695/CIP3/DIV8 - SQLv4
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-541-8587
TELEFAX: 919-541-8689
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "reverse primer used to make
HYPOTHETICAL: NO
US-08-471-046A-34

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 ATGCAGCTGAAGCTT 840
| | | | |
Db 15 AAGGAGCTGAAGCTT 1

RESULT 482
US-08-774-306A-201
Sequence 201, Application US/08774306A
Patent No. 5869253
GENERAL INFORMATION:
APPLICANT: Draper, Kenneth G.
TITLE OF INVENTION: METHOD AND REAGENT FOR
TITLE OF INVENTION: INHIBITING HEPATITIS C
TITLE OF INVENTION: VIRUS REPLICATION
NUMBER OF SEQUENCES: 497
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/774,306A
FILING DATE: December 26, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/182,968
FILING DATE: January 13, 1994
APPLICATION NUMBER: 07/882,888
FILING DATE: May 14, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 223/227
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 201:
SEQUENCE CHARACTERISTICS:
LENGTH: 15
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-774-306A-201

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1190 TGAGTGTGGACCTT 1204
:|:|:|:|:|:
Db 1 UGUGUGUGGACCGU 15

RESULT 483
US-08-470-566B-34/c
Sequence 34, Application US/08470566B
Patent No. 5872212
GENERAL INFORMATION:
APPLICANT: Warren, Gregory W
APPLICANT: Koziel, Michael G
APPLICANT: Mullins, Martha A
APPLICANT: Nye, Gordon J
APPLICANT: Carr, Brian
APPLICANT: Desai, Nalini M
APPLICANT: Kostichka, N. Kristy
APPLICANT: Duck, Nicholas B
APPLICANT: Estruch, Juan J
TITLE OF INVENTION: No. 5872212el Pesticidal Proteins and Strains
NUMBER OF SEQUENCES: 52
CORRESPONDENCE ADDRESS:
ADDRESSEE: No. 5872212artis Corporation
STREET: 3054 Cornwallis Road
CITY: Research Triangle Park
STATE: NC
COUNTRY: USA
ZIP: 27709
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.30B
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/470,566B
FILING DATE: 06-JUN-1995
CLASSIFICATION: 530
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/463,483
FILING DATE: 05-JUN-1995
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/314,594
FILING DATE: 09-SEP-1994

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/218,018
FILING DATE: 23-MAR-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/037,057
FILING DATE: 25-MAR-1993
ATTORNEY/AGENT INFORMATION:
NAME: Meigs, J. Timothy
REGISTRATION NUMBER: 38,241
REFERENCE/DOCKET NUMBER: CGC1695/CIP3/DIV4 - SOLv4
TELECOMMUNICATION INFORMATION:
TELEPHONE: 919-541-8587
TELEFAX: 919-541-8689
INFORMATION FOR SEQ ID NO: 34:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "reverse primer used to make
DESCRIPTION: PCIB5526"
HYPOTHETICAL: NO
US-08-470-566B-34

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 ATGCAGCTGAGCTT 840
|:|:|:|:|:|:
Db 15 AAGGAGCTGAGCTT 1

RESULT 484
US-08-585-684B-775/c
Sequence 775, Application US/08585684B
Patent No. 5877021
GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
APPLICANT: McSwiggen, James
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
INDUCTION OF GRAFT TOLERANCE
TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
NUMBER OF SEQUENCES: 2751
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/585,684B
FILING DATE: January 16, 1996
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/000,951
FILING DATE: July 7, 1995
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440

; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 775:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-775

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1157 GGAAGTAAAGCAGCT 1171
Db 15 GGAAGCAAGCAGT 1

RESULT 485
US-08-585-684B-776/c
; Sequence 776, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585.684B
; FILING DATE: January 16, 1996

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 776:

; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-776

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1157 GGAAGTAAAGCAGCT 1171
Db 15 GGAAGCAAGCAGT 1

RESULT 486

US-08-585-684B-1365/c
; Sequence 1365, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071

; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/585.684B
; FILING DATE: January 16, 1996

; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 60/000,951
; FILING DATE: July 7, 1995
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard

; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510

; INFORMATION FOR SEQ ID NO: 1365:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-08-585-684B-1365

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1155 TTGGAAGTAAAGCAGC 1169
Db 15 TTGGAAGTACAGCTG 1

RESULT 487

US-08-585-684B-1376
; Sequence 1376, Application US/08585684B
; Patent No. 5877021
; GENERAL INFORMATION:

; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:

; ADDRESSEE: Lyon & Lyon

```

/ STREET: 633 West Fifth Street
/ STREET: Suite 4700
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/585,684B
/ FILING DATE: January 16, 1996
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 60/000,951
/ FILING DATE: July 7, 1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 218/078
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 1376:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-585-684B-1376

```

Query Match 0.9%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 33.3%; Pred. No. 1.9e+02;
 Matches 5; Conservative 8; Mismatches 2; Indels 0; Gaps 0;

```

QY 1109 TAGTTTCTGTGTTAA 1123
   :|:::|:|
Db 1 UGGUUCUGUCUAA 15

```

```

RESULT 488
US-08-585-684B-2270
/ Sequence 2270, Application US/08585684B
/ Patent No. 5877021
/ GENERAL INFORMATION:
/ APPLICANT: Stinchcomb, Daniel T.
/ APPLICANT: Jarvis, Thale
/ APPLICANT: McSwigen, James
/ TITLE OF INVENTION: METHOD AND REAGENT FOR THE
/ TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
/ TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
/ NUMBER OF SEQUENCES: 2/51
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: Lyon & Lyon
/ STREET: 633 West Fifth Street
/ CITY: Los Angeles
/ STATE: California
/ COUNTRY: U.S.A.
/ ZIP: 90071
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
/ MEDIUM TYPE: storage
/ COMPUTER: IBM Compatible
/ OPERATING SYSTEM: IBM P.C. DOS 5.0
/ SOFTWARE: FastSeq Version 1.5
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/585,684B
/ FILING DATE: January 16, 1996
/ PRIOR APPLICATION DATA:

```

```

/ APPLICATION NUMBER: 60/000,951
/ FILING DATE: July 7, 1995
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Warburg, Richard
/ REGISTRATION NUMBER: 32,327
/ REFERENCE/DOCKET NUMBER: 218/078
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (213) 489-1600
/ TELEFAX: (213) 955-0440
/ TELEX: 67-3510
/ INFORMATION FOR SEQ ID NO: 2270:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-585-684B-2270

```

Query Match 0.9%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 73.3%; Pred. No. 1.9e+02;
 Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

```

QY 929 CAGATCTGGAGAAGA 943
   |||:|:|
Db 1 CAGCUCUGAGAAGA 15

```

```

RESULT 489
US-08-854-041-4/c
/ Sequence 4, Application US/08854041
/ Patent No. 5916779
/ GENERAL INFORMATION:
/ APPLICANT: Pearson, Robert E.
/ APPLICANT: Dickson, Julie A.
/ APPLICANT: Mehropouyan, Majid
/ TITLE OF INVENTION: STRAND DISPLACEMENT AMPLIFICATION OF RNA
/ TITLE OF INVENTION: TARGETS
/ NUMBER OF SEQUENCES: 5
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: R. J. Rodrick, Becton Dickinson and Company
/ STREET: 1 Becton Drive
/ CITY: Franklin Lakes
/ STATE: NJ
/ COUNTRY: US
/ ZIP: 07417
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: Patent In Release #1.0, Version #1.30
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/08/854,041
/ FILING DATE:
/ CLASSIFICATION: 435
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Fugit, Donna R.
/ REGISTRATION NUMBER: 32,135
/ REFERENCE/DOCKET NUMBER: P-3853
/ INFORMATION FOR SEQ ID NO: 4:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 15 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ US-08-854-041-4

```

Query Match 0.9%; Score 11.8; DB 1; Length 15;
 Best Local Similarity 86.7%; Pred. No. 1.9e+02;
 Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

```

QY 276 CAAAGAGGAAGCAGC 290
   |||:|:|
Db 15 CAATGAGGAAGCTGC 1

```

```
RESULT 490
US-08-485-133-7/c
; Sequence 7, Application US/08485133
; Patent No. 5976789
; GENERAL INFORMATION:
; APPLICANT: Allibert, Patrice A.
; APPLICANT: Cros, Philippe
; APPLICANT: Mach, Bernard F.
; APPLICANT: Mandrand, Bernard F.
; APPLICANT: Tiercy, Jean-Marie
; TITLE OF INVENTION: SYSTEM OF PROBES ENABLING HLA-DR TYPING
; TITLE OF INVENTION: TO BE PERFORMED, AND TYPING METHOD USING SAID PROBES
; NUMBER OF SEQUENCES: 81
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OLIFF & BERRIDGE
; STREET: P.O. Box 19928
; CITY: Alexandria
; STATE: Virginia
; ZIP: 22320
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION NUMBER: US/08/485,133
; FILING DATE: 7-JUN-1995
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/030,143
; FILING DATE: 11-MAR-1993
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Berridge, William P.
; REGISTRATION NUMBER: 30,024
; REFERENCE/DOCKET NUMBER: WPB 28596A
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 703-836-6400
; TELEFAX: 703-836-2787
; INFORMATION FOR SEQ ID NO: 7:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-485-133-7
Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 782 TCTCCACAGTGCC 796
Db 15 TGTCCACAGGGCC 1

RESULT 491
US-08-469-334-34/c
; Sequence 34, Application US/08469334
; Patent No. 5990383
; GENERAL INFORMATION:
; APPLICANT: Warren, Gregory W
; APPLICANT: Koziel, Michael G
; APPLICANT: Mullins, Martha A
; APPLICANT: Nye, Gordon J
; APPLICANT: Carr, Brian
; APPLICANT: Desai, Nalini M
; APPLICANT: Kostichka, N. Kristy
; APPLICANT: Duck, Nicholas B
; APPLICANT: Estruch, Juan J
; TITLE OF INVENTION: No. 5990383el Pesticidal Proteins and Strains
```

```
; NUMBER OF SEQUENCES: 50
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CIBA-GEIGY Corporation
; STREET: 7 Skyline Drive
; CITY: Hawthorne
; STATE: NY
; COUNTRY: USA
; ZIP: 10532
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30B
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/469,334
; FILING DATE: 06-JUN-1995
; CLASSIFICATION: 800
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/463,483
; FILING DATE:
; APPLICATION NUMBER: US 08/314,594
; FILING DATE: 09-SEP-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/218,018
; FILING DATE: 23-MAR-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/037,057
; FILING DATE: 25-MAR-1993
; ATTORNEY/AGENT INFORMATION:
; NAME: Spruill, W. Murray
; REGISTRATION NUMBER: 32,943
; REFERENCE/DOCKET NUMBER: CGC 1695/CIP3
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: 919-541-8615
; TELEFAX: 919-541-8689
; INFORMATION FOR SEQ ID NO: 34:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: other nucleic acid
; DESCRIPTION: /desc = "reverse primer used to make
; DESCRIPTION: PCIB5526"
; HYPOTHETICAL: NO
; US-08-469-334-34
Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 ATGCAGCTGAAGCTT 840
Db 15 AAGGAGCTGAAGCTT 1

RESULT 492
US-08-343-998-24
; Sequence 24, Application US/08343998A
; Patent No. 6020123
; GENERAL INFORMATION:
; APPLICANT: Sonigo, Pierre
; APPLICANT: Brechot, Christian
; APPLICANT: Courghard, Valerie
; TITLE OF INVENTION: OLIGONUCLEOTIDE SEQUENCES FOR THE AMPLIFICATION OF THE
; TITLE OF INVENTION: GENOME OF THE RETROVIRUSES OF THE HIV-2 AND SIV TYPE,
; TITLE OF INVENTION: AND THEIR USES FOR IN VITRO DIAGNOSIS OF THE INFECTIONS
; TITLE OF INVENTION: DUE TO THESE VIRUSES
; FILE REFERENCE: 2356.0065-01
; CURRENT APPLICATION NUMBER: US/08/343,998A
; CURRENT FILING DATE: 1994-11-18
; EARLIER APPLICATION NUMBER: 07/820,600
; EARLIER FILING DATE: 1992-01-22
```

```
; EARLIER APPLICATION NUMBER: PCT/FR90/00394
; EARLIER FILING DATE: 1990-06-05
; NUMBER OF SEQ ID NOS: 25
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 24
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Simian immunodeficiency virus
; FEATURE:
US-08-343-998-24

Query Match          0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 387 AGAGTGGCAGCAAT 401
DB 1 AGAGTGGCAGCAACT 15

RESULT 493
US-08-832-021-25
; Sequence 25, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
; APPLICANT: Combates, N.
; APPLICANT: Pardinas, J.
; APPLICANT: Parimoo, S.
; APPLICANT: Prouty, S.
; APPLICANT: Stenn, K.
; FILE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
; CURRENT APPLICATION NUMBER: US/08/832,021
; CURRENT FILING DATE: 1997-04-02
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 25
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-25

Query Match          0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGA 1159
DB 1 TTTTTCCTTTTGA 15

RESULT 494
US-08-832-021-37
; Sequence 37, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
; APPLICANT: Combates, N.
; APPLICANT: Pardinas, J.
; APPLICANT: Parimoo, S.
; APPLICANT: Prouty, S.
; APPLICANT: Stenn, K.
; FILE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
; CURRENT APPLICATION NUMBER: US/08/832,021
; CURRENT FILING DATE: 1997-04-02
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 37
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-37

Query Match          0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGA 1159
DB 1 TTTTTCCTTTTGA 15

RESULT 496
US-08-832-021-43
; Sequence 43, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
; APPLICANT: Combates, N.
; APPLICANT: Pardinas, J.
; APPLICANT: Parimoo, S.
; APPLICANT: Prouty, S.
; APPLICANT: Stenn, K.
; FILE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
; CURRENT APPLICATION NUMBER: US/08/832,021
; CURRENT FILING DATE: 1997-04-02
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 43
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-43

Query Match          0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGA 1159
DB 1 TTTTTCCTTTTGA 15

RESULT 498
US-08-832-021-43
; Sequence 43, Application US/08832021
; Patent No. 6045998
; GENERAL INFORMATION:
; APPLICANT: Combates, N.
; APPLICANT: Pardinas, J.
; APPLICANT: Parimoo, S.
; APPLICANT: Prouty, S.
; APPLICANT: Stenn, K.
; FILE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY
; CURRENT APPLICATION NUMBER: US/08/832,021
; CURRENT FILING DATE: 1997-04-02
; NUMBER OF SEQ ID NOS: 64
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 43
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-08-832-021-43

Query Match          0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
```

QY 1144 TTTTTCCTTTTGG 1158
Db 1 TTTTTCCTTTTGG 15

RESULT 497

US-08-832-021-45
; Sequence 45, Application US/08832021

; Patent No. 6045998

; GENERAL INFORMATION:

; APPLICANT: Combates, N.

; APPLICANT: Pardinas, J.

; APPLICANT: Parimoo, S.

; APPLICANT: Prouty, S.

; APPLICANT: Stenn, K.

; TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY

; FILE REFERENCE: JBP-382

; CURRENT APPLICATION NUMBER: US/08/832,021

; CURRENT FILING DATE: 1997-04-02

; NUMBER OF SEQ ID NOS: 64

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 45

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: primer

US-08-832-021-45

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGG 1159
Db 1 TTTTTCCTTTTGG 15

RESULT 498

US-08-832-021-47

; Sequence 47, Application US/08832021

; Patent No. 6045998

; GENERAL INFORMATION:

; APPLICANT: Combates, N.

; APPLICANT: Pardinas, J.

; APPLICANT: Parimoo, S.

; APPLICANT: Prouty, S.

; APPLICANT: Stenn, K.

; TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY

; FILE REFERENCE: JBP-382

; CURRENT APPLICATION NUMBER: US/08/832,021

; CURRENT FILING DATE: 1997-04-02

; NUMBER OF SEQ ID NOS: 64

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 47

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: primer

US-08-832-021-47

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1144 TTTTTCCTTTTGG 1158
Db 1 TTTTTCCTTTTGG 15

RESULT 499

US-08-832-021-61
; Sequence 61, Application US/08832021

; Patent No. 6045998

; GENERAL INFORMATION:

; APPLICANT: Combates, N.

; APPLICANT: Pardinas, J.

; APPLICANT: Parimoo, S.

; APPLICANT: Prouty, S.

; APPLICANT: Stenn, K.

; TITLE OF INVENTION: IMPROVED TECHNIQUE FOR DIFFERENTIAL DISPLAY

; FILE REFERENCE: JBP-382

; CURRENT APPLICATION NUMBER: US/08/832,021

; CURRENT FILING DATE: 1997-04-02

; NUMBER OF SEQ ID NOS: 64

; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 61

; LENGTH: 15

; TYPE: DNA

; ORGANISM: Artificial Sequence

; FEATURE:

; OTHER INFORMATION: Description of Artificial Sequence: primer

US-08-832-021-61

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1145 TTTTTCCTTTTGG 1159
Db 1 TTTTTCCTTTTGG 15

RESULT 500

US-09-300-529-34/c

; Sequence 34, Application US/09300529

; Patent No. 6066783

; GENERAL INFORMATION:

; APPLICANT: Warren, Gregory W

; APPLICANT: Kozziel, Michael G

; APPLICANT: Mullins, Martha A

; APPLICANT: Nye, Gordon J

; APPLICANT: Carr, Brian

; APPLICANT: Desai, Nalini M

; APPLICANT: Kostichka, N. Kristy

; APPLICANT: Duck, Nicholas B

; APPLICANT: Estruch, Juan J

; TITLE OF INVENTION: Genes Encoding Insecticidal Proteins

; NUMBER OF SEQUENCES: 50

; CORRESPONDENCE ADDRESS:

; ADDRESSEE: No. 6066783artis Corporation

; STREET: 3054 Cornwallis Road

; CITY: Research Triangle Park

; STATE: NC

; COUNTRY: USA

; ZIP: 27709

; COMPUTER READABLE FORM:

; MEDIUM TYPE: Floppy disk

; COMPUTER: IBM PC compatible

; OPERATING SYSTEM: PC-DOS/MS-DOS

; SOFTWARE: PatentIn Release #1.0, Version #1.30B

; CURRENT APPLICATION DATA:

; APPLICATION NUMBER: US/09/300,529

; FILING DATE: TBA

; CLASSIFICATION:

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/469,334

; FILING DATE: 06-JUN-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/463,483

; FILING DATE: 05-JUN-1995

; PRIOR APPLICATION DATA:

; APPLICATION NUMBER: US 08/314,594

; FILING DATE: 09-SEP-1994

;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER: US 08/218,018
;; FILING DATE: 23-MAR-1994
;; PRIOR APPLICATION DATA: US 08/037,057
;; FILING DATE: 25-MAR-1993
;; ATTORNEY/AGENT INFORMATION:
;; NAME: Meigs, J. Timothy
;; REGISTRATION NUMBER: 38,241
;; REFERENCE/DOCKET NUMBER: S-19506L
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 919-541-8587
;; TELEFAX: 919-541-8689
;; INFORMATION FOR SEQ ID NO: 34:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: other nucleic acid
;; DESCRIPTION: /desc = "reverse primer used to make
;; HYPOTHETICAL: NO
;; US-09-300-529-34

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 826 ATGCAGCTGAAGCTT 840
Db 15 AAGGAGCTGAAGCTT 1

RESULT 501

US-09-064-156A-201
; Sequence 201, Application US/09064156A
; Patent No. 6132966
; GENERAL INFORMATION:
; APPLICANT: Draper, Kenneth G.
; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: INHIBITING HEPATITIS C
; TITLE OF INVENTION: VIRUS REPLICATION
; NUMBER OF SEQUENCES: 498
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/064,156A
; FILING DATE: April 21, 1998
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/774,306
; FILING DATE: December 26, 1996
; APPLICATION NUMBER: 08/182,968
; FILING DATE: January 13, 1994
; APPLICATION NUMBER: 07/882,888
; FILING DATE: May 14, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 234/083
; TELECOMMUNICATION INFORMATION:

;; TELEPHONE: (213) 489-1600
;; TELEFAX: (213) 955-0440
;; TELEX: 67-3510
;; INFORMATION FOR SEQ ID NO: 201:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 15
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; US-09-064-156A-201

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 53.3%; Pred. No. 1.9e+02;
Matches 8; Conservative 5; Mismatches 2; Indels 0; Gaps 0;

QY 1190 TGAGTGTGGACCTT 1204
Db 1 UGUGUGUGGACCGU 15

RESULT 502

US-09-071-845-74
; Sequence 74, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 74:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid

STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-74

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 908 CCCTGGTCTTAAGG 922
DB 1 CCCGGGUCCUAGAG 15

RESULT 503

US-09-071-845-105/c
Sequence 105, Application US/09071845
Patent No. 6132967

GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071.845
FILING DATE:
CLASSIFICATION:

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 105:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-105

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 308 GGGCTGCAACTCCAT 322
DB 15 GGGCTGGAACCCCAT 1

RESULT 504

US-09-071-845-393/c
Sequence 393, Application US/09071845
Patent No. 6132967

GENERAL INFORMATION:

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggen
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/071,845
FILING DATE:
CLASSIFICATION:

PRIOR APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620
FILING DATE: August 17, 1994
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 393:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-071-845-393

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1260 CCAGGTTGAGGCCT 1274
DB 15 CCAGGCTGAGTCTC 1

RESULT 505

```

US-09-071-845-656/c
; Sequence 656, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan
; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 656:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-656

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1260 CCAGGTGAGGCCT 1274
Db 15 CCAGGTGAGGTCT 1

RESULT 506
US-09-038-073-775/c
; Sequence 775, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible

```

```

; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSEQ Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 775:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-038-073-775

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1157 GGAAGTAAGCAGCT 1171
Db 15 GGAAGCAAGCAGGT 1

RESULT 507
US-09-038-073-776/c
; Sequence 776, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible

```

OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 776:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-776

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1157 GGAAGTAAAGCAGCT 1171
Db 15 GGAAGCAAGCAGGT 1

RESULT 508

US-09-038-073-1365/c
Sequence 1365, Application US/09038073
Patent No. 6194150

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510

INFORMATION FOR SEQ ID NO: 1365:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1365

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

INFORMATION FOR SEQ ID NO: 1365:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1365

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1155 TTGGAAGTAAAGCAG 1169
Db 15 TTGGAAGTAAAGCAGCTG 1

RESULT 509

US-09-038-073-1376
Sequence 1376, Application US/09038073
Patent No. 6194150

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Daniel T.
APPLICANT: Jarvis, Thale
TITLE OF INVENTION: METHOD AND REAGENT FOR THE
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1376:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1376

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1157 GGAAGTAAAGCAGCT 1171
Db 15 GGAAGCAAGCAGGT 1

COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: FastSeq Version 1.5
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/038,073
FILING DATE:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/585,684
FILING DATE:
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 218/078
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1376:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1376

INFORMATION FOR SEQ ID NO: 1376:
SEQUENCE CHARACTERISTICS:
LENGTH: 15 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-09-038-073-1376

Query Match

Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1109 TAGTTTCTGTTTAA 1123
Db 1 UGGUUCUGUCUAA 15

```
RESULT 510
US-09-038-073-2270
; Sequence 2270, Application US/09038073
; Patent No. 6194150
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Daniel T.
; APPLICANT: Jarvis, Thale
; APPLICANT: McSwigen, James
; TITLE OF INVENTION: METHOD AND REAGENT FOR THE
; TITLE OF INVENTION: INDUCTION OF GRAFT TOLERANCE
; TITLE OF INVENTION: AND REVERSAL OF IMMUNE RESPONSES
; NUMBER OF SEQUENCES: 2751
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: FastSeq Version 1.5
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/038,073
; FILING DATE:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: 08/585,684
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 218/078
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 2270:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 15 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-038-073-2270

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 73.3%; Pred. No. 1.9e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 929 CAGATCTGGAGAGA 943
Db 1 CAGCUCUUGAGAGA 15

RESULT 511
US-09-275-850-19
; Sequence 19, Application US/09275850A
; Patent No. 6261774
; GENERAL INFORMATION:
; APPLICANT: Pagratis, Nikos
; APPLICANT: Gold, Larry
; APPLICANT: Shatland, Timur
; APPLICANT: Javornik, Brenda
; TITLE OF INVENTION: Truncation SELEX Method
; FILE REFERENCE: NEX 79
; CURRENT APPLICATION NUMBER: US/09/275,850A
; CURRENT FILING DATE: 1999-03-24
; NUMBER OF SEQ ID NOS: 351
; SOFTWARE: PatentIn Ver. 2.0

; SEQ ID NO 19
; LENGTH: 15
; TYPE: RNA
; ORGANISM: E. coli
US-09-275-850-19

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 719 CCCAGCAGCAGGGG 733
Db 1 CCCAGCACAGCGG 15

RESULT 512
US-09-344-888A-9/c
; Sequence 9, Application US/09344888A
; Patent No. 6291245
; GENERAL INFORMATION:
; APPLICANT: Kopetzki, Erhard
; APPLICANT: Schantz, Christian
; TITLE OF INVENTION: New Host-Vector System
; FILE REFERENCE: CD20315
; CURRENT APPLICATION NUMBER: US/09/344,888A
; CURRENT FILING DATE: 1999-06-25
; PRIOR APPLICATION NUMBER: EP98113156.8
; PRIOR FILING DATE: 1998-07-15
; PRIOR APPLICATION NUMBER: EP98119078.8
; PRIOR FILING DATE: 1998-10-09
; NUMBER OF SEQ ID NOS: 24
; SOFTWARE: PatentIn Ver. 2.0
; SEQ ID NO 9
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Artificial Sequence
; FEATURE:
; OTHER INFORMATION: Description of Artificial Sequence: primer
US-09-344-888A-9

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 591 GCCCCCCCAGCGCT 605
Db 15 GCCCCCCCAGCGCT 1

RESULT 513
US-09-081-646-513/c
; Sequence 513, Application US/09081646
; Patent No. 633152
; GENERAL INFORMATION:
; APPLICANT: Kinzler, Kenneth
; APPLICANT: Vogelstein, Bert
; APPLICANT: Zhang, Lin
; APPLICANT: Zhou, Wei
; TITLE OF INVENTION: Gene Expression Profiles in No. 6333152mal and
; TITLE OF INVENTION: Cancer Cells
; FILE REFERENCE: 01107.74664
; CURRENT APPLICATION NUMBER: US/09/081,646
; CURRENT FILING DATE: 1998-05-20
; EARLIER APPLICATION NUMBER: 60/047,352
; EARLIER FILING DATE: 1997-05-21
; NUMBER OF SEQ ID NOS: 871
; SOFTWARE: FastSeq for Windows Version 3.0
; SEQ ID NO 513
; LENGTH: 15
; TYPE: DNA
; ORGANISM: Homo sapiens
US-09-081-646-513
```


5182195-24

Query Match 0.9%; Score 11.8; DB 1; Length 15;
Best Local Similarity 86.7%; Pred. No. 1.9e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 672 GGCCAGCGTGGTATT 686
| | | | | | | | | |
Db 1 GGCTACGCTGGTATT 15

RESULT 518

US-07-988-194A-16/c
; Sequence 16, Application US/07988194A
; Patent No. 5359046
; GENERAL INFORMATION:
; APPLICANT: Capon, Daniel J.
; APPLICANT: Weiss, Arthur
; APPLICANT: Irving, Brian A.
; APPLICANT: Roberts, Margo R.
; APPLICANT: Zsebo, Krisztina
; TITLE OF INVENTION: Chimeric Chains for Receptor
; TITLE OF INVENTION: Associated Signal Transduction Pathways
; NUMBER OF SEQUENCES: 49
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Flehr, Hobbach, Test, Albritton &
; ADDRESSEE: Herbert
; STREET: 4 Embarcadero Center, Suite 3400
; CITY: San Francisco
; STATE: CA
; COUNTRY: USA
; ZIP: 94111-4187

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy Disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/07/988,194A
FILING DATE: December 9, 1992
CLASSIFICATION: 536
ATTORNEY/AGENT INFORMATION:
NAME: Rowland, Bertram I.
REGISTRATION NUMBER: 20015
REFERENCE/DOCKET NUMBER: A-55107-1 CELL-0051
TELEPHONE: 415-781-1989
TELEFAX: 415-398-3249
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cdna
US-07-988-194A-16

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1239 GCTGGACGTGGCCAT 1253
| | | | | | | | | |
Db 15 GCTGGACATGGCCCT 1

RESULT 519

US-08-233-030-52
; Sequence 52, Application US/08233030
; Patent No. 5639655
; GENERAL INFORMATION:
; APPLICANT: James D. Thompson
; APPLICANT: Kenneth G. Draper

; TITLE OF INVENTION: METHOD AND REAGENT FOR
; TITLE OF INVENTION: TREATMENT OF PROMYELOCYTIC
; TITLE OF INVENTION: LEUKEMIA
; NUMBER OF SEQUENCES: 62
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; CITY: Los Angeles
; STATE: California
; COUNTRY: USA
; ZIP: 90017
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM MS-DOS (Version 5.0)
; SOFTWARE: WordPerfect (Version 5.1)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/233,030
; FILING DATE:
; CLASSIFICATION: 536
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/008,910
; FILING DATE:
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 197/240
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 52:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-233-030-52

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 73.3%; Pred. No. 2.3e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 1053 CAGCCCTGGCCTTCC 1067
| | | | | | | | | |
Db 1 CAGCCCTGGCCTTCC 15

RESULT 520

US-08-291-932A-780
; Sequence 780, Application US/08291932A
; Patent No. 5658780
; GENERAL INFORMATION:
; APPLICANT: Stinchcomb, Dan T.
; APPLICANT: Draper, Kenneth G.
; APPLICANT: McSwiggen, James
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; TITLE OF INVENTION: DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: NF-KB
; NUMBER OF SEQUENCES: 830
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; STREET: Suite 4700
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible

OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA: US/08/291,932A
APPLICATION NUMBER: 08/245,466
FILING DATE: August 15, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/245,466
FILING DATE: May 18, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 780:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-291-932A-780

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 80.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 480 GGACTGCCGAGCG 494
Db 1 GGACUGCGGGAUGG 15

RESULT 521

US-08-291-932A-814
Sequence 814, Application US/08291932A
Patent No. 5658780

GENERAL INFORMATION:
APPLICANT: Stinchcomb, Dan T.
APPLICANT: Draper, Kenneth G.
APPLICANT: McSwiggen, James
TITLE OF INVENTION: RIBOZYME TREATMENT OF
TITLE OF INVENTION: DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: NF-KB
NUMBER OF SEQUENCES: 830
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: Storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/291,932A
FILING DATE: August 15, 1994
CLASSIFICATION: 514
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/245,466

Two

FILING DATE: May 18, 1994
APPLICATION NUMBER: 07/987,132
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/157
TELECOMMUNICATION INFORMATION:
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 814:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-291-932A-814

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 80.0%; Pred. No. 2.3e+02;
Matches 12; Conservative 1; Mismatches 2; Indels 0; Gaps 0;

Qy 480 GGACTGCCGAGCG 494
Db 1 GGACUGCGGGAUGG 15

RESULT 522

US-08-258-152-18/c
Sequence 18, Application US/08258152
Patent No. 5686279

GENERAL INFORMATION:
APPLICANT: FINER, MITCHELL H.
APPLICANT: ROBERTS, MARGO R.
APPLICANT: DULL, THOMAS J.
APPLICANT: ZSEBO, KRISZTINA M.
APPLICANT: QIN, LU

TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL TRANSDUCTION
TITLE OF INVENTION: OF MAMMALIAN CELLS
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: CELL GENESYS, INC.
STREET: 322 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94404

COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent In Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/258,152
FILING DATE: 10-JUN-1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/076,299
FILING DATE: 11-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: KRUPEN, KAREN I.
REGISTRATION NUMBER: 34,647
REFERENCE/DOCKET NUMBER: CELL 13.1
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-358-9600 X131
TELEFAX: 415-349-7392
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single

```
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
US-08-258-152-18

Query Match      0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1239 GCTGGACGAGGCGCAT 1253
Db 15 GCTGGACATGGCCCT 1

RESULT 523
US-08-241-465B-17
; Sequence 17, Application US/08241465B
; Patent No. 5719125
; GENERAL INFORMATION:
; APPLICANT: FUJIO SUZUKI
; APPLICANT: YUJI HIRAKI
; APPLICANT: KAZUHIRO TAKAHASHI
; APPLICANT: JUNKO SUZUKI
; APPLICANT: JUN KONDO
; APPLICANT: ATSUKO KOHARA
; APPLICANT: AKIKO MORI
; APPLICANT: EI YAMADA
; TITLE OF INVENTION: HUMAN CHONDROMODULIN-I PROTEIN
; NUMBER OF SEQUENCES: 21
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Wenderoth, Lind & Ponack
; STREET: 805 Fifteenth Street, N.W., #700
; CITY: Washington
; COUNTRY: D.C.
; ZIP: 20005
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/241,465B
; FILING DATE: May 11, 1994
; CLASSIFICATION: 435
; ATTORNEY/AGENT INFORMATION:
; NAME: Warren M. Cheek, Jr.
; REGISTRATION NUMBER: 33,367
; REFERENCE/DOCKET NUMBER:
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 371-8850
; TELEFAX:
; TELEX:
; INFORMATION FOR SEQ ID NO: 17:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: Other nucleic acid, Synthetic DNA
US-08-241-465B-17

Query Match      0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 420 CCTAGACAGGAGGCAC 434
Db 2 CCTAGACTGGATCAC 16

RESULT 524
US-08-465-485A-16/c
; Sequence 16, Application US/08465485A
; Patent No. 5831066
```

```
; GENERAL INFORMATION:
; APPLICANT: Read, John
; TITLE OF INVENTION: Regulation of bcl-2 Gene Expression
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCLELLAND, MAIER & NEUSTADT,
; ADDRESSEE: P.C.
; STREET: 1755 S. Jefferson Davis Hwy., Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/465,485A
; FILING DATE: 05-JUN-1995
; CLASSIFICATION: 514
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/124,256
; FILING DATE: 20-SEP-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/840,716
; FILING DATE: 21-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/288,692
; FILING DATE: 22-DEC-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Fortney, Andrew D.
; REGISTRATION NUMBER: 34,600
; REFERENCE/DOCKET NUMBER: 3335-070-55 CONT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (408) 436-2070
; TELEFAX: (408) 436-2075
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: YES
US-08-465-485A-16

Query Match      0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 187 CCGCGCGCCCGCCG 201
Db 15 CCGCGCGCGCTCCG 1

RESULT 525
US-08-076-299A-18/c
; Sequence 18, Application US/08076299A
; Patent No. 5834256
; GENERAL INFORMATION:
; APPLICANT: FINER, MITCHELL H.
; APPLICANT: ROBERTS, MARGO R.
; APPLICANT: DULL, THOMAS J.
; APPLICANT: ZSEHO, KRISZTINA M.
; APPLICANT: QIN, LU
; TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
; TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL TRANSDUCTION
; TITLE OF INVENTION: OF MAMMALIAN CELLS
; NUMBER OF SEQUENCES: 30
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CELL GENESYS, INC.
; STREET: 322 LAKESIDE DRIVE
```


;; CITY: POSTER CITY
;; STATE: CALIFORNIA
;; COUNTRY: USA
;; ZIP: 94404
;;
;; COMPUTER READABLE FORM:
;; MEDIUM TYPE: Floppy disk
;; COMPUTER: IBM PC compatible
;; OPERATING SYSTEM: PC-DOS/MS-DOS
;; SOFTWARE: Patent In Release #1.0, Version #1.25
;; CURRENT APPLICATION DATA:
;; APPLICATION NUMBER: US/08/076,299A
;; FILING DATE: 11-JUN-1993
;; CLASSIFICATION: 435
;; PRIOR APPLICATION DATA:
;; APPLICATION NUMBER:
;; FILING DATE:
;; ATTORNEY/AGENT INFORMATION:
;; NAME: KRUPEN, KAREN I.
;; REGISTRATION NUMBER: 34,647
;; REFERENCE/DOCKET NUMBER: CELL 13.0
;; TELECOMMUNICATION INFORMATION:
;; TELEPHONE: 415-358-9600 X131
;; TELEFAX: 415-349-7392
;; INFORMATION FOR SEQ ID NO: 18:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 16 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;; MOLECULE TYPE: DNA (genomic)
;;
US-08-076-299A-18

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1239 GCTGGACGTGGCCAT 1253
Db 15 GCTGGACATGGCCCT 1

RESULT 526
US-08-527-060-2/c
; Sequence 2, Application US/08527060
; Patent No. 5834440
; GENERAL INFORMATION:
; APPLICANT: Goldenberg, Tsvi
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT
; TITLE OF INVENTION: AND/OR PREVENTION OF RESTENOSIS
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/527,060
; FILING DATE: 12-SEP-1995
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 480124.402C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900

;; TELEFAX: (206) 682-6031
;; INFORMATION FOR SEQ ID NO: 2:
;; SEQUENCE CHARACTERISTICS:
;; LENGTH: 16 base pairs
;; TYPE: nucleic acid
;; STRANDEDNESS: single
;; TOPOLOGY: linear
;;
US-08-527-060-2

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 601 AGCTGAAGCTGAC 615
Db 16 ATCTGAAGACTGAC 2

RESULT 527
US-08-527-060-12
; Sequence 12, Application US/08527060
; Patent No. 5834440
; GENERAL INFORMATION:
; APPLICANT: Goldenberg, Tsvi
; TITLE OF INVENTION: RIBOZYME THERAPY FOR THE TREATMENT
; TITLE OF INVENTION: AND/OR PREVENTION OF RESTENOSIS
; NUMBER OF SEQUENCES: 35
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: SEED and BERRY
; STREET: 6300 Columbia Center, 701 Fifth Avenue
; CITY: Seattle
; STATE: Washington
; COUNTRY: USA
; ZIP: 98104-7092
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/527,060
; FILING DATE: 12-SEP-1995
; CLASSIFICATION: 514
; ATTORNEY/AGENT INFORMATION:
; NAME: Mcmasters, David D.
; REGISTRATION NUMBER: 33,963
; REFERENCE/DOCKET NUMBER: 480124.402C1
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (206) 622-4900
; TELEFAX: (206) 682-6031
; INFORMATION FOR SEQ ID NO: 12:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
;
US-08-527-060-12

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 1039 GACTCTTCCACGAC 1053
Db 1 GACTGTCCACGTC 15

RESULT 528
US-08-292-620A-1628/c
; Sequence 1628, Application US/08292620A
; Patent No. 5837542
; GENERAL INFORMATION:
; TELEPHONE: (206) 622-4900

APPLICANT: Susan Grimm
APPLICANT: Dan T. Stinchcomb
APPLICANT: James McSwiggan
APPLICANT: Sean Sullivan
APPLICANT: Kenneth G. Draper
TITLE OF INVENTION: RIBOZYME TREATMENT OF
DISEASES OR CONDITIONS
TITLE OF INVENTION: RELATED TO LEVELS OF
TITLE OF INVENTION: INTRACELLULAR ADHESION
TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
NUMBER OF SEQUENCES: 2390
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/292,620A
FILING DATE: August 17, 1994
CLASSIFICATION: 435
PRIOR APPLICATION DATA: including application
PRIOR APPLICATION DATA: described below:
APPLICATION NUMBER: 08/008,895
FILING DATE: January 19, 1993
APPLICATION NUMBER: 07/989,849
FILING DATE: December 7, 1992
ATTORNEY/AGENT INFORMATION:
NAME: Warburg, Richard J.
REGISTRATION NUMBER: 32,327
REFERENCE/DOCKET NUMBER: 208/149
TELEPHONE: (213) 489-1600
TELEFAX: (213) 955-0440
TELEX: 67-3510
INFORMATION FOR SEQ ID NO: 1628:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
US-08-292-620A-1628

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 595 CCCACCGCTGAG 609
Db 15 CCCACCGCTGTAG 1

RESULT 529
US-08-438-582-18/c
Sequence 18, Application US/08438582
Patent No. 5858740
GENERAL INFORMATION:
APPLICANT: FINER, MITCHELL H.
APPLICANT: ROBERTS, MARGO R.
APPLICANT: DULL, THOMAS J.
APPLICANT: ZSEBO, KRISTINA M.
APPLICANT: QIN, LU
TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTION

two

TITLE OF INVENTION: OF MAMMALIAN CELLS
NUMBER OF SEQUENCES: 32
CORRESPONDENCE ADDRESS:
ADDRESSEE: CELL GENESYS, INC.
STREET: 322 LAKESIDE DRIVE
CITY: FOSTER CITY
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/438,582
FILING DATE: 10-MAY-1995
CLASSIFICATION: 435
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/258,152
FILING DATE: 10-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/076,299
FILING DATE: 11-JUN-93
ATTORNEY/AGENT INFORMATION:
NAME: KRUPEN, KAREN I.
REGISTRATION NUMBER: 34,647
REFERENCE/DOCKET NUMBER: CELL 13.2
TELEPHONE: 415-358-9600 X131
TELEFAX: 415-349-7392
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-438-582-18

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1239 GCTGGACGTGCCAT 1253
Db 15 GCTGGACATGCCCT 1

RESULT 530
US-08-282-197C-20
Sequence 20, Application US/08282197C
Patent No. 5871730
GENERAL INFORMATION:
APPLICANT: Brzezinski, Ryszard
APPLICANT: Dery, Claude V
APPLICANT: Beaulieu, Carole
TITLE OF INVENTION: Thermostable Xylanase DNA, Protein and
NUMBER OF SEQUENCES: 67
CORRESPONDENCE ADDRESS:
ADDRESSEE: Sterne, Kessler, Goldstein & Fox P.L.L.C.
STREET: 1100 New York Ave., NW
CITY: Washington
STATE: DC
COUNTRY: USA
ZIP: 20005
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.25
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/282,197C
FILING DATE: 29-JUL-1994
CLASSIFICATION: 435
ATTORNEY/AGENT INFORMATION:
NAME: Cimbala, Michele A.
REGISTRATION NUMBER: 33,851
REFERENCE/DOCKET NUMBER: 1050.0410000
TELECOMMUNICATION INFORMATION:
TELEPHONE: 202-371-2600
TELEFAX: 202-371-2540
INFORMATION FOR SEQ ID NO: 20:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: both
TOPOLOGY: both
US-08-282-197C-20

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 73.3%; Pred. No. 2.3e+02;
Matches 11; Conservative 2; Mismatches 2; Indels 0; Gaps 0;

QY 530 AGGAGCAGCTGGTG 544
|||||:|:|:|:|:
DB 2 AGGAGGAGCUGAUG 16

RESULT 531

US-08-137-024-2
Sequence 2, Application US/08137024
Patent No. 6005167

GENERAL INFORMATION:
APPLICANT: VAN TUNEN, Adrianus, J.
APPLICANT: VAN DER MEER, Ingrid M.
APPLICANT: MOL, Josephus N.M.
TITLE OF INVENTION: MALE-STERILE PLANTS, METHODS
TITLE OF INVENTION: FOR OBTAINING MALE STERILE
TITLE OF INVENTION: PLANTS AND RECOMBINANT DNA FOR
NUMBER OF SEQUENCES: 7
CORRESPONDENCE ADDRESS:
ADDRESSEE: Ladas & Parry
STREET: 26 West 61st Street
CITY: New York
STATE: New York
COUNTRY: USA
ZIP: 10023

COMPUTER READABLE FORM:
MEDIUM TYPE: Diskette 3.50 inch, DS, DD 720
MEDIUM TYPE: Kb/720Kb
COMPUTER: IBM PC Compatible 286 SX 12 Mhz
OPERATING SYSTEM: DOS
SOFTWARE: WordPerfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/137,024
FILING DATE: 14-OCT-1993
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: PCT/NL92/00075
FILING DATE: 15-APR-1992
PRIOR APPLICATION DATA:
APPLICATION NUMBER: EP 91200910
FILING DATE: 16-APR-1991
ATTORNEY/AGENT INFORMATION:
NAME: MASS, Clifford, J.
REGISTRATION NUMBER: 30086
REFERENCE/DOCKET NUMBER: U-9373
TELECOMMUNICATION INFORMATION:
TELEPHONE: (212) 708-1800
TELEFAX: (212) 246-8959
INFORMATION FOR SEQ ID NO: 2:
SEQUENCE CHARACTERISTICS:

LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: double
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
HYPOTHETICAL: YES
ANTI-SENSE: NO
ORIGINAL SOURCE:
ORGANISM: Petunia hybrida
US-08-137-024-2

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 387 AGAGGTGGCAGCAAT 401
|||||:|:|:|:|:
DB 2 AGAGTGCACAGAAAT 16

RESULT 532

US-08-817-145-8/c
Sequence 8, Application US/08817145
Patent No. 6025329

GENERAL INFORMATION:
APPLICANT: UTSUMI, Jun
APPLICANT: SUDO, Tetsuo
APPLICANT: TANAKA, Yasuhiko
APPLICANT: MATSUI, Mizuo
TITLE OF INVENTION: THERAPEUTIC AGENT FOR OPHTHALMIC
TITLE OF INVENTION: DISEASES
NUMBER OF SEQUENCES: 19
CORRESPONDENCE ADDRESS:
ADDRESSEE: Birch, Stewart, Kolasch & Birch, LLP.
STREET: P.O. Box 747
CITY: Falls Church
STATE: VA
COUNTRY: USA
ZIP: 22040-0747
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/817,145
FILING DATE: 02-JUL-1997
CLASSIFICATION: 514
ATTORNEY/AGENT INFORMATION:
NAME: MURPHY Jr., Gerald M.
REGISTRATION NUMBER: 28,977
REFERENCE/DOCKET NUMBER: 760-230P
TELECOMMUNICATION INFORMATION:
TELEPHONE: 703-205-8000
TELEFAX: 703-205-8050
INFORMATION FOR SEQ ID NO: 8:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: other nucleic acid
DESCRIPTION: /desc = "Synthetic Primer"

US-08-817-145-8

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY 625 GACCGGCTCCAGGAG 639
|||||:|:|:|:|:
DB 16 GACGGGCTCCAGGAG 2

RESULT 533
US-09-080-285-16/c
; Sequence 16, Application US/09080285
; Patent No. 6040181
; GENERAL INFORMATION:
; APPLICANT: Reed, John
; TITLE OF INVENTION: Regulation of bcl-2 Gene Expression
; NUMBER OF SEQUENCES: 29
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: OBLON, SPIVAK, MCLELLAND, MAIER & NEUSTADT,
; ADDRESSEE: P.C.
; STREET: 1755 S. Jefferson Davis Hwy., Suite 400
; CITY: Arlington
; STATE: Virginia
; COUNTRY: U.S.A.
; ZIP: 22202
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent In Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/080,285
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/465,485
; FILING DATE: 05-JUN-1995
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/124,256
; FILING DATE: 20-SEP-1993
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/840,716
; FILING DATE: 21-FEB-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/288,692
; FILING DATE: 22-DEC-1988
; ATTORNEY/AGENT INFORMATION:
; NAME: Fortney, Andrew D.
; REGISTRATION NUMBER: 34,600
; REFERENCE/DOCKET NUMBER: 3335-070-55 CONT
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (408) 436-2070
; TELEFAX: (408) 436-2075
; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; ANTI-SENSE: YES
US-09-080-285-16
Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 187 CCCGCCGCCGCCGCCG 201
Db 15 CCCGCCGCCGCCGCCG 1
RESULT 534
US-09-071-845-1628/c
; Sequence 1628, Application US/09071845
; Patent No. 6132967
; GENERAL INFORMATION:
; APPLICANT: Susan Grimm
; APPLICANT: Dan T. Stinchcomb
; APPLICANT: James McSwiggen
; APPLICANT: Sean Sullivan

; APPLICANT: Kenneth G. Draper
; TITLE OF INVENTION: RIBOZYME TREATMENT OF
; DISEASES OR CONDITIONS
; TITLE OF INVENTION: RELATED TO LEVELS OF
; TITLE OF INVENTION: INTRACELLULAR ADHESION
; TITLE OF INVENTION: MOLECULE-1 (I-CAM-1)
; NUMBER OF SEQUENCES: 2390
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Lyon & Lyon
; STREET: 633 West Fifth Street
; CITY: Los Angeles
; STATE: California
; COUNTRY: U.S.A.
; ZIP: 90071-2066
; COMPUTER READABLE FORM:
; MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
; MEDIUM TYPE: storage
; COMPUTER: IBM Compatible
; OPERATING SYSTEM: IBM P.C. DOS 5.0
; SOFTWARE: Word Perfect 5.1
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/071,845
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/292,620
; FILING DATE: August 17, 1994
; APPLICATION NUMBER: 08/008,895
; FILING DATE: January 19, 1993
; APPLICATION NUMBER: 07/989,849
; FILING DATE: December 7, 1992
; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 208/149
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 1628:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
US-09-071-845-1628
Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;
QY 595 CCCACCAGCTGAAG 609
Db 15 CCCACCAGCTGTAG 1
RESULT 535
US-09-266-596-18/c
; Sequence 18, Application US/09266596
; Patent No. 6218187
; GENERAL INFORMATION:
; APPLICANT: FINER, MITCHELL H.
; APPLICANT: DULL, THOMAS J.
; APPLICANT: ZSEBO, KRISTINA M.
; APPLICANT: COOKE, KEEGAN
; APPLICANT: FARSON, DEBORAH A.
; TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
; TITLE OF INVENTION: VIRUS AND HIGH EFFICIENCY RETROVIRAL TRANSDUCTION
; NUMBER OF SEQUENCES: 48
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CELL GENESYS, INC.

STREET: 322 LAKESIDE DRIVE
CITY: POSTER CITY
STATE: CALIFORNIA
COUNTRY: USA
ZIP: 94404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/09/266,596
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/517,488
FILING DATE: 21-AUG-1995
APPLICATION NUMBER: US 08/258,152
FILING DATE: 10-JUN-1994
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/076,299
FILING DATE: 11-JUN-1993
ATTORNEY/AGENT INFORMATION:
NAME: KRUPEN, KAREN I.
REGISTRATION NUMBER: 34,647
REFERENCE/DOCKET NUMBER: CELL 13.3
TELECOMMUNICATION INFORMATION:
TELEPHONE: 415-358-9600 X131
TELEFAX: 415-349-7392
INFORMATION FOR SEQ ID NO: 18:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-09-266-596-18

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1239 GCTGGACGTGGCCAT 1253
Db 15 GCTGGACATGGCCCT 1

RESULT 536
US-08-479-737-16/c
Sequence 16, Application US/08479737
Patent No. 6319494
GENERAL INFORMATION:
APPLICANT: Capon, Daniel J
Weiss, Arthur
Irving, Brian A
Roberts, Margo R
Zeebo, Kristina
TITLE OF INVENTION: CHIMERIC CHAINS FOR RECEPTOR ASSOCIATED
SIGNAL TRANSDUCTION PATHWAYS
NUMBER OF SEQUENCES: 51
CORRESPONDENCE ADDRESS:
ADDRESSEE: CELL GENESYS, INC.
STREET: 322 Lakeside Drive
CITY: Foster City
STATE: California
COUNTRY: USA
ZIP: 94404
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: Patent in Release #1.0, Version #1.25
CURRENT APPLICATION DATA:

APPLICATION NUMBER: US/08/479,737
FILING DATE: 07-JUN-1995
CLASSIFICATION: <Unknown>
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 08/238,405
FILING DATE: 05-MAY-1994
ATTORNEY/AGENT INFORMATION:
NAME: Mandel, SaraLynn
REGISTRATION NUMBER: 31,853
REFERENCE/DOCKET NUMBER: Cell 5.3
TELECOMMUNICATION INFORMATION:
TELEPHONE: (415) 358-9600
TELEFAX: (415) 358-0803
INFORMATION FOR SEQ ID NO: 16:
SEQUENCE CHARACTERISTICS:
LENGTH: 16 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: cDNA
SEQUENCE DESCRIPTION: SEQ ID NO: 16:
US-08-479-737-16

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1239 GCTGGACGTGGCCAT 1253
Db 15 GCTGGACATGGCCCT 1

RESULT 537
US-08-679-645-523
Sequence 523, Application US/08679645
Patent No. 6350934
GENERAL INFORMATION:
APPLICANT: Zwick, Michael G.
Edington, Brent E.
APPLICANT: McSwiggen, James A.
APPLICANT: Merlo, Patricia Ann Owens
APPLICANT: Guo, Lining
APPLICANT: Skokut, Thomas A.
APPLICANT: Young, Scott A.
APPLICANT: Folkerts, Otto
APPLICANT: Merlo, Donald J.
TITLE OF INVENTION: COMPOSITION AND METHODS FOR
MODULATION OF GENE EXPRESSION
TITLE OF INVENTION: IN PLANTS
NUMBER OF SEQUENCES: 1263
CORRESPONDENCE ADDRESS:
ADDRESSEE: Lyon & Lyon
STREET: 633 West Fifth Street
STREET: Suite 4700
CITY: Los Angeles
STATE: California
COUNTRY: U.S.A.
ZIP: 90071-2066
COMPUTER READABLE FORM:
MEDIUM TYPE: 3.5" Diskette, 1.44 Mb
MEDIUM TYPE: storage
COMPUTER: IBM Compatible
OPERATING SYSTEM: IBM P.C. DOS 5.0
SOFTWARE: Word Perfect 5.1
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/679,645
FILING DATE: July 12, 1996
CLASSIFICATION: 800
PRIOR APPLICATION DATA:
APPLICATION NUMBER: 60/001,135
FILING DATE: July 13, 1995
APPLICATION NUMBER: 08/300,726
FILING DATE: September 2, 1994

```

; ATTORNEY/AGENT INFORMATION:
; NAME: Warburg, Richard J.
; REGISTRATION NUMBER: 32,327
; REFERENCE/DOCKET NUMBER: 219/247
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (213) 489-1600
; TELEFAX: (213) 955-0440
; TELEX: 67-3510
; INFORMATION FOR SEQ ID NO: 523:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; US-08-679-645-523

Query Match      0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 66.7%; Pred. No. 2.3e+02;
Matches 10; Conservative 3; Mismatches 2; Indels 0; Gaps 0;

QY      892 CTGCGGTACGCGTG 906
DB      1 CUGCGGUUCAGCCUG 15

RESULT 538
US-08-475-442A-16/c
; Sequence 16, Application US/08475442A
; Patent No. 6407221
; GENERAL INFORMATION:
; APPLICANT: CAPON, DANIEL J
; APPLICANT: WEISS, ARTHUR
; APPLICANT: IRVING, BRIAN A
; APPLICANT: ROBERTS, MARGO R
; APPLICANT: ZSEBO, KRISTINA
; TITLE OF INVENTION: CHIMERIC CHAINS FOR
; TITLE OF INVENTION: RECEPTOR-ASSOCIATED SIGNAL TRANSDUCTION PATHWAYS
; NUMBER OF SEQUENCES: 51
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: CELL GENESYS, INC.
; STREET: 322 LAKESIDE DRIVE
; CITY: FOSTER CITY
; STATE: CALIFORNIA
; COUNTRY: USA
; ZIP: 94404
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/475,442A
; FILING DATE: 06-JUN-1995
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 08/238,405
; FILING DATE: 05-MAY-1994
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/988,194
; FILING DATE: 09-DEC-1992
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 07/627,643
; FILING DATE: 14-DEC-1990
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/US91/09431
; FILING DATE: 12-DEC-1991
; ATTORNEY/AGENT INFORMATION:
; NAME: KRUPEN, KAREN I
; REGISTRATION NUMBER: 34,647
; REFERENCE/DOCKET NUMBER: CELLS.5
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (415)358-9600x131
; TELEFAX: (415)349-7392

```

```

; INFORMATION FOR SEQ ID NO: 16:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: cDNA
; US-08-475-442A-16

Query Match      0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      1239 GCTGGACGTGGCCAT 1253
DB      15 GCTGGACGAGCCCT 1

RESULT 539
US-09-724-426-16/c
; Sequence 16, Application US/09724426
; Patent No. 6414134
; GENERAL INFORMATION:
; APPLICANT: Reed, John
; TITLE OF INVENTION: Regulation of BCL-2 Gene Expression
; FILE REFERENCE: 10412-024
; CURRENT APPLICATION NUMBER: US/09/724,426
; CURRENT FILING DATE: 2000-11-28
; NUMBER OF SEQ ID NOS: 29
; SOFTWARE: PatentIn version 3.0
; SEQ ID NO 16
; LENGTH: 16
; TYPE: DNA
; ORGANISM: Homo sapiens
; US-09-724-426-16

Query Match      0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

QY      187 CCGCGCGCCGCCG 201
DB      15 CCGCGCGCGCTCCG 1

RESULT 540
US-08-535-249-97
; Sequence 97, Application US/08535249
; Patent No. 6455689
; GENERAL INFORMATION:
; APPLICANT: Schlingensiepen, Georg-Ferdinand
; APPLICANT: Brysch, Wolfgang
; APPLICANT: Schlingensiepen, Karl-Hermann
; APPLICANT: Schlingensiepen, Reimar
; APPLICANT: Bogdahn, Ulrich
; TITLE OF INVENTION: Antisense-oligonucleotides for the treatment of
; TITLE OF INVENTION: immuno-suppressive effect of transforming-growth-factor bet
; NUMBER OF SEQUENCES: 137
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Jacobson, Price, Holman & Stern
; STREET: 400 Seventh St. N.W.
; CITY: Washington D.C
; COUNTRY: U.S.A.
; ZIP: 20004
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.25
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/535,249
; FILING DATE:
; CLASSIFICATION: 514

```

```
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: EP 93 107 089.0
/ FILING DATE: 30-APR-1993
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: EP 93 107 849.7
/ FILING DATE: 13-MAY-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: Player, William E.
/ REGISTRATION NUMBER: 31,409
/ REFERENCE/DOCKET NUMBER: 10577/P58418
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: (202)638-6666
/ TELEFAX: (202)393-5350
/ TELEX: RCA 248593 IDEA UR
/ INFORMATION FOR SEQ ID NO: 97:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: unknown
/ TOPOLOGY: unknown
/ MOLECULE TYPE: DNA (genomic)
/ ANTI-SENSE: YES
/ US-08-535-249-97

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1023 GTGCAAGTGCAGC 1037
Db 1 GTACAAAGTGCAGC 15

RESULT 541
US-09-916-228-14
/ Sequence 14, Application US/09916228
/ Patent No. 6498013
/ GENERAL INFORMATION:
/ APPLICANT: Velculescu, Victor
/ APPLICANT: Sparks, Andrew
/ APPLICANT: Kinzler, Kenneth
/ APPLICANT: Vogelstein, Bert
/ TITLE OF INVENTION: Serial analysis of transcript expression
/ TITLE OF INVENTION: using long tags
/ FILE REFERENCE: 00107.00172
/ CURRENT APPLICATION NUMBER: US/09/916,228
/ CURRENT FILING DATE: 2001-07-27
/ PRIOR APPLICATION NUMBER: 60/221,556
/ PRIOR FILING DATE: 2000-07-28
/ PRIOR APPLICATION NUMBER: 60/233,431
/ PRIOR FILING DATE: 2000-09-18
/ NUMBER OF SEQ ID NOS: 30
/ SOFTWARE: FastSeq for Windows Version 4.0
/ SEQ ID NO 14
/ LENGTH: 16
/ TYPE: DNA
/ ORGANISM: Artificial Sequence
/ FEATURE:
/ OTHER INFORMATION: tag or tag concatenamer
/ US-09-916-228-14

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 190 GCCGCCACCCGGAC 204
Db 1 GCCGCTCTCCCGAC 15

RESULT 542
US-09-944-411-18/c
/ Sequence 18, Application US/09944411
/ Patent No. 6506604
/ GENERAL INFORMATION:
/ APPLICANT: FINER, MITCHELL H.
/ DULL, THOMAS J.
/ ZSEBO, KRISTINA M.
/ COOKER, KERSAN
/ FARSON, DEBORAH A.
/ TITLE OF INVENTION: METHOD FOR PRODUCTION OF HIGH TITER
/ VIRUS AND HIGH EFFICIENCY RETROVIRAL MEDIATED TRANSDUCTI
/ OF MAMMALIAN CELLS
/ NUMBER OF SEQUENCES: 48
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: CELL GENESYS, INC.
/ STREET: 322 LAKESIDE DRIVE
/ CITY: FOSTER CITY
/ STATE: CALIFORNIA
/ COUNTRY: USA
/ ZIP: 94404
/ COMPUTER READABLE FORM:
/ MEDIUM TYPE: Floppy disk
/ COMPUTER: IBM PC compatible
/ OPERATING SYSTEM: PC-DOS/MS-DOS
/ SOFTWARE: PatentIn Release #1.0, Version #1.25
/ CURRENT APPLICATION DATA:
/ APPLICATION NUMBER: US/09/944,411
/ FILING DATE: 04-Sep-2001
/ CLASSIFICATION: <Unknown>
/ PRIOR APPLICATION DATA:
/ APPLICATION NUMBER: 08/914,893
/ FILING DATE: <Unknown>
/ APPLICATION NUMBER: US 08/258,152
/ FILING DATE: 10-JUN-1994
/ APPLICATION NUMBER: US 08/076,299
/ FILING DATE: 11-JUN-1993
/ ATTORNEY/AGENT INFORMATION:
/ NAME: KRUPEN, KAREN I.
/ REGISTRATION NUMBER: 34,647
/ REFERENCE/DOCKET NUMBER: CELL 13.3
/ TELECOMMUNICATION INFORMATION:
/ TELEPHONE: 415-358-9600 X131
/ TELEFAX: 415-349-7392
/ INFORMATION FOR SEQ ID NO: 18:
/ SEQUENCE CHARACTERISTICS:
/ LENGTH: 16 base pairs
/ TYPE: nucleic acid
/ STRANDEDNESS: single
/ TOPOLOGY: linear
/ MOLECULE TYPE: DNA (genomic)
/ SEQUENCE DESCRIPTION: SEQ ID NO: 18:
/ US-09-944-411-18

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 1239 GCTGGACGTGGCCAT 1253
Db 15 GCTGGACATGGCCCT 1

RESULT 543
US-08-754-477A-38/c
/ Sequence 38, Application US/08754477A
/ Patent No. 6518411
/ GENERAL INFORMATION:
/ APPLICANT: Murray, Jeffrey
/ APPLICANT: Semina, Elena
/ TITLE OF INVENTION: RIEG COMPOSITIONS AND THERAPEUTIC
/ TITLE OF INVENTION: AND DIAGNOSTIC USES THEREFOR
/ NUMBER OF SEQUENCES: 139
/ CORRESPONDENCE ADDRESS:
/ ADDRESSEE: FOLEY, HOAG & ELIOT LLP
/ STREET: One Post Office Square
```

;
; CITY: Boston
; STATE: MA
; COUNTRY: USA
; ZIP: 02109-2170
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/754,477A
; FILING DATE: 22-NOV-1996
; ATTORNEY/AGENT INFORMATION:
; NAME: Arnold, Beth E. 430
; REGISTRATION NUMBER: 35,430
; REFERENCE/DOCKET NUMBER: UIA-022.01
; TELEPHONE: 617-832-1000
; TELEFAX: 617-832-7000
; INFORMATION FOR SEQ ID NO: 38:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: CDNA
; US-08-754-477A-38

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 81.2%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 3; Indels 0; Gaps 0;

Qy 720 CCAGCAGCGGGGCC 735
Db 16 CCAGGAGCGGAGGCC 1

RESULT 544
US-09-060-299-420
; Sequence 420, Application US/09060299
; Patent No. 6545137
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; APPLICANT: Hess, John W
; APPLICANT: Caskey, Charles T
; APPLICANT: Cox, Roger D
; APPLICANT: Gerhold, David
; APPLICANT: Hammond, Holly
; APPLICANT: Hey, Patricia
; APPLICANT: Kawaguchi, Yoshihiko
; APPLICANT: Merriman, Tony R
; APPLICANT: Metzker, Michael L
; TITLE OF INVENTION: No. 6545137el Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. 6545137th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia
; COUNTRY: US
; ZIP: VA 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25 (BPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/060,299
; FILING DATE: 15-APR-1998
; CLASSIFICATION: 435
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; INFORMATION FOR SEQ ID NO: 420:

;
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-35
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 420:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 16 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: double
; TOPOLOGY: linear
; US-09-060-299-420

Query Match 0.9%; Score 11.8; DB 1; Length 16;
Best Local Similarity 86.7%; Pred. No. 2.3e+02;
Matches 13; Conservative 0; Mismatches 2; Indels 0; Gaps 0;

Qy 5 AGGAGTTGAGTGG 19
Db 1 AGGAGGTGAGGCGG 15

RESULT 545
US-09-402-923A-420
; Sequence 420, Application US/09402923A
; Patent No. 6555654
; GENERAL INFORMATION:
; APPLICANT: Todd, John A
; APPLICANT: Hess, John W
; APPLICANT: Caskey, Charles T
; APPLICANT: Cox, Roger D
; APPLICANT: Gerhold, David
; APPLICANT: Hammond, Holly
; APPLICANT: Hey, Patricia
; APPLICANT: Kawaguchi, Yoshihiko
; APPLICANT: Merriman, Tony R
; APPLICANT: Metzker, Michael L
; TITLE OF INVENTION: No. 6555654el LDL-Receptor
; NUMBER OF SEQUENCES: 455
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Nixon and Vanderhye
; STREET: 1100 No. 6555654th Glebe Road, Eighth Floor
; CITY: Arlington
; STATE: Virginia
; COUNTRY: US
; ZIP: VA 22201-4714
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: Patent in Release #1.0, Version #1.25 (BPO)
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/09/402,923A
; FILING DATE: 14-Feb-2001
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: PCT/GB98/01102
; FILING DATE: 15-APR-1998
; APPLICATION NUMBER: US 60/043,553
; FILING DATE: 15-APR-1997
; APPLICATION NUMBER: US 60/048,740
; FILING DATE: 05-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: B.J.Sadoff
; REGISTRATION NUMBER: 36,663
; REFERENCE/DOCKET NUMBER: 620-81
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (703)816-4091
; TELEFAX: (703)816-4100
; INFORMATION FOR SEQ ID NO: 420:


```
US-08-702-105A-33
; Sequence 33, Application US/08702105A
; Patent No. 5908839
; GENERAL INFORMATION:
; APPLICANT: Levitt, Roy C.
; APPLICANT: Maloy, W. Lee
; APPLICANT: Kari, U. Prasad
; APPLICANT: Nicolaides, Nicholas C.
; TITLE OF INVENTION: Asthma Associated Factors As Targets For
; TITLE OF INVENTION: Treating Atopic Allergies Including Asthma And Related
; TITLE OF INVENTION: Disorders
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner L.L.P.
; STREET: 1300 I Street N.W., Suite 700
; CITY: Washington
; STATE: D.C.
; COUNTRY: USA
; ZIP: 20005-3315
; COMPUTER READABLE FORM:
; MEDIUM TYPE: Floppy disk
; COMPUTER: IBM PC compatible
; OPERATING SYSTEM: PC-DOS/MS-DOS
; SOFTWARE: PatentIn Release #1.0, Version #1.30
; CURRENT APPLICATION DATA:
; APPLICATION NUMBER: US/08/702.105A
; FILING DATE:
; CLASSIFICATION:
; PRIOR APPLICATION DATA:
; APPLICATION NUMBER: US/08/874.503
; FILING DATE: 13-JUN-1997
; ATTORNEY/AGENT INFORMATION:
; NAME: Fordis, Jean B.
; REGISTRATION NUMBER: 32984
; REFERENCE/DOCKET NUMBER: 05387.0056-01000
; TELECOMMUNICATION INFORMATION:
; TELEPHONE: (202) 408-4400
; TELEFAX: (202) 408-4400
; INFORMATION FOR SEQ ID NO: 33:
; SEQUENCE CHARACTERISTICS:
; LENGTH: 18 base pairs
; TYPE: nucleic acid
; STRANDEDNESS: single
; TOPOLOGY: linear
; MOLECULE TYPE: DNA (genomic)
; US-08-702-105A-33

Query Match 0.9%; Score 11.6; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 802 CGCTCCCTGCAGCGCAGC 819
Db 1 CTCCTCCCTGCAGCGCTACC 18

RESULT 550
US-08-702-110A-33
; Sequence 33, Application US/08702110A
; Patent No. 6037149
; GENERAL INFORMATION:
; APPLICANT: Levitt, Roy C.
; APPLICANT: Maloy, W. Lee
; APPLICANT: Kari, U. Prasad
; APPLICANT: Nicolaides, Nicholas C.
; TITLE OF INVENTION: Asthma Associated Factors As Targets For
; TITLE OF INVENTION: Treating Atopic Allergies Including Asthma And Related
; TITLE OF INVENTION: Disorders
; NUMBER OF SEQUENCES: 41
; CORRESPONDENCE ADDRESS:
; ADDRESSEE: Finnegan, Henderson, Farabow, Garrett &
; ADDRESSEE: Dunner L.L.P.
```

```
STREET: 1300 I Street N.W., Suite 700
CITY: Washington
STATE: D.C.
COUNTRY: USA
ZIP: 20005-3315
COMPUTER READABLE FORM:
MEDIUM TYPE: Floppy disk
COMPUTER: IBM PC compatible
OPERATING SYSTEM: PC-DOS/MS-DOS
SOFTWARE: PatentIn Release #1.0, Version #1.30
CURRENT APPLICATION DATA:
APPLICATION NUMBER: US/08/702.110A
FILING DATE:
CLASSIFICATION:
PRIOR APPLICATION DATA:
APPLICATION NUMBER: US 08/874.503
FILING DATE: 13-JUN-1997
ATTORNEY/AGENT INFORMATION:
NAME: Fordis, Jean B.
REGISTRATION NUMBER: 32984
REFERENCE/DOCKET NUMBER: 05387.0056-01000
TELECOMMUNICATION INFORMATION:
TELEPHONE: (202) 408-4000
TELEFAX: (202) 408-4400
INFORMATION FOR SEQ ID NO: 33:
SEQUENCE CHARACTERISTICS:
LENGTH: 18 base pairs
TYPE: nucleic acid
STRANDEDNESS: single
TOPOLOGY: linear
MOLECULE TYPE: DNA (genomic)
US-08-702-110A-33

Query Match 0.9%; Score 11.6; DB 1; Length 18;
Best Local Similarity 77.8%; Pred. No. 3.2e+02;
Matches 14; Conservative 0; Mismatches 4; Indels 0; Gaps 0;

QY 802 CGCTCCCTGCAGCGCAGC 819
Db 1 CTCCTCCCTGCAGCGCTACC 18

Search completed: January 8, 2004, 16:43:46
Job time : 17 secs
```